




Guide

to the 2016 Annual Meeting

AMERICAN
PSYCHIATRIC
ASSOCIATION

ANNUAL MEETING
May 14-18, 2016 • Atlanta



**LATUDA helps your patients
with bipolar depression
experience more of life's
everyday moments**

Visit Sunovion
at booth **#1237**



Latuda[®]
(lurasidone HCl) tablets
20mg | 40mg | 60mg | 80mg | 120mg

INDICATIONS AND USAGE

LATUDA is indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of LATUDA was established in a 6-week monotherapy study and a 6-week adjunctive therapy study with lithium or valproate in adult patients with bipolar depression. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

IMPORTANT SAFETY INFORMATION FOR LATUDA

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.

Please see additional Important Safety Information, including **Boxed Warning**, and Brief Summary of Prescribing Information on adjacent pages.



**Bipolar depression is different than other types of depression.
LATUDA treats bipolar depression so patients can take part in life's everyday moments.**

- **Efficacy established** in both a monotherapy study and an adjunctive therapy study with lithium or valproate!
—In these studies LATUDA was superior to placebo in reduction of Montgomery-Åsberg Depression Rating Scale (MADRS) scores at Week 6¹
- **Safety and tolerability** evaluated in multiple bipolar depression studies for 6 weeks and 24 weeks¹
- **Once-daily dosing**, taken with food (at least 350 calories)¹

Learn more at www.LATUDAhcp.com

CONTRAINDICATIONS

LATUDA is contraindicated in the following:

- Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone.
- Strong CYP3A4 inhibitors (e.g., ketoconazole)
- Strong CYP3A4 inducers (e.g., rifampin)

WARNINGS AND PRECAUTIONS

Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs, including LATUDA. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment of any concomitant serious medical problems.

IMPORTANT SAFETY INFORMATION FOR Latuda® (lurasidone HCl) (Continued)

Tardive Dyskinesia (TD): TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of TD. If signs and symptoms appear in a patient on LATUDA, drug discontinuation should be considered.

Metabolic Changes

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D₂ receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

In the short-term, placebo-controlled monotherapy study, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was 3.1 ng/mL and was 1.5 ng/mL for males. The proportion of female patients with prolactin elevations $\geq 5x$ ULN was 0.6% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5x$ ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated male patients.

In the short-term, placebo-controlled adjunctive therapy with lithium or valproate study, the median change from baseline to endpoint in prolactin levels for LATUDA-treated females was 3.2 ng/mL and was 2.4 ng/mL for males. The proportion of female patients with prolactin elevations $\geq 5x$ ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5x$ ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated male patients.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Patients with a preexisting low white blood cell count (WBC) or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy, and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: LATUDA may cause orthostatic hypotension. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension, in patients with known cardiovascular disease or history of cerebrovascular disease and in patients who are antipsychotic-naïve.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold (e.g., Alzheimer's dementia).

Potential for Cognitive and Motor Impairment: Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

Suicide: The possibility of suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

ADVERSE REACTIONS

Commonly observed adverse reactions ($\geq 5\%$ incidence and at least twice the rate of placebo) for LATUDA were akathisia, extrapyramidal symptoms, and somnolence.


INDICATIONS

LATUDA is indicated for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate in adults.

Please see Brief Summary of Prescribing Information, including **Boxed Warning**, on adjacent pages.

Reference: 1. LATUDA prescribing information. Sunovion Pharmaceuticals Inc. July 2013.



LATUDA, SUNOVION, and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ©2016 Sunovion Pharmaceuticals Inc. All rights reserved. 4/16 LAT244-16

BRIEF SUMMARY OF LATUDA FULL PRESCRIBING INFORMATION

WARNINGS:

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1)].
- LATUDA is not approved for use in patients with dementia-related psychosis [see Warnings and Precautions (5.1)].
- Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2)].
- In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE

1.1 Schizophrenia

LATUDA is indicated for the treatment of patients with schizophrenia.

The efficacy of LATUDA in schizophrenia was established in five 6-week controlled studies of adult patients with schizophrenia [see Clinical Studies (14.1)].

The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2)].

1.2 Depressive Episodes Associated with Bipolar I Disorder

Monotherapy: LATUDA is indicated as monotherapy for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). The efficacy of LATUDA was established in a 6-week monotherapy study in adult patients with bipolar depression [see Clinical Studies (14.2)].

Adjunctive Therapy with Lithium or Valproate: LATUDA is indicated as adjunctive therapy with either lithium or valproate for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). The efficacy of LATUDA as adjunctive therapy was established in a 6-week study in adult patients with bipolar depression who were treated with lithium or valproate [see Clinical Studies (14.2)].

The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2)].

The efficacy of LATUDA in the treatment of mania associated with bipolar disorder has not been established.

4 CONTRAINDICATIONS

- Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].
- Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6- to 1.7-times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning].

5.2 Suicidal Thoughts and Behaviors in Adolescents and Young Adults

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.

Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive

compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk of differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.

Table 1

Age Range	Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated
	Increases Compared to Placebo
<18	14 additional cases
18-24	5 additional cases
	Decreases Compared to Placebo
25-64	1 fewer case
>65	6 fewer cases

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidal thoughts and behaviors, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for LATUDA should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.

5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis

In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see also Boxed Warning and Warnings and Precautions (5.1)].

5.4 Neuroleptic Malignant Syndrome

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including LATUDA.

Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. If reintroduced, the patient should be carefully monitored, since recurrences of NMS have been reported.

5.5 Tardive Dyskinesia

Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which

patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on LATUDA, drug discontinuation should be considered. However, some patients may require treatment with LATUDA despite the presence of the syndrome.

5.6 Metabolic Changes

Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Because LATUDA was not marketed at the time these studies were performed, it is not known if LATUDA is associated with this increased risk.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Schizophrenia

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 2.

Table 2: Change in Fasting Glucose in Schizophrenia Studies

	Placebo	LATUDA				
		20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
Mean Change from Baseline (mg/dL)						
	n=680	n=71	n=478	n=508	n=283	n=113
Serum Glucose	-0.0	-0.6	+2.6	-0.4	+2.5	+2.5
Proportion of Patients with Shifts to ≥ 126 mg/dL						
Serum Glucose (≥ 126 mg/dL)	8.3% (52/628)	11.7% (7/60)	12.7% (57/449)	6.8% (32/472)	10.0% (26/260)	5.6% (6/108)

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a mean change in glucose of +1.8 mg/dL at week 24 (n=355), +0.8 mg/dL at week 36 (n=299) and +2.3 mg/dL at week 52 (n=307).

Bipolar Depression

Monotherapy

Data from the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study are presented in Table 3.

Table 3: Change in Fasting Glucose in the Monotherapy Bipolar Depression Study

	Placebo	LATUDA	
		20 to 60 mg/day	80 to 120 mg/day
	n=148	n=140	n=143
Mean Change from Baseline (mg/dL)			
Serum Glucose	+1.8	-0.8	+1.8
Proportion of Patients with Shifts to ≥ 126 mg/dL			
Serum Glucose (≥ 126 mg/dL)	4.3% (6/141)	2.2% (3/138)	6.4% (9/141)

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.2 mg/dL at week 24 (n=129).

Adjunctive Therapy with Lithium or Valproate

Data from the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 4.

Table 4: Change in Fasting Glucose in the Adjunctive Therapy Bipolar Depression Studies

	Placebo	LATUDA
		20 to 120 mg/day
Mean Change from Baseline (mg/dL)		
	n=302	n=319
Serum Glucose	-0.9	+1.2
Proportion of Patients with Shifts to ≥ 126 mg/dL		
Serum Glucose (≥ 126 mg/dL)	1.0% (3/290)	1.3% (4/316)

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.7 mg/dL at week 24 (n=88).

Dyslipidemia

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Schizophrenia

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 5.

Table 5: Change in Fasting Lipids in Schizophrenia Studies

	Placebo	LATUDA				
		20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
Mean Change from Baseline (mg/dL)						
	n=660	n=71	n=466	n=499	n=268	n=115
Total Cholesterol	-5.8	-12.3	-5.7	-6.2	-3.8	-6.9
Triglycerides	-13.4	-29.1	-5.1	-13.0	-3.1	-10.6
Proportion of Patients with Shifts						
Total Cholesterol (≥ 240 mg/dL)	5.3% (30/571)	13.8% (8/58)	6.2% (25/402)	5.3% (23/434)	3.8% (9/238)	4.0% (4/101)
Triglycerides (≥ 200 mg/dL)	10.1% (53/526)	14.3% (7/49)	10.8% (41/379)	6.3% (25/400)	10.5% (22/209)	7.0% (7/100)

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a mean change in total cholesterol and triglycerides of -3.8 (n=356) and -15.1 (n=357) mg/dL at week 24, -3.1 (n=303) and -4.8 (n=303) mg/dL at week 36 and -2.5 (n=307) and -6.9 (n=307) mg/dL at week 52, respectively.

Bipolar Depression

Monotherapy

Data from the short-term, flexible-dosed, placebo-controlled, monotherapy bipolar depression study are presented in Table 6.

Table 6: Change in Fasting Lipids in the Monotherapy Bipolar Depression Study

	Placebo	LATUDA	
		20 to 60 mg/day	80 to 120 mg/day
Mean Change from Baseline (mg/dL)			
	n=147	n=140	n=144
Total cholesterol	-3.2	+1.2	-4.6
Triglycerides	+6.0	+5.6	+0.4
Proportion of Patients with Shifts			
Total cholesterol (≥ 240 mg/dL)	4.2% (5/118)	4.4% (5/113)	4.4% (5/114)
Triglycerides (≥ 200 mg/dL)	4.8% (6/126)	10.1% (12/119)	9.8% (12/122)

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy in the short-term and continued in the longer-term study had a mean change in total cholesterol and triglycerides of -0.5 (n=130) and -1.0 (n=130) mg/dL at week 24, respectively.

Adjunctive Therapy with Lithium or Valproate

Data from the short-term, flexible-dosed, placebo-controlled, adjunctive therapy bipolar depression studies are presented in Table 7.

Table 7: Change in Fasting Lipids in the Adjunctive Therapy Bipolar Depression Studies

	Placebo	LATUDA
		20 to 120 mg/day
Mean Change from Baseline (mg/dL)		
	n=303	n=321
Total cholesterol	-2.9	-3.1
Triglycerides	-4.6	+4.6
Proportion of Patients with Shifts		
Total cholesterol (≥ 240 mg/dL)	5.7% (15/263)	5.4% (15/276)
Triglycerides (≥ 200 mg/dL)	8.6% (21/243)	10.8% (28/260)

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA, as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in total cholesterol and triglycerides of -0.9 (n=88) and 5.3 (n=88) mg/dL at week 24, respectively.

Weight Gain

Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Schizophrenia

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 8. The mean weight gain was +0.43 kg for LATUDA-treated patients compared to -0.02 kg for placebo-treated patients. Change in weight from baseline for olanzapine was +4.15 kg and for quetiapine extended-release was +2.09 kg in Studies 3 and 5 [see *Clinical Studies (14.1)*], respectively. The proportion of patients with a $\geq 7\%$ increase in body weight (at Endpoint) was 4.8% for LATUDA-treated patients versus 3.3% for placebo-treated patients.

Table 8: Mean Change in Weight (kg) from Baseline in Schizophrenia Studies

	Placebo (n=696)	LATUDA				
		20 mg/day (n=71)	40 mg/day (n=484)	80 mg/day (n=526)	120 mg/day (n=291)	160 mg/day (n=114)
All Patients	-0.02	-0.15	+0.22	+0.54	+0.68	+0.60

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a mean change in weight of -0.69 kg at week 24 (n=755), -0.59 kg at week 36 (n=443) and -0.73 kg at week 52 (n=377).

Bipolar Depression

Monotherapy

Data from the short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study are presented in Table 9. The mean weight gain was +0.29 kg for LATUDA-treated patients compared to -0.04 kg for placebo-treated patients. The proportion of patients with a $\geq 7\%$ increase in body weight (at Endpoint) was 2.4% for LATUDA-treated patients versus 0.7% for placebo-treated patients.

Table 9: Mean Change in Weight (kg) from Baseline in the Monotherapy Bipolar Depression Study

	Placebo (n=151)	LATUDA	
		20 to 60 mg/day (n=143)	80 to 120 mg/day (n=147)
All Patients	-0.04	+0.56	+0.02

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received LATUDA as monotherapy in the short-term and continued in the longer-term study had a mean change in weight of -0.02 kg at week 24 (n=130).

Adjunctive Therapy with Lithium or Valproate

Data from the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 10. The mean weight gain was +0.11 kg for LATUDA-treated patients compared to +0.16 kg for placebo-treated patients. The proportion of patients with a $\geq 7\%$ increase in body weight (at Endpoint) was 3.1% for LATUDA-treated patients versus 0.3% for placebo-treated patients.

Table 10: Mean Change in Weight (kg) from Baseline in the Adjunctive Therapy Bipolar Depression Studies

	Placebo (n=307)	LATUDA 20 to 120 mg/day (n=327)
All Patients	+0.16	+0.11

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA, as adjunctive therapy with either lithium or valproate in the short-term and continued in the longer-term study, had a mean change in weight of +1.28 kg at week 24 (n=86).

5.7 Hyperprolactinemia

As with other drugs that antagonize dopamine D₂ receptors, LATUDA elevates prolactin levels.

Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients [see *Adverse Reactions (6)*].

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent *in vitro*, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in a LATUDA carcinogenicity study conducted in rats and mice [see *Nonclinical Toxicology (13)*]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated patients was +0.4 ng/mL and was -1.9 ng/mL in the placebo-treated patients. The median change from baseline to endpoint for males was +0.5 ng/mL and for females was -0.2 ng/mL. Median changes for prolactin by dose are shown in Table 11.

Table 11: Median Change in Prolactin (ng/mL) from Baseline in Schizophrenia Studies

	Placebo	LATUDA				
		20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
All Patients	-1.9 (n=672)	-1.1 (n=70)	-1.4 (n=476)	-0.2 (n=495)	+3.3 (n=284)	+3.3 (n=115)
Females	-5.1 (n=200)	-0.7 (n=19)	-4.0 (n=149)	-0.2 (n=150)	+6.7 (n=70)	+7.1 (n=36)
Males	-1.3 (n=472)	-1.2 (n=51)	-0.7 (n=327)	-0.2 (n=345)	+3.1 (n=214)	+2.4 (n=79)

The proportion of patients with prolactin elevations $\geq 5\times$ upper limit of normal (ULN) was 2.8% for LATUDA-treated patients versus 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations $\geq 5\times$ ULN was 5.7% for LATUDA-treated patients versus 2.0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5\times$ ULN was 1.6% versus 0.6% for placebo-treated male patients.

In the uncontrolled longer-term schizophrenia studies (primarily open-label extension studies), LATUDA was associated with a median change in prolactin of -0.9 ng/mL at week 24 (n=357), -5.3 ng/mL at week 36 (n=190) and -2.2 ng/mL at week 52 (n=307).

Bipolar Depression

Monotherapy

The median change from baseline to endpoint in prolactin levels, in the short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, was +1.7 ng/mL and +3.5 ng/mL with LATUDA 20 to 60 mg/day and 80 to 120 mg/day, respectively compared to +0.3 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +1.5 ng/mL and for females was +3.1 ng/mL. Median changes for prolactin by dose range are shown in Table 12.

Table 12: Median Change in Prolactin (ng/mL) from Baseline in the Monotherapy Bipolar Depression Study

	Placebo	LATUDA	
		20 to 60 mg/day	80 to 120 mg/day
All Patients	+0.3 (n=147)	+1.7 (n=140)	+3.5 (n=144)
Females	0.0 (n=82)	+1.8 (n=78)	+5.3 (n=88)
Males	+0.4 (n=65)	+1.2 (n=62)	+1.9 (n=56)

Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo

The proportion of patients with prolactin elevations $\geq 5\times$ upper limit of normal (ULN) was 0.4% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations $\geq 5\times$ ULN was 0.6% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5\times$ ULN was 0% versus 0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA as monotherapy in the short-term and continued in the longer-term study, had a median change in prolactin of -1.15 ng/mL at week 24 (n=130).

Adjunctive Therapy with Lithium or Valproate

The median change from baseline to endpoint in prolactin levels, in the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies was +2.8 ng/mL with LATUDA 20 to 120 mg/day compared to 0.0 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +2.4 ng/mL and for females was +3.2 ng/mL. Median changes for prolactin across the dose range are shown in Table 13.

Table 13: Median Change in Prolactin (ng/mL) from Baseline in the Adjunctive Therapy Bipolar Depression Studies

	Placebo	LATUDA
		20 to 120 mg/day
All Patients	0.0 (n=301)	+2.8 (n=321)
Females	+0.4 (n=156)	+3.2 (n=162)
Males	-0.1 (n=145)	+2.4 (n=159)

Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

The proportion of patients with prolactin elevations $\geq 5\times$ upper limit of normal (ULN) was 0.0% for LATUDA-treated patients versus 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations $\geq 5\times$ ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5\times$ ULN was 0% versus 0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with LATUDA, as adjunctive therapy with either lithium or valproate, in the short-term and continued in the longer-term study, had a median change in prolactin of -2.9 ng/mL at week 24 (n=88).

5.8 Leukopenia, Neutropenia and Agranulocytosis

Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and LATUDA should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.

Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count < 1000/mm³) should discontinue LATUDA and have their WBC followed until recovery.

5.9 Orthostatic Hypotension and Syncope

LATUDA may cause orthostatic hypotension and syncope, perhaps due to its α 1-adrenergic receptor antagonism. Associated adverse reactions can include dizziness, lightheadedness, tachycardia, and bradycardia. Generally, these risks are greatest at the beginning of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. In such patients, consider using a lower starting dose and slower titration, and monitor orthostatic vital signs.

Orthostatic hypotension, as assessed by vital sign measurement, was defined by the following vital sign changes: ≥ 20 mm Hg decrease in systolic blood pressure and ≥ 10 bpm increase in pulse from sitting to standing or supine to standing position.

Schizophrenia

The incidence of orthostatic hypotension and syncope reported as adverse events from short-term, placebo-controlled schizophrenia studies was (LATUDA incidence, placebo incidence): orthostatic hypotension [0.3% (5/1508), 0.1% (1/708)] and syncope [0.1% (2/1508), 0% (0/708)].

In short-term schizophrenia clinical studies, orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.8% with LATUDA 40 mg, 2.1% with LATUDA 80 mg, 1.7% with LATUDA 120 mg and 0.8% with LATUDA 160 mg compared to 0.7% with placebo.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, there were no reported adverse events of orthostatic hypotension and syncope.

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.6% with LATUDA 20 to 60 mg and 0.6% with LATUDA 80 to 120 mg compared to 0% with placebo.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, there were no reported adverse events of orthostatic hypotension and syncope. Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with LATUDA 20 to 120 mg compared to 0.9% with placebo.

5.10 Seizures

As with other antipsychotic drugs, LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, seizures/convulsions occurred in 0.1% (2/1508) of patients treated with LATUDA compared to 0.1% (1/708) placebo-treated patients.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, no patient experienced seizures/convulsions.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, no patient experienced seizures/convulsions.

5.11 Potential for Cognitive and Motor Impairment

LATUDA, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

In clinical studies with LATUDA, somnolence included: hypersomnia, hypersomnolence, sedation and somnolence.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, somnolence was reported by 17.0% (256/1508) of patients treated with LATUDA (15.5% LATUDA 20 mg, 15.6% LATUDA 40 mg, 15.2% LATUDA 80 mg, 26.5% LATUDA 120 mg and 8.3% LATUDA 160 mg/day) compared to 7.1% (50/708) of placebo patients.

Bipolar Depression

Monotherapy

In the short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, somnolence was reported by 7.3% (12/164) and 13.8% (23/167) with LATUDA 20 to 60 mg and 80 to 120 mg, respectively compared to 6.5% (11/168) of placebo patients.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies, somnolence was reported by 11.4% (41/360) of patients treated with LATUDA 20-120 mg compared to 5.1% (17/334) of placebo patients.

5.12 Body Temperature Dysregulation

Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration [see Patient Counseling Information (17.9)].

5.13 Suicide

The possibility of a suicide attempt is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy. Prescriptions for LATUDA should be written for the

smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose.

Schizophrenia

In short-term, placebo-controlled schizophrenia studies, the incidence of treatment-emergent suicidal ideation was 0.4% (6/1508) for LATUDA-treated patients compared to 0.8% (6/708) on placebo. No suicide attempts or completed suicides were reported in these studies.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the incidence of treatment-emergent suicidal ideation was 0.0% (0/331) with LATUDA-treated patients compared to 0.0% (0/168) with placebo-treated patients. No suicide attempts or completed suicides were reported in this study.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, the incidence of treatment-emergent suicidal ideation was 1.1% (4/360) for LATUDA-treated patients compared to 0.3% (1/334) on placebo. No suicide attempts or completed suicides were reported in these studies.

5.14 Activation of Mania/Hypomania

Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. Monitor patients for the emergence of such episodes.

In the bipolar depression monotherapy and adjunctive therapy (with lithium or valproate) studies, less than 1% of subjects in the LATUDA and placebo groups developed manic or hypomanic episodes.

5.15 Dysphagia

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

5.16 Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions (5.1)]
- Suicidal Thoughts and Behaviors [see Boxed Warning and Warnings and Precautions (5.2)]
- Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-related Psychosis [see Warnings and Precautions (5.23)]
- Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.4)]
- Tardive Dyskinesia [see Warnings and Precautions (5.5)]
- Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.6)]
- Hyperprolactinemia [see Warnings and Precautions (5.7)]
- Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.8)]
- Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.9)]
- Seizures [see Warnings and Precautions (5.10)]
- Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.11)]
- Body Temperature Dysregulation [see Warnings and Precautions (5.12)]
- Suicide [see Warnings and Precautions (5.13)]
- Activation of Mania/Hypomania [see Warnings and Precautions (5.14)]
- Dysphagia [see Warnings and Precautions (5.15)]
- Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies [see Warnings and Precautions (5.16)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The information below is derived from an integrated clinical study database for LATUDA consisting of 3799 patients exposed to one or more doses of LATUDA for the treatment of schizophrenia and bipolar depression in placebo-controlled studies. This experience corresponds with a total experience of 1250.9 patient-years. A total of 1106 LATUDA-treated patients had at least 24 weeks and 371 LATUDA-treated patients had at least 52 weeks of exposure.

Adverse events during exposure to study treatment were obtained by general inquiry and voluntarily reported adverse experiences, as well as results from physical examinations, vital signs, ECGs, weights and laboratory investigations. Adverse experiences were recorded by clinical investigators using their own terminology. In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

Schizophrenia

The following findings are based on the short-term, placebo-controlled premarketing studies for schizophrenia in which LATUDA was administered at daily doses ranging from 20 to 160 mg (n=1508).

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence $\geq 5\%$ and at least twice the rate of placebo) in patients treated with LATUDA were somnolence, akathisia, extrapyramidal symptoms, and nausea.

Adverse Reactions Associated with Discontinuation of Treatment: A total of 9.5% (143/1508) LATUDA-treated patients and 9.3% (66/708) of placebo-treated patients discontinued due to

adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.

Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients: Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with schizophrenia) are shown in Table 14.

Table 14: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Short-term Schizophrenia Studies

Body System or Organ Class	Percentage of Patients Reporting Reaction						
	Placebo (N=708) (%)	20 mg/day (N=71) (%)	40 mg/day (N=487) (%)	80 mg/day (N=538) (%)	120 mg/day (N=291) (%)	160 mg/day (N=121) (%)	All LATUDA (N=1508) (%)
Gastrointestinal Disorders							
Nausea	5	11	10	9	13	7	10
Vomiting	6	7	6	9	9	7	8
Dyspepsia	5	11	6	5	8	6	6
Salivary Hypersecretion	<1	1	1	2	4	2	2
Musculoskeletal and Connective Tissue Disorders							
Back Pain	2	0	4	3	4	0	3
Nervous System Disorders							
Somnolence*	7	15	16	15	26	8	17
Akathisia	3	6	11	12	22	7	13
Extrapyramidal Disorder**	6	6	11	12	22	13	14
Dizziness	2	6	4	4	5	6	4
Psychiatric Disorders							
Insomnia	8	8	10	11	9	7	10
Agitation	4	10	7	3	6	5	5
Anxiety	4	3	6	4	7	3	5
Restlessness	1	1	3	1	3	2	2

Note: Figures rounded to the nearest integer
 *Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence
 **Extrapyramidal symptoms includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus

Dose-Related Adverse Reactions in the Schizophrenia Studies

Akathisia and extrapyramidal symptoms were dose-related. The frequency of akathisia increased with dose up to 120 mg/day (5.6% for LATUDA 20 mg, 10.7% for LATUDA 40 mg, 12.3% for LATUDA 80 mg, and 22.0% for LATUDA 120 mg). Akathisia was reported by 7.4% (9/121) of patients receiving 160 mg/day. Akathisia occurred in 3.0% of subjects receiving placebo. The frequency of extrapyramidal symptoms increased with dose up to 120 mg/day (5.6% for LATUDA 20 mg, 11.5% for LATUDA 40 mg, 11.9% for LATUDA 80 mg, and 22.0% for LATUDA 120 mg).

Bipolar Depression (Monotherapy)

The following findings are based on the short-term, placebo-controlled premarketing study for bipolar depression in which LATUDA was administered at daily doses ranging from 20 to 120 mg (n=331).

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence ≥ 5%, in either dose group, and at least twice the rate of placebo) in patients treated with LATUDA were akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, and anxiety.

Adverse Reactions Associated with Discontinuation of Treatment: A total of 6.0% (20/331) LATUDA-treated patients and 5.4% (9/168) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.

Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients: Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 15.

Table 15: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in a Short-term Monotherapy Bipolar Depression Study

Body System or Organ Class	Percentage of Patients Reporting Reaction			
	Placebo (N=168) (%)	LATUDA 20-60 mg/day (N=164) (%)	LATUDA 80-120 mg/day (N=167) (%)	All LATUDA (N=331) (%)
Gastrointestinal Disorders				
Nausea	8	10	17	14
Dry Mouth	4	6	4	5
Vomiting	2	2	6	4
Diarrhea	2	5	3	4

Body System or Organ Class	Percentage of Patients Reporting Reaction			
	Placebo (N=168) (%)	LATUDA 20-60 mg/day (N=164) (%)	LATUDA 80-120 mg/day (N=167) (%)	All LATUDA (N=331) (%)
Infections and Infestations				
Nasopharyngitis	1	4	4	4
Influenza	1	<1	2	2
Urinary Tract Infection	<1	2	1	2
Musculoskeletal and Connective Tissue Disorders				
Back Pain	<1	3	<1	2
Nervous System Disorders				
Extrapyramidal Symptoms*	2	5	9	7
Akathisia	2	8	11	9
Somnolence**	7	7	14	11
Psychiatric Disorders				
Anxiety	1	4	5	4

Note: Figures rounded to the nearest integer
 *Extrapyramidal symptoms includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus
 **Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence

Dose-Related Adverse Reactions in the Monotherapy Study:

In the short-term, placebo-controlled study (involving lower and higher LATUDA dose ranges) [see Clinical Studies (14.2)] the adverse reactions that occurred with a greater than 5% incidence in the patients treated with LATUDA in any dose group and greater than placebo in both groups were nausea (10.4%, 17.4%), somnolence (7.3%, 13.8%), akathisia (7.9%, 10.8%), and extrapyramidal symptoms (4.9%, 9.0%) for LATUDA 20 to 60 mg/day and LATUDA 80 to 120 mg/day, respectively.

Bipolar Depression

Adjunctive Therapy with Lithium or Valproate

The following findings are based on two short-term, placebo-controlled premarketing studies for bipolar depression in which LATUDA was administered at daily doses ranging from 20 to 120 mg as adjunctive therapy with lithium or valproate (n=360).

Commonly Observed Adverse Reactions: The most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo) in subjects treated with LATUDA were akathisia and somnolence.

Adverse Reactions Associated with Discontinuation of Treatment: A total of 5.8% (21/360) LATUDA-treated patients and 4.8% (16/334) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.

Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients: Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 16.

Table 16: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Short-term Adjunctive Therapy Bipolar Depression Studies

Body System or Organ Class	Percentage of Patients Reporting Reaction	
	Placebo (N=334) (%)	LATUDA 20 to 120 mg/day (N=360) (%)
Gastrointestinal Disorders		
Nausea	10	14
Vomiting	1	4
General Disorders		
Fatigue	1	3
Infections and Infestations		
Nasopharyngitis	2	4
Investigations		
Weight Increased	<1	3
Metabolism and Nutrition Disorders		
Increased Appetite	1	3
Nervous System Disorders		
Extrapyramidal Symptoms*	9	14
Somnolence**	5	11
Akathisia	5	11
Psychiatric Disorders		
Restlessness	<1	4

Note: Figures rounded to the nearest integer
 *Extrapyramidal symptoms includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus
 **Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence

Extrapyramidal Symptoms

Schizophrenia

In the short-term, placebo-controlled schizophrenia studies, for LATUDA-treated patients, the incidence of reported events related to extrapyramidal symptoms (EPS), excluding akathisia and restlessness, was 13.5% versus 5.8% for placebo-treated patients. The incidence of akathisia for LATUDA-treated patients was 12.9% versus 3.0% for placebo-treated patients. Incidence of EPS by dose is provided in Table 17.

Table 17: Incidence of EPS Compared to Placebo in Schizophrenia Studies

Adverse Event Term	Placebo (N=708) (%)	LATUDA				
		20 mg/day (N=71) (%)	40 mg/day (N=487) (%)	80 mg/day (N=538) (%)	120 mg/day (N=291) (%)	160 mg/day (N=121) (%)
All EPS events	9	10	21	23	39	20
All EPS events, excluding Akathisia/ Restlessness	6	6	11	12	22	13
Akathisia	3	6	11	12	22	7
Dystonia*	<1	0	4	5	7	2
Parkinsonism**	5	6	9	8	17	11
Restlessness	1	1	3	1	3	2

Note: Figures rounded to the nearest integer
 *Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus
 **Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

Bipolar Depression

Monotherapy

In the short-term, placebo-controlled monotherapy bipolar depression study, for LATUDA-treated patients, the incidence of reported events related to EPS, excluding akathisia and restlessness was 6.9% versus 2.4% for placebo-treated patients. The incidence of akathisia for LATUDA-treated patients was 9.4% versus 2.4% for placebo-treated patients. Incidence of EPS by dose groups is provided in Table 18.

Table 18: Incidence of EPS Compared to Placebo in the Monotherapy Bipolar Depression Study

Adverse Event Term	Placebo (N=168) (%)	LATUDA	
		20 to 60 mg/day (N=164) (%)	80 to 120 mg/day (N=167) (%)
All EPS events	5	12	20
All EPS events, excluding Akathisia/ Restlessness	2	5	9
Akathisia	2	8	11
Dystonia*	0	0	2
Parkinsonism**	2	5	8
Restlessness	<1	0	3

Note: Figures rounded to the nearest integer
 *Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus
 **Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

Adjunctive Therapy with Lithium or Valproate

In the short-term, placebo-controlled adjunctive therapy bipolar depression studies, for LATUDA-treated patients, the incidence of EPS, excluding akathisia and restlessness, was 13.9% versus 8.7% for placebo. The incidence of akathisia for LATUDA-treated patients was 10.8% versus 4.8% for placebo-treated patients. Incidence of EPS is provided in Table 19.

Table 19: Incidence of EPS Compared to Placebo in the Adjunctive Therapy Bipolar Depression Studies

Adverse Event Term	Placebo (N=334) (%)	LATUDA 20 to 120 mg/day (N=360) (%)
All EPS events, excluding Akathisia/ Restlessness	9	14
Akathisia	5	11
Dystonia*	<1	1
Parkinsonism**	8	13
Restlessness	<1	4

Note: Figures rounded to the nearest integer
 *Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus
 **Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

In the short-term, placebo-controlled schizophrenia and bipolar depression studies, data was objectively collected on the Simpson Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (BAS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesias.

Schizophrenia

The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes Akathisia Scale global score (LATUDA, 0.1; placebo, 0.0). The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 14.4%; placebo, 7.1%), the SAS (LATUDA, 5.0%; placebo, 2.3%) and the AIMS (LATUDA, 7.4%; placebo, 5.8%).

Bipolar Depression

Monotherapy

The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.4%; placebo, 5.6%), the SAS (LATUDA, 3.7%; placebo, 1.9%) and the AIMS (LATUDA, 3.4%; placebo, 1.2%).

Adjunctive Therapy with Lithium or Valproate

The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.7%; placebo, 2.1%), the SAS (LATUDA, 2.8%; placebo, 2.1%) and the AIMS (LATUDA, 2.8%; placebo, 0.6%).

Dystonia

Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Schizophrenia

In the short-term, placebo-controlled schizophrenia clinical studies, dystonia occurred in 4.2% of LATUDA-treated subjects (0.0% LATUDA 20 mg, 3.5% LATUDA 40 mg, 4.5% LATUDA 80 mg, 6.5% LATUDA 120 mg and 2.5% LATUDA 160 mg) compared to 0.8% of subjects receiving placebo. Seven subjects (0.5%, 7/1508) discontinued clinical trials due to dystonic events – four were receiving LATUDA 80 mg/day and three were receiving LATUDA 120 mg/day.

Bipolar Depression

Monotherapy

In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, dystonia occurred in 0.9% of LATUDA-treated subjects (0.0% and 1.8% for LATUDA 20 to 60 mg/day and LATUDA 80 to 120 mg/day, respectively) compared to 0.0% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

Adjunctive Therapy with Lithium or Valproate

In the short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred in 1.1% of LATUDA-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

Other Adverse Reactions Observed During the Premarketing Evaluation of LATUDA

Following is a list of adverse reactions reported by patients treated with LATUDA at multiple doses of ≥ 20 mg once daily within the premarketing database of 2905 patients with schizophrenia. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions listed in Table 14 or those that appear elsewhere in the LATUDA label are not included. Although the reactions reported occurred during treatment with LATUDA, they were not necessarily caused by it.

Reactions are further categorized by organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled studies appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 patients (rare).

Blood and Lymphatic System Disorders: Infrequent: anemia

Cardiac Disorders: Frequent: tachycardia; **Infrequent:** AV block 1st degree, angina pectoris, bradycardia

Ear and Labyrinth Disorders: Infrequent: vertigo

Eye Disorders: Frequent: blurred vision

Gastrointestinal Disorders: Frequent: abdominal pain, diarrhea; **Infrequent:** gastritis

General Disorders and Administrative Site Conditions: Rare: sudden death

Investigations: Frequent: CPK increased

Metabolism and Nutritional System Disorders: Frequent: decreased appetite

Musculoskeletal and Connective Tissue Disorders: Rare: rhabdomyolysis

Nervous System Disorders: Infrequent: cerebrovascular accident, dysarthria

Psychiatric Disorders: Infrequent: abnormal dreams, panic attack, sleep disorder

Renal and Urinary Disorders: Infrequent: dysuria; **Rare:** renal failure

Reproductive System and Breast Disorders: Infrequent: amenorrhea, dysmenorrhea; **Rare:** breast enlargement, breast pain, galactorrhea, erectile dysfunction

Skin and Subcutaneous Tissue Disorders: Frequent: rash, pruritus; **Rare:** angioedema

Vascular Disorders: Frequent: hypertension

Clinical Laboratory Changes

Schizophrenia

Serum Creatinine: In short-term, placebo-controlled trials, the mean change from Baseline in serum creatinine was +0.05 mg/dL for LATUDA-treated patients compared to +0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 3.0% (43/1453) of LATUDA-

treated patients and 1.6% (11/681) on placebo. The threshold for high creatinine value varied from > 0.79 to > 1.3 mg/dL based on the centralized laboratory definition for each study (Table 20).

Table 20: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in Schizophrenia Studies

Laboratory Parameter	Placebo (N=708)	LATUDA 20 mg/day (N=71)	LATUDA 40 mg/day (N=487)	LATUDA 80 mg/day (N=538)	LATUDA 120 mg/day (N=291)	LATUDA 160 mg/day (N=121)
Serum Creatinine Elevated	2%	1%	2%	2%	5%	7%

Bipolar Depression

Monotherapy

Serum Creatinine: In the short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the mean change from Baseline in serum creatinine was +0.01 mg/dL for LATUDA-treated patients compared to -0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 2.8% (9/322) of LATUDA-treated patients and 0.6% (1/162) on placebo (Table 21).

Table 21: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in a Monotherapy Bipolar Depression Study

Laboratory Parameter	Placebo (N=168)	LATUDA 20 to 60 mg/day (N=164)	LATUDA 80 to 120 mg/day (N=167)
Serum Creatinine Elevated	<1%	2%	4%

Adjunctive Therapy with Lithium or Valproate

Serum Creatinine: In short-term, placebo-controlled premarketing adjunctive studies for bipolar depression, the mean change from Baseline in serum creatinine was +0.04 mg/dL for LATUDA-treated patients compared to -0.01 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 4.3% (15/360) of LATUDA-treated patients and 1.6% (5/334) on placebo (Table 22).

Table 22: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adjunctive Therapy Bipolar Depression Studies

Laboratory Parameter	Placebo (N=334)	LATUDA 20 to 120 mg/day (N=360)
Serum Creatinine Elevated	2%	4%

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect LATUDA


LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see *Contraindications (4)*]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose [see *Dosage and Administration (2.5)*].

Lithium: It is not necessary to adjust the LATUDA dose when used concomitantly with lithium (Figure 1).

Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lurasidone, and lurasidone concentrations were not affected by valproate.

Grapefruit: Grapefruit and grapefruit juice should be avoided in patients taking LATUDA, since these may inhibit CYP3A4 and alter LATUDA concentrations [see *Dosage and Administration (2.5)*].


Figure 1: Impact of Other Drugs on LATUDA Pharmacokinetics



7.2 Potential for LATUDA to Affect Other Drugs

No adjustment is needed for lithium, substrates of P-gp, CYP3A4 (Figure 2) or valproate when coadministered with LATUDA.

Figure 2: Impact of LATUDA on Other Drugs



*Steady state lithium Ctrough on Day 4 vs Day 8 when lithium was coadministered with lurasidone at steady state

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B

Risk Summary

There are no adequate and well controlled studies of LATUDA use in pregnant women. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.

LATUDA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Human Data

Safe use of LATUDA during pregnancy or lactation has not been established; therefore, use of LATUDA in pregnancy, in nursing mothers, or in women of childbearing potential requires that the benefits of treatment be weighed against the possible risks to mother and child.

Animal Data

No adverse developmental effects were observed in a study in which pregnant rats were given lurasidone during the period of organogenesis and continuing through weaning at doses up to 10 mg/kg/day, which is approximately half of the maximum recommended human dose (MRHD) of 160 mg/day, based on mg/m² body surface area.

No teratogenic effects were seen in studies in which pregnant rats and rabbits were given lurasidone during the period of organogenesis at doses up to 25 and 50 mg/kg/day, respectively. These doses are 1.5- and 6-times, in rats and rabbits, respectively, the MRHD of 160 mg/day based on mg/m² body surface area.

8.3 Nursing Mothers

LATUDA was excreted in milk of rats during lactation. It is not known whether LATUDA or its metabolites are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, considering the risk of drug discontinuation to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use


Clinical studies with LATUDA did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients. In elderly patients with psychosis (65 to 85), LATUDA concentrations (20 mg/day) were similar to those in young subjects. It is unknown whether dose adjustment is necessary on the basis of age alone.

Elderly patients with dementia-related psychosis treated with LATUDA are at an increased risk of death compared to placebo. LATUDA is not approved for the treatment of patients with dementia-related psychosis [see *Boxed Warning*].

8.6 Other Patient Factors

The effect of intrinsic patient factors on the pharmacokinetics of LATUDA is presented in Figure 3.

Figure 3: Impact of Other Patient Factors on LATUDA Pharmacokinetics



*Compare to Caucasian

10 OVERDOSAGE

10.1 Human Experience

In premarketing clinical studies, accidental or intentional overdosage of LATUDA was identified in one patient who ingested an estimated 560 mg of LATUDA. This patient recovered without sequelae. This patient resumed LATUDA treatment for an additional two months.

10.2 Management of Overdosage

Consult a Certified Poison Control Center for up-to-date guidance and advice. There is no specific antidote to LATUDA, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Consider the possibility of multiple-drug overdose.

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of LATUDA. Similarly, the alpha-blocking properties of bretylium might be additive to those of LATUDA, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of LATUDA-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.


The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.



Manufactured for:
Sunovion Pharmaceuticals Inc.
Marlborough, MA 01752 USA

For Customer Service, call 1-888-394-7377.
For Medical Information, call 1-800-739-0565.
To report suspected adverse reactions, call 1-877-737-7226.

Revised: July 2013
901456R10

LATUDA and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of
Sumitomo Dainippon Pharma Co., Ltd.

© 2014 Sunovion Pharmaceuticals Inc.

About this Guide

In this book, you will find three main sections: Program, New Research and the Exhibits Guide. Use these sections to navigate the 2016 Annual Meeting and experience all the meeting has to offer.

Located within the Program, you will find a description of the various scientific session formats, along with a log where you can record your daily attendance for the purpose of obtaining CME credit for your activities. The Program is first organized by day, then by session start time, with formats and sessions listed alphabetically under those times. Individual meeting days and program tracks are color-coded to make navigating the Program simple and easy.

New Research lists the posters that will be presented at this meeting, organized numerically by session/day. There is a topic index at the end of the New Research section to assist you in finding the posters most interesting to you.

The Exhibits Guide contains a list of the exhibitors and a floor plan of the Exhibit Hall, along with information about the Product Theaters, Therapeutic Update, Career Fair and Publishers' Book Fair. Use this guide and the included exhibitor and author/presenter indices to navigate the exhibit hall and find precisely the booth you're looking for.

If you have any questions about this book or the scientific program, please feel free to stop by the Education Center, Escalator to B3-B4, Level 2, Georgia World Congress Center, and a member of the APA Administration will be happy to assist you. All members of the APA Administration will wear green badges.

Welcome to the Annual Meeting!



THE STRENGTH
TO HEAL *and*
address our Soldiers'
deepest wounds.

You'll provide care that makes a difference to our Soldiers and their Families. As a psychiatrist in the Army or Army Reserve, you'll practice in a collaborative environment, with no overhead or concerns about malpractice insurance. You'll experience the pride of serving your country and helping our Soldiers when they need it most.

Visit the Army Medical Recruiting Booth #716 to talk with an Army Psychiatrist or go to healthcare.goarmy.com/eh79 to learn more.



Table of Contents

About this Guide	1	Product Theaters	188
Welcome from the Scientific Program Committee, Steve H. Koh, M.D., M.B.A., M.P.H.	4	Therapeutic Update	197
Scientific Program Committee Photo	4	Exhibitors with Product/Service Descriptions	198
Welcome from the APA President, Renée L. Binder, M.D.	5	Exhibitors by Product/Service Listing ..	240
Welcome from the APA CEO and Medical Director, Saul Levin, M.D., M.P.A.	6	Career Fair and Publishers' Book Fair Exhibitors	244
Georgia Psychiatric Physicians Association ..	7	Numerical List of Exhibitors by Booth Number	246
General Information	11	Exhibit Hall Floor Plan	250
Shuttle Service	18	Presenters Index	259
Hotel Locations and City Map	19		
Special Acknowledgments	21		
Disclosure Index	23		
Program	55		
Format Descriptions	56		
Daily Attendance Log	58		
Saturday's Program	59		
Sunday's Program	73		
Monday's Program	97		
Tuesday's Program	123		
Wednesday's Program	141		
New Research	151		
Saturday's Poster Sessions	152		
Sunday's Poster Sessions	161		
Monday's Poster Sessions	163		
Tuesday's Poster Sessions	171		
Topic Index	180		
Exhibits Guide	183		
Exhibitor Sponsorship Acknowledgments ..	184		
General Information	186		

American Psychiatric Association

1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209

1-888-35-PSYCH or 1-703-907-7300
apa@psych.org | psychiatry.org/annualmeeting

 Join the conversation: #APAAM16

Welcome from the Scientific Program Committee

Dear Colleagues and Guests,

Welcome to Atlanta and to the 2016 Annual Meeting of the American Psychiatric Association. The meeting offers many opportunities for education, new experiences and connecting with colleagues.

Under the leadership of APA President Renée L. Binder, M.D., the Scientific Program Committee has planned a diverse educational program reflecting the presidential theme, "Psychiatry: Claiming Our Future." The APA Annual Meeting, the largest psychiatric meeting in the world, offers more than 400 sessions, more than 40 courses and up to 40 CME credits.

The Opening Session for the 2016 meeting will start at 4:30 p.m. on Sunday, May 15, and will feature a presentation by Atul Gawande, M.D., a renowned surgeon and researcher and author of *Being Mortal* and *The Checklist Manifesto*. We are honored to have Tom Frieden, M.D., M.P.H., Director of the Centers for Disease Control and Prevention, present the William C. Menninger Lecture at the Convocation of Distinguished Fellows on Monday, May 16, at 5:30 p.m. At 10:30 a.m. on Tuesday, May 17, General Robert B. Neller will address mental health issues in the Marine Corps, and on Tuesday, May 17, at 1:00 p.m. U.S. Supreme Court Justice Stephen Breyer will join the meeting in a special session to discuss connections between U.S. courts and global issues.

This year, the APA has once again partnered with the National Institute on Drug Abuse (NIDA) to present a series of sessions focusing on substance abuse issues. NIDA Director Nora D. Volkow, M.D., will chair the session on assessing marijuana risks in a changing environment, and NIDA Deputy Director Wilson Compton, M.D., will address integrated treatment of both tobacco addiction

and psychiatric illness. The Annual Meeting will also feature a symposium addressing important ways that the *DSM-5* and the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC), a new framework for classifying mental disorders in psychiatric research, are highly complementary and mutually necessary for the advancement of the field of psychiatry and its patients.

Several new formats will offer attendees a variety of learning experiences. A series of sessions on integrated behavioral health care will include a unique simulation experience where attendees will be able to simulate working on a collaborative care team. In our new Learning Lab format, interactive session participants will propose ideas for new apps, tools or systems that can improve the quality and delivery of mental health care. A panel of experts will respond to the proposals and hear reaction from the audience. A second learning lab will involve a mock trial with APA President Binder as an expert witness. A debate format will be used to explore the use of the controversial treatments ketamine and marijuana.

If you haven't already, I encourage you to download and use the APA Meetings app at psychiatry.org/app.

The app can help you make the most of your meeting experience: connect with colleagues, get the latest updates, find sessions by speaker and topic, plan your itinerary, and more.

Welcome to Atlanta!

Steve H. Koh, M.D., M.B.A., M.P.H.
Chair, Scientific Program Committee

Sitting Left to Right: *Tristan Gorrindo, M.D., Catherine C. Crone, M.D., Saul Levin, M.D., M.P.A., Robert M. McCarron, D.O., Philip R. Muskin, M.D., Linda Worley, M.D., Laura K. Kent, M.D.*

Standing Left to Right: *Steve H. Koh, M.D., M.B.A., M.P.H., Charles S. Price, M.D., Barry D. Sarvet, M.D., Godfrey D. Pearlson, M.D., Elisabeth B. Guthrie, M.D., Robert J. Boland, M.D., Julio Licinio, M.D., Michael F. Myers, M.D., Uyen-Khanh Quang-Dang, M.D., Lara J. Cox, M.D., Sidney Zisook, M.D., Anna L. Dickerman, M.D.*

Not Pictured: *Uche Achebe, M.D., Renée L. Binder, M.D., Josepha Cheong, M.D., Donald C. Goff, M.D., John Luo, M.D., Arnaldo Moreno, M.D., Edmond Hsin T. Pi, M.D., Nyapati R. Rao, M.D., Kenneth R. Silk, M.D., Andrea M. Brownridge, M.D., J.D., M.H.A., Kimberly A. Gordon, M.D., Stephen A. McLeod-Bryant, M.D., Daniel S. Pine, M.D., Jerrold F. Rosenbaum, M.D., Alan Schatzberg, M.D.*



Welcome from the APA President

Dear Colleagues and Guests,

Welcome to the 2016 APA Annual Meeting. Some of the best minds in psychiatry have gathered here in Atlanta to offer a modern, dynamic meeting for our members and guests.



The theme of this year's meeting is "Psychiatry: Claiming Our Future." It's an exciting time to be a psychiatrist.

Our passion for and commitment to providing high-quality, effective treatments for all persons with mental disorders will not change, but we must adapt to meet the demands of an ever more complex, evolving world. This means that education and professional growth are extremely important. At this year's meeting, many of our sessions will address some of the most pressing issues that face psychiatrists today, such as exploring new models of care and how psychiatry complements them, hearing about the latest research, and meeting the needs of our patients while leading professionally satisfying careers as medical leaders for mind, brain and body.

With that in mind, we are honored to have a group of very distinguished speakers lined up for this year's meeting. Our Opening Session will be followed by a special lecture by renowned surgeon and author Atul Gawande, M.D. He is the author of the highly praised *Complications*, *Better*, and *The Checklist Manifesto*, as well as his new book, *Being Mortal: Medicine and What Matters in the End*. Dr. Gawande is a MacArthur "Genius" Fellowship winner and is regarded by many as the definitive voice on improving health care.

U.S. Supreme Court Justice Stephen Breyer will also give a special session on Tuesday, May 17, at the Georgia World Congress Center. Before he was appointed by President Bill Clinton in 1994, Justice Breyer taught law for many years at Harvard Law School and the Kennedy School of Government. His published works include

books and articles about administrative law, economic regulation and constitutional law, such as *Regulation and Its Reform*, *Breaking the Vicious Circle: Toward Effective Risk Regulation*, *Active Liberty*, *Making Our Democracy Work: A Judge's View* and *The Court and the World*.

The William Menninger Memorial Lecture will be delivered by Tom Frieden, M.D., M.P.H., Director of the Centers for Disease Control and Prevention, at the Convocation of Distinguished Fellows on Monday, May 16. In his role as CDC Director, Dr. Frieden has worked to control health threats from infectious diseases, to respond to emergencies and to battle the leading causes of suffering and death in our nation and around the world.

We really are lucky to have such a distinguished panel of speakers and exhibitors all converging on Atlanta for our meeting. It is a vibrant, bustling metropolis with a rich history that makes it ripe for exploration. Those with a thirst for culture will be well served in Atlanta, which boasts a diverse palette of art, dining and historical attractions. Many of our members' hotels are right in the epicenter of Atlanta's culinary scene, which offers some of the best dining experiences available in all of the South.

I have to thank the Scientific Program Committee, led by chair Steve H. Koh, M.D., M.B.A., M.P.H., for the outstanding work they have done in developing the programs and sessions at the meeting. Between our excellent scientific program and the diverse offering of cultural attractions from our host city, I am certain that the 2016 APA Annual Meeting will be a truly great experience for all who attend.

I look forward to seeing you at the meeting and sharing all of the education and excitement it has to offer.

Renée L. Binder, M.D.
President, American Psychiatric Association

Welcome from the APA CEO and Medical Director

Dear Colleagues and Guests,

Welcome to Atlanta for the 2016 Annual Meeting of the American Psychiatric Association.

The meeting offers an extensive educational program, featuring the latest scientific research, advances in clinical practice, and innovative, interactive sessions that will both enhance knowledge and be enjoyable in the process. In addition, the meeting provides a myriad of special events and networking opportunities.

Please join me in honoring APA distinguished fellows, distinguished life fellows, international fellows, award winners, and others at the Convocation of Distinguished Fellows, as well as at the different sessions where awardees will give a synopsis of their careers and their work leading up to an award.

This year we are honored to have Tom Frieden, M.D., M.P.H., Director of the Centers for Disease Control and Prevention (CDC), presenting the William C. Menninger Lecture at the Convocation. The Convocation will take place on Monday, May 16, at 5:30 p.m. at the Georgia World Congress Center.

Other award lectures that will be presented at the meeting include:

- ▶ Simon Bolivar Award Lecture — Gabriel de Erasquin, M.D., Ph.D.
- ▶ George Tarjan Award Lecture — Emmanuel Cassimatis, M.D.
- ▶ Solomon Carter Fuller Award Lecture — Eduardo Bonilla-Silva, Ph.D.
- ▶ Oskar Pfister Award Lecture — James W. Lomax, M.D.

This year's American Psychiatric Association Foundation's annual benefit to support its public education and research initiatives will be held on Saturday, May 14, from 7 p.m. to 10 p.m. at the famous Georgia Aquarium in downtown Atlanta. This special



event at the Oceans Ballroom promises a delightful look at two whale exhibitions through a private window, as well as a program honoring the 2016 recipients of the Awards for Advancing Minority Mental Health. (Ticket required.)

Additionally, we will bid a farewell to Paul Burke, M.A., the executive director of the APA Foundation (APAF), who is retiring at the end of June. Come to the reception to bid him a bon voyage as he moves into his retirement and thank him for his service to the APA, the APAF, and as an amazing professional who has helped increase the visibility of mental health and mental illness in the nation.

A special series of scientific sessions have been developed especially for residents this year. MindGames, the ever-popular Jeopardy-like competition for residents, makes its return. It's a great way for residents to go head-to-head with each other on patient care, medical knowledge and psychiatric history while earning bragging rights for their program.

If you haven't done so already, I encourage you to download the APA Meetings app for easy access to program information and the latest updates and alerts during the meeting. The app has been completely revamped from last year's meeting, and boasts a treasure trove of content in a very user-friendly package. Download the app today at psychiatry.org/app.

If you're on Twitter or Facebook, be sure to share your thoughts and experiences on the meeting by using #APAAM16.

Thank you, and welcome to Atlanta!

Saul Levin, M.D., M.P.A.
*CEO and Medical Director,
American Psychiatric Association*

Georgia Psychiatric Physicians Association

Dear Colleagues and Guests,

On behalf of the Georgia Psychiatric Physicians Association (GPPA), I am thrilled to welcome you to the state of Georgia. A district branch of the APA, our organization envisions a Georgia where quality psychiatric care is accessible to all. GPPA is committed to promoting the advancement of quality psychiatric practice and mental health through education, advocacy and engagement with the Georgia community.



As APA members, we are bound together by our common dedication to lifelong learning, and as you expand your knowledge during our 2016 Annual Meeting, I hope that you find some time to enjoy the city.

Atlanta's symbol is the Egyptian mythological phoenix, because it rose from the ashes to transform into an international gateway city with a rich cultural history. Atlanta blends traditional Southern charm with a diverse population: more than 5.5 million people live in the Atlanta metro area, and the city is more racially diverse than the nation as a whole and is the fastest-growing city in the United States.

An economic engine of the Southeast, Atlanta has been called the "Silicon Valley of the South" and ranks

among *fDi's* top 10 "American Cities of the Future." Considered a national leader in health care technology, more than 300 bioscience companies have operations in Atlanta. We are home to the Centers for Disease Control and Prevention (CDC), and research facilities at Emory University, Georgia State University, Georgia Institute of Technology, Morehouse School of Medicine, University of Georgia and Georgia Health Sciences University are abundant and thriving.

Atlanta's cultural tapestry is particularly informed by its history as a Civil Rights landmark. The city boasts a wide selection of museums, a thriving theatre scene and three professional sports teams, all within a cityscape that blends seamlessly with nature—Atlanta ranks first among major American cities in tree coverage at 54%. Whether you like to be indoors or outdoors, Atlanta has something for you.

Once again, on behalf of the GPPA, I would like to extend our sincerest welcome, and I wish you an enlightening and memorable experience.

Kevin J. Winders, M.D.
*President, Georgia Psychiatric
Physicians Association*





APA Foundation Annual Benefit

at the Annual Meeting

Join us at one of world's most magical aquariums in recognition of the fields of psychiatry and mental health. Snap selfies with beluga whales, whale sharks and manta rays as you network with peers and colleagues. Let the atmosphere take you away—all while supporting a very important cause.

Exploring New Depths

- > Take delight in our private window to two incredible whale and sea life exhibits
- > Enjoy delicious food and beverages
- > Help raise funds for the APA Foundation's public education, fellowships, grants, research and awards programs

Oceans Ballroom at the Georgia Aquarium

Saturday | May 14, 2016 | 7 - 10 p.m.

Tickets:

\$125, Purchase at apafdn.org/benefit

Questions?

Email: lmcclenathan@psych.org
Or visit APA Central

AMERICAN
PSYCHIATRIC
ASSOCIATION
FOUNDATION





How do you sleep?

**See how your sleep
compares to others**

Visit Booth 837



Copyright © 2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
All rights reserved. NEUR-1177198-0001 04/16

Visit booth #1300

McLean Hospital

Unsurpassed in compassionate care, innovative research, and exceptional education

Discuss the latest advances in psychiatry with McLean's "Top Docs."



Brent P. Forester, MD, MSc

Chief of the Division of Geriatric Psychiatry

Sunday, May 15, 2016 ■ Noon



Kerry J. Ressler, MD, PhD

Chief Scientific Officer

Monday, May 16, 2016 ■ 10 am



Roger D. Weiss, MD

Chief of the Division of Alcohol and Drug Abuse

Monday, May 16, 2016 ■ Noon



John Gunderson, MD

Founder of the McLean Borderline Center

Monday, May 16, 2016 ■ Noon



McLean HOSPITAL
HARVARD MEDICAL SCHOOL AFFILIATE



HARVARD MEDICAL SCHOOL
TEACHING HOSPITAL

844.425.8962

mcleanhospital.org

U.S. News & World Report consistently ranks McLean Hospital the #1 freestanding psychiatric hospital in the country.

General Information

Key Locations in the Georgia World Congress Center

2017 Annual Meeting Booth (San Diego, CA) . . . Main Lobby, International Boulevard Entrance	Exhibits/Publishers' Book Fair Exhibit Hall B3-B4, Level 1
APA Art Association Exhibit Water Feature Wall, Level 2	First Aid Room I Exhibit Hall B3-B4 Level 1
APA Bookstore Exhibit Hall B3-B4, Level 1	First Aid Room II Room B410 Level 4
APA Cafés Exhibit Hall B3-B4, Level 1	International Housing Desk (in Registration) Exhibit Hall B3-B4, Level 1
APA Central Exhibit Hall B3-B4, Level 1	Lost and Found Room B204, Level 2
<i>APA Daily</i> Room B317, Level 3	Luggage/Coat Check Registration Hall, Main Lobby, International Boulevard Entrance
APA Education Center Escalator to B3-B4, Level 2	Meditation Zone Room B319, Level 3
APA Housing Desk Main Lobby, International Boulevard Entrance	Meetings Office Room B204, Level 2
APA Information Center Main Lobby, International Boulevard Entrance	Mothers Room Room B205, Level 2
APA JobCentral Exhibit Hall B3-B4, Level 1	On Demand Sales Exhibit Hall B3-B4, Level 1 and Escalator to B3-B4, Level 2
APA Newsroom Room B305, Level 3	<i>Psychiatric News</i> Room B317, Level 3
Brain Breaks (in the APA Education Center) Escalator to B3-B4, Level 2	Registration Exhibit Hall B3-B4, Level 1 and Marquis Fountain, Marquis Level, Marriott Marquis
CME Certificate of Attendance and Evaluation . . . Escalator to B3-B4, Level 2	Scientific Program Office . . . Room B210, Level 2
Exhibitor Registration Exhibit Hall B3-B4, Level 1	Shuttle Bus Desk Curbside, Building A/B Entrance



APA Central

All attendees are invited to visit APA Central in the Exhibit Hall to learn how APA provides medical leadership for mind, brain and body. Representatives from the APA are available to answer your questions.

Not an APA Member?

Discover the value of APA membership. Join onsite through the Rebate Program and save up to \$640. The Rebate Program is open to fully trained psychiatrists, residents/fellows, and international psychiatrists and residents who paid the full-program or resident non-member Annual Meeting registration fee. Stop by APA Central for more details and to apply.

Find a Psychiatrist/ Professional Headshots

APA's Find a Psychiatrist database helps connect patients to APA members accepting new patients. Visit the Find a Psychiatrist area in APA Central to opt-in to the directory and have your professional headshot taken for your Find a Psychiatrist profile and other professional uses. All are welcome to participate.

APA Foundation

The APA Foundation has two goals: 1) support APA members through grants, fellowships and awards; and 2) embed programs across the nation that reduce stigma and foster early identification and treatment for mental illnesses. This means that the APA Foundation is *your* foundation and one of the strongest public outreach forums for mental health in the country. Learn about programs that are making a difference in our nation's most pressing mental health issues and make a donation to invest in the future of psychiatry.

APAPAC & Congressional Advocacy Network

Together, we're making a difference to boost psychiatry, evidence-based treatments, reimbursement and patient care. Members can get involved through the American Psychiatric Association Political Action Committee (APAPAC) and the Congressional Advocacy Network (CAN). APAPAC identifies and makes political contributions to candidates' campaigns for federal office who are supportive of mental health issues affecting our specialty and our patients, through the generous contributions of members. The Congressional Advocacy Network helps to develop, train and energize a national network of psychiatrists committed to building personal

relationships with members of Congress to help educate them on mental health issues and the profession of psychiatry. Please stop by APA Central to learn how you can get involved.

APA JobCentral

Looking for your next career move, or need to make a hire? Visit the APA JobCentral booth located in APA Central to discover available jobs across the country or post a position. A representative will be available to demonstrate the user-friendly system and assist you. Using the Event Connection tool, candidates and employers can flag their resume and/or posting to show their attendance at this year's meeting. New this year, be sure to stop by and pick up a copy of the 2016 APA JobCentral Recruitment Guide. Visit online at jobs.psychiatry.org.

Lunch-and-Learn Sessions for Residents and Early Career Psychiatrists

Grab your lunch and join us for daily sessions on emerging topics:

Topic:	Date:	Location:
Global Mental Health	Saturday, May 14 Noon - 1:00 p.m.	Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall
Organized Medicine and Your Career	Saturday, May 14 4:15 p.m. - 5:15 p.m.	Resident Resource Center, Room A310, Level 3
Managing Personal Finances and Student Loans	Sunday, May 15 Noon - 1:00 p.m.	Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall
Marketing Yourself and Finding Opportunities in Your Early Career	Monday, May 16 Noon - 1:00 p.m.	Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall
Tips for Your First Job Out of Residency	Tuesday, May 17 Noon - 1:00 p.m.	Resident and Early Career Psychiatrist Hub, APA Central in the Exhibit Hall

Connect with Your Resident and Fellow Colleagues

The meeting may be over for the day, but the fun is just beginning! The Resident and Fellow Caucus will be hosting nightly happy hours at nearby locations where you can network and mingle with your colleagues. New to the Annual Meeting? Resident and Fellow leaders will be on hand to welcome you. Stop by the Resident Resource Center (Room A310, Level 3) or APA Central for more details.

General Information

APA Art Association Exhibit

Water Feature Wall, Level 2

Sunday	10:00 a.m. – 4:00 p.m.
Monday – Tuesday	10:00 a.m. – 5:00 p.m.
Wednesday	10:00 a.m. – 2:00 p.m.

This exhibit includes paintings, photography, ceramics and crafts created by APA members and/or their significant others. Stop by for information on joining the APA Art Association.

APA Bookstore

Exhibit Hall B3-B4, Level 1

Saturday	9:00 a.m. – 4:00 p.m.
Sunday – Tuesday	10:00 a.m. – 4:00 p.m.

Stop by the APA Bookstore to see the latest books, journals and online content. You'll find new bestselling titles and classic reference works on every area of psychiatry, including the *DSM-5*. APA members can take advantage of a 20% discount, and APA resident-fellow members receive a 25% discount on all book purchases. Special member prices are available on subscription products.

Administration from APA's CME journal *Focus* will also be available at booth 1528 to answer questions about this publication.

APA Daily and Psychiatric News

The *APA Daily* is the official Annual Meeting publication that highlights events, news, special sessions, and other meeting attractions, as well as provides information on the host city of Atlanta. Print copies of the *APA Daily* are available at the Georgia World Congress Center and will be delivered to meeting registrants staying at APA's official hotels. A digital version will be sent to meeting registrants via the APA Meetings app and email. *Psychiatric News* will also cover Annual Meeting news, and the latest issue will be available onsite at the Georgia World Congress Center.

APA Foundation Benefit

Saturday, May 14 7:00 p.m. – 10:00 p.m.
Spend an evening with some of the biggest names in psychiatry and fish in the sea! The American Psychiatric Association Foundation will host its annual benefit event at the Georgia Aquarium. Be transported to an underwater world as you dine alongside beluga whales, whale sharks and other sea life, viewing their splendor from the largest aquarium windows in North America.

Tickets are required and are available for purchase at APA Central, or visit apafdn.org for more information.

APA Meetings App

The new APA Meetings app gives you all the information you need to navigate the Annual Meeting.

Search the scientific program by day, format, topic or speaker. Use maps to find meeting spaces and the Exhibit Hall. Receive real-time alerts from APA and provide feedback through surveys.

To download the app for Apple and Android devices, visit the App Store or Google Play and search for "APA Meetings" or visit psychiatry.org/app from your mobile device.

Continuing Medical Education

Certificate of Attendance and Evaluation

The general meeting evaluation and CME certificate of attendance are available at the CME Certificate of Attendance Booth located in the Education Center, Escalator to B3-B4, Level 2, Georgia World Congress Center, or online at psychiatry.org/annualmeetingcme. The website will be available during the meeting and for three months afterward. Participants can claim CME certificates on or before August 18, 2016. You will need your badge number to access the evaluation and obtain your certificate.

Educational Objectives

By participating in this meeting, you will

- ▶ Describe new research findings in psychiatry and neuroscience and how they may impact practice;
- ▶ Apply quality improvement strategies to improve clinical care;
- ▶ Provide culturally competent care for diverse populations;
- ▶ Describe the utility of psychotherapeutic and pharmacological treatment options;
- ▶ Integrate knowledge of current psychiatry into discussions with patients; and
- ▶ Identify barriers to care, including health service delivery issues.

Accreditation

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide

General Information

continuing medical education for physicians. The APA designates this live activity for a maximum of *40 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unless otherwise specified, scientific sessions on the Annual Meeting program meet the criteria for *AMA PRA Category 1 Credit™*. Sessions in the following program formats are designated as Category 1: the **“advances in...” series, case conferences, courses and master courses, FOCUS Live!, forums, lectures, symposia and presidential symposia, scientific and clinical reports, seminars, interactive sessions and workshops, and media workshops.**

Poster sessions are NOT designated for *AMA PRA Category 1 Credit™*.

Please note that the scientific program schedule is subject to change. Please see the *APA Daily* or the *APA Meetings* app for details on changes to the scientific program.

Presenter Changes

We understand that emergencies and unforeseen circumstances can necessitate a last-minute presenter change. If you need to replace, add or remove a presenter for your scientific session, please contact the Office of Scientific Programs, located in the Education Center, Escalator to B3-B4, Level 2, Georgia World Congress Center, no less than two (2) hours in advance of the start of your session.

Attendance

Scientific sessions are open to all Annual Meeting registrants with the exception of case conferences, which are open to APA members only. Courses and master courses require a ticket and an additional fee.

To document CME credit earned at the Annual Meeting, participants should maintain a list of sessions they attend. Credit is earned on an hour-for-hour basis. A daily attendance log is provided in this book for tracking your sessions and credits.

Education Center

Escalator to B3-B4, Level 2

Saturday – Wednesday 8:00 a.m. – 5:30 p.m.

Exhibitor Registration

Exhibit Hall B3-B4, Level 1

Friday 8:00 a.m. – 6:00 p.m.

Saturday – Tuesday 7:30 a.m. – 5:00 p.m.

Registered exhibitors will receive red badges that will permit access only to his/her exhibit booth in the Exhibit Hall and to ride the APA shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

Exhibits (Commercial and Educational)

Exhibit Hall B3-B4, Level 1

Sunday – Tuesday 10:00 a.m. – 4:00 p.m.

All exhibits in the Exhibit Hall close at 4:00 p.m. on Tuesday.

First Aid

First Aid Room I, Exhibit Hall B3-B4, Level 1

Tuesday (May 10) –

Wednesday (May 18) 7:00 a.m. – 6:00 p.m.

First Aid Room II, Room B410, Level 4

Friday (May 13) –

Wednesday (May 18) 7:00 a.m. – 6:00 p.m.

International Pavilion

Exhibit Hall B3-B4, Level 1

Sunday – Tuesday 10:00 a.m. – 4:00 p.m.

Learning Lab

The Learning Lab introduces an exciting new way to learn at the APA Annual Meeting. Every session in the Learning Lab transforms learning through collaboration, rich discussion around issues impacting psychiatry, and hands-on learning. Sessions include a mock trial on risk management, expert debates on ketamine and cannabis, collaborative care simulation games, a shark tank-style psychiatric innovation lab, a resident leadership boot camp and more.

General Information

Attendees who bring their own devices to the Learning Lab will get the most out of this experience. Please bring your laptops, tablets and smart phones to engage with the facilitators, participate in polling and interact with other attendees through group work.

Learning Lab 1

Room B211-212, Level 2

- ▶ Sunday, May 15, at 1:00 p.m. **Psychiatry Innovation Lab, Where Quality Improvement Meets Silicon Valley: Pitch and Idea. Build a Team. Design a Venture** with Nina Vasan, M.D.
- ▶ Monday, May 16, at 9:00 a.m. **Mock Trial: Lessons for Psychiatrists From the Bar and Risk Management** with Kristen Lambert, J.D., M.S.W.
- ▶ Wednesday, May 18, at 9:00 a.m. **Collaborative Care Lab: Experience the Newest Way to Practice** with Erik Vanderlip, M.D., M.P.H.

Learning Lab 2

Room B207-208, Level 2

- ▶ Monday, May 16, at 9:00 a.m. **A Leadership Boot Camp for Residents and Fellows** with Laura Roberts, M.D., M.A.
- ▶ Monday, May 16, at 1:30 p.m. **FOCUS Live! OCD and Related Disorders: Diagnosis to Treatment** with Michele Pato, M.D., and Katherine Phillips, M.D.
- ▶ Monday, May 16, at 3:30 p.m. **FOCUS Live! Understanding the Evidence for Off-Label Use of Atypical Antipsychotics** with David Fogelson, M.D., and Joel Yager, M.D.

Be sure to check the APA Meetings app for a full schedule of Learning Lab events.

Lost and Found

Room B204, Level 2

Friday	8:30 a.m. – 5:00 p.m.
Saturday	6:30 a.m. – 5:30 p.m.
Sunday – Wednesday	7:00 a.m. – 5:30 p.m.

Meditation Zone

Room B319, Level 3

Saturday-Wednesday	7:30 a.m. – 5:00 p.m.
---------------------------	-----------------------

Stop in and refresh and renew. Soft lighting and soft seating provided. Bring your own yoga mat. No talking and please remember to turn off your cell phone before entering.

Meetings Office

Room B204, Level 2

Friday	8:30 a.m. – 5:00 p.m.
Saturday	6:30 a.m. – 5:30 p.m.
Sunday – Wednesday	7:00 a.m. – 5:30 p.m.

Members of the APA Administration located in the Meetings Office are in charge of the logistics for the meeting. Lost and found is also located in this office.

Mothers Room

Room B205, Level 2

Friday	8:00 a.m. – 5:00 p.m.
Saturday-Wednesday	7:30 a.m. – 5:00 p.m.

Please first stop in Room B204 to obtain a key. Private area with changing table and comfortable seating.

Newsroom and Communications Office

Room B305, Level 3

Friday	3:00 p.m. – 5:00 p.m.
Saturday – Tuesday	8:00 a.m. – 5:00 p.m.
Wednesday	8:00 a.m. – 2:00 p.m.

These rooms are for the use of registered press and credentialed public relations representatives only.

On Demand Sales

Exhibit Hall B3-B4, Level 1

Friday	Noon – 6:00 p.m.
Saturday-Tuesday	7:30 a.m.–5:00 p.m.

Education Center, Escalator to B3-B4, Level 2

Saturday-Wednesday	7:30 a.m.–5:30 p.m.
---------------------------	---------------------

APA Annual Meeting On Demand includes over 300 hours of educational content from the Annual Meeting. Content is available online within 24 hours, on USB drive and through mobile streaming. Additional CME is available.

Publishers' Book Fair/Career Fair

Exhibit Hall B3-B4, Level 1

Saturday	9:00 a.m. – 4:00 p.m.
Sunday – Tuesday	10:00 a.m. – 4:00 p.m.

General Information

Registration

Admission to all sessions is by registration badge only. A separate fee and ticket purchase is required for all courses.

Exhibit Hall B3-B4, Level 1

Friday Noon – 6:00 p.m.

Exhibit Hall B3-B4, Level 1

Saturday – Wednesday* 7:30 a.m. – 5:00 p.m.

***Escalator to B3-B4, Level 2 (Wednesday Only)**

Marriott Marquis

Marquis Fountain, Marquis Level

Friday Noon – 6:00 p.m.

Saturday – Tuesday 7:30 a.m. – 5:00 p.m.

The registration fee covers admission to all sessions (except courses) and shuttle buses, and includes a badge, \$10.00 food voucher (for paid registrants only) and copy of the *Guide to the 2016 Annual Meeting*. The *Syllabus and Proceedings*, the *Guide and Poster Abstracts* will be published online for downloading.

Registration badges are required for all sessions and the Exhibit Hall. Only an APA member badge will admit you to the Business Meeting. Badge Color Codes: Blue=Members; Yellow=Nonmembers; Silver=Press; Red=Exhibitors; Green=APA Administration; and Clear=Temporary Personnel.

Course tickets not sold in advance will be available for purchase onsite at Registration beginning at Noon on Friday. You must be registered for the meeting before you can enroll in courses.

Scientific Program Office

Education Center, Escalator to Exhibit Hall B3-B4, Level 2

Friday Noon – 6:00 p.m.

Saturday – Wednesday 7:30 a.m. – 5:00 p.m.

Come to this office if you have questions about 1) scientific sessions listed in the *Program* or *Syllabus*; 2) adding audiovisual equipment to scientific sessions; 3) scientific program changes; 4) submitting a scientific session for the 2017 Annual Meeting; or 5) the 2016 IPS: Mental Health Services Conference.

Scientific Session Capacity Guidelines

If overcrowding occurs in a scientific session, we ask for your assistance in abiding by the following guidelines so that all in attendance can benefit.

- ▶ Take a seat as close to the front of the room as possible.
- ▶ Move to the center of the row and fill all seats so that chairs are available near the aisles for additional attendees.
- ▶ Don't stand or sit in the aisles or lean against walls. The Fire Marshall may shut down an overcrowded session; therefore, please either find a seat or choose another session to attend.

Shuttle Bus Desk and Service

Curbside Building A/B Entrance

Pick up at hotels

Saturday, May 14 – Wednesday, May 18 7:00 a.m.

Last departure from the Georgia World Congress Center

Saturday, May 14 5:30 p.m.

Sunday, May 15 7:30 p.m.

Monday, May 16 7:30 p.m.

Tuesday, May 17 5:30 p.m.

Wednesday, May 18 5:30 p.m.

A 2016 meeting badge is required to ride on the courtesy shuttle bus. The Georgia World Congress Center will serve as the “hub” for all shuttle bus routes. A detailed shuttle bus schedule will be available onsite and will be posted in the lobbies of participating hotels.

Smoking Policy

Smoking is not allowed anywhere in the Georgia World Congress Center.

General Information

Audio and Visual Reproduction Policies

Registrants are not permitted to photograph or video record any session, as the intrusive nature of recording may be disruptive. This includes photographs taken with cell phone cameras. Audio recording is permitted for personal use only. Registrants are welcome to use their own small, portable audio recorders to record any session except case conferences or unless prohibited by the presenters. Larger professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA press policies. Media will be identified with silver badges, and approved equipment will be identified with APA Newsroom stickers. The APA has authorized a professional taping firm, which will be clearly identified, to record sessions.

Wi-Fi

Attendees will have free wireless access in all public spaces and meeting rooms.

There is also free wireless in the two APA Cafés (Exhibit Hall B3-B4, Level 1, open during exhibit hours), which also include free coffee and charging stations for laptops, cell phones and other devices. The Cafés are supported by Takeda Pharmaceuticals USA Inc. and Lundbeck Inc.

Future APA Meetings

APA Annual Meetings

May 20 – 24, 2017	San Diego, CA
May 5 – 9, 2018	New York, NY
May 18 – 22, 2019	San Francisco, CA

IPS: The Mental Health Services Conference

October 6 – 9, 2016	Washington, DC
October 19 – 22, 2017	New Orleans, LA
October 4 – 7, 2018	Chicago, IL

The *Preliminary Program* for the 2016 IPS: The Mental Health Services Conference, which includes registration, housing, air travel and program information, will be available in June on the web at psychiatry.org.

INJECTING A ONCE-MONTHLY LAI INTO THE SCHIZOPHRENIA TREATMENT CONVERSATION

LAI=LONG-ACTING INJECTABLE.

FEATURED FACULTY

Henry A. Nasrallah, MD
 Sydney W. Souers Endowed Chair,
 Chairman,
 Professor,
 Department of Neurology and Psychiatry
 Saint Louis University
 St. Louis, Missouri

Rebecca S. Roma, MD
 Medical Director,
 Community Treatment Team Program
 Assertive Community Treatment Teams
 Mercy Behavioral Health and UPMC Mercy
 Pittsburgh, Pennsylvania

LOCATION

Georgia World Congress Center
 Product Theater 2—Booth #1913
 285 Andrew Young International
 Boulevard Northwest
 Atlanta, Georgia 30313

AGENDA

SUNDAY, MAY 15, 2016
 2:00PM EDT | Presentation
 2:50PM EDT | Question and Answer Session

Dr. Nasrallah and Dr. Roma are paid consultants for Otsuka America Pharmaceutical, Inc. and Lundbeck.

The intended audience for this program is healthcare professionals involved in the treatment of patients with schizophrenia.

The Industry Product Theater's content and the views expressed therein are those of the supporting company and not of APA or APAF. This program is not part of the scientific program and is not providing CME credits.

This program is sponsored by Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck LLC (Lundbeck) and is not a CME activity.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this educational program is limited to only Healthcare Professionals (Physicians, Nurse Practitioners, Physician Assistants, RNs, Clinical Pharmacists, Social Workers). Accordingly, attendance by guests or spouses is not permitted.

This is a promotional program and no CME credits are offered. This educational program may include the provision of a modest meal. Otsuka and Lundbeck do not offer such a meal to healthcare professionals (HCPs) whose institutions prohibit such hospitality, nor do Otsuka and Lundbeck offer a meal where federal or state laws (e.g., Vermont and Minnesota) limit an HCP's ability to accept such a meal. Accordingly, please consult your legal or ethics advisor regarding any applicable limitation before attending this educational program. If you are licensed to practice in a state where meals are either prohibited and/or restricted and you accept a meal, you understand that you will be required to reimburse Otsuka for the cost of this meal.

Please note that Otsuka and Lundbeck are required to report the value of a provided meal pursuant to applicable federal and/or state laws.

Shuttle Service

The Georgia World Congress Center will operate as the “hub” for the APA shuttle bus system. All routes will begin and end there. The shuttle will operate during the following days and times:



Route 1 – Blue

Westin	Curbside on Spring Street
Doubletree by Hilton Downtown	At Westin
Holiday Inn Downtown	At Westin
Holiday Inn Express	At Westin



Route 2 – Red

Ritz Carlton	Across the street on Ellis Street
Courtyard Marriott Downtown	At Ritz Carlton
Ellis Hotel	At Ritz Carlton
Sheraton Atlanta	Across the street on Andrew Young International Boulevard



Route 3 – Green

Marriott Marquis	Across the street on Baker at Peachtree Center
-------------------------	--



Route 4 – Orange

Hilton	Across the street on John Portman at Courtland Street
Hyatt Regency	Across the street on Baker at Peachtree Street



Route 5 – Purple

Aloft Atlanta Downtown	Curbside on Baker Street
W Downtown	Across the street on Spring Street

Shuttle information signs will be posted in the lobby of each shuttle hotel. Check the sign in your hotel lobby for additional information and changes. For questions regarding the shuttle or to make an advance reservation for a wheelchair accessible shuttle, please see the shuttle supervisor at the Georgia World Congress Center during shuttle hours.

Hours of Operation:

Saturday, May 14
7:00 a.m. – 5:30 p.m.

Sunday, May 15
7:00 a.m. – 7:30 p.m.

Monday, May 16
7:00 a.m. – 7:30 p.m.

Tuesday, May 17
7:00 a.m. – 5:30 p.m.

Wednesday, May 18
7:00 a.m. – 5:30 p.m.

Walking Distance Hotels, NOT on shuttle bus routes:


**Embassy Suites
Centennial Park**

Glenn Hotel

Hilton Garden Inn

Omni

Hotel Map



Hotel Names and Locations

- | | |
|---|--|
| 1. Aloft, 300 Spring Street, NW | 9. Hilton Garden Inn, 275 Baker Street |
| 2. Marriot Marquis, 265 Peachtree Center Avenue | 10. Holiday Inn Downtown, 101 Andrew Young International Boulevard, NW |
| 3. Courtyard Marriott Downtown, 133 Carnegie Way | 11. Holiday Inn Express, 111 Cone Street, NW |
| 4. Doubletree by Hilton Downtown, 160 Spring Street, NW | 12. Hyatt Regency, 265 Peachtree, NE |
| 5. The Glenn Hotel, 110 Marietta Street, NW | 13. Omni, 100 CNN Center |
| 6. Embassy Suites Centennial Park, 267 Marietta Street | 14. Ritz Carlton, 181 Peachtree Street |
| 7. Glenn Hotel, 110 Marietta Street, NW | 15. Sheraton Atlanta, 165 Courtland Street |
| 8. Hilton, 255 Courtland Street, NE | 16. W Downtown, 45 Ivan Allen Boulevard |
| | 17. Westin, 210 Peachtree Street, NE |

American Professional Agency, Inc.

The APA-endorsed Psychiatrists
Medical Liability Insurance Program

Please Visit us at

Booth #1217

to learn more about our Risk Management Services



www.ApaMalpractice.com

(877) 740-1777

Special Acknowledgments

American Association of Chairs of Departments of Psychiatry: support of the APAF/AACDP Research Mentorship Award.

American Psychiatric Association Foundation: support of the Child and Adolescent Psychiatry Fellowship; Public Psychiatry Fellowship; Diversity Leadership Fellowship and Jeanne Spurlock Congressional Fellowship; American Psychiatric Leadership Fellowship; and the David Mrazek Memorial Lecture Endowment.

Association of Women Psychiatrists: co-support of the Alexandra Symonds Award Lecture.

Estate of Agnes Purcell McGavin: support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent Psychiatry, and for Prevention.

Estate of Dorothy C. Kempf: support of Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

Estate of Kun-Po Soo, M.D. Ph.D.: support of the Kun-Po Soo Award.

Helen Johnson-Leipold and Assurex Health: principal support of the Mrazek Memorial Lecture.

Lilly USA LLC: co-support of the Simon Bolivar Award.

American College of Neuropsychopharmacology and Society of Biological Psychiatry: the Research Colloquium for Junior Investigators.

Penn/Scattergood Ethics Program: recognized for its collaboration with the 2016 Scientific Program Committee and APA Ethics Committee chairperson in the development of an ethics track for the 2016 Annual Meeting.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program and support of the APA's HIV-related education programs and materials.

The Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for Persons with Mental Retardation/Developmental Disabilities.



Understanding Parkinson's Disease Psychosis and Its Treatment

DATE & TIME

Sunday, May 15, 2016 · 1:00 PM-2:00 PM · with Q/A (Box lunch included)

LOCATION

Atlanta, GA · Georgia World Congress Center · Exhibit Hall B3/4, Level 1

PRESENTED BY



Daniel E. Kremens, MD, JD
Associate Professor of Neurology
Co-Director, Parkinson's Disease and
Movement Disorders
Department of Neurology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA



Henry A. Nasrallah, MD
The Sydney W. Souers Endowed Chair
Professor & Chairman
Department of Neurology & Psychiatry
Saint Louis University School of Medicine
St. Louis, MO

PROGRAM OVERVIEW AND LEARNING OBJECTIVES

Parkinson's disease (PD), a progressive neurodegenerative disease that affects approximately 1 million Americans, is primarily considered to be a movement disorder.^{1,2} PD psychosis is a common non-motor symptom that affects more than half of patients with PD over the course of their disease.³ Non-motor symptoms are common in PD and may have a greater impact on quality of life than motor symptoms.^{1,4}

Please join us for a program to review:

- What PD psychosis is and its diagnostic criteria
- The prevalence of PD psychosis
- The impact of PD psychosis on both patients and caregivers
- How PD psychosis is treated

References: **1.** Jankovic J. Parkinson's disease: clinical features and diagnosis. *J Neural Neurosurg Psychiatry*. 2008;79:368-376. **2.** Parkinson's Disease Foundation. Statistics on Parkinson's. Available at: http://www.pdf.org/en/parkinson_statistics. Accessed December 1, 2014. **3.** Forsaa EB, et al. A 12-year population-based study of psychosis in Parkinson disease. *Arch Neurol*. 2010;67:996-1001. **4.** Bernal-Pacheco O, et al. Nonmotor manifestations in Parkinson disease. *Neurologist*. 2012;18:1-16.

SEATING IS AVAILABLE ON A FIRST-COME, FIRST-SERVED BASIS; NO PRE-REGISTRATION REQUIRED.

Learn more about advances in PD Psychosis at booth #1437

Disclosure Index

American Psychiatric Association Continuing Medical Education Policy on Full Disclosure

The American Psychiatric Association requires disclosure by all program planners and presenters at CME activities of any financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the educational activity. A “financial interest” may include, but is not limited to: being an employee and/or being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An “affiliation” may include holding a position on an advisory committee, speakers’ bureau or some other role or benefit to a commercial interest.

In compliance with the ACCME’s Standards for Commercial Support, the APA has a management of conflict (MCI) process for all CME activities. This process ensures that all conflicts of interest are identified, managed and resolved prior to the educational activity. Additionally, the prospective audience must be informed of the presenters’ or program planners’ affiliations with every commercial interest by an acknowledgment in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide is required if audiovisual equipment is used for the presentation). Disclosing to learners the relevant financial relationships that were

present and resolved assists learners in assessing the potential for bias in the information that is presented. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters and planners on the following pages indicated that either they or a spouse/partner have a financial interest or other affiliation with a commercial entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients; the company name and affiliation is also listed. Providers of clinical service directly to patients are not considered to be commercial interests. The second group of presenters and planners indicated neither they nor a spouse/partner have any relationship to disclose.

All presenters and planners must complete a disclosure in order to participate in an APA CME activity. This disclosure listing includes both the presenters and planners of the Scientific Program and New Research Poster Sessions.



Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Abbey, Susan.	Pfizer	Purdue Pharma	
Aggarwal, Neil K.			
Alexopoulos, George S.		AstraZeneca Pharmaceuticals Otsuka Pharmaceuticals Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals	
Alphs, Larry D.			Janssen
Amadio, Jordan			
Anderson, Karen E	Teva Pharmaceuticals		
Anthony, James C.			
Artigas, Francesc	Lundbeck		
Ash, Peter	Forest Laboratories, Inc.		
Attia, Evelyn			
Baggott, Matthew J.			Genentech
Bailey, John			
Bailey, Rahn	Janssen Eli Lilly and Company Sunovion Pharmaceuticals Inc		
Baker, Ross A.			Otsuka Pharmaceuticals
Benjamin, Sheldon			
Bennett, Jeffrey I.			
Bierut, Laura J.			
Bisaga, Adam			
Blanch, Jordi		Gilead Sciences Janssen-Cilag	
Blier, Pierre	Bristol-Myers Squibb Eli Lilly and Company Actavis Allergan Lundbeck Takeda Pharmaceuticals Janssen		
Brannan, Stephen			Forum Pharmaceuticals
Bravata, Dena			Lyra Health
Brock, David G.			Neuronetics Inc.
Brody, Benjamin			
Brown, Brianne			Janssen-Ortho
Brown, Richard P.	Humanetics		
Brown, Thomas	Lundbeck		Shire
Buckley, Peter	AstraZeneca Pharmaceuticals Eli Lilly and Company Janssen Pfizer		
Bussing, Regina			

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
National Institute of Mental Health		
	Johnson and Johnson	
		Founder/Partner at NeuroLaunch, a neuroscience investment firm
National Institutes of Health NIDA CSR American Association for the Advancement of Science		
Lundbeck		Author of patent WO/2011/131693 for siRNA and ASO molecules Consults with attorneys to provide expert testimony
Eli Lilly and Company		
		Part owner of TMS Patient Care of Tallahassee. Also employed to do consultation and mapping for this company.
Robert Wood Johnson Pharmaceutical.		
		Author/partner in Brain Educators, LLC
Janssen		
		Inventor on U.S. Patent 8,080,371 "Markers for Addiction" covering the use of certain SNPs in determining the diagnosis, prognosis and treatment of addiction
Alkermes		
Bristol-Myers Squibb Lundbeck Takeda Pharmaceuticals Janssen Actavis		
	Takeda Pharmaceuticals	
	Lyra Health Castlight Health	
Pritzker Neuropsychiatric Disorders Research Consortium		Expert witness to the law firm of Wilson, Bowling and McKinney
	Johnson and Johnson	
	Humanetics	
Eli Lilly and Company Shire		
Pfizer Janssen Sunovion Pharmaceuticals Inc. AstraZeneca Pharmaceuticals Eli Lilly and Company		
Pfizer		

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Calabrese, Joseph	Abbott Laboratories AstraZeneca Pharmaceuticals Bristol-Myers Squibb Cephalon Inc. Dainippon Sumitomo Pharma Co., Ltd Elan Pharmaceuticals EPI-Q GlaxcoSmithKline Hoffman-LaRoche Pharmaceuticals Janssen Johnson and Johnson Lundbeck Merck and Co. Neurosearch Ortho McNeil Pharmaceuticals Otsuka Pharmaceuticals Pfizer Repligen Servier Solvay Sunovion Pharmaceuticals Inc. Supernus Synosia Takeda Pharmaceuticals Teva Pharmaceuticals Wyeth-Ayerst	AstraZeneca Pharmaceuticals Bristol-Myers Squibb GlaxcoSmithKline Janssen Johnson and Johnson Merck and Co. Sanofi Pharmaceuticals, Inc. Schering Corporation Pfizer Solvay Sunovion Pharmaceuticals Inc. Wyeth-Ayerst France Foundation	
Candilis, Philip.			
Carrothers, Timothy J.			Allergan
Carvalho, Adriana	AbbVie Pharmaceutical	AbbVie Pharmaceutical	
Castilla-Puentes, Ruby C.		Janssen	Johnson and Johnson
Chaimowitz, Gary	Sunovion Pharmaceuticals Inc. Janssen-Ortho	Janssen-Ortho Sunovion Pharmaceuticals Inc.	
Chang, Kiki	GlaxcoSmithKline Actavis Sunovion Pharmaceuticals Inc. Janssen Bristol-Myers Squibb		
Childress, Ann C.	Shionogi Inc Ironshore Pharmaceuticals Next Wave Novartis Pharmaceuticals Corporation Pfizer Shire Neurovance Arbor Neos Rhodes Pharmaceuticals		
Choudhry, Zia			Genomind
Ciotoli, Carlo	Pfizer		
Citrome, Leslie	Alexza Pharmaceuticals Alkermes Allergan Boehringer Ingelheim Pharmaceuticals Bristol-Myers Squibb Eli Lilly and Company Forum Pharmaceuticals Genentech Janssen Jazz Pharmaceutical Lundbeck Merck and Co. Medivation Mylan Novartis Pharmaceuticals Corporation Noven Pharmaceutical Otsuka Pharmaceuticals Pfizer Reckitt Benckiser Pharmaceuticals Shire Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Teva Pharmaceuticals Valeant Pharmaceuticals Vanda Pharmaceuticals	Allergan Alkermes AstraZeneca Pharmaceuticals Janssen Jazz Pharmaceutical Lundbeck Merck and Co. Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Shire Sunovion Pharmaceuticals Inc. Teva Pharmaceuticals Takeda Pharmaceuticals	
Clayton, Anita	Lundbeck Palatin Technologies Pfizer S1 Biopharmaceuticals Inc Sprout Pharmaceuticals		
Clemow, David B.			Eli Lilly and Company
Coccaro, Emil	Azevan Pharmaceuticals, Inc.		
Coghill, David	Shire Novartis Pharmaceuticals Corporation Sandoz Pharmaceuticals Corporation	Shire Eli Lilly and Company	
Craig, Thomas K. J.			
Cress, Kim K.	Neuronetics Inc.	Neuronetics Inc.	
Cubells, Joseph F.	AbbVie Pharmaceutical		

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
Abbott Laboratories AstraZeneca Pharmaceuticals Bristol-Myers Squibb Cephalon Inc. Eli Lilly and Company GlaxcoSmithKline Janssen Lundbeck Repligen Takeda Pharmaceuticals Wyeth-Ayerst		
	Dow Chemical Merck and Co. Pfizer Praxair	
	Johnson and Johnson GlaxcoSmithKline Sanofi Aventis Merck and Co.	
	Bristol-Myers Squibb Eli Lilly and Company Johnson and Johnson Merck and Co. Pfizer	
Auspex Pharm Genomind Palatin Technologies Forest Laboratories, Inc.	Euthymics Bioscience Inc. S1 Biopharmaceuticals Inc	
	Azevan Pharmaceuticals, Inc.	
Sanofi Aventis		
Roche Seaside Therapeutics SmithKline Beecham BioMarin	Pfizer Lilly USA, LLC Biotech Holders Trust Genzyme	

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Cutler, Andrew J.	AbbVie Pharmaceutical Alkermes Allergan AstraZeneca Pharmaceuticals Bristol-Myers Squibb Forum Pharmaceuticals Janssen Jazz Pharmaceutical Eli Lilly and Company Lundbeck Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Teva Pharmaceuticals Vanda Pharmaceuticals	Alkermes Allergan AstraZeneca Pharmaceuticals Bristol-Myers Squibb Janssen Jazz Pharmaceutical Eli Lilly and Company Lundbeck Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Teva Pharmaceuticals Vanda Pharmaceuticals	
Davine, Jon S.	Lundbeck	Lundbeck	
De Dios, Consuelo		Janssen-Cilag	
De Faria, Ludmila		Alkermes Sunovion Pharmaceuticals Inc. Otsuka Pharmaceuticals	
de la Gandara, Jose E.			
Dell'Osso, Bernardo		Pfizer Lundbeck	
DeMille, Steven M.			RedCliff Ascent
Devanand, Davangere P	AbbVie Pharmaceutical Lundbeck Intracellular Therapies Astellas Pharma US, Inc.		
Doghramji, Karl	Pfizer Jazz Pharmaceutical Teva Pharmaceuticals Merck and Co.		
Douaihy, Antoine			
Doumas, Stacy J.			
Duffy, Farifteh F.			
Durgam, Suresh			Allergan
Earley, Willie			Allergan
Elefant, Erica			Janssen
El-Mallakh, Rif S.		Aventis Pharmaceuticals AstraZeneca Pharmaceuticals Lundbeck Merck and Co. Otsuka Pharmaceuticals	
Eriksson, Hans			Lundbeck
Ernst, Carrie L.	(Spouse/Partner)Sunovion Pharmaceuticals Inc.	(Spouse/Partner)AstraZeneca Pharmaceuticals (Spouse/Partner)Janssen (Spouse/Partner)Merck and Co. (Spouse/Partner)Sunovion Pharmaceuticals Inc. (Spouse/Partner)Takeda Pharmaceuticals (Spouse/Partner)Lundbeck	
Fallu, Angelo	Janssen-Ortho Shire Sunovion Pharmaceuticals Inc. Purdue Pharma Pfizer Lundbeck	Janssen Bristol-Myers Squibb Pfizer Perdue Pharmaceuticals Shire Sunovion Pharmaceuticals Inc. Lundbeck	

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
<p>AbbVie Pharmaceutical Alkermes Allergan AstraZeneca Pharmaceuticals Bristol-Myers Squibb Forum Pharmaceuticals Janssen Eli Lilly and Company Lundbeck Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Reckitt Benckiser Pharmaceuticals Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Vanda Pharmaceuticals</p>		
	Lundbeck	
	Lundbeck	Supported by the Spanish grant FIS PI13/00352 from Instituto de Salud Carlos III
<p>Avanir Corporation Avid Biogen Eli Lilly and Company Eisai Inc. Elan Pharmaceuticals Genentech Gliacure Inc. Hoffman-LaRoche Pharmaceuticals Merck and Co. Myriad Pharmaceuticals Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Quintiles Roche Sanofi Aventis Scirex Sonexa Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals United BioSource Parexel International Corporation</p>		
	Merck and Co.	
Alkermes Orexo		
Sunovion Pharmaceuticals Inc. Forest Laboratories, Inc.		
Forest Laboratories, Inc. Lundbeck Takeda Pharmaceuticals		
	Allergan	
	Allergan AstraZeneca Pharmaceuticals	
	Johnson and Johnson	
Merck and Co. Teva Pharmaceuticals PsychNostics, LLC National Institute of Mental Health		
	AstraZeneca Pharmaceuticals Lundbeck	
		Spouse has received an editorial stipend from Frontline Medical Communications
Perdue Pharmaceuticals Merck Frosst		

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Faraone, Stephen V.			
Fayad, Sarah M.	Acadia Pharmaceuticals		
First, Michael B.	Lundbeck		
Fisher, Carl	TalkSession		
Fogelson, David L.	Roxane Pharmaceuticals		
Fong, Tim		Reckitt Benckiser Pharmaceuticals	
Forester, Brent	Eli Lilly and Company		
Formella, Andrea			Avanir Corporation
Foster, Norman L.			
Frasch, Karel J.			
Fu, Dong-Jing			Janssen
Gache, Chris			Actavis
Gao, Keming		Sunovion Pharmaceuticals Inc.	
George, Tony P.	Novartis Pharmaceuticals Corporation		
Gerbarg, Patricia L.	(Spouse/Partner)Humanetics		
Gibbs, Ayana			Roche
Goldberg, Joseph F.	Sunovion Pharmaceuticals Inc.	AstraZeneca Pharmaceuticals Janssen-Cilag Merck and Co. Takeda Pharmaceuticals Lundbeck	
Gomez-Trigo Baldominos, Jesus			
Gopal, Srihari	Janssen		Janssen
Grace, Anthony A.	Johnson and Johnson Lundbeck	Pfizer Otsuka Pharmaceuticals	
Grebla, Regina			Shire
Green, Alan I.			
Harvey, Philip D.	Boehringer Ingelheim Pharmaceuticals Forum Pharmaceuticals Genentech Lundbeck Otsuka Pharmaceuticals Sanofi Pharmaceuticals, Inc. Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals AbbVie Pharmaceutical Roche		
Hatch, Ainslie			Otsuka Pharmaceuticals
Herman, Barry K.			Shire
Hildebrandt, Tom	Noom, Inc		
Hilt, Dana			Forum Pharmaceuticals
Hodgson, Richard E.		Janssen-Cilag Lundbeck	
Holland, Peter J.	Eli Lilly and Company		
Hsiung, Robert			
Iosifescu, Dan V.	Lundbeck Sunovion Pharmaceuticals Inc. Axsome CNS Response		
Iyer, Sharat P.	Truven Health Analytics		
Jacobs, Karen		Takeda Pharmaceuticals	
Jacobson, William			Takeda Pharmaceuticals

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
Arbor Pfizer Ironshore Pharmaceuticals Shire Akili Interactive Labs CogCubed Alcobra, Ltd. VAYA Pharma Neurovance Impax NeuroLifeSciences		U.S. patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD
	TalkSession	
Biogen		
GE Healthcare Inc.		
Lundbeck	Stada Rhoen Kliniken Johnson and Johnson	
AstraZeneca Pharmaceuticals Pfizer	(Spouse/Partner)Humanetics	
Janssen	Janssen Johnson and Johnson	
Johnson and Johnson Janssen		Autofony grant pending
Alkermes	Shire	
Takeda Pharmaceuticals		
	Shire	Equity owner in Noom, Inc.
	Forum Pharmaceuticals	
Eli Lilly and Company Biogen Genentech	Dr. Bob, LLC	
Brainsway Inc Alkermes		
	Pfizer Takeda Pharmaceuticals United Health	

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Janicak, Philip G.	Neuronetics Inc.		
Joshi, Kruti			Janssen
Josiassen, Richard C.	Otsuka Pharmaceuticals		
Kalnik, Matthew W.			Antidote Therapeutics, Inc.
Kane, John M.	Alkermes Amgen Bristol-Myers Squibb Cephalon Inc. Eisai Inc. Boehringer Ingelheim Pharmaceuticals Eli Lilly and Company Genentech Intracellular Therapies Janssen Johnson and Johnson Lundbeck Merck and Co. Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Pierre Fabre Proteus Biomedical Roche Sunovion Pharmaceuticals Inc. Targacept Forrest Reviva	Alkermes Amgen Bristol-Myers Squibb Cephalon Inc. Eisai Inc. Boehringer Ingelheim Pharmaceuticals Eli Lilly and Company Genentech Intracellular Therapies Janssen Johnson and Johnson Lundbeck Otsuka Pharmaceuticals Merck and Co. Novartis Pharmaceuticals Corporation Pfizer Pierre Fabre Proteus Biomedical Roche Sunovion Pharmaceuticals Inc. Targacept Forrest Reviva	
Karnik, Niranjan			
Keefe, Richard	AbbVie Pharmaceutical Avanir Corporation Boehringer Ingelheim Pharmaceuticals Forum Pharmaceuticals Janssen Johnson and Johnson Lundbeck Merck and Co. Mitsubishi Pharma Corporation Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Roche Sanofi Aventis Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Akebia AviNeuro/ChemRar Minerva NY State Department of Mental Health Reviva		
Kent, Justine M.			Janssen
Ketter, Terence A.	Sunovion Pharmaceuticals Inc. Teva Pharmaceuticals Janssen Myriad Genetics, Inc. Allergan	GlaxoSmithKline Sunovion Pharmaceuticals Inc.	(Spouse/ Partner)Janssen
Khan, Christina T.			
Khattak, Sohail	Shire Janssen Purdue Pharma	Janssen Shire	
Kiss, Béla			Gedeon Richter
Kleber, Herbert D.		Alkermes	
Kleiner, Oliver			Boehringer Ingelheim Pharmaceuticals
Knable, Michael B.	ProPhase LLC		
Ko, Mancía			Ameritox, Ltd.
Kolli, Venkata B.			
Kott, Alan			Bracket Global, LLC
Kramer, Kenneth			Allergan
Kratochvil, Christopher		Mapp Chimerix NewLink Genetics Tekmira G W Pharmaceutical	
Krystal, John	Pfizer Naurex Forum Pharmaceuticals Sunovion Pharmaceuticals Inc. Otsuka Pharmaceuticals Biohaven Pharmaceutical		
Kung, Simon			

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
Neuronetics Inc. Sunovion Pharmaceuticals Inc. Ortho-McNeil Janssen Scientific Affairs, LLC	Janssen	
Otsuka Pharmaceuticals		
	Medavante	
Hoffman-LaRoche Pharmaceuticals		
Department of Veterans' Affairs National Institute of Mental Health Singapore Medical Research Council	NeuroCog Trials, Inc. Sengenix	Royalties received: BACS testing battery, the MATRICS battery (BACS symbol coding) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
	Johnson and Johnson	
Merck and Co. Sunovion Pharmaceuticals Inc.	(Spouse/Partner)Janssen	
Lilly USA, LLC		
Shire Janssen-Ortho		
	Medavante Orexigen Alexza Pharmaceuticals	
Janssen		
	Allergan	
Mapp Chimerix NewLink Genetics Tekmira G W Pharmaceutical	Janssen Biohaven Pharmaceutical	Patents licensed by Janssen, Biohaven Medical Sciences
		Employer (Mayo Clinic) receives some royalties from pharmacogenetic technology licensed from Mayo to AssureRx

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Lavretsky, Helen		Forest Laboratories, Inc.	
Lefebvre, Patrick			
Lerner, Debra			
Levin, Frances R.			
Lev-Ran, Shaul	Pfizer Lundbeck Reckitt Benckiser Pharmaceuticals NovaMedica	Pfizer Janssen-Cilag Lundbeck Reckitt Benckiser Pharmaceuticals Sanofi Pharmaceuticals, Inc.	
Lewis-Fernandez, Roberto			
Lewy, Alfred J.	Servier Pfizer		
Lindenmayer, Jean-Pierre	Janssen Forum Pharmaceuticals Lundbeck Johnson and Johnson		
Loewen, Gordon R.			Forum Pharmaceuticals
López-Jaramillo, Carlos	Abbott Laboratories AstraZeneca Pharmaceuticals Lundbeck Sanofi Aventis Eli Lilly and Company Pfizer GlaxoSmithKline	Abbott Laboratories Sanofi Aventis Eli Lilly and Company AstraZeneca Pharmaceuticals GlaxoSmithKline Lundbeck Pfizer	
Luo, John	Otsuka Pharmaceuticals		
Luskin, Shari I.	Pfizer		
Mago, Rajnish	Actavis Sunovion Pharmaceuticals Inc. Otsuka Pharmaceuticals Lundbeck Genomind Jina Pharmaceuticals		
Mancevski, Branislav			Janssen
Mao, Alice R.	Shire	Otsuka Pharmaceuticals Shire Takeda Pharmaceuticals (Spouse/Partner) Takeda Pharmaceuticals (Spouse/Partner) Otsuka Pharmaceuticals	
Marder, Stephen R.	AbbVie Pharmaceutical Allergan Lundbeck Otsuka Pharmaceuticals Pfizer Takeda Pharmaceuticals Teva Pharmaceuticals Jazz Pharmaceutical		
Markovitz, Paul J.			(Spouse/Partner) Avanir Corporation
Marmar, Charles R.			
Mattingly, Greg	Alkermes Forum Pharmaceuticals Lundbeck Merck and Co. Novartis Pharmaceuticals Corporation Noven Pharmaceutical Otsuka Pharmaceuticals Purdue Pharma Shire Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Vanda Pharmaceuticals Rhodes Pharmaceuticals	Forest Laboratories, Inc. Lundbeck Merck and Co. Otsuka Pharmaceuticals Shire Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals	
Mayberg, Helen			
McBurnett, Keith			
McCracken, James T.			
McDonald, William M.	U.S. Food and Drug Administration (FDA)		

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
Forest Laboratories, Inc.		Grants from the Alzheimer's Research and Preventions Foundation; NIH
Janssen		
Janssen		
US World Med		
Reckitt Benckiser Pharmaceuticals		
Eli Lilly and Company		
		Co-inventor of several melatonin process patents owned by Oregon Health and Science University and currently not licensed to any company
Avanir Corporation Alkermes Janssen Forum Pharmaceuticals Roche		Multi-Health Systems Royalties for publication of SCI-PANSS
Covance Takeda Abbott Pharmaceuticals Novartis Pharmaceuticals Corporation Colciencias National Institute of Mental Health Universidad de Antioquia		
		Consultant to Pfizer regarding litigation
Actavis Genomind Alkermes		
Amgen		
Eli Lilly and Company Pfizer		
Alcobra, Ltd. Alkermes Forest Laboratories, Inc. Forum Pharmaceuticals Janssen Lundbeck Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer Reckitt Benckiser Pharmaceuticals Shire Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals		
		IP licensing fees from St. Jude Medical Group
Pfizer Sunovion Pharmaceuticals Inc.		
AstraZeneca Pharmaceuticals		
National Institute of Mental Health National Institute of Neurological Disease and Stroke Stanley Foundation Soterix Neuronetics and Cervel Neurotherapeutics		

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
McIntyre, Roger S.	AstraZeneca Pharmaceuticals Bristol-Myers Squibb Eli Lilly and Company Lundbeck Pfizer Merck and Co. Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Allergan Otsuka Pharmaceuticals	AstraZeneca Pharmaceuticals Eli Lilly and Company Janssen-Ortho Lundbeck Merck and Co. Pfizer Otsuka Pharmaceuticals Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Allergan	
McLeod-Bryant, Stephen A.			
Meltzer, Herbert Y.	Forest Laboratories, Inc. Boehringer Ingelheim Pharmaceuticals Forum Pharmaceuticals Sunovion Pharmaceuticals Inc. Dainippon Sumitomo Pharma Co., Ltd Janssen Teva Pharmaceuticals Novartis Pharmaceuticals Corporation Astellas Pharma US, Inc. Alkermes Eli Lilly and Company Guidepoint Global Gerson Lerman	Forum Pharmaceuticals Sunovion Pharmaceuticals Inc. Dainippon Sumitomo Pharma Co., Ltd Novartis Pharmaceuticals Corporation ProPhase LLC	
Mischoulon, David			
Misri, Shaila	AstraZeneca Pharmaceuticals Lundbeck Pfizer		
Moller, Hans-Jurgen	AstraZeneca Pharmaceuticals Eli Lilly and Company Janssen-Cilag Lundbeck Pfizer Schwabe Servier Otsuka Pharmaceuticals Takeda Pharmaceuticals		
Monahan, John			
Morse, Michael D.			
Moussaoui, Driss	Servier Lundbeck		
Murray, Robin M.		Lundbeck Otsuka Pharmaceuticals	
Muser, Erik			Janssen
Naber, Dieter	Eli Lilly and Company Janssen-Cilag Lundbeck Otsuka Pharmaceuticals Servier	AstraZeneca Pharmaceuticals Janssen-Cilag Eli Lilly and Company Lundbeck Otsuka Pharmaceuticals	
Nasrallah, Henry A.	Acadia Pharmaceuticals Alkermes Boehringer Ingelheim Pharmaceuticals Forum Pharmaceuticals Janssen Lundbeck Sunovion Pharmaceuticals Inc. Allergan Otsuka Pharmaceuticals	Janssen Lundbeck Otsuka Pharmaceuticals Sunovion Pharmaceuticals Inc. Alkermes Acadia Pharmaceuticals Forum Pharmaceuticals	
Nemeroff, Charles B.	Xhale Takeda Pharmaceuticals Mitsubishi Pharma Corporation Taisho Toyama Pharmaceutical Co., Ltd. Lundbeck Bracket Pharmaceuticals Gerson Lerman Prismic Pharmaceuticals Total Pain Solutions		
Ng-Mak, Daisy S.			Sunovion Pharmaceuticals Inc.
Nguyen, Charles S.	Otsuka Pharmaceuticals Eisai Inc.	Eisai Inc. Otsuka Pharmaceuticals	
Nielsen, Rebecca Z.			Lundbeck
Norquist, Grayson			
Okereke, Olivia I.			
Oquendo, Maria			
Owens, Samuel M.			Intervexion Therapeutic
Pan, Xiaoyun			

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
Eli Lilly and Company Janssen-Ortho AstraZeneca Pharmaceuticals Lundbeck Merck and Co. Pfizer Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Allergan		
		Partnership share in an information technology firm, Electronic Health Networks, Inc.
Forum Pharmaceuticals Forest Laboratories, Inc. Boehringer Ingelheim Pharmaceuticals Sunovion Pharmaceuticals Inc. Dainippon Sumitomo Pharma Co., Ltd Janssen Teva Pharmaceuticals Novartis Pharmaceuticals Corporation Astellas Pharma US, Inc. Alkermes Takeda Pharmaceuticals Lundbeck Eli Lilly and Company Naurex Auspex Pharm Magceutics	Acadia Pharmaceuticals GlaxoSmithKline	SureGene LLC, Reviva Pharmaceuticals, Inc., Clearview Health Partners, Neurotherapeutics
Nordic Naturals		
Pfizer		
		Co-owner of COVR, Inc., which owns the intellectual property rights to the Classification of Violence Risk
	Abbott Laboratories	
	Johnson and Johnson	
Alkermes Forum Pharmaceuticals		
	Xhale Celgene Corporation AbbVie Pharmaceutical Titan Pharmaceuticals Inc. Seattle Genetics OPKO Health, Inc.	SAB: AFSP, BBRF, Xhale, ADAA, Skyland Trail, Bracket, RiverMend
		Chair of the Board of Governors for the Patient Centered Outcomes Research Institute
		Depression prevention research supported by R01MH091448 and R01MH096776
	Bristol-Myers Squibb	Royalties for the use of the Columbia Suicide Severity Rating Scale
	Intervexion Therapeutic, LLC	
Janssen		

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Pandey, Ghanshyam N.			
Pardes, Herbert	W.M. Keck Foundation		
Parks, Joseph	Otsuka Pharmaceuticals		
Pasternak, Gavrill	AstraZeneca Pharmaceuticals Cytogel		
Penninx, Brenda W.			
Periclou, Antonia			Allergan
Peters-Strickland, Timothy			Otsuka Pharmaceuticals
Phillips, Katharine A.			
Pi, Edmond H. T.	Bracket Pharmaceuticals		
Pilon, Dominic			Analysis Group, Inc.
Pogarell, Oliver	Lundbeck	Lundbeck Otsuka Pharmaceuticals	
Posner, Jonathan			
Potkin, Steven	Sunovion Pharmaceuticals Inc. Forum Pharmaceuticals Alkermes Forest Laboratories, Inc. Allergan Health Advances Health and Wellness Partners	Otsuka Pharmaceuticals Gerson Lerman Avant Health Care Marketing	
Price, Charles S.		Actavis AstraZeneca Pharmaceuticals Forest Laboratories, Inc. Genomind Lundbeck Novartis Pharmaceuticals Corporation Pam Lab LLC Shire Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals	
Primm, Annelle	Johnson and Johnson		
Pumariega, Andres J.			
Rado, Jeffrey T.			
Raj, Pritham	AstraZeneca Pharmaceuticals	Allergan, Merck & Co. AstraZeneca Pharmaceuticals	
Rakofsky, Jeffrey J.			
Rasgon, Natalie		Magceutics Corcept Therapeutics, Inc.	
Remington, Gary	Neurocrine Biosciences Inc. Synchronuron Medicare Laboratorios Farmaceuticos Rovi		
Reynolds, Charles F.			
Rich, Kelly	Janssen		
Risinger, Robert			Alkermes
Rosenbaum, Jerrold F.			
Rosenthal, Richard N.			
Rostain, Anthony	Alcobra, Ltd.		
Rothbaum, Barbara			
Rovner, Barry			
Roy, Alphonse K.	Orexo	Alkermes Biodelivery Sciences, Inc.	
Rush, A. John	Cyberonics Inc. Brain Resource Ltd.		
Saeed, Aliya			
Sajatovic, Martha	Bracket Pharmaceuticals ProPhase LLC Otsuka Pharmaceuticals Pfizer Amgen Sunovion Pharmaceuticals Inc.		

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
		Work supported by NIMH RO1 MH 048153 and NIMH RO1 MH 098554
Relmada Cytogel Janssen	Sarentis	
	Allergan	
	Merck and Co.	
Janssen		
Shire		
Eli Lilly and Company Eisai Inc. Forum Pharmaceuticals Toyama Otsuka Pharmaceuticals Alkermes		
	(Spouse/Partner)Actavis	
Neuronetics Inc. Otsuka Pharmaceuticals Alkermes		
Takeda Pharmaceuticals Assure RX	Magceutics Corcept Therapeutics, Inc.	
		Depression prevention research supported by P30MH90333
	Alkermes	
Braeburn Pharmaceuticals	Medavante PsyBrain	
	Virtually Better, Inc.	
Merck and Co.		
		May receive royalty payments from UT Southwestern for rating scales.
	Pfizer	
Pfizer Merck and Co. Ortho-McNeil Janssen Scientific Affairs, LLC Janssen		

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Samalin, Ludovic	Janssen Bristol-Myers Squibb	Bristol-Myers Squibb Janssen Lundbeck Otsuka Pharmaceuticals AstraZeneca Pharmaceuticals	
Sánchez-Gómez, Pedro M.	Janssen-Cilag Ferrer International	Janssen-Cilag Ferrer International Lundbeck	
Saragoussi, Delphine			Lundbeck
Sauve, William		Otsuka Pharmaceuticals Avanir Corporation Sunovion Pharmaceuticals Inc. Neuroscience Education Institute	
Savitz, Adam	Janssen		Janssen
Schatzberg, Alan F.	Forum Pharmaceuticals Lundbeck McK insey Pharmaceuticals Myriad Genetics, Inc. Naurex Neuronetics Inc. Pfizer Sunovion Pharmaceuticals Inc.	Pfizer	
Schulz, S. Charles	Forum Pharmaceuticals Myriad Pharmaceuticals		
Seibyl, John	GE Healthcare Inc.		
Serfaty, Marc A.			
Shah, Asim			
Sheehan, David V.	Actavis Shire Janssen ProPhase LLC Roche AstraZeneca Pharmaceuticals Pfizer Lundbeck Takeda Pharmaceuticals PHT Corporation ERT	Pfizer Glaxo Pharmaceuticals Sunovion Pharmaceuticals Inc. Forest Laboratories, Inc. Actavis Allergan	
Sivrioglu, Yusuf		Pfizer Novartis Pharmaceuticals Corporation	
Small, Gary W.	Actavis Pfizer Novartis Pharmaceuticals Corporation Forum Pharmaceuticals Forest Laboratories, Inc. Janssen	Actavis Pfizer Forest Laboratories, Inc. Forum Pharmaceuticals Janssen	
Stahl, Stephen M.	Acadia Pharmaceuticals BioMarin Forum Pharmaceuticals Jazz Pharmaceutical Orexigen Otsuka Pharmaceuticals Pam Lab LLC Servier Sprout Pharmaceuticals Shire Taisho Toyama Pharmaceutical Co., Ltd. Lundbeck	Forum Pharmaceuticals Servier Takeda Pharmaceuticals Sunovion Pharmaceuticals Inc.	
State, Matthew	Pfizer SynapDx Blackthorn Therapeutics		
Sudak, Donna M.	Takeda Pharmaceuticals		
Summers, Richard F.			(Spouse/ Partner) Hummingbird IRB
Sung, Victor	Lundbeck		
Swann, Alan C.	Teva Pharmaceuticals Otsuka Pharmaceuticals Lundbeck	Lundbeck Otsuka Pharmaceuticals	
Tendler, Aron			Brainsway Inc
Thase, Michael E.	Actavis Alkermes Allergan Assure RX Avanir Corporation AstraZeneca Pharmaceuticals Cenerx Cerecor, Inc. Forest Laboratories, Inc. Genentech Janssen Johnson and Johnson Lundbeck Naurex Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pfizer PharmaNeuroBoost Roche Shionogi Inc Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Teva Pharmaceuticals		(Spouse/ Partner) Peloton Advantage

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
	Janssen	
Janssen	Amnestix Inc Cervel Neurotech, Inc. Corcept Therapeutics, Inc. Delpor Technology Merck and Co. Neurocrine Biosciences Xhale	Named inventor on pharmacogenetic and antiglucocorticoid use patents on prediction of antidepressant response
Myriad Pharmaceuticals Otsuka Pharmaceuticals		Equity in Molecular Neuroimaging, LLC
Assure RX Janssen		Chief investigator on all U.K. National Institute of Health Research-funded studies
	Medical Outcomes Systems	Data Safety Monitoring Board: Daiichi Sankyo MMS Holdings
	TauMark, LLC	
Alkermes Eli Lilly and Company Forest Laboratories, Inc. Forum Pharmaceuticals Merck and Co. Novartis Pharmaceuticals Corporation Otsuka Pharmaceuticals Pam Lab LLC Pfizer Servier Shire Sprout Pharmaceuticals Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals Teva Pharmaceuticals	Adamas Genomind	
	(Spouse/Partner) Bristol-Myers Squibb (Spouse/Partner) Gilead Sciences (Spouse/Partner) AbbVie Pharmaceutical (Spouse/Partner) Biogen (Spouse/Partner) Merck and Co. (Spouse/Partner) Pfizer (Spouse/Partner) Eli Lilly and Company	
Elan Pharmaceuticals		
Brainsway Inc	Brainsway Inc	
AstraZeneca Pharmaceuticals Avanir Corporation Bristol-Myers Squibb Assure RX Eli Lilly and Company Forest Laboratories, Inc. Janssen Johnson and Johnson Alkermes NeoSyn PharmaNeuroBoost	Medavante Mensante Corporation	

Disclosure Index

Name	Consultant/Advisory Board	Speakers Bureau/Speaker Honoraria	Employee
Torres Vilamajó, Imma			
Trudeau, Kimberlee J.			
Turkingdon, Douglas		Janssen-Cilag	
Van Ameringen, Michael	Forest Laboratories, Inc.	Lundbeck Pfizer Shire	
Vieta, Eduard	AstraZeneca Pharmaceuticals Ferrer International Forest Laboratories, Inc. GlaxoSmithKline Janssen-Cilag Otsuka Pharmaceuticals Pfizer Sanofi Aventis Sunovion Pharmaceuticals Inc. Takeda Pharmaceuticals		
Vinogradov, Sophia			
Viswanathan, Ramaswamy		(Spouse/Partner)Novartis Pharmaceuticals Corporation	
Weiller, Emmanuelle			Otsuka Pharmaceuticals
Weintraub Brendel, Rebecca	Beacon Health Strategies		
Weiss, Catherine			Otsuka Pharmaceuticals
West, Joyce C.			
Wigal, Sharon B.	Eli Lilly and Company Ironshore Pharmaceuticals NextWave Noven Pharmaceutical Pfizer Purdue Pharma Shionogi Inc. Shire	Eli Lilly and Company Ironshore Pharmaceuticals NextWave Noven Pharmaceutical Pfizer Purdue Pharma Shionogi Inc. Shire	
Wilcox, Marsha A.			Janssen
Wilens, Timothy	Ironshore Pharmaceuticals Sunovion Pharmaceuticals Inc. Euthymics Bioscience Inc. Neurovance NIDA Tris ERM Associates		
Williams, Jill M.	Pfizer		
Winsberg, Mirene			Lyra Health
Wise, Thomas N.	Otsuka Pharmaceuticals		
Wittenberg, Gayle M.			Janssen
Wong, Donovan			Doctor on Demand
Wright, Jesse H.			
Yatham, Lakshmi	Sunovion Pharmaceuticals Inc. Allergan Dainippon Sumitomo Pharma Co., Ltd. Lundbeck	Sunovion Pharmaceuticals Inc. Lundbeck Dainippon Sumitomo Pharma Co., Ltd.	
Zeller, Scott		Teva Pharmaceuticals Ferrer International	
Zohar, Joseph	Servier Pfizer Abbott Laboratories Eli Lilly and Company Actellion AstraZeneca Pharmaceuticals Roche	Lundbeck Roche Eli Lilly and Company Pfizer Abbott Laboratories	

Grant/Research Support	Stock/Other Financial Relationship	Other Disclosure
		PFIS Contract for IT (FI11/00502), Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Spain and the grant FIS PI12/01139 to the ADHD Unit at Vall d'Hebron Hospital, Instituto de Salud Carlos III.
Janssen		Director of the Insight-CBT partnership
Janssen-Ortho Pfizer		Has received research grants, honoraria related to continuing medical education or consulting fees from Centro para la Investigación Biomédica en Red de Salud Mental (CIBERSAM), Grups Consolidats de Recerca 2014 (SGR 398), the Seventh European Framework Programme (ENBREC) and the Stanley Medical Research Institute.
(Spouse/Partner)Emmaus		Site investigator on an SBIR multisite grant to PositScience, Inc.
Takeda Pharmaceuticals Forest Laboratories, Inc. Robert Wood Johnson Foundation		
Eli Lilly and Company Forest Laboratories, Inc. Ironshore Pharmaceuticals NextWave Noven Pharmaceutical Purdue Pharma Shire Sunovion Pharmaceuticals Inc.	Johnson and Johnson	
NIDA		Co-owner of Before School Functioning Questionnaire, licensed with Ironshore
Pfizer	Lyra Health	
	Johnson and Johnson	
	Doctor on Demand	
	Empower Interactive Mindstreet	
Lundbeck Valeant Pharmaceuticals Janssen-Ortho Eli Lilly and Company Dainippon Sumitomo Pharma Co., Ltd.		
Lundbeck Servier Brainsway Inc Pfizer		

Disclosure Index

The following presenters and planners indicated neither they nor a spouse/partner have any relationship to disclose.

Aaronson, Alexandra L.	Al-Hassani, Ghanem	Azam, Mohammed A.	Benedek, Elissa P.	Brenner, Adam
Abdel Gawad, Noha	Ali, Arshand	Azizi, Hafizullah	Benson, R. Scott	Breur, Jorien G.
Aboraya, Ahmed	Ali, Shahla	Babalola, Ronke L.	Benson, Timothy	Breyer, Stephen
Aboueid, Lila	Alkis, Andrew R.	Babatope, Taiwo	Bentman, Adrienne	Brichant-Petitjean, Clara
Acar, Selin	Allen, Rebecca M.	Bachem, Rahel C.	Bera, Rimal B.	Briggs, Jessica
Acharya, Bibhav	Almas, Aysha	Baer, Wendy	Beresin, Eugene V.	Brooks, James
Achebe, Uchenna	Alosaimi, Fahad D.	Bagewadi Ellur, Mallikarjuna	Berlin, Jon	Brooks, John
Acosta-Uribe, Juliana	Alptekin, Koksal	Baird, Mimi	Berman, Ellen	Brown, Adam
Adams, Caitlin	Al-Rubaye, Safa	Baker, Megan E.	Bermeo-Ovalle, Adriana	Brown, Frank W.
Adams, Samantha	Alvarez, Kiara	Balasundaram, Janooshsheya	Bermudes, Richard A.	Brown, Gregory K.
Adelsheim, Steven	Alwahibi, Abdulrahman	Baler, Ruben	Bernardi, Silvia	Brown, Jordan
Adelsky, Sol	Aly, Tarek	Ballestas, Julio	Bernstein, Carol A.	Brown, Kevin
Adelson, Stewart L.	Amin, Abdel F.	Balon, Richard	Bhatia, Subhash C.	Brown, Millard
Adi, Ahmad	Amin, Ritesh	Banu, Sophia	Bhugra, Dinesh	Brownridge, Andrea M.
Adler, Amy B.	Amin, Rohul	Baranoski, Madelon	Binder, Renée	Brozyna, Caroline D.
Aeschbach Jachmann, Crispa	An, Seung-Min	Barber, Keila D.	Biskin, Robert	Bubl, Emanuel
Aftab, Awais	Ananthamoorthy, Renuka	Barber, Mary	Blair, Thomas	Busch, Alisa B.
Afzal, Fariha	Andersen, Aaron K.	Barkil-Oteo, Andres	Blanco, Carlos	Busch, Fredric N.
Afzal, Saba	Anderson, Frederick	Barnea, Yael	Blank, Arthur S.	Buwalda, Victor J. A.
Aga, Vimal M.	Anderson, Otis	Barnhill, John W.	Blazer, Dan G.	Byne, William M.
Agarwal, Vishesh	Anderson, Tyler	Barry, Declan	Blevins, Derek	Bysani, Sailaja
Agbonyitor, Mawuena	Andruskevicius, Sergejus	Barry, John	Bloom, Mia M.	Caban-Aleman, Carissa
Aggarwal, Rashi	Anees, Muhammad A.	Basalay, Nicholas P.	Blumenfield, Michael	Cadenhead, Kristin
Aguilar, Maria E.	Anglero Diaz, Yohanis L.	Baslet, Gaston	Blyta, Afrim A.	Cai, Stella
Ah Quin, Dyanna Leolani	Annamalai, Aniyizhai	Bassi, Bruce	Boland, Robert J.	Caligor, Eve
Ahmad, Ammar Y.	Anzia, Joan	Bassirnia, Anahita	Bonilla-Silva, Eduardo	Calkins, Monica E.
Ahmed, Iqbal	Aoun, Elie	Bateman, Anthony	Bonnie, Richard J.	Campbell, Marc L.
Ahmed, Mohammed W.	Appelbaum, Paul S.	Bath, Eraka	Borcherding, Breck	Camps-Romero, Eduardo
Ahmed, Saeed	Apter, Gisele	Batista, Sharon	Bordoloi, Meelie	Cano, Miguel Angel
Ahmedani, Brian K.	Aragon, Darinka	Batta, Priya	Borenstein, Jeffrey	Canton, Ali
Ahuja, Amir	Arbuckle, Melissa	Baum, Antonia L.	Bostwick, J. Michael	Canuso, Amy A.
Aimienwanu, Osarhiemen R.	Ardalan, Firouz	Baweja, Raman	Bota, Robert G.	Capaldi, Vincent F.
Akerele, Evaristo	Arditti, Joyce	Bayner, Jessica S.	Boursiquot, Philippe- Edouard	Caplan, Rochelle
Akhtar, Sameerah	Arman, Farid	Bazzi, Lama	Boutros, Nashaat	Carlo, Andrew D.
Akil, Mayada	Arroyo, William	Beahrs, John O.	Bowen, Lynneice	Carlson, Stephan M.
Akinsanya, Adefolake	Aschbacher, Kirstin	Bean, Jennifer	Bowering, Tricia	Carnall, Amy B.
Akiyama, Tsyuyoshi	Ash, David M.	Beck Busis, Deborah	Bowes, Michael R.	Carter, Arthur T.
Aklin, Will M.	Ashley, Kenneth	Beck, Judith S.	Boyce, Cheryl A.	Carter, Dakota
Akpinar, Abdullah	Asif, Muhammad	Becker, Anne	Boyce, Niall	Carter, Debbie R.
Aksoy Poyraz, Cana	Atluru, Aparna	Becker, Daniel F.	Boyd, Carol J.	Caruso, Keith A.
Alarcon, Renato D.	Auchincloss, Elizabeth L.	Begel, Daniel	Boyd, J. Wesley	Casey, Patricia R.
Alavi, Nazanin	Auger, R. Robert	Belhadj-Tahar, Hafid	Boyer, Matthew	Cassimatis, Emmanuel
Albassam, Ahmed	Avery, Jonathan	Bell, Carl C.	Braaten, Ellen	Cassin, Stephanie
Albright, Brittany B.	Ayaz, Sumayya B.	Bell, Holly S.	Bradley, John	Castellanos, Daniel
Alegria, Margarita	Aycock, Jean E.	Bell, Tiffani	Brady, Kathleen	Castilla-Puentes, Wilma I.
Alexander, Ricky	Ayub, Shahana	Belnap, Barri	Brandstetter, Jennifer M.	Castro, Carl
Alhadi, Ahmad	Ayub, Shehzad	Benassi, Paul V.	Braun, Ilana M.	Cauidill, Robert
	Ayuel, Atong		Breen, Ellen K. R.	Cazares, Paulette

Disclosure Index

Certa, Kenneth M.	Cole, Steven	Dela Cruz, Milania	Elkady, Rasha	Foglesong, Dana
Chae, Jeong-Ho	Collins, Ashley D.	Dell, Mary Lynn	Ellison, James M.	Foidel, Sarah
Chakraborty, Amarsha	Colombo, Francesca	DeMarco, Austin	Elmi, Sarah	Foo, Kalvin
Champion, Michael	Colon, Omar A.	DePaolo, Antonio	Elswick, Daniel	Ford, Elizabeth
Chan, Stephanie H.	Colon-Rivera, Hector	DePaolo, J. Raymond	Enomoto, Kana	Fore, Peter
Chaney, Michelle	Compton, Wilson M.	Dereczyk, Aimee	Epstein, Igor	Forrester, Anique
Chang, Grace	Conant-Norville, David O.	Derish, Nicole E.	Epstein, Steve E.	Forstein, Marshall
Chang, Sung Man	Conrad, Rachel	DeRubeis, Laura	Erb, Alexis	Forster, Janice
Charara, Raghid	Conroy, Michelle	Desai, Pratikumar	Erickson, Jennifer M.	Fortuna, Lisa R.
Charles Malveaux, Wilsa M. S.	Conway, Kevin P.	Desai, Toral	Erickson-Schroth, Laura	Fournis, Gael
Charoensook, Janet	Correa da Costa, Sabrina	Detweiler, Mark B.	Erlich, Matthew D.	Fowler, J. Christopher
Chase, Daria	Correale, Jennifer	Devassy, Cindy	Escamilla, Kristin V.	Franco Cadet, Suhey G.
Chatigny, Ashley H.	Coryell, William	Devlin, Michael	Espi Forcen, Fernando	Franco, Kathleen
Chaudhry, Monika	Costello, Caitlin	Dewan, Mantosh	Eswonia, LeRoy C.	Frangou, Sophia
Cheema, Raminder Pal	Cournos, Francine	Dhaliwal, Arashinder	Etwaroo, Narissa R.	Freedman, Robert
Chen, Alexander	Cox, Lara J.	Dhillon, Kanwaldeep	Eun, Tae Kyung	Freidl, Eve Khlyavich
Chen, Donna	Craig, Thomas J.	di Giacomo, Ester	Everett, Anita	Fritz, Gregory K.
Chen, Justin	Crawford, Allison	Di Nicola, Vincenzo	Everett, Mia	Fromson, John A.
Chen, Pao-Huan	Creed, Jamie O.	Diamond, Diana	Evren, Cuneyt	Frueh, B. Christopher
Chen, Wan-Yi	Cremaschi, Laura Angela	Diaz, Esperanza	Eyler, Evan	Frye, Elizabeth A.
Cheon, Jooah	Crone, Catherine	Dickerman, Anna L.	Faggen, Alec	Fryml, Leah D.
Cheong, Josepha A.	Crumlish, Jennifer A.	Dickstein, Leah	Fairbairn, Jonathan	Fu, Emily
Cheung, Stephanie	Cruz Alvarez, Beatriz	Dike, Charles C.	Fairman, Nathan	Fuehrlein, Brian
Chi, Su Hyuk	Cukor, Judith	Dilley, James	Falcone, Tatiana	Fuller, Linda
Chien, I-Chia	Cullen, Bernadette	Dimsdale, Joel E.	Famador, Mark	Fung, Kenneth P.
Chikvashvili, Irina	Cummings, Hugh	Dineen Wagner, Karen	Fan, Qing	Fung, Wai Lun Alan
Chilton, Julie A.	Curseen, Kim	Divakarla, Swati	Fareed, Ayman	Funk, Margo
Chiu, Simon	Cyrus, Kali	Dixon, Lisa B.	Farooq, Mobeen	Furuta, Michelle
Choi-Kain, Lois W.	D'Aquila, Carolyn	Do, Linda	Farrell, Helen	Gabbard, Glen O.
Chong, Yon J.	D'Mello, Dale	Doblin, Rick	Faulkner, Larry R.	Gage, Fred H.
Chopra, Mehak	D'Souza, Deepak Cyril	Dominguez, Matthew L.	Fauman, Beverly	Galanter, Marc
Chotalia, Jigar K.	Dager, Alecia D.	Dong, Hyunseok	Fawcett, Jan	Gallagher, Keith
Christensen, Aleta	Dakwar, Elias	Dooley, Erin	Feldman, Jacqueline M.	Galles, Elyse
Chudal, Roshan	Danzer, Graham S.	Douglas, John	Feldman, Lara W	Galynker, Igor
Chukwu, Ijeoma	Dar, Syma	Downing, Laura M.	Fernandez, Carlos	Gandhi, Raghu
Chukwueke, Priscilla N.	Darby, William C.	Dragatsi, Dianna	Ferranti, Jessica	Gandhi, Tanuja
Chumley, Frank B.	Das, Smita	Dratcu, Luiz	Ferrer, Daphne	Garavan, Hugh
Chung, In-Won	Datta, Vivek	Dress, Erich M.	Feusner, Jamie	Garrick, Marshall L.
Chung, Moon Yong	Dave, Ananta	Dreyer, Benard	Figee, Martijn	Gatchel, Jennifer
Chung, Sang-Keun	Dave, Shalini D.	Druss, Benjamin G.	Fils-Aimé, Joseph R.	Gaytan, Osvaldo
Chung, Seungwon	Dave, Subodh	Du, Ye B.	Fineberg, Naomi A.	Genova, Nicholas J.
Chung, Wilson	Davidoff, Donald A.	Dube, Anish R.	Fink, Sabina	Gershengoren, Liliya
Chwastiak, Lydia	Davidowitz, Andrew	Duckworth, Ken	Fink, Victoria	Ghairatmal, Mohammad A.
Clark, Scott	Davidson, Deepak M.	Duda, Roger	Finlayson, A. J. Reid	Ghani, Shareh O.
Clarke, Diana E.	De Erasquin, Gabriel	Dumas, Noel, B.	Fiskin, Anna	Ghignone, Erica
Coffin, Phillip O.	De Guzman, Earl Andrew B.	Dunlap, Constance E.	Fitelson, Elizabeth	Ghimire, Shree R.
Cohen, Carl I.	de Julio, Adriana B.	Dusad, Asha	Fjukstad, Katrine K.	Ghiya, Deepti
Cohen, Jenna	Deans, Emily C.	Duval, Fabrice	Flaherty, Marissa	Giliberti, Mary
Cohen, Lisa J.	Deas, Deborah	Eilender, Pamela	Flinton, Christopher	Gillihan, Seth J.
Cohen, Mary Ann A.	DeGraba, Thomas J.	Eisen, Jane L.	Flora, Charles M.	Gilman, Megan L.
Cohen, Mitchell J.	DeJong, Sanda	El Sara, Ammar	Flynn, David	Ginory, Almasi
		Elias, Alby	Fochtmann, Laura J.	Ginory, Laura

Disclosure Index

Gipson, Shih Yee-Marie Tan	Gularte, Valeria S.	Henn, Fritz	Ibeziako, Patricia	Joshi, Pallavi
Giri, Aditi	Gunderson, John	Hermida, Adriana	Ibrahim, Lobna	Joshi, Paramjit
Gise, Leslie H.	Gunturu, Sasidhar	Hernandez, Sergio	Iheagwara, Chioma L.	Joy, Michelle
Glancy, Graham D.	Guo, Qi	Herrera, Cristian Y.	Iheanacho, Theddeus	Judge, Sheila
Glick, Ira	Gupta, Nandni	Herrman, Helen	Ikekwere, Joseph C.	Jun, Tae-Youn
Glick, Rachel	Gupta, Neha	Hersh, Richard	Ilipilla, Geeta S.	Jung, Chan Hyun
Glover, Juliet A.	Gupta, Nitin	Hershey, Benjamin R.	Immanuel, Josepha	Kahlon, Ramandeep S.
Gobbi, Gabriella	Gurski, John	Heru, Alison M.	Imran, Sheema	Kakhi, Sara
Goddu, Sumana	Guthrie, Elisabeth B.	Hidalgo, Marla	Ingram, Douglas H.	Kallivayalil, Roy A.
Goedken, Rebecca E.	Guttikonda, Sameera	Higgins, Napoleon B.	Iqbal, Muhammad N.	Kanba, Shigenobu
Goelitz, Melissa	Guzman, Margarita	Hill, Kevin	Irfan, Muhammad	Kang, Jee In
Goethe, John W.	Habl, Samar	Hill, Wesley	Irwin, Scott	Kang, Suk-Hoon
Goff, Donald C.	Hackman, Ann	Hilty, Donald M.	IsHak, Waguih W.	Kannali, Rajasekhar
Gogineni, Rama Rao	Hagan, Jarred	Ho, Cyrus S. H.	Isinguzo, Chidinma	Kantor, Edward
Gold, Liza H.	Haglund, Margaret	Hoang, Julia L.	Islam, Zahid	Kaplish, Dheeraj
Goldbach, Jeremy	Hah, Jennifer	Hobbs, Jacqueline A.	Ivanova, Danielle	Kapoor, Shweta
Goldenberg, Matthew N.	Hairston, Danielle	Hodson, David S	Ivany, Christopher	Karasic, Dan H.
Goldman, Matthew L	Hall, Ryan	Hoffman, Christopher	Iyer, Veeraraghavan J.	Karim, Reef
Goldwasser, Alberto M.	Haller, Ellen	Hoffman, Perry	Jabeen, Shagufta	Karlsson, Per-Axel L.
Gomez Fuentes, Amy C.	Halperin Rosen, Anna	Hoge, Charles	Jabri, Lamis	Kaster, Tyler
Gomez, Chaska	Haltzman, Scott	Hoge, Steven	Jacob Mathai, Ashwin	Kathol, Roger
Gomez, Juan Carlos	Hamdani, Najma F.	Hoirisch-Clapauch, Silvia	Jacob, Karen L.	Kato, Takahiro A.
Goniewicz, Maciej L.	Hamidovic, Ajna	Holbert, Richard	Jahdi, Maryam	Kaur, Amanjot
Goode, Kimberly D.	Hammamieh, Rasha	Hollander, Eric	Jain, Abhishek	Kazmi, Ajmal
Goodman, Marianne	Han, Doug Hyun	Holloway, Ian W.	Jain, Lakshit	Keenan, Walker D.
Goodwin, Ericka	Hanif, Amina	Holsey, M. D.	James, Christopher	Keith, Asheena
Gordon, Kimberly	Hann, Michael	Hong, Victor	Janda, Kim D.	Kemble, Stephen B.
Gorelick, David	Hanrahan, Mary	Hooshmand, Farnaz	Janofsky, Jeffrey S.	Kendler, Kenneth
Gorrindo, Tristan	Haque, Shariq	Horgan, John	Jayaram, Geetha	Kennedy, Patrick
Goschin, Simona	Hardaway, Rashad	Horowitz, Mardi	Jenkins, Thomas	Kennedy, Robert
Goswami Banerjee, Arpita	Hardeman, Suzanne M.	Horvath, Thomas B.	Jennings, Keith W.	Kennedy, Sidney H.
Goyal, Dharmendra K.	Harding, Richard	Horwitz, Josh	Jeon, Junwon	Kent, Laura K.
Graham, Yolanda P.	Harewood, Meredith	Howe, Edmund G.	Jessica, Moore	Kern, John
Gralnik, Leonard M.	Harrigan, Michael R.	Hoxha, Avjola	Jeste, Dilip V.	Kernberg, Otto F.
Grammer, Geoffrey	Harris, Christopher	Hreish, Mark N.	Jett, Marti	Kertzner, Robert M.
Grant, Cynthia	Harris, Gregory G.	Hsu, Kean J.	Jha, Manish K.	Ketchen, Bethany
Grassi, Giacomo	Harris, Patrice	Hu, Sai	Ji, Ning	Kethini, Vandana
Gray, Kyle J.	Harrison, Nzinga	Huang, Yueqin	Joe, Soohyun	Khairalla, Hanan
Gray, Sheila H.	Hart, Joseph	Hughes-Feltenberger, Megan	Johnson, David	Khairy, Nahed
Greenbaum, Jordan	Harvey, Margaret	Hunzeker, Adam	Johnson, Sarah	Khalafian, Andrey
Greer, Tracy	Hasan, Rabiya	Huremovic, Damir	Johnston, Robert J. H.	Khalid-Khan, Sarosh
Gregoire, Phillip	Hasnain, Mehrul	Hurley, Brian	Joiner, Thomas	Khalil, Afaf H.
Griffith, Ezra	Hassan, Tariq	Hurwitz, Thomas D.	Jones, Jana	Khan, Jaffar
Griffith, James	Hatters-Friedman, Susan J.	Husain, Nusrat	Jones, Meissa M.	Khan, Mohammed A.
Grob, Charles	Hawa, Raed	Hussain, Filza C.	Jones, Travis W.	Khan, Mohsin
Gross, Raz	Hawes, Mariah	Hutton, Todd	Jordan, Ayana	Khan, Muhammad
Gruenberg, Linda F.	Hazlett, Erin	Huynh, Martin K.	Jose, Divya E.	Khan, Qaiser S.
Gspandl, Scott	Hedrick, Saima	Hwang, Michael	Joseph, Courtney	Khanna, Surbhi
Guanci, Nicole	Heeramun, Vineka	Hyde, Lee S.	Joseph, Robert C.	Khawaja, Imran S.
Guerra, Paloma A.	Hemani, Umair M.	Hylar, Steven E.	Josephson, Allan	Khawam, Elias
	Hendryx, Travis	Iarovici, Doris	Joshi, Astik	Khosh-Chashm, Darrow
	Henein, Fady		Joshi, Kaustubh G.	Khushalani, Sunil

Disclosure Index

Khusid, Marina	Kum, Seon	Li, Luming	Mangiardi, Mario	Millard, Hun
Kidd, Jeremy D.	Kumar, Reena	Li, Shuang	Mann, Gurtej S.	Millegan, Jeffrey
Kilani, Jyotsna	Kumari, Meena	Lichtenstein, Max A.	Manocha, Pankaj	Miller, Adam
Kim, Chaeri	Kurdyak, Paul	Licinio, Julio	Marazziti, Donatella	Miller, Andrew
Kim, Chul-Eung	Kurkjian, Natalie	Lim, Jongseok	Marcus, Adeyemi	Miller, Gregory
Kim, Daniel	Kurtz, Kristina E.	Lim, Russell F.	Mariani, John J.	Miller, Shefali
Kim, Daseul	Kuvischansky, Jaime M.	Lima, Ateaya	Marino, Leslie	Mills, Jacob
Kim, Eui-Jung	La Noce, Audrey	Lin, Joy E.	Marino, Patricia	Milrod, Barbara
Kim, Eun Young	LaChance, Laura R.	Lipsitt, Don	Markkula, Niina	Minhas, Hassan M.
Kim, Han-Joon	Lackamp, Jeanne	Lisotto, Maria Jose	Markowitz, John C.	Mintz, David L.
Kim, Helena K.	LaFrance, W. Curt	Liu, Lusha	Marlin, Robert P.	Mistry, Amit
Kim, Hyun	Lagman, Jasmin G.	Liu, Shiyuan	Martinez, Richard	Mitra, Paroma
Kim, Jung W.	Lahera, Guillermo	Liu, Zhaorui	Martino, Steve	Moamai, Javad
Kim, Kahlen Hong Seon	Lai, Hank	Lizano, Paulo L.	Martz, Gloria	Moffic, H. Steven
Kim, Keun You	Lakshmin, Pooja	Lluberes Rincon, Nubia G.	Marumoto, Megan	Mogallapu, Raja
Kim, Kyungwon	Lam, June	Lochhead, Jeannie	Maruyama, Nancy	Moghimi, Yavar
Kim, Minsu	Lambert, Kristen M.	Loehr, Colleen	Mashiana, Amanpreet	Mohite, Satyajit
Kim, Seong Hwan	Lambrese, Jason V.	Lohitsa, Akshay	Maskel, Lynn	Mohyuddin, Farooq
Kim, Siekyeong	Lavender, Ted	Lokko, Hermioni	Mathur, Anu	Mohyuddin, Hira
Kim, Taeho	Lazarus, Arthur	Lolak, Sermsak	Maududi, Syed E.	Mokrani, Marie-Claude
Kim, Won	Lazarus, Joash T.	Lomax, James W.	Mazhar, Mir N.	Molaie, Ali M.
Kim, Yong-Ku	Le, Hoa	Lowenthal, David	McCabe, Sean E.	Montalvo, Cristina
Kim, Young Hoon	Leal, Camilo	Lowy, Daniel L.	McCarron, Robert M.	Montano Arteaga, Pamela C.
Kim, Young Shin	Lee, Byeonghee	Lu, Francis	McClure, Deimante	MontazerAlghaem, Douna
Kimm, Tyler	Lee, Chuan-Mei	Lubarda, Jovana	McDougall, Matthew A.	Montenegro, Roberto E.
Kingdon, David	Lee, Deokjong	Lubin, Molly	McDuff, David R.	Montoya, Ivan D.
Kiong, Timothy	Lee, Elliott K.	Lynch, Alison	McGinnis, MegAnn K.	Mooney, Larissa
Kirsch, Daniel	Lee, Hochang B.	Lytle, Sarah M.	McGlynn, Lawrence	Moore, Kevin D.
Kjær, Jesper N.	Lee, Hyuk	MacDonald, Kelly	McGovern, Amanda	Moore, Lauren E.
Klass, Benjamin O.	Lee, Hyun-Ah	MacKenzie, James G.	McGraw, Kate	Moosey, Matthew
Kleiman, Mark	Lee, Kyoung-UK	Mackey, Sean	McHugh, Paul	Moreira-Almeida, Alexander
Klin, Ami	Lee, Li-Wen Grace	MacLeod, Stephanie	McKenzie, Kwame	Moreno, Arnaldo
Knoll, James L.	Lee, Sang Kyu	Madan, Alok	McLeod, Megan	Moreno, Maria E.
Koenig, Jessica A.	Lee, Sang Yeol	Madhusoodanan, Subramoniam	McMickens, Courtney	Morgan, Theresa A.
Koenigsberg, Harold W.	Lee, Seung-Hwan	Madsen, Helle	McNeil, Shawn E.	Morris, Sapna B.
Koh, Steve H.	Lee, Soyoen	Maeng, Se-Ri	McNiel, Dale	Moscicki, Eve
Kolodner, George	Lee, Woo Hyung	Mahdani, Artin	McVoy, Molly	Mosier, Jessica
Komrad, Mark	Lee, Young Sik	Mahendran, Rathi	Medici, Clara R.	Moukaddam, Nidal
Koniaris, Christine	Leistedt, Samuel J.	Maheshwari, Subani	Medlock, Morgan	Moutier, Christine
Kor, Ariel	Leivent, Jacob	Mahgoub, Yassir	Melicher, Tomas	Mruthyunjaya, Pranathi
Koss, Debra	Lemieux, Anthony	Mahoney, Nicholas	Mellon, Synthia H.	Mudgway, Ross J.
Kosten, Thomas	Levin, Saul	Maj, Mario	Mendiola, Andrea	Munjaj, Sahil
Kothari, Kavita	Levine, Henry S.	Makani, Ramkrishna D.	Merlo, Lisa J.	Munnangi, Lakshmi P.
Koyuncu, Ahmet	Levine, Stephen B.	Makanjuola, Titilayo	Merti, Julia	Murphy, Dewey S.
Krakowski, Menahem I.	Levitt, William	Maldonado, Jose R.	Metzner, Jeffrey L.	Murphy, James
Kraus, Louis	Levounis, Petros	Malik, Arsalan	Meyer, Donald J.	Muskin, Philip R.
Krishna, Swathi	Levy, Sharon	Malik, Mahgul	Meyer, Eric	Musselman, Dominique L.
Kroeger Ptakowski, Kristin	Lewandowski, Cathleen A.	Maloy, Katherine	Meyer-Bahlburg, Heino F. L.	Muszynski, Irvin L.
Krueger, Robert	Lewis, Edward T.	Maltz, Brenda	Miccio, Steve	Myers, Michael F.
Kudler, Harold	Li, Dongmei	Manalai, Partam	Miday, Karen K.	
Kudva, Ganesh	Li, Eun Jung	Mangal, Jed P.	Mihajlovic, Aida S.	

Disclosure Index

Myers, Trenton	Okuda, Mayumi	Pato, Michele T.	Purcell, David W.	Ripperger-Suhler, Jane
Myers, Wade C.	Okwesili, Meredith A.	Patriquin, Michelle	Puri, M. Rehan	Ritchie, Elspeth C.
Nadelson, Carol C.	Olarte, Silvia W.	Paudel, Shreedhar	Quang-Dang, Uyen-Khanh	Rivelli, Sarah
Naeem, Farooq	Oldham, John M.	Pazuniak, Markian	Quintanilla, Maria Beatriz	Rivera, Margo
Nagalla, Madhavi	Olson, David P.	Pearlson, Godfrey D.	Qureshi, Naema	Rivolta, Juan A.
Nagurney, Michelle	Olupona, Tolu	Pelka, Bryan M.	Raad, Raymond	Riyaz, Sonia
Nam, Yoonmin	Ong, Christopher F.	Pender, Vivian	Rachakonda, Saumya	Roberts, Laura
Narasimhan, Meera	Orr, Matt	Pendler, Paul	Radhakrishnan, Rajiv	Robertson, Katherine
Nardi, Antonio E.	Osher, Fred C.	Penesetti, Deepak	Radoncic, Vanja	Robinson, Diana M.
Nascimento, Antonio L.	Osman, Ekatherina	Pengrin, Lauren	Raheja, Uttam	Robinson, Gail E.
Nash, Maureen C.	Osman, Ossama T.	Penn, Joseph V.	Rahmani, Rumana	Robles MartÃ-nez, MarÃ-a
Nasrulla, Insiya	Osofsky, Howard J.	Penska, Keith	Rai, Abhishek	Robles-Ramamurthy, Barbara
Nassan, Malik	OsÃrio, FlÃvia L.	Penumetcha, Varma	Rajewska-Rager, Aleksandra	Roca, Robert
Navarro, Aniceto	Ospina Duque, Jorge	Penzner, Julie B.	Rakesh, Gopalkumar	Rodin, Rebecca
Naveen, M. M.	Ouanes, Sami	Pereira, Luis	Rally, Sanjeev K.	Rodriguez, Lorena
Neff, Daniel	Ouellette, P. Lynn	Perez-Rodriguez, M. Mercedes	Ramaswamy, Sriram	Rodriguez-Cabezas, Lisette
Negbenebor, Nicole	Owen, Andrew	Perkins, Matthew B.	Ramsey, Drew	Rodriguez-Guzman, Juan
Nelson, Christopher	Ozbayrak, R. Kaan	Peroski, Michael S.	Raney, Lori	Rodriguez-Roman, Laura
Nelson, Sally	Ozdemir, Armagan	Perrin, Andrew	Ranganathan, Mohini	Roman, Daniel O.
Nepal, Hitekshya	Ozel-Kizil, Erguvan T.	Pesa, Jacqueline	Rao, Nyapati R.	Romba, Courtney A.
Neramballi, Malini	Padilla Candelario, Auralyd	Peseschkian, Hamid	Rao, Vani	Ronningstam, Elsa F.
Netherton, Elisabeth	Pai, Nagesh	Pestana Knight, Elia M.	Rapaport, Mark H	Roof, Jason
Neufeld, Ron	Palazzolo, Jerome	Peteet, John	Rathod, Shanaya	Rose, Raquel E.
New, Antonia S.	Pallanti, Stefano	Petersen, Christopher A.	Ratnakaran, Badr	Rosenblat, Joshua D.
Newmark, Thomas	Palmer, Brian	Petersen, Daena L.	Ratzliff, Anna	Rosenheck, Robert
Nguyen, Sarah A.	Pao, Maryland	Petitjean, Francois	Rauch, Sheila A. M.	Rosenquist, Peter B.
Ni, Michael	Parekh, Ranna	Pettigrew, Roderic	Razafsha, Mahdi	Roskes, Erik
Nicolas, Samuel A.	Parikh, Niketa	Pflanz, Steven E.	Razdan, Anupriya	Rothe, Eugenio M.
Nijjar, Gursharon	Parikh, Tapan	Phillips, Steven R.	Reddy, Abhishek	Rothenberg, Kasia G.
Nikiforov, Ivan	Park, Bhinna P.	Piddoubny, Walter	Reese, LeRoy	Rotter, Merrill
Nikzad, Wahid	Park, Dongchan	Pier, Katherine	Regenbogen, Alexandra	Roy, Arunima
Nisar, Mohammad A.	Park, Hyemi	Pierce, Andrew	Regincos, Rosa	Roy, Kamalika
Nissan, David A.	Park, Jiyeon (Regina)	Pilla, Malathi	Rehim, Aimy	Rozel, John S.
Nissirios, Kalliopi S.	Park, Sa Eun	Pinals, Debra	Reich, James H.	Ruedrich, Stephen
Nitturkar, Abhishek R.	Park, Seon-Cheol	Pine, Daniel S.	Reid, Czerne M.	Ruiz, Amanda
Niu, Grace C.	Parmar, Arpit	Pinninti, Narsimha	Reid, Racquel E.	Ruiz, Pedro
Niu, Kathy	Parsaik, Ajay	Plakun, Eric M.	Resnick, Phillip J.	Rumbaugh, William D.
Nordon, Clementine	Pary, Robert J.	Pleak, Richard R.	Ressler, Kerry	Runels, Diane
Nordstrom, Kimberly D.	Pashko, Steven	Pollack, Mark H.	Reyes, Maria M.	Russ, Mark
Norko, Michael	Pate, R. Jill	Poon, Amy	Riba, Michelle B.	Ryan, Deirdre M.
Notman, Malkah T.	Patel, Ankur	Porche, Michelle V.	Ribeiro Caldas Domingues, Isabel	Sabatello, Maya
Nowicki, Stephen	Patel, Erin L.	Porter-O'Grady, Tim	Rice, Alexandra K.	Sachdeva, Shilpa
Nunes, Edward V.	Patel, Mitesh	Portilla, GarcÃ-a	Richards, Lawrence K.	Sadat Azizi, Nargis
Nurmi, Erika L.	Patel, Rachit	Potter, Nancy	Richards, Misty	Saeed, Sy A.
Nusair, Furqan	Patel, Rahul Kumar	Pourrezaei, Kimia	Richardson, Elizabeth J.	Safar, Laura
Nwankwo, Vincent N.	Patel, Ronak	Powsner, Seth	Richardson, Rita R.	Safin, Daniel
O'Brien, Virginia	Patel, Ronak	Prabhakar, Deepak	Richter, Matthew	Sahu, Geetanjali
O'Gorman, Cedric	Patel, Ruchirkumar A.	Preti, Emanuele	Ridout, Kathryn K.	Salerno, Karen E.
O'Reardon, John P.	Patel, Rupal	Price, Marilyn	Ridout, Samuel J.	
Obi Berry, Obianuju "Uju"	Patel, Shama	Puchakayala, Nandita		
Okoronkwo, Joshua	Patel, Shirali S.	Pula, Jack		
	Patnaik, Mitali			

Disclosure Index

Salgado, Cassandra	Shah, Ravi N.	Sohn, Sungyun	Suryadevara, Uma	Trager, Evan J.
Sampathgiri, Kruthika	Shah, Saloni	Sola, Christopher	Susaimanickam, Bibiana M.	Tran, David
Samsel, Chase	Shahzadi, Ulfat	Soldinger, Steve	Susser, Leah	Tran, Shelly T.
Samuels, Susan	Shakeri, Jalal	Soloway, Scott	Suzuki, Amanda	Trestman, Robert L.
Sanchez, Katherine	Shao, Wanda	Song, Jaemin	Swartz, Marvin S.	Trevisan, Louis
Sanchez-Rivero, Yuliet	Shapiro, Anna P.	Sonty, Ramana	Swiggart, William H.	Trimble, Michael
Sanislow, Charles A.	Shapiro, Edward R.	Sood, Shabnam	Syed, Sharif	Trivedi, Madhukar
Santiago, Vincent A.	Shapiro, Gabrielle L.	Sorel, Eliot	Szerman, Nestor	Truong, Anh L.
Santos, Eric	Sharfstein, Steven S.	Sorrentino, Renee	Tafet, Gustavo E.	Tseng, Mei-Chih M.
Sapieha, Michal	Sharma, Ashish	Sosunmolu, Shoyinka O.	Takada, Ryohei	Tsuang, John W.
Sarhan, Walid	Sharma, Shridhar	Spencer, Andrea E.	Takahashi, Hidetoshi	Tucci, Veronica
Sarikaya Varlik, Dilek	Sharon, Haggai	Sperber, Jacob	Takayasu, Alexandra	Tuck, Andrew N.
Sarvet, Barry D.	Sharp, Carla	Sperry, Len	Talbott, John A.	Tucker, Phebe M.
Satcher, David	Shayanpour, Mahrokh	Spiegel, David	Tamburello, Anthony	Turner, Ana
Sattar, Ayesha	Shear, Matthew	Spokas, Laima	Tampi, Rajesh R.	Turner, Andia H.
Savu, Vasile	Sheehan, Kathleen	Spollen, John	Tandon, Rajiv	Ucok, Alp
Saxena, Ashwini	Sheehan, Matthew M.	Spoth, Richard	Tapias, Rafael E.	Ulaj, Jusuf S.
Saxon, Andrew J.	Sheikh, Sarah	Sreepathi, Ananya R.	Tardelli, Vitor S.	Umrانيا, Hiren
Scahill, Lawrence	Sheline, Yvette	Sreshta, Nina E.	Tarman, Daniel D.	Unützer, Jürgen
Schaaf, Kathy	Shenava, Manisha	Srinivasan, Shilpa	Tarshis, Thomas P.	Uzal Fernandez, Cristina
Scheiber, Stephen C.	Sher, Leo	Srinivasaraghavan, Jagannathan	Taube-Schiff, Marlene	Vaaler, Arne E.
Schiff, Miriam	Sher, Yelizaveta	St. Victor, Guitelle	Taylor, Doug	Vahia, Ipsit
Schindzielorz, Adam H.	Shim, Ruth	Starner, Meghan N.	Taylor, Geoffrey P.	Vanderlip, Erik
Schlozman, Steven	Shim, Se-Hoon	Stein, Aliza T.	Taylor, Jared K.	Vannucci, Adriana
Schmahl, Christian	Shindler, Maria L.	Steinberg, Leah R.	Taylor, Jerome H.	Vargas Cruz, Cindy
Schmidt, Luisa C.	Shivaneekar, Sharvari P.	Steinberg, Louisa J.	Taylor-Desir, Monica	Varghese, Celia
Schmidt, Scott	Short, Jessica M.	Stepp, Stephanie	Tegin, Cuneyt	Varlik, Cenk
Schneider, Brett	Shrivastava, Amresh	Sterling, Stacy	Teo, Alan R.	Vasan, Nina
Schneidman, Barbara S.	Shtasel, Derri	Stern, Barry L.	Thakrar, Tina S.	Vaughn, Rubiahna
Schnellbacher, Sebastian	Shuara, Saoda	Stern, Stephen L.	Thangaraj, Swaminathan	Vela, Ricardo M.
Schott, Meghan	Shulman, Barbara	Stewart, Altha J.	Thelen, Mindi	Velliz, Philip
Schuermeyer, Isabel	Sidaros, Rafik	Stokes, Wesley	Thelen, Tim	Vemuri, Divya
Schwartz, Ann	Siegele, Harry	Stone, Alan	Thiam, Melinda A.	Venigalla, Hema
Schwartz, Patricia	Sierzchula, Jessica J.	Stone, Alice E.	Thiara, Gurneet S.	Verduin, Marcia L.
Schwartz, Thomas L.	Silk, Kenneth R.	Stotland, Nada L.	Thielman, Samuel	Vergare, Michael
Schwartz, Victor	Simkin, Deborah R.	Strain, James J.	Thomas, Anil A.	Verma, Chittranjan B.
Scoggin, Steven	Simon, Kevin M.	Stratton, Tyler E	Thomas, Christopher	Vermetten, Eric
Scott, Charles	Simpson, Annabelle K.	Stubbeman, William F.	Thomas, Connie	Veveva, Jan
Scully, Stephenie A.	Singh, Balwinder	Stupinski, John	Thomas, Jean M.	Vijapura, Sagar
Secarea, Cristina M.	Singh, Gurjot	Subedi, Jagannath	Thompson, Kenneth	Vinacour, Carlos
Sederer, Lloyd I.	Singh, Harvinder	Subhash, Ajith	Thompson, Sonda	Vinson, Sarah Y.
Seegan, Alexis A.	Singh, Jasbir	Subramaniam, Geetha A.	Thompson, William W.	Vito, Jose
Segal, Andrea G.	Sinha, Preeti	Sugumar, Archana	Tillman, Jane G.	Vo, Lan Chi Krysti L.
Seibell, Phillip J.	Sinkeviciute, Igne	Suh, Ho-Suk	Timmons-Mitchell, Jane C.	Volkow, Nora
Serhal, Eva	Siragusa, Joseph	Suh, HwaGyu	Titcombe-Parekh, Roseann F.	Volman, Susan F.
Serrano, Patricia	Sisti, Dominic	Sultan, Ryan S.	Tobkes, Taylor	von Hafften, Alexander
Serrano-Villar, Maria	Sjöstrand, Hanna	Summergrad, Paul	Toledo, Theresa	Vora, Ankita
Sethi Dalai, Shebani	Skolnick, Phil	Sung II, Jung	Toll, Alba	Wager, Tor
Setlow, Barry	Smith, Mary Kay	Sung, Dawn	Torbey, Souraya	Waggoner, Thuy Hong N.
Severe, Jennifer	Smith, Paula Marie	Sung, Hyung-Mo	Torous, John	Wainberg, Milton
Shah, Apeksha	Snyder, Elise	Suo, Shannon		Waits, Wendi
Shah, Pooja	Sockalingam, Sanjeev			

Disclosure Index

Walaszek, Art	Weisensel, Nicolette	Witter, Daniel	Yehia, Baligh R.	Zhang, Yuqun
Waldman, Randee	Weiss, Kenneth J.	Wnuk, Susan	Yehuda, Rachel	Zhong, Jun
Walker, Anitra	Weiss, Roger D.	Wolf, Jonathan P.	Yellowlees, Peter	Zimmerman, Mark
Walker, Melissa	Weiss, Susan R. B.	Wolf, Kari M.	Yeomans, Frank E.	Zinns, Rachel
Walker, Sandra C.	Weisser, Lydia E.	Wonodi, Ikwunga	Yin, Yingying	Zisook, Sidney
Wallack, Joel J.	Weissman, Anna	Woo, Benjamin	Yohanan, Monique	Zonana, Howard
Walsh, B. Timothy	Weissman, Sidney	Woo, Jong Min	Yohanna, Daniel	Zonana, Jess
Wang, Dana	Welch, Stephen	Wood, Keith	Young, Allan H.	Zun, Leslie
Wang, Dora	Wendt, Burdette	Woolley, Stephen	Young, John Q.	Zuschlag, Zachary
Wang, Jack	Wertheimer, Moira	Works, Lindsay	Yousuf, Mohammad	D.Zdanys, Kristina
Wang, Paul	West, James C.	Worley, Linda L. M.	Yue, Yingying	Zembrzuska, Hanna
Wang, Philip	Westermeyer, Joseph J.	Wrenn, Glenda	Yuen, Laura D.	Zerbo, Erin
Wang, Po	White, Christopher	Wu, Hanjing E.	Yur'yev, Andriy	Zhand, Naista
Wang, Shao-Cheng	White, Leigh	Wynn, Gary H.	Yurgelen-Todd, Deborah	Zhang, Layan
Ward, Herbert	Wick, Paul H.	Xiang, Shuo	Zafar, Jawad	Zhang, Melvyn
Ward, Martha C.	Wiechers, Ilse	Yager, Joel	Zafer, Maryam	Ziedonis, Douglas
Warner, Christopher H.	Wiegand, Hauke F.	Yakov, Svetlana	Zakers, Aleema	Zielinska, Anna
Warnick, Stephen J.	Wiles, Preston	Yam, Philip M.	Zalpuri, Isheeta	Zilber, Claire
Wasser, Tobias	Wilkins, Kirsten	Yamamuro, Kazuhiko	Zanarini, Mary C.	Zimmerman, Mark
Watson, Clarence	Wilkins, Victoria	Yancovitch, Alan C.	Zarra, Julio C.	Zisook, Sidney
Watson, Hunna J.	Wilkinson, Samuel	Yang, Fang	Zeid, Dana	Zobel, Craig
Webb, Allison	Williamson, Johnny	Yang, Jong-Chul	Zeng, Mary C.	Zonana, Howard
Weber, Jenine	Wills, Cheryl	Yao, Lihua	Zerrate, Maria C.	Zubera, Atika
Wei, Mike	Winfrey, Chris	Yap, Yen Ling	Zeshan, Muhammad	Zurowski, Mateusz
Weinberg, Igor	Winger, Bryce	Yaseen, Zimri S.	Zhan, Chang-Guo	Zuschlag, Zachary
Weine, Stevan M.	Winter, Christine A.	Ye, Chuangzhong	Zhang, Layan	
Weinstock, Robert	Wiste, Anna K.	Yeaw, Jennifer	Zhang, Tingting	

Certificate of Attendance

How do you obtain it?



GET YOUR CERTIFICATE ONLINE OR IN PERSON



To receive your certificate online:

Complete the online evaluation at psychiatry.org/AnnualMeetingCME

**Retain badge number to access evaluation online*

The website will remain active until:

August 18, 2016

CME credit for APA members will be recorded at apaeducation.org and transferred to your ABPN Physician Folio in October 2016.

CME Certificate of Attendance Booth
Location: Escalator to B3-B4, Level 2

Hours of Operation:

May 14-18 8:00 a.m. - 5:30p.m. Daily

CERTIFICATE IS AVAILABLE DURING OR AFTER THE MEETING

To receive your certificate in person:

Complete the general evaluation form at the
CME Certificate of Attendance Booth
Located in the Escalator to B3-B4, Level 2

Types of Certificates

- Certificate of Credit for physicians
- Certificate of Attendance for non-physicians

Accreditation & Designation

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates this live activity for a maximum of *40 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions, contact the American Psychiatric Association Department of CME:
educme@psych.org



Can't Attend Every Session?

Order APA Annual Meeting On Demand and Save \$1,000!

With many sessions occurring simultaneously, your On Demand program gives you the opportunity to participate in all key presentations, helping you maximize the investment you've made in attending the live meeting.

Features of APA Annual Meeting on Demand:

- Online access to 400 hours* of presentations from any computer or mobile device (available within 24 hours of the live session)
- CME credit available via integrated online tests
- Downloadable MP3 audio files for enhanced mobility
- Complimentary portable USB drive** for offline viewing

	LIST PRICE	YOUR PRICE
Attendee: MD's	\$1,399	\$399 <i>You save \$1,000</i>
Attendee: Residents	\$1,399	\$199 <i>You save \$1,200</i>

Order Today!

Special offer ends May 18, 2016.

Visit One of Our Sales Booths Education Center – Level 2 or Registration Area – Level 1

Order Online Orders.OnDemand.org/APA/Atlanta

Order by Phone 800-501-2303 (U.S Only) or 818-844-3299

Monday – Friday 6 a.m. – 5 p.m. PST

* Specific presentations within a session may not be available or may be audio only if the presenter has confidential patient information or otherwise declines to be recorded.

** USB drive does not include all the functionality available online, such as Advanced Search, Recently Viewed, MP3 Downloads, Bookmarks and CME testing.



LET'S CONNECT

**LEARN HOW ACADIA PHARMACEUTICALS
IS CHANGING THE CONVERSATION IN
PARKINSON'S DISEASE PSYCHOSIS.**

BOOTH #1437

**THE AMERICAN PSYCHIATRIC ASSOCIATION
ANNUAL MEETING**

57,000+

PSYCHIATRY-SPECIFIC RISK MANAGEMENT ISSUES ADDRESSED



WE SUPPORT YOU

Having addressed over 57,000 psychiatry-specific risk management issues on the Risk Management Consultation Service helpline since 1997, our knowledgeable team of in-house risk managers is committed to providing assistance when you need it most. With a library of 360 risk management articles and tips, our clients have access to informative and timely resources free of charge.



CHARLES D. CASH, JD, LL.M, ARM
ASSISTANT VICE PRESIDENT, RISK MANAGEMENT



In California, d/b/a Transatlantic Professional Risk Management and Insurance Services.

Unparalleled risk management services are just one component of our comprehensive professional liability insurance program. When selecting a partner to protect you and your practice, consider the program that puts psychiatrists first. **Contact us today.**

More than an insurance policy

800.245.3333 | PsychProgram.com/Dedicated | TheProgram@prms.com



Actual terms, coverages, conditions and exclusions may vary by state. Unlimited consent to settle does not extend to sexual misconduct.

Insurance coverage provided by Fair American Insurance and Reinsurance Company (NAIC 35157). FAIRCO is an authorized carrier in California, ID number 3175-7. www.fairco.com

Program

Format Descriptions	56
Daily Attendance Log	58
Saturday's Program	59
Sunday's Program	73
Monday's Program	97
Tuesday's Program	123
Wednesday's Program	141



Format Descriptions

Advances in Series

These sessions highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. Some of these sessions are chaired by editors of recent textbooks published by American Psychiatric Association Publishing and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased onsite and online at the APA Bookstore.

Advances in Research

In these sessions, leading clinical researchers will present the latest developments in research.

Advances in Medicine

This format includes sessions designed to provide psychiatrists with the latest in clinical developments in other areas of medicine. The intent is to give participants an update from a physician in a particular specialty. These sessions will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine.

Case Conferences

These 90-minute sessions begin with clinical material presented by videotape or the treating therapist. One or more experts then discuss the case. These sessions are open to APA members only.

Courses

Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day) and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

FOCUS Live!

These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small-group consultation with an expert clinician. Experts, who served as guest editors of *FOCUS*, will lead lively multiple-choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen. Participants should plan to bring their own mobile device to *FOCUS Live!* sessions.

Forums

Forums are flexible 90-minute to two-hour presentations that afford an opportunity to highlight and select timely topics that are of interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

Interactive Sessions

This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the expert, to obtain consultations around problems in research from senior researchers or to use clinical material offered by the participants and hear clinically based seminars presented by outstanding educators. Some interactive sessions are reserved for residents only. These sessions are limited to a set number of attendees on a first-come, first-served basis.

Lectures

Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers. Award lectures are selected by the various APA Award Boards.

Format Descriptions

Media Workshops

Media Workshops are three-hour sessions in which a panel of presenters shows and then discusses a feature-length film. This discussion is usually open to audience participation.

Poster Sessions

This format highlights presentations of very recent findings. Posters are visual, self-explanatory presentations offered in four categories: International, Medical Student and Resident Competition, New Research and Young Investigators' New Research. See the New Research section of this book for a complete schedule of poster presentations.

Scientific and Clinical Reports

Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with discussion from the audience following the presentation of each paper. There is no formal discussion.

Seminars

This is a format allowing for in-depth teaching and learning related to "niche" topics or covering issues that represent a service to the profession (e.g., impaired physician programs, patient suicide, etc.). It is also a venue for testing the feasibility of new courses by offering the content free for the first year.

Symposia

Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view and stimulate discussion with the audience.

Workshops

Workshops are 90-minute sessions that typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and is highly interactive.

Daily Attendance Log

2016 Annual Meeting of the American Psychiatric Association • MAY 14-18, 2016 • Atlanta, Georgia



This form is **for your records** and not for submission. Use this page to keep track of your attendance. Reporting is on an honor basis, claim one credit for each hour of participation.

All scientific sessions listed in the Annual Meeting Program Book are designated for **AMA PRA Category 1 Credits™**, except for Poster Sessions and where otherwise specified.

Date/Time	Title of Session	# of Hours
Total		

Saturday

May 14, 2016



8:00 a.m. Sessions

Courses



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Conversion Disorder: Update on Evaluation and Management



8:00 a.m. – Noon

International 4, International Level
Marriott Marquis

Directors:

Gaston Baslet, M.D.
John Barry, M.D.

Faculty:

James Brooks
W. Curt LaFrance Jr., M.D., M.P.H.
Adriana Bermeo-Ovalle, M.D.

Cognitive Behavior Therapy for Severe Mental Disorders: Building Treatment Skills That Work



8:00 a.m. – Noon

International 5, International Level
Marriott Marquis

Directors:

James Brooks
Jesse H. Wright, M.D., Ph.D.

Faculty:

David Kingdon, M.D.
Douglas Turkington, M.D.
Michael E. Thase, M.D.



This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Mood Disorders in Later Life: Achieving Accurate Diagnosis and Effective Treatment



8:00 a.m. – Noon

International 6, International Level
Marriott Marquis

Directors:

James M. Ellison, M.D., M.P.H.
Yusuf Sivrioglu, M.D.

Faculty:

Donald A. Davidoff, Ph.D.
Brent Forester, M.D., M.Sc.
Grace C. Niu, Ph.D.

Management of Psychiatric Disorders in Pregnant and Postpartum Women



8:00 a.m. – Noon

M103-105, Marquis Level
Marriott Marquis

Directors:

Shaila Misri, M.D.
Deirdre M. Ryan, M.B.

Faculty:

Barbara Shulman, M.D.
Tricia Bowering, M.D.
Shari I. Lusskin, M.D.

Seminar

Why Sex Is Important: A Seminar on the Impediments to Adult Love



8:00 a.m. – Noon

International 7, International Level
Marriott Marquis

Director:

Stephen B. Levine, M.D.



Program changes are printed each day in the *APA Daily*, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.

Course

Buprenorphine and Office-Based Treatment of Opioid Use Disorder

APA Council on Addiction Psychiatry



8:00 a.m. – 5:00 p.m.

Marquis Ballroom A, Marquis Level
Marriott Marquis

Chair:

James Brooks

Director:

Petros Levounis, M.D.

9:00 a.m. Sessions

Scientific and Clinical Reports

Weight Issues and Bariatric Surgery



9:00 a.m. – 10:30 a.m.

Room B405, Level 4
Georgia World Congress Center

1. Toronto Bariatric Interprofessional Psychosocial Assessment Suitability Scale (BIPASS): A Retrospective Pilot Study Evaluating a New Clinical Tool
Gurneet S. Thiara, M.D.
2. Evidence for Neurocognitive Improvement After Bariatric Surgery: A Systematic Review
Gurneet S. Thiara, M.D.
3. Childhood Abuse Associated With an Increase in Body Mass Index (BMI), Sleep Disturbances, and Psychological and Physical Symptoms Among Midlife Women
Wilma Ines Castilla-Puentes, M.D.



Workshops

The What, When and Why of EKGs in Psychiatric Practice

4

9:00 a.m. – 10:30 a.m.

Room A303, Level 3

Georgia World Congress Center

Chairs:

Rohul Amin, M.D.

Adam Hunzeker, M.D.

Speakers:

Jed P. Mangal, M.D.

Aniceto Navarro, M.D.

Making Your Presentation More Interactive: The Better Way!

9:00 a.m. – 10:30 a.m.

Room A304, Level 3

Georgia World Congress Center

Chair:

Jon S. Davine, M.D.

Leading System Change Toward Integrated Care: Unfunded, Not Ready, Unsure? Start Here

5

9:00 a.m. – 10:30 a.m.

Room A313, Level 3

Georgia World Congress Center

Chair:

Glenda Wrenn, M.D.

Speakers:

Christopher Hoffman, M.D.

Courtney L. McMickens, M.D., M.P.H.

Kevin M. Simon, M.D.

Elizabeth A. Frye, M.D., M.P.H.

Fort Hood Tragedy: An Inside Perspective

3

9:00 a.m. – 10:30 a.m.

Room B310, Level 3

Georgia World Congress Center

Chair:

Kaustubh G. Joshi, M.D.

Dimensional Conceptualization and Diagnosis of Narcissistic Personality Disorder

9:00 a.m. – 10:30 a.m.

Room B311, Level 3

Georgia World Congress Center

Chairs:

Elsa F. Ronningstam, Ph.D.

Igor Weinberg

East and West: Integrating Concepts of Mental Health Through Storytelling in the Refugee Population

5

9:00 a.m. – 10:30 a.m.

Room B315, Level 3

Georgia World Congress Center

Chairs:

Shirali S. Patel, M.D.

Sophia Banu, M.D.

Speakers:

Ye B. Du, M.D., M.P.H.

Elisabeth Netherton, M.D.

Asim Shah, M.D.

When You Hear Hoof Beats, Think Horses and Zebras: The Importance of a Wide Differential in Delirium/Dementia Cases

5

9:00 a.m. – 10:30 a.m.

Room B316, Level 3

Georgia World Congress Center

Chair:

Ana Turner, M.D.

Speakers:

Sai Hu, D.O.

Bruce Bassi, M.D., M.S.

Uma Suryadevara, M.D.

Stephen Welch, M.D.

Cognitive Behavior Therapy for Personality Disorders

9:00 a.m. – 10:30 a.m.

Room B403, Level 4

Georgia World Congress Center

Chair:

Judith S. Beck, Ph.D.

Online Education: Opportunities for Teaching, Collaboration, Funding and Advancement

1

9:00 a.m. – 10:30 a.m.

Room B404, Level 4

Georgia World Congress Center

Chairs:

Czerne M. Reid, Ph.D.

Regina Bussing, M.D.

Speakers:

Czerne M. Reid, Ph.D.

Jacqueline A. Hobbs, M.D., Ph.D.

Barry Setlow, Ph.D.

Regina Bussing, M.D.

Media Workshop

120 Years of Inpatient Psychiatry: "Stonehearth Asylum" and Discussion of the Evolution of Psychiatric Hospitalization into the 21st Century

9:00 a.m. – Noon

Room B308, Level 3

Georgia World Congress Center

Chair:

Mark Komrad, M.D.

Speakers:

Mimi Baird

Steven S. Sharfstein, M.D., M.P.A.

Mark Komrad, M.D.

Symposia

Improving the Effectiveness of CBT Across Cultures

D

9:00 a.m. – Noon

Room B309, Level 3

Georgia World Congress Center

Chair:

Muhammad Irfan, M.B.B.S., M.S.

! SESSION TRACKS

- 1 Addiction Psychiatry
- 2 Child and Adolescent Psychiatry
- 3 Forensic Psychiatry
- 4 Geriatric Psychiatry
- 5 Psychosomatic Psychiatry
- 6 NIDA
- 7 Residents, Fellows and Medical Students
- D APA Annual Meeting On Demand
- 📱 Bring Your Own Device

Discussant:

Farooq Naeem, Ph.D., M.Sc.

1. Developing a Model for Cultural Adaptation of CBT for an English-Speaking Caribbean Origin Group
Kwame McKenzie, M.D.
2. Cultural Issues on the Use of CBT and ACT
Kenneth P. Fung, M.D.
3. Cultural Adaptation of CBT: Process, Methods and Findings
Farooq Naeem, Ph.D., M.Sc.
4. Cultural Adaptation of CBT for Psychotic Disorders
Shanaya Rathod, M.D.
5. A Depressed British South Asian Mother's "Voices Within the Four Walls": A Mixed Methods Study
Nusrat Husain, M.D.
6. Evaluation of Culturally Adapted CBT (CaCBT) Through Randomized Controlled Trials (RCTs) in Low- and Middle-Income (LAMI) Countries: Developing the Evidence Base
Muhammad Irfan, M.B.B.S., M.S.

! Program changes are printed each day in the *APA Daily*, which can be picked up in the Georgia World Congress Center. The program is also available in the APA Meetings app.

! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- D** APA Annual Meeting On Demand
📱 Bring Your Own Device

Comorbid Psychiatric and Substance Use Disorders: Recent Research to Improve Diagnosis and Treatment

National Institute on Drug Abuse



9:00 a.m. – Noon

Room B312, Level 3

Georgia World Congress Center

Chairs:

Susan F. Volman, Ph.D.

Carlos Blanco, M.D.

Discussant:

Carlos Blanco, M.D.

1. Diagnostic Dilemmas in Co-Occurring Mental and Substance Use Disorders
Edward V. Nunes, M.D.
2. Neuroimaging Correlates of Psychopathology and Substance Abuse
Deborah Yurgelen-Todd, Ph.D.
3. Comorbidity in Substance Abuse and Depression: Common Substrates Linked Through Amygdala-Dependent Dopamine System Down-Regulation
Anthony A. Grace, Ph.D.
4. Treatment of Co-Occurring Mental and Substance Use Disorders: Focus on Depression
Kathleen Brady, M.D., Ph.D.

Smoking Cessation: What Psychiatrists Need to Know to Help Bring About Change

9:00 a.m. – Noon

Room B314, Level 3

Georgia World Congress Center

Chairs:

Stephan M. Carlson, M.D.

Jose Vito, M.D.

Discussant:

Aniyizhai Annamalai, M.D.

1. The History of Smoking Cessation in Psychiatry and the Current Epidemiology in Patients With Mental Illness
Hugh Cummings, M.D.
2. Smoking Cessation Through Quality Improvement and System Change in Inpatient Psychiatry

3. An Update on Smoking Cessation Pharmacology for Psychiatrists
Jose Vito, M.D.
4. Evidence-Based Psychosocial Treatments for Smoking Cessation in Patients with Mental Illness
Anil A. Thomas, M.D.

Established Curricula on Religion, Spirituality and Psychiatry in Psychiatric Residency Programs: A Longitudinal Perspective

APA Caucus on Religion, Spirituality and Psychiatry



9:00 a.m. – Noon

Room B401, Level 4

Georgia World Congress Center

Chairs:

Francis Lu, M.D.

John Peteet, M.D.

Discussant:

Steven Scoggin, Psy.D.

1. Religion, Spirituality and Psychiatry: The Harvard Longwood Course 20 Years Later
John Peteet, M.D.
2. Personal and Institutional Consequences of Educational Efforts to Integrate Religious and Spiritual Resources Into the Care of Psychiatric Patients: A 17-Year "Perspective"
James W. Lomax, M.D.
3. A 25-Year Evolution From Teaching Cultural Sensitivity to Teaching the Social Neuroscience of Spirituality in Psychiatric Care
James Griffith, M.D.
4. Religion and Spirituality in Child and Adolescent Psychiatry Training
Mary Lynn Dell, D.Min., M.D.
5. Residency Education on Spirituality/Religion and Psychiatry: A Canadian Perspective
Wai Lun Alan Fung, M.D., Sc.D.

D This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.



Marijuana: A Clinical Update on the Therapeutic and Recreational Uses of Cannabis for General Psychiatrists and Researchers



9:00 a.m. – Noon
Room B407, Level 4
Georgia World Congress Center

Chair:

Godfrey D. Pearlson, M.D.

Discussant:

Deepak Cyril D'Souza, M.D., M.B.B.S.

1. Therapeutic Potential of Cannabinoids
Donald C. Goff, M.D.
2. Predictors and Consequences of Adolescent Cannabis Abuse
Hugh Garavan, Ph.D.
3. Driving While Stoned: How Dangerous?
Godfrey D. Pearlson, M.D.
4. Medical Cannabis: For Which Conditions and Under What Circumstances?
Deepak Cyril D'Souza, M.D., M.B.B.S.
5. Neurocognitive Implications of Heavy Marijuana Use in Adolescence: Insights From Neuroimaging
Alecia D. Dager, Ph.D.

Courses



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Transgender and Intersex for the Practicing Psychiatrist

APA Council on Quality Care



9:00 a.m. – 4:00 p.m.
International 8, International Level
Marriott Marquis

Director:

William M. Byne, M.D.

Faculty:

*Evan Eyler
Dan H. Karasic, M.D.
Heino F. L. Meyer-Bahlburg, Ph.D.
Richard R. Pleak, M.D.
Jack Pula, M.D.*

Neuropsychiatric Masquerades: Medical and Neurological Disorders That Present With Psychiatric Symptoms

Academy of Psychosomatic Medicine



9:00 a.m. – 4:00 p.m.
Marquis Ballroom C, Marquis Level
Marriott Marquis

Director:

Jose R. Maldonado, M.D.

Faculty:

Yelizaveta Sher, M.D.

Updates in Geriatric Psychiatry



9:00 a.m. – 4:00 p.m.
Imperial Ballroom A, Marquis Level
Marriott Marquis

Director:

Rajesh R. Tampi, M.D., M.S.

Faculty:

*Louis Trevisan, M.D., M.Ed.
Ilse Wiechers, M.D., M.H.S.
Kirsten Wilkins, M.D.
Rajesh R. Tampi, M.D., M.S.*

Sleep Medicine: A Review and Update for Psychiatrists



9:00 a.m. – 4:00 p.m.
M301 – 302, Marquis Level
Marriott Marquis

Directors:

*Thomas D. Hurwitz, M.D.
Imran S. Khawaja, M.B.B.S.*

Faculty:

*Elliott K. Lee, M.D.
R. Robert Auger, M.D.*

Master Course



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Update on Pediatric Psychopharmacology



9:00 a.m. – 4:00 p.m.
Imperial Ballroom B, Marquis Level
Marriott Marquis

Director:

Christopher Kratochvil, M.D.

Seminar

Treatment of Schizophrenia



9:00 a.m. – 4:00 p.m.
Marquis Ballroom D, Marquis Level
Marriott Marquis

Directors:

*Philip G. Janicak, M.D.
Stephen R. Marder, M.D.*

Faculty:

Rajiv Tandon, M.D.

10:00 a.m. Session

Poster Session

Medical Student-Resident Competition Poster 1

10:00 a.m. – Noon
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

11:00 a.m. Sessions

Scientific and Clinical Reports

Perioperative and Peripartum Situations



5

11:00 a.m. – 12:30 p.m.

Room B405, Level 4

Georgia World Congress Center

1. Serotonergic Antidepressants and Perioperative Bleeding Risk: A Systematic Review
Artin Mahdanian, M.D.

5

2. The Cornell Peripartum Psychosis Management Tool: A Case Series and Template
Benjamin Brody, M.D.

5

Workshops

Prodromal Psychosis: Ethical Challenges in Classification, Diagnosis and Treatment

APA Ethics Committee and Penn-Scattergood Ethics Program

11:00 a.m. – 12:30 p.m.

Room B218, Level 2

Georgia World Congress Center

Chairs:

Raquel Gur, M.D.

Dominic Sisti, Ph.D.

Speakers:

Dominic Sisti, Ph.D.

Monica E. Calkins, Ph.D.

Erich M. Dress, B.S.

Andrea G. Segal, M.S.

Teaching Diagnostic Reasoning Skills and the Mitigation of Cognitive Bias

5

11:00 a.m. – 12:30 p.m.

Room A303, Level 3

Georgia World Congress Center

Chairs:

Adam Hunzeker, M.D.

Rohul Amin, M.D.

Speakers:

Jarred Hagan, D.O.

Allison Webb, M.D.

Adam Hunzeker, M.D.

Rohul Amin, M.D.

Trauma, Conduct Disorder and Violence Prevention in the Community

3

11:00 a.m. – 12:30 p.m.

Room A304, Level 3

Georgia World Congress Center

Chair:

Lara J. Cox, M.D., M.S.

Speakers:

Matthew L. Dominguez, M.D., M.P.H.

Anish R. Dube, M.D., M.P.H.

Diagnosing Dementia: A Guide to Biomarker Testing in the Clinic

4

11:00 a.m. – 12:30 p.m.

Room A307, Level 3

Georgia World Congress Center

Chair:

Vimal M. Aga, M.D.

Sports Psychiatry: Providing Behavioral Health and Performance Services to Sports Organizations/Teams at High School/Club, College and Professional Levels

2

11:00 a.m. – 12:30 p.m.

Room B310, Level 3

Georgia World Congress Center

Chair:

David R. McDuff, M.D.

How to Use Alcoholics Anonymous in Clinical Practice

1

11:00 a.m. – 12:30 p.m.

Room B315, Level 3

Georgia World Congress Center

Chair:

Marc Galanter, M.D.

Speakers:

Joseph J. Westermeyer, M.D., Ph.D.

John A. Fromson, M.D.

Alphonse Kenison Roy III, M.D.

Effective Management of Reassurance-Seeking Behavior in OCD: Strategies for Clinicians and Family Members

11:00 a.m. – 12:30 p.m.

Room B316, Level 3

Georgia World Congress Center

Chairs:

Phillip J. Seibell, M.D.

Megan Hughes-Feltenberger, Ph.D.

Speakers:

Phillip J. Seibell, M.D.

Megan Hughes-Feltenberger, Ph.D.

Practicing Cognitive Behavior Therapy: An Experiential Workshop

11:00 a.m. – 12:30 p.m.

Room B403, Level 4

Georgia World Congress Center

Chair:

Judith S. Beck, Ph.D.

! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- ▶ APA Annual Meeting On Demand
- 📱 Bring Your Own Device



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

1:00 p.m. Sessions

Courses



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

What Every Psychiatrist Needs to Know About Epilepsy



1:00 p.m. – 5:00 p.m.

International 4, International Level
Marriott Marquis

Director:

Rochelle Caplan, M.D.

Faculty:

Tatiana Falcone, M.D.

Jana Jones, Ph.D.

Elia M. Pestana Knight, M.D.

Gaston Baslet, M.D.

A Psychiatrist's Guide to Patients With Severe Obesity: Assessment and Beyond



1:00 p.m. – 5:00 p.m.

International 5, International Level
Marriott Marquis

Directors:

Raed Hawa, M.D.

Sanjeev Sockalingam, M.D.

Faculty:

Stephanie Cassin, Ph.D.

Timothy Jackson

Marlene Taube-Schiff, Ph.D.

Susan Wnuk, Ph.D.

Identifying and Helping Older Adults With Mild Neurocognitive Disorders



1:00 p.m. – 5:00 p.m.

International 6, International Level
Marriott Marquis

Director:

James M. Ellison, M.D., M.P.H.

Faculty:

Jennifer Gatchel, M.D., Ph.D.

David P. Olson, M.D., Ph.D.

Donald A. Davidoff, Ph.D.

Melatonin and Light Treatment of SAD, Sleep and Other Body Clock Disorders



1:00 p.m. – 5:00 p.m.

International 7, International Level
Marriott Marquis

Director:

Alfred J. Lewy, M.D.

Mentalization-Based Treatment for Borderline Personality Disorder



1:00 p.m. – 5:00 p.m.

M103-105, Marquis Level
Marriott Marquis

Director:

Anthony Bateman, M.D.

1:30 p.m. Sessions

Scientific and Clinical Reports

Forensic and Medical-Legal Issues



1:30 p.m. – 3:00 p.m.

Room B405, Level 4
Georgia World Congress Center

1. Empirical Findings on Legal Difficulties Among Practicing Psychiatrists
James H. Reich, M.D., M.P.H.



2. Traumatophobia: Paradoxical Amplification of Post-Traumatic Symptoms and the Role of Third Parties
John O. Beahrs, M.D.

3. Development and Implementation of a Correctional Skills-Based Psychotherapy: START NOW
Robert L. Trestman, M.D., Ph.D.



Workshops

Drawing Healing From Within: Art Therapy and Soldiers in Crisis



1:30 p.m. – 3:00 p.m.

Rooms B211-212, Level 2
Georgia World Congress Center

Chairs:

Sebastian Schnellbacher, D.O.

Brenda Maltz, M.A., R.N.

Speaker:

Brenda Maltz, M.A., R.N.

Child and Adolescent Psychiatry "Novelties": New Trends in Adolescent Addiction, Eating/Feeding Disorders and Psychosomatic Medicine



1:30 p.m. – 3:00 p.m.

Room B218, Level 2
Georgia World Congress Center

Chair:

Susan Samuels, M.D.

Speakers:

Matthew Shear, M.D.

Jonathan Avery, M.D.

Susan Samuels, M.D.

At What Cost? Psychiatry, the Finances Involved and the Future of the Field

1:30 p.m. – 3:00 p.m.

Room A303, Level 3
Georgia World Congress Center

Chairs:

Matthew D. Erlich, M.D.

Sharat P. Iyer, M.D., M.S.

Speakers:

Matthew D. Erlich, M.D.

Sharat P. Iyer, M.D., M.S.

Andres Barkil-Oteo, M.D., M.Sc.

Leslie Marino, M.D., M.P.H.

Mindfulness and Qigong for Stress Reduction

3

1:30 p.m. – 3:00 p.m.

Room A304, Level 3

Georgia World Congress Center

Chair:

Colleen Loehr, M.D.

Mental Health and the Case for Single Payer Post-ACA

1:30 p.m. – 3:00 p.m.

Room A307, Level 3

Georgia World Congress Center

Chairs:

Leslie H. Gise, M.D.

Steven S. Sharfstein, M.D., M.P.A.

Speakers:

J. Wesley Boyd, M.D., Ph.D.

Stephen B. Kemble, M.D.

The Ultimate Balancing Act: Medicine, Marriage, Motherhood and Me

1:30 p.m. – 3:00 p.m.

Room A309, Level 3

Georgia World Congress Center

Chairs:

Sarah M. Fayad, M.D.

Almari Ginory, D.O.

Speakers:

Jacqueline A. Hobbs, M.D., Ph.D.

Sarah Johnson, M.D.

Misty Richards, M.D., M.S.

Kimberly Gordon, M.D.

Molly McVoy, M.D.

Nonverbal Learning Disability (NVLD): Myth and Reality

2

APA Council on Children, Adolescents and Their Families

1:30 p.m. – 3:00 p.m.

Room B310, Level 3

Georgia World Congress Center

Chairs:

Cindy Vargas Cruz, M.D., M.B.A.

Auralyd Padilla Candelario, M.D.

Speakers:

Sheldon Benjamin, M.D.

Ellen Braaten, Ph.D.

Stephen Nowicki, Ph.D.

Steven Schlozman, M.D.

A Cognitive Behavioral Approach to Weight Loss and Maintenance

1:30 p.m. – 3:00 p.m.

Room B403, Level 4

Georgia World Congress Center

Chairs:

Judith S. Beck, Ph.D.

Deborah Beck Busis, L.C.S.W.

2:00 p.m. Sessions

Poster Session

Medical Student-Resident Competition Poster 2

2:00 p.m. – 4:00 p.m.

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

Advances in Medicine

Medical Mysteries and Practical Medical Psychiatry Updates: Is It “Medical,” “Psychiatric” or a Little of Both?

D

2:00 p.m. – 5:00 p.m.

Rooms B207-208, Level 2

Georgia World Congress Center

Chair:

Robert M. McCarron, D.O.

Speakers:

Pritham Raj, M.D.

Sarah Rivelli, M.D.

Shannon Suo, M.D.

Advances in Series

Advances in Psychodynamic Psychiatry

American Psychiatric Association Publishing Editorial Board

D

2:00 p.m. – 5:00 p.m.

Room A305, Level 3

Georgia World Congress Center

Chair:

Elizabeth L. Auchincloss, M.D.

1. The Role of Psychoeducation in Psychodynamic Psychiatry
Fredric N. Busch, M.D.
2. Advances in the Understanding and Treatment of Narcissistic Personality Disorder
Eve Caligor, M.D.
3. Advances in Understanding and Treating Borderline Personality Disorder
Otto F. Kernberg, M.D.
4. The Role of Separation Anxiety in Psychodynamic Psychiatry
Barbara Milrod, M.D.

Media Workshop

“Astu—So Be It”: The Strength of Digital Media in the Training of Health Professionals and in Public Awareness

2:00 p.m. – 5:00 p.m.

Room A314, Level 3

Georgia World Congress Center

Chair:

Mohan Agashe

Symposia

Interventions for Early Psychosis in Children and Adolescents: New Advances in Community and Policy Approaches

APA Child and Adolescent Psychiatry Fellowship

D 2

2:00 p.m. – 5:00 p.m.

Rooms B216-217, Level 2

Georgia World Congress Center

! SESSION TRACKS

1 Addiction Psychiatry

2 Child and Adolescent Psychiatry

3 Forensic Psychiatry

4 Geriatric Psychiatry

5 Psychosomatic Psychiatry

6 NIDA

7 Residents, Fellows and Medical Students

D APA Annual Meeting On Demand

D Bring Your Own Device



Chairs:*Stephanie H. Chan, M.D.**Ken Duckworth, M.D.*

1. Offering Hope and Revolutionary Care: Changing Approaches to Early Onset Psychosis
Jacqueline M. Feldman, M.D.
2. Early Detection and Intervention for Adolescents With Early Psychosis: Promising New Approaches
Steven Adelsheim, M.D.
3. The Promise of Team-Based Comprehensive Early Interventions Services: From RAISE Connection to OnTrackNY
Lisa B. Dixon, M.D., M.P.H.
4. Early Psychosis Intervention Momentum in Advocacy and Policy
Ken Duckworth, M.D.

Psychiatry in the Arab World: A Decade of Progress and a Future of Expectations

Arab American Psychiatric Association

2:00 p.m. – 5:00 p.m.

Room B308, Level 3

Georgia World Congress Center

Chairs:*Ossama Tawakol Osman, M.D.**Abdel F. Amin, M.D., M.P.H.***Discussant:***David V. Sheehan, M.D.*

1. Highlights of Arab Psychiatry Over the Past Decade: Elements of Progress and Demands for the Future
Ossama Tawakol Osman, M.D.
2. Mental Health and Psychiatry in Egypt: A Decade of Progress
Afaf Hamed Khalil, M.D., Ph.D.
3. A Decisive Decade for Psychiatry and Mental Health in Morocco: 2006 – 2015
Driss Moussaoui, M.D.
4. Psychiatry in the United Arab Emirates: A Decade of Transformative Progress
Ghanem Al-Hassani, M.D.

New Neural Treatment Targets in Compulsive Disorders



2:00 p.m. – 5:00 p.m.

Room B309, Level 3

Georgia World Congress Center

Chair:*Stefano Pallanti, M.D., Ph.D.***Discussant:***Martijn Figeet, M.D., Ph.D.*

1. Compulsivity in the OCD Spectrum: Cognitive Domains and Neural Circuitry
Naomi A. Fineberg, M.B.B.S.
2. Exploring Transcranial Magnetic Stimulation (TMS) as a Treatment and an Investigational Tool Targeting the Supplementary Motor Area (SMA) in OCD
Giacomo Grassi, M.D.
3. Transcranial Magnetic Stimulation (TMS) Targets (Including the Supplementary Motor Area [SMA]) for the Repetitive Behavior Domain in Autism Spectrum Disorders (ASD)
Eric Hollander, M.D.
4. Network Changes of Deep Brain Stimulation for Compulsive Disorders
Martijn Figeet, M.D., Ph.D.

Marijuana: Assessing Its Risks in a Changing Environment

National Institute on Drug Abuse

2:00 p.m. – 5:00 p.m.

Room B312, Level 3

Georgia World Congress Center

Chairs:*Nora Volkow, M.D.**Susan R. B. Weiss, Ph.D.***Discussant:***Mark Kleiman, Ph.D., M.P.P.*

1. Effects of Marijuana on the Brain and Cognition
Deborah Yurgelen-Todd, Ph.D.

2. Traditional Marijuana, High-Potency Cannabis and Synthetic Cannabinoids: Increasing Risk of Psychosis?
Robin M. Murray, M.D.
3. Cannabis Use Disorder: Diagnosis and Treatment
Frances R. Levin, M.D.
4. Cannabis: Patterns of Use and Risk
James C. Anthony, M.Sc., Ph.D.

Emergency Psychiatry: Changing Issues for Training and Supervision in Psychiatric Emergency Services (PES)

*American Psychiatric Association**Publishing Editorial Board*

2:00 p.m. – 5:00 p.m.

Room B314, Level 3

Georgia World Congress Center

Chair:*Michelle B. Riba, M.D.*

1. Legal Issues in the Emergency Room
Debra Pinals, M.D.
2. Evaluating and Managing Agitated Patients
Rachel Glick, M.D.
3. Suicide Risk Assessment and Management
Jose R. Maldonado, M.D.
4. Substance-Related Psychiatric Emergencies
Adam Miller, M.D.
5. Clinical Manual of Emergency Psychiatry
Katherine Maloy, M.D.
6. Depression, Euphoria and Anger in the Emergency Department
Philippe-Edouard Boursiquot, M.D., B.Sc.
7. The Psychotic Patient
Patricia Schwartz, M.D.



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

Advancing Biological Markers for PTSD



2:00 p.m. – 5:00 p.m.

Room B401, Level 4

Georgia World Congress Center

Chairs:

Marti Jett, Ph.D.

Charles R. Marmar, M.D.

Discussant:

Eric Vermetten, M.D., Ph.D.

1. GWAS Approaches to Understanding the Genomic Architecture of PTSD
Kerry Ressler, M.D., Ph.D.
2. Panomic Markers of PTSD
Rasha Hammamieh, Ph.D., Pharm.D.
3. Metabolism, Inflammation and Cell Aging Markers for PTSD
Synthia H. Mellon, Ph.D.
4. Neuroendocrine and Molecular Markers and PTSD
Rachel Yehuda, Ph.D.
5. PTSD and White Matter Abnormalities
Kirstin Aschbacher, Ph.D.

Impact of Mental Illness in an Army Basic Training Environment: From the Recruits Who Join the Military to the Individuals Who Recruit and Train Them



2:00 p.m. – 5:00 p.m.

Room B402, Level 4

Georgia World Congress Center

SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Chairs:

Melinda A. Thiam, M.D.

Keith Penska, M.D.

Discussant:

Sonda Thompson, M.S.N.

1. “Ghosts” That Join the Military: Psychological Challenges of Recruits Who Seek to Join the Military
Melinda A. Thiam, M.D.
2. For Those Who Sneak Through: Challenges of Separating Individuals Who Are Mentally Unfit for Duty
Keith Penska, M.D.
3. “How Did This Person Get Into the Military?” The Challenges of Severe Mental Illness in Army Recruits and the Impact on Basic Training Missions
David S Hodson, Ed.D., Sonda Thompson, M.S.N.
4. Army Ambassador to the Public: The Psychological Requirements as Well as Challenges of Becoming an Army Recruiter
Chaska Gomez, Psy.D.
5. The Challenge of Wearing the Hat: Stressors and Mental Health Challenges of Drill Sergeant Duty
Wesley N. Stokes, Psy.D., Kimberly D. Goode, A.A.S.

Defining the Syndrome of the Acute Suicidal Crisis



2:00 p.m. – 5:00 p.m.

Room B407, Level 4

Georgia World Congress Center

Chairs:

Igor Galynker, M.D., Ph.D.

Thomas Joiner, Ph.D.

1. The Existence, Necessity, Validity and Clinical Utility of a New Diagnostic Entity: Acute Suicidal Affective Disturbance (ASAD)
Thomas Joiner, Ph.D.



Program changes are printed each day in the *APA Daily*, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.

2. Agitation at Psychiatric Inpatient Admission: Sign of Acute Suicidal Crisis and Predictor of Suicide After Discharge?
Arne E. Vaaler, M.D., Ph.D.
3. Understanding Suicide Risk Through the Patient’s Eyes
Keith W. Jennings, Ph.D.
4. Development of an Implicit Measure of Suicidal Risk
Lisa J. Cohen, Ph.D.
5. Understanding the Acute Suicidal Crisis
Igor Galynker, M.D., Ph.D.

3:30 p.m. Sessions Interactive Session

Grief and Bereavement

3:30 p.m. – 5:00 p.m.

Room A301, Level 3

Georgia World Congress Center

Chair:

Sidney Zisook, M.D.

Scientific and Clinical Reports

PTSD and Military Psychiatry



3:30 p.m. – 5:00 p.m.

Room B405, Level 4

Georgia World Congress Center

1. Active Duty Women With PTSD Associated With Military Sexual Trauma: Who Gets Referred for Medical Retirement?
Paulette Cazares, M.D., M.P.H.



This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

2. PTSD and Risk of Alzheimer's Disease in Vietnam Veterans: Preliminary Amyloid PET Findings From AIBL-VETS

Alby Elias, M.B.B.S., M.D.

4

3. Five Enduring Psychiatric Responses to War: Freud, Gonda, Salmon, Rivers and Ferenczi

Thomas B. Horvath, M.D.

Workshops

Not Your Grandfather's VA: Innovative Health Care Offering Exceptional Psychiatric Careers



3:30 p.m. – 5:00 p.m.

Room B215, Level 2

Georgia World Congress Center

Chair:

R. Jill Pate, M.D.

Speakers:

Shahla Ali, M.D.

Erin L. Patel, Psy.D.

Shagufta Jabeen, M.D.

Jennifer Bean, Pharm.D.

Challenges and Successes in Conducting Practice-Based Research in Psychiatry

3:30 p.m. – 5:00 p.m.

Room B218, Level 2

Georgia World Congress Center

Chairs:

Farifteh F. Duffy, Ph.D.

Diana E. Clarke, Ph.D., M.Sc.

Speakers:

Joyce C. West, Ph.D., M.P.P.

Eve Moscicki, Sc.D., M.P.H.

Farifteh F. Duffy, Ph.D.

Keila D. Barber, M.H.S.

Diana E. Clarke, Ph.D., M.Sc.

Bernadette Cullen, M.B.

Focusing on Improvement Every Day: The Context and Application of a Lean Daily Management System at a Behavioral Health Care System

3:30 p.m. – 5:00 p.m.

Room A303, Level 3

Georgia World Congress Center

Chair:

Sunil Khushalani, M.D.

Speakers:

Steven S. Sharfstein, M.D., M.P.A.

Robert Roca, M.D., M.P.H.

Antonio DePaolo, Ph.D.

Enhancing Resilience in College Students: Developmental Perspectives in the Practice of College Psychiatry

APA College Mental Health Caucus

3:30 p.m. – 5:00 p.m.

Room A307, Level 3

Georgia World Congress Center

Chair:

Doris Iarovici, M.D.

Speakers:

Doris Iarovici, M.D.

Preston Wiles, M.D.

Daniel Kirsch, M.D.

Physician Burnout, Depression, Suicide: Identification, Assessment, Treatment and Prevention

7

3:30 p.m. – 5:00 p.m.

Room A309, Level 3

Georgia World Congress Center

Chairs:

Almari Ginory, D.O.

Michelle Chaney, M.D., M.Sc.

Speakers:

Anu Mathur, M.D.

Jacqueline A. Hobbs, M.D., Ph.D.

Lisa J. Merlo, Ph.D.

Drawing Depression: A Look at Mental Health Themes in Visual Media

APA Council on Communications

3:30 p.m. – 5:00 p.m.

Room A313, Level 3

Georgia World Congress Center

Chair:

Swathi Krishna, M.D.

Speakers:

Deepak Penesetti, M.D.

Aparna Atluru, M.D.

Swathi Krishna, M.D.

Diversity Experiences in Residency Training

American Association for Social Psychiatry

3:30 p.m. – 5:00 p.m.

Room B310, Level 3

Georgia World Congress Center

Chair:

Beverly Fauman, M.D.

Speakers:

Aida Spahic Mihajlovic, M.D., M.S.

Jacob Sperber, M.D.

The Exploration of Faith and Spirituality in the Psychiatric Assessment and Treatment of Minority Patients

APA/SAMHSA Minority Fellows

3:30 p.m. – 5:00 p.m.

Room B311, Level 3

Georgia World Congress Center

Chair:

Danielle Hairston, M.D.

Speakers:

Lynneice Bowen, M.D., M.Ed.

Matthew L. Dominguez, M.D., M.P.H.

Joseph Immanuel, M.D.

Ayana Jordan, M.D., Ph.D.

Jennifer Severe, M.D.

Annabelle K. Simpson, M.D.

5:30 p.m. Session

Forum

Ragtime: The Mind and Music of Scott Joplin



5:30 p.m. – 7:00 p.m.

Sidney Marcus Auditorium, Level 4

Georgia World Congress Center

Speaker:

Richard Kogan, M.D.

Understanding Mental Disorders

Your Guide to DSM-5®

American Psychiatric Association

A consumer guide for anyone who has been touched by mental illness!


Understanding Mental Disorders: Your Guide to DSM-5® is a vital resource for anyone who has been touched by mental illness.

Most of us know someone who suffers from a mental illness. This book helps those who may be struggling with mental health problems, as well as those who want to help others achieve mental health and well-being.

Based on the latest, fifth edition of the Diagnostic and Statistical Manual of Mental Disorders—known as DSM-5®—**Understanding Mental Disorders** provides valuable insight on what to expect from an illness and its treatment—and will help readers recognize symptoms, know when to seek help, and get the right care. Featured disorders include depression, schizophrenia, ADHD, autism spectrum disorder, posttraumatic stress disorder, and bipolar disorder, among others.

The common language for diagnosing mental illness used in DSM-5® for mental health professionals has been adapted into clear, concise descriptions of disorders for nonexperts. In addition to specific symptoms for each disorder, readers will find:

- Risk factors and warning signs
- Related disorders
- Ways to cope
- Tips to promote mental health
- Personal stories
- Key points about the disorders and treatment options
- A special chapter dedicated to treatment essentials and ways to get help
- Helpful resources that include a glossary, list of medications and support groups



*With Foreword by
Patrick J. Kennedy*

For more resources and information, go to www.psychiatry.org/UnderstandingMentalDisorders

2015 • 370 pages • ISBN 978-1-58562-491-1 • Paperback • \$24.95 • Item #62491

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



Order Online: www.appi.org

Phone: 703-907-7322 • Toll Free: 1-800-368-5777

Email: appi@psych.org

20% Discount for American Psychiatric Association Members

25% Discount for APA Resident-Fellow Members

AH1628AMG


Sunday

May 15, 2016



SUNDAY, MAY 15

Fred H. Gage, Ph.D., a Professor with the Laboratory of Genetics, joined The



Salk Institute in 1995. He received his Ph.D. in 1976 from The Johns Hopkins University. Dr. Gage's work concentrates

on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals. In addition, he models human neurological and psychiatric diseases in vitro using human stem cells. His lab studies the genomic mosaicism that exists in the brain as a result of mobile elements that are active during neurogenesis.

Dale E. McNiel, Ph.D., is Professor of Clinical Psychology in the Department of



Psychiatry at the University of California, San Francisco, School of Medicine and Chief Psychologist

at Langley Porter Psychiatric Hospital and Clinics. He is Director of the Clinical Psychology Training Program in the Department of Psychiatry at UCSF, which includes an American Psychological Association-accredited internship and a postdoctoral fellowship. He is board certified in both clinical neuropsychology and forensic psychology and by the American Board of Professional Psychology. He is a fellow of the American Psychological Association (Divisions of Clinical Psychology and Psychology and Law) and is a former president of the Section on Clinical Emergencies and Crises in the APA's Division of Clinical Psychology. He has published extensively on topics related to behavioral emergencies such as violence, self-harm and trauma.

Matthew State, M.D., received his medical degree from Stanford



University, completed a residency in psychiatry and a fellowship in child psychiatry at UCLA and earned a PhD in

genetics from Yale University, where he joined the faculty in 2001. In 2013, he moved to UCSF as the Oberndorf Family Distinguished Professor and Chair of the Department of Psychiatry. Dr. State's lab studies the genetics and genomics of childhood neuropsychiatric disorders. He co-leads several international genomics collaborations, including the NIH-funded Autism Sequencing Consortium, and has been the recipient of multiple awards, including recent induction into the Institute of Medicine and the AACAP George Tarjan Award for Contributions in Developmental Disabilities.

Michael R. Trimble, M.D., is Emeritus Professor of Behavioral Neurology at



the Institute of Neurology, Queen Square, London. His initial degree was in neuroanatomy, a discipline he has followed

throughout his career. His interests include neuropsychopharmacology with special reference to neuropsychiatric disorders: epilepsy, its treatment and relationship to disturbances of behavior, and the effects of antiepileptic drugs and other treatment for epilepsy on the brain and behavior. Other research and clinical interests include movement disorders and their treatment, especially the development of psychiatric disorders in Parkinson's disease and Gilles de la Tourette syndrome; head injuries; dementia; and the spectrum of presentations in the neurology and psychiatry of patients with medically unexplained neurological symptoms.

8:00 a.m. Sessions

Forum

LGBT Psychiatry: Update for 2016

8:00 a.m. – 9:30 a.m.
Room B206, Level 2
Georgia World Congress Center

Chair:

Ellen Haller, M.D.

Speakers:

Amir Ahuja, M.D.
Laura Erickson-Schroth
Ellen Haller, M.D.

Interactive Session

Psychiatry at the Forefront of Leadership: Why You? Why Now?

8:00 a.m. – 9:30 a.m.
Room A301, Level 3
Georgia World Congress Center

Chair:

Patrice Harris, M.D.

Lectures

Why Humans Like to Cry: Tragedy, Evolution and the Brain

APA International Psychiatrist Lecture Series



8:00 a.m. – 9:30 a.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center

Lecture Chair:

Renée Binder, M.D.

Lecturer:

Michael Trimble, M.D.

The Person in Personalized Medicine: Lessons from the IMAGES Study

Simon Bolivar Award



8:00 a.m. – 9:30 a.m.
Room B406, Level 4
Georgia World Congress Center

Lecturer:

Gabriel De Erausquin, M.D., Ph.D.

Scientific and Clinical Reports

Terror and Community Violence



8:00 a.m. – 9:30 a.m.
Room B405, Level 4
Georgia World Congress Center

1. Homicides of Mental Health Workers by Patients
Michael B. Knable, D.O.

2. Exposure to Community Violence, Use of Mental Health Services and Depressive Symptoms Among Adolescents and Young Adults
Wan-Yi Chen, Ph.D., M.S.W.



3. What Are Terrorism Survivors' Long-Term Needs? Formal Rating Scales Versus Open-Ended Questions and Reflections
Phebe M. Tucker, M.D.



Workshops

The Clinical Evaluation and Management of Substance Use Disorders in Transgender Patient Populations

APA Council on Addiction Psychiatry



8:00 a.m. – 9:30 a.m.
Room B215, Level 2
Georgia World Congress Center

Chairs:

Hector Colon-Rivera, M.D.
Elie Aoun, M.D.



SESSION TRACKS

- 1 Addiction Psychiatry
- 2 Child and Adolescent Psychiatry
- 3 Forensic Psychiatry
- 4 Geriatric Psychiatry
- 5 Psychosomatic Psychiatry
- 6 NIDA
- 7 Residents, Fellows and Medical Students

APA Annual Meeting On Demand

Bring Your Own Device

Speakers:

Jack Pula, M.D.
Brian Hurley, M.D., M.B.A.
Petros Levounis, M.D.

The Aging Physician: Possibilities and Perils

Senior Psychiatrists

8:00 a.m. – 9:30 a.m.
Room B218, Level 2
Georgia World Congress Center

Chairs:

Barbara S. Schneidman, M.D., M.P.H.
Paul H. Wick, M.D.

Speaker:

Glen O. Gabbard, M.D.

Social Networking in Psychiatric Practice and Training: Do's and Don'ts for Physicians



8:00 a.m. – 9:30 a.m.
Room A303, Level 3
Georgia World Congress Center

Chair:

Almari Ginory, D.O.

Speakers:

Wesley Hill, M.D.
Michelle Chaney, M.D., M.Sc.

Treating PTSD in Veterans Using New Modalities: Social Media, Virtual Reality, rTMS and Advanced Pharmacotherapies Like Ketamine and MDMA

8:00 a.m. – 9:30 a.m.
Room A304, Level 3
Georgia World Congress Center

Chair:

Niranjan Karnik, M.D., Ph.D.

Speakers:

Barbara Rothbaum, Ph.D.
Sheila A. M. Rauch, Ph.D.
Margaret Harvey, Psy.D.
Mark H. Pollack, M.D.

Functional Imaging to Improve Diagnosis in Patients With Suspected Dementia



8:00 a.m. – 9:30 a.m.
Room A309, Level 3
Georgia World Congress Center

Chairs:

Saima Hedrick, M.P.H.
Yvette Sheline, M.D., M.S.

Speakers:

Norman L. Foster, M.D.
John Seibyl, M.D.
Yvette Sheline, M.D., M.S.

The Nightmare of Cyberbullying: A Review and Discussion of Cyberbullying in Middle School-Through College-Aged Youth

APA Council on Children, Adolescents and Their Families

2

8:00 a.m. – 9:30 a.m.
Room A313, Level 3
Georgia World Congress Center

Chair:

Gabrielle L. Shapiro, M.D.

Speakers:

James Murphy, M.D.
Louis Kraus, M.D.
Isheeta Zalpuri, M.D.

Balancing Safety and Support on College Campuses: The Role of Behavioral Intervention Teams

APA College Mental Health Caucus

2

8:00 a.m. – 9:30 a.m.
Room B306, Level 3
Georgia World Congress Center

Chairs:

Leigh White, M.D.
Victor Schwartz, M.D.

! SESSION TRACKS

- 1** Addiction Psychiatry
- 2** Child and Adolescent Psychiatry
- 3** Forensic Psychiatry
- 4** Geriatric Psychiatry
- 5** Psychosomatic Psychiatry
- 6** NIDA
- 7** Residents, Fellows and Medical Students
- D** APA Annual Meeting On Demand
- 📱** Bring Your Own Device

Best Practice in International Medical Graduates—Training and Assessment

7

8:00 a.m. – 9:30 a.m.
Room B310, Level 3
Georgia World Congress Center

Chair:

Subodh Dave, M.D.

Speaker:

Nyapati R. Rao, M.D.

The Use of Buprenorphine in Abstinence-Based Treatment for Addiction

1

8:00 a.m. – 9:30 a.m.
Room B315, Level 3
Georgia World Congress Center

Chair:

Alphonse Kenison Roy III, M.D.

The Academic Hospital Clinic: Adapting to Changing Needs in Patient Care, Residency Training, Regulations and Reimbursement

8:00 a.m. – 9:30 a.m.
Room A408, Level 4
Georgia World Congress Center

Chair:

Jess Zonana, M.D.

Speakers:

Breck Borcharding, M.D.
John Q. Young, M.D., M.P.H.
Mark Zimmerman, M.D.

Physicians for Criminal Justice Reform: How Do I Fit in?

3

8:00 a.m. – 9:30 a.m.
Room B403, Level 4
Georgia World Congress Center

Chairs:

Nzinga Harrison, M.D.
Osvaldo Gaytan Jr., M.D., Ph.D.

Learning From Each Other: Facilitators and Barriers in Health Care Organizations for Improving Quality of Care—Insights From the U.S., U.K. and Zambia

8:00 a.m. – 9:30 a.m.
Room B404, Level 4
Georgia World Congress Center

Chair:

Sunil Khushalani, M.D.

Speakers:

Steven S. Sharfstein, M.D., M.P.A.
Ananta Dave, M.D.
Subodh Dave, M.D.

Advances in Series

Advances in Medicine:**Positive Psychiatry**

American Psychiatric Association
Publishing Editorial Board

D 4

8:00 a.m. – 11:00 a.m.
Room A305, Level 3
Georgia World Congress Center

Chair:

Dilip V. Jeste, M.D.

Discussant:

Dan G. Blazer II, M.D., M.P.H.

1. Resilience-Building Interventions and Aging
Helen Lavretsky, M.D.
2. Prevention in Psychiatry
Carl C. Bell, M.D.

Learning Lab

New Guideline Recommendations for Strengthening Psychiatric Practice: From the Rationale to the Real World

📱

8:00 a.m. – 11:00 a.m.
Rooms B207-208, Level 2
Georgia World Congress Center

D This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Chair:

Michael J. Vergare, M.D.

Discussant:

Thomas J. Craig, M.D.

1. Developing Practice Guidelines: Why and How
Michael J. Vergare, M.D.
2. Physical Health Assessment as Part of the Psychiatric Evaluation
Joel J. Silverman, M.D.
3. Aligning Practice Guideline Recommendations With Evidence: When and How Should Antipsychotics Be Used in Individuals With Dementia
Victor I. Reus, M.D.
4. Quantitative Measurement in Psychiatry: Positives and Pitfalls
Laura J. Fochtmann, M.D.

Media Workshop

“Inside Out”: Emotions, Imagination and Growing Up

2

8:00 a.m. – 11:00 a.m.

Room A314, Level 3
Georgia World Congress Center

Chairs:

Martin K. Huynh, B.S.
Harry Siegele, B.S.

Speaker:

Alice R. Mao, M.D.

Presidential Symposia

Issues for Child and Adolescent Psychiatry in the 21st Century

American Academy of Child and Adolescent Psychiatry
The Agnes Purcell McGavin Awards will be presented during this session.

D 2

8:00 a.m. – 11:00 a.m.

Rooms B213-214, Level 2
Georgia World Congress Center



All scientific sessions listed in the Program are designated for AMA PRA Category 1 Credits™, except for Poster Sessions.

Chair:

Gregory K. Fritz, M.D.

1. Pediatric Integrated Care: Children Are Not Short Adults
Gregory K. Fritz, M.D.
2. Global Mental Health: Why Partnerships Are Important
Paramjit Joshi, M.D.
3. Management of Depression in Children and Adolescents
Karen Dineen Wagner, M.D., Ph.D.
4. “Acting Out” Youth: Timely Forensic and Correctional Approaches
Joseph V. Penn, M.D.

Translating the Evidence for the Next Generation: Addressing the Mental Health of Youth and Emerging Adults of Color

D 2

8:00 a.m. – 11:00 a.m.

Room B313, Level 3
Georgia World Congress Center

Chair:

Lisa R. Fortuna, M.D., M.P.H.

1. Between Two Worlds: Culture, Environment, Race and Mental Health for First- and Second-Generation Immigrant Emerging Adults
Kiara Alvarez, Ph.D.
2. Can We Train Providers and Patients to Do Shared Decision Making in Behavioral Health Encounters?
Margarita Alegria, Ph.D.
3. Why Capable Young People Struggle: Educational Attainment and Mental Health in Communities of Color
Michelle V. Porche, Ed.D.
4. Psychiatry Serving the Needs of a Diverse Next Generation: Where We Hit It and Where We Miss It
Lisa R. Fortuna, M.D., M.P.H.

Symposia

Deconstructing the Neurobiology of Depression

D

8:00 a.m. – 11:00 a.m.

Rooms B216-217, Level 2
Georgia World Congress Center

Chairs:

Amresh Shrivastava, M.D.
Charles B. Nemeroff, M.D., Ph.D.
James Brooks

1. Central and Peripheral Immune Markers in Depression and Suicide
Ghanshyam N. Pandey, Ph.D.
2. Inflammation in Mood/Cognitive Disorders: Conceptual and Practical Considerations
Roger S. McIntyre, M.D.
3. Personalized Medicine: Depression
Charles B. Nemeroff, M.D., Ph.D.
4. Psychoneurobiology of Resilience
Gustavo E. Tafet, M.D., Ph.D.
5. Resilience: A Psychobiological Construct for Suicidality
Amresh Shrivastava, M.D.
6. HPA Axis Genetic Variation, Psychosis and Cognition in Depression
Alan F. Schatzberg, M.D.

The Athlete: Homosexuality and Transgenderism

International Society for Sport Psychiatry

D

8:00 a.m. – 11:00 a.m.

Room B308, Level 3
Georgia World Congress Center

Chair:

Antonia L. Baum, M.D.

Discussant:

David O. Conant-Norville, M.D.

1. Transgenderism and the Athlete
Paul McHugh, M.D.
2. The Dilemma of Coming Out as a Gay or Lesbian Athlete
Daniel Beigel, M.D.
3. Team Dynamics When the Coach Is Gay or Transgender
Antonia L. Baum, M.D.

Autism Spectrum Disorders (ASD): Epidemiology, Genetics, Revisiting Risperidone, Parent Training and Early Detection

APA Council on Children, Adolescents and Their Families



8:00 a.m. – 11:00 a.m.

Room B309, Level 3

Georgia World Congress Center

Chairs:

Lan Chi Krysti L. Vo, M.D.

Lawrence Scahill, Ph.D., M.S.N.

Discussant:

Paul Wang, M.D.

1. Epidemiology of Autism Spectrum Disorders (ASD): To Know What We See Rather Than to See What We Know
Young Shin Kim, M.D., Ph.D.
2. Advances in Molecular Genetics of Autism Spectrum Disorders (ASD): Applications in the Clinic, New Perspectives in Clinical Neuroscience
Joseph F. Cubells, M.D., Ph.D.
3. Revisiting Risperidone
Lan Chi Krysti L. Vo, M.D.
4. Parent Training in Children With Autism Spectrum Disorders (ASD): Results of a Randomized Clinical Trial
Lawrence Scahill, Ph.D., M.S.N.
5. Toward Universal Screening and Improved Access to Early Intervention in Autism Spectrum Disorders (ASD)
Ami Klin, Ph.D.

! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Mood, Art and Politics: Abraham Lincoln, Vincent Van Gogh, Sylvia Plath and Robin Williams—Resilience and Creativity in the Face of Great Odds



8:00 a.m. – 11:00 a.m.

Room B312, Level 3

Georgia World Congress Center

Chair:

John P. O'Reardon, M.D.

Discussant:

John P. O'Reardon, M.D.

1. Mood, Art and Politics: Abraham Lincoln, Vincent Van Gogh, Sylvia Plath and Robin Williams—Resilience and Creativity in the Face of Great Odds
Thomas Newmark, M.D.
2. Sylvia Plath and Robin Williams
Michelle Nagurney, M.D.
3. Abraham Lincoln and Vincent Van Gogh
John P. O'Reardon, M.D.

Forgiveness, Trauma and Psychiatry: The Clinical Relevance From Diverse Faith Perspectives in the Wake of the Charleston Church Tragedy

APA Caucus on Religion, Spirituality and Psychiatry



8:00 a.m. – 11:00 a.m.

Room B401, Level 4

Georgia World Congress Center

Chairs:

Chris Winfrey, M.D.

Rama Rao Gogineni, M.D.

Discussant:

John Peteet, M.D.

1. Emmanuel AME Massacre: Baha'i Faith Perspective on Forgiveness
Deborah Deas, M.D., M.P.H.
2. Forgiveness and Trauma: Clinical Perspectives From the Christian Faith
Kevin Brown
3. Jewish Perspectives on Forgiveness Related to Psychiatry
H. Steven Moffic, M.D.
4. Forgiveness, Islamic Religion/Culture and Psychiatry
Driss Moussaoui, M.D.

5. Forgiveness: Hindu and Buddhist Perspectives
Shridhar Sharma, M.D., D.P.M.

Integrating Sociocultural Perspectives of Postpartum Depression (PPD) Among Diverse Women Improves Care

APA Council on Minority Mental Health and Health Disparities



8:00 a.m. – 11:00 a.m.

Room B402, Level 4

Georgia World Congress Center

Chairs:

Pamela C. Montano Arteaga, M.D.

Maria Jose Lisotto, M.D.

Discussants:

Roberto Lewis-Fernandez, M.D.

Elizabeth Fitelson, M.D.

1. Sociocultural Risk Factors for Postpartum Depression Among Immigrant and Minority Women
Pamela C. Montano Arteaga, M.D.
2. Overview of the Assessment and Treatment of Postpartum Depression
Elizabeth Fitelson, M.D.
3. Postpartum Rituals and Other Cultural Considerations in the Management of Postpartum Depression (PPD)
Kenneth P. Fung, M.D.
4. Intimate Partner Violence and Postpartum Depression
Ludmila De Faria, M.D.
5. An End to Painting by Numbers: A Culturally Informed Assessment and Treatment Model for Postpartum Depression
Matthew L. Dominguez, M.D., M.P.H.

Bipolar Disorder in Children and Adults in France and North America: Vive La Difference!



8:00 a.m. – 11:00 a.m.

Room B407, Level 4

Georgia World Congress Center

Chairs:

John A. Talbott, M.D.

Francois Petitjean, M.Psy.

1. French Guidelines for the Treatment of Bipolar Disorder: Interests and Limits
Ludovic Samalin, M.D.

2. Antidepressant-Emergent Manic Switch: Identifying At-Risk Bipolar I and II Patients
Clara Brichant-Petitjean, M.D.
3. An American Approach to Bipolar Disorder: Patient and Family Education
J. Raymond DePaulo Jr., M.D.
4. The North American Approach to Bipolar Disorder During Pregnancy
Gail Erlick Robinson, M.D.
5. Bipolar Disorder During the Peripartum Period: A French Integrative Model
Gisele Apter, M.D., Ph.D.

Courses

! Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Interpersonal Psychotherapy



8:00 a.m. – Noon
International 4, International Level
Marriott Marquis

Director:
John C. Markowitz, M.D.

Good Psychiatric Management for Borderline Personality Disorder: What Every Psychiatrist Should Know



8:00 a.m. – Noon
International 6, International Level
Marriott Marquis

Directors:
John Gunderson, M.D.
Paul Links

Faculty:
Brian Palmer, M.D., M.P.H.

Street Drugs and Mental Disorders: Overview and Treatment of Dual Diagnosis Patients



8:00 a.m. – Noon
Marquis Ballroom D, Marquis Level
Marriott Marquis

Director:
John W. Tsuang, M.D.

Faculty:
Tim Fong, M.D.
Reef Karim, D.O.
Larissa Mooney

Understanding and Treating Narcissistic Personality Disorder



8:00 a.m. – Noon
M103-105, Marquis Level
Marriott Marquis

Directors:
Frank E. Yeomans, M.D.
Otto F. Kernberg, M.D.

Faculty:
Eve Caligor, M.D.
Diana Diamond, Ph.D.

Seminar

Training Practitioners to Use a Psychopathology Clinical Rating Scale



8:00 a.m. – Noon
International 7, International Level
Marriott Marquis

Director:
Ahmed Aboraya, M.D., D.P.H.

Faculty:
Daniel Elswick, M.D.
Henry A. Nasrallah, M.D.

9:00 a.m. Sessions

Courses

! Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Practical Assessment and Management of Behavior Disturbance in Patients With Moderate to Severe Dementia

American Association for Geriatric Psychiatry



9:00 a.m. – 4:00 p.m.
International 8, International Level
Marriott Marquis

Director:
Maureen C. Nash, M.D., M.S.

Faculty:
Sarah Foidel, O.T.R./L.
Maria L. Shindler, M.S.N.

Integrating Behavioral Health and Primary Care: Practical Skills for the Consulting Psychiatrist



9:00 a.m. – 4:00 p.m.
Marquis Ballroom A, Marquis Level
Marriott Marquis

Directors:
Anna Ratzliff, M.D., Ph.D.
Lori Raney, M.D.

Faculty:
John Kern, M.D.

Psychodynamic Psychopharmacology: Applying Practical Psychodynamics to Improve Pharmacological Outcomes With Treatment-Resistant Patients



9:00 a.m. – 4:00 p.m.
M301-302, Marquis Level
Marriott Marquis

Director:*David L. Mintz, M.D.***Faculty:***Barri Belnap, M.D.**David Flynn, M.D.**Samar Habl, M.D.**David L. Mintz, M.D.***Master Courses**

Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Advances in the Treatment of Bipolar Disorder

9:00 a.m. – 4:00 p.m.

Marquis Ballroom C, Marquis Level
Marriott Marquis**Director:***Terence A. Ketter, M.D.***Faculty:***Po Wang, M.D.**Shefali Miller, M.D.**Kiki Chang, M.D.**Natalie Rasgon**John Brooks***SESSION TRACKS**

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Assessment and Treatment of Eating Disorders

9:00 a.m. – 4:00 p.m.

Imperial Ballroom B, Marquis Level
Marriott Marquis**Director:***B. Timothy Walsh, M.D.***Faculty:***Evelyn Attia, M.D.**Eve Khlyavich Freidl, M.D.**Michael Devlin, M.D.**Tom Hildebrandt, Psy.D.**Anne Becker, M.D., Ph.D.***10:00 a.m. Sessions****Case Conference**

These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

Early Neuroimaging for Atypical Psychiatric Symptoms

10:00 a.m. – 11:30 a.m.

Rooms A315-316, Level 3
Georgia World Congress Center**Chair:***Sahil Munjal, M.D.***Forum****AASP Abraham L. Halpern Humanitarian Award Forum—Abortion: What's Happening and Why It Matters to Women, Society and Psychiatry***American Association for Social Psychiatry*

10:00 a.m. – 11:30 a.m.

Room B206, Level 2
Georgia World Congress Center**Chairs:***Rama Rao Gogineni, M.D.**Kenneth Thompson, M.D.***Speakers:***Nada L. Stotland, M.D., M.P.H.**Helen Herrman, M.D., M.B.**Mary Barber, M.D.***Interactive Session****Leading**

10:00 a.m. – 11:30 a.m.

Room A301, Level 3
Georgia World Congress Center**Chair:***Paul Summergrad, M.D.***Lectures****Keeping Pace: The UCSF Alliance Health Project—A Community Psychiatry Response to the AIDS Epidemic***Adolf Meyer Award*

10:00 a.m. – 11:30 a.m.

Room A302, Level 3
Georgia World Congress Center**Lecture Chair:***Robert M. McCarron, D.O.***Lecturer:***James Dilley, M.D.***Neuronal Plasticity and Genomic Diversity***APA Frontiers of Science Lecture Series*

10:00 a.m. – 11:30 a.m.

Sidney Marcus Auditorium, Level 4
Georgia World Congress Center**Lecture Chair:***Steve H. Koh, M.D., M.P.H.***Lecturer:***Fred H. Gage, Ph.D.***Scientific and Clinical Reports****Psychiatric Considerations in Pre-Op and Transplant**

10:00 a.m. – 11:30 a.m.

Room B405, Level 4
Georgia World Congress Center

1. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): A Prospective Study of Medical and Psychosocial Outcomes
Jose R. Maldonado, M.D.





2. Preoperative Opioid Reduction Program: A Pilot Study
Sameer Hassamal, M.D.

5

3. Delirium in Lung Transplant Recipients and Its Effects on Post-Transplant Outcomes
Yelizaveta Sher, M.D.

5

Workshops

CBT for Suicide Risk



10:00 a.m. – 11:30 a.m.
Room B215, Level 2
Georgia World Congress Center

Chair:

Donna M. Sudak, M.D.

Speakers:

Jesse H. Wright, M.D., Ph.D.
Judith S. Beck, Ph.D.

Placebo: Parsing and Using Its Therapeutic Action

5

10:00 a.m. – 11:30 a.m.
Room B218, Level 2
Georgia World Congress Center

Chair:

Donald J. Meyer, M.D.

Speakers:

Robert C. Joseph, M.D., M.S.
Don Lipsitt, M.D., M.A.
Philip R. Muskin, M.D., M.A.
Malkah T. Notman, M.D.

The “F-Word” Feedback: If It’s So Important, Why Is It So Difficult to Do?

4

10:00 a.m. – 11:30 a.m.
Room A303, Level 3
Georgia World Congress Center

Chairs:

Josepha A. Cheong, M.D.
Marcia L. Verduin, M.D.

Speakers:

John Luo, M.D.
Robert J. Boland, M.D.

Military Behavioral Health Through the Lens of the 4077th: The Realities and Myths of Military Behavioral Health Shown on M.A.S.H.

10:00 a.m. – 11:30 a.m.
Room A304, Level 3
Georgia World Congress Center

Chairs:

Sebastian Schnellbacher, D.O.
Wendi Waits, M.D.

Psychiatry in the Courts: APA Confronts Legal Issues of Concern to the Field

APA Committee on Judicial Action

3

10:00 a.m. – 11:30 a.m.
Room A307, Level 3
Georgia World Congress Center

Chair:

Marvin S. Swartz, M.D.

Speakers:

Paul S. Appelbaum, M.D.
Howard Zonana, M.D.

The Impact of Social Media and Societal Change on Young Gay Men’s Development: Implications for Intimacy, Sexuality and Psychotherapy

Association of Gay and Lesbian Psychiatrists

5

10:00 a.m. – 11:30 a.m.
Room A309, Level 3
Georgia World Congress Center

Chair:

Marshall Forstein, M.D.

Speaker:

Lawrence McGlynn, M.D., M.S.

The DSM-5 Anxious Distress Specifier: Convergent Validity and Clinical Implications

10:00 a.m. – 11:30 a.m.
Room A313, Level 3
Georgia World Congress Center

Chairs:

Gayle M. Wittenberg, Ph.D.
Jan Fawcett, M.D.

Speakers:

Jan Fawcett, M.D.
Brenda W. Penninx, Ph.D.
Marsha Ann Wilcox, Ed.D., Sc.D.
Justine M. Kent, M.D.

Traumatic Brain Injury and PTSD: Easing the Pain

10:00 a.m. – 11:30 a.m.
Room B306, Level 3
Georgia World Congress Center

Chairs:

Subhash C. Bhatia, M.D.
Venkata B. Kolli, M.B.B.S.

Speakers:

Sriram Ramaswamy, M.D.
Vani Rao, M.D.

She for All: Engaging Community Leaders to Advance Global Mental Health

Association of Women Psychiatrists
10:00 a.m. – 11:30 a.m.
Room B310, Level 3
Georgia World Congress Center

Chair:

Christina Tara Khan, M.D., Ph.D.

Speakers:

Mary Kay Smith, M.D.
P. Lynn Ouellette, M.D.
Geetha Jayaram, M.D.

Treatment of People With First-Episode Psychosis in Forensic Psychiatric Hospitals: Challenges and Outpatient Follow-Up

American Association of Community Psychiatrists

3

10:00 a.m. – 11:30 a.m.
Room B311, Level 3
Georgia World Congress Center

Chair:

Ann Hackman, M.D.

Speakers:

Keith Gallagher, M.D.
Elizabeth Jane Richardson, M.D.

Children of Psychiatrists

2

10:00 a.m. – 11:30 a.m.
Room B315, Level 3
Georgia World Congress Center

Chairs:

Michelle B. Riba, M.D.
Leah Dickstein, M.D.

Evidence-Based Mindfulness Meditation Interventions for Mental Health Conditions

10:00 a.m. – 11:30 a.m.

Room B316, Level 3

Georgia World Congress Center

Chair:

Marina Khusid, M.D.

Speaker:

Marina Khusid, M.D.

Psychiatric Communication Strategies: Intervention Models for Inpatient Medical/Surgical Settings

5

10:00 a.m. – 11:30 a.m.

Room A408, Level 4

Georgia World Congress Center

Chair:

Daniel Safin, M.D.

Speakers:

Joel J. Wallack, M.D.

Nancy Maruyama, M.D.

Stephanie Cheung, M.D.

Simona Goschin

Seeking Refuge: Effects of Psychological Evaluations in Asylum Cases

3

10:00 a.m. – 11:30 a.m.

Room B403, Level 4

Georgia World Congress Center

Chairs:

Nina E. Sreshta, M.D.

J. Wesley Boyd, M.D., Ph.D.

Speakers:

Robert P. Marlin, M.D., Ph.D., M.P.H.

Sarah R. Sherman-Stokes, J.D.

Our Toughest Addiction Challenge: Treating Tobacco Use Disorders in Patients With Mental Illness and Addictions and Informing Them About E-Cigarettes

1

10:00 a.m. – 11:30 a.m.

Room B404, Level 4

Georgia World Congress Center

Chairs:

Sunil Khushalani, M.D.

George Kolodner, M.D.

Addressing the Demand for Mental Health Care Needs of Hispanics in the United States

APA Caucus of Hispanic Psychiatrists

10:00 a.m. – 11:30 a.m.

Room B408, Level 4

Georgia World Congress Center

Chairs:

Esperanza Diaz, M.D.

Jose E. de la Gandara, M.D.

Speakers:

Julio Ballestas, M.D.

Andres Barkil-Oteo, M.D., M.Sc.

Daniel Castellanos, M.D.

Poster Session

International Poster Session 1

10:00 a.m. – Noon

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

12:30 p.m. Sessions

Session

APA Business Meeting

APA Members only

12:30 p.m. – 1:30 p.m.

Rooms A411-412, Level 4

Georgia World Congress Center

Case Conference



These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

I Just Want to Be Clean

5

12:30 p.m. – 2:00 p.m.

Rooms A315-316, Level 3

Georgia World Congress Center

Chairs:

Philip R. Muskin, M.D., M.A.

Geoffrey P. Taylor, M.D.

Speakers:

Donna Chen, M.D., M.P.H.

David Lowenthal, M.D., J.D.

Interactive Session

Using the DSM-5 Cultural Formulation Interview in Daily Practice

American Psychiatric Association Publishing Editorial Board

12:30 p.m. – 2:00 p.m.

Room A301, Level 3

Georgia World Congress Center

Chair:

Roberto Lewis-Fernandez, M.D.

Learning Lab

Controversial Treatment Debate: Should I Prescribe Ketamine and Marijuana? (Part 1)

12:30 p.m. – 2:00 p.m.

Rooms B207-208, Level 2

Georgia World Congress Center

Chair:

Erika L. Nurmi, M.D., Ph.D.

Speakers:

John Krystal, M.D.

J. Michael Bostwick, M.D.

Stephen R. Marder, M.D.

James T. McCracken, M.D.

Kristin Cadenhead, M.D.

Charles Grob, M.D.



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Lecture

From Genes to Neurobiology in Autism Spectrum Disorders

APA Distinguished Psychiatrist
Lecture Series



12:30 p.m. – 2:00 p.m.

Sidney Marcus Auditorium, Level 4
Georgia World Congress Center

Lecture Chair:

Steve H. Koh, M.D., M.P.H.

Lecturer:

Matthew State, M.D.

Scientific and Clinical Reports

Childhood Experiences and Adolescent Suicide Risk



12:30 p.m. – 2:00 p.m.

Room B405, Level 4
Georgia World Congress Center

1. Physically Bullied and Cyberbullied Adolescents: Associations With Suicide Feelings and Behaviors in Private School Students
Stephen Woolley, D.Sc.



2. Bullying Increases Risk of Suicidal Behavior
Nazanin Alavi, M.D.



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

3. Early Life Adversities, Personality Function, and Subsequent Depression and Suicide Risk in Adolescence: Examining Their Direct and Indirect Effects
Diana E. Clarke, Ph.D., M.Sc.



Workshops

Marijuana: What Clinicians Need to Know



12:30 p.m. – 2:00 p.m.

Room B215, Level 2
Georgia World Congress Center

Chair:

John Douglas, M.D.

Speakers:

Kevin Hill, M.D., M.H.S.
Brian Hurley, M.D., M.B.A.
Petros Levounis, M.D.

A Penny for Your Thoughts: Paying Cash to Foster Medication Compliance in Patients With Serious and Persistent Mental Illness

APA Ethics Committee and Penn-Scattergood Ethics Program

12:30 p.m. – 2:00 p.m.

Room B218, Level 2
Georgia World Congress Center

Chair:

John Maher, M.D.

Whose Information Is It Anyway? Ethical Issues in the Age of Electronic Health Records

12:30 p.m. – 2:00 p.m.

Room A303, Level 3
Georgia World Congress Center

Chair:

Mark Komrad, M.D.

Sexual Assault in the Military: Failures to Report, False Allegations, Source Monitoring Errors and Revising the System



12:30 p.m. – 2:00 p.m.

Room A304, Level 3
Georgia World Congress Center

Chair:

Connie Thomas, M.D.

Speakers:

Philip Candilis, M.D.
David Johnson, M.D.
Jennifer Yeaw, Psy.D.

Brain-Friendly Teaching: Incorporating Brain Learning Principles Into Teaching Activities

12:30 p.m. – 2:00 p.m.

Room A309, Level 3
Georgia World Congress Center

Chairs:

Jane Ripperger-Suhler, M.D., M.A.
Kari M. Wolf, M.D.

Advanced Ethical Analysis and Practical, Clinical Guidelines for Psychiatrists, Especially Those Who Are Ethics Consultants or on Ethics Committees



12:30 p.m. – 2:00 p.m.

Room A313, Level 3
Georgia World Congress Center

Chair:

Edmund G. Howe III, M.D.

A Resident's Guide to Borderline Personality Disorder: From the Experts (Part 1 of 2)

12:30 p.m. – 2:00 p.m.

Room B306, Level 3
Georgia World Congress Center

Chair:

Brian Palmer, M.D., M.P.H.

Speakers:

Brian Palmer, M.D., M.P.H.
John Gunderson, M.D.
Marianne Goodman, M.D.
Kenneth R. Silk, M.D.
Perry Hoffman, Ph.D.

Infectious Disease/Psychiatry HIV Collaborative Care: An Innovative Model for Person-Centered Care for the Southern Underserved

APA Council on Minority Mental Health and Health Disparities



12:30 p.m. – 2:00 p.m.

Room B310, Level 3
Georgia World Congress Center

Chair:

Daena L. Petersen, M.D., M.P.H.

APA Annual Business Meeting

Sunday, May 16

12:30 p.m. – 1:30 p.m.

Voting Members Only

Room A411-412, Level 4

Georgia World Congress Center

Call to Order

Renée L. Binder, M.D., President

Memorial to Deceased Members

Announcement of Election Results

Catharine S. May, M.D.

Chairperson, Committee of Tellers

Reports to the Membership

Saul Levin, M.D., M.P.A.

CEO and Medical Director

Frank W. Brown, M.D.

Treasurer

Altha J. Stewart, M.D.

Secretary

Glenn Martin, M.D.

Speaker

Daniel Anzia, M.D.

Speaker-elect

Rebecca Weintraub Brendel, M.D., J.D.

Chairperson, Committee on By-Laws

Barry K. Herman, M.D.

Chairperson, Elections Committee

Rahn K. Bailey, M.D.

Chairperson, Membership Committee

Chairpersons of Councils

(written reports only)

Annual Forum

Adjournment

Resident-Fellow Members, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows and Life Members only permitted to attend. Registration badge and/or APA membership access card necessary for admission. No cameras or tape recorders are permitted in this meeting.

Speakers:

Edward Kantor, M.D.

Cassandra Salgado, M.D., M.S.

“Closed” Resident Tales From the Front Line—and What We Can Learn—When a Psychiatric Emergency Department Shuts Its Doors

APA Child and Adolescent Psychiatry Fellowship

12:30 p.m. – 2:00 p.m.

Room B311, Level 3

Georgia World Congress Center

Chairs:

Sol Adelsky, M.D., M.P.P.

Jon Berlin, M.D.

Speakers:

Rachel Glick, M.D.

Steve Miccio, B.A.

Leslie Zun, M.D.

Close Encounters of Three Kinds: Challenges in the Residents’ Clinic

7

12:30 p.m. – 2:00 p.m.

Room B315, Level 3

Georgia World Congress Center

Chair:

Joan Anzia, M.D.

Speakers:

Molly Lubin, M.D.

Alexandra Regenbogen, M.D.

Brave New Technology for the Next Generation: A Case Formulation for Internet Gaming Disorder

1

12:30 p.m. – 2:00 p.m.

Room B316, Level 3

Georgia World Congress Center

Chair:

Dongchan Park, M.D.

Speaker:

Tim Fong, M.D.

GRADEing “Evidence” in Psychiatry: The Case of Medical Marijuana for Psychiatric Indications

12:30 p.m. – 2:00 p.m.

Room B403, Level 4

Georgia World Congress Center

Chairs:

Deepak Cyril D’Souza, M.D., M.B.B.S.

Rajiv Radhakrishnan, M.D., M.B.B.S.

Speakers:

Rajiv Radhakrishnan, M.D., M.B.B.S.

Samuel Wilkinson, M.D.

Challenges in Cognitive Behavior Therapy: Overcoming Barriers to Effective Treatment

12:30 p.m. – 2:00 p.m.

Room B404, Level 4

Georgia World Congress Center

Chairs:

Jesse H. Wright, M.D., Ph.D.

Judith S. Beck, Ph.D.

1:00 p.m. Sessions

Learning Lab

Psychiatry Innovation Lab—Where Quality Improvement Meets Silicon Valley: Pitch an Idea. Build a Team. Design a Venture.

APA Council on Quality Care



1:00 p.m. – 4:00 p.m.

Rooms B211-212, Level 2

Georgia World Congress Center

Chair:

Nina Vasan, M.D.

Judges:

Grayson Norquist, M.D.
Philip Wang, M.D., Dr.P.H.
Mary Giliberti, J.D.
Kana Enomoto
Dena Bravata
Mirene Winsberg, M.D.
Jordan Amadio
Donovan Wong

Media Workshop

Using the 2014/15 Movie “American Sniper” to Teach About Combat’s Stimuli and Stresses—and the Positive Role of Psychiatry and Training for the Same

1:00 p.m. – 4:00 p.m.

Room A314, Level 3
 Georgia World Congress Center

Chairs:

Lawrence K. Richards, M.D.
H. Steven Moffic, M.D.

Speaker:

Melissa Goelitz, M.D.

Presidential Symposia

AAGP Presidential Symposium: New Strategies in Geriatric Psychiatry Research and Practice

American Association for Geriatric Psychiatry
The Hartford-Jeste Award for Future Leaders in Geriatric Psychiatry and the Jack Weinberg Memorial Award for Geriatric Psychiatry will be presented during this session.

D 4

1:00 p.m. – 4:00 p.m.
 Rooms B213-214, Level 2
 Georgia World Congress Center

Chair:

Gary W. Small, M.D.

Discussant:

Charles F. Reynolds III, M.D.

1. Geriatric Depression
William M. McDonald, M.D.
2. Olfactory Identification Deficits and Noninvasive Markers of Alzheimer’s Disease
Davangere P. Devanand, M.D.

3. Paradoxical Improvement in Mental Health With Aging
Dilip V. Jeste, M.D.
4. Detection and Prevention of Cognitive Decline
Gary W. Small, M.D.

Ethical Issues in Psychodynamic Practice

American Academy of Psychoanalysis and Dynamic Psychiatry

D 3

1:00 p.m. – 4:00 p.m.
 Room B314, Level 3
 Georgia World Congress Center

Chair:

Michael Blumenfeld, M.D.

Discussant:

Paul S. Appelbaum, M.D.

1. Therapist Personal Disclosure and Psychodynamic Psychiatry
Silvia W. Olarte, M.D.
2. Helping the Patient to Change: The Problem of Undue Influence
Elizabeth L. Auchincloss, M.D.
3. Third-Party Involvements in Psychotherapeutic and Psychiatric Treatment Relationships
Sharon Batista, M.D.
4. An Experience as Plaintiff in a High-Profile Tarasoff-Type Case
Douglas H. Ingram, M.D.
5. Moral and Ethical Codes: Similarities and Differences in Chinese and American Psychodynamic Psychotherapy
Elise Snyder, M.D.

Symposia

You’re Taking What? Understanding New Commonly Used Medicines for Medical Disorders: A Case-Based Approach for the General Psychiatrist

D 5

1:00 p.m. – 4:00 p.m.
 Rooms B216-217, Level 2
 Georgia World Congress Center

Chairs:

Jeffrey T. Rado, M.D., M.P.H.
Robert M. McCarron, D.O.

1. Cancer and Psychiatric Medications
Virginia O’Brien, M.D.
2. Beyond Metformin: New Medications for Diabetes Mellitus and Review of Novel Anticoagulants
Sarah Rivelli, M.D.
3. New Medications for Hepatitis C
Jeffrey T. Rado, M.D., M.P.H.

Readjustment of Combat Veterans in Vet Centers and Psychiatric Clinics: Competition or Collaboration

D

1:00 p.m. – 4:00 p.m.
 Room B309, Level 3
 Georgia World Congress Center

Chair:

Thomas B. Horvath, M.D.

Discussant:

Charles Hoge, M.D.

1. Origins of VA Readjustment Counseling: The Rise and Fall and Rise of Understanding the Psychological Effects of War
Arthur S. Blank Jr., M.D.
2. Perspectives on the Vet Center Service Mission
Charles M. Flora, L.C.S.W.
3. Good Fences and Better Neighbors: A Veteran-Centered Community Approach
Harold Kudler, M.D.
4. The Combat Veterans’ Perspective: Reducing Barriers to Accessing Care and Establishing a Therapeutic Alliance
Cathleen A. Lewandowski, Ph.D., M.S.W.

Opioids: Crisis and Solutions

National Institute on Drug Abuse

D 1 6

1:00 p.m. – 4:00 p.m.
 Room B312, Level 3
 Georgia World Congress Center

Chairs:

Phil Skolnick, Ph.D.
Ivan D. Montoya, M.D., M.P.H.

Discussant:

Ivan D. Montoya, M.D., M.P.H.

1. Abuse-Deterrent Opioids: Advancing Beyond Tamper Resistance
Thomas Jenkins, Ph.D.
2. Lay Naloxone for Opioid Safety
Phillip O. Coffin, M.D., M.A.
3. Opiate Analgesics: Separating the Good, the Bad and the Ugly
Gavril Pasternak, M.D., Ph.D.
4. Vaccination as a Means to Mitigate Opioid Addiction
Kim D. Janda, Ph.D.

“Fresh off the Boat” Learning From a TV Sitcom About Acculturation, Family Dynamics and Mental Health in Asian-American Immigrant Families

APA Caucus of Asian-American Psychiatrists



1:00 p.m. – 4:00 p.m.
Rooms A406-407, Level 4
Georgia World Congress Center

Chairs:

Dana Wang, M.D.
Justin Chen, M.D., M.P.H.

Discussant:

Edmond H. T. Pi, M.D.

1. Struggles of an ABC (American-Born Chinese)
Justin Chen, M.D., M.P.H.
2. The Double-Edged Sword of Parental Expectations
Lusha Liu, M.D.
3. “I Love You, I’m Sorry”: Communication Challenges in Immigrant Families
Dana Wang, M.D.

Top 10 Genetic Syndromes That Psychiatrists Need to Know



1:00 p.m. – 4:00 p.m.
Room B409, Level 4
Georgia World Congress Center

Chairs:

Robert J. Pary, M.D.
Janice Forster, M.D.

1. Overview of DiGeorge, Phelan-McDermid and Klinefelter Syndromes
Jeffrey I. Bennett, M.D.

2. Overview of Fragile X Syndrome and Cornelia de Lange Syndrome
Stephen Ruedrich, M.D.
3. Overview of Prader Willi and Angelman Syndromes
Janice Forster, M.D.
4. Overview of Down and Smith-Magenis Syndromes
Robert J. Pary, M.D.

Breaking the Cycle of Serious Mental Illness



1:00 p.m. – 4:00 p.m.
Room B401, Level 4
Georgia World Congress Center

Chairs:

John M. Oldham, M.D., M.S.
B. Christopher Frueh, Ph.D.

1. Clinical Course and Six-Month Outcomes for Hospitalized Adults With Serious Mental Illness
J. Christopher Fowler, Ph.D.
2. The Role of Emotion Regulation and Functional Connectivity in Predicting Internalizing Symptom Recovery During Adolescents’ Inpatient Hospitalization
Carla Sharp, Ph.D.
3. Improvements in Somatic Complaints Among Individuals With Serious Mental Illness Receiving Treatment in a Psychiatric Hospital
Alok Madan, Ph.D., M.P.H.
4. Intensive Inpatient Treatment of Borderline Personality Disorder (BPD)
John M. Oldham, M.D., M.S.
5. Identification of Habenula Resting-State and White Matter Patterns Associated With Suicide in a Large Inpatient Psychiatric Sample
Michelle Patriquin, Ph.D.

Black Lives and Racial Disparities in the Juvenile Justice System: Implications for Policy, Psychiatric Practice and Advocacy



1:00 p.m. – 4:00 p.m.
Room B407, Level 4
Georgia World Congress Center

Chair:

Sarah Y. Vinson, M.D.

Discussant:

Ezra Griffith, M.D.

1. Youth Violence
Peter Ash, M.D.
2. Racial Disparities in Juvenile Justice
Randee Waldman, Esq.
3. The Psychology of Racial Injustice in Juvenile Justice and Resilience in Black Youth
LeRoy Reese, Ph.D.

2:00 p.m. Session

Poster Session

International Poster Session 2

2:00 p.m. – 4:00 p.m.
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

2:30 p.m. Sessions

Learning Lab

Controversial Treatment Debate: Should I Prescribe Ketamine and Marijuana? (Part 2)

2:30 p.m. – 4:00 p.m.
Rooms B207-208, Level 2
Georgia World Congress Center

Chair:

Erika L. Nurmi, M.D., Ph.D.

! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Speakers:

John Krystal, M.D.
 J. Michael Bostwick, M.D.
 Stephen R. Marder, M.D.
 James T. McCracken, M.D.
 Kristin Cadenhead, M.D.
 Charles Grob, M.D.

Lectures**The Oxford Textbook of Correctional Psychiatry: A Return to Our Roots**

APAF/AAPL Manfred S. Guttmacher Award

The Isaac Ray Award will also be presented during this session.



2:30 p.m. – 4:00 p.m.
 Room A302, Level 3
 Georgia World Congress Center

Lecturers:

Jeffrey Metzner, M.D.
 Kenneth Appelbaum
 Robert Trestman, M.D., Ph.D.

Advances in Assessment and Management of Risk of Violence

APA Frontiers of Science Lecture Series



2:30 p.m. – 4:00 p.m.
 Sidney Marcus Auditorium, Level 4
 Georgia World Congress Center

Lecturer:

Dale McNiel, Ph.D.

! SESSION TRACKS

- 1** Addiction Psychiatry
- 2** Child and Adolescent Psychiatry
- 3** Forensic Psychiatry
- 4** Geriatric Psychiatry
- 5** Psychosomatic Psychiatry
- 6** NIDA
- 7** Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Scientific and Clinical Reports**Suicide**

2:30 p.m. – 4:00 p.m.
 Room B405, Level 4
 Georgia World Congress Center

1. Driving Suicide to Zero: Redesigning the Clinical System of Care to Systematically Address Suicide Prevention
Shareh O. Ghani, M.D.
2. Depressed Multiple Suicide Attempters: A High-Risk Phenotype
Leo Sher, M.D.
3. A Retrospective Review of 100 Suicides in Phoenix, Ariz., 2009 – 2012
Shareh O. Ghani, M.D.

Workshops**Teaching the DSM-5 Cultural Formulation Interview: Innovative Web-Based Approaches and Videos to Demonstrate Culturally Appropriate Assessment Skills**

2:30 p.m. – 4:00 p.m.
 Room B215, Level 2
 Georgia World Congress Center

Chairs:

Russell F. Lim, M.D., M.Ed.
 Roberto Lewis-Fernandez, M.D.

Speakers:

Roberto Lewis-Fernandez, M.D.
 Francis Lu, M.D.
 Russell F. Lim, M.D., M.Ed.

Recovering Inside: Is Correctional Psychiatry an Oxymoron?

APA Ethics Committee and Penn-Scattergood Ethics Program

2:30 p.m. – 4:00 p.m.
 Room B218, Level 2
 Georgia World Congress Center

Chair:

Dominic Sisti, Ph.D.

Speakers:

Philip Candilis, M.D.
 Jeffrey L. Metzner, M.D.

Intimacy After Injury: Combat Trauma and Sexual Health

2:30 p.m. – 4:00 p.m.
 Room A303, Level 3
 Georgia World Congress Center

Chairs:

Elspeth C. Ritchie, M.D., M.P.H.
 Christopher Nelson, M.D.

Speakers:

Elspeth C. Ritchie, M.D., M.P.H.
 Christopher Nelson, M.D.

Resident Well-Being: Strategies to Prevent Burnout

2:30 p.m. – 4:00 p.m.
 Room A304, Level 3
 Georgia World Congress Center

Chair:

Ijeoma Chukwu, M.D., M.P.H.

Speakers:

Ijeoma Chukwu, M.D., M.P.H.
 Stella Cai, M.D.

Interactive Training and Dissemination of Tobacco Cessation in Psychiatry: An Rx for Change
Council on Addiction Psychiatry

2:30 p.m. – 4:00 p.m.
 Room A307, Level 3
 Georgia World Congress Center

Chair:

Smita Das, M.D., Ph.D.

Speakers:

Smita Das, M.D., Ph.D.
 Andrew J. Saxon, M.D.
 Jill M. Williams, M.D.

Breaking Bad: Communicating “Bad News” to Patients and Families

2:30 p.m. – 4:00 p.m.
 Room A309, Level 3
 Georgia World Congress Center

Chair:

Jeanne Lackamp, M.D.

Speakers:

Jennifer M. Brandstetter, M.D.
 Christine Koniaris, M.D.



Treating Adolescents With Eating Disorders: Special Issues

2

2:30 p.m. – 4:00 p.m.
Room A313, Level 3
Georgia World Congress Center

Chair:

Matthew Shear, M.D.

Speakers:

Tom Hildebrandt, Psy.D.
Evelyn Attia, M.D.

Advocating for Our Patients by Fighting Stigma: Overview of Stigma, How to Advocate, and Using Media and TED Talks to Combat Stigma

2:30 p.m. – 4:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center

Chairs:

Amy Poon, M.D.
Helen Farrell, M.D.

Speaker:

Laura Roberts, M.D., M.A.

A Resident's Guide to Borderline Personality Disorder: From the Experts (Part 2 of 2)

2:30 p.m. – 4:00 p.m.
Room B306, Level 3
Georgia World Congress Center

Chair:

Brian Palmer, M.D., M.P.H.

Speakers:

Brian Palmer, M.D., M.P.H.
John Gunderson, M.D.
Marianne Goodman, M.D.
Kenneth R. Silk, M.D.
Perry Hoffman, Ph.D.



SESSION TRACKS

- 1** Addiction Psychiatry
- 2** Child and Adolescent Psychiatry
- 3** Forensic Psychiatry
- 4** Geriatric Psychiatry
- 5** Psychosomatic Psychiatry
- 6** NIDA
- 7** Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Addressing Diversity in Psychiatric Training: Our Past, Present and Future With Diversity Systemic/Academic Strategic Initiatives

APA/SAMHSA Minority Fellows

7

2:30 p.m. – 4:00 p.m.
Room B310, Level 3
Georgia World Congress Center

Chairs:

Roberto E. Montenegro, M.D., Ph.D.
Auralyd Padilla Candelario, M.D.

Speakers:

Roberto E. Montenegro, M.D., Ph.D.
Paula Marie Smith, M.D.
Daena L. Petersen, M.D., M.P.H.
Ed Childs
Ranna Parekh, M.D., M.P.H.
Lisette Rodriguez-Cabezas, M.D.

Optimizing Psychopharmacology Training During Residency

2:30 p.m. – 4:00 p.m.
Room B315, Level 3
Georgia World Congress Center

Chair:

Jeffrey J. Rakofsky, M.D.

Speakers:

Jeffrey J. Rakofsky, M.D.
Sidney Zisook, M.D.
John Q. Young, M.D., M.P.H.
Ira Glick, M.D.

Addressing Stigma Using Acceptance and Commitment Therapy

2:30 p.m. – 4:00 p.m.
Room B316, Level 3
Georgia World Congress Center

Chair:

Kenneth P. Fung, M.D.

Speaker:

Kenneth P. Fung, M.D.

Crisis in Transit: Perspectives on Global Refugee and Migrant Mental Health

2:30 p.m. – 4:00 p.m.
Room B403, Level 4
Georgia World Congress Center

Chairs:

Damir Huremovic, M.D., M.P.P.
Nyapati R. Rao, M.D.

Speakers:

Guitelle St. Victor, M.D.
Jacob Sperber, M.D.

Online Dating, Cyberbullying and Harassment in the 21st Century: Prevalence, Psychiatric Consequences and Strategies for Prevention

2

2:30 p.m. – 4:00 p.m.
Room B404, Level 4
Georgia World Congress Center

Chairs:

Christopher F. Ong, M.D.
Almari Ginory, D.O.

Speakers:

Laura Ginory, M.D.
Yuliet Sanchez-Rivero, M.D.

What Can Mental Health Providers Learn From Pediatric Practices Regarding Prevention and Management of Cannabis Use by Youth?

National Institute on Drug Abuse

2 6

2:30 p.m. – 4:00 p.m.
Room B406, Level 4
Georgia World Congress Center

Chair:

Geetha A. Subramaniam, M.D.

Speakers:

Sharon Levy, M.D., M.P.H.
Stacy Sterling, M.P.H., M.S.W.

4:30 p.m. Session

Opening Session

4:30 p.m. – 6:45 p.m.
Hall B2, Level 1
Georgia World Congress Center

Opening Session

May 15, 2016

4:30 p.m.

Hall B2, Building B, Level 1
Georgia World Congress Center

Call to Order by APA President

Renée L. Binder, M.D.

Presentation of APA Gives Back Check
to Skyline Trails

Renée L. Binder, M.D.

Introduction of Stage Guests

Renée L. Binder, M.D.

Introduction of Dr. Steve H. Koh

Renée L. Binder, M.D.

Report from the Chairperson of the
Scientific Program Committee

Steve H. Koh, M.D.

Introduction of Presidents and
Representatives of United States and
International Allied Organizations

Renée L. Binder, M.D.

Introduction of the President for the
Presidential Address

Paul Summergrad, M.D.

Presidential Address

Renée L. Binder, M.D.

Introduction of the President-Elect for
the Response to the Presidential Address

Robert Freedman, M.D.

Response of the President-Elect

Maria A. Oquendo, M.D.

Brief break before Special Lecture.

Introduction of Dr. Atul Gawande

Renée L. Binder, M.D.

Special Lecture by Atul Gawande, M.D., M.P.H.

Atul Gawande's bold visions for improving performance and safety in health-care have made him one of the most sought-after speakers in medicine. His three books, *Complications*, *Better* and *The Checklist Manifesto*, have all been highly praised inside and outside the medical community. His new book is *Being Mortal: Medicine and What Matters in the End*. *TIME* placed him among the world's 100 most influential thinkers.

Atul Gawande is a MacArthur "Genius" Fellowship winner, a *New Yorker* columnist, an author — but, most of all, a physician, with a practitioner's grasp of the everyday challenges of healthcare delivery. Atul explains that medical practice and philosophy has not kept pace with the changes in healthcare over the last hundred years. We need reform — and Atul is on a lifelong search to discover what shape that reform should take. What does an effective healthcare system look like in the 21st century? How can we improve quality, manage risk and measure performance more effectively? Atul brings an eloquence and an intellect to these questions that allow him to offer deeply considered and beautifully expressed solutions with implications for health-care and beyond.

Dr. Gawande is broadly known for his influential articles, two of which won him the National Magazine Award. He has written about the shift from lone-ranger physicians to teams of co-operating specialists, and the new values this shift requires. He popularized the checklist as a means of co-ordinating complex work in hospitals. His ideas about how to rein in healthcare costs while increasing efficiency and quality have transformed the national discussion of these issues. His writing sets itself apart by its depth of thought and research, but also by its willingness to look outside of healthcare and see how other fields have delivered high-quality service in complex industries.

Atul is a general and endocrine surgeon at Brigham and Women's Hospital in Boston, and a professor in both the Department of Health Policy and Management at Harvard School of Public Health and the Department of Surgery at Harvard Medical School. He is the Executive Director of Ariadne Labs, a joint center for health systems innovation, and chairman of Lifebox, a nonprofit making surgery safer globally. He has won Academy Health's Impact Award for highest research impact on health care, and the Lewis Thomas Award for Writing about Science.





Visit the APA Bookstore in the Exhibit Hall May 14-17, 2016

The APA Bookstore has over 400 titles that can help you grow professionally and expand your knowledge!

Bookstore Hours

Saturday 9:00am – 4:00pm
 Sunday 10:00am – 4:00pm
 Monday 10:00am – 4:00pm
 Tuesday 10:00am – 4:00pm

Special Discounts!

20% for APA Members
 25% for APA Resident-Fellow Members
 15% for Non-Members

Don't miss the Author Book Signings at the APA Bookstore!

Saturday, May 14

Noon – 1:00pm

Otto F. Kernberg, M.D.

Sunday, May 15

11:00am – Noon

Mina K. Dulcan, M.D.
 Glen O. Gabbard, M.D.

Noon – 1:00pm

Petros Levounis, M.D., M.A.

Tuesday, May 17

Noon – 1:00pm

Patricia R. Casey, M.D., F.R.C.Psych
 Liza H. Gold, M.D.
 David Read Johnson, Ph.D.
 Hadar Lubin, M.D.
 James J. Strain, M.D.



Presidents/Representatives of U.S. Allied Organizations

Academy of Organizational and Occupational Psychiatry
Andrew O. Brown, M.D.

Academy of Cognitive Therapy
John P. Williams, M.D.

American Academy of Addiction Psychiatry
John A. Renner, M.D.

American Academy of Child and Adolescent Psychiatry
Gregory K. Fritz, M.D.

American Academy of Family Physicians
Wanda Filer, M.D.

American Academy of Neurology
Terrence L. Cascino, M.D.

American Academy of Psychiatry and the Law
Emily A.H. Keram, M.D.

American Academy of Psychoanalysis and Dynamic Psychiatry
Jennifer I. Downey, M.D.

American Association for Emergency Psychiatry
Leslie S. Zun, M.D.

American Association for Social Psychiatry
Kenneth S. Thompson, M.D.

American Association for the Advancement of Science
Barbara A. Schaal, M.D.

American Association of Chairs of Departments of Psychiatry
Gregory W. Dalack, M.D.

American Association of Community Psychiatrists
Anita S. Everett, M.D.

American Association of Directors of Psychiatric Residency Training
Art C. Walaszek, M.D.

American Association of Practicing Psychiatrists
Janis G. Chester, M.D.

American Association of Psychiatric Administrators
Geetha Jayaram, M.D.

American Board of Psychiatry and Neurology, Inc
Larry R. Faulkner, M.D.

American College of Emergency Physicians
Jay A. Kaplan, M.D.

American College of Obstetricians and Gynecologists
Mark S. DeFrancesco, M.D.

American College of Physicians
Nitin S. Damle, M.D.

American College of Psychiatrists
Frank W. Brown, M.D.

American College of Psychoanalysts
Norman A. Clemens, M.D.

American College of Surgeons
J. David Richardson, M.D.

American Group Psychotherapy Association
Eleanor F. Counselman, M.D.

American Medical Association
Stephen R. Permut, M.D., J.D.

American Medical Women's Association
Kimberly Templeton, M.D.

American Neurological Association
Barbara Vickrey, M.D.

American Neuropsychiatric Association
Jeremy Schmahmann, M.D.

American Nurses Association
Pamela Cipriano, M.D.

American Orthopsychiatric Association
Deborah Klein Walker, M.D.

American Psychoanalytic Association
Mark Smaller, M.D.

American Psychological Association
Susan H. McDaniel, M.D.

American Psychosomatic Society
Christoph Herrmann-Lingen, M.D.

American Society for Adolescent Psychiatry
Manuel Lopez, M.D.

American Society of Addiction Medicine
R. Jeffrey Goldsmith, M.D.

American Society of Clinical Psychopharmacology, Inc.
Mark H. Rapaport, M.D.

American Society of Hispanic Psychiatry
Mauricio Tohen, M.D.

Arab American Psychiatric Association
Abdel F. Amin, M.D., M.P.H.

Association for Academic Psychiatry
Jason P. Caplan, M.D.

Association for Behavioral and Cognitive Therapies
Michelle Craske, M.D.

Association of American Medical Colleges
Darrell G. Kirch, M.D.

Association of Chinese American Psychiatrists
Edmond H. Pi, M.D.

Association of Directors of Medical Student Education in Psychiatry
Brenda Roman, M.D.

Association of Gay and Lesbian Psychiatrists
Eric Yarbrough, M.D.

Association of Korean American Psychiatrists
Jaesu Han, M.D.

Association of Women Psychiatrists
Mary Barber, M.D.

College for Behavioral Health Leadership
Leigh Steiner, M.D.

Council of Medical Specialty Societies
Norman Kahn, M.D.

Depression and Bipolar Support Alliance
Allen Doederlein, M.D.

Group for the Advancement of Psychiatry
Steven S. Sharfstein, M.D.

Haitian American Psychiatric Association
Frantz H. Lubin, M.D.

Hellenic American Psychiatric Association
Philip Candilis, M.D.

Indo-American Psychiatric Association
Ashwin A. Patkar, M.D.

Mental Health America
Paul Gionfriddo, M.D.

National Alliance on Mental Illness (NAMI)
Marilyn Ricci, M.D.

National Association of County Behavioral Health and Developmental Disability Directors
Cherryl May Ramirez, M.D.

Presidents/Representatives of U.S. Allied Organizations

National Association of Psychiatric Health Systems

John Stupak, M.D.

National Association of Social Workers, Inc

Darrell P. Wheeler, M.D.

National Council for Community Behavioral Healthcare

Linda Rosenberg, M.D.

National Institute of Mental Health (NIMH)

Bruce Cuthbert, M.D.

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

George Koob, M.D.

National Institute on Drug Abuse (NIDA)

Nora D. Volkow, M.D.

Nigerian American Psychiatric Association

Charles C. Dike, M.D.

Philippine Psychiatrists in America

Maria I. Lapid, M.D.

Substance Abuse and Mental Health Services Administration (SAMHSA)

Kana Enomoto, M.A.

Turkish American Neuropsychiatric Association

Erol Ucer, M.D.

Presidents of International Allied Organizations

Albanian Psychiatric Association

Dr. Fatime Elezi

Algerian Psychiatric Association

Dr. Farid Kacha

Arab Gulf Psychiatric Association

Dr. Mohamed Al-Haddad

Argentinean Association of Psychiatrists

Dr. Nestor Marchant

Argentinean Psychiatrists Association

Dr. Analia Elena Ravenna

Armenian Psychiatric Association

Dr. Armen Soghoyan

Association of Free Psychiatrists of Romania

Dr. Aurel Romila

Association of Psychiatric Institutions of Serbia

Dr. Milutin Nenadović

Association of Psychiatrists in Nigeria

Dr. Joseph D. Adeyemi

Association of Psychiatrists of Uzbekistan

Dr. Ulugbek Alimov

Austrian Association of Psychiatry and Psychotherapy

Dr. Georg Psota

Azerbaijan Psychiatric Association

Dr. Nadir Ismayilov

Bangladesh Association of Psychiatrists

Dr. Md. Golam Rabbani

Barbados Association of Psychiatrists

Dr. Sharon Harvey

Belarusian Psychiatric Association

Dr. Oleg Skugarevsky

Bolivian Society of Psychiatry

Dr. Lupe Isnelda Gomez Montalvo

Brazilian Association of Psychiatry

Dr. Antonio Geraldo da Silva

Bulgarian Psychiatric Association

Dr. Hristo Kozhuharov

Canadian Psychiatric Association

Dr. Sonu Gaind

Chinese Society of Psychiatry

Dr. Xin Yu

College of Psychiatry of Ireland

Dr. Anthony McCarthy

Colombian Association of Psychiatry

Dr. Iván A. Jiménez R.

Costa Rican Psychiatric Association

Dr. Francisco Gólcher Valverde

Croatian Psychiatric Association

Dr. Vlado Jukic

Cuban Society of Psychiatry

Dr. Miguel Valdes Mier

Cyprus Psychiatric Association

Dr. Giannis Kalakoutas

Czech Psychiatric Association

Dr. Tomas Kasperek

Danish Psychiatric Society

Dr. Thomas Middelboe

Dominican Society of Psychiatry

Dr. Fior Solis de Mendez

Ecuadorian Psychiatric Association

Dr. José Mosquera A.

Egyptian Psychiatric Association

Dr. Ahmed Okasha

Emirates Psychiatric Society

Dr. Adel Karrani

Estonian Psychiatric Association

Dr. Andres Lehtmets

Ethiopian Psychiatric Association

Dr. Solomon Teferra

Finnish Psychiatric Association

Dr. Minna Valkonen-Korhonen

Flemish Psychiatric Association

Dr. Jürgen De Fruyt

Foundation for Interdisciplinary Investigation of Communication (Argentina)

Dr. Miguel Angel Materazzi

French Association of Psychiatrists in Private Practice

Dr. Patrice Charbit

French Association of Psychiatry

Dr. Jean-Yves Cozic

French Psychiatric Information Society

Dr. Gisèle Apter

Presidents of International Allied Organizations

German Association for Psychiatry, Psychotherapy and Psychosomatics

Dr. Iris Hauth

Ghana Psychiatric Association

Dr. Sammy Ohene

Guatemalan Psychiatric Association

Dr. Nery Adolfo Ortiz Alvarez

Hellenic Psychiatric Association (Greece)

Dr. Dimitrios Ploumpidis

Hellenic Society of Neurology and Psychiatry (Greece)

Dr. Costas Stefanis

Honduran Society of Psychiatry

Dr. Alejandra María Munguía Matamoros

Hong Kong College of Psychiatrists

Dr. Eric Chen Yu Hai

Hungarian Psychiatric Association

Dr. Károly Molnár

Icelandic Psychiatric Association

Dr. Thorgunnur Ársaelsdóttir

Independent Psychiatric Association of Russia

Dr. Yury Savenko

Indian Association for Social Psychiatry

Dr. Sudhir Khandelwal

Indian Psychiatric Society

Dr. Vidyadhar Watve

Indonesian Psychiatric Association

Dr. Danardi Sosrosumahardjo

International Society of Psychopathology of Expression (France)

Dr. Laurent Schmitt

Iranian Psychiatric Association

Dr. Ahmad Jalili

Iraqi Society of Psychiatrists

Dr. Qassim Hadi Al-Awadi

Israeli Psychiatric Association

Dr. Haim Belmaker

Italian Association for Research in Schizophrenia

Dr. Massimo Clerici

Italian Psychiatric Association

Dr. Claudio Mencacci

Jamaica Psychiatric Association

Dr. Geoffrey Omar Walcott

Japanese Society of Psychiatry and Neurology

Dr. Masatoshi Takeda

Jordanian Association of Psychiatrists

Dr. Walid Moh'd Shnaigat

Kazakh Association of Psychiatrists and Narcologists

Dr. Saltanat Nurmagambetova

Kenya Psychiatric Association

Dr. Simon Njuguna Kahonge Mutiso

Korean Neuropsychiatric Association

Dr. Young-Hoo Kim

Kuwait Psychiatric Association

Dr. Sulaiman Al-Khadhari

Kyrgyz Psychiatric Association

Dr. T. I. Galako

Latvian Psychiatric Association

Dr. Elmars Terauds

League for Mental Health from Republic of Moldova

Dr. Mihail Hotineanu

Lebanese Psychiatric Society

Dr. Charles Baddoura

Lithuanian Psychiatric Association

Dr. Alvydas Navickas

Luxembourgese Society of Psychiatry, Neurology and Psychotherapy

Dr. Chretien Jacoby

Malaysian Psychiatric Association

Dr. Teck Hoe Yen

Mauritius Psychiatric Association

Dr. Jagessur Arye Kumar

Medical Psychologic Society (France)

Dr. Aimé Charles-Nicolas

Mental Health Association of Cambodia

Dr. Kim Savuon

Mexican Psychiatric Association

Dr. Enrique Chavez-Leon

Mexican Society of Neurology and Psychiatry

Dr. Juan Ignacio Rosales

Mongolian Mental Health Association

Dr. Ayushjav Bayankhuu

Montenegrin Psychiatric Association

Dr. Lidija Injac-Stevovic

Moroccan Society of Psychiatry

Dr. Fatima-Zahra Sekkat

Mozambican Association of Psychiatry and Mental Health

Dr. Maria Lídia Chaúque Gouveia

Myanmar Medico-Psychological Society

Dr. Win Aung Myint

Netherlands Psychiatric Association

Dr. Aartjan Beekman

Nicaraguan Psychiatric Association

Dr. Elda Yessenia Jiron Gonzalez

Norwegian Psychiatric Association

Dr. Ketil Joachim Ødegaard

Pakistan Psychiatric Society

Dr. Syed Muhammad Sultan

Palestinian Psychiatric Association

Dr. Ziad Naji Arandi

Panamanian Society of Psychiatry

Dr. Lexma Magalis Ruiz Martez

Papua New Guinea Psychiatric Association

Dr. Umadevi Ambihaipahar

Paraguayan Society of Psychiatry

Dr. Martin Moreno

Peruvian Psychiatric Association

Dr. Juan Manuel Yori

Philippine Psychiatric Association

Dr. Edgardo Juan Tolentino Jr.

Polish Psychiatric Association

Dr. Andrzej Rajewski

Portuguese Association of Psychiatry

Dr. João Marques Teixeira

Portuguese Society of Psychiatry and Mental Health

Dr. Maria Luisa Figueira

Presidents of International Allied Organizations

Psychiatric Association of Bosnia-Herzegovina

Dr. Abdulah Kućukalić

Psychiatric Association of Macedonia

Dr. Dimitar Bonevski

Psychiatric Association of Rio de Janeiro State (Brazil)

Dr. Paulo Cesar Geraldés

Psychiatric Association of Rio Grande do Sul (Brazil)

Dr. Carlos Alberto Iglesias Salgado

Psychiatric Association of Slovenia

Dr. Peter Pregelj

Psychiatric Association of Thailand

Dr. Nawaporn Hirunviwatgul

Psychiatric Association of Turkey

Dr. Simavi Vahip

Psychiatrists' Association of Nepal

Dr. Saroj Prasad Ojha

Puerto Rican Society of Psychiatry

Dr. Edgardo Prieto-Agostini

Romanian Association of Psychiatry and Psychotherapy

Dr. Aurel Nirestean

Royal Society of Mental Medicine of Belgium

Dr. William Pitchot

Russian Society of Psychiatrists

Dr. Nikolay Neznanov

Salvadorean Association of Psychiatry

Dr. Tirza Merino Gomez

Saudi Psychiatric Association

Dr. Mahdi Saed Abumadini

Scientific Society of Neurologists, Psychiatrists and
Narcologists of Ukraine

Dr. Petro V. Voloshyn

Serbian Psychiatric Association

Dr. Dusica Lecic-Tosevski

Singapore Psychiatric Association

Dr. Lee Cheng

Slovak Psychiatric Association

Dr. Ľubomíra Izáková

Society of Georgian Psychiatrists

Dr. Eka Chkonia

Society of Neurology, Psychiatry and Neurosurgery (Chile)

Dr. Rodrigo Chamorro Oschilewsky

Society of Psychiatry of Uruguay

Dr. Rafael Sibils

South African Society of Psychiatrists

Dr. Mvuyiso Talatala

Spanish Association of Neuropsychiatry

Dr. Eudoxia Gay Pamos

Spanish Society of Psychiatry

Dr. Miguel Gutiérrez

Sri Lanka College of Psychiatrists

Dr. Samudra Kathriarachchi

Sudanese Association of Psychiatrists

Dr. Abdalla Abdelrahman

Swedish Psychiatric Association

Dr. Lena Flyckt

Swiss Society of Psychiatry

Dr. Pierre Vallon

Syrian Arab Association of Psychiatrists

Dr. Mazen Hedar

Taiwanese Society of Psychiatry

Dr. Te-Jen Lai

The Psychiatric Evolution (France)

Dr. Eric Marcel

The Royal Australian and New Zealand College of Psychiatrists

Dr. Malcolm Hopwood

The Royal College of Psychiatrists (United Kingdom)

Dr. Simon Wessely

Tunisian Society of Psychiatry

Dr. Rym Ghachem Attia

Turkish Neuropsychiatric Society

Dr. Mustafa Sercan

Uganda Psychiatric Association

Dr. David Kyemba Basangwa

Ukrainian Psychiatric Association

Dr. Viktor Shumlyansky

Venezuelan Society of Psychiatry

Dr. Yolanda P. Alvarado

World Federation for Mental Health

Dr. Gabriel Ivbijaro

World Psychiatric Association

Dr. Dinesh Bhugra

Yemen Psychiatrists and Neurologists Association

Dr. Abdelmagid S. Al-Khulaidi

Officers reported to the American Psychiatric Association as of
January 1, 2016

Monday

May 16, 2016



MONDAY, MAY 16

Richard J. Bonnie, J.D., is Harrison Foundation Professor of Law and Medicine; Professor of Public Policy; Professor of Psychiatry and Neurobehavioral Science; and Director of the Institute



of Law, Psychiatry and Public Policy at the University of Virginia. He specializes in health law and policy, bioethics, criminal law and public policies relating to mental health, substance abuse and public health. Professor Bonnie has participated in public service throughout his career. He was Associate Director of the National Commission on Marihuana and Drug Abuse (1971-1973), Secretary of the first National Advisory Council on Drug Abuse (1975-1980), Chair of Virginia's State Human Rights Committee responsible for protecting the rights of persons with mental disabilities (1979-1985) and Chief Advisor for the ABA Criminal Justice Mental Health Standards Project (1981-1988). He recently chaired the Commission on Mental Health Law Reform at the request of the Chief Justice of Virginia (2006-2011).

Jeffrey L. Metzner, M.D., received his medical degree from the University of Maryland Medical School in 1975 and completed his psychiatric residency at the University of Colorado's Department



of Psychiatry in 1979. He is Clinical Professor of Psychiatry at the University of Colorado School of Medicine in Denver, Colo. Dr. Metzner has written extensively on the psychiatric care of prison populations. He has provided consultation to judges, special masters, monitors, state departments of corrections, city and county jails, the U.S. Department of Justice, the

National Prison Project and others involved in the field of correctional psychiatry in 35 states. Dr. Metzner was a member (2006) of the Institute of Medicine Committee on Ethical Considerations for Revisions to DHHS Regulations for Protection of Prisoners Involved in Research. He was part of the APA workgroups that produced the first and third editions of the guidelines for psychiatric services in correctional facilities.

John Monahan, Ph.D., is the John S. Shannon Distinguished Professor of



Law at the University of Virginia, where he is also Professor of Psychology and Professor of Psychiatry and Neurobehavioral Sciences. He is a member of the National Academy of Medicine and serves on the National Research Council. Monahan was the founding President of the American Psychological Association's Division of Psychology and Law and has been a fellow of the John Simon Guggenheim Foundation and the Center for Advanced Study in the Behavioral Sciences. He twice directed research networks on mental health law for the John D. and Catherine T. MacArthur Foundation. He has received an honorary law degree from the City University of New York and the Isaac Ray Award of the American Psychiatric Association.

Roy O'Shaughnessy, M.D., completed his medical school education at the University of Ottawa in 1974. Afterward, he completed one year of internal medicine and two years of postgraduate training in



psychiatry at the University of British Columbia and two years at Yale University. In 1980, he completed his

fellowship in forensic psychiatry at Yale University. From 1981 through 2005, Dr. O'Shaughnessy was the Clinical Director of the Youth Forensic Psychiatric Services of the Province of British Columbia, responsible for the assessment and treatment of juvenile offenders. He is Clinical Professor in the Department of Psychiatry, UBC. From 1985 through 2012, he was Head of the Division of Forensic Psychiatry at UBC. After stepping down as Head in 2012, he remained as the Site Director for Civil Forensic Psychiatry at St. Paul's Hospital.

Dr. Stephen M. Stahl, M.D., Ph.D., received his undergraduate and medical



degrees from Northwestern University in Chicago and his Ph.D. degree in pharmacology and physiology from the University of Chicago. He has trained in three specialties: internal medicine at the University of Chicago, neurology at the University of California, San Francisco, and psychiatry at Stanford University. He is board certified in psychiatry. Dr. Stahl has held faculty positions at Stanford University, the University of California, Los Angeles, the Institute of Psychiatry, London, the Institute of Neurology, London, and, currently, the University of California, San Diego. Dr. Stahl's major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the Internet and teaching how to teach.

8:00 a.m. Sessions

Courses



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Restoring Professionalism: Integrating Mind, Brain and Body for Distressed Physicians



8:00 a.m. – Noon

International 4, International Level
Marriott Marquis

Chairs:

A. J. Reid Finlayson, M.D.
Linda L. M. Worley, M.D.

Directors:

A. J. Reid Finlayson, M.D.
Linda L. M. Worley, M.D.

Faculty:

Ron Neufeld, Ph.D.
William H. Swiggart, M.S.

Exploring Technologies in Psychiatry

American Association for Technology in Psychiatry



8:00 a.m. – Noon

International 5, International Level
Marriott Marquis

Directors:

Robert Kennedy, M.D.
John Luo, M.D.

Faculty:

Carlyle Chan
Steven Chan
John Torous, M.D.

Emergency Psychiatry: The Basics and Beyond

American Association for Emergency Psychiatry



8:00 a.m. – Noon

International 6, International Level
Marriott Marquis

Director:

Kimberly D. Nordstrom, M.D., J.D.

Faculty:

Scott Zeller, M.D.
Leslie Zun, M.D.
Jon Berlin, M.D.
Seth Powsner, M.D.

The Clinical Assessment of Malingered Mental Illness



8:00 a.m. – Noon

M103-105, Marquis Level
Marriott Marquis

Director:

Phillip J. Resnick, M.D.

Seminars

CPT Coding



8:00 a.m. – Noon

International 7, International Level
Marriott Marquis

Director:

Gregory G. Harris, M.D., M.P.H.

9:00 a.m. Sessions

Advances in Medicine

When Inflammation Weeps: The Emerging Role of the Immune System in Depression

9:00 a.m. – 10:30 a.m.

Rooms A315-316, Level 3
Georgia World Congress Center

Chair:

Andrew Miller, M.D.

Forum

Re-Examining ECT: From Patient Perspectives on Stigma to Benefit for Veteran Mental Health

9:00 a.m. – Noon

Room B407, Level 4
Georgia World Congress Center

Chairs:

Peter Hauser, M.D.
Richard Weiner

Speakers:

Kitty Dukakis
Richard Weiner
Georgios Petrides
Mark George

Interactive Session

Comorbid Medical Illness in Serious Psychiatric Disorders

9:00 a.m. – 10:30 a.m.

Room A301, Level 3
Georgia World Congress Center

Chair:

Henry A. Nasrallah, M.D.



SESSION TRACKS

- 1** Addiction Psychiatry
 - 2** Child and Adolescent Psychiatry
 - 3** Forensic Psychiatry
 - 4** Geriatric Psychiatry
 - 5** Psychosomatic Psychiatry
 - 6** NIDA
 - 7** Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.



This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Lectures

Future of Psychopharmacology: Is New Treatment Innovation “Dead” and Is Pharmacogenomics Irrelevant?

David A. Mrazek, M.D., Memorial Award

9:00 a.m. – 10:30 a.m.

Room B206, Level 2

Georgia World Congress Center

Lecturer:

Stephen M. Stahl, M.D., Ph.D.

Correctional Psychiatry: Current Issues and Future Directions

APA Distinguished Psychiatrist Lecture Series



9:00 a.m. – 10:30 a.m.

Sidney Marcus Auditorium, Level 4

Georgia World Congress Center

Lecture Chair:

Steve H. Koh, M.D., M.P.H.

Lecturer:

Jeffrey L. Metzner, M.D.

Scientific and Clinical Reports

Topics in Geriatrics



9:00 a.m. – 10:30 a.m.

Room B405, Level 4

Georgia World Congress Center

1. Homebound Older Adults: Prevalence, Characteristics, Health Care Utilization and Quality of Care
Stephanie MacLeod, M.Sc.

4

2. Differential Mortality Rates in Late-Life Depression and Subthreshold Depression: 10-Year Follow-Up in the Community
Cyrus S. H. Ho, M.B.B.S.

4

3. Structural Integrity and Functional Connectivity of Default Mode Network Underlying the Cognitive Impairment in Late-Onset Depression
Yingying Yin, M.Med.

4

4. Helping Aged Victims of Crime (HAVoC) Study: The Impact of Crime on Older People and the Feasibility of a CBT Intervention
Marc A. Serfaty, M.D., M.B.B.S.

Mood Disorders



9:00 a.m. – 10:30 a.m.

Room B406, Level 4

Georgia World Congress Center

1. The Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: A Review of Studies of the Past 20 Years
Mark Zimmerman, M.D.
2. Predictors of Length of Stay and Readmission in Inpatients With Mood Disorders
John W. Goethe, M.D.
3. Role of Age and Concurrent Medications in Titration Method for Seizure Threshold Determination in Bilateral ECT: A Retrospective Study
Preeti Sinha, M.D.

Workshops

Involuntary Inpatient Psychiatric Treatment: Past, Present and Future



9:00 a.m. – 10:30 a.m.

Room B215, Level 2

Georgia World Congress Center

Chairs:

David A. Nissan, M.D.

Julie B. Penzner, M.D.

Speakers:

Raymond Raad, M.D., M.P.H.

David A. Nissan, M.D.

Paul S. Appelbaum, M.D.

Julie B. Penzner, M.D.

Mark J. Russ, M.D.

Structured Clinical Interview for DSM-5 – Clinician Version (SCID-5-CV)

American Psychiatric Association Publishing Editorial Board

9:00 a.m. – 10:30 a.m.

Room B218, Level 2

Georgia World Congress Center

Chair:

Michael B. First, M.D.

Neuromodulation Primer for Residents: An Introduction to ECT, TMS and DBS

9:00 a.m. – 10:30 a.m.

Room A303, Level 3

Georgia World Congress Center

Chair:

Almari Ginory, D.O.

Speakers:

Richard Holbert, M.D.

Herbert Ward, M.D.

Jacqueline A. Hobbs, M.D., Ph.D.

Training American Psychiatrists as Global Mental Health Investigators, Implementers and Partners: What Have We Learned That Can Inform Best Practices?

APA Council on International Psychiatry

9:00 a.m. – 10:30 a.m.

Room A304, Level 3

Georgia World Congress Center

Chairs:

Michael D. Morse, M.D., M.P.A.

Anne Becker, M.D., Ph.D.

Speakers:

James Griffith, M.D.

Bibhav Acharya, M.D.

Joseph Reginald Fils-Aimé, M.D., M.Sc.

Milton Wainberg, M.D.

The Behavioral Addictions and the Brave New World of the DSM-6 (Yes, Six)

APA Council on Addiction Psychiatry



9:00 a.m. – 10:30 a.m.

Room B306, Level 3

Georgia World Congress Center

SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device

Chairs:

Mayumi Okuda, M.D.
Petros Levounis, M.D.

Speakers:

Silvia Bernardi, M.D.
Ariel Kor, M.S.
Mayumi Okuda, M.D.
Petros Levounis, M.D.

The AshleyMadison.com Hack: Understanding and Treatment of Infidelity From Discovery to Recovery

9:00 a.m. – 10:30 a.m.
Room A307, Level 3
Georgia World Congress Center

Chair:

Scott Haltzman, M.D.

Speakers:

Robert Hsiung, M.D.
Scott Haltzman, M.D.

The Kids Are Not All Right: Mental Health Impact of Parental Incarceration

APA Council on Children, Adolescents and Their Families

2

9:00 a.m. – 10:30 a.m.
Room A313, Level 3
Georgia World Congress Center

Chairs:

Courtney L. McMickens, M.D., M.P.H.
Barbara Robles-Ramamurthy, M.D.

Speakers:

Joyce Arditti, Ph.D.
Mia Everett, M.D.
Otis Anderson, M.D.
Anish R. Dube, M.D., M.P.H.
Courtney L. McMickens, M.D., M.P.H.

Telepsychiatry and Its Myriad Applications for Treating People With Serious Mental Illness in the Public Sector (and for Residency Training)

9:00 a.m. – 10:30 a.m.
Room B310, Level 3
Georgia World Congress Center

Chair:

Rachel Zinns, M.D., Ed.M.

Speakers:

Li-Wen Grace Lee, M.D.
Gregory Miller, M.D., M.B.A.
Matthew B. Perkins, M.D., M.P.H.
Matthew D. Erlich, M.D.
Rachel Zinns, M.D., Ed.M.

Pre-Exposure Prophylaxis (PrEP) for HIV: The Science, Psychology and Implications for Clinical Practice

5

9:00 a.m. – 10:30 a.m.
Room B311, Level 3
Georgia World Congress Center

Chair:

Kenneth Ashley, M.D.

Speakers:

Marshall Forstein, M.D.
David W. Purcell, J.D., Ph.D.

The Context of Psychosis: Cultural Curiosity and Enhanced Clinical Care

APA Council on Minority Mental Health and Health Disparities

9:00 a.m. – 10:30 a.m.
Room B315, Level 3
Georgia World Congress Center

Chairs:

Jerome H. Taylor, M.D.
Jennifer Severe, M.D.

Speakers:

Hector Colon-Rivera, M.D.
Tanuja Gandhi, M.D.
Roberto Lewis-Fernandez, M.D.
Mohini Ranganathan, M.B.B.S.
Caroline D. Brozyna, M.D.

Does Open Access Beat Traditional Scheduling?

9:00 a.m. – 10:30 a.m.
Room B316, Level 3
Georgia World Congress Center

Chair:

R. Kaan Ozbayrak, M.D., M.B.A.

Speakers:

R. Kaan Ozbayrak, M.D., M.B.A.
Cynthia Grant, Ph.D., L.C.S.W.

How Should We Determine What Is Most Ethical? A Framework for Analyzing Ethics Dilemmas in Psychiatric Practice

3

9:00 a.m. – 10:30 a.m.
Room B408, Level 4
Georgia World Congress Center

Chair:

Robert Weinstock, M.D.

Speakers:

William C. Darby, M.D.
Robert Weinstock, M.D.

No Poster. No Publication. No Problem! A Step-by-Step Guide to Get You Started in the Scholarly Activity Process

9:00 a.m. – 10:30 a.m.
Room B403, Level 4
Georgia World Congress Center

Chair:

Rashi Aggarwal, M.D.

Speakers:

Nicole Guanci
Cristina Montalvo, M.D.

EEG in Psychiatric Practice

World Psychiatric Association

9:00 a.m. – 10:30 a.m.
Room B404, Level 4
Georgia World Congress Center

Chairs:

Nashaat Boutros, M.D.
Oliver Pogarell, M.D.

Speakers:

Oliver Pogarell, M.D.
Nashaat Boutros, M.D.

Residents Teaching About Racism: A Novel Educational Approach to Combating Racial Discrimination in Mental Health Care

APA Council on Medical Education and Lifelong Learning

9:00 a.m. – 10:30 a.m.
Room B409, Level 4
Georgia World Congress Center

Chairs:

Andrew D. Carlo, M.D.
Jerrold F. Rosenbaum, M.D.

Speakers:

Morgan Medlock, M.D.
 Anna Weissman, M.D.
 Andrew D. Carlo, M.D.
 Mary C. Zeng, M.D.
 Derri Shtasel, M.D., M.P.H.
 Jerrold F. Rosenbaum, M.D.

Advances in Research

New Developments in Clinical Psychiatry

9:00 a.m. – Noon

Rooms A411-412, Level 4

Georgia World Congress Center

Chair:

Herbert Pardes, M.D.

1. Treatment of Minority Young Adults With Anxiety Disorders: Closing the Disparity Gap
Maria Carolina Zerrate, M.D., M.H.S.
2. Depression: An Update on Research and New Treatment Options
Fritz A. Henn, M.D., Ph.D.
3. Advances in the Care of Late-Life Depression
George S. Alexopoulos, M.D.
4. Introduction of a Precision Medicine-Based Approach in Psychiatry
Sander Markx, M.D.
5. Eating Disorders
Evelyn Attia, M.D.

Advances in Series

Managing the Side Effects of Psychotropic Medications

American Psychiatric Association
 Publishing Editorial Board



9:00 a.m. – Noon

Room A305, Level 3

Georgia World Congress Center

Chairs:

Joseph F. Goldberg, M.D.
 Carrie L. Ernst, M.D.

1. Clinical and Pharmacologic Considerations in Assessing Adverse Effects of Psychotropic Drugs
Joseph F. Goldberg, M.D.
2. State-of-the-Art Assessment and Management of Latrogenic Weight Gain and Metabolic Dysregulation
Roger S. McIntyre, M.D.

3. Evaluating and Managing Sexual Dysfunction From Psychotropic Medications
Anita Clayton
4. An Update on Cardiovascular and Arrhythmogenic Risks of Psychotropic Drugs
Carrie L. Ernst, M.D.

Learning Labs

A Leadership Boot Camp for Residents and Fellows (Part 1): Defining Your Professional Goals, Developing Leadership Strengths, Giving Feedback and Managing Difficult Conversations



9:00 a.m. – Noon

Rooms B207-208, Level 2

Georgia World Congress Center

Chair:

Laura Roberts, M.D., M.A.

Mock Trial: Lessons for Psychiatrists From the Bar and Risk Management



9:00 a.m. – Noon

Rooms B211-212, Level 2

Georgia World Congress Center

Chair:

Kristen M. Lambert, J.D., M.S.W.

Speakers:

Renée Binder, M.D.
 Anton Bland, M.D.
 Noel B. Dumas
 Holly S. Bell
 Ted Lavender



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
 Bring Your Own Device

Media Workshops

Remaking the Bad Seed in Blood Red

2

9:00 a.m. – Noon

Room A314, Level 3

Georgia World Congress Center

Chair:

Lynn Maskel, M.D.

Speakers:

Elissa P. Benedek, M.D.
 Kevin D. Moore, M.D.

Presidential Symposia

Critical Issues in the Delivery of Psychiatric Care Through Videoconferencing



9:00 a.m. – Noon

Rooms B213-214, Level 2

Georgia World Congress Center

Chair:

Jay Shore, M.D., M.P.H.

1. APA Telepsychiatry Resources for Advancing Telepsychiatric Care and Training: Website Toolkit and Work Group
Jay Shore, M.D., M.P.H.
2. Training Yourself and Others in Telepsychiatry
Jeffrey I. Bennett, M.D.
3. Virtual Roundtable on Practical Policy Issues in Telepsychiatry
Jay Shore, M.D., M.P.H., Alexander H. von Hafften, M.D., Steven Roy Davis, M.D., Robert Caudill, M.D., Donald M. Hilty, M.D., Peter Yellowlees, M.D.
4. Direct In-Home Telepsychiatry
Meera Narasimhan, M.D., Jay Shore, M.D., M.P.H.



This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.



Correctional Psychiatry, Criminalization of the Mentally Ill and Avoiding the Criminal Justice System

9:00 a.m. – Noon

Rooms A311-312, Level 3

Georgia World Congress Center

Chair:

Rebecca Weintraub Brendel, M.D., J.D.

1. Engaging Ethical Challenges in Psychiatry: Past and Present
Laura Roberts, M.D., M.A.
2. The APA Commentary on Ethics in Practice (2015): Current and Emerging Ethical Issues in Psychiatry
Rebecca Weintraub Brendel, M.D., J.D.
3. Universal, Unifying Ethics: The New Hope
Philip Candilis, M.D.
4. Psychiatric Ethics: A Peek at the Future
Paul S. Appelbaum, M.D.

Critical Issues in Addiction Psychiatry

American Academy of Addiction Psychiatry



9:00 a.m. – Noon

Room B313, Level 3

Georgia World Congress Center

Chairs:

Laurence Westreich, M.D.
Brian S. Fuehrlein, M.D.

1. Choice vs. Compulsion in Addiction Psychiatry
Richard N. Rosenthal, M.D., M.A.

SESSION TRACKS

- 1 Addiction Psychiatry
- 2 Child and Adolescent Psychiatry
- 3 Forensic Psychiatry
- 4 Geriatric Psychiatry
- 5 Psychosomatic Psychiatry
- 6 NIDA
- 7 Residents, Fellows and Medical Students
- ▶ APA Annual Meeting On Demand
- 📱 Bring Your Own Device

2. Common Psychiatric Emergency Department Problems
John S. Rozel, M.D.
3. Opioid Use Disorder and the Psychiatric Emergency Room: The VA Model
Brian Fuehrlein, M.D.
4. Malpractice in Addiction Psychiatry
Laurence Westreich, M.D.

Symposia

Senior Psychiatrists and Positive Aging



9:00 a.m. – Noon

Rooms B216-217, Level 2

Georgia World Congress Center

Chairs:

Dilip V. Jeste, M.D.
Glen O. Gabbard, M.D.

Discussant:

Michelle Conroy

1. Successful Aging of Psychiatrists
Dilip V. Jeste, M.D.
2. Identity Issues in the Senior Psychiatrist
Glen O. Gabbard, M.D.
3. Positive Aging: The Role of Meaning
Michelle B. Riba, M.D.
4. Lifers and Senior Psychiatrists: Identifying Problems and Solutions
Stephen C. Scheiber, M.D.
5. Sociocultural Issues in the Aging of Ethnically Diverse Senior Psychiatrists
Renato D. Alarcon, M.D., M.P.H.

Street Psychiatry: Integrated Care for Atlanta’s Unsheltered Homeless



9:00 a.m. – Noon

Room B308, Level 3

Georgia World Congress Center

Chair:

Elizabeth A. Frye, M.D., M.P.H.

Discussant:

Anitra Walker, L.C.S.W.

1. Care Integration on the Streets: Primary Care and Wound Care as Methods of Engaging Mentally Ill Homeless People
Sapna B. Morris, M.D., M.B.A., Tim Porter-O’Grady, Ed.D., R.N.
2. Technology on the Streets: Telemedicine as a Tool to Expand Psychiatric Care for Rough Sleepers
Kathy Schaaf, B.Sc., R.N.
3. Peer Specialists and Their Unique Role in Street Medicine Teams
Ricky Alexander
4. Student Perspectives and Education With Homeless Populations/ Patient Satisfaction and Quality Improvement on the Streets
Aleta Christensen, M.P.H.

Contemporary Issues in Juvenile Justice



9:00 a.m. – Noon

Room B309, Level 3

Georgia World Congress Center

Chairs:

William Arroyo, M.D.
Jorien Gemma Breur, M.D.

Discussant:

Louis Kraus, M.D.

1. The Impact of Changing Views of Adolescent Culpability
Peter Ash, M.D.
2. Current Issues and Future Directions in the Assessment of Juvenile Competency to Stand Trial
Caitlin Costello, M.D.
3. Adolescent Parricide: Personality, Crime Characteristics and Sentencing
Wade C. Myers, M.D.
4. Education of Youth in Juvenile Justice Systems
William Arroyo, M.D.

Brief Therapy With “Difficult” Patients

American Psychiatric Association Publishing Editorial Board



9:00 a.m. – Noon

Room B314, Level 3

Georgia World Congress Center

Chair:

Mantosh Dewan, M.D.

1. The “Difficult” Patient and Poor Outcomes
Mantosh Dewan, M.D.
2. A Motivational Interviewing Perspective on the “Difficult” Patient
Steve Martino, Ph.D.
3. Exposure Therapy for Trauma Survivors With Severe PTSD
Seth J. Gillihan, Ph.D.
4. CBT for Challenging Problems
Judith S. Beck, Ph.D.

Psychodynamic Psychotherapy Across Personality Disorders: Transference-Focused Psychotherapy

American Psychiatric Association Publishing Editorial Board



9:00 a.m. – Noon

Rooms A402-403, Level 4
Georgia World Congress Center

Chairs:

Frank E. Yeomans, M.D.
Otto F. Kernberg, M.D.

1. The Four Fundamental Techniques of Psychodynamic Psychotherapy
Otto F. Kernberg, M.D.
2. The Essential and Multiple Roles of the Treatment Frame
Frank E. Yeomans, M.D.
3. Reconsidering Exploratory Interventions in Dynamic Therapy: Beyond Insight
Eve Caligor, M.D.
4. Addressing the Challenges of Narcissistic Personality Disorder
Diana Diamond, Ph.D.

Current Challenges and Opportunities in Psychiatric Administration and Leadership

American Association of Psychiatric Administrators



9:00 a.m. – Noon

Rooms A404-405, Level 4
Georgia World Congress Center

Chairs:

Victor J. A. Buwalda, M.D., Ph.D.
Sy A. Saeed, M.D., M.S.

Discussants:

Steven S. Sharfstein, M.D., M.P.A.
Saul Levin, M.D., M.P.A.

1. Lean Management in Mental Health Care
Lydia E. Weisser, D.O., M.B.A.
2. Role of Leadership in Narrowing the Gap Between Science and Practice: Improving Treatment Outcomes at the Systems Level
Sy A. Saeed, M.D., M.S.
3. Training Future Leaders: Challenges and Opportunities
Farooq Mohyuddin, M.D., M.B.B.S.
4. Cultural Issues in Psychiatric Administration
Neil K. Aggarwal, M.D., M.B.A.
5. Ethical Leadership in Psychiatry
H. Steven Moffic, M.D.

The Surgeon General’s Report on Mental Health, Parity and Integrated Care

APA Council on International Psychiatry
The Human Rights Award will be presented during this session.



9:00 a.m. – Noon

Room B402, Level 4
Georgia World Congress Center

Chairs:

Eliot Sorel, M.D.
Constance E. Dunlap, M.D.

1. Mental Health: A Report of the Surgeon General
David Satcher, M.D., Ph.D.
2. Mental Health Parity, the Domenici-Wellstone Law and the Affordable Care Act
Patrick Kennedy

3. Making Mental Health Count
Francesca Colombo
4. Integrated Care in Clinical Practice
Eliot Sorel, M.D.

Breakthroughs in the Understanding and Treatment of Personality Pathology

Association for Research in Personality Disorders



9:00 a.m. – Noon

Room A410, Level 4
Georgia World Congress Center

Chair:

James H. Reich, M.D., M.P.H.

Discussants:

Erin Hazlett, Ph.D.
Alan F. Schatzberg, M.D.

1. Social Cognition as a New Therapeutic Target in Personality Disorders
M. Mercedes Perez-Rodriguez, M.D., Ph.D.
2. Neurobiology and Treatment of Impulsive Aggression in Human Subjects
Emil Coccaro, M.D.
3. Therapeutic Implications of Recent Neuroimaging Findings on Emotion Dysregulation in Personality Disorders
Harold W. Koenigsberg, M.D.
4. Neurobiological Evidence for Impaired Mentalization in Borderline Personality Disorder
Antonia S. New, M.D.
5. Moving From Treatment as Usual to Good Clinical Care for Personality Disorder: Traits for the Office-Based Clinician
James H. Reich, M.D., M.P.H.

New Issues in Understanding and Addressing Tobacco Use and Mental Illness

National Institute on Drug Abuse



9:00 a.m. – Noon

Room B401, Level 4
Georgia World Congress Center



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

Chair:

Wilson M. Compton, M.D.

Discussant:

Tony P. George, M.D.

1. It's Not Just Cigarettes: The Evolving Epidemiology of Tobacco Product Use, Substance Use and Symptoms of Mental Illness in the U.S.
Kevin P. Conway, Ph.D.
2. Tobacco Use as a Risk for Psychosis?
Kenneth Kendler, M.D.
3. Shared Genetic Risk Factors Between Schizophrenia and Nicotine Dependence
Laura J. Bierut, M.D.
4. E-Cigarettes: Promise and Peril
Maciej L. Goniewicz, Ph.D., Pharm.D.
5. Integration of Tobacco Cessation and Mental Health Care for Veterans With PTSD
Andrew J. Saxon, M.D.

Disentangling Guns and Mental Illness: The Sandy Hook Effect



9:00 a.m. – Noon
Rooms A406–407, Level 4
Georgia World Congress Center

Chair:

Tobias Wasser, M.D.

Discussant:

Ezra Griffith, M.D.

1. Gun Control Legislation and Reporting Requirements
Michael Norko, M.D., M.A.
2. Permit Prohibition and Gun Seizure Statutes
Madelon Baranoski, Ph.D.
3. Psychiatric Admissions and Gun Ownership Following Sandy Hook
Tobias Wasser, M.D.
4. The Sandy Hook Advisory Commission: Lessons Learned
Ezra Griffith, M.D.

Courses



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Psychodynamic Principles With Treatment-Resistant Mood Disorders: Breaking Through Treatment Resistance by Focusing on Comorbidity



9:00 a.m. – 4:00 p.m.
International 8, International Level
Marriott Marquis

Director:

Eric M. Plakun, M.D.

Faculty:

Edward R. Shapiro, M.D., M.A.
David L. Mintz, M.D.

Integrating Behavioral Health and Primary Care: Practical Skills for the Consulting Psychiatrist



9:00 a.m. – 4:00 p.m.
Marquis Ballroom A, Marquis Level
Marriott Marquis

Directors:

Anna Ratzliff, M.D., Ph.D.
Lori Raney, M.D.

Faculty:

John Kern, M.D.

Mind-Body Programs: Stress, Anxiety, Depression, PTSD, Military Trauma and Mass Disasters: Lecture and Experiential (Replaces Yoga of the East and West)

APA Caucus on Complementary and Alternative Medicine



9:00 a.m. – 4:00 p.m.
Marquis Ballroom D, Marquis Level
Marriott Marquis

Director:

Patricia L. Gerbarg, M.D.

Faculty:

Richard P. Brown, M.D.

Essentials of Assessing and Treating ADHD in Adults and Children



9:00 a.m. – 4:00 p.m.
Imperial Ballroom A, Marquis Level
Marriott Marquis

Director:

Thomas Brown, Ph.D.

Faculty:

Anthony Rostain, M.D.

Master Course



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

2016 Psychiatry Review




9:00 a.m. – 4:00 p.m.
Imperial Ballroom B, Marquis Level
Marriott Marquis

Director:

Robert J. Boland, M.D.



SESSION TRACKS

- 1** Addiction Psychiatry
- 2** Child and Adolescent Psychiatry
- 3** Forensic Psychiatry
- 4** Geriatric Psychiatry
- 5** Psychosomatic Psychiatry
- 6** NIDA
- 7** Residents, Fellows and Medical Students
-  APA Annual Meeting On Demand
-  Bring Your Own Device

Seminar

Primary Care Skills for Psychiatrists



9:00 a.m. – 4:00 p.m.
M301-302, Marquis Level
Marriott Marquis

Directors:

Erik Vanderlip, M.D., M.P.H.
Jeffrey T. Rado, M.D., M.P.H.

10:00 a.m. Session

Poster Session

Young Investigators' New Research 1

10:00 a.m. – Noon
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

11:00 a.m. Sessions

Case Conference



These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

Multidisciplinary Approach to Treatment of Patients With First-Episode Psychosis

11:00 a.m. – 12:30 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center

Chair:

S. Charles Schulz, M.D.

Speaker:

Sophia Vinogradov, M.D.

Forum

The Aging Physician: Possibilities and Perils

11:00 a.m. – 12:30 p.m.
Room B206, Level 2
Georgia World Congress Center

Chairs:

Nada L. Stotland, M.D., M.P.H.
Paul H. Wick, M.D.

Speaker:

Glen O. Gabbard, M.D.

Interactive Session

Boundaries and Boundary Violations

*American Psychiatric Association
Publishing Editorial Board*

11:00 a.m. – 12:30 p.m.
Room A301, Level 3
Georgia World Congress Center

Chair:

Glen O. Gabbard, M.D.

Lectures

Seeking the Sacred in Psychotherapy and in Life

Oskar Pfister Award



11:00 a.m. – 12:30 p.m.
Room A302, Level 3
Georgia World Congress Center

Lecturer:

James W. Lomax, M.D.

The Sudden Collapse of Marijuana Prohibition: Now What?

APA Guest Lecture Series



11:00 a.m. – 12:30 p.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center

Lecturer:

Richard J. Bonnie, J.D.

Scientific and Clinical Reports

Medical Care Reform and Psychiatry



11:00 a.m. – 12:30 p.m.
Room B405, Level 4
Georgia World Congress Center

1. A Century of Health Care Reform: Analysis and Predictions for the Affordable Care Act
Dora Wang, M.D., M.A.



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

2. Changes in Mental Health Care Spending and Quality Associated With Accountable Care Organizations in Medicare
Alisa B. Busch, M.D., M.S.

3. Prioritizing Quality Measures for Physical Health Assessment in a Community Mental Health Organization: A Stakeholder-Based Approach
Sharat P. Iyer, M.D., M.S.

Availability and Community Satisfaction in Psychiatry



11:00 a.m. – 12:30 p.m.
Room B406, Level 4
Georgia World Congress Center

1. A Clinically Useful Self-Report Measure of Psychiatric Patients' Satisfaction With the Initial Evaluation
Mark Zimmerman, M.D.
2. Psychiatrists' Reports of Mental Health and Substance Use Treatment Access Problems
Joyce C. West, Ph.D., M.P.P.
3. Reducing Readmissions to the Acute Psychiatric Services of an Inner City Community Hospital: A Systematic Approach
Renuka Ananthamoorthy, M.D.

Workshops

Stigma, Discrimination and the Criminalization of HIV/AIDS in the United States: Challenges for Psychiatrists in the Delivery of Compassionate Care



11:00 a.m. – 12:30 p.m.
Room B215, Level 2
Georgia World Congress Center

Chairs:

Lawrence McGlynn, M.D., M.S.
Mary Ann A. Cohen, M.D.

Speakers:

Mary Ann A. Cohen, M.D.
Antoine Douaihy, M.D.
Daena L. Petersen, M.D., M.P.H.
Lawrence McGlynn, M.D., M.S.

Medical Conditions Mimicking Psychiatric Disorders Versus Psychiatric Disorders Mimicking Medical Conditions: Diagnostic and Treatment Challenges

11:00 a.m. – 12:30 p.m.

Room B218, Level 2

Georgia World Congress Center

Chair:

Catherine Crone, M.D.

The History, Ethics and Promise of Psychedelic Therapies

APA Ethics Committee and Penn-Scattergood Ethics Program

11:00 a.m. – 12:30 p.m.

Room A303, Level 3

Georgia World Congress Center

Chair:

Dominic Sisti, Ph.D.

Speakers:

Paul Summergrad, M.D.

Rick Doblin, Ph.D.

Matthew J. Baggott, Ph.D.

Exploring Barriers to Treatment for Child Transgender Patients in the Institutional and Inpatient Psychiatric Settings

2

11:00 a.m. – 12:30 p.m.

Room A304, Level 3

Georgia World Congress Center

Chairs:

Rabiya Hasan, M.D.

Speaker:

Chioma Linda Iheagwara, D.O.

Criminalization of Black Males: The Effects of Untreated Bipolar, ADHD and Substance Abuse Disorders

APA Caucus of Black Psychiatrists

3

11:00 a.m. – 12:30 p.m.

Room A313, Level 3

Georgia World Congress Center

Chair:

Napoleon B. Higgins Jr., M.D.

Speakers:

Otis Anderson, M.D.

Timothy Benson, M.D.

Ericka Goodwin, M.D.

Johnny Williamson, M.D.

Rahn Bailey, M.D.

Future of the DSM: An Update From the DSM Steering Committee

11:00 a.m. – 12:30 p.m.

Room B306, Level 3

Georgia World Congress Center

Chair:

Paul S. Appelbaum, M.D.

Speakers:

Michael B. First, M.D.

Kenneth Kendler, M.D.

Top 10 Geriatric Psychiatry Issues for the General Psychiatrist: An Update

4

11:00 a.m. – 12:30 p.m.

Room B310, Level 3

Georgia World Congress Center

Chairs:

Josepha A. Cheong, M.D.

Iqbal Ahmed, M.D.

Speaker:

Shilpa Srinivasan, M.D.

Disruptive Behavior in Preschool Children: What Does It Mean? Differential Diagnosis and Pharmacologic Approaches

APA Council on Children, Adolescents and Their Families

2

11:00 a.m. – 12:30 p.m.

Room B311, Level 3

Georgia World Congress Center

Chair:

Jean M. Thomas, M.D.

Speakers:

Jean M. Thomas, M.D.

Swathi Krishna, M.D.

Caroline D. Brozyna, M.D.

Achieving Health Equity: Psychiatry, Public Policy and the Elimination of Childhood Poverty

2

11:00 a.m. – 12:30 p.m.

Room B315, Level 3

Georgia World Congress Center

Chairs:

Kenneth Thompson, M.D.

Steven Adelsheim, M.D.

Speakers:

Benard Dreyer, M.D.

Steven Adelsheim, M.D.

Kenneth Thompson, M.D.

The Collaborative Assessment and Management of Suicidality at Walter Reed: A Clinical Intervention for Suicidal Patients at Walter Reed Medical Center

11:00 a.m. – 12:30 p.m.

Room B316, Level 3

Georgia World Congress Center

Chair:

Benjamin R. Hershey, M.D.

Speakers:

Jennifer A. Crumlish, Ph.D.

Lobna Ibrahim, M.D.

Bryan M. Pelka, M.D.

Family and Culture: Clinical Tools for Everyday Practice

APA Alliance

2

11:00 a.m. – 12:30 p.m.

Room A408, Level 4

Georgia World Congress Center

Chair:

Alison M. Heru, M.D.

Acknowledging and Accommodating Age and Ability Senior Psychiatrists

4

11:00 a.m. – 12:30 p.m.

Room B403, Level 4

Georgia World Congress Center

Chairs:

Paul H. Wick, M.D.

Nada L. Stotland, M.D., M.P.H.

Speakers:

Paul H. Wick, M.D.

James W. Lomax, M.D.

Sheila Hafter Gray, M.D.



This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Using Star Wars to Teach Psychopathology

3

11:00 a.m. – 12:30 p.m.
Room B404, Level 4
Georgia World Congress Center

Chair:

Susan Joy Hatters-Friedman, M.D.

Speaker:

Ryan Hall, M.D.

International Medical Graduates: Reflections on Cross-Cultural Training and Learning

11:00 a.m. – 12:30 p.m.
Room B408, Level 4
Georgia World Congress Center

Chairs:

Tanuja Gandhi, M.D.

Rama Rao Gogineni, M.D.

Speakers:

Pedro Ruiz, M.D.

Dinesh Bhugra

Ranna Parekh, M.D., M.P.H.

Jasmin G. Lagman, M.D.

Meredith A. Okwesili, M.D.

Daniel Kim, M.D.

LORETA Neurofeedback and Quantitative EEG: An Approach Consistent With NIMH Research Domain Criteria

APA Caucus on Complementary and Alternative Medicine

2

11:00 a.m. – 12:30 p.m.
Room B409, Level 4
Georgia World Congress Center

Chair:

Deborah R. Simkin, M.D.

Speaker:

Deborah R. Simkin, M.D.

! Program changes are printed each day in the *APA Daily*, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.

1:00 p.m. Sessions

Courses

! Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Evaluation and Treatment of Sexual Dysfunctions



1:00 p.m. – 5:00 p.m.
International 4, International Level
Marriott Marquis

Director:

Waguih William IsHak, M.D.

Risk Assessment for Violence



3

1:00 p.m. – 5:00 p.m.
International 5, International Level
Marriott Marquis

Director:

Phillip J. Resnick, M.D.

Acute Brain Failure: Neurobiology, Prevention and Treatment of Delirium

Academy of Psychosomatic Medicine



5

1:00 p.m. – 5:00 p.m.
International 6, International Level
Marriott Marquis

Director:

Jose R. Maldonado, M.D.

Neuroanatomy of Emotions



1:00 p.m. – 5:00 p.m.
M103-105, Marquis Level
Marriott Marquis

Chair:

Ricardo M. Vela, M.D.

Director:

Ricardo M. Vela, M.D.

Learning Lab

Participant Debates: Ethical Issues in Psychiatry



1:00 p.m. – 4:00 p.m.
Rooms B211-212, Level 2
Georgia World Congress Center

Chair:

Rebecca Weintraub Brendel, M.D., J.D.

Seminars

Women in Psychiatry: Career Advancement, Academics, Advocacy and Balance: The Real World



1:00 p.m. – 5:00 p.m.
International 7, International Level
Marriott Marquis

Directors:

Isabel Schuermeyer, M.D., M.S.

Margo Funk, M.D., M.A.

Faculty:

Kathleen Franco

Karen Jacobs, D.O.

Tatiana Falcone, M.D.



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

1:30 p.m. Sessions

Advances in Medicine

Top 10 Medical Stories 2015: A Comprehensive and Practical Review of What Psychiatrists Need to Know

5

1:30 p.m. – 3:00 p.m.

Rooms A315-316, Level 3

Georgia World Congress Center

Chair:

Monique Yohanan, M.D., M.P.H.

Conversations

Diversity 3.0: From Fairness to Excellence

1:30 p.m. – 3:00 p.m.

Room B409, Level 4

Georgia World Congress Center

Speaker:

Marc Nivet

Focus Live

Focus Live! OCD and Related Disorders (OCDD): Diagnosis to Treatment

0

1:30 p.m. – 3:00 p.m.

Rooms B207-208, Level 2

Georgia World Congress Center

Moderators:

Mark H. Rapaport, M.D.

Tristan Gorrindo, M.D.

Speakers:

Michele T. Pato, M.D.

Katharine A. Phillips, M.D.

Forum

The Financing of Psychiatric Care: Past, Present and Future

1:30 p.m. – 3:00 p.m.

Room B206, Level 2

Georgia World Congress Center

Chair:

Steven S. Sharfstein, M.D., M.P.A.

Speakers:

Steven S. Sharfstein, M.D., M.P.A.

Frank W. Brown, M.D.

Anita Everett, M.D.

Interactive Sessions

Women's Mental Health: What Is It? How to Do It? Why Do It?

1:30 p.m. – 3:00 p.m.

Room A301, Level 3

Georgia World Congress Center

Chair:

Gail Erlick Robinson, M.D.

Lectures

Thinking Differently About Mental Illness and Gun Violence: Balancing Risk and Rights for Effective Policy
APA Frontiers of Science Lecture Series

D

1:30 p.m. – 3:00 p.m.

Rooms A411-412, Level 4

Georgia World Congress Center

Lecturer:

Jeff O. Swanson, M.D.

The Sweet Enchantment of "Post-Racial" Racism in America

Solomon Carter Fuller Award

D

1:30 p.m. – 3:00 p.m.

Room A302, Level 3

Georgia World Congress Center

Lecturer:

Eduardo Bonilla-Silva, Ph.D.

Beyond MacArthur: The Past, Present and Probable Future of Violence Risk Assessment

APA Frontiers of Science Lecture Series

D 3

1:30 p.m. – 3:00 p.m.

Sidney Marcus Auditorium, Level 4

Georgia World Congress Center

Lecture Chair:

Lara J. Cox, M.D., M.S.

Lecturer:

John Monahan, Ph.D.

Scientific and Clinical Reports

Schizophrenia: Caregiver Techniques and Post-Discharge Strategies

D 2

1:30 p.m. – 3:00 p.m.

Room B405, Level 4

Georgia World Congress Center

1. Caregiving for Individuals With Schizophrenia and Its Impact on Caregiver Employment and Work Productivity
Debra Lerner, Ph.D., M.Sc.

2

2. Caregiver-Directed Psychosocial Interventions in Schizophrenia: Systematic Review and Meta-Analysis
Branislav Mancevski, M.D.

3. Post-Discharge Physician Visits and Readmission Rates in a Population-Based Sample of Patients With Schizophrenia

Paul Kurdyak, M.D., Ph.D.

Biological Psychiatry

D 3 5

1:30 p.m. – 3:00 p.m.

Room B406, Level 4

Georgia World Congress Center

1. Inflammatory Markers in PTSD: A Meta-Analysis and Meta-Regression Study
Fang Yang, M.D., Ph.D.

2. Analysis of Baseline Mental Health Data From the Sonya Slifka Longitudinal Multiple Sclerosis Study
Laura Safar, M.D.

5

3. Brain-Derived Neurotrophic Factor (BDNF) as a Predictive Biomarker of the Occurrence of PTSD: Pilot Prospective Study
Hafid Belhadj-Tahar, M.D., Ph.D.

3

4. CACNA1C Gene and Schizophrenia: A Case-Control and Pharmacogenetic Study
Tae-Youn Jun, M.D., Ph.D.



Workshops

Addressing the Social Determinants of Mental Health Through Integrated Behavioral Health

5

1:30 p.m. – 3:00 p.m.

Room B215, Level 2

Georgia World Congress Center

Chair:

Monica Taylor-Desir, M.D., M.P.H.

Speakers:

Ruth Shim, M.D., M.P.H.

Lori Raney, M.D.

Dyanna Leolani Ah Quin, M.S.W.

LeRoy C. Eswonia, B.S.

A Collaboratory for Psychiatric App Development

American Association for Technology in Psychiatry

1:30 p.m. – 3:00 p.m.

Room B218, Level 2

Georgia World Congress Center

Chairs:

Seth Powsner, M.D.

Victor J. A. Buwalda, M.D., Ph.D.

Speakers:

Robert Kennedy, M.D.

John Torous, M.D.

Victor J. A. Buwalda, M.D., Ph.D.

Seth Powsner, M.D.

John Luo, M.D.

My Patient Just Got Pharmacogenetic Testing; What Do I Do Now?

1:30 p.m. – 3:00 p.m.

Room A303, Level 3

Georgia World Congress Center

Chairs:

Simon Kung, M.D.

Scott Schmidt, D.O.

From Dementia to Neurocognitive Disorder: Understanding the Changes Made in the DSM-5

4

1:30 p.m. – 3:00 p.m.

Room A304, Level 3

Georgia World Congress Center

Chair:

Mehrul Hasnain, M.D.

Sexuality During Pregnancy and the Postpartum Period

5

1:30 p.m. – 3:00 p.m.

Room B306, Level 3

Georgia World Congress Center

Chairs:

Damir Huremovic, M.D., M.P.P.

Guitelle St. Victor, M.D.

Speakers:

Madhavi Nagalla, M.D.

Nyapati R. Rao, M.D.

Ateaya Lima, M.D.

“Oh, the Places You’ll Go”: Opportunities to Teach Child Psychiatry in Low- and Middle-Income Countries Through IACAPAP Volunteer Programs

2

1:30 p.m. – 3:00 p.m.

Room B310, Level 3

Georgia World Congress Center

Chair:

Julie A. Chilton, M.D.

Joining Forces: The Neurology-Psychiatry Connection: Bridging Education and Patient Care Across Disciplines

5

1:30 p.m. – 3:00 p.m.

Room B315, Level 3

Georgia World Congress Center

Chairs:

Ann Schwartz, M.D.

Wendy Baer, M.D.

Speakers:

Jaffar Khan, M.D.

Adriana Hermida, M.D.

Martha C. Ward, M.D.

Joash T. Lazarus, M.D.

Evidence-Based Management of Patients at Risk for Suicide: VA/DoD Clinical Practice Guidelines for the Prevention of Suicide

3

1:30 p.m. – 3:00 p.m.

Room B316, Level 3

Georgia World Congress Center

Chairs:

John Bradley, M.D.

Brett Schneider, M.D.

Active Shooter Hospital Lockdown: To Treat or Not to Treat

3

1:30 p.m. – 3:00 p.m.

Room A408, Level 4

Georgia World Congress Center

Chair:

Edmund G. Howe III, M.D.

Speakers:

Kyle J. Gray, M.D., M.A.

James C. West Jr., M.D.

Gary H. Wynn, M.D.

Comorbid Post-Traumatic Stress Disorder, Pain and Opiate Addiction

1

1:30 p.m. – 3:00 p.m.

Room B404, Level 4

Georgia World Congress Center

Chair:

Ayman Fareed

Speakers:

Pamela Eilender, Psy.D.

Bethany Ketchen, Ph.D.

Psychiatry and Health Care Reform: Where Are We? What’s Ahead?

1:30 p.m. – 3:00 p.m.

Room A408, Level 4

Georgia World Congress Center

Chairs:

Joyce C. West, Ph.D., M.P.P.

Kristin Kroeger Ptakowski

Speakers:

Philip Wang, M.D., Dr.P.H.

Anita Everett, M.D.

Irvin L. Muszynski, J.D.

! SESSION TRACKS

- 1** Addiction Psychiatry
 - 2** Child and Adolescent Psychiatry
 - 3** Forensic Psychiatry
 - 4** Geriatric Psychiatry
 - 5** Psychosomatic Psychiatry
 - 6** NIDA
 - 7** Residents, Fellows and Medical Students
- D** APA Annual Meeting On Demand
- D** Bring Your Own Device

2:00 p.m. Sessions

Poster Session

New Research Poster 1

2:00 p.m. – 4:00 p.m.
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

Lectures

Psychiatric Faculty Development: Challenges for the 21st Century

Vestermark Psychiatry Educator Award



2:00 p.m. – 5:00 p.m.
Rooms A406-407, Level 4
Georgia World Congress Center

Lecture Chairs:

Christopher R. Thomas, M.D.
Richard Summers, M.D.

Lecturers:

Robert E. Hales, M.D.
John H. Coverdale, M.D.

Media Workshops

The Resilience of the Family in Film: “Aparajito” (Part 2 of “The Apu Trilogy”)

*APA Caucus of Asian-American
Psychiatrists*

2:00 p.m. – 5:00 p.m.
Room A314, Level 3
Georgia World Congress Center

Chairs:

Francis Lu, M.D.
Edmond H. T. Pi, M.D.

Speakers:

Ramaswamy Viswanathan, M.D.
Russell F. Lim, M.D., M.Ed.
Jagannathan Srinivasaraghavan, M.D.

“Timbuktu”: An APA Film Symposium

2:00 p.m. – 5:00 p.m.
Room B313, Level 3
Georgia World Congress Center

Chairs:

Lloyd I. Sederer, M.D.
Alan Stone, M.D.

Speakers:

Mayada Akil, M.D.
Lloyd I. Sederer, M.D.
Alan Stone, M.D.

Presidential Symposium

Let’s Talk About Psychiatry “Now”: A Different Sort of Integration

*American Association of Directors of
Psychiatric Residency Training*



2:00 p.m. – 5:00 p.m.
Rooms B213-214, Level 2
Georgia World Congress Center

Chair:

Adrienne L. Bentman, M.D.

1. The General Psychiatrist as Team and Systems Thinker
Adrienne L. Bentman, M.D.
2. Let’s Talk About Psychiatry “Now”: A Different Sort of Integration
Adam Brenner
3. Transitional Age Youth/Emerging Adults: Biopsychosocial Concepts for Integrated Training
Sanda DeJong, M.D.
4. Four Facts About Older Adults in General Psychiatric Practice
Art Walaszek, M.D.
5. Neuropsychiatry and Cognitive Neuroscience in General Psychiatric Practice
Sheldon Benjamin, M.D.

Symposia

New Perspectives on Treatment of Borderline Personality Disorder (BPD)



2:00 p.m. – 5:00 p.m.
Rooms B216-217, Level 2
Georgia World Congress Center

Chairs:

John Gunderson, M.D.
Victor Hong, M.D.

Discussant:

Joan Anzia, M.D.

1. Pros and Cons of Inter-Session Contact With Borderline Personality Disorder (BPD) Patients
Karen L. Jacob, Ph.D.
2. Rejection Sensitivity as a Paradigm for Understanding Borderline Personality Disorder (BPD) and Its Comorbidities
Lois W. Choi-Kain, M.D., M.Ed.

3. A Generalist Model Is “Good Enough” for Treating Most Borderline Personality Disorder (BPD) Patients
John Gunderson, M.D.
4. Guidelines for Emergency Room Management of Borderline Personality Disorder (BPD) Patients
Victor Hong, M.D.
5. A 40-Year Retrospective on Borderline Personality Disorder (BPD) and Countertransference
Glen O. Gabbard, M.D.

The Evolving Role of Psychiatrists in Medicine: From East to West



2:00 p.m. – 5:00 p.m.
Rooms A311-312, Level 3
Georgia World Congress Center

Chairs:

Saul Levin, M.D., M.P.A.
Michelle B. Riba, M.D.

Discussant:

Edmond Hsin. T. Pi, M.D.

1. The Evolving Role of Psychiatrists in Medicine: Japan
Tsyuyoshi Akiyama, M.D., D.Phil.
2. The Evolving Role of Psychiatrists in Medicine: The United States
Saul Levin, M.D., M.P.A.
3. The Role of Psychiatrists in Mental Health Disorder Awareness and Prevention: Suicide in Japan
Shigenobu Kanba, M.D., Ph.D.
4. Global Mental Health: The Road Forward
Maria A. Oquendo, M.D.



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

Are Involuntary Outpatient Commitment Laws a Good Thing? Ethics Considerations and Analysis

APA Ethics Committee



2:00 p.m. – 5:00 p.m.

Room B308, Level 3

Georgia World Congress Center

Chair:

Robert Weinstock, M.D.

Discussant:

Steven Hoge, M.D., M.B.A.

1. For Whom and Under What Conditions Can Involuntary Outpatient Commitment Be Effective?
Marvin S. Swartz, M.D.
2. An Ethics-Based View of Involuntary Outpatient Commitment
Ezra Griffith, M.D.
3. Dialectical Principlism: An Approach to Analyzing and Resolving Ethical Dilemmas
Robert Weinstock, M.D.
4. Balancing Conflicting Ethical Considerations in Involuntary Outpatient Commitment
William C. Darby, M.D.

The Face of Resilience: Working With Survivors of Intimate Partner Violence (IPV)—A Holistic Model to Care



2:00 p.m. – 5:00 p.m.

Room B309, Level 3

Georgia World Congress Center

! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting On Demand
- Bring Your Own Device

Chairs:

Mayumi Okuda, M.D.

Obianuju "Uju" Obi Berry, M.D., M.P.H.

1. Cultural Barriers and Novel Strategies in Working Within the IPV Community
Obianuju "Uju" Obi Berry, M.D., M.P.H.
2. A Model of Collaborative Care Between Mental Health and IPV Services
Elizabeth Fitelson, M.D.
3. New York City Family Justice Centers of the Mayor's Office to Combat Domestic Violence
Margarita Guzman, J.D., M.B.
4. Evidence-Based Psychotherapies for Intimate Partner Violence (IPV) Victims
Rosa Regincos, L.C.S.W.
5. Implementing Psychiatric Treatments in a Nonspecialty Setting
Mayumi Okuda, M.D.

Evil, Psychopathy and Terror: Lessons Psychiatry Learned From Nazi Germany



2:00 p.m. – 5:00 p.m.

Room B309, Level 3

Georgia World Congress Center

Chair:

Joel E. Dimsdale, M.D.

Discussant:

Paul Summergrad, M.D.

1. Anatomy of Malice: Using Research Archives to Study Psychopathology in Nazi War Criminals
Joel E. Dimsdale, M.D.
2. How Could It Happen? From Social Darwinism to the Nazi Euthanasia Program
Hans-Jurgen Moller, M.D.
3. Using Fiction to Tell the Story of Aktion T4
Stephen M. Stahl, M.D., Ph.D.

Biologics (Vaccines, Monoclonal Antibodies and Enzymes) to Treat Substance Use Disorders

National Institute on Drug Abuse



2:00 p.m. – 5:00 p.m.

Room B312, Level 3

Georgia World Congress Center

Chairs:

Ivan D. Montoya, M.D., M.P.H.

Phil Skolnick, Ph.D.

Discussant:

Phil Skolnick, Ph.D.

1. Enzyme Therapies for Cocaine Addiction and Overdose
Chang-Guo Zhan, Ph.D., M.Sc.
2. Monoclonal Antibodies to Treat Substance Use Disorders and Overdose
Samuel M. Owens, Ph.D.
3. Pharmacokinetic Strategies to Mitigate Nicotine's Psychoactive Effects
Matthew W. Kalnik, Ph.D.
4. Vaccines for Cocaine and Methamphetamine Addictions
Thomas Kosten, M.D.

Effective Responses to Justice-Involved Persons With Mental Illnesses

American Psychiatric Association

Publishing Editorial Board



2:00 p.m. – 5:00 p.m.

Room B314, Level 3

Georgia World Congress Center

Chairs:

Robert L. Trestman, M.D., Ph.D.

Fred C. Osher, M.D.

Discussant:

Debra Pinals, M.D.

1. Effective Responses to Justice-Involved Persons With Mental Illnesses
Robert L. Trestman, M.D., Ph.D.
2. What Can We Do to Prevent Incarceration?
Fred C. Osher, M.D.
3. Treatment Options for Incarceration
Merrill Rotter, M.D.

4. Correctional Mental Health Treatment: What Is Adequate?
Elizabeth Ford, M.D.

Global Mental Health: Current Clinical and Cultural Perspectives and Innovations



2:00 p.m. – 5:00 p.m.
Rooms A402-403, Level 4
Georgia World Congress Center

Chair:

Renato D. Alarcon, M.D., M.P.H.

Discussant:

Renato D. Alarcon, M.D., M.P.H.

1. Realities of Psychiatric Practice in Pakistan: A Brief Overview
Filza C. Hussain, M.D.
2. When Doctors Stigmatize and Discriminate: The Culture of Medical Practice About Mental Health in the Middle East
Ahmad Adi, M.B.B.S., M.P.H.
3. Mental Health Outcomes of the Syrian Conflict: An Emphasis on PTSD
Malik Nassan, M.B.B.S.
4. Telepsychiatry: It Is Effective, Versatile and Knocks Down Barriers Related to Geography, Culture and Language Across the Globe
Donald M. Hilty, M.D.

An Update on Diagnostic and Assessment Considerations for the Treatment of Comorbid Opioid Addiction and Chronic Pain

National Institute on Drug Abuse



2:00 p.m. – 5:00 p.m.
Rooms A404-405, Level 4
Georgia World Congress Center

Chair:

Will M. Aklin, Ph.D.

Discussant:

Wilson M. Compton, M.D.

1. Neuroimaging of Pain and Distress: From Biomarkers to Brain Representation
Tor Wager, Ph.D.

2. Prescription Opioid Use and the Transition of Acute to Chronic Pain: Preventing Problematic Opioid Use and Persistent Pain After Surgery
Jennifer Hah, M.D., M.S.
3. Treatment of Co-Occurring Chronic Pain and Opioid Use Disorder
Declan Barry, Ph.D.
4. Update on the Treatment of Acute and Chronic Pain in the Patient With a History of Substance Abuse
Sean Mackey, M.D., Ph.D.
5. Long-Term Outcomes From the Prescription Opioid Addiction Treatment Study
Roger D. Weiss, M.D.

Treatment of Cognitive Impairment and Functional Disability Across Psychiatric Conditions: What Has Been Achieved



2:00 p.m. – 5:00 p.m.
Room A410, Level 4
Georgia World Congress Center

Chairs:

Herbert Y. Meltzer, M.D.
Philip D. Harvey, Ph.D.

1. Treatment of Cognition and Disability: Rationale and Strategies
Philip D. Harvey, Ph.D.
2. Atypical Antipsychotic Drugs Partially Correct Cognitive Dysfunction in Some Schizophrenia Patients: Understanding the Effect of Antipsychotic Drugs on Neuroplasticity Critical for Learning and Memory
Herbert Y. Meltzer, M.D.
3. Treatment of Cognitive Deficits in Patients With Schizophrenia and Major Depression
Richard Keefe, Ph.D.
4. fMRI and MEG Studies of Cortical Plasticity Induced by Cognitive Training in Schizophrenia
Sophia Vinogradov, M.D.

The Science of Late-Life Depression Prevention: Updates From the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) Study



2:00 p.m. – 5:00 p.m.
Room B401, Level 4
Georgia World Congress Center

Chairs:

Olivia I. Okereke, M.D., S.M.
Charles F. Reynolds III, M.D.

Discussant:

Barry Rovner, M.D.

1. The VITAL-DEP Trial of Late-Life Depression Prevention: Design, Objectives, Progress and Plans
Olivia I. Okereke, M.D., S.M.
2. Association Between Late-Life Depression and Dietary Vitamin D, Omega-3 Fatty Acids and Other Nutrients
David Mischoulon, M.D., Ph.D.
3. Comparison of Risk and Protective Factors for Depression in Racially and Ethnically Diverse Older Adults
Charles F. Reynolds III, M.D.
4. Recognizing Problem Drinking in Older Adults: Implications for Late-Life Depression
Grace Chang, M.D., M.P.H.

Countering Violent Extremism



2:00 p.m. – 5:00 p.m.
Room B402, Level 4
Georgia World Congress Center

Chairs:

Stevan M. Weine, M.D.
Aliya Saeed, M.D.

Discussant:

Neil K. Aggarwal, M.D., M.B.A.

1. A Comparative Analysis of Terrorist Propaganda Magazines: Understanding the Motivational Dimensions
Anthony Lemieux, Ph.D., M.A.



All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

2. **Violent Extremism: Challenges Faced by Muslim Communities**
Aliya Saeed, M.D.
3. **Suffer the Little Children: Child Recruitment Into Violent Extremist Groups**
Mia M. Bloom, Ph.D.
4. **Moving Beyond Motive-Based Categories of Targeted Violence Interventions**
Stevan M. Weine, M.D.
5. **Evaluating CVE Programs: Lessons Learned and Future Directions for Research**
John Horgan, Ph.D.

Changing Behavioral Health Systems to Treat Tobacco Through Training and Policy Initiatives

American Academy of Addiction Psychiatry



2:00 p.m. – 5:00 p.m.
Room B407, Level 4
Georgia World Congress Center

Chair:
Jill M. Williams, M.D.

Discussant:
Andrew J. Saxon, M.D.

1. **Training Psychiatrists and Behavioral Health Providers in Treating Tobacco Through Continuing Education**
Jill M. Williams, M.D.
2. **Dissemination of an Evidence-Based Tobacco Treatment Curriculum to Psychiatric Residency Programs**
Smita Das, M.D., Ph.D.

3. **Lessons Learned From Creating a Tobacco-Free Health System**
Tim Fong, M.D.
4. **Implementation of Integrated Tobacco Treatment Into Mental Health Care for Veterans With PTSD**
Andrew J. Saxon, M.D.

3:30 p.m. Sessions

Case Conference

! These sessions are open to APA members only. A blue registration badge or an APA membership card are required for admittance.

Catatonia and Serotonin Syndrome Following Abrupt Cessation of Clozapine: Considerations for a Consultation-Liaison Psychiatrist

3:30 p.m. – 5:00 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center

Chair:
Ewald Horwath, M.D.

Speaker:
Mohsina Ahmed, M.D.

Focus Live

Focus Live! Understanding the Evidence for Off-Label Use of Atypical Antipsychotics

📱
3:30 p.m. – 5:00 p.m.

Moderators:
Mark H Rapaport, M.D.
Tristan Gorrindo, M.D.

Speakers:
David L. Fogelson M.D.
Joel Yager, M.D.

▶ This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Forum

The Refugee Experience: The Psychological and Neurobiological Impact

3:30 p.m. – 5:00 p.m.
Room B206, Level 2
Georgia World Congress Center

Chair:
Julio Licinio, M.D.

Constrained Access to Psychiatrists in Washington, DC, Among the Largest Health Insurance Exchange Carriers' Networks

3:30 p.m. – 5:00 p.m.
Room A305, Level 3
Georgia World Congress Center

Chair:
Colleen Coyle

Speaker:
Joyce C. West, Ph.D., M.P.P.

Discussants:
Steven S. Sharfstein, M.D., M.P.A.
Irvin L. Muszynski, J.D.

Interactive Session

The Difficult Patient

3:30 p.m. – 5:00 p.m.
Room A301, Level 3
Georgia World Congress Center

Chair:
Philip R. Muskin, M.D., M.A.

Lectures

Unfreezing the Gun Debate: How New Research at the Intersection of Guns, Violence and Mental Illness Creates Opportunities for Policy Change

APA Frontiers of Science Lecture Series



3:30 p.m. – 5:00 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Lecturer:
Josh Horwitz, M.D.

! SESSION TRACKS

- 1** Addiction Psychiatry
- 2** Child and Adolescent Psychiatry
- 3** Forensic Psychiatry
- 4** Geriatric Psychiatry
- 5** Psychosomatic Psychiatry
- 6** NIDA
- 7** Residents, Fellows and Medical Students
- ▶** APA Annual Meeting On Demand
- 📱** Bring Your Own Device

Role Conflicts in the Management of Sexual Offenders

APA International Psychiatrist Lecture Series



3:30 p.m. – 5:00 p.m.

Sidney Marcus Auditorium, Level 4
Georgia World Congress Center

Lecturer:

Roy O'Shaughnessy, M.D.

Scientific and Clinical Reports

Addiction: Tobacco



3:30 p.m. – 5:00 p.m.

Room B405, Level 4
Georgia World Congress Center

1. Tobacco Treatment in Hospitalized Patients With Acute Psychiatric and Addictive Disorders
Smita Das, M.D., Ph.D.

1

2. Intranasal Insulin for Treatment of Tobacco Abstinence Syndrome
Ajna Hamidovic, Pharm.D.

1

3. Tailored Behavioral Interventions for Smoking Cessation in the HIV-Positive Population: A Meta-Analysis of Randomized Controlled Trials
Asheena Keith, M.D.

5

Management of Schizophrenia and Psychosis



3:30 p.m. – 5:00 p.m.

Room B406, Level 4
Georgia World Congress Center

1. Treatment of Negative Symptoms of Schizophrenia With Dextromethorphan/Quinidine Augmentation of Antipsychotics: An Open Trial in 42 Patients
Paul J. Markovitz, M.D., Ph.D.

2. Case Challenge to Manage Psychosis in Patients With Trisomy X
Sheema Imran, M.D.

2

3. Personality Deficits, Impairments in Cognition and Emotion Recognition: Interconnections and Relationship to Violence in Schizophrenia
Menahem I. Krakowski, M.D.

3

Workshops

The Evolution of Integrated Care for HIV and Mental Illness



3:30 p.m. – 5:00 p.m.

Room B215, Level 2
Georgia World Congress Center

Chair:

Francine Cournos, M.D.

Speakers:

Marshall Forstein, M.D.
William W. Thompson, Ph.D.

Brief Cognitive Behavioral Interventions to Augment Psychopharmacology in Mood and Psychotic Disorders

5

3:30 p.m. – 5:00 p.m.

Room B218, Level 2
Georgia World Congress Center

Chairs:

Mohammed A. Khan, M.D.
Mark Famador, M.D.

Speakers:

Dana Foglesong, B.S.
Narsimha Pinninti, M.D., D.P.M.
Donna M. Sudak, M.D.

Update on Body Dysmorphic Disorder: Clinical Features, Neurobiology and Treatment

3:30 p.m. – 5:00 p.m.

Room A303, Level 3
Georgia World Congress Center

Chairs:

Katharine A. Phillips, M.D.
Jamie Feusner, M.D.

Sexual Offenders: A Psychiatric Perspective

3

3:30 p.m. – 5:00 p.m.

Room A304, Level 3
Georgia World Congress Center

Chair:

Renee Sorrentino, M.D.

Speakers:

Abhishek Jain, M.D.
Susan Joy Hatters-Friedman, M.D.

Not Just National News: Can Multiple Isolated Incidents of Racially or Ethnically Motivated Violence Traumatize the Larger Minority Group?

APA Council on Minority Mental Health and Health Disparities

3:30 p.m. – 5:00 p.m.

Room A307, Level 3
Georgia World Congress Center

Chair:

Mawuena Agbonyitor, M.D., M.Sc.

Speakers:

Meredith Harewood, M.D.
Racquel E. Reid, M.D.
Rubiahna Vaughn, M.D., M.P.H.
Aleema Zakers, M.D., M.P.H.
Danielle Hairston, M.D.
Mawuena Agbonyitor, M.D., M.Sc.

Planes, Trains, Automobiles and Boats: Psychiatrists as Emergency First Responders

5

3:30 p.m. – 5:00 p.m.

Room B306, Level 3
Georgia World Congress Center

Chairs:

Jean E. Aycock, M.D.
Lee S. Hyde, M.D.

From the Geriatric Hospital Bed to the Witness Stand: Delirium in the Courtroom

3

3:30 p.m. – 5:00 p.m.

Room B310, Level 3
Georgia World Congress Center

Chair:

Alberto M. Goldwaser, M.D.

Speaker:

Alberto M. Goldwaser, M.D.



All scientific sessions listed in the Program are designated for AMA PRA Category 1 Credits™, except for Poster Sessions.

How Does Countertransference Fit in Modern Health Care: Impact of Provider Feelings on Diagnosis and Medical Decision Making

5

3:30 p.m. – 5:00 p.m.

Room B311, Level 3

Georgia World Congress Center

Chair:

Nidal Moukaddam, M.D., Ph.D.

Speakers:

Asim Shah, M.D.

Veronica Tucci, M.D., J.D.

Nidal Moukaddam, M.D., Ph.D.

Access to Physician-Assisted Suicide for Intractable Suffering and Chronic Mental Illness: An Approaching Ethics Crisis

3:30 p.m. – 5:00 p.m.

Room A313, Level 3

Georgia World Congress Center

Chair:

Mark Komrad, M.D.

Speakers:

Mark Komrad, M.D.

Robert Roca, M.D., M.P.H.

Samuel J. Leistedt, M.D., Ph.D.

Clinical Issues in Schizophrenia With Comorbid Disorders: Update

3:30 p.m. – 5:00 p.m.

Room B315, Level 3

Georgia World Congress Center

Chair:

Jean-Pierre Lindenmayer, M.D.

PTSD in Psychiatrists: A Hidden Epidemic

3:30 p.m. – 5:00 p.m.

Room B316, Level 3

Georgia World Congress Center

Chair:

Arthur Lazarus, M.D., M.B.A.

Speakers:

Michael F. Myers, M.D.

H. Steven Moffic, M.D.

Managing Violence Risk and Interview Safety: A Primer for Residents

7 3

3:30 p.m. – 5:00 p.m.

Room A408, Level 4

Georgia World Congress Center

Chair:

Tobias Wasser, M.D.

Cultural Family Therapy: Integrating Family Therapy With Cultural Psychiatry

Association of Family Psychiatrists

2

3:30 p.m. – 5:00 p.m.

Room B403, Level 4

Georgia World Congress Center

Chairs:

Vincenzo Di Nicola, M.D., Ph.D.

Ellen Berman, M.D.

Speakers:

Vincenzo Di Nicola, M.D., Ph.D.

Ellen Berman, M.D.

The General Psychiatrist's Approach to Personality Disorders: Practical Applications of Transference-Focused Psychotherapy (TFP) Principles

3:30 p.m. – 5:00 p.m.

Room B404, Level 4

Georgia World Congress Center

Chair:

Richard Hersh, M.D.

Speakers:

Frank E. Yeomans, M.D.

Eve Caligor, M.D.

The Extension for Community Health Outcomes (ECHO) Model: Creating a Community of Mental Health and Addictions Practice

3:30 p.m. – 5:00 p.m.

Room B408, Level 4

Georgia World Congress Center

Chairs:

Allison Crawford, M.D., M.A.

Sanjeev Sockalingam, M.D.

Speakers:

Allison Crawford, M.D., M.A.

Sanjeev Sockalingam, M.D.

Paul Kurdyak, M.D., Ph.D.

Eva Serhal, M.B.A.

One Doctor, One Hat: Ending Psychiatry's Mixed Loyalties

APA Ethics Committee and Penn-Scattergood Ethics Program

3:30 p.m. – 5:00 p.m.

Room B409, Level 4

Georgia World Congress Center

Chair:

Philip Candilis, M.D.

Speakers:

Richard Martinez

Laura Roberts, M.D., M.A.

5:30 p.m. Session

Convocation

Convocation of

Distinguished Fellows

5:30 p.m. – 6:30 p.m.

Hall B2, Level 1

Georgia World Congress Center

William C. Menninger Memorial Lecture

Immediately follows the Convocation of Distinguished Fellows

Reciprocal Revolution: The Potential and Challenges of Collaboration Between Psychiatry and Public Health

Speaker:

Tom Frieden, M.D., M.P.H.

! SESSION TRACKS

- 1 Addiction Psychiatry
- 2 Child and Adolescent Psychiatry
- 3 Forensic Psychiatry
- 4 Geriatric Psychiatry
- 5 Psychosomatic Psychiatry
- 6 NIDA
- 7 Residents, Fellows and Medical Students
- ▶ APA Annual Meeting On Demand
- 📱 Bring Your Own Device

60th Convocation of Distinguished Fellows

5:30 p.m. – 6:30 p.m.

Hall B2, Level 1,
Georgia World Congress Center

Call to Order

Renée L. Binder, M.D.
APA President

Introduction of Distinguished Life Fellows,
Induction of Distinguished Fellows and
the Pledge of Distinguished Fellowship

Maria A. Oquendo, M.D.
APA President-Elect

Introduction of Fellows and Life
Fellows; Introduction of the 50-Year
Distinguished Life Fellows, Life Fellows
and Life Members; Introduction of the
International Distinguished Fellows and
Introduction of International Fellows

Renée L. Binder, M.D.

Awards for 2016

*All awards will be presented by
Renée L. Binder, M.D.*

Special Presidential Commendations

Richard J. Bonnie, J.D.

Larry R. Faulkner, M.D.

Robert L. Hendren, D.O.

Francis G. Lu, M.D.

Jeffrey L. Metzner, M.D.

Distinguished Service Awards

Donna M. Norris, M.D.

Steven S. Sharfstein, M.D.

Daniel K. Winstead, M.D.

Organizational Distinguished
Service Award

American Academy of Psychiatry and the Law

Introduction of the Membership
Committee and Its Chairperson

Renée L. Binder, M.D.



All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, APA Members and Registered Guests are invited to attend.

The William C. Menninger Memorial Convocation Lecture

Established in 1972, this lecture honors the late William C. Menninger, M.D., President of APA 1948–49, who brought to the association a formalized Convocation of Fellows, first held in 1956.

Tom Frieden, M.D., M.P.H.

Director, Centers for Disease Control and Prevention



Tom Frieden, M.D., M.P.H., is Director of the Centers for Disease Control and Prevention (CDC). Since 2009, Dr. Frieden has intensified CDC's constant work to protect the health, safety and security of the American people, including leading the agency's response to the recent Ebola epidemic and other health emergencies. Under his direction, new CDC programs have focused on combating antibiotic resistance, preventing foodborne and health care-associated infections, helping people quit smoking, addressing the prescription drug overdose epidemic, and advancing global health security worldwide. He previously led New York City's program that cut multidrug-resistant tuberculosis by 90% and helped India prevent more than 3 million tuberculosis deaths. As New York City's health commissioner from 2002 to 2009, he helped reduce teen smoking by half and adult smoking by one-third. Dr. Frieden received his medical and master of public health degrees from Columbia University. He completed infectious disease training at Yale University.

Focus LIVE!



Test Your Knowledge!

May 16, 2016

**Georgia World Congress Center
Learning Lab, Rooms B207-208, Level 2**

Sessions will be moderated by Mark H. Rapaport, M.D., Editor of FOCUS and Tristan Gorrindo, M.D., Director of Education, American Psychiatric Association

Focus Live! 1 Obsessive-Compulsive and Related Disorders

Monday, May 16, 1:30pm - 3:00pm

Michele T. Pato M.D., Director, Institute for Genomic Health, Professor and Vice Chair for Research- Department of Psychiatry/College of Medicine, SUNY Downstate- Brooklyn, N.Y.

Katharine A. Phillips, M.D., Senior Research Scientist and Director of the Body Dysmorphic Disorder Program, Rhode Island Hospital, and Professor of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, R.I.

Focus Live! 2 Understanding the Evidence for Off-label Use of Atypical Antipsychotics

Monday, May 16, 3:30pm - 5:00pm

David L. Fogelson, M.D., Clinical Professor of Psychiatry, David Geffen School of Medicine at UCLA, and The Semel Institute for Neuroscience and Human Behavior at UCLA

Joel Yager, M.D., Professor of Psychiatry, University of Colorado School of Medicine



Each FOCUS LIVE session is approved by ABPN for 2 MOC part 2 self-assessment credits.

The American Board Of Psychiatry And Neurology Has Reviewed Focus Live: Understanding The Evidence For Off-Label Use Of Atypical Antipsychotics And Focus Live: Obsessive-Compulsive And Related Disorders And Has Approved This Program As Part Of A Comprehensive Self-Assessment Program, Which Is Mandated By The ABMS As A Necessary Component Of Maintenance Of Certification.

Special Interactive Multiple choice Q & A Session using FXP technology.

Participants answer multiple choice questions using personal computer/smart phone technology in OCD and Related Disorders topic areas and compare results anonymously to peers for self-assessment credit.



Searching for the perfect psychiatric career?

Let APA JobCentral help!

Visit our booth in APA Central in the Exhibit Hall

APA JobCentral is FREE to job-seekers.

As a job-seeker you will be able to:


- Browse over 1,800 active job listings.
- **New! 2016 APA JobCentral Recruitment Guide!**
- Sign up for a free account and upload your resume for employers to view.
- Register for job alerts and receive immediate information when jobs are posted in a preferred location and/or specialty.
- Post your Annual Meeting contact information along with your resume and be contacted by interested employers attending the meeting.

Please visit jobs.psychiatry.org to begin your search. An APA JobCentral representative will be available during exhibit hours to answer any questions you may have!



JOBCENTRAL
The Career Hub for Psychiatry

jobs.psychiatry.org



Subscribe today to
the highest-ranking
mental health journal
in the Health Policy &
Services category!*

▶ **Don't miss the May issue:**

- Supply-side solutions to increasing the number of psychiatric beds
- Use of evidence-based treatments in state systems, 2001-2012
- Interventions to increase treatment retention: a systematic review
- Growth in behavioral health service use after the Great Recession

▶ **Coming in the June issue:**

- Recovery-oriented practice in inpatient settings: a literature review
- Effects of Housing First on participants' employment and income
- Marketing residential eating disorder programs: a call for transparency
- Use of services by firefighters with suicidal thoughts and behaviors

Don't miss another issue of *Psychiatric Services*.

Visit the APA Bookstore to subscribe.

ps.psychiatryonline.org

*A total of 71 peer-reviewed journals are rated in this JCR category. *Psychiatric Services* is ranked 15th, making it the highest-ranking mental health journal in the category.



www.appi.org • 1-800-368-5777 • Fax: 703-907-1091 • Email: appi@psych.org

Priority Code AH1622A

Tuesday

May 17, 2016



Emmanuel G. Cassimatis, M.D., is President and CEO of the Educational



Commission for Foreign Medical Graduates and Chair of the Foundation for Advancement of International

Medical Education and Research. He was formerly Vice President for Affiliations and International Affairs at the Uniformed Services University of the Health Sciences, Associate Dean for Clinical Affairs and Professor of Psychiatry at the university's F. Edward Hébert School of Medicine. Dr. Cassimatis received his B.A. from the University of Chicago, his M.D. from Harvard Medical School and his psychoanalytic training at the Washington Psychoanalytic Institute. Dr. Cassimatis continues to serve as Professor of Psychiatry at USUHS and is a member of the Executive Council of the World Federation for Medical Education and the Composite Committee of the U.S. Medical Licensing Examination. He is a past Chair of the ACGME and the AMA Council on Medical Education.

Larry R. Faulkner, M.D., is currently the President and CEO of the American Board of Psychiatry and Neurology (ABPN) and Clinical Professor of Neuropsychiatry and Behavioral Science at the



University of South Carolina School of Medicine (USCSM). From 1994 until he assumed his current position at the ABPN in 2006, Dr. Faulkner served as Vice President for Medical Affairs and Dean of the School of Medicine at USC. From 1990 to 1996, he was Chair of the Department of Neuropsychiatry and Behavioral Science and Director of the William S. Hall Psychiatric Institute at USCSM, and from 1980 to 1990, he was Director of Psychiatric Education at the Oregon Health Sciences University. Dr. Faulkner is a past Director of the ABPN, a past member and current ex-officio member of the Psychiatry RRC, a current ex-officio member of the Neurology RRC and a past President of the American Academy of Psychiatry and the Law.

Mardi Horowitz, M.D., is a Distinguished Professor of Psychiatry at



the University of California, San Francisco. He has been president of the San Francisco Center for Psychoanalysis and

the International Society for Psychotherapy Research. He has directed the NIMH Center for the Study of Neuroses and the John D. and Catherine T. MacArthur Foundation's Program on Conscious and Unconscious Mental Processes. He is a founding member of the International Society for Traumatic Stress Studies and the Society to Explore Psychotherapy Integration. Dr. Horowitz is the recipient of multiple awards, including the Pioneer Award of the International Society

for Traumatic Stress Studies for his achievements in developing the diagnoses of post-traumatic stress disorder and disorders of complicated grief. He also received the Foundation's Fund Prize for psychiatric research "for his distinguished contribution to an understanding of the psychological processes following serious life events, and of the adaptive changes facilitated by psychotherapy."

Francis G. Lu, M.D., is the Luke and Grace Kim Professor in Cultural



Psychiatry, Emeritus, and Assistant Dean for Faculty Diversity, Emeritus, at the University of California, Davis, School

of Medicine. From 1977 to 2009, he was a UCSF faculty member at the UCSF/San Francisco General Hospital inpatient psychiatric services. As a Distinguished Life Fellow of the American Psychiatric Association, Dr. Lu has contributed to the areas of cultural psychiatry; psychiatric education; film and psychiatry; and the interface of psychiatry, religion and spirituality. Since 2003, he has served on the APA Council on Minority Mental Health and Health Disparities. He is currently Secretary of the Society for the Study of Psychiatry and Culture, a member of the Group for the Advancement of Psychiatry Cultural Psychiatry Committee and a board member of the World Association of Cultural Psychiatry.

8:00 a.m. Sessions

Courses

! Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Evidence-Based Psychodynamic Therapy: A Pragmatic Clinician's Workshop



8:00 a.m. – Noon
International 4, International Level
Marriott Marquis

Director:
Richard F. Summers, M.D.

ECT Practice Update for the General Psychiatrist



8:00 a.m. – Noon
M103-105, Marquis Level
Marriott Marquis

Director:
Peter B. Rosenquist, M.D.

Seminar

The Psychiatrist as Expert Witness



8:00 a.m. – Noon
International 7, International Level
Marriott Marquis

Director:
Phillip J. Resnick, M.D.

! Program changes are printed each day in the *APA Daily*, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.

Master Course

! Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Essential Psychopharmacology



8:00 a.m. – 5:00 p.m.
Imperial Ballroom B, Marquis Level
Marriott Marquis

Director:
Alan F. Schatzberg, M.D.

9:00 a.m. Sessions

Advances in Medicine

Critical Advances in Sleep Medicine for the Psychiatrist

9:00 a.m. – 10:30 a.m.
Rooms A315-316, Level 3
Georgia World Congress Center

Chair:
Karl Doghramji, M.D.

SESSION TRACKS

- 1** Addiction Psychiatry
 - 2** Child and Adolescent Psychiatry
 - 3** Forensic Psychiatry
 - 4** Geriatric Psychiatry
 - 5** Psychosomatic Psychiatry
 - 6** NIDA
 - 7** Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
 Bring Your Own Device

Interactive Session

Meet the Authors: *Clinical Manual of Palliative Care Psychiatry*
*American Psychiatric Association
Publishing Editorial Board*

5

9:00 a.m. – 10:30 a.m.
Room A301, Level 3
Georgia World Congress Center

Chair:
*Nathan Fairman, M.D., M.P.H.
Scott A. Irwin, M.D., Ph.D.*

Lectures

Regulating the Entry of International Medical Graduates into U.S. Medicine and Psychiatry and endeavoring to contribute to their professional development: The Role of the ECFMG
George Tarjan Award

9:00 a.m. – 10:30 a.m.
Room A302, Level 3
Georgia World Congress Center

Lecturer:
Emmanuel Cassimatis, M.D.

Perspectives on Physician Competence and Lifelong Learning
APA Distinguished Psychiatrist Lecture Series

9:00 a.m. – 10:30 a.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Lecture Chair:
Steve H. Koh, M.D., M.P.H.

Lecturer:
Larry R. Faulkner, M.D.

This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Scientific and Clinical Reports

Further Topics in

Biological Psychiatry

D 2 5

9:00 a.m. – 10:30 a.m.

Room B405, Level 4

Georgia World Congress Center

1. Vagal Activity Predicts Survival in Women With Advanced Breast Cancer
David Spiegel, M.D.
5
2. Serum Levels and mRNA Expression of Neurotrophic Factors and Related Receptors Are Crucial in Different Subtypes of Depression
Yingying Yue, M.Med.
3. Hypothalamic Gastrin-Releasing Peptide Receptor Mediates an Antidepressant-Like Effect in a Mouse Model of Stress
Lihua Yao, M.Psy.
2
4. Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS): A New Tool for the Prediction of Patients at Risk for AWS
Jose R. Maldonado, M.D.
5

! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- D** APA Annual Meeting on Demand
📱 Bring Your Own Device

Workshops

Adaptation and Dissemination of Evidence-Based Psychotherapies for Use in Acute Psychiatric Care

D

9:00 a.m. – 10:30 a.m.

Room B215, Level 2

Georgia World Congress Center

Chairs:

Aliza T. Stein, B.A.

Patricia Marino, Ph.D.

Speakers:

Kean J. Hsu, Ph.D.

Patricia Marino, Ph.D.

Amanda McGovern, Ph.D.

Theresa A. Morgan, Ph.D.

Victoria Wilkins, Ph.D.

What Is New in Suicide Prevention? From Primary to Tertiary Prevention in Physicians, Youth and Medically Ill Patients

9:00 a.m. – 10:30 a.m.

Room B218, Level 2

Georgia World Congress Center

Chairs:

Tatiana Falcone, M.D.

Jane C. Timmons-Mitchell, Ph.D.

Speakers:

Ruby C. Castilla-Puentes, M.D., Dr.P.H.

Fernando Espi Forcen, M.D.

Tatiana Falcone, M.D.

Jane C. Timmons-Mitchell, Ph.D.

Margo Funk, M.D., M.A.

Adolescents' Decision Making Capacity in the Consultation-Liaison Setting: From Juvenile Rights to Case Law

APA Council on Children, Adolescents and Their Families

2

9:00 a.m. – 10:30 a.m.

Room A303, Level 3

Georgia World Congress Center

!

All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

Chairs:

Anish R. Dube, M.D., M.P.H.

Barbara Robles-Ramamurthy, M.D.

Speakers:

Megan E. Baker, M.D.

Hassan M. Minhas, M.D., M.B.B.S.

Lara J. Cox, M.D., M.S.

Elements for Effective Advocacy for the Profession of Psychiatry

APA Council on Advocacy and Government Relations

9:00 a.m. – 10:30 a.m.

Room A304, Level 3

Georgia World Congress Center

Chair:

John Bailey, D.O.

Speakers:

Debra Koss, M.D.

Matthew D. Erlich, M.D.

Michael Hann, M.D., M.S.

Altha J. Stewart, M.D.

Treatment in Narcissistic Patients

9:00 a.m. – 10:30 a.m.

Rooms A311-312, Level 3

Georgia World Congress Center

Chair:

Glen O. Gabbard, M.D.

Novel Approaches to the Treatment of Catatonia

5

9:00 a.m. – 10:30 a.m.

Room A313, Level 3

Georgia World Congress Center

Chairs:

Stephen J. Warnick Jr., M.D.

Kamalika Roy, M.D.

Speaker:

Richard Balon, M.D.

"I Want to Check Myself In": Determining Who Needs Psychiatric Hospitalization

D 5

9:00 a.m. – 10:30 a.m.

Room B306, Level 3

Georgia World Congress Center

Chairs:

Kenneth M. Certa, M.D.

Jessica Mosier, M.D.

Speaker:

Daniel Neff, M.D.

Transcranial Magnetic Stimulation: What You Need to Know

9:00 a.m. – 10:30 a.m.

Room B310, Level 3
Georgia World Congress Center

Chairs:

Todd Hutton, M.D.
Philip G. Janicak, M.D.

Speakers:

Kim K. Cress, M.D.
Richard A. Bermudes, M.D.

Comorbidity in Schizophrenia: Biological Pathogenesis and Clinical Implications

9:00 a.m. – 10:30 a.m.

Room B311, Level 3
Georgia World Congress Center

Chairs:

Michael Hwang, M.D.
Henry A. Nasrallah, M.D.

Speaker:

Leslie Citrome, M.D., M.P.H.

A Clinician's Guide to Structured Assessment of Personality Disorder and Functioning: The Structured Interview of Personality Organization-R (STIPO-R)

9:00 a.m. – 10:30 a.m.

Room B316, Level 3
Georgia World Congress Center

Chair:

Eve Caligor, M.D.

Speakers:

Barry L. Stern, Ph.D.
Emanuele Preti, Ph.D.
John M. Oldham, M.D., M.S.

Stigma of Psychiatry Among Ethnic Minorities and the Use of Social Media and the Internet to Reach Underserved Populations

APA/SAMHSA Minority Fellows

9:00 a.m. – 10:30 a.m.

Room B403, Level 4
Georgia World Congress Center

Chair:

*Wilsa M. S. Charles Malveaux,
M.D., M.A.*

Speakers:

Tiffani Bell, M.D.
Jeffrey Borenstein, M.D.
Chuan-Mei Lee, M.D., M.A.
Racquel E. Reid, M.D.

Beyond Googling: Psychiatric Monitoring of Patients' Electronic Communication

*APA Ethics Committee and Penn-
Scattergood Ethics Program*

9:00 a.m. – 10:30 a.m.

Room B404, Level 4
Georgia World Congress Center

Chair:

Paul S. Appelbaum, M.D.

Speaker:

Carl Fisher

Learning Lab

A Leadership Boot Camp for Residents and Fellows (Part 2): Developing Your Negotiation Skills, Balancing Professional and Personal Commitments



9:00 a.m. – 11:00 a.m.

Rooms B211-212, Level 2
Georgia World Congress Center

Chair:

Laura Roberts, M.D., M.A.

Advances in Series

Advances in Trauma Disorders and Trauma Psychotherapy

*American Psychiatric Association
Publishing Editorial Board*



9:00 a.m. – Noon

Room A305, Level 3
Georgia World Congress Center

Chair:

James J. Strain, M.D.

1. Trauma-Centered Psychotherapy: Challenges in Conducting an Intensive, Detailed Trauma Inquiry
David Johnson, M.D.
 2. Do Profiles of Depressive Symptoms Differentiate Adjustment Disorder and Depressive Disorder Diagnoses?
Patricia R. Casey, M.D.
-

3. Low-Threshold Interventions for Adjustment Disorders: Development and Evaluation of a Self-Help Manual
Rahel C. Bachem, D.Phil.

Lecture

Opioids and Cannabis: Myths and Misperceptions

6

9:00 a.m. – 10:30 a.m.

Sidney Marcus Auditorium, Level 4
Georgia World Congress Center

Lecturer:

Nora Volkow, M.D.

Media Workshops

What Happened, Miss Simone?

9:00 a.m. – Noon

Room A314, Level 3
Georgia World Congress Center

Chair:

Sarah Y. Vinson, M.D.

Speakers:

Ruth Shim, M.D., M.P.H.
Annelle Primm, M.D., M.P.H.

Presidential Symposia

New Nomenclature for Medications (Neuroscience-Based Nomenclature —NbN)



9:00 a.m. – Noon

Rooms B213-214, Level 2
Georgia World Congress Center

Chair:

Maria A. Oquendo, M.D.

1. How Neuroscience-Based Nomenclature (NbN) Can Change Your Prescribing Practice
Joseph Zohar, M.D.
2. How Neuroscience-Based Nomenclature Helps Reduce Stigma
Pierre Blier
3. Neuroscience-Based Nomenclature: Focus on Treatments for Psychosis
Stephen M. Stahl, M.D., Ph.D.

Correctional Psychiatry: Journey Into the Heart of Darkness

American Academy of Psychiatry and the Law



9:00 a.m. – Noon

Room B313, Level 3

Georgia World Congress Center

Chair:

Graham D. Glancy, M.B.

1. The What and Why of Correctional Psychiatry
Robert L. Trestman, M.D., Ph.D.
2. Suicide Prevention in Correctional Facilities
Jeffrey L. Metzner, M.D.
3. Assessment and Prescribing in Correctional Settings
Anthony Tamburello
4. Get Out and Stay Out! Helping Inmates Return to Their Communities
Erik Roskes, M.D.

Symposia

Mentally Ill and Traumatized Populations in South Sudan: A Novel Mind-Body Treatment for Healing a War-Torn Country

APA Caucus on Complementary and Alternative Medicine



9:00 a.m. – Noon

Rooms B207-208, Level 2

Georgia World Congress Center

Chair:

Patricia L. Gerbarg, M.D.

Discussant:

Richard P. Brown, M.D.

1. Project for Mentally Ill Survivors in South Sudan: Transforming the Present, Shaping the Future
Atong Ayuel, M.D.
2. Neurophysiology, Clinical Studies and Observations: War Survivors and Mentally Ill South Sudanese
Patricia L. Gerbarg, M.D.
3. Experience the Effects of Breath-Body-Mind as It Is Taught in Sudan
Richard P. Brown, M.D.

Borderline Personality Disorder (BPD) Across the Lifespan: Developmental Precursors in Infancy Through Old Age

North American Association for the Study of Personality Disorders



9:00 a.m. – Noon

Rooms B216-217, Level 2

Georgia World Congress Center

Chairs:

Marianne Goodman, M.D.

Mary C. Zanarini, Ed.D.

Discussant:

John Gunderson, M.D.

1. Infancy, Childhood and Adolescent Precursors to the Development of Borderline Personality in Male and Female Offspring
Marianne Goodman, M.D.
2. The Course of Borderline Symptoms in Adolescents With and Without DSM-IV Criteria-Defined Borderline Personality Disorder (BPD)
Carla Sharp, Ph.D.
3. The Course of Borderline Personality Disorder (BPD) From Adolescence to Young Adulthood
Stephanie Stepp, Ph.D.
4. Levels of Acceptance and Forgiveness Reported by Borderline Patients and Axis II Comparison Subjects Over 16 Years of Prospective Follow-Up
Mary C. Zanarini, Ed.D.
5. Borderline Personality Disorder (BPD) in an Aging Population
Robert Biskin, M.D., M.Sc.

Sexuality and Psychiatry: Ethical and Policy Dilemmas

APA Ethics Committee and Penn-Scattergood Ethics Program



9:00 a.m. – Noon

Room B308, Level 3

Georgia World Congress Center

Chair:

Kenneth J. Weiss, M.D.

1. Sexual Self-Determination in Persons With Dementia
Kenneth J. Weiss, M.D.
2. Beyond a Question of Competency:

The Rights of Individuals With Mental Illness to Engage in Voluntary Sexual Acts

Alison J. Lynch, Esq.

3. Reporting Child Pornography Use: Psychiatrists as Police
Michelle Joy, M.D.
4. Sexual Victimization in Correctional Settings
Clarence Watson

Food and the Brain



9:00 a.m. – Noon

Room B309, Level 3

Georgia World Congress Center

Chairs:

Emily C. Deans, M.D.

Laura R. LaChance, M.D.

1. Food as a Vital Sign: The Simple Food Assessment
Drew Ramsey, M.D.
2. Animals, Vegetables and Minerals: The Fundamentals of Nutrition and Psychopathology
Laura R. LaChance, M.D.
3. You Are What You Eat: Special Diets and Their Implications in Mental Health and Guest or Host—The Microbiome and Behavior
Emily C. Deans, M.D.

DSM-5 and RDoC: Moving Toward a Common Agenda for Understanding Mental Disorders



9:00 a.m. – Noon

Room B314, Level 3

Georgia World Congress Center

Chairs:

Philip Wang, M.D., Dr.P.H.

Diana E. Clarke, Ph.D., M.Sc.

Discussant:

Mario Maj, M.D., Ph.D.

1. Using the NIMH RDoC to Help Clarify Psychiatric Disorders
Charles A. Sanislow, Ph.D.
2. The Conceptual Bridging of DSM-5 and RDoC: Moving the Field of Psychiatry Forward?
Philip Wang, M.D., Dr.P.H.

3. A Cross-Walk Between RDoC Domains and *DSM-5* Cross-Cutting Dimensional Measures: Evidence From *DSM-5* Field Trials
Diana E. Clarke, Ph.D., M.Sc.
4. The *DSM-5* Maladaptive Personality Trait Model: Phenotypes for RDoC
Robert Krueger, Ph.D.

Social Trauma

American Association for Social Psychiatry



9:00 a.m. – Noon

Rooms A402-403, Level 4
Georgia World Congress Center

Chairs:

Sheila Judge, M.D.
Roy Abraham Kallivayalil, M.D.

Discussant:

Kenneth Thompson, M.D.

1. Social Trauma: Culture, Psyche and Symptom Development
Driss Moussaoui, M.D.
2. Social Trauma Research I: Epigenetic Inheritance in Descendants of Trauma Survivors
Rachel Yehuda, Ph.D.
3. Social Trauma Research II: Childhood Experience and the Onset of Psychosis
Thomas K. J. Craig, Ph.D., M.B.B.S.
4. Social Trauma in U.S. Populations I: Human Trafficking
Vivian Pender, M.D.
5. Social Trauma in U.S. Populations II: Institutionalized Youth
Andres J. Pumariega, M.D.

Choosing the Right Treatment for Substance Use Disorders

APA Council on Addiction Psychiatry



9:00 a.m. – Noon

Rooms A404-405, Level 4
Georgia World Congress Center

Chairs:

Herbert D. Kleber, M.D.
Edward V. Nunes, M.D.

1. Detecting and Managing Misuse of Prescription Stimulants and Sedative Hypnotics
John J. Mariani, M.D.
2. Managing Opioid Use Disorder Using Medications: Role for Opioid Agonists and Antagonists
Adam Bisaga, M.D.
3. Choosing Treatment for Problematic Non-Prescription Stimulant Use
Elias Dakwar, M.D.
4. Choosing Treatment for Cannabis Use Disorders
Frances R. Levin, M.D.
5. Combining Medication and Psychosocial Interventions in the Treatment of Substance Use Disorders
Edward V. Nunes, M.D.

Biomarkers of Treatment Response and Tolerability in Psychotic and Mood Disorders

Royal College of Psychiatrists



9:00 a.m. – Noon

Rooms A406-407, Level 4
Georgia World Congress Center

Chairs:

Sophia Frangou, M.D., Ph.D.
Peter Buckley, M.B.B.S.

Discussant:

Godfrey D. Pearlson, M.D.

1. Reliable Biomarkers, Personalized Medicine and the Treatment of Schizophrenia: Will Science (Ever?) Trump Clinical “Trial and Error?”
Peter Buckley, M.B.B.S.

2. Effective Connectivity Changes in Working Memory and Affect Processing Networks in Affective/Nonaffective Psychosis: Relation to Treatment Response
Sophia Frangou, M.D., Ph.D.
3. Biomarkers for Treatment Response and Tolerability in Bipolar Disorder
Allan H. Young, M.D., Ph.D.
4. Multimodal Markers of Treatment Response in Depression
Sidney H. Kennedy, M.B.B.S.

The War on Women Continues

APA Women's Caucus



9:00 a.m. – Noon

Room A410, Level 4
Georgia World Congress Center

Chairs:

Gail Erlick Robinson, M.D.
Gisele Apter, M.D., Ph.D.

1. Is There a War on Women?
Carol C. Nadelson, M.D.
2. Barriers in Access to Mental Health Care for Women
Helen Herrman, M.D., M.B.
3. The History of Contraception
Malkah T. Notman, M.D.
4. The Real Abortion Tragedies: Silence and Misinformation
Nada L. Stotland, M.D., M.P.H.
5. The Myth of the “Maternal-Fetal Conflict”
Gail Erlick Robinson, M.D.
6. Maternity Leave: All in Favor?
Gisele Apter, M.D., Ph.D.

Patient Suicide in Residency Training: The Ripple Effect



9:00 a.m. – Noon

Room B402, Level 4
Georgia World Congress Center

Chairs:

Alexis A. Seegan, M.D.
Sidney Zisook, M.D.

1. Experiencing Patient Suicide as a Psychiatric Intern
Daphne Ferrer, M.D.



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device

- Impact of Patient Suicide on Trainees: The Role of Educational Curricula
Deepak Prabhakar, M.D., M.P.H.
- Impact of Patient Suicide on Residents and Helping Residents Cope With Suicide
James W. Lomax, M.D.
- Emotional and Cognitive Responses of Clinicians to Patient Suicide
Joan Anzia, M.D.

Dual Disorders: Two Different Disorders or One?



9:00 a.m. – Noon
Room B407, Level 4
Georgia World Congress Center

Chair:

Alan I. Green, M.D.

Discussant:

Roger D. Weiss, M.D.

- Epidemiology of Dual Disorders: The Current State of Research and Methodological Challenges
Shaul Lev-Ran, M.D.
- Dual Disorders: Two Different Mental Disorders?
Nestor Szerman, M.D.
- Is Criticality Critical to Understand Dual Disorders?
Ruben Baler, Ph.D.
- Suicidal Behavior in Patients With Dual Disorders
Leo Sher, M.D.
- Schizophrenia and Substance Use Disorder: Is It All About Reward?
Alan I. Green, M.D.

Courses



Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Integrating Behavioral Health and Primary Care: Practical Skills for the Consulting Psychiatrist



9:00 a.m. – 4:00 p.m.
Marquis Ballroom A, Marquis Level
Marriott Marquis

Directors:

Anna Ratzliff, M.D., Ph.D.
Lori Raney, M.D.

Faculty:

John Kern, M.D.

DSM-5 Changes: Overview and Practical Applications (Including the Transition to ICD-10-CM)



9:00 a.m. – 4:00 p.m.
M301-302, Marquis Level
Marriott Marquis

Director:

Michael B. First, M.D.

10:00 a.m. Session

Poster Session

Young Investigators' New Research 2

10:00 a.m. – Noon
Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

10:30 a.m. Session

Lecture

The Marine Corps and Mental Health Issues

10:30 a.m. – Noon
Room B406, Level 4
Georgia World Congress Center

Lecturer:

Gen. Robert B. Neller

11:00 a.m. Sessions

Advances in Medicine

The Evolving Role of Imaging in Optimizing Treatment for Depression: From CBT to DBS

11:00 a.m. – 12:30 p.m.
Rooms A315-316, Level 3
Georgia World Congress Center

Chair:

Helen Mayberg, M.D.

Lecture

How the Mind Works: Using Trauma and Grief as Models

*APA Distinguished Psychiatrist
Lecture Series*

11:00 a.m. – 12:30 p.m.
Rooms A411-412, Level 4
Georgia World Congress Center

Lecture Chair:

Renée Binder, M.D.

Lecturer:

Mardi Horowitz, M.D.

Media Workshops

Mad Men (and Women): Is Character Immutable? Case Studies From the TV Series



11:00 a.m. – 12:30 p.m.
Room B306, Level 3
Georgia World Congress Center

Chairs:

Joseph A. Cheong, M.D.
Kenneth R. Silk, M.D.

Speaker:

Steven E. Hyler, M.D.

SESSION TRACKS

- Addiction Psychiatry
- Child and Adolescent Psychiatry
- Forensic Psychiatry
- Geriatric Psychiatry
- Psychosomatic Psychiatry
- NIDA
- Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device

General Robert B. Neller

General Robert B. Neller is the 37th Commandant of the United States Marine Corps. Prior to his current assignment, he served as the Commander, Marine Forces Command, from July 2014 to September 2015 and Commander, Marine Forces Central Command, from September 2012 to June 2014.

A native of East Lansing, Mich., General Neller graduated from the University of Virginia and was commissioned in 1975. He has served as an infantry officer at all levels, including command of Marine Security Force Company Panama during Operations JUST CAUSE and PROMOTE LIBERTY, 3rd Light Armored Infantry Battalion during Operation RESTORE HOPE, 6th Marine Regiment, and 3rd Marine Division.

General Neller also served as Deputy Commanding General, I Marine Expeditionary Force (Forward) during Operation IRAQI FREEDOM (05-07), Assistant Division Commander for 1st and 2nd Marine Divisions and President of Marine Corps University.

His joint assignments include service in the Policy Division of Supreme Headquarters Allied Powers Europe (SHAPE) in Casteau, Belgium, and as the Director of Operations (J-3) of the Joint Staff in Washington, D.C.

General Neller is a graduate of the Armor Officer Advanced Course, Marine Corps Command and Staff College, NATO Defense College, and the Armed Forces Staff College. He holds a master's degree in human resource management from Pepperdine University.



Scientific and Clinical Reports

Measurements and Scales

1 5

11:00 a.m. – 12:30 p.m.

Room B405, Level 4

Georgia World Congress Center

1. A Scale of Partner Addiction: Underlying Mechanisms in Reward Deficits and Insecure Attachments and Manifestations in Clinical Issues
Jacob Mills, B.S.
1
2. Self-Monitoring and Psychoeducation in Bipolar Patients With a Smartphone Application (SIMPLe) Project: Preliminary Results From a Feasibility Study
Eduard Vieta, M.D., Ph.D.
3. The Proxy Test for Delirium (PTD): A New Tool for the Screening of Delirium Based on *DSM-5* and ICD-10 Criteria
Jose R. Maldonado, M.D.
5

Workshops

Are You a Sitting Duck Online? What You Can (and Can't, or Shouldn't) Do to Avoid, and to Respond to, Negative Reviews by Patients

D

11:00 a.m. – 12:30 p.m.

Room B215, Level 2

Georgia World Congress Center

Chair:

Robert Hsiung, M.D.

Speakers:

Samantha Adams, Ph.D.

Paul S. Appelbaum, M.D.

Robert Hsiung, M.D.

Laura Roberts, M.D., M.A.

Psychiatrists Who Have Survived the Suicide Death of a Loved One: Their Insights

11:00 a.m. – 12:30 p.m.

Room B218, Level 2

Georgia World Congress Center

Chair:

Michael F. Myers, M.D.

Speakers:

Anna Halperin Rosen, M.D.

Akshay Lohitsa, M.D.

Karen K. Miday, M.D.

The Biopsychosocial Revolution: Assessing Patients in Psychiatry Using the *DSM-5* Cultural Formulation Interview

American Psychiatric Leadership Fellowship

5

11:00 a.m. – 12:30 p.m.

Room A303, Level 3

Georgia World Congress Center

Chairs:

Michael Hann, M.D., M.S.

Misty Richards, M.D., M.S.

Speakers:

Nina Vasan, M.D.

Jeremy D. Kidd, M.D., M.P.H.

D This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Standing Up to Violence in Police Encounters: The Players, the Victims, the Trauma and the Solutions

APA Council on Minority Mental Health and Health Disparities

4

11:00 a.m. – 12:30 p.m.
Room A304, Level 3
Georgia World Congress Center

Chairs:

Elie Aoun, M.D.
Racquel E. Reid, M.D.

Speakers:

Sandra C. Walker, M.D.
Amanda Ruiz, M.D.
Moore Jessica, M.D.
Matthew L. Dominguez, M.D., M.P.H.
Jared K. Taylor, M.D.
Lama Bazzi, M.D.

A Year After Winning Marriage: The Impact of *Obergefell v. Hodges* on LGBT Mental Health

11:00 a.m. – 12:30 p.m.
Room A307, Level 3
Georgia World Congress Center

Chair:

Robert M. Kertzner, M.D.

Speakers:

Stewart L. Adelson, M.D.
Mary Barber, M.D.
Marshall Forstein, M.D.

APA Council on Psychiatry and the Law: Update

APA Council on Psychiatry and Law

3

11:00 a.m. – 12:30 p.m.
Rooms A311-312, Level 3
Georgia World Congress Center

Chair:

Steven Hoge, M.D., M.B.A.

Speakers:

Richard J. Bonnie, J.D.
Marvin S. Swartz, M.D.

The Art of the Curbside Consultation: Nicely Done

11:00 a.m. – 12:30 p.m.
Room A313, Level 3
Georgia World Congress Center

Chair:

Lori Raney, M.D.

Speakers:

Erik Vanderlip, M.D., M.P.H.
Anna Ratzliff, M.D., Ph.D.
John Kern, M.D.

Developing and Running a Successful Research Track for Psychiatry Residents

11:00 a.m. – 12:30 p.m.
Room B310, Level 3
Georgia World Congress Center

Chair:

Katharine A. Phillips, M.D.

Speakers:

Melissa Arbuckle, M.D., Ph.D.
Jane L. Eisen, M.D.
Kathryn K. Ridout, M.D., Ph.D.
Samuel J. Ridout, M.D., Ph.D.
Louisa J. Steinberg, M.D., Ph.D.

Risk Management Considerations When Prescribing Controlled Substances

3

11:00 a.m. – 12:30 p.m.
Room B311, Level 3
Georgia World Congress Center

Chair:

Kristen M. Lambert, J.D., M.S.W.

Speaker:

Maira Wertheimer, J.D., B.S.N.

Treatment in the Immediate Aftermath of Trauma: From the Hospital to the Battlefield

11:00 a.m. – 12:30 p.m.
Room B315, Level 3
Georgia World Congress Center

Chair:

Judith Cukor, Ph.D.

Speakers:

John W. Barnhill, M.D.
Judith Cukor, Ph.D.
David A. Nissan, M.D.
Amy B. Adler, Ph.D.

Feeling Burned Out? Using Science and Wisdom of Contemplative Practices to Manage Your Stress and Reduce Burnout

5

11:00 a.m. – 12:30 p.m.
Room B316, Level 3
Georgia World Congress Center

Chair:

Sermsak Lolak, M.D.

Speaker:

Sermsak Lolak, M.D.

What a Pain! How Pills, Talking and Marijuana May Help Your Patients With Chronic Pain

Academy of Psychosomatic Medicine

5

11:00 a.m. – 12:30 p.m.
Room B403, Level 4
Georgia World Congress Center

Chair:

Wendy Baer, M.D.

Speakers:

Kim Curseen, M.D.
Shweta Kapoor, Ph.D., M.B.B.S.
Ann Schwartz, M.D.
Martha C. Ward, M.D.

Dynamic Therapy With Self-Destructive Borderline Patients: An Alliance-Based Intervention for Suicide

11:00 a.m. – 12:30 p.m.
Room B404, Level 4
Georgia World Congress Center

Chairs:

Eric M. Plakun, M.D.
Samar Habl, M.D.

1:00 p.m. Sessions

Lecture

The Court and the World



1:00 p.m. – 2:30 p.m.
Sidney Marcus Auditorium, Level 4
Georgia World Congress Center

Lecture Chair:

Renée Binder, M.D.

Lecturer:


Stephen Breyer



This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Justice Stephen Breyer

Stephen Breyer, born in San Francisco in 1938, is a Justice on the Supreme Court of the United States. He is a graduate of Stanford University, Oxford University and Harvard Law School. He taught law for many years as a professor at Harvard Law School and at the Kennedy School of Government. He has also worked as a Supreme Court law clerk (for Justice Arthur Goldberg), a Justice Department lawyer (antitrust division), an Assistant Watergate Special Prosecutor, and Chief Counsel of the Senate Judiciary Committee (working closely with Senator Edward M. Kennedy to pass the Airline Deregulation Act). In 1980, he was appointed to the United States Court of Appeals for the First Circuit by President Carter, becoming Chief Judge in 1990. In 1994, he was appointed Supreme Court Justice by President Clinton. He has written books and articles about administrative law, economic regulation and constitutional law, including *Regulation and Its Reform*, *Breaking the Vicious Circle: Toward Effective Risk Regulation*, *Active Liberty*, *Making Our Democracy Work: A Judge's View* and *The Court and the World*, published in 2015. His wife, Joanna, was born in Great Britain and is a retired clinical psychologist. They have three children (Chloe, Nell and Michael) and five grandchildren.



Courses

! Course descriptions are available in the APA Meetings app. Admission to all courses, including master courses, is by ticket only. Course tickets can be purchased at Registration at the Marquis Fountain, Marquis Level in the Marriott Marquis, or at Registration in Exhibit Hall B3-B4, Level 1 in the Georgia World Congress Center.

Talking With Your Patients About Marijuana Use: What Every Psychiatrist Should Know



1:00 p.m. – 5:00 p.m.
International 4, International Level
Marriott Marquis

Director:

Henry S. Levine, M.D.

Advanced Assessment and Treatment of ADHD



1:00 p.m. – 5:00 p.m.
International 5, International Level
Marriott Marquis

Director:

Thomas Brown, Ph.D.

Faculty:

Anthony Rostain, M.D.

Motivational Interviewing for the Routine Practice of Psychiatry



1:00 p.m. – 5:00 p.m.
M103-105, Marquis Level
Marriott Marquis

Director:

Steven Cole, M.D., M.A.

Seminar

How to Give More Effective Lectures: Punch, Passion and Polish



1:00 p.m. – 5:00 p.m.
International 7, International Level
Marriott Marquis

Director:

Phillip J. Resnick, M.D.

1:30 p.m. Sessions

Scientific and Clinical Reports

Marijuana and Opiates



1:30 p.m. – 3:00 p.m.
Room B405, Level 4
Georgia World Congress Center

1. Reasons for Relapse and Natural Quitting in Adult Recreational Cannabis Smokers
David Gorelick, M.D., Ph.D.

! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device

! All scientific sessions listed in the Program are designated for *AMA PRA Category 1 Credits™*, except for Poster Sessions.

1

- 2. Generating Medical Marijuana Guidelines at Your Institution
Ilana M. Braun, M.D.

5

- 3. Long-Term Outcomes From the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study
Roger D. Weiss, M.D.

Workshops

Assisted Outpatient Treatment for Individuals With Mental Illness Referred by Correctional Services: Synergy or Redundancy?

3

1:30 p.m. – 3:00 p.m.
Room B404, Level 4
Georgia World Congress Center

Chair:
Scott Soloway, M.D.

Speakers:
Jennifer Correale, J.D., Esq.
Carolyn D'Aquila, L.C.S.W., M.P.H.
Patricia Schwartz, M.D.

Social Withdrawal in Modern Society: An Emerging Cultural Concept of Distress in East Asia

▶ 2

1:30 p.m. – 3:00 p.m.
Room B215, Level 2
Georgia World Congress Center

Chairs:
Takahiro A. Kato, M.D., Ph.D.
Alan R. Teo, M.D., M.S.

Speakers:
Takahiro A. Kato, M.D., Ph.D.
Alan R. Teo, M.D., M.S.
Francis Lu, M.D.
Shigenobu Kanba, M.D., Ph.D.

The Management of Acute Agitation on Medical Units and in the Intensive Care Unit

5

1:30 p.m. – 3:00 p.m.
Room A303, Level 3
Georgia World Congress Center

Chair:
Michael S. Peroski, D.O.

Speakers:
Ellen K. R. Breen, M.D.
Anique Forrester, M.D.
Bhinna Pearl Park, M.D.

The APA: An NGO of The United Nations

APA Council on International Psychiatry
1:30 p.m. – 3:00 p.m.
Room A304, Level 3
Georgia World Congress Center

Chair:
Vivian Pender, M.D.

Speaker:
Andriy Yur'yev, M.D., Ph.D.

Promoting Overall Wellness and Eliminating Risk of Burnout in Trainees (POWER BIT)

7

1:30 p.m. – 3:00 p.m.
Room B306, Level 3
Georgia World Congress Center

Chairs:
Deepak Prabhakar, M.D., M.P.H.
Cindy Devassy, M.D.

Speaker:
Theresa Toledo

Writing a Scholarly Article: *The American Journal of Psychiatry Residents' Journal* Workshop

1:30 p.m. – 3:00 p.m.
Room B310, Level 3
Georgia World Congress Center

Chairs:
Rajiv Radhakrishnan, M.D., M.B.B.S.
Robert Freedman, M.D.

Speakers:
Hun Millard, M.D.
Katherine Pier, M.D.

New Directions in CBT for Psychosis (CBTp): CBTp in Busy Clinics Using a Guided Self-Help Approach

5

1:30 p.m. – 3:00 p.m.
Room B311, Level 3
Georgia World Congress Center

Chair:
Farooq Naeem, Ph.D., M.Sc.

Transformation in New York State: Will Town and Gown Really Partner? The DSRIP Experience of the Behavioral Health Team at NYPH

1

1:30 p.m. – 3:00 p.m.
Room B315, Level 3
Georgia World Congress Center

Chair:
Dianna Dragatsi, M.D.

Speakers:
Mary Hanrahan, L.C.S.W.
Daniel L. Lowy, L.C.S.W.

The Civilian Soldiers: Expanding Our Approach to Mental Health for Our One Million Military Reservists and Guardsmen

1:30 p.m. – 3:00 p.m.
Room B403, Level 4
Georgia World Congress Center

Chair:
Philip Michael Yam, M.D.

Speakers:
Hoa Le, D.O.
Rita R. Richardson, M.D.
Christine A. Winter, D.O., M.B.A.
Vincent F. Capaldi II, M.D., M.Sc.

Twists in the Double Helix: Ethical Challenges in Genetic Testing in Psychiatry

APA Ethics Committee and Penn-Scattergood Ethics Program

1:30 p.m. – 3:00 p.m.
Room B404, Level 4
Georgia World Congress Center



SESSION TRACKS

- 1 Addiction Psychiatry
- 2 Child and Adolescent Psychiatry
- 3 Forensic Psychiatry
- 4 Geriatric Psychiatry
- 5 Psychosomatic Psychiatry
- 6 NIDA
- 7 Residents, Fellows and Medical Students
- ▶ APA Annual Meeting on Demand
- 📱 Bring Your Own Device

Chair:

Paul S. Appelbaum, M.D.

Speaker:

Maya Sabatello, Ph.D., LL.B.

2:00 p.m. Sessions

Poster Session

New Research Poster 2

2:00 p.m. – 4:00 p.m.

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

Advances in Series

Gun Violence and Mental Health

American Psychiatric Association

Publishing Editorial Board



2:00 p.m. – 5:00 p.m.

Room A305, Level 3

Georgia World Congress Center

Chair:

Liza H. Gold, M.D.

1. Suicide and Firearms
Liza H. Gold, M.D.
2. NICS, Mental Illness and Firearms Legislation: What You Should Know
Marilyn Price, M.D.
3. When Firearms Affect Children: Clinical and Forensic Evaluation
Cheryl Wills, M.D.
4. Mass Shootings: Mass Distractions and Sociocultural Factors
James L. Knoll IV, M.D.
5. Firearm Risk Prevention: Considering Legal and Clinical Reforms
Debra Pinals, M.D.

Presidential Symposia

Psychosomatic Medicine: Offering a Multifaceted Approach to Clinical, Educational and Research Challenges Impacting Patient Care

Academy of Psychosomatic Medicine



2:00 p.m. – 5:00 p.m.

Rooms B216-217, Level 2

Georgia World Congress Center

Chair:

Catherine Crone, M.D.

1. An Update on Conversion Disorder
Steve E. Epstein, M.D.
2. ASQ: Pediatric Suicide Risk Screening in Medical Settings
Maryland Pao, M.D.
3. Proactive Consultation-Liaison Psychiatric Services: A New Model for Delivery of Psychiatric Service for Hospitalized Medico-Surgical Patients
Hochang B. Lee, M.D.
4. Training for Complexity: Psychosomatic Medicine as the Model for the 21st Century
Sanjeev Sockalingam, M.D.
5. Collaborative Care: Evolving Models of Care
Thomas N. Wise, M.D.

Back to the Future: Integrating Primary Care and Behavioral Health 2020



2:00 p.m. – 5:00 p.m.

Room B313, Level 3

Georgia World Congress Center

Chair:

Lori Raney, M.D.

Discussant:

Paul Summergrad, M.D.

1. Collaborative Care in the Year 2020
Jürgen Unützer, M.D., M.P.H.
2. Financial and Administrative Models of Care Integration: Transitioning to Successful and Sustainable Care Delivery Support
Roger Kathol, M.D.
3. Improving Health and Health Care for Patients With Serious Mental Illnesses in a Postintegration Era
Benjamin G. Druss, M.D.
4. Integration at the State Level: A Payer Perspective
Joseph Parks, M.D.

Symposia

Understanding Borderline Personality Disorder: 35 Years of Progress Through Empirical Research: Part 2



2:00 p.m. – 5:00 p.m.

Room B309, Level 3

Georgia World Congress Center

Chairs:

Kenneth R. Silk, M.D.

Perry Hoffman, Ph.D.

Discussant:

Mary C. Zanarini, Ed.D.

1. Family Interventions for Borderline Personality Disorder (BPD) in the Age of EBTs
Lois W. Choi-Kain, M.D., M.Ed.
2. How Neurobiology Can Help to Improve Psychotherapy for Borderline Personality Disorder (BPD)
Christian Schmahl, M.D.
3. Pharmacologic Treatment in Borderline Personality Disorder (BPD)
Kenneth R. Silk, M.D.
4. Dimensional Versus Categorical Diagnosis of Borderline Personality Disorder (BPD)
John M. Oldham, M.D., M.S.
5. Future Direction of Research and Clinical Approaches to Borderline Personality Disorder (BPD)
Otto F. Kernberg, M.D.



Program changes are printed each day in the *APA Daily*, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the *APA Meetings* app.

Teen and Young Adult Misuse and Abuse of Prescription Drugs: Pathways to Drug Addiction?

National Institute on Drug Abuse



2:00 p.m. – 5:00 p.m.

Room B312, Level 3

Georgia World Congress Center

Chairs:

Cheryl A. Boyce, Ph.D.

Timothy Wilens, M.D.

Discussant:

Carol J. Boyd, Ph.D., R.N.

1. Adolescent Athletes: Exercise, Performance and Prescription Drug Abuse of Opioids
Philip Velliz, Ph.D.
2. Trends and Trajectories of Prescription Drug Misuse Among U.S. Adolescents
Sean Esteban McCabe, Ph.D.
3. Characteristics of College Students Who Misuse Stimulant Medications
Timothy Wilens, M.D.
4. Three RCTs Evaluating Universal Preventive Interventions: Longitudinal Effects on Prescription Drug Misuse and Cost-Effectiveness
Richard Spoth, Ph.D.

Psychiatrists as Leaders: The Importance of Leadership Development in a New Era of Health Care



2:00 p.m. – 5:00 p.m.

Room B314, Level 3

Georgia World Congress Center

Chair:

William D. Rumbaugh Jr., M.D.

1. Leadership as a Behavioral Science and Clinical Competency: From Odysseus to the Present
Matthew Moosey, M.S.
2. Managing Behavioral Health Providers: The Nuances of Leading This Unique Population
Wendi Waits, M.D.
3. Building Teams and Morale by Bringing Fun Into the Workplace
Ashley H. Chatigny, D.O.

Physician Suicide: Toward Prevention



2:00 p.m. – 5:00 p.m.

Rooms A402-403, Level 4

Georgia World Congress Center

Chair:

Michael F. Myers, M.D.

1. Why Do Physicians Kill Themselves?
Michael F. Myers, M.D.
2. Suicide in Medical Students: Interventions and Culture Change
Christine Moutier, M.D.
3. Suicide in Residents and Fellows: ACGME Initiatives and Recommendations
Matthew L Goldman, M.D., M.S., Ravi N. Shah, M.D., M.B.A., Carol A. Bernstein, M.D.
4. Critical Issues in the Treatment of Suicidal Physicians
Glen O. Gabbard, M.D.
5. Saving Lives: One Medical Center's Response to a Faculty Member's Suicide
Sidney Zisook, M.D.

Innovative Practices in College Mental Health



2:00 p.m. – 5:00 p.m.

Rooms A404-405, Level 4

Georgia World Congress Center

Chairs:

Michelle B. Riba, M.D.

Daniel Kirsch, M.D.

Discussant:

Victor Schwartz, M.D.



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device

1. Clinical Illustrations of Management Issues in College Mental Health
Richard Balon, M.D.
2. Developing and Implementing Wellness Programs for Medical Students
Preston Wiles, M.D.
3. Improving Collaborative Depression Care in College Health: The National College Depression Partnership
Carlo Ciotoli, M.D.
4. Innovations in Service Provision for International Students
Leigh White, M.D.
5. A Curriculum for College Mental Health and Young Adult Psychiatry
Daniel Kirsch, M.D.

Queerly Invisible: LGBTQ People of Color as Psychiatrists and Patients

APA/SAMHSA Minority Fellows



2:00 p.m. – 5:00 p.m.

Rooms A406-407, Level 4

Georgia World Congress Center

Chairs:

Vivek Datta, M.D., M.P.H.

Dinesh Bhugra

Discussants:

Debbie R. Carter, M.D.

Dinesh Bhugra

1. Multiple Minorities as Multiply Marginalized: Applying the Minority Stress Theory to LGBTQ People of Color
Kali Cyrus, M.D., M.P.H.
2. Traumatic Identities: A Trauma-Based Approach to the Mental Health Treatment of LGBTQ People of Color
Matthew L. Dominguez, M.D., M.P.H.
3. Understand the Challenge of LGBTQ Adolescents of Color
Rashad Hardaway, M.D., James Murphy, M.D.
4. Gray, Gay, Black and Blue: Depression in Older LGBTQ People of Color
Seon Kum, M.D.

Undocumented and Refugee Children Arriving at U.S. Borders: Mental Health Issues and Treatment Interventions

American Association for Social Psychiatry

D 2

2:00 p.m. – 5:00 p.m.

Room A410, Level 4

Georgia World Congress Center

Chair:

Eugenio M. Rothe, M.D.

Discussant:

Pedro Ruiz, M.D.

1. Young Newcomers' Gritty Struggle to Safety
William Arroyo, M.D.
2. Briefing on Background and Challenges Presented to the U.S. Legal System Related to the Recent Migration of Youth and Children From Central America
Juan Carlos Gomez, Esq.
3. Undocumented and Refugee Children in South Florida: Past and Present and Lessons Learned
Eugenio M. Rothe, M.D.
4. Treatment for Undocumented Refugee and Immigrant Youth: Practice Parameter and Evidence-Based Approaches
Andres J. Pumariega, M.D.

Updates in HIV Psychiatry 2016

D 5

2:00 p.m. – 5:00 p.m.

Room B407, Level 4

Georgia World Congress Center

Chair:

Lawrence McGlynn, M.D., M.S.

Discussant:

Marshall Forstein, M.D.

1. Depression in Persons With HIV
Jordi Blanch
2. Prescribed Stimulants in HIV: Indications, Safety and Controversies
Lawrence McGlynn, M.D., M.S.
3. Tobacco and HIV: An Urgent Need to Take Action
Antoine Douaihy, M.D.
4. Compassionate Care of Transgender People Living With HIV
Yavar Moghimi, M.D.

3:30 p.m. Sessions

Lecture

Personal Transformations Through an Encounter With Death: A Study of Akira Kurosawa's "Ikiru"

APA Distinguished Psychiatrist Lecture Series

D

3:30 p.m. – 5:00 p.m.

Rooms A411-412, Level 4

Georgia World Congress Center

Lecture Chair:

Robert M. McCarron, D.O.

Lecturer:

Francis Lu, M.D.

Scientific and Clinical Reports

Further Topics in Schizophrenia

D 4 5

3:30 p.m. – 5:00 p.m.

Room B405, Level 4

Georgia World Congress Center

1. Fluctuation in Cognitive Functioning in Community-Dwelling Older Adults With Schizophrenia: Implications for Treatment
Carl I. Cohen, M.D.
4
2. Multiple Retinal Pathologies in Schizophrenia
Selin Acar, B.S.
5
3. The Missing Link: Role of Human Endogenous Retroviruses in Schizophrenia
Awais Aftab, M.B.B.S.
5

D This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

Workshops

Burnout in Resident Physicians: What Can We Do?

7 D

3:30 p.m. – 5:00 p.m.

Room B215, Level 2

Georgia World Congress Center

Chair:

Mahgul Malik, M.D.

Speaker:

Michal Sapieha, M.D.

Sex Ed: A Psychiatric Primer on Managing Patients' Sexual Behaviors

3

3:30 p.m. – 5:00 p.m.

Room A303, Level 3

Georgia World Congress Center

Chair:

Abhishek Jain, M.D.

Speakers:

Renee Sorrentino, M.D.

Ryan Hall, M.D.

Susan Joy Hatters-Friedman, M.D.

In Harm's Way: Job Stress and Mental Health in the Military

3:30 p.m. – 5:00 p.m.

Room A304, Level 3

Georgia World Congress Center

Chair:

Steven E. Pflanz, M.D.

Speaker:

Steven E. Pflanz, M.D.

Getting Back to Work: Guidance for Clinicians From an Employer Perspective

APAF Partnership Advisory Council

3:30 p.m. – 5:00 p.m.

Room B310, Level 3

Georgia World Congress Center

Chairs:

Paul Pender, Psy.D.

R. Scott Benson, M.D.

Designer Drugs, Legal Highs: Is It Really Plant Food and Bathing Salts?

1

3:30 p.m. – 5:00 p.m.
Room B311, Level 3
Georgia World Congress Center

Chair:

Roger Duda, M.D.

Speaker:

Tyler E. Stratton, M.D.

Smartphones, Sensors and Mobile Mental Health: Regulations, Research and Real Life

3:30 p.m. – 5:00 p.m.
Room B315, Level 3
Georgia World Congress Center

Chair:

John Torous, M.D.

Speakers:

Gregory G. Harris, M.D., M.P.H.
John Torous, M.D.
Jung W. Kim, M.D.
Shih Yee-Marie Tan Gipson, M.D.

Women at War: Medical and Psychological Challenges for U.S. Female Service Members

3:30 p.m. – 5:00 p.m.
Room B316, Level 3
Georgia World Congress Center

Chairs:

Elsbeth C. Ritchie, M.D., M.P.H.
Paulette Cazares, M.D., M.P.H.

Speakers:

Kate McGraw, Ph.D.
Paulette Cazares, M.D., M.P.H.
Elsbeth C. Ritchie, M.D., M.P.H.
Amy A. Canuso, D.O.

Responding to the Impact of Suicide on Clinicians

3:30 p.m. – 5:00 p.m.
Room B404, Level 4
Georgia World Congress Center

Chair:

Eric M. Plakun, M.D.

Speaker:

Jane G. Tillman, Ph.D.

Ethical Dilemmas in Psychiatric Practice

3:30 p.m. – 5:00 p.m.
Room A313, Level 3
Georgia World Congress Center

Chairs:

Ezra Griffith, M.D.
Richard K. Harding, M.D.


5:15 p.m. Session

Session

MindGames

5:15 p.m. – 6:15 p.m.
Room B206, Level 2
Georgia World Congress Center

















! SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
-  APA Annual Meeting on Demand
-  Bring Your Own Device

American Psychiatric Association Publishing
Visit the APA Bookstore in the Exhibit Hall
May 14-17, 2016

Bookstore Hours
 Saturday 9:00 am - 4:00 pm
 Sunday 10:00 am - 4:00 pm
 Monday 10:00 am - 4:00 pm
 Tuesday 10:00 am - 4:00 pm

Special Discounts!
 20% for APA Members
 25% for APA Resident-Fellow Members
 15% for Non-Members



psychiatryonline.org

Your Destination for Lifelong Learning in Psychiatry

Your one-stop resource for information on diagnosis, treatment, guidelines, the latest research, and breaking news from the field.

Visit the APA Bookstore for a demo!



Subscribe to products individually or to the DSM Select package that includes the DSM-5® library, books and select journals.

Go to www.appi.org to subscribe, or visit the APA Bookstore in the Exhibit Hall.



Wednesday

May 18, 2016



9:00 a.m. Sessions

Interactive Session

The Making of a Forensic Psychiatrist: Personal Reflections

9:00 a.m. – 10:30 a.m.

Room B408, Level 4

Georgia World Congress Center

Chair:

Phillip J. Resnick, M.D.

Lecture

VHA's Plan to Transform Veterans' Access to Community Care

9:00 a.m. – 10:30 a.m.

Rooms B216-217, Level 2

Georgia World Congress Center

Lecturer:

Baligh R. Yehia

Scientific and Clinical Reports

PTSD and Stress

4

9:00 a.m. – 10:30 a.m.

Room B405, Level 4

Georgia World Congress Center

1. Neural Alterations in Recalling the Past and Imagining the Future in PTSD

Adam Brown, Ph.D.

2. Pharmacological Treatment of Combat Nightmares: A Veteran's Hospital Experience

Mark Budd Detweiler, M.D., M.S.

4

3. Stress Across the Life Course and Depression in a Rapidly Developing Population: The Guangzhou Biobank Cohort Study

Michael Ni, M.B.B.S., M.P.H.

Workshops

The Interface of Ethics and Psychiatry: A Collaborative Consultation Approach

APA Ethics Committee and Penn-Scattergood Ethics Program

9:00 a.m. – 10:30 a.m.

Room B218, Level 2

Georgia World Congress Center

Chair:

Nancy N. Potter, Ph.D.

Speaker:

Rif S. El-Mallakh, M.D.

Slidecraft: How to Fashion Your Slide Presentation, Captivate and Resonate With Your Audience

9:00 a.m. – 10:30 a.m.

Room B306, Level 3

Georgia World Congress Center

Chairs:

Sunil Khushalani, M.D.

Mark Komrad, M.D.

Speaking for One's Self: Psychiatric Advanced Directives

3

9:00 a.m. – 10:30 a.m.

Room B310, Level 3

Georgia World Congress Center

Chairs:

Nubia G. Llubes Rincon, M.D.

Abhishek Jain, M.D.

Speaker:

John S. Rozel, M.D.

Combat-Related PTSD, Homicide and Attempted Suicide-by-Cop

3

9:00 a.m. – 10:30 a.m.

Room B311, Level 3

Georgia World Congress Center

Chairs:

Elspeth C. Ritchie, M.D., M.P.H.

Keith A. Caruso, M.D.

Speakers:

Elspeth C. Ritchie, M.D., M.P.H.

Keith A. Caruso, M.D.

Kevin D. Moore, M.D.

College Mental Health Practice: Adjusting for Seasonality, Setting and Scope of Services

APA College Mental Health Caucus

2

9:00 a.m. – 10:30 a.m.

Room B315, Level 3

Georgia World Congress Center

Chair:

Marshall L. Garrick, M.D.

Speaker:

Amy Poon, M.D.

Build a Skill: Interactive Screening, Brief Intervention and Referral to Treatment (SBIRT) Training to Enhance Clinical Practice

1

9:00 a.m. – 10:30 a.m.

Room B316, Level 3

Georgia World Congress Center

Chair:

Shilpa Srinivasan, M.D.

Speakers:

Suzanne M. Hardeman, N.P.

Matt Orr, Ph.D.

Shilpa Srinivasan, M.D.

SESSION TRACKS

- 1** Addiction Psychiatry
- 2** Child and Adolescent Psychiatry
- 3** Forensic Psychiatry
- 4** Geriatric Psychiatry
- 5** Psychosomatic Psychiatry
- 6** NIDA
- 7** Residents, Fellows and Medical Students
- D** APA Annual Meeting on Demand
- M** Bring Your Own Device

! Program changes are printed each day in the *APA Daily*, which is available at locations throughout the Georgia World Congress Center. Up to date program listings are also available and searchable in the APA Meetings app.

Explorations of Medical Students' Choice of Psychiatry as a Career

7

9:00 a.m. – 10:30 a.m.
Room B403, Level 4
Georgia World Congress Center

Chairs:

Leonard M. Galnik, M.D., Ph.D.
Mitchell J. Cohen, M.D.

Speakers:

Matthew N. Goldenberg, M.D., M.Sc.
Sergio Hernandez, M.D.
Peter J. Holland, M.D.
John Spollen, M.D.
Thomas L. Schwartz, M.D.

Addressing the Commercial Sexual Exploitation of Children

APA Council on Children, Adolescents and Their Families

2

9:00 a.m. – 10:30 a.m.
Room B404, Level 4
Georgia World Congress Center

Chair:

Shama Patel, M.D.

Speakers:

Eraka Bath, M.D., LL.B.
Yolanda P. Graham, M.D.
Jordan Greenbaum, M.D.

Learning Lab

Collaborative Care Lab: Experience the Newest Way to Practice

APA Council on Psychosomatic Medicine

5

9:00 a.m. – Noon
Rooms B211-212, Level 2
Georgia World Congress Center

Chairs:

Erik Vanderlip, M.D., M.P.H.
Lori Raney, M.D.

Speakers:

Anna Ratzliff, M.D., Ph.D.
Lydia Chwastiak, M.D., M.P.H.

Media Workshop

The Art of Storytelling

9:00 a.m. – Noon
Room B402, Level 4
Georgia World Congress Center

Chair:

Michelle Furuta, M.D.

Speakers:

Linda Do, D.O.
Arsalan Malik, M.D.
Steve Soldinger, M.D.
Mindi Thelen
Tim Thelen

Symposia

Consequences of Polypharmacy in Patients With Traumatic Brain Injury and Comorbid Psychological Health Conditions

5

9:00 a.m. – Noon
Room B308, Level 3
Georgia World Congress Center

Chair:

Geoffrey Grammer, M.D.

Discussant:

Linda Fuller, D.O.

1. Case Report of a Service Member With Severe Postconcussive Syndrome and Polypharmacy and Their Recovery Facilitated by Creative Art Therapy
Melissa Walker, M.A.
2. Polypharmacy Patterns in Active Duty Service Members With Traumatic Brain Injury and Comorbid Psychological Health Conditions
Thomas J. DeGraba, M.D.
3. Practice Guidelines and Meta-Analyses for Medication Management of Traumatic Brain Injury and PTSD
Jonathan P. Wolf, M.D.
4. Severe Medication Interactions Associated With Increased Morbidity in Service Members With Mild Traumatic Brain Injury and Comorbid Psychological Health Conditions
Christopher Flinton, M.D.

“High Tech” Solutions to Improving Interprofessional Communication and Patient Care in Integrated Psychosomatic Medicine Programs

5

9:00 a.m. – Noon
Room B309, Level 3
Georgia World Congress Center

Chair:

Sanjeev Sockalingam, M.D.

Discussant:

Susan Abbey, M.D.

1. Supporting HIV-Positive Women in Ways That Work
Adriana Carvalhal, M.D., Ph.D.
2. Experiencing the Unexpected: A Mixed Methods Study of Clinician Experiences Using a Novel Advanced Clinical Documentation iPad Tool in a Consultation-Liaison Psychiatry Setting
Kathleen Sheehan, M.D., Ph.D.
3. “There’s an App for That”: Using Mental Health Smartphone Applications in Integrated Care Settings
Raed Hawa, M.D.
4. An Integrated Telephone-Based CBT Intervention After Bariatric Surgery: A Model for Increasing Access
Sanjeev Sockalingam, M.D.

The Evolving Picture of ADHD

2

9:00 a.m. – Noon
Room B312, Level 3
Georgia World Congress Center

Chair:

Niall Boyce, Ph.D., M.B.

1. Clinical Care Pathways for ADHD
David Coghill, M.D.
2. The Genetic and Neural Basis of ADHD
Jonathan Posner, M.D.
3. ADHD as a Lifespan Disorder
Philip Asherson, Ph.D., M.B.B.S.

Building Capacity for Psychiatric Care and Research in Nigeria: Challenges and Opportunities for International Collaboration



9:00 a.m. – Noon

Room B314, Level 3

Georgia World Congress Center

Chairs:

Theddeus Iheanacho, M.D.

Charles C. Dike, M.D.

Discussant:

Shoyinka O. Sosunmolu, M.D.

1. Building Capacity for and Conducting Biomedical Research in Nigeria: Lessons Learned and Prospects
Ikwunga Wonodi, M.B.B.S.
2. Child Mental Health Care and Training in Child and Adolescent Psychiatry in Nigeria: Opportunities and Prospects
Patricia Ibeziako, M.D.
3. The Role of Health Services Research in Improving Access to Mental Health Care in Nigeria
Robert Rosenheck, M.D.
4. Mental Health in Nigeria: Suffering in the Midst of Plenty
Theddeus Iheanacho, M.D.
5. Psychiatry and the Law in Nigeria: Challenges and Prospects
Charles C. Dike, M.D.

Ethical Challenges at the Interface Between Psychiatry and Religion/Spirituality

APA Caucus on Religion, Spirituality and Psychiatry



9:00 a.m. – Noon

Room B401, Level 4

Georgia World Congress Center

Chair:

John Peteet, M.D.

1. Addressing Ethical Issues of Psychiatrists Who Respond to Emergencies and Disasters
Samuel Thielman, M.D., Ph.D.
2. Ethical Challenges at the Interface Between Psychiatry and Religion/Spirituality: Diagnostic Considerations
Allan Josephson, M.D.
3. Ethical Challenges of the Interface Between Psychiatry and Religion/Spirituality: Community and International Psychiatry
Walid Sarhan, M.D.
4. Ethical Considerations Regarding Religion/Spirituality in Psychiatric Research
Alexander Moreira-Almeida, M.D., Ph.D.
5. Religious/Spiritual Needs in Treatment
Len Sperry, M.D.

What Is the Emotional Pain of Suicide?



9:00 a.m. – Noon

Room B406, Level 4

Georgia World Congress Center

Chair:

Igor Galynker, M.D., Ph.D.

1. The Measurement of Psychological Pain and Suicide Risk
Gregory K. Brown, Ph.D.
2. Anxiety Severity as an Acute Risk Factor for Suicide
Jan Fawcett, M.D.
3. Reward- and Threat-Processing Contributions to Suicidality
Zimri S. Yaseen, M.D.
4. Negative Emotions Predictive of Near-Term Suicidal Behavior
Igor Galynker, M.D., Ph.D.

11:00 a.m. Sessions

Scientific and Clinical Reports

Cross-Cultural Psychiatry



11:00 a.m. – 12:30 p.m.

Room B405, Level 4

Georgia World Congress Center

1. Evidence-Based Psychiatric Rehabilitation Practices: Illness Management and Recovery, Psychoeducation, and Case Management in Karachi, Pakistan
Ajmal Kazmi, M.D., D.P.M.
2. A Comparison of Stigma in Dementia and Diabetes Among Chinese Americans
Benjamin Woo, M.D.



Workshops

Creating a Leadership Development Program to Prepare Your Department/Organization to Successfully Navigate Turnover of Key Leadership Positions

11:00 a.m. – 12:30 p.m.

Room B310, Level 3

Georgia World Congress Center

Chair:

Kari M. Wolf, M.D.

Speaker:

Jane Ripperger-Suhler, M.D., M.A.

VitalSign6: Partnering With Primary Care Providers in Using Innovative Software to Implement Universal Depression Screening and Measurement-Based Care

11:00 a.m. – 12:30 p.m.

Room B315, Level 3

Georgia World Congress Center

Chairs:

Manish K. Jha, M.B.B.S.

Madhukar Trivedi, M.D.

Speakers:

Madhukar Trivedi, M.D.

Manish K. Jha, M.B.B.S.

Katherine Sanchez, Ph.D., L.C.S.W.

Tracy Greer, Ph.D.



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device

The Transcultural Competent Psychiatrist: Characteristics, Challenges and Abilities

11:00 a.m. – 12:30 p.m.

Room B316, Level 3
Georgia World Congress Center

Chair:

Hamid Peseschkian, M.D., D.M.Sc.

Speakers:

Hamid Peseschkian, M.D., D.M.Sc.
Afrim A. Blyta, M.D.
Jusuf S. Ulaj, M.D.

LGBT in the Military

11:00 a.m. – 12:30 p.m.

Room B403, Level 4
Georgia World Congress Center

Chairs:

Christopher H. Warner, M.D.
Carl Castro, Ph.D.

Speakers:

Jeremy Goldbach, Ph.D.
Ian W. Holloway, Ph.D., M.P.H.

Psychology Prescription Privileges: The Illinois Experience

11:00 a.m. – 12:30 p.m.

Room B404, Level 4
Georgia World Congress Center

Chair:

Daniel Yohanna, M.D.

Speakers:

Peter Fore, M.D.
Linda F. Gruenberg, D.O.
Sidney Weissman, M.D.
James G. MacKenzie, D.O.



This session will be captured as part of APA Annual Meeting On Demand, subject to speaker permission. Visit the On Demand sales booth in the Education Center to learn more and purchase.

1:30 p.m. Sessions

Scientific and Clinical Reports

Mental State Disorders



1:30 p.m. – 3:00 p.m.

Room B405, Level 4
Georgia World Congress Center

1. Anxiety Disorders Co-Occurring With Binge Eating Disorder: Sequence and Associations With Other Comorbidities and With Eating Disorder Psychopathology
Daniel F. Becker, M.D.
2. Does Negative Emotional Temperament Link Both PUFA Concentrations and Childhood Adversity to Persistent Depressive Symptoms?
William Coryell, M.D.



3. Postpartum Depression, Maternal Acceptance-Rejection and Child Behavioral Problems in Early Childhood
Miriam Schiff, Ph.D.



Workshops

Working With African Immigrant Adolescents and Young Adults: From the Experts



1:30 p.m. – 3:00 p.m.

Room B306, Level 3
Georgia World Congress Center

Chairs:

Tolu Olupona, M.D.
Evaristo Akerele, M.D.

What We've Learned From Genetic Obesity Syndromes: Are Overweight/Obesity, Anorexia Nervosa, Bulimia Nervosa and Binge Eating Disorder So Dissimilar?



1:30 p.m. – 3:00 p.m.

Room B310, Level 3
Georgia World Congress Center

Chair:

Janice Forster, M.D.

Speakers:

Janice Forster, M.D.
Nicolette Weisensel, M.D.

Serving the Household and the Homeless: Behavioral Health-Primary Care Integration in Two Health Care Models Focused on Social Determinants of Health

1:30 p.m. – 3:00 p.m.

Room B311, Level 3
Georgia World Congress Center

Chair:

Eduardo Camps-Romero, M.D.

Speakers:

Frederick Anderson, M.D.
Mohammad Asim Nisar, M.D.
Carissa Caban-Aleman, M.D.

Transformation of Mental Health Care for U.S. Soldiers and Families During the Iraq and Afghanistan Wars: Where Science and Politics Intersect

1:30 p.m. – 3:00 p.m.

Room B315, Level 3
Georgia World Congress Center

Chair:

Christopher H. Warner, M.D.

Speakers:

Millard Brown, M.D.
Christopher Ivany, M.D.
Charles Hoge, M.D.

Foreign Body Ingestors: Management Challenges for Consultation Liaison Psychiatrists



1:30 p.m. – 3:00 p.m.

Room B403, Level 4
Georgia World Congress Center

Chair:

Elias Khawam, M.D.

Speakers:

Syma Dar, M.D.
Margo Funk, M.D., M.A.
Karen E. Salerno, M.S.W.
Lara W. Feldman, D.O.
Christopher Sola, D.O.

2:00 p.m. Sessions

Symposia

Health Policy and Social Justice: The Role of Psychiatry in Promoting Integrated Health Care



2:00 p.m. – 5:00 p.m.

Room B309, Level 3

Georgia World Congress Center

Chair:

Howard J. Osofsky, M.D., Ph.D.

Discussant:

John M. Oldham, M.D., M.S.

1. Innovative Academic-Community Partnerships to Address Special-Population Mental Health Needs
Laura Roberts, M.D., M.A.
2. The Critical Role of Public Education in Patient-Centered Collaborative Care
Eugene V. Beresin, M.D., M.A.
3. The Role of Psychiatry in Advancing Integrated Care for Underserved and Rural Populations
Howard J. Osofsky, M.D., Ph.D.

Your Patient at Work: Privacy, Peril and Public Safety



2:00 p.m. – 5:00 p.m.

Room B401, Level 4

Georgia World Congress Center

Chair:

Jessica Ferranti, M.D.

Discussant:

Charles Scott, M.D.



SESSION TRACKS

- 1 Addiction Psychiatry
 - 2 Child and Adolescent Psychiatry
 - 3 Forensic Psychiatry
 - 4 Geriatric Psychiatry
 - 5 Psychosomatic Psychiatry
 - 6 NIDA
 - 7 Residents, Fellows and Medical Students
- APA Annual Meeting on Demand
- Bring Your Own Device

1. Persons With Mental Illness at Work: Are They More Violent?

Jessica Ferranti, M.D.

2. Fundamental Foundation of Risk Assessment

Jason Roof, M.D.

3. How to Handle At-Risk Scenarios

Charles Scott, M.D.

Online Psychotherapy: A New Method of Delivering Therapy



2:00 p.m. – 5:00 p.m.

Room B406, Level 4

Georgia World Congress Center

Chair:

Nazanin Alavi, M.D.

1. CBT by Email for Children and Adolescents With Anxiety/Depression
Sarosh Khalid-Khan, M.D.
2. CBT by Email in Patients With Depression and/or Anxiety
Nazanin Alavi, M.D.
3. Dialectical Behavior Therapy (DBT)? There Is an App for That!
Margo Rivera

3:30 p.m. Sessions

Scientific and Clinical Reports

The Broad Interest of Psychiatry



3:30 p.m. – 5:00 p.m.

Room B405, Level 4

Georgia World Congress Center

1. Undocumented Immigrants in Psychiatric Wards: A Case Report and Concise Review
Mike Wei, B.S.
2. Normalization of Increased Background Noise After Treatment in ADHD: A Neuronal Correlate
Emanuel Bubl, M.D.
3. Motivational Interviewing Education and Psychiatry Residents' Attitude Toward Addiction Training and Treatment
Manish K. Jha, M.B.B.S.



Workshops

Don't Tell Me to Calm Down! Identifying Triggers and Nonpharmacological Management of Child and Adolescent Patients at Risk for Agitation



3:30 p.m. – 5:00 p.m.

Room B306, Level 3

Georgia World Congress Center

Chairs:

Chase Samsel, M.D.

Ronke L. Babalola, M.D., M.P.H.

Speaker:

Sally Nelson, M.Ed., R.N.

Accelerated Resolution Therapy: A "Magic Bullet" for PTSD?

3:30 p.m. – 5:00 p.m.

Room B310, Level 3

Georgia World Congress Center

Chairs:

Wendi Waits, M.D.

Megan Marumoto, M.D.

Research Literacy in Psychiatry: How to Critically Appraise the Scientific Literature

3:30 p.m. – 5:00 p.m.

Room B311, Level 3

Georgia World Congress Center

Chair:

Diana E. Clarke, Ph.D., M.Sc.

Speakers:

Diana E. Clarke, Ph.D., M.Sc.

Farifteh F. Duffy, Ph.D.

Engaging the Unengaged Patients With Severe Mental Illnesses: Community-Based Cross-Cultural Experiences From India and Canada

3:30 p.m. – 5:00 p.m.

Room B403, Level 4

Georgia World Congress Center

Chairs:


Nitin Gupta, M.D.

Amresh Shrivastava, M.D.





The DSM-5 Collection



Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5®)

American Psychiatric Association

This new edition of *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5®), used by clinicians and researchers to diagnose and classify mental disorders, is the product of more than 10 years of effort by hundreds of international experts in all aspects of mental health. Their dedication and hard work have yielded an authoritative volume that defines and classifies mental disorders in order to improve diagnosis, treatment, and research.

The criteria are concise and explicit, intended to facilitate an objective assessment of symptom presentations in a variety of clinical settings—inpatient, outpatient, partial hospital, consultation-liaison, clinical, private practice, and primary care.

- The latest findings in neuroimaging and genetics have been integrated into each disorder along with gender and cultural considerations.
- The revised organizational structure recognizes symptoms that span multiple diagnostic categories, providing new clinical insights in diagnosis.

- Both ICD-9-CM and ICD-10-CM codes are included for each disorder.

The *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition, is the most comprehensive, current, and critical resource for clinical practice available to today's mental health professionals.

2013 • 991 pages • ISBN 978-0-89042-554-1 • Hardcover • \$205.00 • Item #2554

2013 • 991 pages • ISBN 978-0-89042-555-8 • Paperback • \$155.00 • Item #2555

2013 • 991 pages • ISBN 978-0-89042-557-2 • eBook • \$124.00 • Item #2557



Focus

The Journal of Lifelong Learning in Psychiatry


Visit Focus Booth #1528 or the APA Bookstore to subscribe!

**The Best Resource for
Guidance for Clinical Practice • Lifelong Learning
Maintenance of Certification • Self-Assessment**

In four issues, a quarterly subscription to **Focus** provides a review of current clinical practice based on the content outlined by the ABPN recertification exam.

A subscription offers:

- New articles that brief you on new developments and review the current state of practice.
- Features designed to improve your ability to evaluate, diagnose, and manage clinical problems; communicate with your patients; and handle ethical dilemmas.
- Curation of the publications that have shaped the thinking in the field, with some reprinted in the issue itself.
- Quizzes that allow you to earn up to five *AMA PRA Category 1 Credits™* by completing CME credits for each issue—for a total of up to 20 credits per year.
- An annual 120-question self-assessment exam for 24 self-assessment CME credits—with the opportunity to anonymously compare your results against those of your peers.
- Online access to current and back issues with CME credits available only for your subscription year.



CONFERENCE DISCOUNT

\$50 off subscription price
Valid May 14-17, 2016

Focus covers core clinical areas:

- Volume XI (2013): Geriatric Psychiatry; Personality Disorders; Posttraumatic Stress Disorder and Traumatic Brain Injury; Integrated Care and Psychosomatic Medicine
- Volume XII (2014): Sleep: New Biologies and New Therapies; Psychopharmacology; Psychotherapies; Eating Disorders
- Volume XIII (2015): Bipolar Disorders; Obsessive Compulsive Disorders; Substance-Related and Addictive Disorders; Psychiatry and Society
- Volume XIV (2016): Child and Adolescent Psychiatry; Depression; Schizophrenia; Neuropsychiatry

With your paid subscription, you'll also get unlimited online access to all past volumes at no extra charge.

(CME for past volumes not included.) **Focus gives you the opportunity to earn 44 or more AMA PRA Category 1 Credits™ per year.**

One-Year Prices: U.S. APA Members: ~~\$394~~ **\$344** APA International Member: ~~\$495~~ **\$445** APA Resident-Fellow Member (Online Only): ~~\$128~~ **\$78**
 Non-Member price: ~~\$616~~ **\$566** International Non-Members: ~~\$733~~ **\$683**

The American Board of Psychiatry and Neurology (ABPN) has reviewed **Focus: The Journal of Lifelong Learning in Psychiatry** and the **Focus Self-Assessment Examination** and has approved this program as part of a comprehensive lifelong learning and self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification ABPN has reviewed and approved each of the following Focus Performance in Practice clinical chart review tools for ABPN MOC Part 4 (clinical module) requirements for Improvement in Medical Practice:

- *Screening for Adults with Substance Use Disorder*
- *Assessment and Treatment of Adults with Substance Use Disorder*
- *Assessment and Treatment of Adults at Risk for Suicide and Suicide-Related Behaviors*
- *Physician Practice Assessment Tool for the Care of Adults with Schizophrenia*

- *Clinical Module for the Care of Patients with Major Depressive Disorder*
- *Clinical Module for the Care of Patients with Posttraumatic Stress Disorder*

The Focus Self Assessment Examination is approved for up to 24 hours of continuing professional development per year under Section 3 of the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Psychiatric Association designates this journal- based CME activity for a maximum of 44 *AMA PRA Category 1 Credits™*.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Self-Assessment CME programs listed below have been reviewed and are approved for a maximum of 24 AAPA Category 1 Self-Assessment CME credits by the Physician Assistant Review Panel. Approval is valid until the expiration date listed below.

Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity. These programs were planned in accordance with AAPA's CME Standards.

*FOCUS Self-Assessment Exam Volume XI (2013) – Expires 10/31/2016
FOCUS Self-Assessment Exam Volume XII (2014) – Expires 10/31/2017*

focus.psychiatryonline.org

Priority Code AH1622A

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
1-800-368-5777
appi@psych.org

New Research

Poster Session 1, Saturday, May 14	152
Poster Session 2, Saturday, May 14	157
Poster Session 3, Sunday, May 15	161
Poster Session 4, Sunday, May 15	162
Poster Session 5, Monday, May 16	163
Poster Session 6, Monday, May 16	166
Poster Session 7, Tuesday, May 17	171
Poster Session 8, Tuesday, May 17	174
New Research Topic Index	180



1

Poster Session 1
Saturday, May 14Medical Student-
Resident
Competition Poster 1

10:00 A.M. – Noon

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

P1-001

Clinical Characteristic of Synthetic Cannabinoid Users Admitted to the Inpatient Psychiatric Service

*Sabina Fink, M.D.***P1-002**

A Unique Case of Post-Electroconvulsive Therapy Status Epilepticus

*Sameera Guttikonda, M.D.***P1-003**

Combined Loxapine and Cyproheptadine Limits Clozapine Rebound Psychosis and May Also Predict Clozapine Response

*Lila Aboueid, D.O.***P1-004**

Body Snatchers: The Neuropsychiatry of the Capgras Delusion

*Caitlin Adams, M.D.***P1-005**

Demoralization: Two Cases From a Cancer Center Setting and Literature Review

*Crispa Aeschbach Jachmann, M.D.***P1-006**

Geriatric Olfactory Reference Syndrome Responding to Duloxetine: Case Report and Literature Review

*Awais Aftab, M.B.B.S.***P1-007**

Rare Clinical Manifestation of Neurosyphilis: Role of Psychiatrists and Importance of a Routine Screening Test

*Saba Afzal, M.D.***P1-008**

Case Report on Munchausen Syndrome

*Fariha Afzal, M.B.B.S.***P1-009**

The Presentation of Somatic Delusions in the Setting of Lyme Disease: A Case Report and Literature Review

*Ammar Y. Ahmad, M.D.***P1-010**

Cyber-Mania in Bipolar Disorder

*Saeed Ahmed, M.D.***P1-011**

Can Bullying Lead to Development of Dissociation Identity Disorder?

*Sameerah Akhtar, M.D.***P1-012**

Somatic Delusions in Psychosis

*Sameerah Akhtar, M.D.***P1-013**

Medication-Induced Myoclonus: A Case Report

*Ahmed Albassam, M.D.***P1-014**

Dissociative Rage: Fact or Myth?

*Arshad Ali, M.D.***P1-015**

Treatment of Pseudobulbar Affect With Bupropion: Case Report

*Safa Al-Rubaye, M.D.***P1-016**

Does Time Heal All Wounds? A Case of First-Time Manic Episode and Bereavement

*Tarek Aly, M.D.***P1-017**

Alprazolam-Induced Rhabdomyolysis Associated With Buprenorphine-Naloxone Maintenance Therapy

*Tarek Aly, M.D.***P1-018**

Erotic Hypoglycemia? A Patient With Multiple Episodes of Insulin Overdose for Euphoric Experience

*Ritesh Amin, M.D.***P1-019**

Aripiprazole Treatment for Hallucinations in a Patient With PTSD

*Aaron K. Andersen, D.O.***P1-020**

Treatment of Mania Secondary to HIV

*Yohanis L. Anglero Diaz, M.D.***P1-021**

Interesting Case Highlighting Typical Antipsychotic-Induced Depression and Olanzapine-Fluoxetine-Induced Mania

*Darinka Aragon, M.D.***P1-022**

Influenza-Induced Mania

*Shehzad Ayub, D.O.***P1-023**

Lithium Toxicity in a Bariatric Surgery Patient: A Case Report

*Shahana Ayub, M.D.***P1-024**

Takotsubo Cardiomyopathy: Rare Cardiac Syndrome Linked to Neuropsychiatric Illness

*Shahana Ayub, M.D.***P1-025**

Synthetic Cannabinoid Use in Pregnancy: A Case Report and Literature Review

*Mallikarjuna Bagewadi Ellur, M.D.***P1-026**

Trazodone-Induced Nightmares

*Nicholas P. Basalay, M.D.***P1-027**

Schizoaffective Disorder and Comorbid Bartter Syndrome: A Case Report

*Jessica S. Bayner, M.D.***P1-028**

Case Report: Five Supplements and Multiple Psychotic Symptoms

*Robert G. Bota, M.D.***P1-029**

Late-Onset Bipolar Disorder: A Case Report and Literature Review

*Matthew Boyer, B.A.***P1-030**

Synthetic Cannabis: Diverse Case Presentations, Literature Review, and Treatment Modalities and Recommendations in the Adolescent Population

*Dakota Carter, M.D.***P1-031**

Childhood Functional Abdominal Pain Syndrome

*Amarsha Chakraborty, M.D.***P1-032**

Case Report: Renal Transplantation in a Patient With Schizoaffective Disorder, Bipolar Type

Monika Chaudhry, M.D.

P1-033

Challenges in Diagnosing Factitious Disorder: A Case Report
Raminder Pal Cheema, M.D.

P1-034

Clozapine-Induced Tachycardia: Clinical Considerations
Yon J. Chong, M.D., M.P.H.

P1-035

Self-Induced DKA in a Patient With Diabetes Type 1 and Anorexia Nervosa With Comorbid Depression and Anxiety: A Case Report
Mehak Chopra, D.O.

P1-036

Marchiafava-Bignami Disease (MBD) and Diffusion Tensor Image (DTI) Tractography
Priscilla N. Chukwueke, M.D., M.P.H.

P1-037

Olfactory Reference Syndrome: A Case Series Demonstrating Different Underlying Pathologies Manifesting With Similar Signs and Symptoms
Frank Breckenridge Chumley, M.D.

P1-038

Leptomeningeal Carcinomatosis Presenting Primarily as Psychosis
Wilson Chung, D.O.

P1-039

A Case Report of Namenda (Memantine) Use in ADHD
Omar A. Colon, M.D.

P1-040

“Scary Thoughts” and Pregnancy: A Case Series and Literature Review
Shalini D. Dave, D.O.

P1-041

Observed Difference Between Intramuscular and Oral Lorazepam for Treatment of Catatonia: A Case Report and Literature Review
Andrew Davidowitz, M.S.

P1-042

Reemergence of Adult Onset PICA: A New Presentation of an Old Problem
Deepak M. Davidson, M.D.

P1-043

Visualizing Pharmacodynamic Interactions: PRN Medications Can Be a Window to Drug Interactions
Arashinder Dhaliwal, M.D.

P1-044

Anti-N-Methyl-D-Aspartate Receptor Encephalitis Presenting as an Emerging Culprit for Conversion Disorder: An Adolescent Case Report
Swati Divakarla, M.D.

P1-045

A Rare Case of Wrist Fracture Resulting From Electroconvulsive Therapy: A Case Report
Erin Dooley, M.D.

P1-046

Visualization of Medication Response in the Long-Term Institutionalized Mentally Ill Utilizing PSYCKES Data
Ammar El Sara, M.D.

P1-047

Psychiatric Comorbidities With CHARGE Syndrome: A Case Report
Rasha Elkady, M.D.

P1-048

Refractory Psychosis in a Patient With Mega Cisterna Magna
Narissa R. Etwaroo

P1-049

The Case of a “Queer Heterosexual”: Exploring the Concept of ‘Mostly Heterosexuals’ and Their Unique Experiences of Mental Illness
Alec Faggen

P1-050

Absent Septum Pellucidum and Gray Matter Heteropia in a Patient With MDD With Psychotic Features and Intractable Epileptic Seizures: A Case Report
Mobeen Farooq

P1-051

Improvement of Catatonia After Cardiac Arrest
Michael Peroski, D.O.

P1-052

Intentional Ingestion: A Case Series Regarding Swallowing of Foreign Objects: Treatment Alternatives
Suhey G. Franco Cadet, M.D.

P1-053

Sleep State Misperception or Subjective Insomnia in Patients With Depression and Anxiety: A Case Report
Suhey G. Franco Cadet, M.D.

P1-054

The Role of Amantadine Withdrawal in Treatment-Refractory Altered Mental Status
Leah D. Fryml, M.D.

P1-055

Recurrent Priapism Associated With Olanzapine Treatment: Case Report
Emily Fu, M.D.

P1-056

Electroconvulsive Therapy in a Patient With Moyamoya Syndrome
Erica Ghignone, M.D., M.A.

P1-057

“Do No Harm”: Ethical Implications of Treating Psychosis in Two Patients With Delusional Denial of Insulin-Dependent Diabetes Mellitus (IDDM)
Deepti Ghiya, M.D.

P1-058

Anxiety Treatment Improves Lichen Simplex Chronicus
Amy C. Gomez Fuentes, M.D.

P1-059

Let’s Build Bridges and Not Walls: For Bridge-to-Transplantation: The Power of Effective Doctor-Patient Communication in Patients With LVAD Implant
Arpita Goswami Banerjee, M.D.

P1-060

Acute Psychosis Associated With Septo-Optic Dysplasia (de Morsier Syndrome)
Dharmendra K. Goyal, M.B.B.S.

P1-061

The Contribution of Childhood Attachment Failure to Development of Borderline Personality Disorder in Adulthood: A Case Report and Literature Review
Neha Gupta, M.D.

P1-062

Substance-Induced Psychosis Versus Substance Withdrawal: A Case Report and Discussion of Treatment Approach and Diagnostic Framework
Pranathi Mruthyunjaya, M.D.

P1-063

SLE-Induced Mania and Psychosis: A Case Report
Pranathi Mruthyunjaya, M.D.

P1-064

The Thyroid Connection: A Case of New Onset Psychosis
Najma F. Hamdani, M.D., M.H.A.

P1-065

Safety Precautions for a Psychotic Patient With PICA on the Inpatient Service

Amina Hanif, M.D.

P1-066

A Case of Laryngeal Dystonia in a Young Male Receiving Paliperidone Palmitate

Shariq Haque, M.D.

P1-067

A Case Report of Adderall-Induced Bizarre Delusions

Michael R. Harrigan, M.D., M.B.A.

P1-068

A Case of Mistaken Identity: When Organic Pathology Is Thought to Be Psychological in Origin

Christopher Harris, D.O.

P1-069

Psychiatric Manifestations Co-Occurring in a Father-Son Pair With Waardenburg Syndrome

Joseph Hart, B.A.

P1-070

Exploring Staff Issues for Child Transgender Patients in the Child Psychiatric Inpatient Unit: A Case Report

Rabiya Hasan, M.D.

P1-071

Fatal Multi-Organ Failure From Diphenhydramine Overdose

Vineka Heeramun, M.D.

P1-072

Seizures Dismissed as Pseudoseizures

Vineka Heeramun, M.D.

P1-073

Use of Clozapine in a Chronic Schizophrenic During Induction Chemotherapy and Stem Cell Transplant: Anticipatory Measure to Consider

Umair M. Hemani, D.O., M.S.

P1-074

Case Report of Aripiprazole Use in the Treatment of Adolescent Stuttering

Julia L. Hoang, M.D.

P1-075

Brown Sugar: A Case of Opiate-Induced Paralytic Ileus

M. Daniel Holsey, D.O.

P1-076

“This Is Serious”: Delay in Cancer Treatment in a 70-Year-Old Female With Delusional Parasitosis: A Case Report

Avjola Hoxha, M.D.

P1-077

Challenges in the Management of Psychosis in Teenage Pregnancy: A Case Report and Review of Literature

Geeta S. Ilipilla, M.D.

P1-078

Rapid Development of Pulmonary Emboli Two Days After Onset of Catatonic Symptoms: A Case Report and Literature Review

Danielle Ivanova, D.O.

P1-079

Elopement in Autism Spectrum Disorders (ASD) and Evolving Case Presentations: A Case Report and Review

Veeraraghavan J. Iyer, M.D., M.B.B.S.

P1-080

The “Caitlyn Jenner” Effect

Robert J. H. Johnston, M.D.

P1-081

Use of Ketamine Infusion in Chronic Refractory Depression and Pain: A Case Report

Travis W. Jones, M.D.

P1-082

Anti-NMDA Receptor Encephalitis: From Love to Madness

Courtney Joseph, D.O.

P1-083

Clozapine-Induced Sialorrhea and Incontinence of Bowel and Bladder

Astik Joshi, M.D.

P1-084

Novel Psychiatric Disorders (NPD): Pediatric Bipolar and Obsessive Compulsive Disorder (OCD) After Traumatic Head Injury

Rajasekhar Kannali, M.D.

P1-085

A Case of Psychosis in a Patient With Grave’s Disease and Hashimoto’s Disease

Vandana Kethini, M.D.

P1-086

Broken Heart Syndrome: A Case of Takotsubo Cardiomyopathy in a Female Presenting With Bereavement

Mohsin Khan, M.D.

P1-087

To Feed or Not to Feed? The Moral Dilemma of Feeding a Patient With Treatment Refractory Depression Who Refuses to Eat

Surbhi Khanna, M.B.B.S.

P1-088

Levofloxacin-Induced Delirium and Acute Psychosis: A Clinical Case Report

Jyotsna Kilani, M.D.

P1-089

Delirious Mania in Bipolar Disorder: A Case Report

Tyler Kimm, M.D.

P1-090

Borderline Personality Disorder in the Geriatric Patient: Remission and Relapse

Benjamin O. Klass, M.D.

P1-091

Educating a Geriatric Patient About Somatic Symptom Disorder: A Resident’s Challenge

Kavita Kothari, M.B.B.S.

P1-092

Minimal Hepatic Encephalopathy Presenting as Psychosis

Kristina E. Kurtz, D.O.

P1-093

Coprolalia as a Presentation of Severe Aphasia Status Post-CVA: A Case Report

Audrey La Noce, D.O.

P1-094

Double Trouble: A Case of Kleine-Levin Syndrome in an Adolescent Female After a Road Traffic Accident

Jasmin G. Lagman, M.D.

P1-095

Malignant Catatonia in a Patient With Hydrocephalus Responsive to Electroconvulsive Therapy (ECT)

Hank Lai, M.D.

P1-096

WITHDRAWN

P1-097

Testimonial Therapy in Latin American Survivors of Intimate Partner Violence: Implications for the Application of a Transcultural Therapeutic Ritual

Pooja Lakshmin, M.D.

P1-098

Topiramate-Induced Psychosis

Camilo Leal, M.D.

P1-099

Making the Covert Overt: Fine Grain Analysis of Medication History Can Reveal Effective Treatments, Recognize Problems and Improve Care

Jacob Leivent, M.D.

P1-100

The Impact of High Expressed Emotion and the Environment on Twins With the Development of Psychosis in One

William Levitt, M.D.

P1-101

A Tale of Two Brothers: Psychosis, Suicidality, Homicidality and Substance Abuse

William Levitt, M.D.

P1-102

A Curious Case of Capgras: The Psychodynamic and Neurocognitive Approaches to Capgras Syndrome

William Levitt, M.D.

P1-103

A Case of Sertraline-Induced Vaginal Hemorrhagia

William Levitt, M.D.

P1-104

Early Recognition of Tricyclic Antidepressant Overdose: A Case Report

Kevin J. Li

P1-105

Decoding Detox: Troubling Interactions Between Aripiprazole and Over-The-Counter Dietary Supplements

Max A. Lichtenstein, M.D.

P1-106

Citalopram and Escitalopram: Adverse Cardiac Outcomes in Medically Ill Inpatients

Artin Mahdanian, M.D.

P1-107

Pulmonary Embolism in Catatonia: Assessing Risk in Specific Populations in the Inpatient Setting: A Case Report

Mario Mangiardi, M.D.

P1-108

A Case Report of Mania in a Patient During Aripiprazole Treatment

Adeyemi Marcus, M.D.

P1-109

A Bad Trip From "The Bomb": A Case Report

Gloria Martz, D.O.

P1-110

Case Report: Irregular Menses and PMS Alleviated With the Use of Bupirone

Syed E. Maududi, M.D.

P1-111

The Potential Therapeutic Role of Oxytocin in Autism Spectrum Disorder Patients

Syed E. Maududi, M.D.

P1-112

Decreasing Morbidity Through Early Detection of Clozapine-Induced Cardiotoxicity: A Case Report

Shawn E. McNeil, M.D.

P1-113

Differential Diagnosis in Patients With Psychosis: A Case of Hypothyroidism-Induced Mental Disorder

Tomas Melicher, M.D.

P1-114

Snakes in the Hospital

Amit Mistry, M.D.

P1-115

Postictal Psychosis: Recognition and Impact on Long-Term Psychological Care

Paroma Mitra, M.D., M.P.H.

P1-116

SSRI-Induced Sleep Paralysis

Raja Mogallapu, M.D.

P1-117

Hyperosmolar Hyperglycemic State With Olanzapine: A Case Report and Review of Literature

Lauren E. Moore, M.D.

P1-118

Lisdexamfetamine for the Treatment of Binge Eating Disorder: A Case Report and Literature Review

Maria E. Moreno, M.D.

P1-119

Assessment of Decision Making Capacity in a Psychiatric Patient: A Common Myth

Sahil Munjal, M.D.

P1-120

Bupropion-Induced Hyponatremia: A Case Report and Literature Review

Sahil Munjal, M.D.

P1-121

Psychiatric Sequelae of Urea Cycle Disorders: A Case Report and Literature Review

Dewey S. Murphy, M.D.

P1-122

Diabulimia: A Case Report and Literature Review on a Rare and Unusual Eating Disorder

Trenton Myers, M.D.

P1-123

Undiagnosed Trauma in Severe Mentally Ill Patients

Vahid Nikzad, M.D.

P1-124

PTSD After a BERT Alert in a Patient With Acute MI and a Past History of Depression

Abhishek R. Nitturkar, M.B.B.S.

P1-125

Recall of Delusions During Delirium Related to Development of PTSD After Delirium in the ICU: A Case Report

Abhishek R. Nitturkar, M.B.B.S.

P1-126

Multi-Modal Approach to Management of Reflex Sympathetic Dystrophy: A Case Report

Vincent N. Nwankwo, M.B.B.S.

P1-127

Mental Health Considerations in the GI Patient: Reclassifying Diagnosis of Functional GI Complaints

Andrew Owen, M.S.

P1-128

Educating a Schizophrenic Patient About MET: Challenges of Starting on the Inpatient Unit

Ronak Patel, M.D.

P1-129

Treatment of Catatonic Syndrome in Bipolar Disorder With Aripiprazole

Mitesh Patel, M.D.

P1-130

Usher's Syndrome and Psychopathology: A Case Report

Irina Chikvashvili, D.O.

P1-131

Very Late Onset Schizophrenia-Like Psychosis: A Case Study

Markian Pazuniak, M.D.

P1-132

Case Report: Tactile Hallucinations: An Atypical Presentation of Creutzfeldt-Jakob Disease

Luis Pereira, M.D.

P1-133

The Psychedelic Renaissance in Psychiatry: An Evidence-Based Review

Kimia Pourrezaei, D.O.

P1-134

Role of Inflammatory Cytokines and a New Outlook on Pathophysiology and Treatment Modalities in Bipolar Disorder

Rumana Rahmani, M.D.

P1-135

Antisocial Personality Disorder: Where and How Should We Manage These Patients?

Rumana Rahmani, M.D.

P1-136

Clozapine Use in HIV-Positive Refractory Schizophrenia Patients: Where Does Filgrastim Fit in?

Anupriya Razdan, M.B.B.S.

P1-137

Foreign Accent Syndrome (FAS) Presenting as Conversion Disorder: A Rare Presentation

Abhishek Reddy, M.D.

P1-138

The Stalker Who Became Her Own Victim: A Case and Literature Review on Stalking Phenomenology

Sonia Riyaz, M.D.

P1-139

Six Ways to Die: A Case Report of a High-Lethality Multi-Method Suicide Attempt

Diana Mungall Robinson, M.D.

P1-140

Atypical Mania Presentation: Was It Caused by Corticosteroids, a Mycoplasma Infection or Just Late Onset Bipolar Disorder?

Laura Rodriguez-Roman, M.D.

P1-141

Ritualistic Behavior Leading to Long-Term Hospitalization in Patients With Schizoaffective Disorder

Daniel O. Roman, M.D.

P1-142

Refractory Catatonia: Role of N-Methyl-D-Aspartic Acid Antagonist

Kamalika Roy, M.D.

P1-143

Negative Countertransference in Borderline Personality Disorder: Case Report, Literature Review and Treatment Recommendations

Kruthika Sampathgiri, M.D.

P1-144

A Case of a Patient With K2 Use Presenting With Prolonged Delirium

Eric Santos, M.D.

P1-145

Case Report of Neutropenia in a Patient Diagnosed With Schizophrenia and Treated With Lurasidone

Ayesha Sattar, M.D., M.B.B.S.

P1-146

Case Report of "Folie a Deux" Between Two Sisters

Adam H. Schindzielorz, M.D.

P1-147

Foreign Accent Syndrome as an Under-Recognized Manifestation of Chronic Psychological Trauma

Alexis A. Seegan, M.D.

P1-148

The Case of the Bright Splenium

Patricia Serrano, M.D.

P1-149

Psychosis Resulting From Fahr's Syndrome: Case Report and Review of Literature

Apeksha Shah, M.B.B.S.

P1-150

Low Dose Testosterone Replacement Therapy-Induced Psychotic Mania

Wanda Shao, D.O.

P1-151

The Importance of Considering Delirium Due to Polypharmacy in Psychiatric Patients With Neurologic Disorders: A Case Report and Review of Literature

Anna P. Shapiro, B.A.

P1-152

Lithium-Induced Dental Complications

Ashish Sharma, M.D.

P1-153

Pharmacogenomic Testing Predicts a More Favorable Clinical Outcome in a Patient With Treatment-Resistant Depression and "Borderline Personality"

Matthew M. Sheehan, B.A.

P1-154

Neuropsychiatric Manifestations of Wilson's Disease in the Inpatient Hospital Setting

Sarah Sheikh, M.D.

P1-155

Differentiating Between Psychiatric Disorders and Wernicke-Korsakoff Syndrome: A Case Report

Manisha Shenava, M.D.

P1-156

Valproic Acid-Induced Delirium: A Case Study

Saoda Shuara, M.D.

P1-157

Clozapine Refractory Schizophrenia: Augmentation Therapy With Fluphenazine

Gurjot Singh, M.D.

P1-158

K2/Spice-Induced Seizures: Tip of an Iceberg

Jasbir Singh, M.D.

P1-159

The Need for Maintenance ECT in Preventing Relapse in Elderly Populations With Major Depression: A Case Report

Laima Spokas, M.D.

P1-160

The Therapeutic Interventions for Pediatric Bipolar Disorder

Laima Spokas, M.D.

P1-161

Use of THC Analogs in Cannabis Use Disorder

Ananya R. Sreepathi, M.D.

P1-162

Impulse-Control, Conduct Disorders and Intellectual Disability: A Concerning Combination

Ananya R. Sreepathi, M.D.

P1-163

WITHDRAWN

P1-164

Erotomania and the Frontal Lobe: A Case Report of Delusional Disorder Arising From a CNS Neoplasm

John Stupinski, B.A.

P1-165

Menstrual Psychosis: A Case of Estrogen Withdrawal Psychosis

Leah Susser, M.D.

P1-166

Electroconvulsive Therapy in the Treatment of Delirious Catatonic Mania: A Case Presentation

Cuneyt Tegin, M.D.

P1-167

K2-Induced Psychosis: Recurrent Relapse and Treatment Challenges

Swaminathan Thangaraj, D.O.

P1-168

Serotonin Syndrome in the Burn ICU

Taylor Tobkes, M.D.

P1-169

Metabolic Side Effects of the Rise: The Use of Metformin to Counteract Clozapine-Induced Adverse Reactions: A Case Report

Celia Varghese, M.D.

P1-170

12-Year-Old With Landau-Kleffner Syndrome and Nonepileptic Seizures: A Complex Case Presentation With Literature Review

Divya Vemuri, M.D.

P1-171

Rage Against Self and Object: A Case Report of Treatment-Resistant Schizophrenia With Literature Review

Chitranjan B. Verma, M.D.

P1-172

Microvascular CNS Lesions, Hypomania, Seizure Activity and Pseudobulbar Affect in the Elderly: A Case Report

Ankita Vora, M.D., M.P.H.

P1-173

WITHDRAWN

P1-174

Undocumented Immigrants in Psychiatric Wards: A Case Report and Concise Review

Mike Wei, B.S.

P1-175

Depersonalization/Derealization: Neurobiology, Psychodynamics and a Case in Schizophrenia

Bryce Winingar, M.D.

P1-176

The Impact of Medication on Teeth Pulling and Skin Picking

Mohammad Yousuf, M.D.

P1-177

Prediction Challenges of Readmission in the Psychiatric Inpatient Setting: A Resident-Run Performance Improvement Initiative

Muhammad Zeshan, M.D.

2

Poster Session 2 Saturday, May 14

Medical Student-Resident Competition Poster 2

2:00 P.M. - 4:00 P.M.

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

P2-001

Dissemination and Implementation of CBT for Depression: Examining Attitudes, Therapy Patterns and Level of Competency Among Third-Year Clinic Residents

Earl Andrew B. De Guzman, M.D.

P2-002

Prevalence of Metabolic Syndrome in a Population Being Served by an Assertive Community Treatment Team

Jonathan Fairbairn, M.D.

P2-003

Integrating and Redesigning Mental Health at Primary Care Level: TRipleaim Universal MPsychiatry (TRIUMPH) Model

Abhishek Rai, M.D.

P2-004

Program Development of a Buprenorphine/Naloxone (Bup/Nx) Outpatient Program in a Safety Net Hospital

William Levitt, M.D.

P2-005

The University of Virginia-Guatemala Initiative: Mental Health Care Delivery in Low-Resource Settings

Souraya Torbey, M.D.

P2-006

Clinical Implications of Companion Animals in Patients With Serious Mental Illness

Sa Eun Park, M.D.

P2-007

Impediments Toward Clozapine Use: A Survey of Psychiatric Trainees

Katherine Robertson, M.D.

P2-008

Development of a Metric for Evaluating Infectious Disease Risk Communication Strategies

Daniel Witter, M.D., Ph.D.

P2-009

Vista Improvement Program: A Longitudinal Care Model for the Inpatient Psychiatric Setting

Andrew Pierce, M.D.

P2-010

Promising Employability Interventions Tailored to Clients With Severe and Persistent Mental Illness: An Intersectoral Endeavor in Saint John, NB

Laura M. Downing, M.D.

P2-011

The Necessity of a Child and Adolescent Detox Unit Within a Child and Adolescent Psychiatric Unit

Kalliopi S. Nissirios, M.D.

P2-012

The Need for Initial Assessment Intake in the Prison Population

Kalliopi S. Nissirios, M.D.

P2-013

Can Examination of Haitian Vodou in a Different Light Open Doors of Potential Collaboration Long Closed in the Mental Health Field?

Jennifer Severe, M.D.

P2-014

Filling the Gaps: Improving Medical Residents' Education on Alcohol Use Disorders

Igor Epstein, D.O.

P2-015

Optimizing Psychopharmacology Education In Psychiatric Residency Training: An Overview of the Eighth Edition of the ASCP's Model Curriculum

Aimee Dereczyk, M.D.

P2-016

Seeking a Better Outcome:
A Survey About LGBTQQI2S
Knowledge

Juan A. Rivolta, M.D.

P2-017

Standardization of the Handoffs in
Psychiatry Residency Training

Amanpreet K. Mashiana, B.S.

P2-018

Is My Evaluation Truly Anonymous?
A Survey of Residents About Their
Evaluation of Faculty Physicians in
a Community Hospital

Varma Penumetcha, M.D.

P2-019

Coping With Patient Suicide: A
Cross-Sectional Study on the
Effects of Patient Suicide on
Psychiatry Residents and Faculty

Archana Sugumar, M.B.B.S.

P2-020

Improving Resident Handoffs Using
Quality Improvement Matrix

Katherine Robertson, M.D.

P2-021

An Assessment of Attitudes
Towards Homeless Individuals
With Mental Illness Among Medical
Students and Physicians

Pallavi Joshi, M.A.

P2-022

The Compassion Crisis in Medical
Education

Rachel Conrad, M.D.

P2-023

Effective Mentorship During
Residency Training: Needs
Assessment and Perspectives of
Residents

Hermioni Lokko, M.D., M.P.P.

P2-024

Feasibility and Acceptability
of Performing Screening, Brief
Intervention and Referral to
Treatment (SBIRT) on an Inpatient
Unit at UVA

Andrew R. Alkis, M.D.

P2-025

Special-“T” Training: Pre-, Post-
and 90-Day Outcomes From a
Residency-Wide Professionalism
Workshop on Transgender Health

Jeremy D. Kidd, M.D., M.P.H.

P2-026

Dissemination of an Evidence-
Based Tobacco Treatment
Curriculum to Psychiatry Residency
Programs

Smita Das, M.D., Ph.D.

P2-027

Guidelines for Discontinuing
Benzodiazepines in Patients Who
Are Chronic Users

Joseph Siragusa, M.D.

P2-028

Understanding the Role of
Morbidity and Mortality Rounds in
Psychiatry: A Systematic Review of
Implementation and Educational
Outcomes

Paul V. Benassi, M.D.

P2-029

Are Medical Doctors Educated
Research Consumers?

Priscilla N. Chukwueke, M.D., M.P.H.

P2-030

A Call for the Increase in Clozapine
Clinics to Improve the Treatment of
Schizophrenia

Balwinder Singh, M.D., M.S.

P2-031

Assisted Death From a Psychiatric
Perspective: An Overview and
Review of Literature

Tanuja Gandhi, M.D.

P2-032

Difficult Interactions: A Reason for
Inpatient Psychiatric Consultation?

Meena Kumari, M.D.

P2-033

Self-Injurious Behavior in Patients
With Eating Disorders: A Literature
Review

M. Rehan Puri, M.D., M.P.H.

P2-034

Training and Assessment of
Psychiatry Residents' De-
Escalation Competency in
Standardized Patients

Jenine Weber, D.O.

P2-035

Patient-Targeted Googling and
Psychiatric Professionals

Liliya Gershengoren, M.D., M.P.H.

P2-036

The Efficacy of Complementary
and Alternative Therapies to Treat
Depression During Pregnancy: A
Meta-Analysis

Alexandra K. Rice, M.D., M.A.

P2-037

Sexual Offenders With
Substance Usage: Do Psychiatric
Comorbidities Differ in This
Population?

Edward Thomas Lewis, M.D.

P2-038

Correlates of 1-Year Prospective
Depression Severity in Bipolar
Disorder: Results From the
Systemic Treatment Enhancement
Program for Bipolar Disorder

Sharif Syed

P2-039

Prevalence and Correlates of
Pseudobulbar Affect Symptoms
in Urban Setting Nursing Home
Residents With Dementia

Milania Dela Cruz, M.D., M.P.H.

P2-040

Inpatient Burden of Alcohol
Withdrawal (Delirium Tremens) in
the United States: An Analysis of
National Trends

Raghu Gandhi, M.D., M.B.B.S.

P2-041

The Right to Keep and Bear Arms
When Mentally Ill

Furqan Nusair, M.B.B.S.

P2-042

Gender Differences in the
Experience of Depression in
Parkinson's Disease

Andrew Perrin, M.D., Ph.D.

P2-043

Sex Differences in Psychiatry
Comorbidity Profiles Among Adults
With ADHD and Alcoholism

Maria M. Reyes, M.D.

P2-044

Internal State Scale (ISS): A
Promising Patient-Rated Screen for
Identifying Bipolar NOS?

Travis Hendryx, M.D.

P2-045

PRN Hospitalization for Borderline
Personality Disorder: Our
Experience and Literature Review

Lakshit Jain, M.D.

P2-046

Does Presenting Mood State
Predict Length of Inpatient Stay in
Bipolar Disorder?

Jigar K. Chotalia, M.B.B.S., M.P.H.

P2-047

“She’s Not My Sister!” A Case
Report of Capgras Syndrome in
a Patient With Schizophrenia and
Vascular Dementia

Lauren Pengrin, D.O.

P2-048

National Trends, Rates of Cardiac Catheterizations, Revascularization After Myocardial Infarction in Patients With Dementia

Malathi Pilla, M.D.

P2-049

Whoonga or Nyaope: Antiretroviral Medication Abuse: An Emerging Problem or Media Hype?

Subani Maheshwari, M.D.

P2-050

Prevalence of Comorbid Anxiety-Anxiety Disorders Among Adult Outpatients in an Academic Psychiatric Setting

Jessica M. Short, D.O.

P2-051

Substance Use Disorders in Psychiatric Inpatients With Primary Mood or Chronic Psychotic Disorders: Prevalence and Relationship to Comorbid PTSD

Pratikkumar Desai, M.D., M.P.H.

P2-052

Comparing the Efficacy, Safety and Tolerability of ATX vs Stimulants for ADHD Treatment in Children and Adolescents: A Systematic Review and Meta-Analysis

M. M. Naveen, M.D.

P2-053

Interrater Variability Among Intraining Psychiatric Residents in Identifying Diagnoses of Schizophrenic Disorder and Treatment-Resistant Schizophrenia

Balwinder Singh, M.D., M.S.

P2-054

Examining Racial Differences in Diabetes Among People With Serious Mental Illness

Walker Daniel Keenan, B.S.

P2-055

Patient Feedback of Electronic Medical Records in an Outpatient Psychiatric Setting

Walter Piddoubny, M.D.

P2-056

PTSD Symptoms in Acute Psychiatric Inpatients: Prevalence and Impact on Comorbid Diagnoses, Demographics and Length of Stay (LOS)

Christopher James

P2-057

Borderline Personality Traits in Psychiatric Inpatients: A Positive Predictor?

Shelly T. Tran, M.D.

P2-058

Delirium: Could Be a Nightmare on Call at an Inpatient Psychiatric Facility

Reena Kumar, M.D.

P2-059

Religiosity in Acute Psychiatric Inpatients: Relationship With Demographics, Clinical Features and Length of Stay

Noha Abdel Gawad, M.D.

P2-060

Conversion Disorder: Modalities of Treatment

Muhammad A. Anees, M.D.

P2-061

Weight Effects of Aripiprazole Monotherapy Versus Aripiprazole Antidepressant Polypharmacy in an Outpatient Sample: A Retrospective Chart Review

Amanda Suzuki, M.D.

P2-062

Associations of Alcohol Consumption and Marijuana Use With Major Depressive Episode: Results From the 2011 National Survey on Drug Use and Health Data

Joseph C. Ikekwere, M.D., M.P.H.

P2-063

Suicide Crisis on Campus: Suicide Attempts and Ideation in the Collegiate Population Evaluated in the Emergency Department

Souraya Torbey, M.D.

P2-064

GGT as a Marker of Alcohol Abuse: Is It a Must?

Narissa R. Etwaroo

P2-065

Where Do We Stand in Therapeutic Drug Monitoring for Mood Stabilizers in Patients With Bipolar Disorder?

Zahid Islam, M.D.

P2-066

Homicidal Ideation in Psychiatric Emergency Room

Jack Wang, D.O.

P2-067

Schizoaffective Disorder Depressive Type and Psychosis

Qaiser S. Khan, M.D.

P2-068

Sensory Reduction of Internal Milieu as a Means of Reducing Physical Restraints in a High-Acuity Inpatient Psychiatric Unit: A QI Project

Svetlana Yakov, M.D., Ph.D.

P2-069

Relevance of Obtaining Magnesium Levels in Patients With Alcohol Abuse

Astik Joshi, M.D.

P2-070

Relationship of Physical Activity to Depression in Adolescents With and Without History of Psychological Trauma

Andriy Yur'yev, M.D., Ph.D.

P2-071

Tobacco Use and Associated Factors Among Patients Presenting to a Psychiatric ER

Ashley D. Collins, D.O.

P2-072

Determinants for Follow-Up in Treatment-Resistant Schizophrenia Patients Started on Clozapine: Retrospective Analysis From Atlanta Public Hospital

Rafael E. Tapias, M.D.

P2-073

Increasing Cardiometabolic Risk Screening and Reduction of the Risk Among the Patients on Antipsychotics in the Adult Outpatient Psychiatry Clinic

Sasidhar Gunturu, M.D., M.B.B.S.

P2-074

Psychiatric and Legal Challenges in the Care of Transgender Inmates

Rafik Sidaros, M.D.

P2-075

Chronic Phencyclidine (PCP) Use as a Dissociative Respite in Stress Exposure and Mode of Self-Medication in Post-Traumatic Stress Disorder (PTSD)

Megan L. Gilman, M.D.

P2-076

Hyperprolactinemia During Antipsychotic Use in the Pediatric Population: Early Identification and Management

Chidinma Isinguzo, M.D.

P2-077

Trazodone-Induced Acute Urinary Retention: A Case Report

Vasile Savu, M.D.

P2-078

Mastering the Interpreter Phone: An Integrated Literature Review With Draft Recommendations

Darrow Khosh-Chashm, M.D.

P2-079

Impact of Substance Abuse Discharge Recommendation Compliance on ED Readmission Rate in a College Population

Derek Blevins, M.D.

P2-080

Impact of the Affordable Care Act on Psychiatric Patients' Access to Care at a California University Hospital Emergency Room

Andia H. Turner, B.Sc.

P2-081

Long-Term Injectable Use and Psychiatric Readmission Rates at a State Safety Net Hospital

William Levitt, M.D.

P2-082

Comfort Level and Barriers to the Appropriate Use of Clozapine for Patients With Schizophrenic Disorders Among U.S. Psychiatric Residents: A Proposal

Balwinder Singh, M.D., M.S.

P2-083

Literature Review of Effects of Atypical Antipsychotics on Infants of Breastfeeding Mothers

Tapan Parikh, M.D., M.P.H.

P2-084

Mindfulness-Based Cognitive Therapy for Major Depressive Disorder

Jeannie Lochhead, M.D.

P2-085

Relationship Between ASD and FXS Regional Expression of Fmr1 MRNAs in the Brains of Wild Type and Fmr1 Null Mice

Jun Zhong, M.D.

P2-086

Effects of Childhood Adversity and Adulthood Trauma on C-Reactive Protein in the Health and Retirement Study

Joy E. Lin, B.S.

P2-087

The DSM-5-Defined Attenuated Psychosis Syndrome and Conversion to Schizophrenia Spectrum Disorders: An Institution-Wide Retrospective Review

Zachary D. Zuschlag, D.O.

P2-088

Serum BDNF, TNF α , IL-2, IL-6 and IL-8 Changes and Correlation in Schizophrenia Patients

Hanjing E. Wu, M.D., Ph.D.

P2-089

Trans-Cranial Magnetic Stimulation (TMS) in Psychiatry: Review of Current Updates and Future Directions

Ramkrishna D. Makani, M.D., M.P.H.

P2-090

A Study on the Awareness, Utility and Barriers to the Utilization of Psychiatric Advanced Directives

Tanuja Gandhi, M.D.

P2-091

Evidence for Using Acetylcholinesterase Inhibitors and Memantine in Individuals With Traumatic Brain Injury (TBI): A Systematic Review

Rajesh R. Tampi, M.D., M.S.

P2-092

The Effect of Social Networking Sites on the Relationship Between Perceived Social Support and Depression

Matthew A. McDougall, M.D.

P2-093

Evidence for Using Electroconvulsive Therapy in Individuals With Dementia: A Systematic Review

Rajesh R. Tampi, M.D., M.S.

P2-094

Efficacy of Prazosin in Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis

Balwinder Singh, M.D., M.S.

P2-095

Comparison Between GAF and World Health Organization Disability Assessment Schedule (WHODAS-2) in Patients With Schizophrenia-Spectrum Illness

Scott Gspandl, M.D.

P2-096

Early Life Trauma in Hospitalized Mood Disorder Patients and Its Association With Clinical Outcomes

Ajay Parsaik, M.D., M.S.

P2-097

Use of Nicotine Replacement Among Psychiatric Inpatients Treated With Clozapine Versus Other Antipsychotic Drugs

Maryam Jahdi, M.D., M.P.H.

P2-098

Reel Comfort: A Pilot Study of the Therapeutic Effect of Facilitated Film Screenings and Discussions on General Psychiatric Inpatients

Phillip Gregoire, M.Sc.

P2-099

5-HTTLPR Association With Childhood Characteristics in Mood Disorder

Tae Kyung Eun, M.D.

P2-100

The Psychiatric Perspective: Factors Affecting Medical Students' View of Psychiatry

William Levitt, M.D.

P2-101

Climate Change and Mental Health: A Need for Increased Research

Ekatherina Osman, D.O.

P2-102

A Randomized Double-Blind Clinical Trial Comparing Qsymia (Phentermine-Topiramate) Versus Placebo in Patients With Bulimia and Binge Eating Disorder

Shebani Sethi Dalai, M.D., M.S.

P2-103

Good Cop, Bad Cop, Killer Cop? A Study of Antisocial Personality Disorder in Police Officers

William Levitt, M.D.

P2-104

Medical Complications Associated With Delays in Public Guardianship Assignment

Rebecca E. Goedken, M.D.

P2-105

Coffee and Tea to Prevent Depression?

Hanan Khairalla, M.D.

P2-106

From Snow White to Elsa: A Transformation of the Disney Princess! How Gender Role Portrayals Present in Disney Films May Influence Children Over Time

Kalliopi S. Nissirios, M.D.

P2-107

Characteristics of Pain Expression in Children Across Developmental Stages

Jawad Zafar, D.O.

P2-108

A Case Report: Schizophrenic Patient Using “Sour Diesel” to Treat His Depression

Rahulkumar Patel, M.D., M.P.H.,

3

**Poster Session 3
Sunday, May 15**

International Poster Session 1

10:00 A.M. - Noon

Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

P3-001

Prevalence of Eating Disorders Among Individuals With Type 1 Diabetes Mellitus (T1DM) and Diabetes-Specific Emotional Distress

Ahmad Alhadi, M.D., M.B.B.S.

P3-002

Smartphone Use Addictive Phenomenon Among University Students in King Saud University in Riyadh, Saudi Arabia

Fahad D. Alosaimi, M.D.

P3-003

The Psychosocial Correlates of Infertility in Saudi Arabia

Fahad D. Alosaimi, M.D.

P3-004

The Effect of Thought Disorder on Remission of Symptoms in Schizophrenia

Koksal Alptekin, M.D.

P3-005

Treatment Options for Spitting Behavior in an Adult Patient With History of Chronic Schizophrenia and Pervasive Developmental Disorder

Muhammad Asif, M.D.

P3-006

Recurring Catatonia in Schizophrenia Following Acute ECT: A Case Report and Review

Muhammad Asif, M.D.

P3-007

Synthetic Marijuana: Potential Pitfalls!

Sumayya B. Ayaz, M.D.

P3-008

Pre- and Perinatal Exposures and Risk of Autism Spectrum Disorders

Yael Barnea, M.D., LL.B.

P3-009

Case Report of an Acute Psychosis Episode Induced by Emerging Cathinone-Like Designer Drug Available on Internet

Hafid Belhadj-Tahar, M.D., Ph.D.

P3-010

Associations of Ethnic Discrimination With Symptoms of Depression and Anxiety Among Hispanic Emerging Adults: A Moderated Mediation Model

Miguel Angel Cano, Ph.D., M.P.H.

P3-011

The HARM: The Development of a Nimble Violence Risk Assessment Tool

Gary Chaimowitz, M.D., M.B.

P3-012

Lifetime Obesity and Diabetes Associated With Cardiovascular Diseases in Old-Age Bipolar Disorder: A 30-Year Retrospective Case-Control Study in Taiwan

Pao-Huan Chen, M.D.

P3-013

Increased Risk of Hyperlipidemia in Patients With Anxiety Disorders: A Population-Based Study

I-Chia Chien, M.D., Ph.D.

P3-014

Are Medical Doctors Educated Research Consumers?

Priscilla N. Chukwueke, M.D., M.P.H.

P3-015

Marchiafava-Bignami Disease (MBD) and Diffusion Tensor Image (DTI) Tractography

Priscilla N. Chukwueke, M.D., M.P.H.

P3-016

Cognitive and Emotional Empathy in Autism Spectrum Disorder: An FMRI Study

Seungwon Chung, M.D.

P3-017

Temperament and Character Traits in Mood Disorders

Sabrina Correa da Costa, M.D.

P3-018

Intergenerational Transmission of Antisocial Personality Disorder: Maternal Role and Its Declination

Ester di Giacomo, M.D.

P3-019

New Onset Psychosis in Patient With Cerebral Palsy

Asha Dusad, M.D.

P3-020

Overconsumption of Benzodiazepines: Is VAS the Solution?

Gael Fournis, M.D.

P3-021

Opportunity and Challenges in Mental Health and Psychosocial Support Sector After Mega Earthquake in Nepal

Shree Ram Ghimire, M.D.

P3-022

Factors Associated With Noncompliance in Schizophrenia

Shree Ram Ghimire, M.D.

P3-023

Duloxetine Induced Urinary Retention

Shree Ram Ghimire, M.D.

P3-024

DMDD: A Diagnostic Dilemma in Pediatric and Adolescent Mood Disorders

Pooja Shah, M.D.

P3-025

Psychotic Episode as First Manifestation of Anti-NMDA Encephalitis: Case Report

Jesus Gomez-Trigo Baldominos, M.D.

P3-026

Sociodemographic Characteristics of Children and Adolescents Referred by The School for Mental Health Treatment in a Brazilian University Clinic

Valeria Soares Gularte

P3-027

Frontal Lobe Aboulia Masquerading as MDD: A Case Report and Literature Review

John Gurski, D.O.

P3-028

Canadian Psychiatry Residents' Attitudes to Becoming Mentally Ill

Tariq Hassan

P3-029

The Effect of Exposure to Forest Environment on Cytokines and Anti-Oxidants in Comparison to Urban Among Young Adults With Moderate Level of Stress

Won Kim

P3-030

Associations of Late Onset Bipolar Disorder and Brain Hyperintensities in Patients With High Intelligence: A Case Report

*Muhammad Navaid Iqbal, M.D.,
M.B.B.S.*

P3-031

Therapeutic Modalities for Psychological and Behavioral Manifestations in Patients With Lewy Body Dementia

*Muhammad Navaid Iqbal, M.D.,
M.B.B.S.*

P3-032

Late-Onset Lyme Disease-Induced Psychosis: Is it Treatable?

*Muhammad Navaid Iqbal, M.D.,
M.B.B.S.*

P3-033

Age-Related Differences in Suicidality Between Younger People and Older Adults With Depression

Tae-Youn Jun, M.D., Ph.D.

P3-034

Does Admission to Hospital Improve Short-Term Outcomes in Young People With Severe Somatic Symptom Disorders and Functional Neurological Disorders?

Sara Kakhi, M.D.

P3-035

Heart Rate Variability of Posttraumatic Stress Disorder in Korean Veterans

Suk-Hoon Kang, M.D.

P3-036

Comparison of Neurocognition Between Positional OSA Patients and Nonpositional OSA Patients in the Korean Elderly

Moon Yong Chung, M.D., Ph.D.

P3-037

Bipolar Disorder Severity Robustly Related to Illness Duration and Episode Accumulation

Saloni Shah, B.S.

4

Poster Session 4 Sunday, May 15

International Poster Session 2

2:00 P.M. - 4:00 P.M.

Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

P4-001

I Am Just a Doctor! How Many Hats Must I Have? or Is It Just One Big Magician's Hat?

Nahed Khairy, M.D.

P4-002

Aggressive Behavior in Prader Willi Syndrome

Muhammad Khan, M.D.

P4-003

The Hypothesis of Social Anxiety Disorder Development Secondary to Attention Deficit/Hyperactivity Disorder

Ahmet Koyuncu, M.D.

P4-004

Case Report on a Case of Mania in an Individual With Newly Diagnosed Multiple Sclerosis

Ganesh Kudva, M.B.B.S.

P4-005

Suicidal Behavior in the Department of General Medical Emergency

Jaime M. Kuvischansky, M.D.

P4-006

Differential Response Style on the Personality Assessment Inventory According to Compensation-Seeking Status in Patients With Traumatic Brain Injury

Sang Yeol Lee, M.D., Ph.D.

P4-007

Relationships Between Psychopathology and Tattoos in Those Receiving Physical Examination for Conscriptation at Korean Military Manpower Administration

Sang Yeol Lee, M.D., Ph.D.

P4-008

Standardized Patients in Psychiatry Education and Changes in Perceptions of Their Own Healthcare Experiences

Rathi Mahendran, M.Ed., M.Med.

P4-009

Prevalence of Vitamin D Deficiency in Patients With Mental Illness Who Are Hospitalized in Inpatient Psychiatric Setting

Lakshmi Priya Munnangi, M.D.

P4-010

Evolution of Depressive Symptoms Before, During and After Major Social Protests in Hong Kong

Michael Ni, M.B.B.S., M.P.H.

P4-011

Stress Across the Life Course and Depression in a Rapidly Developing Population: The Guangzhou Biobank Cohort Study

Michael Ni, M.B.B.S., M.P.H.

P4-012

A Multilevel Analysis of Neighbourhood Cohesion, Population Density and Mental and Physical Component of Health-Related Quality of Life

Michael Ni, M.B.B.S., M.P.H.

P4-013

International Case Conference: Interplay of Chinese Culture, Religion, and Psychosis

Kathy Niu, M.D.

P4-014

Use of Emergency Room Services and Risk of Subsequent Hospitalization in Schizophrenia Patients: Results From the CGS Prospective Cohort Study

Clementine Nordon, M.D., Ph.D.

P4-015

Antiepileptic Drugs, Risk of Suicide Attempts and the Impact of Underlying Medical Conditions

Clementine Nordon, M.D., Ph.D.

P4-016

Children and Adolescent Victims of Human Trafficking: Role of Physician in Identification and Treatment

Joshua Okoronkwo

P4-017

Associations Between Recognition of Facial Expressions of Emotion, Active Alcoholism and Associated Clinical Conditions

Flávia L. Osório

P4-018

Assessment of the Acute Effects of Oxytocin on Music Performance Anxiety: Preliminary Results Involving a Situation of Simulated Performance

Flávia L. Osório

P4-019

Cerebral Calcification as a Differential Diagnosis for Psychiatric Disorders: A Review of the Literature

Ossama Tawakol Osman, M.D.

P4-020

Alcohol Dependence and Psychiatric Comorbidity

Jerome Palazzolo, M.D., Ph.D.

P4-021

Contribution of New Technologies in Therapeutic Mediation With Elderly People

Jerome Palazzolo, M.D., Ph.D.

P4-022

Drug-Free Approach in Alzheimer's Disease: A Musical Support of Behavioral Disorder During Daily Care

Jerome Palazzolo, M.D., Ph.D.

P4-023

Animal Mediation With the Help of Dogs and Alzheimer-Type Dementia With Apathetic Behavior Placed in Institutions

Jerome Palazzolo, M.D., Ph.D.

P4-024

The Interpretation of the Evolution of the Grasping Reflex in Dementia: Communication or Symptom?

Jerome Palazzolo, M.D., Ph.D.

P4-025

Factors Affecting the Cosmetic Plastic Surgery Intention of Korean University Students

Hyemi Park, M.D.

P4-026

Brain Neurochemistry as Assessed by 1H-MRS in Unmedicated Obsessive Compulsive Disorder Patients and Changes After 12 Weeks of Escitalopram Treatment

Arpit Parmar, M.D., M.B.B.S.

P4-027

The Use of Anticholinergics in People With Intellectual Developmental Disability and Its Impact on the Management of Dementia

Rupal Patel, M.B.B.S.

P4-028

Burnout and Academic Performance in Medical Students

Maria Beatriz Quintanilla, M.D., Ph.D.

P4-029

Dementia in Indian Cinema: A Narrative Review

Badr Ratnakaran, D.P.M., M.B.B.S.

P4-030

Interaction Between CRP and Cognitive Functions in Relation to APOE Gene Polymorphism in Postmenopausal Women

Kasia Gustaw Rothenberg, M.D., Ph.D.

P4-031

Hepatitis C Virus and Cognitive Impairment: A Longitudinal Study

Pedro M. Sánchez-Gómez, M.D.

P4-032

The Toronto Bariatric Interprofessional Psychosocial Assessment Suitability Scale (BIPASS™): A Delphi Study to Inform Assessment Tool Development

Vincent A. Santiago, B.Sc.

P4-033

Status Post-Cardiac Arrest and Non-ST-Elevation Myocardial Infarction Secondary to Cocaine Abuse: A Case Report

Ulfat Shahzadi, M.D., M.B.B.S.

P4-034

Chronic Pain as a Potential Risk Factor of Suicide: A Case Report

Ulfat Shahzadi, M.D., M.B.B.S.

P4-035

Case Report: Psychiatric Adverse Effects of Tizanidine

Harvinder Singh, M.D.

P4-036

Acetylcholinesterase Inhibitors for Delirium in Older Adults

Rajesh R. Tampi, M.D., M.S.

P4-037

Are Stimulants Beneficial in Individuals With Traumatic Brain Injury?

Rajesh R. Tampi, M.D., M.S.

P4-038

Substance Abuse in Consultation-Liaison Psychiatry Unit

Cristina Uzal Fernandez, M.D.

P4-039

Introducing EGuru

Shuo Xiang, M.D.

P4-040

Intravenous Midazolam-Droperidol (Combination), Droperidol or Olanzapine for Methamphetamine-Related Agitation in the Emergency Department

Yen Ling Yap, M.Sc.

5

Poster Session 5
Monday, May 16

Young Investigators' New Research 1

10:00 A.M. - Noon

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

P5-001

Mental Health During Residency and Fellowship Training: Assessing the Barriers to Seeking Care

Alexandra L. Aaronson, M.D.

P5-002

Association of Platelet Hyperaggregability With Dementia: A Report of a Colombian Kindred

Juliana Acosta-Uribe

P5-003

What's Making Me Feel So Queasy? A Case of Cannabis Hyperemesis Syndrome Exacerbated by Concurrent Use of Fluoxetine

Adefolake Akinsanya, M.D.

P5-004

A Case of Orthostatic Tremor During Risperidone Treatment

Seung-Min An, M.D.

P5-005

Mental Health Screening for the Baby Boomer Generation in South Korea: The Results of a Demonstration Project

Seung-Min An, M.D.

P5-006

Meclofenamic Acid-Reduced Plasma CRP and Improved Scores on the NIH Toolbox Cognitive Test Battery in a Patient With Schizoaffective Disorder

Taiwo Babatope, M.D., M.B.A., M.P.H.

P5-007

Developing a Quality Dashboard for Consultation-Liaison Psychiatry Services in Canada: a Pilot of Two Quality Indicators

Janooshsheya Balasundaram, M.D.

P5-008

Vortioxetine-Induced Distal Interphalangeal Joint Inflammation of the Great Toe

Priya Batta

P5-009

Psychiatric Emergency Workflow: A Resident-Driven Quality Improvement Project

Thomas Blair, M.D., M.S.

P5-010

Systematic Review of Nalmefene in Alcohol Use Disorder

Meelie Bordoloi, M.D.

P5-011

Substance Use Disorder Training in Child and Adolescent Psychiatry Fellowship: The Effect on Fellows' Fund of Knowledge and Confidence to Treat

Ali Canton, M.D.

P5-012

Assessing Newly Developed Educational Tools Targeting Prenatal Care Providers' Knowledge of Perinatal Mental Illnesses

Stephanie H. Chan, M.D.

P5-013

WITHDRAWN

P5-014

Discussing the Bleeding Risk of Co-Administered Paroxetine and Warfarin

Beatriz Cruz Alvarez, M.D.

P5-015

WITHDRAWN

P5-016

Implementing Pharmacogenetic Testing Into Psychiatric Residency Training: A Quality Improvement Project

Adriana B. de Julio, M.D., M.Sc.

P5-017

The Relationship Between Childhood Trauma, Impulsivity and Suicidality in an Inpatient Sample

Laura DeRubeis, B.A.

P5-018

Strep, Tics and PANDAS, Oh My!

Kanwaldeep Dhillon, M.D.

P5-019

Management of Psychosis in an AIDS Patient During Febrile Neutropenia: A Case Report

Jennifer M. Erickson, D.O.

P5-020

Premature Deaths of Consumers in a County Mental Health System in Southern California

Carlos Fernandez, M.D.

P5-021

Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder

Katrine Kveli Fjukstad, M.D.

P5-022

Mental Health Screening in National Collegiate Athletic Association Division I Athletes: Is the Preparticipation Evaluation Form Effective?

Elyse Galles, B.A.

P5-023

Exacerbation of Psychosis During Titration From Fluphenazine to Aripiprazole: A Case Report and Literature Review

Nicholas J. Genova, M.D.

P5-024

Mental Illness Among Bhutanese Refugees Settled in the United States: A Review of Current Evidence

Aditi Giri, M.B.B.S.

P5-025

Health Care Utilization and Costs Associated With a Cluster of Factitious Disorder: A Case Series

Juliet A. Glover, M.D.

P5-026

Self-Inflicted Injury in Children and Adolescents: A Study From Psychiatric Services of a Latin American Hospital

Paloma Andrea Guerra, M.D.

P5-027

Wise, What and How: A Six-Session DBT Mindfulness Group in a Limited-Resource Clinic

Meredith Harewood, M.D.

P5-028

A National Dataset Analysis on the Association Between Depression and Stroke

Vineka Heeramun, M.D.

P5-029

After the First Script: Long-Term Use Trajectory of Opioids Versus NSAIDs for Non-Cancer Pain

Lamis Jabri, M.D.

P5-030

Depression Is Associated With Vitamin D Deficiency, but Not With C-Reactive Protein: A Large Retrospective Observational Study in Korean Adults

Chan Hyun Jung, M.D.

P5-031

Comparison of Depressive Symptoms Between Social Anxiety Disorder and Panic Disorder

Chan Hyun Jung, M.D.

P5-032

The Association of PHQ1 and PHQ9 Screening Results With Readmission Rates of Medically and Surgically Admitted Patients

Dheeraj Kaplish, M.D.

P5-033

Factors Associated With Insomnia in Thyroid Disorder

Minsu Kim

P5-034

Associations Between Actigraphy-Assessed Sleep Onset Latency, Inflammatory Markers and Insulin Resistance: Midlife in the United States (MIDUS) Study

TaeHo Kim, M.D.

P5-035

Mental Imagery and Its Relation to Emotion Regulation in Euthymic Patients With Bipolar I Disorder

Keun You Kim, M.D.

P5-036

Association Between Alu Insertion/Deletion Polymorphism on the tPa Gene and Mirtazapine Response in Koreans With Major Depression

Daseul Kim, M.D.

P5-037

The Role of Filial Piety in Mediating Risk and Recovery in Chinese Women With a History of Suicidal Behavior: A Cross-Cultural Qualitative Study

June Lam, M.D.

P5-038

The Treatment Rate of Five-Year Tendency of Postpartum Depression in Korea: A National Health Insurance Database Study

Soyoen Lee, M.D.

P5-039

Sleep Quality of Korean Workers and Its Association With Depression and Anxiety

Woo Hyung Lee, M.D.

P5-040

Altered Resting State Functional Connectivity in Internet Gaming Disorder With Childhood Attention-Deficit/Hyperactivity Disorder Comorbidity

Deokjong Lee, M.D.

P5-041

Key Stakeholder Perceptions of Psychosocial Rehabilitation in Hunan, China: A Qualitative Study of Community Mental Health Implementation

Luming Li, M.D.

P5-042

Differential Stress Reaction Between Anxiety and Depressive Disorder

Eun Jung Li, M.D.

P5-043

Alteration of Olfactory Identification and Cognitive Function After Chemotherapy in Patients With Breast Cancer

Jongseok Lim

P5-044

Knowledge of and Attitudes Toward Alcoholism Among Church Leaders in Saint Vincent and the Grenadines

Shiyuan Liu, B.A.

P5-045

A Tale of Kraepelin and Ketamine: Using Historic Diagnostics and Experimental Therapy to Reach the Most Ill

Kelly MacDonald, M.D.

P5-046

Innovation in the Age of Health Care Reform: Implementing a "Behavioral Vaccine" to Prevent Adolescent Depression

Nicholas Mahoney, D.O.

P5-047

NIH Toolbox Flanker Inhibitory Control and Attention Test Scores Are Negatively Correlated With Plasma Levels of IL-1? in Patients With Schizophrenia

Titilayo Makanjuola, M.D.

P5-048

Putting the PEP in CPEP: A Lecture Series Designed to Orient Residents to the Psychiatric Emergency Room

Megan McLeod, M.D.

P5-049

Impact of Anti-Inflammatory Drugs on Risk of Depression After Intensive Care Requiring Mechanical Ventilation

Clara Reece Medici, B.S.

P5-050

Analysis of 30-Day Readmissions in the Context of an Atypical Psychiatric Presentation

Sahil Munjal, M.D.

P5-051

Current Trends and Attitudes of Residents Toward Personal Psychotherapy During Residency Training

Sahil Munjal, M.D.

P5-052

Utilization of Crisis Helplines as a Coping Tool: A Case Report

Insiya Nasrulla, M.B.B.S.

P5-053

Use of Involuntary Medication, Seclusion and Restraint in a State Psychiatric Hospital

Malini Neramballi, M.D.

P5-054

Evaluation of Risk Factors for Antipsychotic Polypharmacy in Patients Admitted to Psychiatric Units: A Retrospective Analysis

Shreedhar Paudel, M.D., M.P.H.

P5-055

Metrics of Care Received by Catatonic Patients at Duke University Hospital

Gopalkumar Rakesh, M.D.

P5-056

Health Care Utilization in an Elderly Patient With Somatic Symptom Disorder

Matthew Richter, M.D.

P5-057

Alcoholism and Legal Implications

María Robles Martínez

P5-058

Emotional Flexibility and Post-Traumatic Stress Disorder Among Combat Veterans

Rebecca Rodin, M.Sc.

P5-059

Patient Characteristics, Attitude and Perceptions of Being Physically Restrained During Hospitalization

Lorena Rodriguez, M.D.

P5-060

A Case Study of Acute Onset of Mania in the Context of Mild Traumatic Brain Injury

Courtney Ann Romba, M.D.

P5-061

Childhood Factors Affecting Persistence and Desistence of ADHD Symptoms in Adulthood: Results From the MTA

Arunima Roy, M.B.B.S.

P5-062

Gene-Environment Interplay in Severity of Cognitive Impairment in Psychotic Patients

Geetanjali Sahu, M.B.B.S.

P5-063

A Case of Clinical Confusion: When Lennox-Gastaut Syndrome Is Mistaken for an Anxiety Disorder

Meghan Schott, D.O.

P5-064

Treating Incompetence to Stand Trial

Cristina M. Secarea, M.D.

P5-065

Excited Delirium With Bath Salts and Designer Drugs: A Clinical, Toxicological, Public Health and Legal Perspective

Pooja Shah, M.D.

P5-066

Aftereffects of Legalization of Marijuana: America on the Giant Chill Pill!

Pooja Shah, M.D.

P5-067

Oral Ketamine for Treatment-Resistant Major Depression: A Double-Blind Randomized Controlled Trial

Haggai Sharon, M.D.

P5-068

Left Ventricular Thrombus as a Complication of Clozapine-Induced Cardiomyopathy: A Case Report

Balwinder Singh, M.D., M.S.

P5-069

Explanatory Models of Addictive Behavior Among Ugandans

Hanna Sjöstrand, M.D.

P5-070

Neurobiological Evidence of Vulnerability to PTSD in ADHD: A Controlled MRI Study Assessing Fear Circuitry in Non-Traumatized Adults With ADHD

Andrea E. Spencer, M.D.

P5-071

The King of Spirochetes Goes Wild! Neurosyphilis-Triggered Mania

Leah R. Steinberg, M.D.

P5-072

Changes in FDA Guidelines for a Clozapine Monitoring System in the Veteran Affairs Medical System

Ryan S. Sultan, M.D.

P5-073

Examining the Clinical Course of Major Depressive Disorder in Severely Obese Patients: The Toronto Obesity Psychosocial Cohort Study

Gurneet S. Thiara, M.D.

P5-074

Tobacco Use in First-Episode Psychosis: Clinical Characteristics at Baseline

Alba Toll, M.D.

P5-075

Neurocognitive Performance in Adult Patients With ADHD, Bipolar Disorder (BPD) and Comorbid ADHD/BPD: Are There Different Neurocognitive Profiles?

Imma Torres Vilamajó, Psy.D., M.B.A., M.Sc.

P5-076

The Summer Bridge Program: Recruiting Youth for a New Generation of Mental Health Professionals

David Tran, M.D., M.P.P.

P5-077

Changes in Patient Beliefs Regarding Treatment Assignment Within a Placebo-Controlled Randomized Controlled Trial of Major Depressive Disorder

Sagar Vijapura, M.D.

P5-078

Sociocultural Influence on Delusional Content in a Japanese Woman With Erotomania: A Clinical Case Report

Jose Vito, M.D.

P5-079

How Do We Analyze Long-Term Injection Behavior Among Heroin Abusers?

Shao-Cheng Wang, M.D., Ph.D.

P5-080

Predicting Hospitalization During Emergency Department Visits by Children and Adolescents for Psychiatric Complaints

Anna K. Wiste, M.D., Ph.D.

P5-081

Utilizing Measures of Client Motivation as Indicators of Completion in Residential Substance Use Disorder Treatment in the Public Mental Health System

Keith Wood, M.D.

P5-082

Reminiscence Therapy in a Patient With Depression Following Glioblastoma Multiforme Resection

Lindsay Works, D.O.

P5-083

Pentosan Polysulfate Sodium Specifically Reduced Plasma Level of Soluble P-Selectin in a Patient With Schizoaffective Disorder

Fang Yang, M.D., Ph.D.

P5-084

Longitudinal Impact of Current Irritability in Bipolar Disorder

Laura D. Yuen, B.A.

P5-085

Alcohol and Drug Dependence in Terms of Attachments: Possible Developmental Precursors

Dana Zeid

P5-086

Development of the Working Memory Test Battery in Chinese Older Adults

Layan Zhang, M.B.B.S., M.S.

P5-087

Canine-Assisted Group Psychotherapy for Hospitalized Psychiatric Patients With Mood and Psychotic Disorders: A Pilot Study

Brittany B. Albright, M.D., M.P.H.

P5-088

Polycystic Ovarian Syndrome in Patients Presenting to Mental Health: Incidence, Natural History and Treatment

Eric Meyer, M.D.

6

Poster Session 6
Monday, May 16

New Research Poster 1

2:00 P.M. - 4:00 P.M.

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

P6-001

Mesial Temporal Lobe Resection and Impulse Control Dysfunction in a 33-Year-Old Female

Matthew Richter, M.D.

P6-002

General Medical Conditions Occurring Before Suicide: A Case-Control Study

Brian K. Ahmedani, Ph.D., M.S.W.

P6-003

Use of Lithium in Inpatients With Acute Bipolar Mania

Cana Aksoy Poyraz, M.D.

P6-004

Association Between Neuroticism and Future Occurrence of Cardiovascular Diseases Among Depressed Persons in a Swedish Population

Aysha Almas, M.B.B.S., M.Sc.

P6-005

Depression in Saudi Patients With Systemic Lupus Erythematosus: A Multicenter Study

Abdulrahman Alwahibi, M.D.

P6-006

WITHDRAWN

P6-007

Chronobiological Characteristics of Bipolar and Recurrent Depression

Sergejus Andruskevicius, M.D.

P6-008

How Do Anger Expressed Inward and Anger Expressed Outward Differentially Relate to Depression, Impulsivity and Suicide Risk?

Firouz Ardalan, B.A.

P6-009

Demographic Differences in Disruptive Mood Dysregulation Disorder (DMDD) Symptoms in Psychiatric and General Population Samples

Raman Baweja, M.D., M.S.

P6-010

Comparing Caregiver Burden in Schizophrenia, Bipolar Disorder and Major Depression

Saagar Seth, B.S.

P6-011

The Effects of Long-Acting Injectables on Polypharmacy

Niketa Parikh, B.S.

P6-012

Development of an Educational Resource and Model Curriculum for Psychiatric Trainees on Use of Psychotropic Medications During Pregnancy and Lactation

Sheema Khan, M.D.

P6-013

The Relationship Between ADHD and Substance Use Disorders Among Adolescents in a Residential Setting

Amy B. Carnall, D.N.P., N.P.

P6-014

Relationship of Cariprazine Plasma Concentration to Efficacy and Safety in Patients With Schizophrenia or Bipolar Mania

Timothy J. Carrothers, Sc.D.

P6-015

Medical Comorbidity in Vascular Neurocognitive Disorders: A Matched Case-Control Study

Miguel Habeych, M.D., M.P.H.

P6-016

WITHDRAWN

P6-017

Prevalence of Disruptive Mood Dysregulation Disorder (DMDD) and Its Comorbidity With Other Clinical Disorders

Daria Chase, Ed.M.

P6-018

Efficacy of HLD200 in a Phase III Analog Classroom Study of Children With Attention-Deficit/Hyperactivity Disorder

Ann C. Childress, M.D.

P6-019

Parental Age as a Risk Factor for Obsessive-Compulsive Disorder (OCD) in a Nationwide Population-Based Sample

Roshan Chudal, Ph.D., M.B.B.S., M.P.H.

P6-020

Multidimensional Relationship Between Auditory Verbal Hallucinations and PANSS Factors of Psychopathology in Patients With Schizophrenia

In-Won Chung, M.D., Ph.D.

P6-021

Effectiveness of Electroconvulsive Therapy on Clozapine-Resistant Schizophrenia

In-Won Chung, M.D., Ph.D.

P6-022

Risk Factors and Population Attributable Fractions of Suicidal Ideation Among Korean Elderly

Sang-Keun Chung

P6-023

Mental Health Status Among Users of Mobile Mental Health Application "Mindscan" in Korea

Jong-Il Park, M.D., Ph.D.

P6-024

Impact of Dose on Duration of Atomoxetine Treatment in Adults With ADHD

David B. Clemow, Ph.D.

P6-025

Prehospital Diversion of Patients With Acute Mental Health Crises

Jamie O. Creed, B.S.

P6-026

Age at Onset in Patients With Bipolar I and II Disorders: A Comparison of Large-Sample Studies

Bernardo Dell'Osso, M.D.

P6-027

Treatment of Unipolar, Nonpsychotic Major Depressive Disorder With Transcranial Magnetic Stimulation: Examining Long-Term Efficacy of TMS

Kim K. Cress, M.D.

P6-028

A Retrospective Analysis of Transcranial Magnetic Stimulation Right Dorsolateral Prefrontal Cortex Treatments for Generalized Anxiety Disorder

Kim K. Cress, M.D.

P6-029

Mindfulness-Based Cognitive Therapy Versus Psychoeducation in Bipolar Outpatients With Subthreshold Depressive Symptoms: Preliminary Results

Consuelo De Dios, M.D., Ph.D.

P6-030

Shorter Time to Depressive Recurrence in Bipolar II Versus Bipolar I Disorders

Bernardo Dell'Osso, M.D.

P6-031

General and Mental Health Outcomes in Outdoor Behavioral Health Care: An Integrated Care Approach

Steven M. DeMille, Ph.D.

P6-032

Predictive Validity of the Modular Assessment of Risk for Imminent Suicide (MARIS) Scale: A Novel Approach to Suicide Risk Assessment

Nicole E. Derish, M.D.

P6-033

When Clozapine Fails: Acute Admissions of Patients With Treatment-Resistant Schizophrenia Who Relapsed Following Clozapine Therapy: Preliminary Data

Luiz Dratcu, M.D., Ph.D.

P6-034

Thyroid Axis Activity and Dopamine Function in Major Depression

Marie-Claude Mokrani, Ph.D.

P6-035

Early Changes in Prolactin Secretion During Antidepressant Treatment

Alexis Erb, M.D.

P6-036

An Interesting Relationship in a Psychodermatology Clinic: A Retrospective Study on the Correlation of Delusions of Infestation and Narcotic Use.

Kristin V. Escamilla, M.D.

P6-037

Severity of PTSD Symptoms and Its Relationship With Severity of Alcohol-Related Problems in a Sample of Inpatients With Alcohol Use Disorder

Cuneyt Evren, M.D.

P6-038

Severity of Craving Related to Severity of Adult ADHD Symptoms Among Inpatients With Alcohol Use Disorder

Cuneyt Evren, M.D.

P6-039

Relationship Between Self-Mutilative Behavior and Impulsivity, Suicide Attempt and Early Onset Alcoholism Among Inpatients With Alcohol Use Disorder

Cuneyt Evren, M.D.

P6-040

Relationship Between ADHD and Dissociative Experiences and PTSD in a Sample of Inpatients With Alcohol Use Disorder

Cuneyt Evren, M.D.

P6-041

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Measuring the Efficacy and Safety of MLR Methylphenidate in Adults With ADHD

Angelo Fallu, M.D.

P6-042

Abnormal Resting State Functional Connectivity in the Anterior Cingulate Cortex in Obsessive-Compulsive Disorder Patients

Qing Fan, M.D., Ph.D.

P6-043

Home Treatment in Germany: Current Implementation Status

Karel J. Frasch, M.D.

P6-044

Atomoxetine for Hoarding Disorder: A Preclinical and Clinical Investigation

Giacomo Grassi, M.D.

P6-045

Distribution of Disability Attributable to Mental and Behavioral Disorders Due to Psychoactive Substances in China

Qi Guo, Ph.D.

P6-046

WITHDRAWN

P6-047

Antidepressant Adherence and Prevention of Suicidal Ideation

Fady Henein, M.D.

P6-048

The Use and Value of the Seven-Item Binge Eating Disorder Screener in Clinical Practice

Barry K. Herman, M.D.

P6-049

Adherence and Insight Into the Need for Medication in Schizophrenia: Perspective of Antipsychotic Clinical Trial Participants

Marla Hidalgo, D.O.

P6-050

Two-Year Mirror Image Evaluation of Paliperidone Palmitate in an English Health Trust

Richard E. Hodgson, M.D., M.B.B.S., M.Sc.

P6-051

A Cross-Sectional Study of Common Mental Disorders in Community Dwellers in Beijing

Yueqin Huang, M.D., Ph.D., M.P.H.

P6-052

WITHDRAWN

P6-053

A Cross-Sectional Study of Disability Prevalence Attributable to Autism Spectrum Disorders and Its Distribution in Children and Adolescents in China

Ning Ji

P6-054

Expected and Unexpected Findings in a Study of Depot Medication

Per-Axel L. Karlsson, Ph.D.

P6-055

Soft Signs—a Clinical Reality! Neurological Soft Signs in Patients With Schizophrenia, Schizoaffective Disorder and Bipolar Disorder

Per-Axel L. Karlsson, Ph.D.

P6-056

ECT Augmentation in Schizophrenia—Clinical Effectiveness and Cognitive Impact: A Large Retrospective Review

Tyler Kaster, M.D.

P6-057

Faster Recurrence Related to Episode Accumulation in Bipolar Disorder

Terence A. Ketter, M.D.

P6-058

Difficulties in Managing Alcohol Withdrawal Delirium in a Patient With a History of Schizophrenia

Andrey Khalafian, M.D.

P6-059

Decreased Task-Positive Network Connectivity in Abstinent Patients With Alcohol Dependence

Siekyeong Kim, M.D., Ph.D.

P6-060

VEGF May Have a Neuroprotective Role in the Improvement of Schizophrenia or in the Treatment Effects of Antipsychotics

Yong-Ku Kim, M.D., Ph.D.

P6-061

Mitochondrial Dysfunction and Lipid Peroxidation in Rat Frontal Cortex by Chronic NMDA Administration Can Be Partially Prevented by Lithium Treatment

Helena K. Kim, Ph.D.

P6-062

Discovery of Serum Protein Biomarkers in Drug-Free Patients With Major Depressive Disorder

Eun Young Kim, M.D., Ph.D.

P6-063

A Comparison of Clinical and Sociodemographic Characteristics of Elderly and Nonelderly Suicide Attempters

Hyun Kim, M.D., Ph.D.

P6-064

Early Menarche and Risk-Taking Behavior in Korean Adolescence

Seong Hwan Kim, M.D., Ph.D.

P6-065

Association Between Cytokine Gene (IFN- γ , TNF- α , IL-10) Polymorphisms With Panic Disorder

Han-Joon Kim, M.D.

P6-066

Combination of Maintenance Electroconvulsive Therapy (ECT) and Clozapine in a Patient With Refractory Schizophrenia: A Case Report

Chul-Eung Kim, M.D., Ph.D.

P6-067

Epigenetic Regulation of the Glucocorticoid Receptor Promoter 17 in Maternally Deprived and Restrained Adult Rats

Young Hoon Kim, M.D., Ph.D.

P6-068

Effects of p11 on BDNF-Induced Changes in Dendritic Outgrowth and Spine Formation in Primary Hippocampal Cells

Young Hoon Kim, M.D., Ph.D.

P6-069

Prevalence of Depression and Anxiety in Phase I Clinical Trial Oncology Patients at an Academic Cancer Center: A Pilot Study
Natalie Kurkjian, M.D.

P6-070

Pharmacogenetics of Lithium Response in Bipolar Disorder in a Genetically-Isolated Population of Latin America
Carlos López-Jaramillo, M.D., Ph.D.

P6-071

Emotion Recognition After the Psychotic State: A Longitudinal Study
Guillermo Lahera, M.D., Ph.D.

P6-072

Double-Blind Comparison of Vilazodone and Paroxetine in Geriatric Depression
Helen Lavretsky, M.D.

P6-073

High Use of Psychotropics Overdose Among Suicide Attempters in Korea
Kyoung-UK Lee, M.D.

P6-074

Validation of the Korean Version of the Clinical Assessment Interview for Negative Symptoms
Seung-Hwan Lee, M.D., Ph.D.

P6-075

Transitions in Problematic Internet Use: A One-Year Longitudinal Study of Boys
Sang Kyu Lee, M.D., Ph.D.

P6-076

Smartphone Addiction in Korean Adolescents and Related Factors: Focusing on Smartphone Use Patterns and Parent-Child Relationships
Hyuk Lee, M.D.

P6-077

Gambling Disorder and Concurrent Alcohol Use Disorder Treated With Naltrexone: A Case Report and Review of the Literature
Alexandra Takayesu, M.D., M.P.H.

P6-078

Does Change in Cognition Affect Functioning After Cognitive Remediation Intervention for Patients With Schizophrenia?
Jean-Pierre Lindenmayer, M.D.

P6-079

A Five-Year Follow-up Study of Mild Cognitive Impairment Incidence in Two Urban and Rural Communities in Beijing
Zhaorui Liu, M.D., Ph.D., M.P.H.

P6-080

Association of SFlt-1 With Progressive Cortical Thickness Reduction: A Preliminary Longitudinal Study of Familial High Risk for Psychosis
Paulo L. Lizano, M.D., Ph.D.

P6-081

A Review of the Literature on Long-Acting Injectable Antipsychotics in Children, Adolescents and Transitional-Age Youth
Sarah M. Lytle, M.D.

P6-082

Psychotropic Drug Changes Contributing to Readmissions in Medically Hospitalized Psychiatric Patients: A Retrospective Study
Subramoniam Madhusoodanan, M.D.

P6-083

Associated Factors on Caregiver Burden and Quality of Life in Patients With Schizophrenia
Se-Ri Maeng, M.D.

P6-084

Clinical Response and Symptomatic Remission With Aptensio XR[®] (Methylphenidate Extended-Release Capsules) in Children and Adolescents With ADHD
Greg Mattingly, M.D.

P6-085

Psychiatric and Nonpsychiatric Consultations for Substance-Related Emergency Department Visits in a Canadian University-Affiliated Hospital Setting
Mir N. Mazhar, M.D.

P6-086

Atomoxetine Treatment and Sluggish Cognitive Tempo in Children With ADHD and Comorbid Dyslexia or Dyslexia in a Randomized, Placebo-Controlled Trial
Keith McBurnett, Ph.D.

P6-087

Reducing Burnout in Military Health Care Professionals Through Mind Body Medicine
Jeffrey Millegan, M.D., M.P.H.

P6-088

Advances in Psychodynamic Psychiatry: Separation Anxiety
Elizabeth L. Auchincloss, M.D.

P6-089

Multimorbidity, Gender and Schizophrenia: A Quebec Cross-Sectional Study
Javad Moamai, M.D., M.Sc.

P6-090

Association of Cardiovascular Risk Factors With Cognitive Impairment in Individuals With Schizophrenia: A Systematic Review
Satyajit Mohite, M.D., M.P.H.

P6-091

Impaired Interactions Between Circadian Activity of the HPA and HPT Axes in Depression
Marie-Claude Mokrani, Ph.D.

P6-092

Resource Use and Cost in a Randomized, Non-Inferiority Trial of Paliperidone Palmitate 3- Versus 1-Month Formulations in Patients With Schizophrenia
Carmela Benson, M.S.

P6-093

Long-Term Treatment of Panic Disorder With Clonazepam or Paroxetine Does Not Prevent Relapse After Drug Withdrawal
Antonio E. Nardi, M.D., Ph.D.

P6-094

The Association Between Psychiatric Disorders and Overactive Bladder
Nicole Negbenebor, B.S.

P6-095

Impact of Early Psychiatric Consultation on Length of Hospital Stay
Ivan Nikiforov, M.D.

P6-096

A Psychosocial Assistance Program for Trauma Survivors and Violence Victims in Colombia: Evaluation and Lessons Learned
Jorge Ospina Duque, M.D.

P6-097

Who Eats More Cake? A Comparison of Food Addiction Prevalence in the General Population and a Population With Severe Mental Illness
Nagesh Pai, M.D.

P6-098

Health Care Resource Use in Schizophrenia Patients Treated With Long-Acting Injectable Antipsychotics: Risperidone Versus Paliperidone Palmitate
Kruti Joshi, M.P.H.

P6-099

Depressive Symptom Profiles Indicating the Potential for Depression in Elderly Patients With Chronic Physical Diseases
Seon-Cheol Park

P6-100

Factor Structure of the Clinician-Rated Dimensions of Psychosis Symptom Severity in Patients With Schizophrenia
Seon-Cheol Park

P6-101

Predicting Placebo Responders: Shifting Report Frames
Steven Pashko, Ph.D.

P6-102

Clinical Lycanthropy Exacerbated by Comorbid Cannabis Use Disorder: A Case Report
Rachit Patel, M.D.

P6-103

Trends in Depression-Related Hospitalizations in the United States From 2008 to 2012
Ankur Patel, M.D.

P6-104

Outcomes Among Schizophrenia Patients Recently Hospitalized or Nonadherent to Antipsychotic Therapy
Jacqueline Pesa, Ph.D., M.P.H.

P6-105

Motives to Use Drugs in Body Dysmorphic Disorder
Katharine A. Phillips, M.D.

P6-106

Medicaid Spending in Schizophrenia Patients Reaching Versus Not Reaching Stabilized Maintenance With Once-Monthly Paliperidone Palmitate
Erik Muser, Pharm.D., M.P.H.

P6-107

Low Heritability of Neopterin in the Old Order Amish
Uttam Raheja, M.B.B.S.

P6-108

The Serum S100B as a Potential Marker in Bipolar Spectrum Disorder in Adolescents and Young Adults: Preliminary Results
Aleksandra Rajewska-Rager, M.D., Ph.D.

P6-109

Tardive Dyskinesia and Valbenazine (NBI-98854) Response as a Function of Concomitant Antipsychotic Use
Gary Remington, M.D.

P6-110

Correlates and Patient-Reported Outcomes of Reaching Early Maintenance Therapy on Paliperidone Palmitate in Community Behavioral Health Organizations
Jeffrey Anderson, Sc.D.

P6-111

A Randomized Controlled Trial of Targeted Training in Illness Management Versus Treatment as Usual in People With Serious Mental Illness and Diabetes
Martha Sajatovic, M.D.

P6-112

Residual Patient-Reported Cognitive Dysfunction: A Potential Predictor for Relapse in MDD?
Delphine Saragoussi, M.D., M.P.H.

P6-113

Paliperidone Palmitate Three-Month Versus One-Month Formulation in Patients With Schizophrenia: A Randomized, Double-Blind, Non-Inferiority Study
Srihari Gopal, M.D., M.H.S.

P6-114

Symptomatic Remission Status in Schizophrenia Patients Treated With Paliperidone Palmitate (One-Month and Three-Month Formulations)
Srihari Gopal, M.D., M.H.S.

P6-115

Clinical Anger Scale Among Iranian Admitted Patients With Schizophrenia
Jalal Shakeri, M.D.

P6-116

Psychobiology of Suicidal Behavior in Combat Veterans
Leo Sher, M.D.

P6-117

Positive Psychological Characteristics Among Recently Discharged Patients: Strategy for Prevention of Rehospitalization
Amresh Shrivastava, M.D.

P6-118

Neosensitization to Multiple Drugs Following Valproate-Induced DRESS Syndrome
Jaemin Song, M.D.

P6-119

Clinical Significance of Restless Legs Syndrome in Patients With Late-Life Depression
Jaemin Song, M.D.

P6-120

Trends in Compassionate Use of Investigational Medicines and Implications for Mental Health Professionals
Allitia DiBernardo, M.D.

P6-121

A Study of Dog Adoption in Veterans With PTSD
Stephen L. Stern, M.D.

P6-122

Alcohol Use and Its Relation to Future Time Perspective and Need for Achievement in a Sample of Medical Students
Jagannath Subedi, M.D.

P6-123

Alterations of the Cortisol and Dehydroepiandrosterone in Perinatal Depression
Chan-Hyung Kim, M.D., Ph.D.

P6-124

Relation Between Amyloid PET Data and Clinical Factors Including Cognitive Function in Geriatric Depression: A Pilot Study
Wan-Seok Seo, M.D., Ph.D.

P6-125

Reduced Prefrontal Cortex Hemodynamic Response in Adults With Methamphetamine-Induced Psychosis
Kazuhiko Yamamuro, M.D., Ph.D.

P6-126

Eyes Open/Closed Resting State EEG Source Analysis of Children With Autism Spectrum Disorders and Those With Typical Development: A One-Year Follow-Up
Hidetoshi Takahashi, M.D., Ph.D.

P6-127

Author- and Study-Funding Sources at the American Academy of Adolescent and Child Psychiatry New Research Poster Sessions
Thomas P. Tarshis, M.D., M.P.H.

P6-128

Comparative Evaluation of Vortioxetine as a Switch Therapy in Patients With Major Depressive Disorder
Michael E. Thase, M.D.

P6-129

Clinical and Social Status of Adults With Possible or Probable Schizophrenia Undergoing Substance Abuse Treatment Evaluation
Megan Jones, Pharm.D., M.P.A.

P6-130

Psychiatric Inpatient Suicide: A National Register-Based Study
Mei-Chih M. Tseng, M.D., Ph.D.

P6-131

Hoarding Prevalence in Users of Online Classified Advertisements
Michael Van Ameringen, M.D.

P6-132

A Pilot Study Evaluating the Gut Microbiome in Obsessive-Compulsive Disorder Versus Healthy Controls
Michael Van Ameringen, M.D.

P6-133

Multiple-Rater Assessment of Personality Disorders in a Sample of Substance-Abusing Women
Adriana Vannucci, M.D.

P6-134

Domestic Squalor: A Community Mental Health Issue
Cenk Varlik, M.D.

P6-135

Inclusion of an Expert Patient as Co-Coordinator in Psychoeducation Workshops for Family Members of Bipolar Patients: An Innovative Model
Carlos Vinacour, M.D.

P6-136

A Register-Based Case-Control Study of Prescription Medication Utilization in Binge Eating Disorder
Barry K. Herman, M.D.

P6-137

Randomized, Double-Blind Study of the Time-Course of Effect of MLR Methylphenidate in ADHD Adults in a Simulated Adult Workplace Environment
Sharon B. Wigal, Ph.D.

P6-138

WITHDRAWN

P6-139

Differential Patterns of Blood Oxygenation in the Prefrontal Cortex Between Patients With Methamphetamine-Induced Psychosis and Schizophrenia
Kazuhiko Yamamuro, M.D., Ph.D.

P6-140

Hyperpigmentation and Bizarre Delusions: A Case Report
Alan C. Yancovitch, M.D.

P6-141

Predictors of Fear of Falling Among Community-Living Elderly People in Korea: Mediation Effect of Depression and Subjective Health Status
Jong-Il Park, M.D., Ph.D.

P6-142

Therapeutic Dose of Venlafaxine ER Induced Seizure: A Case Report
Chuanzhong Ye, M.D., Ph.D.

P6-143

Descriptive Epidemiology of Disability Attributable to Behavioral Syndromes Associated With Physiological Disturbances and Physical Factors in China
Tingting Zhang

P6-144

The DSM-5 Anxious Distress Specifier Interview: Reliability and Validity
Mark Zimmerman, M.D.

P6-145

A Clinically Useful Screen for Borderline Personality Disorder in Psychiatric Outpatients
Mark Zimmerman, M.D.

P6-146

ITI-007 for the Treatment of Schizophrenia: Primary and Secondary Efficacy Endpoints and Subgroup Analyses From Two Positive Randomized, Double-Blind, Placebo-Controlled Clinical Trials
Cedric O'Gorman, M.D.

P6-147

ITI-007 for the Treatment of Schizophrenia: Safety and Tolerability Data to Date From Two Double-Blind, Randomized, Placebo-Controlled Clinical Trials
Cedric O'Gorman, M.D.

P6-148

Prescription Drug Monitoring Programs: Does the Arizona CSPMP Provide More Information Than Routinely Collected in an Inpatient Psychiatric Facility?
Shabnam Sood, M.D.

P6-149

Cannabis and Synthetic Cannabinoids' (K2) Association With Psychosis Compared to Other Substances
Anahita Bassirnia, M.D.

P6-150

Metabolic and Inflammatory Parameters of Clinical High Risk (CHR) for Developing Psychosis and Healthy Control Subjects: A Case Control Study
Isabel Ribeiro Caldas Domingues, M.D.



Young Investigators' New Research 2

10:00 A.M. – Noon

Exhibit Hall B3-B4, Level 1

Georgia World Congress Center

P7-001

Childhood Trauma Predicts Cluster B Personality Pathology
Victoria Fink, M.D.

P7-002

Intra-Muscular Olanzapine for Agitation and Aggression in Schizophrenia: A Systematic Review and Meta-Analysis
Vishesh Agarwal, M.D.

P7-003

Olfactory Processing Ability and Risky Decision Making in HIV Patients

Mohammed W. Ahmed, M.D.

P7-004

NIH Toolbox Fluid Cognition Composite Scores Are Associated With IL-1 β and IL-10 in Patients With Schizophrenia

Osarhiemen Ruth Aimienwanu, M.B.B.S.

P7-005

Sociodemographic Variables and Concurrent Substance Use Are Not Predictors of Synthetic Cannabis Use

Mohammed A. Azam, M.D.

P7-006

Telecourt Versus Traditional Court for Involuntary Civil Commitments

Sailaja Bysani, M.D.

P7-007

Group Process While Community Building as a Psychiatric Resident

Marc L. Campbell, D.O., Ph.D.

P7-008

New-Onset Psychosis in a Patient on Ketamine Treatment for Depression: A Case Report

Arthur Thomas Carter, M.D.

P7-009

WITHDRAWN

P7-010

Trends in Asian-American Utilizers of County Mental Health Services

Richard J. Lee, M.D.

P7-011

A Meta-Analysis of Placebo-Controlled Trials of NAC Augmentation in Schizophrenia: Possible Oxidative Profile Effects

Alexander Chen, B.A.

P7-012

Frontal Alpha Asymmetry in People With Early Life Trauma: A Resting-State Magnetoencephalography Study

Jooah Cheon

P7-013

Effects of Psychotropic Drugs on Seizure Threshold During Electroconvulsive Therapy

Su Hyuk Chi

P7-014

The Effects of Caregiver Burden, Depression and Emotion Expression on a Patient's Perceived Criticism in Bipolar Disorder

Jenna Cohen, B.A.

P7-015

Neurocognitive Functions Characteristics of Mild Cognitive Impairment With Depression

Hyunseok Dong, M.D., Psy.D.

P7-016

Efficacy of Azithromycin Treatment for PANDAS in a Pediatric Outpatient Setting

Sarah Elmi, M.D.

P7-017

What Happened to the Fax? Qualitative Evaluation of Specialty Mental Health Referrals to Transition Care to Primary Care

Anna Fiskin, M.D., M.Sc.

P7-018

Patients With Psychotic Disorders Recognize Facial Emotional Expression Better in Emoticons Compared to Images

Mohammad A. Ghairatmal

P7-019

C-Reactive Protein Is Associated With Symptom Severity in Patients With Schizophrenia

Sumana Goddu, M.D., M.P.H.

P7-020

Impulsivity and Anhedonia in Bipolar Patients

Mariah Hawes, B.S.

P7-021

Two Threshold or Four Subthreshold Mood Elevation Symptoms Prolong Time to Recovery From Bipolar Depression

Farnaz Hooshmand, M.D.

P7-022

Trait Aggression and Relationship With Plasma Phenylalanine/Tyrosine Ratio and Toxoplasma Gondii Seropositivity

Ashwin Jacob Mathai, M.D.

P7-023

Exploratory and Confirmatory Factor Analysis of Penn State Worry Questionnaire (PSWQ)

Junwon Jeon, M.D.

P7-024

Work Productivity Improvement in Recurrent MDD Patients: Implications for Future Clinical Improvement

Manish K. Jha, M.B.B.S.

P7-025

Noncompliance to Antipsychotic Medication and Nonpsychiatric Medical Service Utilizations Among Patients With Schizophrenia and Its Related Psychoses

Soohyun Joe

P7-026

WITHDRAWN

P7-027

Hypokinesia, Cognitive Slowing and Emotional Dysregulation in a 17 Year Old: A Diagnostic Conundrum

Amanjot Kaur, M.B.B.S.

P7-028

Self-Esteem, Impulsivity and Suicidal Ideation in Mood Disordered Patients

Kahlen Hong Seon Kim, B.A.

P7-029

The Volumes of Temporal Lobe and Limbic System Are Associated With Treatment Response of Delusional Symptoms to Risperidone in Alzheimer's Disease

Kyungwon Kim, M.D.

P7-030

Anger Coping Styles in Korean Patients With Mood Disorders

HwaGyu Suh, M.D.

P7-031

Case Series: Deliberate Foreign Body Ingestion and Borderline Personality Disorder

Timothy Kiong, M.D.

P7-032

The Dietary Status of Adults With ADHD

Jesper N. Kjaer

P7-033

Evaluating the Risk of Venous Thromboembolism With Atypical Antipsychotic Initiation

Jessica A. Koenig, M.D.

P7-034

Introduction to Psychopharmacology for Psychology Interns: A Pilot Study and Sample Curriculum

Jason V. Lambrese, M.D.

P7-035

Comparison of Wearable Activity Tracker to Actigraphy for Measurement of Sleep-Wake Cycle

Hyun-Ah Lee, M.D.

P7-036

Self-Reported Empathic Responding in Euthymic Patients With Bipolar I Disorder: A Comparison With Schizophrenia Patients and Healthy Controls

Byeonghee Lee, M.D.

P7-037

Rare Occurrence of Covert Dyskinesia After Aripiprazole Discontinuation: A Case Report and Literature Review

Ahmad Hameed, M.D.

P7-038

Mass Shootings and Gun Laws: The Roles of Mental Illness and Psychiatrists on This Debate

Pankaj Manocha, M.D.

P7-039

Illness Insight and Risk for Suicidal Behavior in Bipolar Disorder

Deimante McClure, B.A.

P7-040

The Dilemma of Syrian Refugees

Aida Spahic Mihajlovic, M.D., M.S.

P7-041

Recruitment, Ideology and Strategic Prevention in Radical Extremism: A Literary Review

Aida Spahic Mihajlovic, M.D., M.S.

P7-042

Seasonal Variation in Sleep Duration in the Old Order Amish in Relation to Previously Reported Data in Preindustrial and "Modern" Societies

Hira Mohyuddin

P7-043

Effectiveness of Urgent Outpatient Services in Reducing School-Referred Emergency Room Mental Health Visits

Douna MontazerAlghaem, M.D.

P7-044

Magnetic Resonance Spectroscopy Identifies a Treatment-Resistant "Hyperglutamatergic" Obsessive-Compulsive Disorder Subtype

Ross J. Mudgway

P7-045

Association of Vasomotor Symptoms With Depression, Anxiety, Stress and Metabolic Syndrome in Korean Peri- and Postmenopausal Women

Yoonmin Nam

P7-046

Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine

Malik Nassan, M.B.B.S.

P7-047

Immediate Mental Health and Psychosocial Problems Among Victims of the Mega Earthquake in Nepal: A Cross-Sectional Study

Hitekshya Nepal, M.D.

P7-048

Importance and Utilization of Family Therapy in Training: Resident Perspectives

Sarah A. Nguyen, M.D.

P7-049

Hospital Staff Burnout and Fatigue at a Military Medical Center During Government Shutdown

Samuel A. Nicolas, M.D.

P7-050

Associations Between Metabolic and Cardiovascular Risk Factors and Nitrite Levels in the Old Order Amish

Gursharon Nijjar, M.D.

P7-051

Personality, Cortisol and Cognition in Nondemented Subjects: A Population-Based Study

Sami Ouanes, M.D.

P7-052

NIH Toolbox Dimensional Change Card Sort Test Is Negatively Correlated With Plasma Cytokines in Patients With Schizophrenia

Ruchirkumar Arvind Patel, M.B.B.S.

P7-053

The Assessment of Hedonic Capacity in Depressed and Healthy Populations: The Snaith-Hamilton Pleasure Scale Modified for Clinician Administration

Roderic Pettigrew, B.S.

P7-054

Recurrent Self-Injurious Behavior With Subcutaneous Foreign Body Insertion in a Teenager: An Interesting Case Study

Diana Mungall Robinson, M.D.

P7-055

Admission Crisis Prevention Plan: A Tool for De-Escalation in an Acute Care Adult Psychiatric Setting

Nandita Puchakayala, M.B.B.S.

P7-056

Evaluation and Management of Functional Neurological Symptoms in Patients With Multiple Sclerosis

Naema Qureshi, M.D.

P7-057

A Case of Gender Dysphoria With Comorbid Psychotic Symptoms

Saumya Rachakonda, M.D.

P7-058

Treating Depression: The Art of Self-Healing With Intermittent Fasting

Sanjeev K. Rally, M.D.

P7-059

A Case of Catatonia and Epstein Barr Virus: Review of the Literature for Catatonia and Viral Infection

Aimy Rehim, M.D., M.P.H.

P7-060

Psychiatric Comorbidities in Eating Disordered Patients

Kathryn K. Ridout, M.D., Ph.D.

P7-061

Sex Differences in Adolescent Patients With Eating Disorders

Samuel J. Ridout, M.D., Ph.D.

P7-062

Health Professional Students as Lay Counselors: An Evidence-Informed Model for the Delivery of Behavioral Health to Uninsured Immigrants

Juan Rodriguez-Guzman, B.S.

P7-063

Data Mining of the Stanley Neuropathology Consortium Integrative Database to Understand the Neurobiology of Major Depressive Disorder: GABA

Shilpa Sachdeva, M.D.

P7-064

A Case of Wilson's Disease With Normal Copper Levels Presenting as Mania

Shilpa Sachdeva, M.D.

P7-065

Denying Admission to a "Suicidal" Patient

Stuti Bhandari, M.D.

P7-066

A Comparison of Schizophrenia Patients With or Without Medication Compliance
Dilek Sarikaya Varlik, M.D.

P7-067

Inpatient Psychiatry Home Medication Protocol: Reducing Health Care Costs While Improving Safe Patient Care at a Navy Medical Center
Stephenie A. Scully, M.D.

P7-068

Evaluation of Relationship Between MBTI Personality Factors and Big Five Personality Traits With Premenstrual Symptoms
Mahrokh Shayanpour, M.D.

P7-069

Substance Use in Post-Bariatric Surgery Patients: A Review of the Literature
Sharvari P. Shivaneekar, M.D.

P7-070

Vaping Special K: A Novel Method of Ketamine Ingestion
Jessica J. Sierzchula, D.O.

P7-071

Influence of HTR3 Genetic Variations on Obsessive-Compulsive Disorder: A Single-Marker and Haplotype-Based Association Study
Sungyun Sohn, M.D.

P7-072

Is There a Link Between Chronic Infection With *Toxoplasma Gondii* and Obesity in Schizophrenia?
Alice E. Stone, M.D.

P7-073

Genetic Influences on Cardiovascular Side Effects of ADHD Pharmacotherapy
Ajith Subhash

P7-074

Can the CANS Be Meaningfully Used to Facilitate Transitions in a County Child Mental Health System?
Dawn Sung, M.D.

P7-075

Enhancing Patient Safety in the Context of Patient Falls on Psychiatric Acute Care Units in a Community Hospital
Bibiana M. Susaimanickam, M.B.B.S.

P7-076

Vitamin D Level in Patients With Alcohol Use Disorders: A Review of the Current Literature
Vitor S. Tardelli, M.D.

P7-077

Public Perceptions of Major Depressive Disorder: A 2015 Disease Awareness Survey
Doug Taylor, M.B.A.

P7-078

"Weeding" the Synthetic Weeds: Cutting-Edge Diagnostic Systems to Assess Designer Drug Use
Tina S. Thakrar, M.D., M.B.A.

P7-079

The Impact of PTSD and Perceived Self-Efficacy on Resting State Functional Connectivity in Combat Veterans
Roseann F. Titcombe-Parekh, M.D., Ph.D.

P7-080

Changes in Child and Adolescent Psychiatric Clients' Prescriptions Following New Regulatory Requirements in California
Evan J. Trager, M.D.

P7-081

Preliminary Findings From the Smartphone and Online Usage-Based Evaluation for Depression (SOLVD) Study: Clinical and Electronic Data Agreement
Anh L. Truong, M.D.

P7-082

Scores on NIH Toolbox Pattern Comparison Processing Speed Test Are Negatively Correlated With Plasma Levels of IL-10 in Patients With Schizophrenia
Hema Venigalla, M.B.B.S.

P7-083

Feasibility and Acceptability of Implementing Telepsychiatry for Monolingual Spanish Speakers in a Community Behavioral Health System
Christopher White, M.D.

P7-084

Personality Disorder Comorbidity in Major Depression Inpatient Treatment: An Analysis of Routine Data From the German VIPP Dataset
Hauke F. Wiegand, M.D., Ph.D.

P7-085

Knowledge of and Attitudes Toward Alcohol Use and Alcoholism Among Bar Tenders and Rum Shopkeepers in Saint Vincent and the Grenadines
Maryam Zafer, M.S.

P7-086

Brain Regional Homogeneity Underlying Asthma With Health Anxiety
Yuqun Zhang

8

Poster Session 8
Tuesday, May 17

New Research Poster 2

2:00 P.M. - 4:00 P.M.

Exhibit Hall B3-B4, Level 1
Georgia World Congress Center

P8-001

Exploring the Association Between the Severity of Attention-Deficit/Hyperactivity Disorder and Smartphone Use
Abdullah Akpınar, M.Med.

P8-002

Sleep-Dependent Emotional Memory Consolidation
Rebecca M. Allen, M.D., M.P.H.

P8-003

Suicide Ideation and Behavior Assessment Tool (SIBAT): A Novel Measure of Suicidal Ideation/Behavior and Perceived Suicide Risk
Larry D. Alphs, M.D., Ph.D.

P8-004

A Randomized, Double-Blind, Placebo-Controlled Trial of Deutetrabenazine for the Treatment of Tardive Dyskinesia (ARM-TD)
Karen E. Anderson, M.D.

P8-005

Subchronic Vortioxetine Treatment –but not Escitalopram– Enhances Pyramidal Neuron Activity in the rat Prefrontal Cortex

Francesc Artigas, Ph.D.

P8-006

Mood Stabilizer Therapy for Bipolar Disorder Also Treats Comorbid Chronic Pain

David M. Ash, M.D., M.B.A., M.S.

P8-007

Atypical Neuroleptic Malignant Syndrome: Diagnostic Dilemmas and Treatment Challenges

Hafizullah Azizi, M.D.

P8-008

Effect of Adjunctive Brexpiprazole on Cognitive and Physical Functioning in Five Exploratory, Open-Label Studies on Major Depressive Disorder

Ross A. Baker

P8-009

Antiviral-Induced Depression: A Case Study

Michael Reid Bowes, D.O.

P8-010

Suicide Crisis Syndrome and Near-Term Suicidal Behavior: Validation of the Suicide Crisis Inventory

Jessica Briggs, B.A.

P8-011

Effectiveness of Neurostar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder With Postpartum Onset

David G. Brock, M.D.

P8-012

Evaluation of Paliperidone Palmitate Long-Acting Injectable (LAI) Therapy in Patients With Schizophrenia by Duration of Illness

Brianne Brown, Psy.D.

P8-013

Lurasidone Adjunctive to Lithium or Valproate for Prevention of Recurrence in Patients With Bipolar I Disorder: Results of a 28-Week Study

Joseph Calabrese, M.D.

P8-014

WITHDRAWN

P8-015

Different Attachment Style and Bereavement Response in Parents After Losing a Child Due to Sewol Ferry Accident

Jeong-Ho Chae

P8-016

Unresolved Bereavement and Other Mental Health Problems Among the Bereaved Parents of Sewol Ferry Accident Victims After 18 Months

Jeong-Ho Chae

P8-017

Mental-Physical Comorbidity in Korean Adults: Results From a Nationwide General Population Survey in Korea

Sung Man Chang, M.D., Ph.D.

P8-018

WITHDRAWN

P8-019

Pilot Study of Cardiovascular Risks and Insulin Resistance in Neuroleptic-Induced Parkinsonism (NIP) in Schizophrenia: A Post-Hoc Analysis of RCT

Simon Chiu, M.D., Ph.D.

P8-020

Genetic Risk Factors Associated With Commonly Prescribed Psychotropic Medications

Zia Choudhry, M.D., Ph.D., M.Sc.

P8-021

Understanding Differences in Evaluating Insight Into Psychosis Between Clinicians and Individuals With Schizophrenia

In-Won Chung, M.D., Ph.D.

P8-022

Efficacy of Cariprazine in Negative, Cognitive and Social Function Symptoms of Schizophrenia: Post-Hoc Analysis of a Randomized Controlled Trial

Andrew J. Cutler, M.D.

P8-023

WITHDRAWN

P8-024

Smartphone Apps as Therapy Extenders in Anxiety, Mood and Cognitive Disorders: The Consumer's Perspective

Dale D'Mello, M.D.

P8-025

Spirituality Training in the Medical Curriculum: A Medical Student Perspective

Stacy J. Doumas, M.D.

P8-026

Early Improvement Is a Predictor of Response and Remission in Bipolar I Disorder: A Pooled Analysis of Three Randomized Cariprazine Trials

Suresh Durgam, M.D.

P8-027

Safety and Efficacy of Cariprazine in FDA-Approved Dose Ranges for Schizophrenia and Bipolar I Disorder: A Pooled Post-Hoc Analysis

Willie Earley, M.D.

P8-028

Injection Site Reactions and Pain Associated With Long-Acting Injectable Antipsychotics Paliperidone Palmitate Once-Monthly and Once-Every-3-Months

Erica Elefant, M.S.W., R.N.

P8-029

Effect of Adjunctive Brexpiprazole on Weight and Metabolic Parameters: An Analysis of Short- and Long-Term Trials in Major Depressive Disorder

Hans Eriksson

P8-030

Drug-Related Mortality in Camden, NJ: Demographics and Substance Misuse Trends During the 2010–2013 Period

Kalvin Foo, B.Sc.

P8-031

Dextromethorphan/Quinidine Improved Symptoms of Pseudobulbar Affect Irrespective of Concomitant Antidepressant Use

Andrea Formella, Pharm.D.

P8-032

Schizophrenia Disease Course Trajectory and Early Illness Intervention: A Review of the Literature and the DREaM Study Design

Dong-Jing Fu, M.D., Ph.D.

P8-033

Efficacy of Asenapine in Pediatric Patients With Manic and Mixed Episodes of Bipolar I Disorder

Chris Gache, M.D.

P8-034

Baseline Differences in Two Depressed Populations: Major Depression With Mixed Features Versus Bipolar I Depression

Keming Gao, M.D., Ph.D.

P8-035

Efficacy and Safety of Adjunctive Bitopertin Versus Placebo in Obsessive-Compulsive Disorder: Results From the Phase II Skylyte Study

Ayana Gibbs, M.D., Ph.D.

P8-036

Treatment Resistant Depression (TRD): Socio-Demographic Profiles and Pharmacological Outcomes

Maykel F. Ghabrash, M.D., M.Sc.

P8-037

Pre- and Intra-Medical School Factors Associated With Psychiatry Specialty Choice: AAMC Data Analysis

Matthew N. Goldenberg, M.D., M.Sc.

P8-038

Caregiver Burden in Schizophrenia: Pooled Analysis of the Involvement Evaluation Questionnaire Data for Paliperidone Palmitate 3-Month Formulation

Srihari Gopal, M.D., M.H.S.

P8-039

Medication Use Among Commercially-Insured Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) in the U.S.

Regina Grebla, Ph.D., M.P.H.

P8-040

Post-Traumatic Stress in Primary Care

Raz Gross, M.D., M.P.H.

P8-041

Ocular Biomarker for Diagnosis of Attention-Deficit/Hyperactivity Disorder

Doug Hyun Han, M.D., Ph.D.

P8-042

Product Features and Support for Optimizing Engagement With Digital Health Tools for Patients With Serious Mental Illness: An Expert Consensus Survey

Ainslie Hatch, Ph.D.

P8-043

Adrenergic Postprandial Syndrome and Hypotension in Anxiety and Affective Spectrum Disorders—a Diet: A Therapeutic Approach in an Outpatient Sample

Cristian Y. Herrera, M.D., Ph.D.

P8-044

Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Encenicline and Ethanol

Dana Hilt, M.D.

P8-045

The Impact of Encenicline on the Cardiometabolic Profile of Patients With Schizophrenia: Results From a Phase 2b Study

Stephen Brannan, M.D.

P8-046

Maternal Lifestyle Within 24 Hours Before Delivery May Be Linked to the Autism Epidemic

Silvia Hoirisch-Clapauch, M.D.

P8-047

New-Onset Anxiety Symptoms Associated With Use of Oxandrolone Bodybuilding Supplement

Mark N. Hreish, M.D.

P8-048

Lurasidone in Bipolar Depression: Acute Stable Response as a Predictor of Long-Term Treatment Response

Dan V. Iosifescu, M.D., M.Sc.

P8-049

Improvement in Psychosocial Functioning Predicts Long-Term Symptomatic Remission: Findings From CO-MED Trial

Manish K. Jha, M.B.B.S.

P8-050

Screening for Depression at a Colocated Behavioral Health Student-Faculty Collaborative Clinic

Meissa M. Jones, M.S.

P8-051

Undiagnosed Medulloblastoma Presenting With Psychiatric Symptoms: A Case Report

Divya E. Jose, M.D.

P8-052

Synthetic Marijuana-Induced Rhabdomyolysis: A Case Report

Divya E. Jose, M.D.

P8-053

Treatment Patterns in Medicaid Patients With Schizophrenia Initiating First- or Second-Generation Long-Acting Injectable Versus Oral Antipsychotics

Kruti Joshi, M.P.H.

P8-054

Valbenazine (NBI-98854) Is Effective for Treating Tardive Dyskinesia in Individuals With Schizophrenia or Mood Disorder

Richard C. Josiassen, Ph.D.

P8-055

Long-Term Tolerability of Aripiprazole Once-Monthly in Patients With Schizophrenia Following Treatment of an Acute Exacerbation

Timothy Peters-Strickland, M.D.

P8-056

Epigenetic Changes of BDNF Promoter Methylation in Post-Traumatic Stress Disorder: Findings From the Korean Combat Veterans of the Vietnam War

Jee In Kang

P8-057

Juvenile Fibromyalgia and Its Neuropsychiatric Implications: Review of Literature and State of Current Research

Amanjot Kaur, M.B.B.S.

P8-058

A Six-Month, Open-Label, Multicenter Study of the Safety and Efficacy of Multi-Layer Release Methylphenidate (MLR) in Adults With ADHD

Sohail Khattak, M.D.

P8-059

Influence of Depression on Working Memory Measured by Digit Backward Span in Subjects With Mild Cognitive Impairment and Dementia

Chaeri Kim

P8-060

Sociodemographic Status, Psychological Problems and Quality of Life in Urban-Dwelling Single Mothers in South Korea

Ga Eun Kim, M.D.

P8-061

Comparison of Behavioral Problems in Children With Newly Diagnosed, Untreated ADHD and Children With Epilepsy

Hee Yeon Choi, M.D.

P8-062

Pharmacological Characteristics of Major Human Metabolites of Cariprazine

Béla Kiss, M.Sc.

P8-063

CSF PK and PD Effects of Multiple Doses of BI 425809, a Novel GlyT1 Inhibitor, in Healthy Volunteers

Oliver Kleiner, Ph.D.

P8-064

Frequency of Urine Drug Monitoring and Illicit Substance Use in Patients With Mental Illness

Mancia Ko, Pharm.D.

P8-065

A Marker of Poor Data Quality: Identical PANSS Ratings During Screening Period Predict Identical PANSS Ratings After Randomization

Alan Kott, M.D.

P8-066

Does Early Improvement With Vilazodone Predict Response and Remission in Patients With MDD?

Kenneth Kramer, Ph.D.

P8-067

A Comparative Study of the Effects of Bupropion and Escitalopram on Internet Gaming Disorder Patients

Young Sik Lee, M.D., Ph.D.

P8-068

Medicaid Spending Associated With Paliperidone Palmitate or Oral Atypical Antipsychotic Treatment Among Adults Recently Diagnosed With Schizophrenia

Patrick Lefebvre, M.A.

P8-069

Antidepressant Effect of Wuling Powder in Learned Helplessness Mice Model

Dongmei Li, M.A.

P8-070

Identify the Role of Attachment and Relational Measures in Predicting Postdischarge Imminent Suicidality

Shuang Li, M.D., Ph.D.

P8-071

Psychiatric Stability Maintained in Tardive Dyskinesia Subjects Treated With Valbenazine (NBI-98854)

Jean-Pierre Lindenmayer, M.D.

P8-072

A Profile of Responders to Neurocognitive Remediation in Schizophrenia

Jean-Pierre Lindenmayer, M.D.

P8-073

Encenicline Is Not Associated With Signals of Abuse Potential in Recreational Drug Users

Gordon R. Loewen, Ph.D.

P8-074

The Adherence Challenge in Schizophrenia: Can Medical Education Improve Physicians' Knowledge of Management Options?

Jovana Lubarda, Ph.D.

P8-075

MDD and GAD: Effect of Continuing Medical Education on Psychiatrists' Knowledge of the Latest Clinical Data

Jovana Lubarda, Ph.D.

P8-076

Seasonal Affective Disorder and Visual Impairment: Association to Eye Diagnoses

Helle Madsen, M.D.

P8-077

A Novel Symptom Assessment Tool for Potential Adverse Effects

Rajnish Mago, M.D.

P8-078

Utilizing Permanent Magnets to Guide the Diffusion of Magnetic Nanoparticle in Brain Tissues or Agarose Gel Simulating These Tissues Is Challenging

Partam Manalai, M.D.

P8-079

Total PANSS Correlated With Interferon Gamma and Interleukin-1 Beta in Patients With Schizophrenia

Gurtej S. Mann, M.D.

P8-080

Increased Levels of Oxytocin in Adult OCD Patients

Donatella Marazziti, M.D.

P8-081

Efficacy of Cariprazine on Predominant Negative Symptoms of Patients With Schizophrenia: Post-Hoc Analysis of PANSS Data, Marder Factors and Cognition

Stephen R. Marder, M.D.

P8-082

KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia

Stephen R. Marder, M.D.

P8-083

Risk Factors for New-Onset Major Depressive Disorder and Dysthymia: Results From the Longitudinal Finnish Health 2011 Survey

Niina Markkula, M.D., M.Sc.

P8-084

Childhood Trauma in Bipolar Patients and Their Romantic Partners

MegAnn Kay McGinnis, B.S.

P8-085

Efficacy of Vortioxetine on Cognitive Function in Working Subjects With Major Depressive Disorder

Raymond Lam, M.D.

P8-086

Direct and Indirect Effects of Levomilnacipran ER on Functional Impairments in MDD Patients With Cognitive Difficulties: Post-Hoc Path Analyses

Roger S. McIntyre, M.D.

P8-087

Diabetes in the Workplace: The Moderational Role of Depressive Symptoms on Cognition and Work Performance

Yena Lee

P8-088

Are Serotonin Reuptake Inhibitors Associated With Increased Risk of Bleeding in Knee and Hip Surgeries? A Case-Control Study

Andrea Mendiola, M.D.

P8-089

Meta-Analysis of Efficacy of Pregabalin in the Treatment of Anxiety Disorders

Ayesha Ashai, M.D.

P8-090

Plasma L-Selectin Is Reduced in Patients With Schizophrenia Versus Healthy Controls

Satyajit Mohite, M.D., M.P.H.

P8-091

Predicting Nonsuicidal Self-Injury: The Effect of Acute Emotional States and Relationship Attachment Styles

Ali M. Molaie, B.A.

P8-092

Should Incarcerated, Psychotic, Postpartum Prisoners Be Allowed to Hold Their Babies?

Vanessa Padilla, M.D.

P8-093

Long-Term Effectiveness of Aripiprazole Once-Monthly Is Maintained in the QUALIFY Extension Study

Steven Potkin, M.D.

P8-094

Psychosis in Machado-Joseph Disease

Antonio L. Nascimento, M.D., M.Sc.

P8-095

Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: Analysis of Additional Efficacy Outcomes

Henry A. Nasrallah, M.D.

P8-096

Clinical Characteristics, Comorbidities and Health Care Utilization Among Patients With Major Depressive Disorder With Mixed Features

Daisy S. Ng-Mak, Ph.D.

P8-097

Cost Savings Associated With Improved Adherence Among Patients With Schizophrenia Using Lurasidone

Daisy S. Ng-Mak, Ph.D.

P8-098

Case Report: Addition of Naltrexone and Bupropion to Lorcaserin to Manage Olanzapine-Induced Weight Gain

Kevin R. Bera, B.S.

P8-099

Symptomatic and Functional Remission as a Therapeutic Objective in Major Depressive Disorder: Vortioxetine Comparative Data in the Working Population

Rebecca Z. Nielsen, M.Sc.

P8-100

Postpartum Patients Admitted to an Inpatient Psychiatric Unit: An 18 Months' Experience

Armagan Ozdemir

P8-101

Psychometric Properties of the Turkish Version of the Brief Cognitive Assessment Tool

Erguvan T. Ozel-Kizil, M.D.

P8-102

Japanese and Caucasian Pharmacokinetics of Single Doses of BI 425809: A Double-Blind Placebo-Controlled Study in Healthy Volunteers

Jiyeon (Regina) Park

P8-103

Testing Intranasal Oxytocin for Enhancing Social Cognition in Borderline and Schizotypal Personality Disorder

M. Mercedes Perez-Rodriguez, M.D.,

Ph.D.

P8-104

Characterization of Population Pharmacokinetics of Cariprazine and Its Major Metabolites

Antonia Periclou, Ph.D.

P8-105

Changing Trends in Child and Adolescent Inpatient Psychiatric Hospitalization: The Association Between Decreasing Length of Stay and Readmission Rate

Christopher A. Petersen, M.D.

P8-106

A Multicenter, Eight-Week Study to Assess Usability of a Digital Health Feedback System in Adults With Schizophrenia Treated With Oral Aripiprazole

John Docherty, M.D.

P8-107

East Versus West: Cultural Variations in Video Game Play Among Adolescents and Associated Violence

Diana Mungall Robinson, M.D.

P8-108

The Influence of Slept Hours on Functioning and Quality of Life in Bipolar Disorder

García Portilla, Ph.D.

P8-109

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Encenicline as Pro-cognitive Treatment in Patients With Schizophrenia

Steven Potkin, M.D.

P8-110

Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies

Steven Potkin, M.D.

P8-111

Stress Reactivity in the Context of Trauma Exposure and Marijuana Use

Vanja Radoncic, B.A.

P8-112

Does Metabolic Monitoring of Patients on Antipsychotic Medication Improve Management?

Mahdi Razafsha, M.D.

P8-113

Long-Term Safety and Durability of Effect of Aripiprazole Lauroxil in a One-Year Schizophrenia Extension Study

Robert Risinger, M.D.

P8-114

Symptom Stability in a 52-Week Schizophrenia Extension Study of Treatment With Long-Acting Injectable Aripiprazole Lauroxil

Robert Risinger, M.D.

P8-115

The Effect of Social Connectedness and Controllability of Suicidal Thoughts on Near-Term Suicidal Ideation and Behavior

Raquel E. Rose, B.S.

P8-116

Anti-Inflammatory Agents in the Treatment of Bipolar Depression: A Meta-Analysis

Joshua D. Rosenblat, M.D.

P8-117

Predictors of Response of a Comparative Trial of Six-Month Buprenorphine Implants and Sublingual Buprenorphine in Stable Opioid Dependent Patients

Richard N. Rosenthal, M.D., M.A.

P8-118

A Concierge Model of CAE Plus Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk for Nonadherence and Homelessness

Martha Sajatovic, M.D.

P8-119

Neurological and Psychiatric Comorbidities Assessment in the PRISM II Study of Dextromethorphan/Quinidine for Treatment of Pseudobulbar Affect

William Sauve, M.D.

P8-120

Total Cholesterol Is Positively Correlated With Scores on the NIH Toolbox Cognitive Test Battery in Patients With Schizophrenia

Ashwini Saxena, M.D., Ph.D.

P8-121

Treatment of Addition in Alzheimer's Disease: The Efficacy of Rationale for Combination Therapy With Galantamine and Memantine

Luisa C. Schmidt, M.D.

P8-122

Gender Differences in Mental Health Among 10- to 14-Year-Old Children Who Were Very Low Weight at Birth

Maria Serrano-Villar, M.S.

P8-123

Privacy Denied: Exploring the Tensions Between Procedural Justice and Respect for Privacy at the Consent and Capacity Board

Janooshsheya Balasundaram, M.D.

P8-124

Factors Affecting Psychiatric Disorders in Offspring of Parents With Bipolar Disorder in South Korea

Se-Hoon Shim, M.D., Dr.P.H.

P8-125

The Normalization of Brain F-18-FDG Hypometabolism Following Electroconvulsive Therapy in a Woman With Treatment-Resistant Depression: A Case Report

Se-Hoon Shim, M.D., Dr.P.H.

P8-126

WITHDRAWN

P8-127

Transcranial Magnetic Stimulation Treatment of Depression Using a 20 Hertz Theta Burst Pulse Pattern: A Consecutive Case Series

William F. Stubbeman, M.D.

P8-128

Comparable Neuropsychiatric Safety Observed With Deutetrabenazine Treatment and Placebo in Patients With Huntington Disease (First-HD)

Victor Sung, M.D.

P8-129

Depression and Social Cognition in Schizophrenia

Jung Sung Il

P8-130

Lurasidone for Major Depressive Disorder With Mixed Features: Effect of Irritability

Alan C. Swann, M.D.

P8-131

Use of Repetitive Transcranial Magnetic Stimulation in ECT-Resistant Major Depression: A Case Series

Daniel Drew Tarman, M.D., M.Eng.

P8-132

Case Series of Deep Repetitive Transcranial Magnetic Stimulation to the Medial Prefrontal and Anterior Cingulate Cortices After H1 Failure

Aron Tendler, M.D.

P8-133

Portrayal of Addiction in The New York Times 1980–2009

Andrew N. Tuck, B.Sc.

P8-134

Correlates of Clozapine Use After a First Episode of Schizophrenia Compared to Patients Not Prescribed Clozapine: A Long-Term Prospective Study

Alp Ucok, M.D.

P8-135

A Look at Implementation of TeamSTEPPS on an Acute Inpatient Psychiatric Unit

Hiren Umrani, M.D.

P8-136

Factors Associated With Assaultive Behavior of Men and Women With Psychosis: The Importance of Victimization

Jan Vevera, M.D., Ph.D.

P8-137

“We Don’t Talk About That Stuff”: A Toolkit for Integrating Sexual and Reproductive Health Services Into Outpatient Psychiatric Practice

Martha C. Ward, M.D.

P8-138

Effects of Adjunctive Brexpiprazole on the Core Symptoms of Depression: A Post-Hoc, Pooled Analysis of Two Pivotal Placebo-Controlled Studies

Emmanuelle Weiller

P8-139

Brexpiprazole and Long-Term Functioning in Adults With Schizophrenia: Results From a Randomized, Double-Blind, Placebo-Controlled Maintenance Study

Catherine Weiss

P8-140

Increased Demand for Psychiatric Services in a Collegiate Setting

Burdette Wendt

P8-141

Brain Activation Associated With Working Memory Maintenance and Distraction

Jong-Chul Yang, M.D., Ph.D.

P8-142

Efficacy of Cariprazine in Bipolar Depression: Post-Hoc Band-Pass Analyses of Two Randomized, Double-Blind, Placebo-Controlled Trials

Lakshmi Yatham, M.B.B.S.

P8-143

Mild Cognitive Disorder and Depression: Treatment With and Association Between Donepezil and Escitalopram

Julio C. Zarra, M.D., Dr.P.H.

P8-144

Do Direct Survivors of Terrorism Remaining in the Disaster Community Show More Resilience Than Survivors Who Relocate?

Phebe Tucker, M.D.

P8-145

Minimal Clinically Important Difference and Treatment Response Determination for UCSD Performance-Based Skills Assessment in Major Depressive Disorder

William Jacobson, Ph.D.

P8-146

Impact of Vortioxetine on Functional Capacity in MDD Patients With Cognitive Dysfunction: A UCSD Performance-Based Skills Assessment Post Hoc Analysis

William Jacobson, Ph.D.

New Research Topic Index

Abuse and Neglect Victims

P4-016, P7-013

Academic Psychiatry and Psychiatric Education

P3-014, P4-008, P4-009, P4-028, P5-009, P5-011, P5-016, P5-048, P6-120, P7-035, P8-026, P8-038, P8-075, P8-076

Addiction Psychiatry/Substance Use and Addictive Disorders

P1-001, P3-002, P3-007, P3-009, P3-015, P4-017, P4-020, P4-033, P4-038, P5-003, P5-010, P5-040, P5-044, P5-057, P5-065, P5-066, P5-069, P5-079, P5-081, P5-085, P6-013, P6-038, P6-039, P6-059, P6-075 through P6-077, P6-085, P6-097, P6-122, P6-125, P6-139, P7-006, P7-072, P7-078, P7-080, P7-087, P8-009, P8-031, P8-065, P8-068, P8-112, P8-118, P8-128

ADHD

P5-061, P5-070, P6-018, P6-024, P6-040, P6-041, P6-084, P6-086, P6-137, P7-033, P8-001, P8-024, P8-040, P8-042, P8-059, P8-062

Administrative Psychiatry (Public, Private and University)

P8-137

Aggressive Behaviors: Etiology, Assessment and Treatment

P5-059, P7-057, P8-138

AIDS and HIV

P5-019, P5-071, P7-003

Anxiety Disorders

P3-020, P4-003, P4-018, P5-031, P5-042, P6-019, P6-028, P6-065, P6-088, P6-093, P6-101, P7-017, P8-048, P8-090

Arts and Humanities (includes Historical Issues)

P8-135

Autism Spectrum Disorders

P3-008, P3-016, P6-126

Biological Psychiatry

P5-043, P5-047, P6-061, P6-070, P6-107, P7-052, P8-047

Bipolar and Related Disorders

P3-012, P3-017, P3-030, P3-37, P5-035, P5-075, P5-084, P6-014, P6-017, P6-026, P6-029, P6-030, P6-057, P6-108, P7-015, P7-021, P7-022, P7-029, P7-037, P7-040, P8-014, P8-027, P8-034, P8-049, P8-085, P8-105, P8-109, P8-117, P8-125, P8-144

Brain Imaging

P7-030, P8-052, P8-126

Child and Adolescent Psychiatry

P3-024, P3-026, P3-034, P5-046, P5-060, P6-009, P6-064, P6-081, P6-127, P7-028, P7-056, P7-076, P7-082, P8-058, P8-106, P8-108, P8-123

Clinical Case Studies (MS-RES)

P1-002 through P1-177

Cognitive Behavioral and Motivational Therapies

P5-082, P8-025

Combined Treatment (Pharmacotherapy and Psychotherapy)

P8-119

Community Development and Service Projects (MS-RES)

P2-001 through P2-013

Computers, Technology and the Internet

P4-039, P7-083, P8-043

Couples and Family Therapies

P7-050

Cultural Psychiatry and Diversity

P3-010, P4-013, P5-037, P5-076, P5-078, P6-103, P7-011, P7-031, P7-064

Curriculum Development and Educational Projects (MS-RES)

P2-014 through P2-034

Depressive Disorders

P3-027, P4-010, P5-030, P5-036, P5-067, P5-077, P6-004, P6-007, P6-027, P6-034, P6-035, P6-062, P6-067, P6-068, P6-091, P6-112, P6-128, P6-144, P7-025, P7-048, P7-055, P7-065, P8-008, P8-030, P8-035, P8-037, P8-050, P8-067, P8-070, P8-077,

New Research Topic Index

P8-084, P8-086, P8-088, P8-097, P8-100,
P8-129, P8-132, P8-140, P8-145, P8-146

Diagnosis/Assessment

P5-032, P5-045, P7-024, P8-051

Disaster Psychiatry

P3-021, P7-042, P8-016, P8-017

Disaster/Assessment

P7-049

Dissociative Disorders

P8-087

Emergency Psychiatry

P4-040, P5-052, P5-053, P5-080, P6-025,
P8-007, P8-053

Epidemiology

P4-011, P6-022, P6-045, P6-051, P6-053,
P6-079, P6-143, P8-018

Ethics

P7-007, P8-124

Feeding and Eating Disorders

P6-048, P6-136, P7-062, P7-063

Forensic Psychiatry

P3-011, P3-018, P5-064, P7-039

Gender Dysphoria

P7-059

Genetics

P7-075, P8-021

Geriatric Psychiatry

P4-021 through P4-024, P4-029, P6-072,
P6-119, P6-124, P6-141, P8-102

Global Mental Health and International Psychiatry

P5-024, P5-026, P5-041, P8-015

Group Therapies

P6-111, P7-005

Health Services Research

P7-079, P7-086

Integrated and Collaborative Care

P5-022, P5-050, P6-010, P7-071

Integrative Medicine (CAM)

P6-087

Military/Veterans and Their Families

P7-051, P7-069

Neurocognitive Disorders

P3-031, P5-002, P6-015, P7-016, P7-053,
P8-060, P8-130, P8-143

Neurodevelopmental Disorders

P4-002

Neuropsychiatry

P3-019, P4-004, P4-006, P4-019, P4-031,
P4-036, P4-037, P5-018, P5-028, P5-086,
P6-001, P7-058, P8-004

Neuroscience

P6-055, P8-005, P8-032, P8-120

Non-Pharmacological Somatic Therapies (ECT, TMS)

P6-021, P6-056, P7-014, P8-012, P8-133,
P8-134

Obsessive-Compulsive and Related Disorders

P3-005, P4-026, P6-042, P6-044, P6-105,
P6-131, P6-132, P7-046, P7-073, P8-036,
P8-081

Pain Management

P5-029, P8-006

Patient Oriented and Epidemiology (MS-RES)

P2-035 through P2-083

Patient Safety

P7-077

Personality Disorders

P5-027, P6-133, P6-145, P7-001, P7-032,
P8-104

Post-Traumatic Stress Disorder (PTSD)

P3-035, P5-058, P6-037, P6-121, P7-081,
P8-041, P8-057

New Research Topic Index

Psychiatric Rehabilitation and Recovery

P6-134, P6-135

Psychiatric Services: Organization and Delivery

P6-043, P6-082, P6-095, P7-018, P7-045, P7-067, P7-085, P8-142

Psychiatrists: Professional and Personal Issues

P4-001

Psychoimmunology

P5-049, P7-023

Psychopharmacology

P4-027, P4-035, P5-004, P5-008, P5-014, P5-021, P5-023, P5-072, P6-003, P6-011, P6-049, P6-050, P6-054, P6-118, P7-002, P7-034, P7-038, P8-010, P8-020, P8-045, P8-063, P8-064, P8-074, P8-089, P8-103, P8-122, P8-145

Psychosocial and Biomedical Research Projects (MS-RES)

P2-084 through P2-108

Psychosomatic Medicine

P3-001, P3-003, P3-013, P3-029, P3-032, P4-032, P5-007, P5-055, P5-063, P5-073, P6-005, P6-036, P6-058, P6-069, P6-099, P6-140, P6-142, P7-061, P7-066, P7-088, P8-044, P8-095

Religion, Spirituality and Psychiatry

P7-060

Research Design/Methodology

P8-078, P8-079

Resident, Fellows and Medical Student Concerns

P3-028, P5-001, P5-051

Schizophrenia Spectrum and Other Psychotic Disorders

P2-109, P3-004, P3-006, P3-022, P3-025, P4-014, P5-006, P5-054, P5-062, P5-068, P5-074, P5-083, P6-020, P6-033, P6-060, P6-066, P6-071, P6-074, P6-078, P6-080, P6-083, P6-089, P6-090, P6-092, P6-098, P6-100, P6-102, P6-106, P6-109, P6-110, P6-

113 through P6-115, P6-129, P6-146, P6-147, P7-004, P7-012, P7-019, P7-020, P7-027, P7-054, P7-068, P7-074, P7-084, P8-013, P8-022, P8-023, P8-028, P8-029, P8-033, P8-039, P8-046, P8-054, P8-055, P8-056, P8-066, P8-069, P8-072, P8-073, P8-080, P8-082, P8-083, P8-091, P8-094, P8-096, P8-098, P8-099, P8-107, P8-110, P8-111, P8-113 through P8-115, P8-121, P8-131, P8-136, P8-141

Sleep-Wake Disorders

P3-036, P5-034, P5-039, P7-036, P7-044, P8-002

Social and Community Psychiatry

P4-007, P4-012, P4-025, P5-005, P5-020, P6-023, P7-008, P7-043, P8-061

Somatic Symptom Disorders

P5-025, P5-056

Suicide

P3-033, P4-005, P4-015, P4-034, P5-017, P6-002, P6-008, P6-032, P6-047, P6-063, P6-073, P6-116, P6-130, P8-003, P8-011, P8-071, P8-092, P8-116

Treatment Techniques and Outcome Studies

P3-023, P6-031, P6-104

Victims of Violence-Domestic/Combat/Crime/Terrorism/War

P6-096

Wellness

P6-117

Women's Health

P4-030, P5-012, P5-033, P5-038, P6-012, P6-094, P6-123, P7-041, P7-047, P7-070, P8-093, P8-101, P8-139

Exhibits Guide

Exhibitor Sponsorship Acknowledgments . . .	184
General Information	186
Product Theaters	188
Therapeutic Update	197
Exhibitors with Product/Service Descriptions	198
Exhibitors by Product/Service Listing	240
Career Fair and Publishers' Book Fair Exhibitors	244
Numerical List of Exhibitors by Booth Number	246
Exhibit Hall Floor Plan	250



Exhibits Guide



The APA thanks our exhibitors for their sponsorship of the Exhibit Hall and for providing additional support for activities and services at the APA Annual Meeting. Their sponsorship supports the Annual Meeting and enriches the meeting experience for attendees. The APA deeply appreciates their support and encourages you to visit the Exhibit Hall.

Sponsorships and Support

APA Cafés (including coffee, charging stations and Wi-Fi):	Takeda Pharmaceuticals USA, Inc. and Lundbeck
APA Doctor's Bag Pocket:	Sunovion Pharmaceuticals, Inc.
Exhibit Hall Charging Stations:	Acadia Pharmaceuticals Inc. and Assurex Health
Hotel Key Cards:	Alkermes, Assurex Health and Sunovion Pharmaceuticals, Inc.
Annual Meetings App:	Alkermes

List of Exhibitors

Acadia Healthcare	<i>Clinical Psychiatry News</i>
ACADIA Pharmaceuticals	Community Health Systems
Admera Health	Community Psychiatry
Air Force Recruiting Services	CompHealth
Align International Recruitment Ltd.	Compulink Business Systems, Inc.
Alkermes, Inc.	Correct Care Solutions, LLC
All Star Recruiting	CoverMyMeds
Allergan	<i>Current Psychiatry</i>
Allina Health	Delta Companies
AltheaDx	Department of Behavioral Health & Developmental Disabilities
American Academy of Addiction Psychiatry	Department of Veterans Affairs
American Board of Psychiatry and Neurology, Inc.	Destination Hope
American Physician Institute—Beat the Boards	Diamond Healthcare Recruitment Division
American Professional Agency, Inc.	DR Wanted
Arbor Pharmaceuticals, LLC	Electromedical Products International, Inc.
Arcadian Telepsychiatry	Elsevier, Inc.
Army Medical Recruiting	EmCare
Association & Meeting Solutions	FCS, Inc.
Association of Gay and Lesbian Psychiatrists (AGLP)	Federal Bureau of Prisons (BOP)
Assurex Health	<i>Focus: The Journal of Lifelong Learning in Psychiatry</i>
Atlanta Center for Medical Research	Fraser Health
Aureus Medical Group	Genomind
Aurora Health Care	Georgia Association of Community Service Boards, Inc.
Austen Riggs Center	Georgia Ketamine
Barton Associates	Glens Falls Hospital
Bassett Healthcare Network	Global Medical Staffing
Behavioral Health Recruitment Services	Gould Farm
Billings Clinic	Greater Hudson Valley Health System
Braeburn Pharmaceuticals, Inc.	Group Health Physicians
Brainsway USA Inc.	Guilford Publications
Brookhaven Retreat	Harmonex Neuroscience Research, Inc.
California Correctional Health Care Services (CCHCS)	HCPLive
Cambridge University Press	Hillside, Inc.
Captive Risk Planners/Perfect Tax & Finance	Hogrefe Publishing Corp.
CareClix	Horizon Health
Carilion Clinic	Hospital Corporation of America (HCA)
Carolinas Healthcare System	Humana Inc.
The Center for Eating Disorders at Sheppard Pratt	IASIS Healthcare
Central Intelligence Agency	Indivior Inc.
Christian Medical & Dental Associations, Psychiatry Section	Infinite Trading, Inc.

Exhibits Guide

Informa Health Care Journals
InSight Telepsychiatry, LLC
Intermountain Healthcare
International Congress on Dual Disorders
Intra-Cellular Therapies Inc.
IPC Healthcare
Iris Telehealth
Ironshore Pharmaceuticals and Development, Inc.
Jackson & Coker
The *JAMA* Network
Janssen Pharmaceuticals, Inc.
JPE Healthcare Staffing, Inc.
Kaiser Permanente, The Permanente Medical Group, Inc.
Liberty Healthcare Corporation
LifePoint Health
Locum Source, Inc.
LocumTenens.com
Magstim
Magventure, Inc.
Maxim Physician Resources
Mayo Clinic
McLean Hospital
MD.com
MECTA Corporation
Medical Billing Professionals
Medical Search
Medicus Healthcare Solutions
MedPartners Locum Tenens
Memorial Hospital of Sweetwater County
Menninger Clinic
Merck & Co.
Metabolic Maintenance
MHM Services, Inc.
Millennium Health
Ministry Health Care
Minnesota Department of Human Services
Mount Sinai Health System
Muse: The Brain Sensing Headband
National Institute of Mental Health (NIMH)
Neba Health, LLC
NEOS Therapeutics
Neurocrine Biosciences, Inc.
Neuronetrix
NeuroScience, Inc.
NeuroStar TMS Therapy
New York-Presbyterian Hospital
North Carolina Office of Rural Health
North GA Partnership (NoGAP)
Northeast Georgia Health System, Inc.
Northern Light Technologies
Novant Health
OmegaBrite
Oregon Health & Science University,
 Department of Psychiatry
Oregon State Hospital
Otsuka America Pharmaceutical, Inc.
Otto Trading, Inc.
Oxford University Press
Physicians for a National Health Program
PracticeLink.com
Providence Health & Services
Psychiatric Times
PsychU
Quotient ADHD System by Pearson
Rhodes Pharmaceuticals L.P.
Riverside Health System
Rochester Regional Health
Rogers Behavioral Health System
Rogers Memorial Hospital
Routledge Journals
Routledge/CRC Press
Rutgers Center of Alcohol Studies
Saint Francis Health System/Laureate Psychiatric Clinic
 and Hospital
SARDAA-Schizophrenia & Related Disorders Alliance
 of America
Sheppard Pratt Health System
Shire
Shire U.S., Inc.
Sierra Tucson
Skyland Trail
Somatics LLC
Soterix Medical, Inc.
Southwest Behavioral Health Services
Spartanburg Regional Healthcare System
Springer
Springstone Inc.
Sun Behavioral Health
Sunovion Pharmaceuticals Inc.
Takeda Pharmaceuticals U.S.A., Inc./Lundbeck
Tallahassee Memorial Healthcare
TeleSage, Inc.
Tenet Health
The TOVA Company
Tris Pharma
TrueLearn
Tséhootsooi Medical Center
U.S. Department of State, Office of Medical Services
Unity Center for Behavioral Health
Universal Health Services, Inc.
University of Florida Department of Psychiatry
Valant Medical Solutions
Vanda Pharmaceuticals Inc.
Vanderbilt Behavioral Health
Veritas Collaborative
Via Christi Health System
Virtual Medical Staff
VISTA Staffing Solutions, Inc.
Weatherby Healthcare
Wellington Retreat
Westchester Medical Center
Wexford Health Sources
Wiley
Wolters Kluwer Health
World Health Information Network
WPA World Congress of Psychiatry 2017 Berlin

General Information



The APA exhibits program is an integral component of the overall Annual Meeting and provides an excellent opportunity for meeting registrants to obtain the latest information on products and services related to the psychiatric profession.

The meeting would not be possible without the generous support of our exhibitors, so please allow adequate time in your daily schedule to visit the exhibits, which are located in Exhibit Hall B3-B4, Level 1, Building B, in the Georgia World Congress Center. When you explore the exhibits, you will have the opportunity to participate in interactive computer programs and speak with the representatives of companies who provide services and products related directly to your professional and personal interests.

To assist in locating a particular company or product, a floor plan of the Exhibit Hall is included in this section, along with a list of: 1) alphabetical list of exhibitors with product/service description; 2) exhibitors listed by product/service; and 3) exhibitors listed numerically by booth number. Exhibit information will also be available on the Interactive Wayfinding Exhibit Hall Monitor in the exhibit hall, within the registration area.

Hospitality Lounges

Two APA Cafés, serving complimentary coffee (Locations #236 and #1837) are located in the rear of the Exhibit Hall. Please utilize these areas to relax and network with colleagues. Charging stations for cell phones and laptops, as well as free Wi-Fi, are also available in each café.

Publishers' Book Fair

Major publishers and book sellers, including American Psychiatric Association Publishing, are located in this designated area. Participating companies are selling and taking orders for new and current professional books in the field of psychiatry.

Career Fair

Exhibitors in this area include government agencies, hospitals, locum tenens, mental health clinics, psychiatric facilities and recruiters seeking psychiatrists to fill open positions. Find **APA JobCentral**, the career hub for psychiatry and ultimate recruitment tool for employers and job seekers alike, located in

APA Central, next to the American Psychiatric Association Publishing Bookstore.

International Pavilion

This area in the Exhibit Hall is comprised of international organizations and associations that will be holding international meetings outside of the United States.

Endorsements

Products and services displayed in the Exhibit Hall occur by the contractual arrangement between the American Psychiatric Association and participating companies. This arrangement does not constitute or imply an endorsement by the American Psychiatric Association of these products or services.

Exhibit Hall Food Voucher

Save money and use your \$10 food voucher (attached to your meeting badge, for paid attendees only) redeemable for food/beverage at the concession areas

Exhibit Dates and Hours

SATURDAY, MAY 14

APA Bookstore, APA Central, Publishers' Book Fair and Career Fair open:

9:00 a.m. – 4:00 p.m.

SUNDAY, MAY 15

All commercial and educational exhibits, the International Pavilion, the APA Bookstore, APA Central, Publishers' Book Fair and the Career Fair are open Sunday, Monday and Tuesday.

10:00 a.m. – 4:00 p.m.

MONDAY, MAY 16

10:00 a.m. – 4:00 p.m.

TUESDAY, MAY 17

10:00 a.m. – 4:00 p.m.

inside the Exhibit Hall only. Note: There is no cash value/cash back, no replacement on vouchers and they are for one-time use only, Sunday, May 15 – Tuesday, May 17, 10:00 a.m. – 4:00 p.m.

Exhibit Hall Activities

All Exhibit Hall activities will take place in Exhibit Hall B3-B4, Level 1, Building B, in the Georgia World Congress Center:

- ▶ APA Cafés with daily coffee service, along with free Wi-Fi and charging stations for cell phones and laptops.
- ▶ Check the schedule in this *Guide* and plan to attend Poster Sessions, which will be held Saturday–Tuesday, and Product Theaters, which will be held Sunday–Tuesday.

General Information


- ▶ The APA Bookstore, APA Central, Publishers' Book Fair and Career Fair will open on Saturday, May 14.
- ▶ Commercial and educational exhibits and the International Pavilion will open on Sunday, May 15.

The Sunshine Act and How It Affects You

The Physician Payment Sunshine Act is a federal law that requires pharmaceutical and device manufacturers under certain circumstances to publicly report any complimentary gift, food, beverage, non-CME certified education or other items of value given to physicians. Some of the food, product theaters and trinkets that may be available to you at this meeting have been sponsored by companies that may be required to report your receipt of that gift. APA recommends that you ask the person providing the complimentary item whether your name will be reported under the Act before accepting complimentary products or food so that you can make an independent and educated decision to accept or not accept it.

! **Badge Color Codes**

BLUE	Members
YELLOW	Nonmembers
RED	Exhibitors
GREEN	APA Administration
SILVER	Press
BLACK	Temporary Staff



Product Theaters

! APA Product Theaters are for informational and promotional purposes only and do not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product. The sessions will take place in a separate theater area built in the Exhibit Hall. There are a total of 13, 60-minute promotional product presentation sessions. Sessions will seat 250 participants on a first-come, first-served basis. The 60-minute sessions are held Sunday, May 15 – Tuesday, May 17, with five sessions each day at 11:00 a.m., Noon, 1:00 p.m., 2:00 p.m. and 3:00 p.m. Only registered meeting participants may attend the presentations, and your meeting badge is required for admittance. Boxed lunches and beverages are provided by the APA for the programs. Supporters of these sessions include Acadia Pharmaceuticals Inc., Alkermes, Allergan, Janssen Pharmaceuticals Inc., NEOS Therapeutics, Inc., Otsuka America Pharmaceutical, Inc., Shire Pharmaceuticals, Inc., Rhodes Pharmaceuticals L.P., Sunovion Pharmaceuticals Inc., Takeda Pharmaceuticals, U.S.A., Inc. and Lundbeck, and Tris Pharma. Plan to attend!

These sessions are covered by the Physician Payment Sunshine Act, and physicians attending will be required to provide their identifying information for public reports.

SUNDAY, MAY 15

11:00 a.m. – Noon

Product Theater 1

Supported by Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck

Assessing Major Depressive Disorder and an Option for Treatment

Presenter:

*Rakesh Jain, M.D., M.P.H.
Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine, Midland, Texas*

Noon – 1:00 p.m.

Product Theater 2

Supported by Allergan

A New Antipsychotic Clinical Overview

Presenter:

*Andrew Cutler, M.D.
Chief Medical Officer, Meridien Research Group, Tampa, Fla.; CEO and Chief Medical Officer, Florida Clinical Research Center, Bradenton, Fla.*

1:00 p.m. – 2:00 p.m.

Product Theater 1

Supported by Acadia Pharmaceuticals Inc.

Understanding Parkinson's Disease Psychosis and Its Treatment

Presenters:

*Daniel E. Kremens, M.D., J.D.
Associate Professor of Neurology, Co-Director of the Parkinson's Disease and Movement Disorders Division, Neurology Clerkship Director, Sidney Kimmel Medical College at Thomas Jefferson University*

*Henry A. Nasrallah, M.D.
The Sydney W. Souers Endowed Chair, Professor and Chairman, Department of Neurology and Psychiatry, Saint Louis University School of Medicine, Chief of Neurology and Psychiatry, University Hospital, Saint Louis University, St. Louis, Mo.*

Locations/Schedule

Exhibit Hall B3-B4,
Level 1, Georgia World
Congress Center

Sunday – Tuesday

Product Theater 1
(Booth #113)

11:00 a.m.– Noon,
1:00 p.m. – 2:00 p.m. and
3:00 p.m. – 4:00 p.m.

Product Theater 2
(Booth #1913)

Noon – 1:00 p.m. and
2:00 p.m. – 3:00 p.m.

2:00 p.m. – 3:00 p.m.

Product Theater 2

Supported by Otsuka America Pharmaceutical, Inc.

Injecting a Once-Monthly Long-Acting Injectable Into the Schizophrenia Treatment Conversation

Presenters:

*Henry A. Nasrallah, M.D.
Sydney W. Souers Endowed Chair, Chairman and Professor, Department of Neurology and Psychiatry, Saint Louis University, St. Louis, Mo.*

*Rebecca S. Roma, M.D.
Medical Director, Community Treatment Team Program, Assertive Community Treatment Teams, Mercy Behavioral Health and UPMC Mercy, Pittsburgh, Pa.*

Product Theaters

3:00 p.m. – 4:00 p.m.

Product Theater 1

Supported by Shire Pharmaceuticals, Inc.

Beyond Childhood: Recognizing the Impact of ADHD in Adults

Presenter:

Rakesh Jain, M.D., M.P.H.
Clinical Professor, Department of Psychiatry, Texas Tech University School of Medicine, Midland, Texas

MONDAY, MAY 16

11:00 a.m. – Noon

Product Theater 1

Supported by Alkermes

Schizophrenia: Treating a Complex Condition with a New Long-Acting Injectable (LAI)

Presenters:

Gustavo Alva, M.D., DFAPA
Medical Director, ATP Clinical Research, Pacific Neuropsychiatric Specialists, Costa Mesa, Calif.

Henry A. Nasrallah, M.D.
Professor and Chairman, Department of Neurology and Psychiatry, St. Louis University School of Medicine, St. Louis, Mo.



APA product theaters are for informational and promotional purposes only, and do not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product.

Noon – 1:00 p.m.

Product Theater 2

Supported by Sunovion Pharmaceuticals Inc.

Clinical Experts in Bipolar Depression: A Collaborative Approach to Care

Presenters:

Vladimir Maletic, M.D.
Clinical Professor, Department of Neuropsychiatry and Behavioral Science, University of South Carolina Columbia, S.C.; Consultant of Sunovion Pharmaceuticals Inc.

James Sloan Manning, M.D.
Adjunct Associate Professor, Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, N.C.; Co-Director, Mood Disorders Clinic, Moses Cone Family Practice Center, Greensboro, N.C.; Consultant of Sunovion Pharmaceuticals Inc.

1:00 p.m. – 2:00 p.m.

Product Theater 1

Supported by Rhodes Pharmaceuticals L.P.

Managing ADHD: What Matters Most When Selecting a Treatment Option

Presenter:

Birgit Amann, M.D.
Psychiatrist, Medical Director and Founder, Behavioral Medical Center, Troy, Mich.

2:00 p.m. – 3:00 p.m.

Product Theater 2

Supported by Otsuka America Pharmaceutical, Inc. and Lundbeck LLC

Make Way for Possibilities of an Adjunctive Therapy for Major Depressive Disorder

Presenter:

Rakesh Jain, M.D., M.P.H.
Clinical Professor, Department of Psychiatry and Behavioral Sciences, Texas Tech University School of Medicine, Midland, Texas

TUESDAY, MAY 17

11:00 a.m. – Noon

Product Theater 1

Supported by Janssen Pharmaceuticals Inc.

A Review of the Safety and Efficacy of Janssen Long-Acting Atypical Antipsychotics: A Sequential Dosing for the Treatment of Schizophrenia

Presenter:

Jason C. Bermak, M.D., Ph.D.
Medical Director/Psychiatrist, SF-CARE, Inc., San Francisco, Calif.



Product Theaters

Noon – 1:00 p.m.

Product Theater 2

Supported by Otsuka America Pharmaceutical, Inc.

Is It Depression or Something More? Patient Identification, Diagnosis and Treatment of Pseudobulbar Affect

Presenters:

*Gerald A. Maguire, M.D., DFAPA
Professor and Chair, Psychiatry and Neuroscience, UC Riverside School of Medicine, Riverside, Calif.*

*Stephen M. Stahl, M.D., Ph.D.
Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, Calif., Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK, Director of Psychopharmacology, California Department of State Hospitals, Chairman, Neuroscience Education Institute (NEI)*

1:00 p.m. – 2:00 p.m.

Product Theater 1

Supported by NEOS Therapeutics, Inc.

A New Product for the Treatment of ADHD

Presenter:

*Gregory W. Mattingly, M.D.
Associate Clinical Professor, Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo.; President, Midwest Research Group, St. Charles, Mo.*

2:00 p.m. – 3:00 p.m.

Product Theater 2

Supported by Tris Pharma

An Update on ADHD and New Developments from Tris Pharma

Presenter:

*Ann Childress, M.D.
President of the Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, Nev.*



Leading the future of health care.

Many organizations have a mission statement; we have a calling: to lead the way to a better future for health care. Through our leadership in the use of advanced technology, our creation of innovative solutions and our influence on health policy and reform efforts, The Permanente Medical Group, Inc. (TPMG) is shaping the future of health care in the nation.

PSYCHIATRIST OPPORTUNITIES
Northern & Central California
 \$100,000 - \$150,000 Psychiatrist Forgivable Loan Program
 (Based On Experience)

TPMG is the largest integrated health care system in the nation with over 9,000 physicians, 22 medical centers, numerous clinics throughout Northern and Central California and an over 65-year tradition of providing quality medical care.

Join The Permanente Medical Group, Inc. and you will enjoy:

- Competitive Salary
- Comprehensive Benefits Package
- Excellent Retirement Plans
- Shareholder Opportunity
- Mortgage Loan Program (approval required)
- Malpractice Insurance Coverage
- Cutting-Edge Technology and Enhanced EMR

Stop by Booth #614 for more information on career opportunities.

Or contact:
 Last Name A-L (Northern CA Opportunities): Denise.M.Bottarini@kp.org
 Last name M-Z (Northern CA Opportunities): Nicholas.Chastain@kp.org
 Central California Opportunities: Kenneth.Baker@kp.org

We are an EOE/AA/M/F/D/V Employer.
 VEVRAA Federal Contractor



<http://physiciancareers-ncal.kp.org> The Permanente Medical Group, Inc.




You will love the outdoor adventures, entertainment, culture & food.

Now Hiring Psychiatrists

In Southern Oregon Your New Life Awaits!
Excellent Benefits Include:

- Competitive salary with step increases
- Generous vacation and sick leave
- Low cost, full-family health insurance benefits
- Public Employees Retirement System
- New modern health services facility

Check out our webpage at:
www.JacksonCounty.org/HHSNewLife

Contact for more information:
 denise.stanford@jacksoncounty.org or call 541.774.7807

Visit us at booth 307

Jackson County HHS is a qualified site of the National Health Service Corps and Oregon Health Sciences. Your employment could qualify you for up to \$50,000 in the NHSC Loan Repayment Program!

The Ohio State University Wexner Medical Center's Department of Psychiatry and Behavioral Health is actively recruiting clinical faculty to join our rapidly growing team.



Celebrating a Century

Tuesday, May 17
 5:30–7:30 p.m.
 Magnolia, M2, North Tower
 Omni Atlanta Hotel
 at CNN Center

psychiatry.osu.edu

Join Us

We are a recognized leader in delivering high-quality clinical care, advancing knowledge in the field and educating the next generation. A diversity of interests can be accommodated and positions can be tailored to emphasize clinical service delivery, teaching, and/or research. Clinical service opportunities span the ambulatory, inpatient and consultative settings. Subspecialty areas of growth including addictions, child and adolescent, forensics, geriatrics, neuropsychiatry and psychosomatic medicine.

For consideration, please email your CV and cover letter to:

Kam Carlberg
 Faculty Recruiter
 The Ohio State University Wexner Medical Center
 kamala.carlberg@osumc.edu

Ohio State is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status or protected veteran status.





a significant unmet need...

Early Morning Functioning in Stimulant-Treated Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, and its Impact on Caregivers

Floyd R. Sallee, MD, PhD

“Conclusions: Control of EMF impairments from inadequately controlled ADHD symptoms is a significant unmet need in children and adolescents with ADHD treated with stable morning doses of stimulant medications. Current orally administered stimulant treatment options have not addressed this challenge.”

READ THE FULL ARTICLE ONLINE:
ironshorepharma.com/ADHD



IRONSHORE
PHARMACEUTICALS & DEVELOPMENT, INC.

Helping People Live the *Healthiest Lives Possible.*



Utah has no shortage of outdoor adventure.

It's also home to one of the best healthcare networks in the nation.

We are recruiting for those looking for better opportunities and a better life.

.....

PSYCHIATRY – ADULT

Logan | Ogden | Provo | Salt Lake City | St. George

MEDICAL HEALTH INTEGRATION MEDICAL DIRECTOR

Salt Lake City

.....

Employment position with the Intermountain Medical Group. Competitive salary and additional income for meeting quality goals. Stipend, signing bonus and student loan repayment. Full Intermountain benefits that include defined pension, 401K match, and CME. Relocation provider, up to 15K.



physicianrecruit@imail.org

800.888.3134

PhysicianJobsIntermountain.org

Unless otherwise specified, visa sponsorship is not available.





Therapeutic Update

! One Therapeutic Update will be held on Monday, May 16. The update is a two-hour informational program supported by Otsuka America Pharmaceutical, Inc. The promotional program is being held as an extension of the Exhibit Hall. It features a presentation by thought leaders in therapeutic areas. CME credit is not provided for the session. Attendees must be registered for the Annual Meeting, and the meeting badge is required for admittance.

The Therapeutic Update is for informational and promotional purposes only and does not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product. Plan to attend!

The Therapeutic Update is covered by the Physician Payment Sunshine Act, and physicians attending will be required to provide their identifying information for public reports.

Food service begins at 6:45 p.m.

Program begins at 7:15 p.m.

MONDAY, MAY 16

6:45 p.m. – 9:00 p.m.

Omni Atlanta Hotel at CNN Center International D-F, M2, North Tower
Supported by Otsuka America Pharmaceutical, Inc.

Reception and Dinner: 6:45 p.m.

Documentary screening to begin at 7:15 p.m.

Join Otsuka for a screening of the first-ever documentary about Pseudobulbar Affect (PBA): *Beyond Laughter & Tears: A Journey of Hope*

Program Host:

*Stephen M. Stahl, M.D., Ph.D.,
Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, Calif.,
Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK, Director of Psychopharmacology, California Department of State Hospitals,
Chairman, Neuroscience Education Institute (NEI)*

! The Therapeutic Update is for informational and promotional purposes only and does not offer CME credit. The information presented is provided by the supporting companies and does not represent any endorsement by the American Psychiatric Association of any company or product.

! The Therapeutic Update is a two-hour supported promotional presentation. Attendees must be registered for the Annual Meeting, and the meeting badge is required for admittance.



Exhibitors with Product/Service Descriptions

Acadia Healthcare

Booth #1922

6100 Tower Cir Ste 1000
Franklin, TN 37067
physiciancareerline.com

We are happy to introduce Acadia Healthcare powered by Physician Career Line. Physician Career Line is dedicated solely to physicians. Its purpose is to provide information on current events related to physicians as well as the conferences we will be attending and educational programs we have to offer. Physicians will also be able to find the latest psychiatrist positions on this site. Visit our website for more information.

ACADIA Pharmaceuticals

Booth #1437

11085 Torreyana Rd Ste 100
San Diego, CA 92121-1104
acadiapharm.com

ACADIA Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.

Admera Health

Booth #1800

126 Corporate Blvd
South Plainfield, NJ 07080-2411
admerahealth.com

Admera Health is a CLIA-certified, CAP accredited laboratory, utilizing next-generation sequencing technology to advance the field of personalized medicine. Our expertise includes pharmacogenomics, cardiovascular disease and noninvasive cancer screening. Diagnostic test results are delivered to physicians and patients in a distilled and manageable report, giving

them the relevant information to make the most informed treatment decisions.

Air Force Recruiting Services

Booth #608

550 D St W Ste 1
Randolph AFB, TX 78150
airforce.com

Air Force Recruiting Service—The world's greatest Air Force powered by airmen, fueled by innovation. Looking for unique challenges, professional growth, and a desire to make a difference in your life as well as others? Consider a career as an Air Force biomedical sciences corps officer. Few firms can match the perks we offer: competitive salary; funded, advanced, and continuing education; comprehensive medical and dental; 30 days paid vacation each year; tax-free food and housing allowances.

Align International Recruitment Ltd.

Booth #619

429 Durham St N
Christchurch, New Zealand
alignrecruitment.com

Align International Recruitment Ltd, recruits board certified psychiatrists for full-time, direct hire positions in New Zealand. Call 1-800-511-6976 or email larry@alignrecruitment.com to explore the adventure and opportunity of a lifetime to live and work in beautiful New Zealand. New Zealand and our fabulous Kiwi lifestyle are closer than you think!

Alkermes, Inc.

Booth #1623, 1811

852 Winter St
Waltham, MA 02451-1420
alkermes.com

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include

Exhibitors with Product/Service Descriptions

schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R & D center in Waltham, Mass., a research and manufacturing facility in Athlone, Ireland, and a manufacturing facility in Wilmington, Ohio.

All Star Recruiting

Booth #617

4400 W Sample Rd Ste 250
Coconut Creek, FL 33073-3476
allstarrecruiting.com

All-Star Recruiting has been providing professional placement services and proven results to hospitals, physician groups and practice management organizations since 2003. We currently service both physician and advance practice needs for both locum and permanent medical positions. Our managing partners have over 30 years of experience, and our recruiters over 100 years of combined experience. We pride ourselves on being a recruitment firm that can provide swift, professional and reliable service without the cost, multiple contacts and headaches of a larger company. All-Star Recruiting is headquartered in Coconut Creek, Fla., and provides strategic staffing solutions for clients in numerous medical specialties.

Allergan

Booth #1337, 1546

400 Interpace Pkwy
Parsippany, NJ 07054-1120
actavis.com

Allergan is a global pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative branded pharmaceutical products for patients around the world.

Allina Health

Booth #602

2925 Chicago Ave
Minneapolis, MN 55407-1321
allinahealth.org

As the largest provider of mental health and addiction services in Minnesota, Allina Health has a long and proud history of providing care to our communities. More than 150 mental health and addiction providers care for more than 100,000 patients each year at 35 primary care clinics, five specialty care clinics and eight hospitals. Services range from hospital inpatient, partial hospitalization, assessment and referral, day treatment, addiction, clinic visits, eConsultation and telemedicine. Stop by our booth or visit our website for information.

AltheaDx

Booth #1410

10578 Science Center Dr
San Diego, CA 92121-1143
altheadx.com

We are a commercial stage molecular diagnostics company specializing in the field of pharmacogenetics, or PGx. IDgenetix, our PGx product testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including neuropsychiatric disorders, cardiovascular disease and pain. Our proprietary algorithm-based bioinformatic platform and PGx product testing portfolio are intended to serve as a tool to assist healthcare providers in identifying optimal drugs for their patients as well as dosing guidelines based on a patient's genetic make-up, current prescription regimen and other key factors. IDgenetix is designed to enable healthcare providers to make timely and evidence-based decisions, which we believe can reduce the overall cost of patient care by reducing adverse events, optimizing patients' overall therapeutic regimen and helping to achieve a faster therapeutic response.

Exhibitors with Product/Service Descriptions

American Academy of Addiction Psychiatry

Booth #1603

400 Massasoit Ave Ste 307
East Providence, RI 02914-2012
aaap.org

The American Academy of Addiction Psychiatry is the professional membership organization for learning and sharing about the art and science of addiction psychiatry research and clinical treatment.

American Board of Psychiatry and Neurology, Inc.

Booth #1429

2150 E Lake Cook Rd Ste 900
Buffalo Grove, IL 60089-1875
abpn.com

The American Board of Psychiatry and Neurology serves the public interest and the professions of psychiatry and neurology by promoting excellence in practice through its certification and maintenance of certification processes. ABPN also oversees the certification process for physicians seeking certification in child and adolescent psychiatry.

American Physician Institute— Beat the Boards

Booth #1419

125 Windsor Dr Ste 111
Oak Brook, IL 60523-4081
americanphysician.com

American Physician Institute (API) provides dynamic medical education, CME and self-assessment credits to thousands of physicians every year. Each course provides high-yield, laser-focused content for the purpose of effectively passing their board exam or to keep up-to-date on the latest advancements. API features CME-accredited learning materials, resident director and physician dashboards,

webinars, a comprehensive Q bank and board-style practice exams.

American Professional Agency, Inc.

Booth #1217

95 Broadway
Amityville, NY 11701-2718
apamalpractice.com

Our company is a leading provider of psychiatrists medical professional liability insurance and is the only program endorsed by the American Psychiatric Association. Our policyholders receive comprehensive protection, many discounts and exceptional risk management services, which include a 24-hour daily hotline in the event of an emergency.

Arbor Pharmaceuticals, LLC

Booth #1717

6 Concourse Pkwy Ste 1800
Atlanta, GA 30328-5353
arborpharma.com

Arbor Pharmaceuticals is an Atlanta, Ga. based specialty pharmaceutical company devoted to the treatment of diseases and disorders affecting pediatric patients. Arbor is dedicated to improving the lives of patients and caregivers by bringing improved treatments to market with an intense focus on quality and effectiveness.

Arcadian Telepsychiatry

Booth #1810

7241 Hollywood Road
Ft. Washington, PA 19034-1204
arcadiantelepsychiatry.com

Founded in 2012, Arcadian has grown to become one of the nation's leading providers of telepsychiatry services. With more than 30 years of behavioral health and management experience, Arcadian is the clear choice among qualified care providers. Psychiatrists can work from home or established office locations, establishing reliable revenue streams without additional logistics or travel times.

Exhibitors with Product/Service Descriptions

Army Medical Recruiting

Booth #716

1307 3rd Ave Bldg 1307
Fort Knox, KY 40121-2725
goarmy.com

Please visit the Army Medical Recruiting booth to speak to learn more about rewarding careers in the Army Reserves or active duty Army.

Association & Meeting Solutions

Booth #1505

6900 Grove Road
Thorofare, NJ 08086-9447
helio.com/psychannels

Please visit the Association & Meeting Solutions exhibit for more information about products and services that will be of interest to you.

Association of Gay and Lesbian Psychiatrists (AGLP)

Booth #1601

4514 Chester Ave
Philadelphia, PA 19143-3707
aglp.org

The AGLP is a professional organization of psychiatrists, psychiatry residents and medical students, which serves as a voice for the concerns of lesbians and gay men within the psychiatric community. The Association is committed to fostering an accurate understanding of homosexuality, opposing discriminatory practices against gay men and lesbians, and promoting supportive, well-informed psychiatric care for lesbian and gay patients. The organization provides opportunities for affiliation and collaboration among psychiatrists who share these concerns.

Assurex Health

Booth #845

6030 S Mason Montgomery Rd
Mason, OH 45040-3706
assurexhealth.com

Assurex Health is the leading personalized medicine company dedicated to helping healthcare providers determine the right medication for patients with behavioral health conditions and chronic pain. We help people achieve mental wellness with advanced genomics technology providing individualized treatment support for neuropsychiatric condition.

Atlanta Center for Medical Research

Booth #1827

501 Fairburn Rd SW
Atlanta, GA 30331-2012
acmr.org

The Atlanta Center for Medical Research (ACMR) is a 150,000 square foot facility that accommodates up to 300 overnight participants and employs over 100 full-time research personnel. ACMR has been a national leader in research studies for more than three decades. The organization's innovations and expertise have led the entire industry to higher standards of precision and safety. Sponsors trust ACMR to conduct the highest quality research and provide them with reliable data. Participants trust ACMR to honor their contribution with obsessive attention to their safety and comfort.

Aureus Medical Group

Booth #706

13609 California St Ste 500
Omaha, NE 68154-5245
aureusmedical.com

Aureus Medical is a nationwide leader in healthcare staffing and recruitment. With decades of experience, extensive resources and a nationwide network of client healthcare organizations, Aureus connects physicians in a wide spectrum of specialties with rewarding locum tenens and direct hire (full-time) opportunities across the country.

Exhibitors with Product/Service Descriptions

Aurora Health Care

Booth #506

PO Box 343930
Milwaukee, WI 53234-3930
aurora.org

Aurora Health Care is the largest integrated health system in Wisconsin providing patient care in 90 communities. Nationally recognized as a leader in quality health care and innovation, our integrated delivery model allows our physicians to support their patients, connect with colleagues and offer state-of-the-art, top tier quality care.

Austen Riggs Center

Booth #1530

25 Main St
Stockbridge, MA 01262-9701
austenriggs.org

The Austen Riggs Center holds patient authority and its completely open, voluntary and therapeutic community setting as core values in the treatment of psychiatrically complex adults. Austen Riggs is a not-for-profit, private residential treatment program and psychiatric hospital with a continuum of care. Patients receive individual psychotherapy four times weekly with a doctoral level clinician, supported by an interdisciplinary treatment team. Visit our website for information, resources, online CME/CE courses and more.

Barton Associates

Booth #1600

300 Jubilee Dr
Peabody, MA 01960-4030
bartonassociates.com

Barton Associates is a leading national locum tenens physician staffing and recruiting firm. Every day, our team engages with hospitals, medical practices and companies across the country in need of locum tenens physicians, dentists, nurse practitioners and physician assistants in a wide variety of medical

specialties. You can trust that Barton Associates has the resources, scale and dedication to your career needed to help you find the perfect locum tenens job. This is all we do. We're the locum tenens experts.

Bassett Healthcare Network

Booth #1309

1 Atwell Rd
Cooperstown, NY 13326-1394
bassett.org

Bassett Medical Center, located in beautiful Cooperstown, N.Y., is seeking well-trained BC/BE adult-psychiatrists to join our progressive multidisciplinary team. The Department of Psychiatry has a 10-bed, inpatient unit and an outpatient facility. Practice opportunities include a director of inpatient psychiatry and outpatient psychiatrist positions. Visit us at our website.

Behavioral Health Recruitment Services

Booth #1446

250 North Ave
Athens, GA 30601-2244
advantagebhs.org

Behavioral Health Recruitment Services is a division of Advantage Behavioral Health System. We are focused on the recruitment and placement of physicians, nurse practitioners, physician assistants as well as other behavioral health professionals for several Community Service Boards in Georgia. A career working for a community service board is rewarding on many levels. We provide comprehensive mental health, substance abuse and developmental disabilities services. We offer our employees medical, dental, legal and vision insurance, tuition reimbursement, CME credits and a matching 401(K). In addition to these benefits, we also participate in the Federal Loan Forgiveness Program.

Exhibitors with Product/Service Descriptions

Billings Clinic

Booth #603

801 N 29th St
Billings, MT 59101
billingsclinic.com

Billings Clinic offers psychiatric opportunities—outpatient, hospitalist seeking BE/BC adult psychiatrists to join a collegial team of 12 psychiatrists. We offer a top tier salary and student loan repayment with hours from 8 a.m. – 5 p.m., Monday through Friday, with a 1:11 weekday backup call, residency teaching opportunities, 44 inpatient beds and a tertiary referral center. Billings Clinic is a multi-specialty, physician-led organization and a proud member of the Mayo Clinic Care Network. Located in the magnificent Rocky Mountains in Billings, Mont., this friendly college community has great schools, safe neighborhoods and family activities. Exciting outdoor recreation minutes from home with 300 days of sunshine!

Braeburn Pharmaceuticals, Inc.

Booth #1405

47 Hulfish St
Princeton, NJ 08542-3713
porettaorr.com

Braeburn Pharmaceuticals, an Apple Tree Partners company, develops and commercializes innovative medical products. The company's first product will be Probuphine®, a buprenorphine implant currently under FDA priority review for the maintenance treatment of opioid dependence. Braeburn's executive team has decades of experience successfully bringing blockbuster pharmaceuticals and medical devices to market, as well as a deep understanding of clinical development and quality assurance processes. Apple Tree Partners is a venture capital firm that seeks to in-license and/or acquire products to build complementary pharmaceutical, medical device and technology-enabled healthcare services companies.

Brainsway USA Inc.

Booth #1617

2 Bala Plz Ste 300
Bala Cynwyd, PA 19004-1512
brainsway.com

Brainsway offers an effective, safe and noninvasive treatment for psychiatric and neurological disorders. Brainsway's revolutionary deep TMS (transcranial magnetic stimulation) is indicated by the Food and Drug Administration for treatment of depressive episodes in adult patients diagnosed with major depressive disorder who failed to achieve satisfactory improvement from antidepressant medication in the current episode. Brainsway's unique technology is based on patents registered by the National Institute of Health and by the company.

Brookhaven Retreat

Booth #1513

1016 Ic King Rd
Seymour, TN 37865-3150
brookhavenretreat.com

Please visit the Brookhaven Retreat, LLC exhibit for more information about The Lily Program®, an individualized mental health program for women.

California Correctional Health Care Services (CCHCS)

Booth #301

8280 Longleaf Dr Bldg D2
Elk Grove, CA 95758
changingprisonhealthcare.org

We are improving our organization's health care services measurably by hiring exceptional, dedicated clinicians like you. Our psychiatrists have rewarding careers providing first-rate mental health care to inmate patients in each of our 35 institutions. Please visit us at Booth 301 for additional information on our great pay and benefits, qualification requirements and the application process. While there, ask us about our Visa Sponsorship Program.

Exhibitors with Product/Service Descriptions

Cambridge University Press

Booth #417

32 Avenue Of The Americas
New York, NY 10013-2473
cambridge.org

Cambridge University Press is a leading publisher of professional books and journals in psychiatry. With dozens of new books in the past year, including important new titles from Dr. Stephen M. Stahl, author of *Stahl's Essential Psychopharmacology*. Cambridge has cutting-edge material for all mental health professionals and is pleased to announce the reconfiguration and relaunch of the journal *CNS Spectrums*, with Dr. Stahl as its Editor-in-Chief.

Captive Risk Planners/ Perfect Tax & Finance

Booth #1404

6850 Tpc Dr Ste 112
McKinney, TX 75070-3145
captiveriskplanners.com

Please visit the Captive Risk Planners/Perfect Tax & Finance exhibit for more information about products and services that will be of interest to you.

CareClix

Booth #1700

1934 Old Gallows Rd Ste 350
Vienna, VA 22182-4050
careclix.com

CareClix is a comprehensive telehealth software as a service solution that combines our online medical suite with clinical patients and doctors to perform consultation similar to face-to-face consultations. Our secure HIPAA-compliant platform enables remote consultations between patients and physicians and allows for the sharing and collaboration of clinical data between all parties involved. CareClix is transforming healthcare worldwide.

Carilion Clinic

Booth #405

213 S Jefferson St Ste 1401
Roanoke, VA 24011
carilionclinic.org

The Virginia Tech Carilion School of Medicine in Roanoke, Va., has an opening for an adult psychiatrist to join the faculty of the Department of Psychiatry and Behavioral Medicine at the physician-led Carilion Clinic. The training program in general psychiatry has 34 residents and there are fellowships in child, geriatric, and addiction psychiatry. This inpatient/outpatient faculty position in psychiatry is associated with Carilion Roanoke Memorial Hospital, a 700-bed teaching/tertiary referral center with 35 acute adult psychiatric beds, and several community partner organizations. Responsibilities include direct clinical services, teaching medical students, supervising residents and fellows in psychiatry, and integrating research with clinical practice. There are opportunities for research collaboration with world-renowned neuroscientists at the Virginia Tech Carilion School of Medicine and Research Institute. Submit CV and cover letter to Amy Silcox Physician Recruiter, amsilcox@carilionclinic.org or call 540-224-5187.

Carolinas Healthcare System

Booth #609

4135 S Stream Blvd Ste 300
Charlotte, NC 28217-4555
carolinashealthcare.org

Please visit the Carolinas Healthcare System-Behavioral Health exhibit for more information about exciting job opportunities for psychiatrists in beautiful Charlotte, N.C., and surrounding areas.

Exhibitors with Product/Service Descriptions

The Center for Eating Disorders at Sheppard Pratt

Booth #1403

6535 N Charles St Fl 3
Baltimore, MD 21204-5826
eatingdisorder.org

The Center for Eating Disorders at Sheppard Pratt offers comprehensive care for children, adolescents and adults with eating disorders. A national leader in evidence-based treatment since 1989, we provide highly specialized individual, group, family, occupational, art and nutritional therapies. Our continuum of care includes an inpatient program, partial hospital program, intensive outpatient program and free support groups and collaborative care workshops for caregivers.

Central Intelligence Agency

Booth #415

Recruitment Center
Washington, DC 20505
cia.gov

The CIA is the premier agency responsible for providing global intelligence on the ever-changing political, social, economic, technological and military environment. Here, your paramount goal and mission will be to protect the national security of the United States. Virtually any job you can imagine is available at the CIA—plus, some you can't even imagine.

Christian Medical & Dental Associations, Psychiatry Section

Booth #1510

PO Box 7500
Bristol, TN 37621-7500
cmda.org

Christian Medical Association, Psychiatry Section is a ministry of the Christian Medical and Dental Associations. We are a 15,000 member organization providing resources, networking, education and a public voice for Christian healthcare professionals and students.

The psychiatry section offers a forum for the interface of psychiatric practice and the Christian faith. APA participants are welcome to attend our concurrent programs. Visit our website for more information.

Clinical Psychiatry News

Booth #1412

7 Century Dr Ste 302
Parsippany, NJ 07054-4609
clinicalpsychiatrynews.com

Clinical Psychiatry News is an independent newspaper that provides the practicing psychiatrist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

Community Health Systems

Booth #601

4000 Meridian Blvd
Franklin, TN 37067-6325
chs.net

Community Health Systems, Inc., is one of the nation's leading operators of general acute care hospitals. The organization's affiliates own, operate or lease 207 hospitals in 29 states with approximately 31,100 licensed beds. Affiliated hospitals are dedicated to providing quality healthcare for local residents and contribute to the economic development of their communities. Based on the unique needs of each community served, these hospitals offer a wide range of diagnostic, medical and surgical services in inpatient and outpatient settings.

Community Psychiatry

Booth #503

3825 N Freeway Blvd Ste 100
Sacramento, CA 95834-1928
communitypsychiatry.com

Community Psychiatry began 20 years ago with one primary objective - improving patient access to psychiatric care by creating collaborative relationships with hospitals, physicians, psychotherapists and insurers. Our goal is to provide patients with knowledgeable,

Exhibitors with Product/Service Descriptions

compassionate treatment and our doctors with the support they need to deliver the best possible care. Our group has grown to over 22 offices and over 50 psychiatrists in small group practices throughout Northern California and two offices near Ann Arbor, Mich. For our physicians, we manage the paperwork so that they can focus on their work with integrity and autonomy.

CompHealth

Booth #1501

6440 S Millrock Drive
Suite 175
Salt Lake City, UT 84121-5892
comphealth.com

CompHealth is a national leader in healthcare staffing, serving providers in more than 100 specialties. Founded in 1979, CompHealth is the largest locum tenens staffing agency in the United States. CompHealth also specializes in permanent physician placement and both temporary and permanent allied healthcare staffing. CompHealth is part of the CHG Healthcare Services family of companies, which is ranked No. 16 on *Fortune* magazine's list of "100 Best Companies to Work For." To learn more, visit our website.

Compulink Business Systems, Inc.

Booth #1424

1100 Business Center Cir
Thousand Oaks, CA 91320-1129
compulinkadvantage.com

A proven leader for over 30 years, Compulink is a recognized leader in ONC-certified, EHR and practice management systems for psychiatry. Offering the industry's most flexible, most complete, and best supported system, our Psych Advantage is designed to help improve patient care and practice profitability.

Correct Care Solutions, LLC

Booth #1814

1283 Murfreesboro Pike Ste 500
Nashville, TN 37217-2421
correctcaresolutions.com

At Correct Care Solutions (CCS), we have the opportunity to serve patients who have traditionally been underserved. Mental Health in jails, prisons, psychiatric hospitals and residential treatment facilities offers an exciting and fulfilling career to psychiatrists. At CCS, we offer psychiatrists flexible career opportunities, competitive pay and benefits, and a support team that is one of the best in the industry. Join us today and grow your career with a company that values patient's health.

CoverMyMeds

Booth #1825

2 Miranova Place
Columbus, OH 43215-5078
covermymeds.com

CoverMyMeds is the nation's largest electronic prior authorization (ePA) platform and one of the fastest growing healthcare technology companies in the U.S. Our technology easily integrates with pharmacy systems, EHRs and PBMs to create the industry's most efficient ePA solution, helping patients receive the medications they need, faster. With more than 1 million PA requests processed each month, we are the only vendor using the NCPDP ePA standard at scale. Over 500,000 providers currently use CoverMyMeds to submit PA requests to PBMs electronically, eliminating timely phone calls and faxes. Providers, on average, save 15 minutes per PA request by using CoverMyMeds' secure web portal. Visit our website for more information or call 866-452-5017 to get started.

Exhibitors with Product/Service Descriptions

Current Psychiatry

Booth #1414

7 Century Dr Ste 302
Parsippany, NJ 07054-4609
currentpsychiatry.com

Sign up for a free subscription to *Current Psychiatry*, a leading monthly review publication and its website that provide timely, practical, peer-reviewed education and advice from leading authorities on common clinical problems, edited by Henry A. Nasrallah, M.D., and published in an educational partnership with Saint Louis University. *Current Psychiatry* is available in print to all practicing U.S. psychiatrists (in private and group settings and in hospitals), psychiatry residents, program faculty and advanced-practice mental health practitioners.

Delta Companies

Booth #1928

1755 Wittington Pl Ste 175
Dallas, TX 75234
thedeltacompanies.com

The Delta Companies offer permanent and temporary staffing solutions nationwide for physicians, physician extenders, allied and therapy healthcare professionals. Physician staffing services are represented by Delta physician placement and Delta locum tenens. All other allied healthcare staffing services are represented by Delta healthcare providers

Department of Behavioral Health and Developmental Disabilities

Booth #1305

Representing Georgia's Community Service Boards
c/o Gateway Behavioral Health Services
700 Coastal Village Drive
Brunswick, GA 31520
dbhdd.ga.gov

The Department of Behavioral Health and Developmental Disabilities, through partnership with its Community Service Boards throughout Georgia, provides a safety-net network of providers focused on offering easy access to

high-quality care that leads to a life of recovery and independence for those with behavioral health challenges, substance abuse issues, and intellectual and developmental disabilities.

Department of Veterans Affairs

Booth #411

1250 Poydras St Ste 1000
New Orleans, LA 70113-1810
vacareers.va.gov

Please visit the Department of Veterans Affairs exhibit for more information about products and services that will be of interest to you.

Destination Hope

Booth #1806

6555 Powerline Road
Ft. Lauderdale, FL 33309-2067
destinationhope.net

Please visit the Destination Hope exhibit for more information about products and services that will be of interest to you.

Diamond Healthcare Recruitment Division

Booth #708

PO Box 85050
Richmond, VA 23285-5050
diamondhealth.com

Diamond Healthcare is a fully integrated population health management organization with a special concentration on Behavioral Health. We own or operate over 80 psychiatric programs in 31 states across the country. Whether you are just starting out or have many years practice experience, physicians of all backgrounds will find many rewarding positions within our very collegial organization.

Exhibitors with Product/Service Descriptions

DR Wanted

Booth #514

950 E Paces Ferry Rd NE Ste 2160
Atlanta, GA 30326-1384
drwanted.com

DR Wanted is a national leader in the locum tenens industry. Our areas of focus include jobs in primary care hospital, emergency medicine and anesthesiology, as well as allied health. We offer A++ malpractice insurance, bi-weekly pay and other great benefits! Best-of-Class technology and an individual high-touch philosophy, these are the cornerstones of the DR Wanted recruitment process. Our seasoned team of staffing professionals provide a personal and unique search experience with an obsessive devotion to finding the right fit. At DR Wanted, we focus on shortening the search process while also providing a precise match for both client and candidate every time. Contact us today to find out more about the resources and candidates currently available.

Electromedical Products International, Inc.

Booth #1211

2201 Garrett Morris Pkwy
Mineral Wells, TX 76067-9034
alpha-stim.com

Overwhelmed by patients with mood and sleep disorders? Alpha-Stim® can help you melt away their anxiety, depression and insomnia so they can experience life again. Alpha-Stim is supported by more research than any other prescription device in its class. Read over 55 studies and reviews revealing robust effect sizes at our website. Side effects are rare, minor and self-limiting. Pocket-sized Alpha-Stim medical devices work through ear clip electrodes that send a weak current directly into the brain for 20-minute sessions. This alters the EEG by increasing Alpha frequencies and decreasing Delta frequencies. Electromedical Products International, Inc., was founded in 1981 and is the world leader in cranial electrotherapy stimulation. Come by our booth to try it for yourself. You will be amazed at how good you will feel. Request a free 60-day loan by visiting

our website or contact us at info@alpha-stim.com or 1-940-328-0788.

Elsevier, Inc.

Booth #525

1600 John F Kennedy Blvd Ste 1800
Philadelphia, PA 19103-2398
elsevier.com

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health and technology professionals, empowering them to make better decisions, deliver better care and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions—among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey—and publishes nearly 2,200 journals, including *The Lancet* and *Cell* and over 26,000 book titles, including a number of iconic reference works.

EmCare

Booth #407

13737 Noel Road, Suite 1600
Dallas, TX 75240-1331
emcare.com

EmCare is the nation's largest multispecialty group with fantastic inpatient psychiatric opportunities in Florida, New Hampshire, Indiana and expanding across the nation. Block schedules, plenty of time off, competitive pay and comprehensive, administrative support, leadership jobs are available! Contact us at 1-214-712-2465 or visit our website for more information.

FCS, Inc.

Booth #605

1711 Ashley Cir Ste 6
Bowling Green, KY 42104-5801
fcpsy.com

Helping psychiatrists find a place to call home for over 30 years, FCS, Inc., is the leader in psychiatric recruitment, and is quickly becoming the primary source for psychiatry Locum Tenens assignments.

Exhibitors with Product/Service Descriptions

Federal Bureau of Prisons (BOP)

Booth #403

320 1st St NW
Washington, DC 20534-0002
bop.gov

Join the Leader in correctional health care! The Federal Bureau of Prisons (BOP) values your unique contribution to our collaborative team medicine approach of providing health care. Experience a level of clinical diversity and continuity of care not commonly available in the private sector. BOP has 122 federal prisons nationwide with full-time physician, dentist, physician assistant, nurse practitioner and nurse vacancies. For more information, contact BOP at 1-800-800-2676 or via email at BOP-HSD/Recruitment@bop.gov.

Focus: The Journal of Lifelong Learning in Psychiatry

Booth #1528

1000 Wilson Blvd Ste 1825
Arlington, VA 22209-3924
psychiatry.org

Focus: The Journal of Lifelong Learning in Psychiatry is the complete system for lifelong learning, maintenance of certification, self-assessment, performance in practice and CME.

Fraser Health

Booth #610

400-13450 102 Ave
Surrey, BC V3T 0H1
Canada
physicians.fraserhealth.ca

Located in the Metro Vancouver and Fraser Valley region of British Columbia, Fraser Health has 20 culturally and geographically diverse communities—from urban to rural. As the fastest-growing region in the province, we provide health services to 1.6 million people with 12 acute care hospitals, tertiary teaching hospitals and services in public health, home health, mental health and residential care facilities. Fraser Health's mental health and substance use program provides a range of services including child, youth/adolescent, adult,

geriatric psychiatry at eight of our 12 University of British Columbia affiliated hospitals and through 12 community mental health teams. Successful applicants with have their FRCPC designation (or equivalent) and be eligible for licensure with the College of Physicians and Surgeons of British Columbia. Visit us at our website.

Genomind

Booth #1227

2200 Renaissance Blvd
King Of Prussia, PA 19406-2755
genomind.com

Genomind is a personalized medicine company bringing innovation to mental healthcare through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology who specialize in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients' lives. Learn more at our website.

Georgia Association of Community Service Boards, Inc.

Booth #1425

3150 Golf Ridge Blvd Ste 202
Douglasville, GA 30135-1930
gacsb.org

Georgia Association of Community Service Boards, Inc. (GACSB) leads the development and operations of mental health, developmental disabilities and addictive diseases services, community-based and comprehensive in range, provided by the 26 community service boards (CSB), Georgia's public safety net. Advocating, initiating and supporting actions designed to improve services, the GACSB serves its member organizations by speaking with one voice on matters involving CSBs.

Exhibitors with Product/Service Descriptions

Georgia Ketamine

Booth #1710

1370 Thompson Bridge Road, Suite 101
Gainesville, GA 30501
georgiaketamine.com

Georgia Ketamine offers IV Ketamine infusion treatments for clinical depression. We focus on treatment resistant depression and other MDD that do not respond adequately to appropriate courses of at least two antidepressants but not limited to treatment resistant depression, major depressive disorders, post-partum depression, bipolar depression and severe anxiety. Having been treated with at least two or more classes with no results, choose Ketamine infusions.

Glens Falls Hospital

Booth #408

100 Park Street
Glens Falls, NY 12801-4431
glensfallshospital.org

Glens Falls Hospital, in Glens Falls N.Y., is an integrated health care system, serving a six-county region of the southern Adirondacks. With 2,700 employees, 400+ credentialed providers and 28 locations, it has the region's longest-established employed physician group. Specializations include primary care, cardiology, endocrinology, hematology/oncology, internal medicine, nephrology, otolaryngology, psychiatry, emergency and inpatient medicine, thoracic surgery and wound healing. Patients are offered a wide range of services and community health improvement programs.

Global Medical Staffing

Booth #613

3995 S 700 E Ste 100
Salt Lake City, UT 84107-2536
gmedical.com

We offer extraordinary locum tenens assignments that last from a few days, to a month, to a year or longer in locations around the globe. We handle all the details so you're free to treat patients, free to boost your expertise, free to earn a competitive living and enjoy practicing medicine - without worrying

about the business of medicine. Let us help you find your perfect place to practice!

Gould Farm

Booth #1411

PO Box 157
Monterey, MA 01245-0157
gouldfarm.org

Within the spectrum of Axis I disorders, those in recovery come to Gould Farm to gain skills to responsibly manage disruptive symptoms and construct a more useful framework for a sustainable sense of positive place in this world. Medication management, counseling, cognitive therapy, open dialogue and practical skills training are integrated into a structured work week. Spending six to 12 months in this normative, thriving community can be life changing.

Greater Hudson Valley Health System

Booth #409

707 E Main Street
Middleton, NY 10940-2650
ormc.org

We are a three hospital, not-for-profit health system coming to recruit psychiatrists for employment with our group.

Group Health Physicians

Booth #504

320 Westlake Ave N
Seattle, WA 98109-5232
grouphealthphysicians.org

Group Health Physicians is one of the nation's largest and most honored multispecialty medical groups. This group of more than 1,400 doctors and clinicians is responsible for clinical quality and care at Group Health, a consumer-governed health system in Washington State and North Idaho with more than 600,000 plan members. In 2010, Group Health Physicians received the prestigious American Medical

Exhibitors with Product/Service Descriptions

Group Association's Acclaim Award for physician-led innovations that have transformed care at Group Health Medical Centers. As a practitioner at Group Health Physicians, you will join a collaborative team in a professionally satisfying, patient-centered environment. Please come by our booth to learn more about the great opportunities awaiting you today at Group Health!

Guilford Publications

Booth #420

370 7th Ave Ste 1200
New York, NY 10001
guilford.com

Visit our booth for new and best-selling titles: Greenberger, *Mind Over Mood, 2e*; Hofmann, *Emotion in Therapy*; Wilens, *Straight Talk about Psychiatric Medications for Kids, 4e*; Corrigan, *Principles and Practice of Psychiatric Rehabilitation, 2e*; Saxe, *Trauma Systems Therapy for Children and Teens, 2e*; Watkins, *Rumination-Focused Cognitive-Behavioral Therapy for Depression*; Scheeringa, *Treating PTSD in Preschoolers*; and Greenfield, *Treating Women with Substance Use Disorders: The Women's Recovery Group Manual*.

Harmonex Neuroscience Research, Inc.

Booth #1514

408 Healthwest Dr
Dothan, AL 36303-2054
clinicom.com

CliniCom is a secure, intuitive, web-based intake and assessment tool developed by Harmonex Neuroscience Research and has been used in mental health settings for the past ten years. CliniCom generates clinical reports by gathering information directly from patients, parents and/or guardians prior to the initial office visit. Users can complete the assessment from any computer, tablet, smart phone or any other mobile devices.

HCPLive

Booth #1311

666 Plainsboro Rd Ste 300
Plainsboro, NJ 08536-3000
hcplive.com

MD Magazine is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty- and disease-specific resources designed to help them provide better care to patients. At *MD Magazine*, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors and more.

Hillside, Inc.

Booth #1521

690 Courtenay Dr NE
Atlanta, GA 30306-3421
hside.org

Hillside is one of Atlanta's oldest not-for-profit organizations. Our mission is to help children and families thrive by providing outstanding residential and community mental health services. Our programs focus on the strengths of our kids and encourage the growth and improvement they need to navigate through life. Hillside is currently the only Dialectical Behavior Therapy (DBT) adherent residential treatment facility in the Southeast providing specialized cutting edge behavioral treatment and education to children and their families. We offer a continuum of care ranging from outpatient DBT clinic to residential treatment. Please visit Hillside's exhibit for more information about our continuum of care.

Hogrefe Publishing Corp.

Booth #522

38 Chauncy St Ste 1002
Boston, MA 02111-2318
hogrefe.com

Hogrefe Publishing has been publishing books, periodicals, and assessment tools in the fields of psychiatry, medicine and psychology for over 60 years. Visit us at Booth 522! We will be presenting the latest print and online editions

Exhibitors with Product/Service Descriptions

of the *Clinical Handbook of Psychotropic Drugs* (CHPD) for adults and for children and adolescents. Take advantage of special offers for combining CHPD print editions and online versions.

Horizon Health

Booth #1400

1965 Lakepointe Dr Ste 100
Lewisville, TX 75057
horizonhealth.com

Founded in 1981, Horizon Health Behavioral Health Services is the leading manager and provider of hospital-based behavioral health programs. We have provided services in 47 states, working with hospitals of all types and sizes to manage their behavioral health programs, providing an additional revenue stream and helping to ease the strain on their emergency departments.

Hospital Corporation of America (HCA)

Booth #1328

2 Maryland Farms Ste 210
Brentwood, TN 37027
practicewithus.com

Hospital Corporation of America (HCA) owns and operates 160 healthcare facilities in 20 states with opportunities coast to coast. HCA was one of the nation's first hospital companies. We are committed to the care and improvement of human life, and we strive to deliver quality healthcare that meets the needs of the communities we serve.

Humana Inc.

Booth #1812

500 W Main St Ste 300
Louisville, KY 40202-4268
humana.com

Please visit the Humana exhibit for more information about products and services that will be of interest to you.

IASIS Healthcare

Booth #505

117 Seaboard Ln Bldg E
Franklin, TN 37067-2855
iasishealthcare.com

IASIS Healthcare is a healthcare services company that seeks to deliver high-quality, cost-effective healthcare through a board and differentiated set of capabilities and assets that include acute care hospitals with related patient access points and a diversified managed care risk platform. With a total annual revenue of approximately \$2.6 billion, IASIS, headquartered in Franklin, Tenn., owns and operates 16 acute care hospitals, one behavioral hospital and multiple other access points in high-growth urban and suburban markets throughout the United States, including Arizona, Arkansas, Colorado, Louisiana, Texas and Utah. This encompasses 132 physician clinics, multiple outpatient surgical units, imaging centers and investments in urgent care centers and onsite employer-based clinics, that serve more than a combined 1.1 million patients.

Indivior Inc.

Booth #1409, 1547, 1713

10710 Midlothian Turnpike
Richmond, VA 23235-4722
indivior.com

Indivior Inc. is a specialty pharmaceutical company at the forefront of providing educational resources and treatment options to physicians and patients dealing with opioid dependence. Please visit the company's medical booth where Indivior medical personnel will be standing by.

Infinite Trading, Inc.

Booth #1614

3651 Lindell Rd Ste D120
Las Vegas, NV 89103
hidow.com

Please visit the Infinite Trading exhibit for more information about products and services that will be of interest to you.

Exhibitors with Product/Service Descriptions

Informa Health Care Journals

Booth #526

4 Park Square, Milton Park
Abingdon, OX14 4R United Kingdom
tandfonline.com

Please visit the Informa Health Care Journals exhibit for more information about products and services that will be of interest to you.

InSight Telepsychiatry, LLC

Booth #1616

765 E Route 70 Bldg A-100
Marlton, NJ 08053-2341
insighttelepsychiatry.com

InSight is the leading national telepsychiatry service provider organization with a mission to increase access to quality behavioral health care through telehealth. InSight's behavioral health providers bring care into any setting on an on-demand or scheduled basis. InSight has over 16 years of telepsychiatry experience and is an industry thought-leader.

Intermountain Healthcare

Booth #501

36 S State St Fl 21
Salt Lake City, UT 84111-1630
physicianjobsintermountain.org

Visit Intermountain Healthcare to learn about exciting physician job opportunities (named by *Forbes* as one of nation's top 25 employers in 2015). Intermountain Healthcare, a Utah-based, nonprofit system of 22 hospitals, 185 clinics, a medical group of over 1,000 employed physicians, a health plans division (Select Health), and other health services, is widely recognized as a leader in clinical quality improvement and efficient healthcare delivery.

International Congress on Dual Disorders

Booth #327

Londres 17
Madrid, 28028 Spain
cipd2015.com

Dual disorder is a mental disorder and an addiction, whether to substance, sex, game, electronic devices or other, is growing exponentially all over the world. The addictions can differ from continent to continent, or from culture to culture, but the disorders themselves and the increase of addictions are there. We wish to address this unsettling reality with rigor, methodology and professionalism, giving a floor for experts, peers, clinicians and mental professionals facing daily these challenges, to share a disquieting reality.

Intra-Cellular Therapies Inc.

Booth #644

430 E 29th St
New York, NY 10016-8367
intracellulartherapies.com

Intra-Cellular Therapies, Inc. (ITCI) is a biopharmaceutical company that is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, ITCI develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. The company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

Exhibitors with Product/Service Descriptions

IPC Healthcare

Booth #401

4605 Lankershim Blvd
North Hollywood, CA 91602-1818
hospitalist.com

IPC is the nation's leading physician group practice company focused on the delivery of hospitalist and facility-based services. IPC's clinicians and affiliated providers practice in hospitals and other inpatient facilities including acute, post-acute and long-term care settings.

Iris Telehealth

Booth #1203

1944 E Pembroke Ave Ste A
Hampton, VA 23663-1326
iristelehealth.com

Iris Telehealth is an innovative telepsychiatry company with a mission to provide underserved communities with access to the best mental health care possible. We have earned a reputation for providing outstanding customer service and excellent clinical care. Iris values building strong professional relationships with our partners and their staff. We are dedicated to understanding your organization's needs and operational goals because we recognize that your success is critical to our own. At Iris, we believe that everyone deserves access to mental health services and we are proud to help provide this care where it is needed most!

Ironshore Pharmaceuticals and Development, Inc.

Booth #1637

10 Market St Ste 715
Camana Bay, KY1-9006 Cayman Islands
highlandtherapeutics.com

Ironshore Pharmaceuticals and Development, Inc., is leveraging its proprietary DELEXIS® drug delivery platform to optimize the delivery of stimulant medications for the treatment of ADHD. Ironshore seeks to fulfill a significant unmet medical need in the treatment of ADHD®inadequate symptom control during the early morning routine. Dosed in the evening, DELEXIS® provides a consistent

delay in initial release of the active drug, followed by controlled, extended-release, to target meaningful control of ADHD symptoms immediately upon waking and throughout the day.

Jackson & Coker

Booth #1622

3000 Old Alabama Rd Ste 119-608
Alpharetta, GA 30022-8555
jacksoncoker.com

At Jackson & Coker, we focus on you—the patient's true hero. When you are looking for flexibility, Jackson & Coker's concierge level service makes it convenient to work locum tenens. Our credentialing department, privileging assistance, and travel coordinators will handle all the details. When you are ready to settle down, our permanent recruiting consultants can help you find the job of a lifetime.

The JAMA Network

Booth #624

330 N Wabash Ave Ste 39300
Chicago, IL 60611-5885
jamanetwork.com

Building on a tradition of editorial excellence, The JAMA Network brings JAMA together with 11 specialty journals to offer enhanced access to the research, viewpoints and medical news shaping medicine today and into the future. *JAMA Cardiology*, a new peer-reviewed journal will publish in early 2016.

Janssen Pharmaceuticals, Inc.

Booth #637

1000 Route 202
Raritan, NJ 08869-1425
janssen.com

Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including diabetes, mental health, pain management and cardiovascular disease.

Exhibitors with Product/Service Descriptions

JPE Healthcare Staffing, Inc.

Booth #404

5665 Atlanta Hwy Ste 103-102
Alpharetta, GA 30004-3932
jpehealth.com

Please visit the JPE Healthcare Staffing, Inc. exhibit for more information about Locum Tenens and permanent placement that will be of interest to you.

Kaiser Permanente, The Permanente Medical Group, Inc.

Booth #614

1800 Harrison St Fl 7
Oakland, CA 94612-3466
physiciancareers.kp.org

Within the Permanente Medical Groups, physicians find recognition, stability, opportunity and independence. Through our leadership in the use of advance technology, creation of innovative solutions, and our influence on health policy and reform efforts, Kaiser Permanente is helping to shape the future of health care in the nation. Contact us today to discover how you can become a part of our innovative model of practice.

Liberty Healthcare Corporation

Booth #612

401 E City Ave Ste 820
Bala Cynwyd, PA 19004-1155
libertyhealthcare.com

Liberty Healthcare Corporation is a Joint Commission-certified and physician-owned health care services organization that provides outpatient, residential, ACT, inpatient, and telepsychiatry services throughout the U.S. Liberty currently seeks psychiatrists who are interested in general/adult, geriatric, child/adolescent and forensic psychiatry for positions in California, Maine, and South Carolina.

LifePoint Health

Booth #606

330 Seven Springs Way
Brentwood, TN 37027-5098
lifepointgoodlife.com

LifePoint Health is a dynamic system of hospitals, private practice groups and academic partnerships focused on providing the best possible healthcare to our 72 communities. Our growth and quality initiatives are unmatched, and so are LifePoint's physician opportunities. We are committed to our behavioral health initiatives and to offering excellent career growth, compensation and lifestyle options for both inpatient and outpatient psychiatrists. Whether your interest is in geriatrics, addiction or general psychiatry, LifePoint has a community that needs your training and experience. Come see us in Booth 606 for details on our opportunities across the United States.

Locum Source, Inc.

Booth #1420

1275 Glenlivet Dr Ste 100
Allentown, PA 18106-3107
locum-source.com

Locum Source, Inc., is a locum tenens and permanent placement agency for physicians, physician assistants and nurse practitioners. Our company was founded by two board-certified surgeons who have significant locum tenens experience. Their experience and expertise offer a unique advantage in the locum tenens market that is not available elsewhere. Our goal is to exceed your expectations with our level of customer service. If you are a hospital or a provider, we look forward to being "The Source" for all your locum tenens needs.

Exhibitors with Product/Service Descriptions

LocumTenens.com

Booth #1323

2655 Northwinds Pkwy
Alpharetta, GA 30009-2280
locumtenens.com

Founded in 1995, LocumTenens.com is a full-service staffing firm serving physicians, advanced practice professionals and healthcare facilities looking to solve employment shortage. The operator of the largest online job board for the locum industry, LocumTenens.com provides job-seeking providers direct access to thousands of jobs, in all specialties, posted directly by facilities and agencies nationwide.

Magstim

Booth #1518

633 Davis Drive
Suite 200
Morrisville, NC 27560
magstim.com

The company that developed the first magnetic stimulator is pleased to present the Magstim Therapy System. Stop by our exhibit to see how the Therapy System can provide you with the rTMS device you need in a more cost effective manner.

Magventure, Inc.

Booth #1707

303 Perimeter Ctr N Ste 300
Atlanta, GA 30346-3401
magventure.com

MagVenture Inc. offers a complete line of magnetic stimulation solutions for a broad range of research and clinical applications. MagVenture's FDA-cleared MagVita TMS depression treatment system is simple, effective and easy to use for psychiatrists wishing to provide an alternative to patients who are not responding to antidepressants. The system, which is offered with no per-use fee, was FDA cleared in 2015 (510(k)), indicated for the treatment of major depressive disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

Maxim Physician Resources

Booth #1225

5001 Lyndon B Johnson Freeway
Ste 900
Dallas, TX 75244-6151
maximphysicians.com

Maxim Physician Resources (MPR) is an industry leader in nationwide physician staffing services, specializing in placing physicians in locum tenens opportunities. Maxim realizes the key to quality is in the details, and as such, MPR focuses on the unique needs that are inherent to physician staffing. Maxim handles the recruitment, screening, credentialing and the eventual placement of highly-qualified physicians in various clinical environments.

Mayo Clinic

Booth #1313

200 1st St SW
Rochester, MN 55905-0002
mayoclinic.org

The Mayo Clinic mission is to inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education and research. Our neuroscience and genomic research in mood and addictive disorders continues to guide cutting edge progressive clinical care to meet the need of our patients. Multidisciplinary teams are constantly seeking innovation in clinical care and sharing it with the psychiatric community. Visit Booth 1313 to meet our psychiatrists and learn more about our research, clinical practice and CME courses.

Exhibitors with Product/Service Descriptions

McLean Hospital

Booth #1300

115 Mill St
Belmont, MA 02478-1048
mclean.harvard.edu

McLean Hospital is an international center for psychiatric treatment, teaching, research and education. McLean offers state-of-the-art diagnostic and treatment services across a full continuum that includes inpatient, residential, partial hospital and outpatient care. McLean is also home to an expanded array of specialized academic programs for children and adolescents as well as dedicated services for older adults with Alzheimer's and other dementias. McLean houses the largest research program of any private psychiatric hospital in the world and as a major teaching affiliate of Harvard Medical School, McLean educates the best and brightest mental health providers.

MD.com

Booth #1602

1908 Marlton Pike E
Cherry Hill, NJ 08003-2118
MD.com

We offer every physician in the U.S. their own virtual clinic to provide secure video visits to their patients. We help doctors attract new patients by promoting these virtual clinics to more than 1 million U.S. consumers visiting MD.com each month. Consumers can find a doctor through the MD.com search engine populated with more than 880,000 doctors. Book or request an appointment online.

MECTA Corporation

Booth #1301

19799 SW 95th Ave Ste B
Tualatin, OR 97062-7584
mectacorp.com

For over 40 years, MECTA has set the standard for unparalleled innovation, based on research through four generations of ECT devices used for the treatment of depression. New optimized ECT includes new, more efficient parameters, resulting in greater efficacy and the minimization

of cognitive side effects. This is combined with the newest, easy-to-use optimized titration methodology, and four treatment menus for Ultrabrief, Near Ultrabrief, Brief Pulse and Full spECTrum dosing. The new MECTA EMR stores treatment data and monitoring that can be saved onto hospital servers and EHRs as pdfs! Up to 700 data points can be viewed in clinician offices, and exported into spreadsheets. The newest form of ECT, FEAST, patented by MECTA, is in clinical trials and promises to change the treatment markedly! MECTA—Evidence Based ECT!

Medical Billing Professionals

Booth #1223

P.O. Box 560
Royersford, PA 19468
mbpros.com

Medical Billing Professionals, with over 18 years of behavioral health billing experience, will submit your claims for as little as \$1.59 per claim. Stop by our booth for information on our free iPad offer.

Medical Search

Booth #412

23 Vreeland Rd Ste 210
Florham Park, NJ 07932-1510
medsearchint.com

Medical Search is a premier Locum Tenens and permanent placement agency, specializing in placing all levels of medical professional into the most opportunistic assignments nationwide. The psychiatry division is solely dedicated to their clients and physicians to ensure the highest level of quality and service in the industry.

Exhibitors with Product/Service Descriptions

Medicus Healthcare Solutions

Booth #604

7 Industrial Way Unit 5
Salem NH 03079-2817
medicushcs.com

Medicus Healthcare Solutions provides nationwide locum and permanent career opportunities for physicians, CRNAs and advanced practitioners. We offer our providers opportunities to work as consultants, interim leaders and specialists on teams assembled for projects such as new program launches. For healthcare facilities and groups, Medicus provides permanent placement, supplemental physician staffing and locum tenens management services.

MedPartners Locum Tenens

Booth #1523

5810 Coral Ridge Dr Ste 250
Coral Springs, FL 33076-3381
medpartnerslt.com

MedPartners Locum Tenens was established to build the best possible staffing organization in the locum tenens industry. Our founders have a simple vision—build a company that never loses sight of taking care of all its highly-talented employees. With more than 25 years of combined healthcare and physician staffing experience, MedPartners Locum Tenens has the knowledge, resources and proven industry commitment to help facilities execute the increasing demands of today's rapidly changing healthcare landscape.

Memorial Hospital of Sweetwater County

Booth #508

1200 College Dr
Rock Springs, WY 82901-5868
sweetwatermemorial.com

Please visit the Memorial Hospital of Sweetwater County exhibit to inquire about their current positions available.

Menninger Clinic

Booth #1317

12301 Main St
Houston, TX 77035-6207
menningerclinic.com

The Menninger Clinic, Houston, is a specialty psychiatric hospital for assessment and treatment of adolescents and adults with difficult-to-treat psychiatric disorders, as well as co-occurring conditions. Inpatient care integrates evidence-based and biopsychosocial therapies with rehabilitation. Outpatient and intensive outpatient services and a psychosocial clubhouse are also offered. Menninger trains clinicians, conducts research and is affiliated with Baylor College of Medicine.

Merck & Co.

Booth #837

2000 Galloping Hill Rd
Kenilworth, NJ 07033-1310
merck.com

Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.

Metabolic Maintenance

Booth #1347

601 N Larch St
Sisters, OR 97759-9320
methylpro.com

Metabolic Maintenance, the parent company of MethylPro®, has been a pioneer in the field of personal nutrition for over 30 years by collaborating with healthcare professionals and delivering quality supplements. With a foundation in medical research, good manufacturing practices, and personalized customer service, we are proud to offer custom formulas, a complete supplement line, and the MethylPro® line of professional strength L-methylfolate supplements.

Exhibitors with Product/Service Descriptions

MHM Services, Inc.

Booth #712

1593 Spring Hill Rd Ste 610
Vienna, VA 22182-2249
mhm-services.com

MHM Services is a leading provider of specialized healthcare services to correctional facilities, state hospitals and community mental health centers nationwide. Today we employ more than 6,000 healthcare professionals in 16 states.

Millennium Health

Booth #1044

15330 Avenue of Science
San Diego, CA 92128
millenniumhealth.com

Millennium Health is a leading health solutions company that delivers accurate, timely, clinically actionable information to inform the right treatment decisions for each patient at the right time. Millennium offers a comprehensive suite of services to better tailor patient care. More information is available at our website.

Ministry Health Care

Booth #410

900 Illinois Ave
Stevens Point, WI 54481-3114
ministryhealth.org

Ministry Health Care is an integrated system of hospitals and clinics serving patients across Wisconsin. We are widely recognized as a top-rated health care system with 15 hospitals, 47 clinics and more than 650 physicians and advanced practice clinicians. We are actively seeking both adult and child/adolescent psychiatrists in both metropolitan and rural areas. Why choose Ministry Health Care? Our physicians say it best! Visit our website to hear why our physicians chose Ministry Health Care and, more importantly, why they stay!

Minnesota Department of Human Services

Booth #512

PO Box 64997
Saint Paul, MN 55164-0997
dhs.state.mn.us

Make a difference working for DHS. Our clinical staff is made up of very talented, dedicated people and we want you to be part of our team. Current opportunities include: adult psychiatrist, forensic psychiatrist, psychologist, psychiatric nurse practitioner and clinician. Programs include: mental health inpatient treatment facility, community behavioral health hospitals, forensic services and the Minnesota sex offender program. Contact us at 651-431-3672 or email to lena.garcia@state.mn.us.

Mount Sinai Health System

Booth #1701

1 Gustave L Levy Pl
New York, NY 10029-6504
icahn.mssm.edu

The Mount Sinai Behavioral Health System is a comprehensive network of psychiatric clinical and addiction services. Through its dynamic integration of clinical care, leading-edge science and education, the Behavioral Health System is able to deliver new models of treatment and support a large-scale research infrastructure—providing patients with unparalleled psychiatric treatments and advancing the field of mental health and substance abuse care.

Muse: The Brain Sensing Headband

Booth #1511

511 King Street West, Suite 303
Toronto, ON, Canada, M5V 1K4
choosemuse.com

Muse: the brain sensing headband, the world's first wearable brain sensing platform, allows clinicians, health professionals and coaches to easily deploy cloud- and app-based meditation and neurofeedback to clients and consumers.

Exhibitors with Product/Service Descriptions

National Institute of Mental Health (NIMH)

Booth #1607

6001 Executive Boulevard
Bethesda, MD 20892-9663
nimh.nih.gov

The National Institute of Mental Health (NIMH) is the lead federal agency for research on mental disorders. NIMH is one of the 27 Institutes and Centers that make up the National Institutes of Health (NIH), the nation's medical research agency. NIH is part of the U.S. Department of Health and Human Services. The mission of NIMH is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure.

Neba Health, LLC

Booth #1503

753 Broad Street, Suite 701
Augusta, GA 30901-1380
nebahealth.com

For kids presented with ADHD-like symptoms, Neba assists in crafting your treatment plan by helping answer the question: Is it ADHD or something else? FDA-cleared Neba is the first brainwave-based neuropsychiatric interpretive aid to integrate with a clinician's traditional ADHD evaluation. Surveys show parents think Neba provides help they are looking for, that NEBA provides useful information and they would recommend Neba to others. Neba is \$79 per month, supplies included. You may cancel anytime.

NEOS Therapeutics

Booth #1049

2940 N Hwy 360 Ste 400
Grand Prairie, TX 75050-6424
neostx.com

Please visit the NEOS Therapeutics exhibit for more information about Adzenys XR-ODT.

Neurocrine Biosciences, Inc.

Booth #1618

12780 El Camino Real
San Diego, CA 92130-2042
neurocrine.com

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals utilizing our novel R&D platform. Neurocrine's efforts are focused on conditions with high unmet medical needs, specifically in neurological and endocrine based diseases and disorders.

Neuronetrix

Booth #1823

1044 E Chestnut St
Louisville, KY 40204-6033
neuronetrix.com

Neuronetrix is transforming the diagnosis of patients with cognitive disorders by providing accurate and meaningful diagnostic information to health care professionals early in the disease process. This information is critical to clinicians who wish to provide optimal care for their patients and to scientists who are searching for ways to treat these devastating disorders.

NeuroScience, Inc.

Booth #1207

373 280th St
Osceola, WI 54020-4120
neuroscienceinc.com

NeuroScience Inc., is committed to personalized health care solutions. We provide sophisticated neurologic, immune and hormone laboratory testing, as well as proprietary nutraceuticals that target identified imbalances. We bring everything together for the practitioner with our "assess and address" approach.

Exhibitors with Product/Service Descriptions

NeuroStar TMS Therapy

Booth #1529

3222 Phoenixville Pike
Malvern, PA 19355-9615
neurostar.com

NeuroStar TMS Therapy is a proven non-drug option for treatment resistant depression. Over half of those treated with NeuroStar achieve durable response, and over one third reach full remission. Visit us in Booth 1529 to learn why NeuroStar is the market leader in transcranial magnetic stimulation, and what's new in 2016.

New York-Presbyterian Hospital

Booth #1522

525 E 68th St # 51
New York, NY 10065-4870
nyp.org

The psychiatry programs of NewYork-Presbyterian, Columbia University College of Physicians and Surgeons and Weill Cornell Medicine, ranked #1 in the nation by *U.S. News and World Report*, offer innovative clinical care from early development through older adulthood. Our teams provide individualized psychiatric, neurobehavioral and psychopharmacological services to acute, sub-acute and recovering patients in discreet and compassionate settings.

North Carolina Office of Rural Health

Booth #413

311 Ashe Ave
Raleigh, NC 27606-2102
ncdhhs.gov/orhcc

Please visit the North Carolina Office of Rural Health Community Care exhibit for more information about their products and services that will be of interest to you.

North GA Partnership (NoGAP)

Booth #509

175 Gwinnett Dr Ste 260
Lawrenceville, GA 30046-8444
northgapartnership.org

North Georgia Partnership for Behavioral Health is a collaborative network ensuring high-quality, accessible integrated services.

Northeast Georgia Health System, Inc.

Booth #710

743 Spring St NE
Gainesville, GA 30501-3715
practicemedicinehere.com

Located on the Gainesville campus of Northeast Georgia Medical Center (NGMC), in Gainesville, Ga., Laurelwood (54 beds) provides a broad range of services for adolescents and adults experiencing mental health or substance abuse problems. Laurelwood offers a variety of treatment options including: detoxification, inpatient treatment, day partial treatment, intensive outpatient treatment and aftercare support. NGMC is a two-hospital system with a 557-bed regional referral center located in Gainesville and a 120-bed hospital located in Braselton. The medical staff of over 650 members represents a vast range of primary care and subspecialty physicians. NGMC is one of the Nation's 100 Top Hospitals according to a study by CareChex. NGMC has been named one of "Metro Atlanta's Top 100 Workplaces" by the *Atlanta Journal Constitution* for 2011-2015.

Northern Light Technologies

Booth #1201

8971 Henri Bourassa West
St. Laurent, QC H4S1P7
Canada
northernlighttechnologies.com

Produced in North America the 10,000 Lux Northern Light Desk Lamp, the Travelite, Flamingo Floor Lamp, Boxelite, ceiling track-

Exhibitors with Product/Service Descriptions

mounted Showoff, the Luxor, and the New Mini-Luxor table lamp are preferred by thousands of healthcare professionals. We are the supplier of choice for affordable, versatile, powerful and adjustable bright light sources that are UV-clean, flicker-free and operate on a 110V to 220V current. Contact us at 1-800-263-0066 or at our website.

Novant Health

Booth #511

2000 Fronlis Plaza Blvd
Winston-Salem, NC 27103
novanthealth.org

Please visit the Novant Health exhibit for more information about products and services that will be of interest to you.

OmegaBrite

Booth #1319

8275 S Eastern Ave Ste 121
Las Vegas, NV 89123-2544
omegabrite.com

The mission of OmegaBrite is to develop natural products of the highest quality that promote health and well-being based on scientific evidence. We are proud of the overwhelming positive response we have received for our flagship product, OmegaBrite 100% Natural Advance Omega-3 Formula.

Oregon Health & Science University, Department of Psychiatry

Booth #502

3181 SW Sam Jackson Park Rd
UHN80
Portland, OR 97239
ohsu.edu

The Department of Psychiatry at Oregon Health & Science University (OHSU) has outstanding opportunities for BC/BE psychiatrists. We are an acclaimed academic health center. We invite you to stop by our exhibit in the Career Fair for more information about psychiatry opportunities in the beautiful Northwest.

Oregon State Hospital

Booth #500

2600 Center St NE
Salem, OR 97301-2682
osh.oregon.gov

Oregon State Hospital is actively recruiting psychiatrists. We are surrounded by ocean beaches, snow-covered mountains and world-famous wineries all within an hour's drive. What more could you ask for? Come by our booth and meet our Superintendent and our Chief of Psychiatry. They are ready to answer your questions.

Otsuka America Pharmaceutical, Inc.

Booth #937, 1037, 1324, 1926

508 Carnegie Center Dr
Princeton, NJ 08540-6492
otsuka-us.com

Otsuka America Pharmaceutical, Inc. is an innovative, fast-growing healthcare company that commercializes Otsuka discovered and in-licensed products in the United States, with a strong focus on neuroscience, oncology, cardiovascular and medical devices. For more information visit our website.

Otto Trading, Inc.

Booth #1308

1921 Carnegie Ave Ste C
Santa Ana, CA 92705
unimedmassager.com

Please visit the Otto Trading, Inc., exhibit for more information about our digital massager and TENS unit.

Oxford University Press

Booth #423

198 Madison Ave
New York, NY 10016-4308
oup.com

Oxford University Press is proud to publish some of the world's premier books, journals and online resources in psychiatry. Visit our booth for a discount on new and classic titles, free journal samples and demos of our online products!

Exhibitors with Product/Service Descriptions

Physicians for a National Health Program

Booth #1613

29 E Madison St Ste 1412
Chicago, IL 60602-4404
pnhp.org

Physicians for a National Health Program is a non-profit research and education organization of 20,000 physicians, medical students and health professionals who support single-payer national health insurance. PNHP performs groundbreaking research and contributes scholarly articles to peer-reviewed medical journals, coordinates speakers and forums, participates in town hall meetings and debates, and appears regularly on national television and news programs advocating for a single-payer system.

PracticeLink.com

Booth #515

415 2nd Ave
Hinton, WV 25951-2427
practicelink.com

Physicians searching for their first or next practice rely on PracticeLink—the career advancement resource for physicians. PracticeLink helps physicians find the practice opportunities that best suit their personal and professional needs and provides helpful career development and job-search information. Find your next practice by visiting our website.

Providence Health & Services

Booth #700

1201 NE Lloyd Blvd Ste 510
Portland, OR 97232-1202
providence.org

Providence Health & Services, rated among the most integrated health systems in the nation, recruits nearly 1,000 physicians and advanced practice providers each year into its network of hospitals, medical groups and private practice partners in Alaska, California, Montana, Oregon and Washington. Join us and help create healthier communities together.

Psychiatric Times

Booth #431

535 Connecticut Ave Ste 300
Norwalk, CT 06854-1713
psychiatrictimes.com

For over 17 years, *Psychiatric Times* has provided accurate, objective and unbiased coverage of the most clinically relevant issues in psychiatry. Each issue features a special report, a collection of several physician authored articles on a topic of broad interest, as well as an article providing readers the opportunity to earn continuing medical education credits. Read more about these hot topics on our website.

PsychU

Booth #1714

163 York St
Gettysburg, PA 17325-1933
psychu.org

PsychU.org is the online community and knowledge center dedicated to understanding, sharing and evolving best practices in mental health treatment. Through the exchange of information, experience and ideas, PsychU members aim to shift the current trajectory of mental health care and improve the future outlook for individuals with mental illnesses. The PsychU community brings together physicians, clinicians, care managers, nurses, recovery coaches, pharmacists, payers, advocates, researchers and all professionals involved in providing, financing, or regulating mental health services.

Quotient® ADHD System by Pearson

Booth #1304

239 Littleton Rd Ste 6A
Westford, MA 01886-3545
quotient-adhd.com

The Quotient® ADHD System is an innovative device that objectively measures three core symptom domains of ADHD: hyperactivity, inattention and impulsivity. Based on research from McLean Hospital, a Harvard Medical School Affiliate, this easy-to-administer tool uses advanced motion tracking technology to track

Exhibitors with Product/Service Descriptions

a child or adult's micro-movements while they complete a computerized test that takes less than half an hour. Visit Quotient® at Booth 1304.

Rhodes Pharmaceuticals L.P.

Booth #1447

498 Washington St
Coventry, RI 02816-5467
rhodespharma.com

Rhodes Pharmaceuticals L.P. is a specialty pharmaceutical company based in Coventry, RI. Rhodes' vision for success is based on a sustainable business platform, competitive costs, high-quality products, reliable supply, excellent customer service and a vertically integrated and robust pipeline. For more information, visit our website and our exhibit at Booth #1447.

Riverside Health System

Booth #313

2 Eaton St Ste 705
Hampton, VA 23669-4073
riversideonline.com

Established in 1915, Riverside was founded by the community as a single hospital. One hundred years later, Riverside has evolved into a large regional healthcare system with multiple hospitals and affiliates throughout the region and more than 550 providers in a full range of specialties. Riverside is proud to be a physician led, not-for-profit, fully integrated, health organization. The Riverside difference is the dedication we give to fully serving the needs of the community, the attention we give to partnering with our patients to improve outcomes and our commitment to caring for our patients and team members as we would care for those we love. For more information regarding opportunities please contact Nicole Laroche at nicole.laroche@rivhs.com.

Rochester Regional Health

Booth #607

1425 Portland Ave
Rochester, NY 14621-3001
rochesterregional.org

Rochester Regional Health is an integrated health services organization serving the people of Western New York, the Finger Lakes and beyond. The system provides care from 150 locations, including five hospitals, more than 100 primary and specialty practices, rehabilitation centers and ambulatory campuses; innovative senior services, facilities and independent housing; a wide range of behavioral health services and ACM Medical Laboratory, a global leader in patient and clinical trials. With 16,000 employees, Rochester Regional Health was named one of "America's Best Employers" by *Forbes* in 2015. The Rochester region's suburbs feature excellent public and private schools and a variety of housing options. The Rochester region offers diverse cultural and recreational opportunities year-round, including the Rochester Philharmonic Orchestra, GeVa Theater Center, Rochester International Jazz Festival as well as easy access.

Rogers Behavioral Health System

Booth #1829

34700 Valley Rd
Oconomowoc, WI 53066-4500
rogersbh.org

Rogers Behavioral Health is a leader in comprehensive and effective behavioral health treatment for children, teens and adults with OCD and anxiety disorders, eating disorders, depression and mood disorders, and addiction. Rogers creates an environment where patients and their families know what tomorrow will bring—Life. Worth. Living. For more information, please visit our website.

Exhibitors with Product/Service Descriptions

Rogers Memorial Hospital

Booth #1712

34700 Valley Rd
Oconomowoc, WI 53066-4599
rogershospital.org

Wisconsin-based Rogers Behavioral Health System is a private, not-for-profit system nationally recognized for its specialized psychiatry and addiction services. Anchored by Rogers Memorial Hospital, Rogers offers multiple levels of evidence-based treatment for adults, children, and adolescents with depression and mood disorders, eating disorders, addiction, obsessive-compulsive and anxiety disorders, and posttraumatic stress disorder in multiple locations. For more information, visit our website.

Routledge Journals

Booth #528

530 Walnut St Ste 850
Philadelphia, PA 19106-3604
tandfonline.com

Routledge Journals, a division of Taylor and Francis, is a leading international publisher of scholarly research in behavioral science and mental health. Visit the Routledge Journals booth to learn about our wide range of products and services and to request free sample copies of our essential publications in the field of psychiatry.

Routledge/CRC Press

Booth #530

711 3rd Ave Fl 8
New York, NY 10017-9209
routledge.com

Routledge and CRC Press publish a comprehensive portfolio of textbooks, professional books, monographs and journals on psychiatry, clinical psychology, and more. Visit our website at Routledge or crcpress.com to keep up-to-date on the newest developments in the field.

Rutgers Center of Alcohol Studies

Booth #527

607 Allison Rd
Piscataway, NJ 08854-8001
alcoholstudies.rutgers.edu

The Rutgers Center of Alcohol Studies publishes the *Journal of Studies on Alcohol and Drugs*, the oldest substance-related journal in the United States (est. 1940). The Center's education and training division offers cutting-edge education for health, mental health and public health professionals working in the addictions field. All programs, including the historic summer school, offer practical, evidence-based education designed to enhance outcomes. Visit our website at jsad.com.

Saint Francis Health System/Laureate Psychiatric Clinic and Hospital

Booth #406

6161 South Yale Avenue
Tulsa, OK 74136-1902
saintfrancis.com

Please visit the Saint Francis Health System/Laureate Psychiatric Clinic and Hospital exhibit for more information about products and services that will be of interest to you.

SARDAA—Schizophrenia & Related Disorders Alliance of America

Booth #747

PO Box 941222
Houston, TX 77094-8222
SARDAA.org

Please visit the SARDAA-Schizophrenia and Related Disorders Alliance of America exhibit for more information about products and services that will be of interest to you.

Exhibitors with Product/Service Descriptions

Sheppard Pratt Health System

Booth #1401

PO Box 6815
Baltimore, MD 21285-6815
sheppardpratt.org

Sheppard Pratt Health System is dedicated to improving quality of life through mental health, special education and addiction services for children, adolescents and adults. Our patient-centered treatment approach, combined with our legacy of clinical excellence, sets us apart from other health systems on a national level. We have been ranked among the nation's top psychiatric hospitals for 25 years by U.S. News & World Report.

Shire

Booth #1209

300 Shire Way
Lexington, MA 02421-2101
shire.com

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. Please visit our website.

Shire U.S., Inc.

Booth #1329

725 Chesterbrook Blvd
Chesterbrook, PA 19087-5649
shire.com

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

Sierra Tucson

Booth #1413

39580 S Lago Del Oro Pkwy
Tucson, AZ 85739-1091
SierraTucson.com

For over 32 years, Sierra Tucson has held a longstanding legacy of clinical excellence and

compassionate care. A multidisciplinary team of professionals utilizes the Sierra Tucson Model®, a bio-psycho-social-spiritual approach for individualized treatment. Sierra Tucson combines integrative and experiential therapies with evidence-based practices to provide a full range of treatment modalities. Residents receive the resources, support and tools necessary for long-term change, including one full year of continuing care and a lifetime of alumni services. Call 800-842-4487 or visit our website.

Skyland Trail

Booth #1416

1961 N Druid Hills Rd NE
Atlanta, GA 30329-1842
skylandtrail.org

Skyland Trail is a nationally recognized, not for profit, evidenced based, JCAHO accredited residential and day treatment facility for adults seeking recovery from mental illness located in Atlanta. Skyland Trail treats adults with bipolar disorder, major depression, schizophrenia, anxiety disorders and dual diagnosis. We accept private insurance. Recovery communities include DBT, dual diagnosis, CBT, young adult and social integration. Please visit our website or call 678-686-5931.

Somatics LLC

Booth #1431

720 Commerce Dr Suite 101
Venice, FL 34292-1750
thymatron.com

Somatics is the manufacturer of the Thymatron® ECT instrument, which is faster and easier than ever to use. Unique benefits include maximum ultrabrief response, age-based stimulus titration, EEG seizure intensity and duration, higher stimulus current, greater cerebral stimulation, best seizure generalization and efficacy by peak heart rate. Unique features include EctoBrain® Stimulus Assurance Analyzer, remote treat handle, automatic optimal stimulus selection at 0.3 and 0.5 ms, 4-channel monitor-printer, postictal suppression index, automatic EEG seizure endpoint detection and digital heart rate printout.

Exhibitors with Product/Service Descriptions

Soterix Medical, Inc.

Booth #1402

237 W 35th St Ste 1401
New York, NY 10001-1950
soterixmedical.com

Soterix Medical, Inc., was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 250 medical centers in the United States and worldwide. Multiple, ongoing trials are currently underway ranging from depression, ADHD, PTSD, schizophrenia, stroke, chronic pain, and epilepsy. Soterix Medical tDCS-LTE is currently CE approved for major depressive disorder.

Southwest Behavioral Health Services

Booth #402

3450 N 3rd St
Phoenix, AZ 85012-2331
sbhservices.org

Please visit the Southwest Behavioral Health Services exhibit for more information about products and services that will be of interest to you.

Spartanburg Regional Healthcare System

Booth #510

101 E Wood St
Spartanburg, SC 29303
spartanburgregional.com

The Spartanburg Regional booth will be recruiting board certified and/or board eligible psychiatrists for Spartanburg Medical Center, located in the beautiful upstate of South Carolina.

Specialists On Call

Booth #1711

1503 Edwards Ferry Road, NE, Suite 310
Leesburg, VA 20176-6692
specialistsoncall.com

Specialists On Call is the nation's leading provider of clinical telemedicine services. We help hospitals deliver effective care to psychiatric patients with immediate, 24/7 access to board certified psychiatrists via a robust and secure telemedicine platform. Our telepsychiatry service reduces the costs associated with such resource intensive patients and improves overall efficiency for hospital emergency departments as well as psychiatric inpatient units.

Springer

Booth #524

233 Spring St Fl 6
New York, NY 10013-1578
springer.com

Springer Science+Business Media is a leading global scientific, technical and medical publisher offering high-quality products across all media. Springer publishes more than 2,000 journals and 8,000 new books per year and is home to the world's largest STM eBook collection as well as the most comprehensive portfolio of open access journals. Make sure to visit our booth or find out more online at our website.

Springstone Inc.

Booth #400

101 S 5th St Ste 3850
Louisville, KY 40202-3127
springstone.com

At Springstone, we develop and operate private behavioral healthcare hospitals. We bring progressive, cutting-edge health and state-of-the-art facilities to underserved communities. Our mission is to deliver compassionate, high-quality treatment for mental health and addiction disorders using innovative, evidence-based approaches. Our levels of service include inpatient, partial hospitalization and intensive outpatient care. We are always seeking psychiatric practitioners who enjoy working in a team-driven atmosphere.

Exhibitors with Product/Service Descriptions

Sun Behavioral Health

Booth #1306

12 Broad St Ste 403
Red Bank, NJ 07701-1938
sunbehavioral.com

Inpatient and outpatient psychiatric hospital services for all ages. Specialized programs to meet the unique needs of each community. Opportunities for psychiatrists and psychiatric and substance abuse registered nurses.

Sunovion Pharmaceuticals Inc.

Booth #1237, 1247

84 Waterford Dr
Marlborough, MA 01752-7010
sunovion.com

Sunovion Pharmaceuticals Inc., is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system and respiratory disease areas to improve the lives of patients and their families. Visit us online at our website.

Takeda Pharmaceuticals U.S.A., Inc./Lundbeck

Booth #1817

1 Takeda Pkwy
Deerfield, IL 60015-5713
takeda.us & lundbeck.com

Takeda Pharmaceuticals Company Limited and Lundbeck formed a strategic alliance in 2007 to co-develop and co-commercialize in the U.S. and Japan several compounds in Lundbeck's pipeline for the treatment of mood and anxiety disorders. Together, both companies are deeply committed to supporting the needs of the mental health community.

Tallahassee Memorial Healthcare

Booth #1519

1300 Miccosukee Rd
Tallahassee, FL 32308
tmh.org

Tallahassee Memorial HealthCare (TMH) is a private, not-for-profit, 501 C3 hospital located in the Florida panhandle. TMH is seeking a general, child and adolescent and addictions psychiatrist to serve both in-patient and out-patient populations. We offer full benefits, malpractice and competitive salaries.

TeleSage, Inc.

Booth #1512

PO Box 750
Chapel Hill, NC 27514-0750
telesage.com

Please visit theTeleSage, Inc., exhibit for more information about products and services that will be of interest to you.

Tenet Health

Booth #513

1445 Ross Ave Ste 1400
Dallas, TX 75202-2703
tenethealth.com

Tenet Healthcare is one of the largest healthcare corporations in the United States. Our hospitals and clinics are constantly looking for psychiatrists to join them. We have very desirable locations and practice types.

The TOVA Company

Booth #1417

3321 Cerritos Ave
Los Alamitos, CA 90720-2105
tovatest.com

T.O.V.A. (Test of Variables of Attention) is a computerized assessment that measures inattention, impulsivity, response time, variance of response time and d prime. LD and languages do not confound results. Its objective and accurate data can provide important necessary information for evaluations and monitoring of treatments of attention related disorders.

Exhibitors with Product/Service Descriptions

Tris Pharma

Booth #1149

2033 US Highway 130 Ste D
Monmouth Junction, NJ 08852-3003
trispharma.com

Please visit the Tris Pharma exhibit for more information about products and services that will be of interest to you.

TrueLearn

Booth #1715

2 Penn Ctr W Ste 220
Pittsburgh, PA 15276-0110
truelearn.com

TrueLearn offers question banks used by thousands of medical students and residents, including those preparing for the ABPN's PRITE, Board Exam and the MOC Exam. Prepare with psychiatry board review questions specifically crafted by board-certified psychiatrists to mirror those tested on ABPN exams. Learn from the most comprehensive assessment platform available to physicians seeking board certification in psychiatry.

Tséhootsoóí Medical Center

Booth #1415

PO Box 649
Fort Defiance, AZ 86504-0649
fdihb.org

Tséhootsoóí Medical Center (TMC) serves 47,000 American Indian beneficiaries in northeastern Arizona. As an acute care hospital, TMC provides comprehensive inpatient and outpatient health services to 16 communities with expansion of specialty services, including construction of a new clinic in Sanders, Ariz., Nahat'á Dził Health Center.

U.S. Department of State, Office of Medical Services

Booth #1322

2401 E St NW
Washington, DC 20522-0001
careers.state.gov

The U.S. Department of State, our country's lead foreign policy agency, provides a rich international experience whether at home or abroad and opportunities to become responsible leaders. Each day, our employees make a difference as they contribute to our global society and defend and advance our country's interests and values. They work on the business of diplomacy and high priority issues that impact the safety, security and prosperity of our world—human rights, environment, energy, food security, public health and technology—all while experiencing a unique career. Our talented and inclusive workforce reflects and champions all of our strengths and diversity—personal, professional and educational. We offer a workplace that values and rewards leadership, collaboration and innovation, and personal and professional development.

Unity Center for Behavioral Health

Booth #507

3181 SW Sam Jackson Park Rd
c/o OHSU Mail Code: UHN80
Portland, OR 97239-3011
ohsu.edu/unity

Please visit the Unity Center for Behavioral Health exhibit. Unity is an unprecedented collaborative between Legacy Health, Oregon Health & Science University (OHSU), Adventist Health and Kaiser Permanente—an innovative patient and family-centered care environment for adults and adolescents experiencing a mental or behavioral health crisis in Portland, Ore.

Exhibitors with Product/Service Descriptions

Universal Health Services, Inc.

Booth #1418

3295 River Exchange Dr Ste 190
Norcross, GA 30092-4221
uhsinc.com

Universal Health Services, Inc., is the largest facilities-based behavioral health provider in the country. The Behavioral Health Division operates through subsidiaries over 220 facilities nationwide offering services that touch more than 420,000 lives each year—from youth and adult programs to dedicated services for military personnel and their families. In addition to our behavioral health facilities, we operate 25 acute care hospitals and three surgery centers. We have locations in 37 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands and the United Kingdom, and employ more than 70,000 people. UHS is actively recruiting psychiatrists nationwide for practice opportunity positions at our behavioral health facilities.

University of Florida Department of Psychiatry

Booth #1310

1149 Newell Dr
Gainesville, FL 32610-3011
psychiatry.ufl.edu

The Department of Psychiatry in the College of Medicine at the University of Florida is the leader in the Southeast for innovative evidence-based treatment programs for mental health disorders, addiction, obsessive compulsive disorder, eating disorders and obesity. Providing a wide variety of services, including inpatient hospital care and detox to outpatient clinics, ECT, TMS, DTMS, DBS, Parent-Child Interaction Therapy (PCIT), and adult, child and adolescent treatment and evaluation.

Uskudar University Npistanbul Neuropsychiatry Hospital

Booth #1406

Uskudar University Npistanbul
Neuropsychiatry Hospital
Inkilap Mah. Siteyolu Sokak. No:29/B
Umraniye, Istanbul
Turkey
npistanbul.com

Please visit the Uskudar University Npistanbul Neuropsychiatry Hospital exhibit for more information about its products and services that will be of interest to you.

Valant Medical Solutions

Booth #1423

2033 6th Ave Ste 500
Seattle, WA 98121-2591
valant.com

Valant was founded in 2005 to provide behavioral health practices, agencies and clinicians with cloud-based software to streamline administration and empower what's most important—improving outcomes. Inspired by the fact that technology has transformed all of our lives in meaningful ways, Valant has reinvented the behavioral health platform.

Vanda Pharmaceuticals Inc.

Booth #537

2200 Pennsylvania Ave NW Ste 300E
Washington, DC 20037-1754
vandapharmaceuticals.com

Vanda Pharmaceuticals Inc., is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs. Vanda is committed to providing education and awareness for schizophrenia and Non-24-Hour Sleep-Wake Disorder (Non-24), a chronic circadian rhythm disorder.

Exhibitors with Product/Service Descriptions

Vanderbilt Behavioral Health

Booth #1500

1601 23rd Ave S
Nashville, TN 37212-3133
vanderbiltbehavioralhealth.com

Vanderbilt Behavioral Health is comprised of Vanderbilt Psychiatric Hospital, an 88-bed inpatient facility, the adult and adolescent partial hospitalization programs; the psychiatry outpatient clinics, which provide more than 60,000 outpatient visits annually; the neuromodulation program, which includes transcranial magnetic stimulation, electroconvulsive therapy and deep brain stimulation; and the Center of Excellence, which provides services for children in state custody or who are at risk of a custodial situation. As a part of Vanderbilt University Medical Center, we provide world-class care for our patients, setting the standard for excellence while advancing our field through education and research.

Veritas Collaborative

Booth #1615

615 Douglas St Ste 500
Durham, NC 27705-6616
veritascollaborative.com

Veritas Collaborative is a Specialty Hospital System for the Treatment of Eating Disorders. Accredited by The Joint Commission, Veritas delivers multidisciplinary, evidence-based care for patients and their families in a warm, inviting and gender-inclusive environment. Located in Durham, N.C., and Richmond, Va., Veritas Collaborative provides inpatient, acute residential, partial hospitalization, and intensive outpatient levels of care for individuals with eating disorder diagnoses (ages 10 and over). For more information, visit our website or call 855-875-5812.

Via Christi Health System

Booth #611

1 Mount Carmel Way
Pittsburg, KS 66762
viachristi.org

Please visit the Via Christi Health System exhibit for more information about products and services that will be of interest to you.

Virtual Medical Staff

Booth #1422

2655 Northwinds Pkwy
Alpharetta, GA 30009-2280
locumtenens.com

Virtual Medical Staff is a telemedicine solution providing physician staffing, telemedicine technology and the technical support needed to provide patients with specialty care and consults.

VISTA Staffing Solutions, Inc.

Booth #600

275 E 200 S
Salt Lake City, UT 84111-2002
vistastaff.com

VISTA Staffing Solutions offers you a full range of job options. We help you work when and where you want, meeting your needs today and in the future. Every time you call, you get a decision-maker empowered to take care of you. Tell us where you'd like to go! Visit our website or call us at 800-366-1884.

Weatherby Healthcare

Booth #1517

6451 N Federal Hwy Ste 800
Ft Lauderdale, FL 33308-1409
weatherbyhealthcare.com

As part of its signature Red Ribbon Service, staffing company Weatherby Healthcare provides healthcare professionals a personal consultant whose priority is to find them the ideal locum tenens or permanent job and negotiate the best terms on their behalf. Enjoy premium services and excellent pay. Call 800-586-5022 or visit our website.

Exhibitors with Product/Service Descriptions

Wellington Retreat

Booth #1408

7051 Seacrest Blvd
Lantana, FL 33462-5139
wellingtonretreat.com

Wellington Retreat is located in Lantana, Fla., offering sunshine and warm weather to visitors and inhabitants. Wellington Retreat is the only addiction and psychiatric rehabilitation center in the state that is run by an addiction psychiatrist involved in all treatment decisions. Wellington Retreat is more than proud of its expert staff who are firmly dedicated to the healing process of each and every one of their patients. Using research-backed, cutting-edge practices, our patients receive the state-of-the-art treatment they deserve. Our leading neuropsychiatrist and addictionologist, Robert A. Moran, M.D., welcomes each patient, spending quality time with them in order to achieve a correct diagnosis and an appropriate, effective treatment plan that will fit their individual needs. Oftentimes, individuals who suffer from substance abuse disorders will have an unknown co-occurring psychiatric disorder as well.

Westchester Medical Center

Booth #704

100 Woods Road
Valhalla, NY 10595
westchestermedicalcenter.com

Please visit the Westchester Medical Center exhibit for more information about products and services that will be of interest to you.

Wexford Health Sources

Booth #945

501 Holiday Dr Foster Plaza 4
Pittsburgh, PA 15220
wexfordhealth.com

Wexford Health Sources, one of the nation's leading innovative correctional health care companies, provides clients with experienced management and technologically advanced services combined with programs that control costs while ensuring quality. For the past two decades, Wexford Health has consistently delivered proven staffing expertise and a full range of medical, behavioral health, pharmacy, utilization management, provider contracting, claims processing and quality management services.

Wiley

Booth #626

350 Main St
Malden, MA 02148-5089
wiley.com

Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Visit our website or Booth 626 for more information.

Wolters Kluwer Health


Booth #416

2001 Market St
Philadelphia, PA 19103-7044
lww.com

Wolters Kluwer Health is a global provider of information, business intelligence, and point-of-care solutions for the healthcare industry. Major brands include Lippincott Williams & Wilkins, Lippincott Solutions, medical books, journals, and electronic media. Please visit our booth to browse our comprehensive product selection including the newly published *Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry*.



imagine



transforming mental health care



The Department of Psychiatry at Dartmouth-Hitchcock is a large academic department. We actively create new knowledge in our field, teach and train others in the knowledge, and apply that knowledge in the care of individuals and populations. Our primary clinical training sites include Dartmouth-Hitchcock Medical Center in Lebanon, NH, the VA Medical Center in White River Junction, VT, and New Hampshire Hospital in Concord, NH. Other important clinical sites include Hanover Psychiatry in Hanover, NH, Cheshire Medical Center in Keene, NH, and Riverview Psychiatric Center in Augusta, ME.



@DHcareers



DartmouthHitchcock



dartmouthhitchcock

Learn more and apply at:
DHproviders.org/Psychiatry

or by contacting Jeffrey.S.Wooten.Jr@hitchcock.org

BECKER'S

Hospital Review

150 "Great Places to Work
in Healthcare" in 2015

imagine **innovative** medicine

Consistently in the top 5 most livable states (CQ Press), New Hampshire boasts four-season living with year-round recreation, a myriad of cultural events and venues and highly-ranked schools. Amenities associated with urban areas in Boston MA, Burlington VT, and Montreal, QC are all within a short drive.

Current opportunities exist for:

- **Social Workers**
Outpatient Clinician, Outpatient Clinician Child and Adolescent, Adult Psychotherapy, HIV Collaborative Care, Behavioral Intervention
- **Addiction Psychiatrist Faculty**
Lebanon, NH
- **Behavioral Medicine Psychologist**
Lebanon, NH
- **Psychologists**
Hanover, NH
- **Child and Adolescent Psychiatrist**
- **Child Psychiatrist**
Keene, NH or Hanover, NH
- **General Medical Leader**
Concord, NH
- **Director of Adult Outpatient Psychiatric Services**
Lebanon, NH
- **Inpatient Psychiatrists**
Augusta, ME or Lebanon, NH



Dartmouth-Hitchcock

Dartmouth-Hitchcock is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, veteran status, gender identity or expression, or any other characteristic protected by law.

BRING BALANCE TO YOUR CAREER

We offer our psychiatrists the **work/life balance** they deserve.

California Correctional Health Care Services has great opportunities for you at 35 locations throughout California. We are seeking dedicated and compassionate individuals to provide efficient, quality care to our diverse patient population. Learn more about exciting careers in correctional medicine.

APA Annual Meeting | May 14-18, 2016
VISIT US AT BOOTH 301

EOE

PSYCHIATRIST

\$237,864 - \$285,072
annual salary (Board Eligible)

\$244,128 - \$293,340
annual salary (Board Certified)

Enjoy a flexible work schedule with all of the security and benefits of State employment:

Night shift/Weekend options available

40-hour work week

Welcome bonus of \$10,000 (*new state employees*)

Generous yearly paid time off

Outstanding benefits

Retirement that vests in 5 years

License reimbursement

DEA fee exemption


Annual paid CME with paid time off to attend

Visa sponsorship opportunities

For more information, please contact
Sharon Lovell at (916) 691-5871 or
Sharon.Lovell@cdcr.ca.gov.



CALIFORNIA DEPARTMENT OF
**CORRECTIONS AND
REHABILITATION**



Exhibitors with Product/Service Descriptions

World Health Information Network

Booth #1516

2738 Camino Capistrano Ste 4
San Clemente, CA 92672
whin.com

Please visit the World Health Information Network exhibit for more information about providing tele-mental health services to your clients or to earn extra income treating patients in your free time.

WPA World Congress of Psychiatry 2017 Berlin

Booth #329

Paulsborner Strabe 44
Berlin, 14193 Germany
wpamadrid2014.com

Please visit the WPA World Congress of Psychiatry exhibit for more information about products and services that will be of interest to you.






COLUMBIA UNIVERSITY

College of Physicians
and Surgeons

NewYork-Presbyterian



Weill Cornell
Medicine



NewYork-Presbyterian's expertise in accurate diagnosis and comprehensive psychiatric care is incomparable, providing services for all ages – from children and adolescents through older adults. Our psychiatry programs offer subspecialty clinical care in the full range of psychiatric diagnoses, provide a continuum of care from outpatient therapy through partial and inpatient hospitalization, and conduct neurobehavioral and psychopharmacological research that is advancing the field.

Come visit us at Booth #1522 to learn more

**NewYork-Presbyterian
Psychiatry ranks #1
in the nation.**





Antidepressants not working?

Let NeuroStar TMS Therapy® help.



In Open Label Clinical Trials:

58% Significantly Responded¹

37% Achieved Remission¹

68% Response among patients followed for 12 months²

**Now covered by
most health plans**

Celebrating One Million Treatments

Booth # 1529 Visit our booth to see NeuroStar® demonstrations and get the latest Reimbursement updates.



For more information on how NeuroStar TMS may work for you and your patients contact us at **877-600-7555** or visit us at **NeuroStar.com**

NeuroStar TMS Therapy® is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

Long term durability of effect has not been established in a randomized controlled trial.

In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment ($P = 0.0173$; odds ratio = 4.05).³

1. Carpenter LL, et al. *Depress Anxiety*, (2012)
2. Dunner, D.L., et al. *J Clin Psych*, (2014)
3. George MS, et al. *Arch Gen Psychiat*, (2010)



Exhibitors by Product/Service Listing

Association/NonProfit

American Academy of Addiction Psychiatry 1603

Physicians for a National Health Program . 1613

SARDAA—Schizophrenia & Related Disorders Alliance of America 747

Behavioral Healthcare

Community Psychiatry 503

Diamond Healthcare Recruitment Division 708

Georgia Association of Community Service Boards, Inc. 1425

Horizon Health 1400

Mount Sinai Health System 1701

Muse: The Brain Sensing Headband 1511

North GA Partnership (NoGAP) 509

Novant Health 511

Riverside Health System 313

Rogers Behavioral Health System 1829

Sierra Tucson 1413

Springstone Inc. 400

Sun Behavioral Health 1306

Vanderbilt Behavioral Health 1500

Clinical Decision Support

Assurex Health 845

TeleSage, Inc. 1512

Computer Software

TrueLearn 1715

Correctional Mental Health

California Correctional Health Care Services (CCHCS) 301

MHM Services, Inc. 712

Wexford Health Sources 945

Diagnostic Laboratory

Admera Health 1800

AltheaDx 1410

Millennium Health 1044

Diagnostic Testing

NeuroScience, Inc. 1207

Diagnostic Tool

Harmonex Neuroscience Research, Inc. . . . 1514

Quotient® ADHD System by Pearson 1304

The TOVA Company 1417

Dietary Supplement

OmegaBrite 1319

Drug and Alcohol Treatment

Destination Hope 1806

Dual Diagnosis Treatment

Wellington Retreat 1408

ECT

MECTA Corporation 1301

Somatics LLC 1431

Educational

American Physician Institute—Beat the Boards 1419

National Institute of Mental Health (NIMH) 1607

PsychU 1714

Electronic Health Record

Compulink Business Systems, Inc. 1424

Valant Medical Solutions 1423

World Health Information Network 1516

Financial Service

Captive Risk Planners/Perfect Tax & Finance 1404

Health Care

Acadia Healthcare 1922

Community Health Systems 601

Exhibitors by Product/Service Listing

Correct Care Solutions, LLC	1814	CompHealth	1501
Humana Inc.	1812	DR Wanted	514
IPC Healthcare	401	Global Medical Staffing.	613
LifePoint Health	606	Locum Source, Inc.	1420
Health Care Technology		LocumTenens.com	1323
CoverMyMeds	1825	Maxim Physician Resources.	1225
Hospital		Medical Search	412
Aurora Health Care	506	VISTA Staffing Solutions, Inc.	600
Austen Riggs Center	1530	Weatherby Healthcare	1517
The Center for Eating Disorders at Sheppard Pratt.	1403	Medical Billing	
Glens Falls Hospital	408	Medical Billing Professionals	1223
McLean Hospital.	1300	Medical Device	
Menninger Clinic.	1317	Brainsway USA Inc.	1617
New York-Presbyterian Hospital.	1522	Electromedical Products International, Inc.	1211
Oregon Health & Science University, Department of Psychiatry	502	Magventure, Inc.	1707
Oregon State Hospital	500	Neba Health, LLC	1503
Sheppard Pratt Health System	1401	Neuronetrix	1823
Unity Center for Behavioral Health	507	NeuroStar TMS Therapy	1529
University of Florida Department of Psychiatry	1310	Otto Trading, Inc.	1308
Uskudar University Npistanbul Neuropsychiatry Hospital.	1406	Soterix Medical, Inc.	1402
Veritas Collaborative	1615	Medical Device, Therapy	
Westchester Medical Center	704	Infinite Trading, Inc.	1614
Insurance		Magstim	1518
American Professional Agency, Inc.	1217	Medical Education	
International Organization		<i>Focus: The Journal of Lifelong Learning in Psychiatry</i>	1528
International Congress on Dual Disorders	327	Mental Health Treatment	
WPA World Congress of Psychiatry 2017 Berlin	329	Genomind	1227
Locum Tenens		Georgia Ketamine	1710
Aureus Medical Group.	706	Hillside, Inc.	1521
Barton Associates	1600	Nutritional Products	
		Metabolic Maintenance.	1347

Exhibitors by Product/Service Listing

Pharmaceutical

ACADIA Pharmaceuticals	1437
Alkermes, Inc.	1623, 1811
Allergan	1337, 1546
Arbor Pharmaceuticals, LLC	1717
Braeburn Pharmaceuticals, Inc.	1405
Indivior Inc.	1409, 1547, 1713
Intra-Cellular Therapies Inc.	644
Ironshore Pharmaceuticals and Development, Inc.	1637
Janssen Pharmaceuticals, Inc.	637
Merck & Co.	837
NEOS Therapeutics	1049
Otsuka America Pharmaceutical, Inc.	937, 1037, 1324, 1926
Rhodes Pharmaceuticals L.P.	1447
Shire	1209
Shire U.S., Inc.	1329
Sunovion Pharmaceuticals Inc.	1237, 1247
Takeda Pharmaceuticals U.S.A., Inc./Lundbeck	1817
Tris Pharma	1149
Vanda Pharmaceuticals Inc.	537

Phototherapy

Northern Light Technologies.	1201
--------------------------------------	------

Professional Support/Organization

American Board of Psychiatry and Neurology, Inc.	1429
Association of Gay and Lesbian Psychiatrists (AGLP)	1601
Christian Medical & Dental Associations, Psychiatry Section	1510

Psychiatric Facility

Gould Farm	1411
Mayo Clinic.	1313
Skyland Trail	1416

Southwest Behavioral Health Services	402
Veritas Collaborative	1615

Publisher/Bookseller

Association & Meeting Solutions	1505
Cambridge University Press	417
<i>Clinical Psychiatry News</i>	1412
<i>Current Psychiatry</i>	1414
Elsevier, Inc.	525
Guilford Publications	420
HCPLive	1311
Hogrefe Publishing Corp.	522
Informa Health Care Journals	526
The JAMA Network	624
Oxford University Press	423
<i>Psychiatric Times</i>	431
Routledge Journals	528
Routledge/CRC Press	530
Rutgers Center of Alcohol Studies.	527
Springer	524
Wiley	626
Wolters Kluwer Health	416

Recruitment

Air Force Recruiting Services	608
Align International Recruitment Ltd.	619
All Star Recruiting	617
Allina Health	602
Army Medical Recruiting	716
Aureus Medical Group.	706
Bassett Healthcare Network	1309
Behavioral Health Recruitment Services.	1446
Billings Clinic	603
Carilion Clinic	405
Carolinas Healthcare System.	609
Central Intelligence Agency.	415

Exhibitors by Product/Service Listing

Delta Companies	1928	Rochester Regional Health	607
Department of Behavioral Health and Developmental Disabilities.	1305	Rogers Memorial Hospital	1712
Department of Veterans Affairs	411	Saint Francis Health System/ Laureate Psychiatric Clinic and Hospital. . .	406
EmCare.	407	Spartanburg Regional Healthcare System. .	510
FCS, Inc.	605	Tallahassee Memorial Healthcare	1519
Federal Bureau of Prisons (BOP).	403	Tenet Health	513
Fraser Health.	610	Tsehootsooi Medical Center	1415
Glens Falls Hospital	408	U.S. Department of State, Office of Medical Services	1322
Greater Hudson Valley Health System . . .	409	Universal Health Services, Inc.	1418
Group Health Physicians.	504	Via Christi Health System.	611
Hospital Corporation of America (HCA) .	1328		
IASIS Healthcare.	505	Research	
Intermountain Healthcare.	501	Atlanta Center for Medical Research.	1827
Jackson & Coker.	1622	Neurocrine Biosciences, Inc.	1618
JPE Healthcare Staffing, Inc.	404		
Kaiser Permanente, The Permanente Medical Group, Inc.	614	Retreat	
Liberty Healthcare Corporation	612	Brookhaven Retreat.	1513
Medicus Healthcare Solutions.	604		
MedPartners Locum Tenens	1523	Telehealth	
Memorial Hospital of Sweetwater County	508	Arcadian Telepsychiatry	1810
Ministry Health Care	410	CareClix	1700
Minnesota Department of Human Services	512	InSight Telepsychiatry, LLC	1616
North Carolina Office of Rural Health	413	Iris Telehealth	1203
Northeast Georgia Health System, Inc.	710	MD.com.	1602
PracticeLink.com	515	Specialists On Call	1711
Providence Health & Services	700	Virtual Medical Staff	1422

Career Fair and Publishers' Book Fair Exhibitors

Career Fair Exhibitors

Air Force Recruiting Services	608
Align International Recruitment Ltd.	619
All Star Recruiting	617
Allina Health	602
Army Medical Recruiting	716
Aureus Medical Group.	706
Aurora Health Care	506
Billings Clinic	603
Carilion Clinic	405
Carolinas Healthcare System.	609
California Correctional Health Care Services (CCHCS).	301
Central Intelligence Agency.	415
Community Health Systems	601
Community Psychiatry	503
Department of Veterans Affairs	411
Diamond Healthcare Recruitment Division.	708
DR Wanted	514
EmCare.	407
FCS, Inc.	605
Federal Bureau of Prisons (BOP)	403
Fraser Health.	610
Glens Falls Hospital	408
Greater Hudson Valley Health System	409
Group Health Physicians.	504
Global Medical Staffing.	613
IASIS Healthcare.	505
Intermountain Healthcare.	501
IPC Healthcare	401
JPE Healthcare Staffing, Inc.	404
Kaiser Permanente, The Permanente Medical Group, Inc.	614
Liberty Healthcare Corporation	612
LifePoint Health	606
Medical Search	412
Medicus Healthcare Solutions.	604
Memorial Hospital of Sweetwater County	508
MHM Services, Inc.	712

Ministry Health Care	410
Minnesota Department of Human Services	512
North Carolina Office of Rural Health	413
North GA Partnership (NoGAP).	509
Northeast Georgia Health System, Inc.	710
Novant Health.	511
Oregon Health & Science University, Department of Psychiatry	502
Oregon State Hospital	500
PracticeLink.com	515
Providence Health & Services	700
Riverside Health System.	313
Rochester Regional Health	607
Saint Francis Health System/ Laureate Psychiatric Clinic and Hospital.	406
Spartanburg Regional Healthcare System.	510
Southwest Behavioral Health Services	402
Springstone Inc.	400
Tenet Health	513
Unity Center for Behavioral Health	507
Via Christi Health System.	611
VISTA Staffing Solutions, Inc.	600
Westchester Medical Center	704

Publishers' Book Fair Exhibitors


Cambridge University Press	417
Elsevier, Inc.	525
Guilford Publications	420
Hogrefe Publishing Corp.	522
Informa Health Care Journals	526
The JAMA Network	624
Oxford University Press	423
<i>Psychiatric Times</i>	431
Routledge Journals	528
Routledge/CRC Press	530
Rutgers Center of Alcohol Studies.	527
Springer	524
Wiley	626
Wolters Kluwer Health	416

Helping Kids in Crisis

Managing Psychiatric Emergencies in Children and Adolescents

Edited by Fadi Haddad, M.D., and Ruth Gerson, M.D.

This is a practical, easy-to-use guide for clinicians working with child and adolescent psychiatric emergencies across a range of settings. This book provides clinical case examples with concrete tools for assessment, de-escalation, and diagnosis, to help clinicians quickly stabilize the crisis and determine when a trip to the emergency room is necessary.



First prize in psychiatry at the 2015 British Medical Association Medical Book Awards.



2015 • 227 pages • ISBN 978-1-58562-482-9 • Paperback • \$55.00 • Item #62482
2015 • 227 pages • ISBN 978-1-58562-547-5 • eBook • \$55.00 • Item #62547

AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
Email: appi@psych.org
Phone: 1-800-368-5777

AH1545A

The Department of Psychiatry at Oregon Health & Science University (OHSU) has an outstanding opportunity for a BC/BE psychiatrist. The position offers an option of four days of clinical work and one day of protected time to pursue community service and academic interests, and is central to a University-State partnership at the Oregon State Hospital. It offers a unique career path opportunity in a creative environment at a time of historic and progressive change in State mental health.

Academic rank begins at the level of Assistant Professor and may be higher depending on credentials. All applicants must be board certified or board-eligible in Psychiatry. Completion of a fellowship training in forensics, addictions, geriatrics and/or public psychiatry provides additional practice opportunities within the hospital. The position offers very competitive pay and benefits, including a relocation allotment.

Oregon Health & Science University is a nationally prominent research university and Oregon's only public academic health center. It educates health professionals and scientists and provides leading-edge patient care, community services and biomedical research.

When you join OHSU, you join a dedicated team of caregivers, educators, researchers and administrative professionals who diligently pursue the advancement and application of knowledge to directly benefit the individuals and communities we serve. Each day at OHSU brings a chance to further your learning, discover something new and touch the lives of people in Oregon and beyond.

We look forward to hearing from you.

Jonathan Betlinski, M.D.

Associate Professor of Clinical Medicine at Oregon Health Sciences University
Director, Division of Public Psychiatry
Medical Director, OHSU ECHO
Chief Medical Officer,
Cascadia Behavioral Healthcare, Inc.
psychjob@ohsu.edu



Be sure to stop by our booth at the APA Career Fair



Patient Care • Education • Research



The Department of Psychiatry in the College of Medicine at the University of Florida is a leader in the Southeast for innovative evidence-based treatment programs for mental-health disorders and addiction. We have over 70 faculty members in a vibrant and expanding department that provides state-of-the-art psychiatric care, educational programs and research to improve the lives of persons with mental illness and addiction. We have academic and clinical expertise in Adult, Addiction, Child/Adolescent, Geriatric, VA, Forensic, Community Psychiatry and Medical Psychology. Our mission is to offer the highest quality clinical and educational programs informed by the latest research.

The College of Medicine, the largest of six colleges at the University of Florida Health Science Center, opened in 1956 with a mission to increase Florida's supply of highly qualified physicians, provide advanced health-care services to the citizens of Florida and foster discovery in health research. The College's Gainesville campus is composed of 28 clinical and basic science departments staffed by more than 1,200 faculty members. Both UF and UF Health have again made the national honor roll as one of America's Best Employers, according to Forbes magazine's annual listing that is featured in the April 2016 edition. This year, UF Health rose nine spots to No. 16 among all health care providers and No. 89 out of the top 500 companies. UF ranked No. 13 among public universities and No. 90 overall. Highly motivated and compassionate psychiatrists are encouraged to join our team.

We are currently recruiting for the following specialties:

- ◆ Assistant/Associate/Full Professor—Adult Psychiatrist (Inpatient and Outpatient)—Gainesville, FL.
- ◆ Assistant/Associate/Professor—2 Community Psychiatrists—Jacksonville, FL.
- ◆ Assistant/Associate/Professor—Adult Psychiatrist—Ocala, FL.
- ◆ Assistant/Associate/Full Professor—Adult & Child Psychiatrist in the Community Psychiatry Division—Vero Beach, FL.
- ◆ Assistant/Associate/Professor—Consult Liaison Child and Adult Psychiatrist—Gainesville, FL.
- ◆ Assistant/Associate/Professor—Psychologist in the Addiction Medicine Division—Gainesville, FL.

Must be Board Certified and/or Board Eligible M.D. in Psychiatry and able to obtain a Florida Medical License. Demonstrated record of clinical excellence, research or teaching interest in an academic medical center. Additional Board Certifications in Addiction Psychiatry, Geropsychiatry or other Psychiatric subspecialties are of particular interest.

For more information regarding Faculty benefits, please visit <http://adminaffairs.med.ufl.edu/fringe-benefits/faculty-benefits/>

Applicants must apply through the Careers at UF website <http://jobs.ufl.edu/>

www.psychiatry.ufl.edu

The University of Florida is an equal opportunity institution dedicated to building a broadly diverse and inclusive faculty & staff.

www.ufhealth.org

Numerical List of Exhibitors by Booth Number

- | | | | |
|-----|--|-----|---|
| 301 | California Correctional Health Care Services (CCHCS) | 511 | Novant Health |
| 313 | Riverside Health System | 512 | Minnesota Department of Human Services |
| 327 | International Congress on Dual Disorders | 513 | Tenet Health |
| 329 | WPA World Congress of Psychiatry 2017 Berlin | 514 | DR Wanted |
| 400 | Springstone Inc. | 515 | PracticeLink.com |
| 401 | IPC Healthcare | 522 | Hogrefe Publishing Corp. |
| 402 | Southwest Behavioral Health Services | 524 | Springer |
| 403 | Federal Bureau of Prisons (BOP) | 525 | Elsevier, Inc. |
| 404 | JPE Healthcare Staffing, Inc. | 526 | Informa Health Care Journals |
| 405 | Carilion Clinic | 527 | Rutgers Center of Alcohol Studies |
| 406 | Saint Francis Health System/Laureate Psychiatric Clinic and Hospital | 528 | Routledge Journals |
| 407 | EmCare | 530 | Routledge/CRC Press |
| 408 | Glens Falls Hospital | 537 | Vanda Pharmaceuticals Inc. |
| 409 | Greater Hudson Valley Health System | 600 | VISTA Staffing Solutions, Inc. |
| 410 | Ministry Health Care | 601 | Community Health Systems |
| 411 | Department of Veterans Affairs | 602 | Allina Health |
| 412 | Medical Search | 603 | Billings Clinic |
| 413 | North Carolina Office of Rural Health | 604 | Medicus Healthcare Solutions |
| 415 | Central Intelligence Agency | 605 | FCS, Inc. |
| 416 | Wolters Kluwer Health | 606 | LifePoint Health |
| 417 | Cambridge University Press | 607 | Rochester Regional Health |
| 420 | Guilford Publications | 608 | Air Force Recruiting Services |
| 423 | Oxford University Press | 609 | Carolinas Healthcare System |
| 431 | <i>Psychiatric Times</i> | 610 | Fraser Health |
| 500 | Oregon State Hospital | 611 | Via Christi Health System |
| 501 | Intermountain Healthcare | 612 | Liberty Healthcare Corporation |
| 502 | Oregon Health & Science University, Department of Psychiatry | 613 | Global Medical Staffing |
| 503 | Community Psychiatry | 614 | Kaiser Permanente, The Permanente Medical Group, Inc. |
| 504 | Group Health Physicians | 617 | All Star Recruiting |
| 505 | IASIS Healthcare | 619 | Align International Recruitment Ltd. |
| 506 | Aurora Health Care | 624 | The JAMA Network |
| 507 | Unity Center for Behavioral Health | 626 | Wiley |
| 508 | Memorial Hospital of Sweetwater County | 637 | Janssen Pharmaceuticals, Inc. |
| 509 | North GA Partnership (NoGAP) | 644 | Intra-Cellular Therapies Inc. |
| 510 | Spartanburg Regional Healthcare System | 700 | Providence Health & Services |
| | | 704 | Westchester Medical Center |
| | | 706 | Aureus Medical Group |

Numerical List of Exhibitors by Booth Number

- | | | | |
|------|--|------|--|
| 708 | Diamond Healthcare Recruitment Division | 1317 | Menninger Clinic |
| 710 | Northeast Georgia Health System, Inc. | 1319 | OmegaBrite |
| 712 | MHM Services, Inc. | 1322 | U.S. Department of State, Office of Medical Services |
| 716 | Army Medical Recruiting | 1323 | LocumTenens.com |
| 747 | SARDAA—Schizophrenia & Related Disorders Alliance of America | 1324 | Otsuka America Pharmaceutical, Inc. |
| 837 | Merck & Co. | 1328 | Hospital Corporation of America |
| 845 | Assurex Health | 1329 | Shire U.S., Inc. |
| 937 | Otsuka America Pharmaceutical, Inc. | 1337 | Allergan |
| 945 | Wexford Health Sources | 1347 | Metabolic Maintenance |
| 1037 | Otsuka America Pharmaceutical, Inc. | 1400 | Horizon Health |
| 1044 | Millennium Health | 1401 | Sheppard Pratt Health System |
| 1049 | NEOS Therapeutics | 1402 | Soterix Medical, Inc. |
| 1149 | Tris Pharma | 1403 | The Center for Eating Disorders at Sheppard Pratt |
| 1201 | Northern Light Technologies | 1404 | Captive Risk Planners/Perfect Tax & Finance |
| 1203 | Iris Telehealth | 1405 | Braeburn Pharmaceuticals, Inc. |
| 1207 | NeuroScience, Inc. | 1406 | Uskudar University Npistanbul Neuropsychiatry Hospital |
| 1209 | Shire | 1408 | Wellington Retreat |
| 1211 | Electromedical Products International, Inc. | 1409 | Indivior Inc. |
| 1217 | American Professional Agency, Inc. | 1410 | AltheaDx |
| 1223 | Medical Billing Professionals | 1411 | Gould Farm |
| 1225 | Maxim Physician Resources | 1412 | <i>Clinical Psychiatry News</i> |
| 1227 | Genomind | 1413 | Sierra Tucson |
| 1237 | Sunovion Pharmaceuticals Inc. | 1414 | <i>Current Psychiatry</i> |
| 1247 | Sunovion Pharmaceuticals Inc. | 1415 | Tsehootsooi Medical Center |
| 1300 | McLean Hospital | 1416 | Skyland Trail |
| 1301 | MECTA Corporation | 1417 | The TOVA Company |
| 1304 | Quotient® ADHD System by Pearson | 1418 | Universal Health Services, Inc. |
| 1305 | Department of Behavioral Health and Developmental Disabilities | 1419 | American Physician Institute — Beat the Boards |
| 1306 | Sun Behavioral Health | 1420 | Locum Source, Inc. |
| 1308 | Otto Trading, Inc. | 1422 | Virtual Medical Staff |
| 1309 | Bassett Healthcare Network | 1423 | Valant Medical Solutions |
| 1310 | University of Florida Department of Psychiatry | 1424 | Compulink Business Systems, Inc. |
| 1311 | HCPLive | 1425 | Georgia Association of Community Service Boards, Inc. |
| 1313 | Mayo Clinic | 1429 | American Board of Psychiatry and Neurology, Inc. |

Numerical List of Exhibitors by Booth Number

- 1431 Somatics LLC
- 1437 ACADIA Pharmaceuticals
- 1446 Behavioral Health Recruitment Services
- 1447 Rhodes Pharmaceuticals L.P.
- 1500 Vanderbilt Behavioral Health
- 1501 CompHealth
- 1503 Neba Health, LLC
- 1505 Association & Meeting Solutions
- 1510 Christian Medical & Dental Associations, Psychiatry Section
- 1511 Muse: The Brain Sensing Headband
- 1512 TeleSage, Inc.
- 1513 Brookhaven Retreat
- 1514 Harmonex Neuroscience Research, Inc.
- 1516 World Health Information Network
- 1517 Weatherby Healthcare
- 1518 Magstim
- 1519 Tallahassee Memorial Healthcare
- 1521 Hillside, Inc.
- 1522 New York-Presbyterian Hospital
- 1523 Medpartners Locum Tenens
- 1528 *Focus: The Journal of Lifelong Learning in Psychiatry*
- 1529 NeuroStar TMS Therapy
- 1530 Austen Riggs Center
- 1546 Allergan
- 1547 Indivior Inc.
- 1600 Barton Associates
- 1601 Association of Gay and Lesbian Psychiatrists (AGLP)
- 1602 MD.com
- 1603 American Academy of Addiction Psychiatry
- 1607 National Institute of Mental Health (NIMH)
- 1613 Physicians for a National Health Program
- 1614 Infinite Trading, Inc.
- 1615 Veritas Collaborative
- 1616 InSight Telepsychiatry, LLC
- 1617 Brainsway USA Inc.
- 1618 Neurocrine Biosciences, Inc.
- 1622 Jackson & Coker
- 1623 Alkermes, Inc.
- 1637 Ironshore Pharmaceuticals and Development, Inc.
- 1700 CareClix
- 1701 Mount Sinai Health System
- 1707 Magventure, Inc.
- 1710 Georgia Ketamine
- 1711 Specialists On Call
- 1712 Rogers Memorial Hospital
- 1713 Indivior Inc.
- 1714 PsychU
- 1715 TrueLearn
- 1717 Arbor Pharmaceuticals, LLC
- 1800 Admera Health
- 1806 Destination Hope
- 1810 Arcadian Telepsychiatry
- 1811 Alkermes, Inc.
- 1812 Humana Inc.
- 1814 Correct Care Solutions, LLC
- 1817 Takeda Pharmaceuticals U.S.A., Inc./Lundbeck
- 1823 Neuronetrix
- 1825 CoverMyMeds
- 1827 Atlanta Center for Medical Research
- 1829 Rogers Behavioral Health System
- 1922 Acadia Healthcare
- 1926 Otsuka America Pharmaceutical, Inc.
- 1928 Delta Companies



Exhibit Hall Floor Plan

American Psychiatric Association 2016
MAY 14-18, 2016
GEORGIA WORLD CONGRESS CENTER - BUILDING B
ATLANTA, GEORGIA





Exhibit Hall Floor Plan



For the treatment of schizophrenia



INDICATION and IMPORTANT SAFETY INFORMATION for ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use

INDICATION

ARISTADA is indicated for the treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.

Contraindication: Known hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis.

Cerebrovascular Adverse Reactions, Including Stroke: Increased incidence of cerebrovascular adverse reactions (eg, stroke, transient ischemic attack), including fatalities, have been reported in placebo-controlled trials of elderly patients with dementia-related psychosis treated with risperidone, aripiprazole, and olanzapine. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex sometimes referred to as NMS may occur with administration of antipsychotic drugs, including ARISTADA. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. The management of NMS should include:

1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal, involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribing should be consistent with the need to minimize TD. Discontinue ARISTADA if clinically appropriate. There is no known treatment for established TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.


Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include:

- **Hyperglycemia/Diabetes Mellitus:** Hyperglycemia, in some cases extreme and associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with oral aripiprazole. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients require continuation of antidiabetic treatment despite discontinuation of the suspect drug.
- **Dyslipidemia:** Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
- **Weight Gain:** Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

ARISTADA helps you match your patients with the efficacy and options they need

Delivering proven efficacy and flexibility for individualized care¹

- Significantly improved Positive and Negative Syndrome Scale (PANSS) total score at day 85 vs placebo
- The 882-mg dose provides extended coverage with monthly or 6-week dosing interval
- The 441-mg and 662-mg doses are given monthly

ARISTADA[®] 
aripiprazole lauroxil
extended-release injectable suspension
441 mg • 662 mg • 882 mg

Expand your options

- ARISTADA[®] (aripiprazole lauroxil) is only to be administered as an intramuscular injection by a healthcare professional. For patients who have never taken aripiprazole, establish tolerability with oral aripiprazole prior to initiating treatment with ARISTADA
- Administer treatment with oral aripiprazole for 21 consecutive days in conjunction with the first ARISTADA injection
- Dose may be adjusted as needed. When making dose and dosing interval adjustments, the pharmacokinetics and prolonged-release characteristics of ARISTADA should be considered
- Missed doses: If time elapsed since last injection exceeds 6 weeks (441 mg) or 8 weeks (662 mg and 882 mg), supplement next injection with oral aripiprazole. Please see full Prescribing Information for more instructions for missed doses

Learn more at Booth 1623

Orthostatic Hypotension: Aripiprazole may cause orthostatic hypotension which can be associated with dizziness, lightheadedness, and tachycardia. Monitor heart rate and blood pressure, and warn patients with known cardiovascular or cerebrovascular disease and risk of dehydration and syncope.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia, neutropenia, and agranulocytosis have been reported. Patients with a history of clinically significant low white blood cell count (WBC)/ absolute neutrophil count (ANC) and history of drug-induced leukopenia/ neutropenia should have frequent complete blood count (CBC) during the first few months of receiving ARISTADA. Consider discontinuation of ARISTADA at the first sign of a clinically significant decline in WBC count in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue ARISTADA in patients with severe neutropenia (absolute neutrophil count <1000/mm³) and follow their WBC until recovery.

Seizures: ARISTADA should be used with caution in patients with a history of seizures or with conditions that lower the seizure threshold.

Potential for Cognitive and Motor Impairment: ARISTADA may impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are certain ARISTADA does not affect them adversely.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Advise patients regarding appropriate care in avoiding overheating and dehydration. Appropriate care is advised for patients who may exercise strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are subject to dehydration.

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use; use caution in patients at risk for aspiration pneumonia.

Concomitant Medication: Decreasing the ARISTADA dosage is recommended in patients taking strong CYP3A4 inhibitors and/or strong

CYP2D6 inhibitors for longer than 2 weeks. Increasing the ARISTADA dosage is recommended in patients taking CYP3A4 inducers for longer than 2 weeks. No ARISTADA dosage changes are recommended for patients taking CYP450 modulators for less than 2 weeks.

Most Commonly Observed Adverse Reaction: The most common adverse reaction (≥5% incidence and at least twice the rate of placebo in patients treated with ARISTADA) was akathisia.

Injection-Site Reactions: Injection-site reactions were reported by 4%, 5%, and 2% of patients treated with 441 mg ARISTADA, 882 mg ARISTADA, and placebo, respectively. Most of these were injection-site pain and associated with the first injection and decreased with each subsequent injection. Other injection-site reactions (induration, swelling, and redness) occurred at less than 1%.

Dystonia: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first days of treatment and at low doses.

Pregnancy/Nursing: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider of a known or suspected pregnancy. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA during pregnancy. Aripiprazole is present in human breast milk. The benefits of breastfeeding should be considered along with the mother's clinical need for ARISTADA and any potential adverse effects on the infant from ARISTADA or from the underlying maternal condition.

Please see Brief Summary of full Prescribing Information, including Boxed Warning, on the following pages.

Reference: 1. ARISTADA [package insert]. Waltham, MA: Alkermes, Inc.; 2016.

 Alkermes

Alkermes[®] is a registered trademark of Alkermes, Inc. and ARISTADA[®] is a registered trademark of Alkermes Pharma Ireland Limited, used by Alkermes Inc. under license.
©2016 Alkermes, Inc. All rights reserved. ARI-001462 Printed in the U.S.A.

ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use

BRIEF SUMMARY OF PRESCRIBING INFORMATION

(For complete details, please see full Prescribing Information and Medication Guide.)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death
- ARISTADA is not approved for the treatment of patients with dementia-related psychosis

INDICATIONS AND USAGE: ARISTADA is an atypical antipsychotic indicated for the treatment of schizophrenia.

CONTRAINDICATIONS: ARISTADA is contraindicated in patients with a known hypersensitivity reaction to aripiprazole. Hypersensitivity reactions have ranged from pruritus/urticaria to anaphylaxis.

WARNINGS AND PRECAUTIONS

Increased Mortality in Elderly Patients With Dementia-related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.

Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.

Cerebrovascular Adverse Reactions, Including Stroke: In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated patients. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome: A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) may occur in association with antipsychotic drugs, including ARISTADA. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient appears to require antipsychotic drug treatment after recovery from NMS, reintroduction of drug therapy should be closely monitored, since recurrences of NMS have been reported.

Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible appear to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase, but the syndrome can develop after relatively brief treatment periods at low doses, although this is uncommon.

There is no known treatment for established tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself may suppress (or partially suppress) the signs and symptoms of the syndrome and may thus mask the underlying process. The effect of symptomatic suppression on the long-term course of the syndrome is unknown.

Given these considerations, ARISTADA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that is known to respond to antipsychotic drugs. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient treated with ARISTADA, drug discontinuation should be considered. However, some patients may require treatment with ARISTADA despite the presence of the syndrome.

Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain. While all drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperglycemia/Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. There have been reports of hyperglycemia in patients treated with oral aripiprazole. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients require continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

In the long-term, open-label schizophrenia study with ARISTADA, 14% of patients with normal hemoglobin A1c (<5.7%) at baseline developed elevated levels (≥5.7%) post-baseline.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

In the long-term, open-label schizophrenia study with ARISTADA, shifts in baseline fasting total cholesterol from normal (<200 mg/dL) to high (≥240 mg/dL) were reported in 1% of patients; shifts in baseline fasting LDL cholesterol from normal (<100 mg/dL) to high (≥160 mg/dL) were reported in 1% of patients; and shifts in baseline fasting triglycerides from normal (<150 mg/dL) to high (≥200 mg/dL) were reported in 8% of patients. In the same study, shifts in baseline fasting total cholesterol from borderline (≥200 mg/dL and <240 mg/dL) to high (≥240 mg/dL) were reported in 15% of patients; shifts in baseline fasting LDL cholesterol from borderline (≥100 mg/dL and <160 mg/dL) to high (≥160 mg/dL) were reported in 8% of patients; and shifts in baseline fasting triglycerides from borderline (≥150 mg/dL and <200 mg/dL) to high (≥200 mg/dL) were reported in 35% of patients. In addition, the proportion of patients with shifts in fasting HDL cholesterol from normal (≥40 mg/dL) to low (<40 mg/dL) was reported in 15% of patients.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

The proportion of adult patients with weight gain ≥7% of body weight is presented in Table 1.

Table 1: Proportion of Adult Patients With Shifts in Weight in the 12-Week, Placebo-Controlled, Fixed-Dose Schizophrenia Trial

	Placebo N = 207 (%)	ARISTADA	
		441 mg N = 207 (%)	882 mg N = 208 (%)
Weight gain			
≥7% increase from baseline	6	10	9

Orthostatic Hypotension: Aripiprazole may cause orthostatic hypotension, perhaps due to its α_1 -adrenergic receptor antagonism. Associated adverse reactions related to orthostatic hypotension can include dizziness, lightheadedness, and tachycardia. Generally, these risks are greatest at the beginning of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. In such patients, consider using a lower starting dose, and monitor orthostatic vital signs.

Orthostatic hypotension was reported for 1 patient in the ARISTADA 882 mg group (0.5%) and no patients in the ARISTADA 441 mg and placebo groups in the 12-week schizophrenia efficacy study. In the long-term open-label schizophrenia study, orthostatic hypotension was reported for 1 (0.2%) patient treated with ARISTADA. Orthostatic hypotension was defined as a decrease in systolic blood pressure ≥20 mmHg accompanied by an increase in heart rate ≥25 bpm when comparing standing to supine values.

Leukopenia, Neutropenia, and Agranulocytosis: In clinical trials and/or postmarketing experience, events of leukopenia and neutropenia have been reported temporally related to antipsychotic agents. Agranulocytosis has also been reported. Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) and history of drug-induced leukopenia/neutropenia. In patients with a history of a clinically significant low WBC/ANC or drug-induced leukopenia/neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of ARISTADA at the first sign of a clinical significant decline in WBC in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue ARISTADA in patients with severe neutropenia (absolute neutrophil count <1000/mm³) and follow their WBC until recovery.

Seizures: As with other antipsychotic drugs, use ARISTADA cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older.

Potential for Cognitive and Motor Impairment: ARISTADA, like other antipsychotics, has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with ARISTADA does not affect them adversely.

Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing ARISTADA for patients who will be experiencing conditions which may contribute to an elevation in core body temperature (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration).

Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. ARISTADA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

ADVERSE REACTIONS

Clinical Studies Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Patient Exposure: ARISTADA has been evaluated for safety in 880 adult patients in clinical trials in schizophrenia.

Commonly Observed Adverse Reactions: The most common adverse reaction (incidence ≥5% and at least twice the rate of placebo in patients treated with ARISTADA) was akathisia.

Adverse Reactions Occurring at an Incidence of 2% or More in ARISTADA-Treated Patients: Adverse reactions associated with the use of ARISTADA (incidence of 2% or greater, rounded to the nearest percent and ARISTADA incidence greater than placebo) that occurred are shown in Table 2.

Table 2: Adverse Reaction in 2% or More of ARISTADA-Treated Patients and That Occurred at Greater Incidence Than in the Placebo-Treated Patients in the 12-Week, Placebo-Controlled, Fixed-Dose Schizophrenia Trial

Adverse Reaction System Organ Class Preferred Term	Placebo N = 207 (%)	Aripiprazole Lauroxil	
		441 mg N = 207 (%)	882 mg N = 208 (%)
General disorders and administration site conditions			
Injection site pain	2	3	4
Investigations			
Increased weight	1	2	2
Increased blood creatine phosphokinase	0	2	1
Nervous system disorders			
Akathisia	4	11	11
Headache	3	3	5
Psychiatric disorders			
Insomnia	2	3	4
Restlessness	1	3	1

Injection Site Reactions: Injection-site reactions were reported by 4% of patients treated with 441 mg ARISTADA and 5% of patients treated with 882 mg ARISTADA compared to 2% of patients treated with placebo. Most of these were injection-site pain (3%, 4%, and 2% in the 441 mg ARISTADA, 882 mg ARISTADA, and placebo groups, respectively), and most were associated with the first injection and decreased with each subsequent injection to less than or equal to 1% for both doses of ARISTADA and placebo. Other injection-site reactions (induration, swelling, and redness) occurred at less than 1%.

Extrapyramidal Symptoms: In the 12-week schizophrenia efficacy study, for ARISTADA-treated patients, the incidence of other EPS-related events, excluding akathisia and restlessness, was 5% and 7% for patients on 441 mg and 882 mg, respectively, versus 4% for placebo-treated patients (Table 3).

Table 3: Incidence of EPS Compared to Placebo

Adverse Reaction Term	Placebo N = 207 (%)	ARISTADA	
		441 mg N = 207 (%)	882 mg N = 208 (%)
Akathisia	4	11	11
Restlessness	1	3	1
Other EPS	4	5	7
Dystonia	1	2	2
Parkinsonism	3	3	4

Dystonia: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Other Adverse Reactions Observed in Clinical Studies: The following listing does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.

Cardiac – angina pectoris, tachycardia, palpitations

Gastrointestinal disorders – constipation, dry mouth

General disorders – asthenia

Musculoskeletal – muscular weakness

Nervous system disorders – dizziness

Psychiatric disorders – anxiety, suicide

Adverse Reactions Reported in Clinical Trials with Oral Aripiprazole: The following is a list of additional adverse reactions that have been reported in clinical trials with oral aripiprazole and not reported above for ARISTADA.

Blood and Lymphatic System Disorders: thrombocytopenia

Cardiac Disorders: bradycardia, atrial flutter, cardiorespiratory arrest, atrioventricular block, atrial fibrillation, myocardial ischemia, myocardial infarction, cardiopulmonary failure

Eye Disorders: photophobia, diplopia

Gastrointestinal Disorders: gastroesophageal reflux disease

General Disorders and Administration-Site Conditions: peripheral edema, chest pain, face edema

Hepatobiliary Disorders: hepatitis, jaundice

Immune System Disorders: hypersensitivity

Injury, Poisoning, and Procedural Complications: fall, heat stroke

Investigations: weight decreased, hepatic enzyme increased, blood glucose increased, blood lactate dehydrogenase increased, gamma glutamyl transferase increased, blood prolactin increased, blood urea increased, blood creatinine increased, blood bilirubin increased, electrocardiogram QT prolonged, glycosylated hemoglobin increased

Metabolism and Nutrition Disorders: anorexia, hypokalemia, hyponatremia, hypoglycemia

Musculoskeletal and Connective Tissue Disorders: muscle tightness, rhabdomyolysis, mobility decreased

Nervous System Disorders: memory impairment, cogwheel rigidity, hypokinesia, myoclonus, bradykinesia, akinesia, myoclonus, coordination abnormal, speech disorder, choreoathetosis

Psychiatric Disorders: aggression, loss of libido, delirium, libido increased, anorgasmia, tic, homicidal ideation, catatonia, sleep walking

Renal and Urinary Disorders: urinary retention, nocturia

Reproductive System and Breast Disorders: erectile dysfunction, gynaecomastia, menstruation irregular, amenorrhea, breast pain, priapism

Respiratory, Thoracic, and Mediastinal Disorders: nasal congestion, dyspnea

Skin and Subcutaneous Tissue Disorders: rash, hyperhidrosis, pruritus, photosensitivity reaction, alopecia, urticaria

Vascular Disorders: hypotension, hypertension

Postmarketing Experience: The following adverse reactions have been identified during post-approval use of oral aripiprazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure: occurrences of allergic reaction (anaphylactic reaction, angioedema, laryngospasm, pruritus/urticaria, or oropharyngeal spasm), pathological gambling, hiccups, and blood glucose fluctuation.

DRUG INTERACTIONS

Drugs Having Clinically Important Interactions With ARISTADA

Table 4: Clinically Important Drug Interactions With ARISTADA

Concomitant Drug Name or Drug Class	Clinical Rationale	Clinical Recommendations
Strong CYP3A4 Inhibitors (e.g., itraconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine)	The concomitant use of oral aripiprazole with strong CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole compared to the use of oral aripiprazole alone.	With concomitant use of ARISTADA with a strong CYP3A4 inhibitor or CYP2D6 inhibitor for more than 2 weeks reduce the ARISTADA dose.

Table 4: Clinically Important Drug Interactions With ARISTADA (cont)

Concomitant Drug Name or Drug Class	Clinical Rationale	Clinical Recommendations
Strong CYP3A4 Inducer (e.g., carbamazepine, rifampin)	The concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of oral aripiprazole alone.	With concomitant use of ARISTADA with a strong CYP3A4 inducer for more than 2 weeks consider increasing the ARISTADA dose.
Antihypertensive Drugs	Due to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.	Monitor blood pressure and adjust dose accordingly.
Benzodiazepines (e.g., lorazepam)	The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone.	Monitor sedation and blood pressure. Adjust dose accordingly.

USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Exposure Registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA during pregnancy. For more information, contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit <http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/>.

Risk Summary: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Limited published data on aripiprazole use in pregnant women are not sufficient to inform any drug-associated risks for birth defects or miscarriage. No teratogenicity was observed in animal reproductive studies with intramuscular administration of aripiprazole lauroxil to rats and rabbits during organogenesis at doses up to 6 and 18 times, respectively, the maximum recommended human dose (MRHD) of 882 mg based on body surface area (mg/m²). However, aripiprazole caused developmental toxicity and possible teratogenic effects in rats and rabbits [see Data in full Prescribing Information]. The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Advise pregnant women of the potential risk to a fetus.

Clinical Considerations: Fetal/Neonatal Adverse Reactions: Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Some neonates recover within hours or days without specific treatment; others required prolonged hospitalization.

Data: Animal Data for Aripiprazole Lauroxil: Aripiprazole lauroxil did not cause adverse developmental or maternal effects in rats or rabbits when administered intramuscularly during the period of organogenesis at doses of 18, 49, or 144 mg/animal in pregnant rats which are approximately 0.7 to 6 times the maximum recommended human dose (MRHD) of 882 mg ARISTADA on a mg/m² basis and at doses of 241, 723, and 2893 mg/animal in pregnant rabbits which are approximately 1 to 18 times the MRHD for ARISTADA on a mg/m² basis. However, aripiprazole caused developmental toxicity and possible teratogenic effects in rats and rabbits.

Animal Data for Aripiprazole: Pregnant rats were treated with oral doses of 3, 10, and 30 mg/kg/day, which are approximately 1 to 10 times the oral maximum recommended human dose (MRHD) of 30 mg/day on mg/m² basis of aripiprazole during the period of organogenesis. Treatment at the highest dose caused a slight prolongation of gestation and delay in fetal development, as evidenced by decreased fetal weight, and undescended testes. Delayed skeletal ossification was observed at 3 and 10 times the oral MRHD on mg/m² basis.

At 3 and 10 times the oral MRHD on mg/m² basis, delivered offspring had decreased body weights. Increased incidences of hepatodiaphragmatic nodules and diaphragmatic hernia were observed in offspring from the highest dose group (the other dose groups were not examined for these findings). A low incidence of diaphragmatic hernia was also seen in the fetuses exposed to the highest dose. Postnatally, delayed vaginal opening was seen at 3 and 10 times the oral MRHD on mg/m² basis and impaired reproductive performance (decreased fertility rate, corpora lutea, implants, live fetuses, and increased post-implantation loss, likely mediated through effects on female offspring) along with some maternal toxicity were seen at the highest dose; however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity.

In pregnant rabbits treated with oral doses of 10, 30, and 100 mg/kg/day, which are 2 to 11 times human exposure at the oral MRHD based on AUC and 6 to 65 times the oral MRHD on mg/m² basis of aripiprazole during the period of organogenesis, decreased maternal food consumption and increased abortions were seen at the highest dose as well as increased fetal mortality. Decreased fetal weight and increased incidence of fused sternbrae were observed at 3 and 11 times the oral MRHD based on AUC.

In rats treated with oral doses of 3, 10, and 30 mg/kg/day which are 1 to 10 times the oral MRHD on mg/m² basis of aripiprazole perinatally and postnatally (from day 17 of gestation through day 21 postpartum), slight maternal toxicity and slightly prolonged gestation were seen at the highest dose. An increase in stillbirths and decreases in pup weight (persisting into adulthood) and survival were also seen at this dose.

Lactation: Risk Summary: Aripiprazole is present in human breast milk; however, there are insufficient data to assess the amount in human milk, the effects on the breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for ARISTADA and any potential adverse effects on the breastfed infant from ARISTADA or from the underlying maternal condition.

Pediatric Use: Safety and effectiveness of ARISTADA in patients <18 years of age have not been evaluated.

Geriatric Use: Safety and effectiveness of ARISTADA in patients >65 years of age have not been evaluated.

Hepatic and Renal Impairment: No dosage adjustment for ARISTADA is required based on a patient's hepatic function (mild to severe hepatic impairment, Child-Pugh score between 5 and 15), or renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 mL/minute).

Other Specific Populations: No dosage adjustment for ARISTADA is required on the basis of a patient's sex, race, or smoking status.

OVERDOSAGE

Human Experience: The largest known case of acute ingestion with a known outcome involved 1260 mg of oral aripiprazole (42 times the maximum recommended daily dose) in a patient who fully recovered.

Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral aripiprazole overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.

Management of Overdosage: In case of overdosage, call the Poison control center immediately at 1-800-222-1222.

To report SUSPECTED ADVERSE REACTIONS, contact Alkermes, Inc. at 1-866-274-7823 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PATIENT COUNSELING INFORMATION

Physicians are advised to discuss the FDA-approved patient labeling (Medication Guide) with patients for whom they prescribe ARISTADA.

This Brief Summary is based on ARISTADA Full Prescribing Information Rev January 2016
Manufactured and marketed by Alkermes, Inc., Waltham, MA 02451-1420

Alkermes® is a registered trademark of Alkermes, Inc. and ARISTADA® is a registered trademark of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license.

©2016 Alkermes, Inc. All rights reserved. ARI-001477





Presenters Index



Presenters Index

A

Aaronson, Alexandra L., M.D.	163	Alosaimi, Fahad D., M.D.	161
Abbey, Susan, M.D.	143	Alphs, Larry D., M.D., Ph.D.	174
Abdel Gawad, Noha, M.D.	159	Alptekin, Koksai, M.D.	161
Aboraya, Ahmed, M.D., D.P.H.	79	Al-Rubaye, Safa, M.D.	152
Aboueid, Lila, D.O.	152	Alva, Gustavo, M.D., DFAPA	189
Acar, Selin, B.S.	137	Alvarez, Kiara, Ph.D.	77
Acharya, Bibhav, M.D.	100	Alwahibi, Abdulrahman, M.D.	166
Acosta-Uribe, Juliana	163	Aly, Tarek, M.D.	152
Adams, Caitlin, M.D.	152	Amadio, Jordan	86
Adams, Samantha, Ph.D.	131	Amann, Birgit, M.D.	189
Adelsheim, Steven, M.D.	69, 108	Amin, Abdel F., M.D., M.P.H.	69
Adelsky, Sol, M.D., M.P.H.	85	Amin, Ritesh, M.D.	152
Adelson, Stewart L., M.D.	132	Amin, Rohul, M.D.	61, 65
Adi, Ahmad, M.B.B.S., M.P.H.	115	Ananthamoorthy, Renuka, M.D.	107
Adler, Amy B., Ph.D.	132	Andersen, Aaron K., D.O.	152
Aeschbach Jachmann, Crispa, M.D.	152	Anderson, Frederick, M.D.	145
Aftab, Awais, M.B.B.S.	137, 152	Anderson, Jeffrey, Sc.D.	170
Afzal, Fariha, M.B.B.S.	152	Anderson, Karen E., M.D.	174
Afzal, Saba, M.D.	152	Anderson, Otis, M.D.	101, 108
Agarwal, Vishesh, M.D.	171	Andruskevicius, Sergejus, M.D.	166
Agashe, Mohan	67	Anees, Muhammad A., M.D.	159
Aga, Vimal M., M.D.	65	Anglero Diaz, Yohanis L., M.D.	152
Agbonyitor, Mawuena, M.D., M.Sc.	117	Annamalai, Aniyizhai, M.D.	62
Aggarwal, Neil K., M.D., M.B.A.	105, 115	An, Seung-Min, M.D.	163
Aggarwal, Rashi, M.D.	101	Anthony, James C., M.Sc., Ph.D.	69
Ahmad, Ammar Y., M.D.	152	Anzia, Daniel, M.D.	85
Ahmedani, Brian K., Ph.D., M.S.W.	166	Anzia, Joan, M.D.	85, 113, 130
Ahmed, Iqbal, M.D.	108	Aoun, Elie, M.D.	75, 132
Ahmed, Mohammed W., M.D.	172	Appelbaum, Kenneth	88
Ahmed, Mohsina, M.D.	116	Appelbaum, Paul S., M.D.	82, 86, 100, 104, 108, 127, 131, 135
Ahmed, Saeed, M.D.	152	Apter, Gisele, M.D., Ph.D.	79, 129
Ahuja, Amir, M.D.	75	Aragon, Darinka, M.D.	152
Aimienwanu, Osarhiemen Ruth, M.B.B.S.	172	Arbuckle, Melissa, M.D., Ph.D.	132
Akerle, Evaristo, M.D.	145	Ardalan, Firouz, B.A.	166
Akhtar, Sameerah, M.D.	152	Arditti, Joyce, Ph.D.	101
Akil, Mayada, M.D.	113	Arroyo, William, M.D.	104, 137
Akinsanya, Adefolake, M.D.	163	Artigas, Francesc, Ph.D.	175
Akiyama, Tsyuyoshi, M.D., D.Phil.	113	Aschbacher, Kirstin, Ph.D.	70
Aklin, Will M., Ph.D.	115	Ashai, Ayesha, M.D.	177
Akpinar, Abdullah, M.Med.	174	Ash, David M., M.D., M.B.A., M.S.	175
Aksoy Poyraz, Cana, M.D.	166	Asherson, Philip, Ph.D., M.B.B.S.	143
Alarcon, Renato D., M.D., M.P.H.	104, 115	Ashley, Kenneth, M.D.	101
Alavi, Nazanin, M.D.	84, 146	Ash, Peter, M.D.	87, 104
Albassam, Ahmed, M.D.	152	Asif, Muhammad, M.D.	161
Albright, Brittany B., M.D., M.P.H.	166	Atluru, Aparna, M.D.	71
Alegria, Margarita, Ph.D.	77	Attia, Evelyn, M.D.	80, 90, 102
Alexander, Ricky	104	Auchincloss, Elizabeth L., M.D.	67, 86, 169
Alexopoulos, George S., M.D.	102	Auger, R. Robert, M.D.	64
Alhadi, Ahmad, M.D., M.B.B.S.	161	Avery, Jonathan, M.D.	66
Al-Hassani, Ghanem, M.D.	69	Ayaz, Sumayya B., M.D.	161
Ali, Arshad, M.D.	152	Aycock, Jean E., M.D.	117
Ali, Shahla, M.D.	71	Ayub, Shahana, M.D.	152
Alkis, Andrew R., M.D.	158	Ayub, Shehzad, D.O.	152
Allen, Rebecca M., M.D., M.P.H.	174	Ayuel, Atong, M.D.	128
Almas, Aysha, M.B.B.S., M.Sc.	166	Azam, Mohammed A., M.D.	172
		Azizi, Hafizullah, M.D.	175

Presenters Index

B

Babalola, Ronke L., M.D., M.P.H.	146
Babatope, Taiwo, M.D., M.B.A., M.P.H.	163
Bachem, Rahel C., D.Phil.	127
Baer, Wendy, M.D.	112, 132
Bagewadi Ellur, Mallikarjuna, M.D.	152
Baggott, Matthew J., Ph.D.	108
Bailey, John, D.O.	126
Bailey, Rahn K., M.D.	85, 108
Baird, Mimi	61
Baker, Megan E., M.D.	126
Baker, Ross A.	175
Balasundaram, Janooshsheya, M.D.	164, 179
Baler, Ruben, Ph.D.	130
Ballestas, Julio, M.D.	83
Balon, Richard, M.D.	126, 136
Banu, Sophia, M.D.	61
Baranoski, Madelon, Ph.D.	106
Barber, Keila D., M.H.S.	71
Barber, Mary, M.D.	80, 132
Barkil-Oteo, Andres, M.D., M.Sc.	66, 83
Barnea, Yael, M.D., LL.B.	161
Barnhill, John W., M.D.	132
Barry, Declan, Ph.D.	115
Barry, John, M.D.	60
Basalay, Nicholas P., M.D.	152
Baslet, Gaston, M.D.	60, 66
Bassi, Bruce, M.D., M.S.	61
Bassirnia, Anahita, M.D.	171
Bateman, Anthony, M.D.	66
Bath, Eraka, M.D., LL.B.	143
Batista, Sharon, M.D.	86
Batta, Priya	164
Baum, Antonia L., M.D.	77
Baweja, Raman, M.D., M.S.	167
Bayner, Jessica S., M.D.	152
Bazzi, Lama, M.D.	132
Beahrs, John O., M.D.	66
Bean, Jennifer, Pharm.D.	71
Becker, Anne, M.D., Ph.D.	80, 100
Becker, Daniel F., M.D.	145
Beck, Judith S., Ph.D.	61, 65, 67, 82, 85, 105
Begel, Daniel, M.D.	77
Belhadj-Tahar, Hafid, M.D., Ph.D.	110, 161
Bell, Carl C., M.D.	76
Bell, Holly S.	102
Bell, Tiffani, M.D.	127
Belnap, Barri, M.D.	80
Benassi, Paul V., M.D.	158
Benedek, Elissa P., M.D.	102
Benjamin, Sheldon, M.D.	67, 113
Bennett, Jeffrey I., M.D.	87, 102
Benson, Carmela, M.S.	169
Benson, R. Scott, M.D.	137
Benson, Timothy, M.D.	108
Bentman, Adrienne L., M.D.	113
Bera, Kevin R., B.S.	178
Beresin, Eugene V., M.D., M.A.	146
Berlin, Jon, M.D.	85, 99
Bermak, Jason C., M.D., Ph.D.	189
Berman, Ellen, M.D.	118
Bermeo-Ovalle, Adriana, M.D.	60
Bermudes, Richard A., M.D.	127
Bernardi, Silvia, M.D.	101
Bernstein, Carol A., M.D.	136
Bhandari, Stuti, M.D.	173
Bhatia, Subhash C., M.D.	82
Bhugra, Dinesh	109, 136
Bierut, Laura J., M.D.	106
Binder, Renée, M.D.	75, 85, 91, 119, 102, 130
Bisaga, Adam, M.D.	129
Biskin, Robert, M.D., M.Sc.	128
Blair, Thomas, M.D., M.S.	164
Blanch, Jordi	137
Blanco, Carlos, M.D.	62
Bland, Anton, M.D.	102
Blank Jr., Arthur S., M.D.	86
Blazer, Dan G. II, M.D., M.P.H.	76
Blevins, Derek, M.D.	160
Blier, Pierre	127
Bloom, Mia M., Ph.D.	116
Blumenfield, Michael, M.D.	86
Blyta, Afrim A., M.D.	145
Boland, Robert J., M.D.	82, 106
Bonilla-Silva, Eduardo, Ph.D.	110
Bonnie, Richard J., J.D.	98, 107, 119, 132
Borcherding, Breck, M.D.	76
Bordoloi, Meelie, M.D.	164
Borenstein, Jeffrey, M.D.	127
Bostwick, J. Michael, M.D.	83, 88
Bota, Robert G., M.D.	152
Boursiquot, Philippe-Edouard, M.D., B.Sc.	69
Boutros, Nashaat, M.D.	101
Bowen, Lynneice, M.D., M.Ed.	71
Bowering, Tricia, M.D.	60
Bowes, Michael Reid, D.O.	175
Boyce, Cheryl A., Ph.D.	136
Boyce, Niall, Ph.D., M.B.	143
Boyd, Carol J., Ph.D., R.N.	136
Boyd, J. Wesley, M.D., Ph.D.	67, 83
Boyer, Matthew, B.A.	152
Braaten, Ellen, Ph.D.	67
Bradley, John, M.D.	112
Brady, Kathleen, M.D., Ph.D.	62
Brandstetter, Jennifer M., M.D.	88
Brannan, Stephen, M.D.	176
Braun, Ilana M., M.D.	134
Bravata, Dena	86
Breen, Ellen K. R., M.D.	134
Brenner, Adam	113
Breur, Jorien Gemma, M.D.	104
Breyer, Stephen	132, 133
Brichant-Petitjean, Clara, M.D.	79

Presenters Index

Briggs, Jessica, B.A.	175	Certa, Kenneth M., M.D.	126
Brock, David G., M.D.	175	Chae, Jeong-Ho	175
Brody, Benjamin, M.D.	65	Chaimowitz, Gary, M.D., M.B.	161
Brooks, James	60, 77	Chakraborty, Amarsha, M.D.	152
Brooks, John	80	Chan, Carlyle	99
Brown, Adam, Ph.D.	142	Chaney, Michelle, M.D., M.Sc.	71, 75
Brown, Brianne, Psy.D.	175	Chang, Grace, M.D., M.P.H.	115
Brown, Frank W., M.D.	85, 110	Chang, Kiki, M.D.	80
Brown, Gregory K., Ph.D.	144	Chang, Sung Man, M.D., Ph.D.	175
Brown, Kevin	78	Chan, Stephanie H., M.D.	69, 164
Brown, Millard, M.D.	145	Chan, Steven	99
Brown, Richard P., M.D.	106, 128	Chase, Daria, Ed.M.	167
Brown, Thomas, Ph.D.	106, 133	Chatigny, Ashley H., D.O.	136
Brozyna, Caroline D., M.D.	101, 108	Chaudhry, Monika, M.D.	152
Bubl, Emanuel, M.D.	146	Cheema, Raminder Pal, M.D.	153
Buckley, Peter, M.B.B.S.	129	Chen, Alexander, B.A.	172
Busch, Alisa B., M.D., M.S.	107	Chen, Donna, M.D., M.P.H.	83
Busch, Fredric N., M.D.	67	Chen, Justin, M.D., M.P.H.	87
Busis, Deborah Beck, L.C.S.W.	67	Chen, Pao-Huan, M.D.	161
Bussing, Regina, M.D.	61	Chen, Wan-Yi, Ph.D., M.S.W.	75
Buwalda, Victor J. A., M.D., Ph.D.	105, 112	Cheong, Josepha A., M.D.	82, 108, 130
Byne, William M., M.D.	64	Cheon, Jooah	172
Bysani, Sailaja, M.D.	172	Cheung, Stephanie, M.D.	83
C		Chien, I-Chia, M.D., Ph.D.	161
Caban-Aleman, Carissa, M.D.	145	Chikvashvili, Irina, D.O.	155
Cadenhead, Kristin, M.D.	83, 88	Childress, Ann C., M.D.	167
Cai, Stella, M.D.	88	Childress, Ann, M.D.	190
Calabrese, Joseph, M.D.	175	Childs, Ed	90
Caligor, Eve, M.D.	67, 79, 105, 118, 127	Chilton, Julie A., M.D.	112
Calkins, Monica E., Ph.D.	65	Chi, Su Hyuk	172
Campbell, Marc L., D.O., Ph.D.	172	Chiu, Simon, M.D., Ph.D.	175
Camps-Romero, Eduardo, M.D.	145	Choi, Hee Yeon, M.D.	176
Candilis, Philip, M.D.	84, 88, 104, 118	Choi-Kain, Lois W., M.D., M.Ed.	113, 135
Cano, Miguel Angel, Ph.D., M.P.H.	161	Chong, Yon J., M.D., M.P.H.	153
Canton, Ali, M.D.	164	Chopra, Mehak, D.O.	153
Canuso, Amy A., D.O.	138	Chotalia, Jigar K., M.B.B.S., M.P.H.	158
Capaldi, Vincent F. II, M.D., M.Sc.	134	Choudhry, Zia, M.D., Ph.D., M.Sc.	175
Caplan, Rochelle, M.D.	66	Christensen, Aleta, M.P.H.	104
Carlo, Andrew D., M.D.	101, 102	Chudal, Roshan, Ph.D., M.B.B.S., M.P.H.	167
Carlson, Stephan M., M.D.	62	Chukwueke, Priscilla N., M.D., M.P.H.	153, 158, 161
Carnall, Amy B., D.N.P., N.P.	167	Chukwu, Ijeoma, M.D., M.P.H.	88
Carrothers, Timothy J., Sc.D.	167	Chumley, Frank Breckenridge, M.D.	153
Carter, Arthur Thomas, M.D.	172	Chung, In-Won, M.D., Ph.D.	167, 175
Carter, Dakota, M.D.	152	Chung, Moon Yong, M.D.	162
Carter, Debbie R., M.D.	136	Chung, Sang-Keun	167
Caruso, Keith A., M.D.	142	Chung, Seungwon, M.D.	161
Carvalho, Adriana, M.D., Ph.D.	143	Chung, Wilson, D.O.	153
Casey, Patricia R., M.D.	127	Chwastiak, Lydia, M.D., M.P.H.	143
Cassimatis, Emmanuel, M.D.	124, 125	Ciotoli, Carlo, M.D.	136
Cassin, Stephanie, Ph.D.	66	Citrome, Leslie, M.D., M.P.H.	127
Castellanos, Daniel, M.D.	83	Clarke, Diana E., Ph.D., M.Sc.	71, 84, 128, 129, 146
Castilla-Puentes, Ruby C., M.D., Dr.P.H.	126	Clayton, Anita	102
Castilla-Puentes, Wilma Ines, M.D.	60	Clemow, David B., Ph.D.	167
Castro, Carl, Ph.D.	145	Coccaro, Emil, M.D.	105
Caudill, Robert, M.D.	102	Coffin, Phillip O., M.D., M.A.	87
Cazares, Paulette, M.D., M.P.H.	70, 138	Coghill, David, M.D.	143
		Cohen, Carl I., M.D.	137

Presenters Index

Cohen, Jenna, B.A.	172	De Dios, Consuelo, M.D., Ph.D.	167
Cohen, Lisa J., Ph.D.	70	De Erausquin, Gabriel, M.D., Ph.D.	75
Cohen, Mary Ann A., M.D.	107	De Faria, Ludmila, M.D.	78
Cohen, Mitchell J., M.D.	143	De Graba, Thomas J., M.D.	143
Cole, Steven, M.D., M.A.	133	De Guzman, Earl Andrew B., M.D.	157
Collins, Ashley D., D.O.	159	Deirdre M. Ryan	60
Colombo, Francesca	105	DeJong, Sanda, M.D.	113
Colon, Omar A., M.D.	153	de Julio, Adriana B., M.D., M.Sc.	164
Colon-Rivera, Hector, M.D.	75, 101	Dela Cruz, Milania, M.D., M.P.H.	158
Compton, Wilson M., M.D.	106, 115	de la Gandara, Jose E., M.D.	83
Conant-Norville, David O., M.D.	77	Dell, Mary Lynn, D.Min., M.D.	62
Conrad, Rachel, M.D.	158	Dell'Osso, Bernardo, M.D.	167
Conroy, Michelle	104	DeMille, Steven M., Ph.D.	167
Conway, Kevin P., Ph.D.	106	DePaolo, Antonio, Ph.D.	71
Correa da Costa, Sabrina, M.D.	161	DePaulo Jr., J. Raymond, M.D.	79
Correale, Jennifer, J.D., Esq.	134	Dereczyk, Aimee, M.D.	157
Coryell, William, M.D.	145	Derish, Nicole E., M.D.	167
Costello, Caitlin, M.D.	104	DeRubeis, Laura, B.A.	164
Cournos, Francine, M.D.	117	Desai, Pratikumar, M.D., M.P.H.	159
Coverdale, John H., M.D.	113	Detweiler, Mark Budd, M.D., M.S.	142
Cox, Lara J., M.D., M.S.	65, 110, 126	Devanand, Davangere P., M.D.	86
Coyle, Colleen	116	Devassy, Cindy, M.D.	134
Craig, Thomas J., M.D.	77	Devlin, Michael, M.D.	80
Craig, Thomas K. J., Ph.D., M.B.B.S.	129	Dewan, Mantosh, M.D.	105
Crawford, Allison, M.D., M.A.	118	Dhaliwal, Arashinder, M.D.	153
Creed, Jamie O., B.S.	167	Dhillon, Kanwaldeep, M.D.	164
Cress, Kim K., M.D.	127, 167	Diamond, Diana, Ph.D.	79, 105
Crone, Catherine, M.D.	108, 135	Diaz, Esperanza, M.D.	83
Crumlish, Jennifer A., Ph.D.	108	DiBernardo, Allitia, M.D.	170
Cruz Alvarez, Beatriz, M.D.	164	Dickstein, Leah, M.D.	82
Cubells, Joseph F., M.D., Ph.D.	78	di Giacomo, Ester, M.D.	161
Cukor, Judith, Ph.D.	132	Dike, Charles C., M.D.	144
Cullen, Bernadette, M.B.	71	Dilley, James, M.D.	80
Cummings, Hugh, M.D.	62	Dimsdale, Joel E., M.D.	114
Curseen, Kim, M.D.	132	Dineen Wagner, Karen, M.D., Ph.D.	77
Cutler, Andrew J., M.D.	175	Di Nicola, Vincenzo, M.D., Ph.D.	118
Cutler, Andrew, M.D.	188	Divakarla, Swati, M.D.	153
Cyrus, Kali, M.D., M.P.H.	136	Dixon, Lisa B., M.D., M.P.H.	69
D			
Dager, Alecia D., Ph.D.	64	D'Mello, Dale, M.D.	175
Dakwar, Elias, M.D.	129	Doblin, Rick, Ph.D.	108
D'Aquila, Carolyn, L.C.S.W., M.P.H.	134	Docherty, John, M.D.	178
Darby, William C., M.D.	101, 114	Doghramji, Karl, M.D.	125
Dar, Syma, M.D.	145	Do, Linda, D.O.	143
Das, Smita, M.D., Ph.D.	88, 116, 117, 158	Dominguez, Matthew L., M.D., M.P.H.	65, 71, 78, 132, 136
Datta, Vivek, M.D., M.P.H.	136	Dong, Hyunseok, M.D., Psy.D.	172
Dave, Ananta, M.D.	76	Dooley, Erin, M.D.	153
Dave, Shalini D., D.O.	153	Douaihy, Antoine, M.D.	107, 137
Dave, Subodh, M.D.	76	Douglas, John, M.D.	84
Davidoff, Donald A., Ph.D.	60, 66	Doumas, Stacy J., M.D.	175
Davidowitz, Andrew, M.S.	153	Downing, Laura M., M.D.	157
Davidson, Deepak M., M.D.	153	Dragatsi, Dianna, M.D.	134
Davine, Jon S., M.D.	61	Dratcu, Luiz, M.D., Ph.D.	167
Davis, Steven Roy, M.D.	102	Dress, Erich M., B.S.	65
Deans, Emily C., M.D.	128	Dreyer, Benard, M.D.	108
Deas, Deborah, M.D., M.P.H.	78	Druss, Benjamin G., M.D.	135
		D'Souza, Deepak Cyril, M.D., M.B.B.S.	64, 85

Presenters Index

Dube, Anish R., M.D., M.P.H.	65, 101, 126	Feldman, Jacqueline M., M.D.	69
Duckworth, Ken, M.D.	69	Feldman, Lara W., D.O.	145
Duda, Roger, M.D.	138	Fernandez, Carlos, M.D.	164
Duffy, Farifteh F., Ph.D.	71, 146	Ferranti, Jessica, M.D.	146
Dukakis, Kitty	99	Ferrer, Daphne, M.D.	129
Dumas, Noel B.	102	Feusner, Jamie, M.D.	117
Dunlap, Constance E., M.D.	105	Figee, Martijn, M.D., Ph.D.	69
Durgam, Suresh, M.D.	175	Fils-Aimé, Joseph Reginald, M.D., M.Sc.	100
Dusad, Asha, M.D.	161	Fineberg, Naomi A., M.B.B.S.	69
Du, Ye B., M.D., M.P.H.	61	Fink, Sabina, M.D.	152

E

Earley, Willie, M.D.	175	Finlayson, A. J. Reid, M.D.	99
Eilender, Pamela, Psy.D.	112	First, Michael B., M.D.	100, 108, 130
Eisen, Jane L., M.D.	132	Fisher, Carl	127
Elefant, Erica, M.S.W., R.N.	175	Fiskin, Anna, M.D., M.Sc.	172
Elias, Alby, M.D., M.B.B.S.	71	Fitelson, Elizabeth, M.D.	78, 114
Elkady, Rasha, M.D.	153	Fjukstad, Katrine Kveli, M.D.	164
Ellison, James M., M.D., M.P.H.	60, 66	Flinton, Christopher, M.D.	143
El-Mallakh, Rif S., M.D.	142	Flora, Charles M., L.C.S.W.	86
Elmi, Sarah, M.D.	172	Flynn, David, M.D.	80
El Sara, Ammar, M.D.	153	Fochtman, Laura J., M.D.	77
Elswick, Daniel, M.D.	79	Fogelson, David L., M.D.	116
Enomoto, Kana	86	Foglesong, Dana, B.S.	117
Epstein, Igor, D.O.	157	Foidel, Sarah, O.T.R./L.	79
Epstein, Steve E., M.D.	135	Fong, Tim, M.D.	79, 85, 116
Erb, Alexis, M.D.	167	Foo, Calvin, B.Sc.	175
Erickson, Jennifer M., D.O.	164	Ford, Elizabeth, M.D.	115
Erickson-Schroth, Laura	75	Fore, Peter, M.D.	145
Eriksson, Hans	175	Forester, Brent, M.D., M.Sc.	60
Erlich, Matthew D., M.D.	66, 101, 126	Formella, Andrea, Pharm.D.	175
Ernst, Carrie L., M.D.	102	Forrester, Anique, M.D.	134
Escamilla, Kristin V., M.D.	167	Forstein, Marshall, M.D.	82, 101, 117, 132, 137
Espi Forcen, Fernando, M.D.	126	Forster, Janice, M.D.	87, 145
Eswonia, LeRoy C., B.S.	112	Fortuna, Lisa R., M.D., M.P.H.	77
Etwaroo, Narissa R.	153, 159	Foster, Norman L., M.D.	76
Eun, Tae Kyung, M.D.	160	Fournis, Gael, M.D.	161
Everett, Anita, M.D.	110, 112	Fowler, J. Christopher, Ph.D.	87
Everett, Mia, M.D.	101	Franco Cadet, Suhey G., M.D.	153
Evren, Cuneyt, M.D.	167, 168	Franco, Kathleen	109
Eyler, Evan, M.D.	64	Frangou, Sophia, M.D., Ph.D.	129

F

Faggen, Alec	153	Freedman, Robert, M.D.	91, 134
Fairbairn, Jonathan, M.D.	157	Freidl, Eve Khlyavich, M.D.	80
Fairman, Nathan, M.D., M.P.H.	125	Frieden, Tom, M.D., M.P.H.	118, 119
Falcone, Tatiana, M.D.	66, 109, 126	Fritz, Gregory K., M.D.	77
Fallu, Angelo, M.D.	168	Fromson, John A., M.D.	65
Famador, Mark, M.D.	117	Frueth, B. Christopher, Ph.D.	87
Fan, Qing, M.D., Ph.D.	168	Frye, Elizabeth A., M.D., M.P.H.	61, 104
Fareed, Ayman	112	Fryml, Leah D., M.D.	153
Farooq, Mobeen	153	Fu, Dong-Jing, M.D., Ph.D.	175
Farrell, Helen, M.D.	90	Fuehrlein, Brian S., M.D.	104
Faulkner, Larry R., M.D.	119, 124, 125	Fu, Emily, M.D.	153
Fauman, Beverly, M.D.	71	Fuller, Linda, D.O.	143
Fawcett, Jan, M.D.	82, 144	Fung, Kenneth P., M.D.	62, 78, 90
Fayad, Sarah M., M.D.	67	Fung, Wai Lun Alan, M.D., Sc.D.	62
		Funk, Margo, M.D., M.A.	109, 126, 145
		Furuta, Michelle, M.D.	143

Presenters Index

G

Gabbard, Glen O., M.D.	75, 104, 107, 113, 126, 136
Gache, Chris, M.D.	175
Gage, Fred H., Ph.D.	74, 80
Galanter, Marc, M.D.	65
Gallagher, Keith, M.D.	82
Galles, Elyse, B.A.	164
Galynker, Igor, M.D., Ph.D.	70, 144
Gandhi, Raghu, M.D., M.B.B.S.	158
Gandhi, Tanuja, M.D.	101, 109, 158, 160
Gao, Keming, M.D., Ph.D.	175
Garavan, Hugh, Ph.D.	64
Garrick, Marshall L., M.D.	142
Gatchel, Jennifer, M.D., Ph.D.	66
Gawande, Atul, M.D., M.P.H.	91
Gaytan Jr., Osvaldo, M.D., Ph.D.	76
Genova, Nicholas J., M.D.	164
George, Mark	99
George, Tony P., M.D.	106
Gerbarg, Patricia L., M.D.	106, 128
Gershengoren, Liliya, M.D., M.P.H.	158
Ghabrash, Maykel F., M.D., M.Sc.	176
Ghairatmal, Mohammad A.	172
Ghani, Shareh O., M.D.	88
Ghignone, Erica, M.D., M.A.	153
Ghimire, Shree Ram, M.D.	161
Ghiya, Deepti, M.D.	153
Gibbs, Ayana, M.D., Ph.D.	176
Giliberti, Mary, J.D.	86
Gillihan, Seth J., Ph.D.	105
Gilman, Megan L., M.D.	159
Ginory, Almari, D.O.	67, 71, 75, 90, 100
Ginory, Laura, M.D.	90
Gipson, Shih Yee-Marie Tan, M.D.	138
Giri, Aditi, M.B.B.S.	164
Gise, Leslie H., M.D.	67
Glancy, Graham D., M.B.	128
Glick, Ira, M.D.	90
Glick, Rachel, M.D.	69, 85
Glover, Juliet A., M.D.	164
Goddu, Sumana, M.D., M.P.H.	172
Goedken, Rebecca E., M.D.	160
Goelitz, Melissa, M.D.	86
Goethe, John W., M.D.	100
Goff, Donald C., M.D.	64
Gogineni, Rama Rao, M.D.	78, 80, 109
Goldbach, Jeremy, Ph.D.	145
Goldberg, Joseph F., M.D.	102
Goldenberg, Matthew N., M.D., M.Sc.	143, 176
Gold, Liza H., M.D.	135
Goldman, Matthew L, M.D., M.S.	136
Goldwasser, Alberto M., M.D.	117
Gomez, Chaska, Psy.D.	70
Gomez Fuentes, Amy C., M.D.	153
Gomez, Juan Carlos, Esq.	137
Gomez-Trigo Baldominos, Jesus, M.D.	161
Goniewicz, Maciej L., Ph.D., Pharm.D.	106
Goode, Kimberly D., A.A.S.	70
Goodman, Marianne, M.D.	84, 90, 128
Goodwin, Ericka, M.D.	108
Gopal, Srihari, M.D., M.H.S.	170, 176
Gordon, Kimberly, M.D.	67
Gorelick, David, M.D., Ph.D.	133
Gorrindo, Tristan, M.D.	110, 116
Goschin, Simona	83
Goswami Banerjee, Arpita, M.D.	153
Goyal, Dharmendra K., M.B.B.S.	153
Grace, Anthony A., Ph.D.	62
Graham, Yolanda P., M.D.	143
Gralnik, Leonard M., M.D., Ph.D.	143
Grammer, Geoffrey, M.D.	143
Grant, Cynthia, Ph.D., L.C.S.W.	101
Grassi, Giacomo, M.D.	69, 168
Gray, Kyle J., M.D., M.A.	112
Gray, Sheila Hafter, M.D.	108
Grebla, Regina, Ph.D., M.P.H.	176
Green, Alan I., M.D.	130
Greenbaum, Jordan, M.D.	143
Greer, Tracy, Ph.D.	144
Gregoire, Phillip, M.Sc.	160
Griffith, Ezra, M.D.	87, 106, 114, 138
Griffith, James, M.D.	62, 100
Grob, Charles, M.D.	83, 88
Gross, Raz, M.D., M.P.H.	176
Gruenberg, Linda F., D.O.	145
Gspandl, Scott, M.D.	160
Guanci, Nicole	101
Guerra, Paloma Andrea, M.D.	164
Gularte, Valeria Soares	161
Gunderson, John, M.D.	79, 84, 90, 113, 128
Gunturu, Sasidhar, M.D., M.B.B.S.	159
Guo, Qi, Ph.D.	168
Gupta, Neha, M.D.	153
Gupta, Nitin, M.D.	146
Gur, Raquel, M.D.	65
Gurski, John, D.O.	161
Guttikonda, Sameera, M.D.	152
Guzman, Margarita, J.D., M.B.	114

H

Habeych, Miguel, M.D., M.P.H.	167
Habl, Samar, M.D.	80, 132
Hackman, Ann, M.D.	82
Hagan, Jarred, D.O.	65
Hah, Jennifer, M.D., M.S.	115
Hairston, Danielle, M.D.	71, 117
Hales, Robert E., M.D.	113
Haller, Ellen, M.D.	75
Hall, Ryan, M.D.	109, 137
Halperin Rosen, Anna, M.D.	131
Haltzman, Scott, M.D.	101
Hamdani, Najma F., M.D., M.H.A.	153
Hameed, Ahmad, M.D.	173

Presenters Index

Iyer, Sharat P., M.D., M.S.	66, 107	Kang, Jee In	176
Iyer, Veeraraghavan J., M.D., M.B.B.S.	154	Kang, Suk-Hoon, M.D.	162
J			
Jabeen, Shagufta, M.D.	71	Kannali, Rajasekhar, M.D.	154
Jabri, Lamis, M.D.	164	Kantor, Edward, M.D.	85
Jackson, Timothy	66	Kaplish, Dheeraj, M.D.	164
Jacob, Karen L., Ph.D.	113	Kapoor, Shweta, Ph.D., M.B.B.S.	132
Jacob Mathai, Ashwin, M.D.	172	Karasic, Dan H., M.D.	64
Jacobs, Karen, D.O.	109	Karim, Reef, D.O.	79
Jacobson, William, Ph.D.	179	Karlsson, Per-Axel L., Ph.D.	168
Jahdi, Maryam, M.D., M.P.H.	160	Karnik, Niranjan, M.D., Ph.D.	75
Jain, Abhishek, M.D.	117, 137, 142	Kaster, Tyler, M.D.	168
Jain, Lakshit, M.D.	158	Kathol, Roger, M.D.	135
Jain, Rakesh, M.D., M.P.H.	188, 189	Kato, Takahiro A., M.D., Ph.D.	134
James, Christopher	159	Kaur, Amanjot, M.B.B.S.	172, 176
Janda, Kim D., Ph.D.	87	Kazmi, Ajmal, M.D., D.P.M.	144
Janicak, Philip G., M.D.	64, 127	Keefe, Richard, Ph.D.	115
Jayaram, Geetha, M.D.	82	Keenan, Walker Daniel, B.S.	159
Jenkins, Thomas, Ph.D.	87	Keith, Asheena, M.D.	117
Jennings, Keith W., Ph.D.	70	Kemble, Stephen B., M.D.	67
Jeon, Junwon, M.D.	172	Kendler, Kenneth, M.D.	106, 108
Jessica, Moore, M.D.	132	Kennedy, Patrick	105
Jeste, Dilip V., M.D.	76, 86, 104	Kennedy, Robert, M.D.	99, 112
Jett, Marti, Ph.D.	70	Kennedy, Sidney H., M.B.B.S.	129
Jha, Manish K., M.B.B.S.	144, 146, 172, 176	Kent, Justine M., M.D.	82
Ji, Ning	168	Kernberg, Otto F., M.D.	79, 105, 135
Joe, Soohyun	172	Kern, John, M.D.	79, 106, 130, 132
Johnson, David, M.D.	84, 127	Kertzner, Robert M., M.D.	132
Johnson, Sarah, M.D.	67	Ketchen, Bethany, Ph.D.	112
Johnston, Robert J. H., M.D.	154	Kethini, Vandana, M.D.	154
Joiner, Thomas, Ph.D.	70	Ketter, Terence A., M.D.	80, 168
Jones, Jana, Ph.D.	66	Khairalla, Hanan, M.D.	160
Jones, Megan, Pharm.D., M.P.A.	171	Khairy, Nahed, M.D.	162
Jones, Meissa M., M.S.	176	Khalafian, Andrey, M.D.	168
Jones, Travis W., M.D.	154	Khalid-Khan, Sarosh, M.D.	146
Jordan, Ayana, M.D., Ph.D.	71	Khalil, Afaf Hamed, M.D., Ph.D.	69
Jose, Divya E., M.D.	176	Khan, Christina Tara, M.D., Ph.D.	82
Joseph, Courtney, D.O.	154	Khan, Jaffar, M.D.	112
Joseph, Robert C., M.D., M.S.	82	Khan, Mohammed A., M.D.	117
Josephson, Allan, M.D.	144	Khan, Mohsin, M.D.	154
Joshi, Astik, M.D.	154, 159	Khan, Muhammad, M.D.	162
Joshi, Kaustubh G., M.D.	61	Khanna, Surbhi, M.B.B.S.	154
Joshi, Kruti, M.P.H.	170, 176	Khan, Qaiser S., M.D.	159
Joshi, Pallavi, M.A.	158	Khan, Sheema, M.D.	167
Joshi, Paramjit, M.D.	77	Khattak, Sohail, M.D.	176
Josiassen, Richard C., Ph.D.	176	Khawaja, Imran S., M.B.B.S.	64
Joy, Michelle, M.D.	128	Khawam, Elias, M.D.	145
Judge, Sheila, M.D.	129	Khosh-Chashm, Darrow, M.D.	160
Jung, Chan Hyun, M.D.	164	Khushalani, Sunil, M.D.	71, 76, 83, 142
Jun, Tae-Youn, M.D., Ph.D.	110, 162	Khusid, Marina, M.D.	83
K			
Kakhi, Sara, M.D.	162	Kidd, Jeremy D., M.D., M.P.H.	131, 158
Kallivayalil, Roy Abraham, M.D.	129	Kilani, Jyotsna, M.D.	154
Kalnik, Matthew W., Ph.D.	114	Kim, Chaeri	176
Kanba, Shigenobu, M.D., Ph.D.	113, 134	Kim, Chan-Hyung, M.D., Ph.D.	170
		Kim, Chul-Eung, M.D., Ph.D.	168
		Kim, Daniel, M.D.	109
		Kim, Daseul, M.D.	164
		Kim, Eun Young, M.D., Ph.D.	168

Presenters Index

Lewis, Edward Thomas, M.D.	158	Maj, Mario, M.D., Ph.D.	128
Lewis-Fernandez, Roberto, M.D.	78, 83, 88, 101	Makani, Ramkrishna D., M.D., M.P.H.	160
Lewy, Alfred J., M.D.	66	Makanjuola, Titilayo, M.D.	165
Lichtenstein, Max A., M.D.	155	Maldonado, Jose R., M.D.	64, 69, 80, 109, 126, 131
Licinio, Julio, M.D.	116	Maletic, Vladimir, M.D.	189
Li, Dongmei, M.A.	177	Malik, Arsalan, M.D.	143
Li, Eun Jung, M.D.	165	Malik, Mahgul, M.D.	137
Li, Kevin J.	155	Maloy, Katherine, M.D.	69
Li, Luming, M.D.	165	Maltz, Brenda, M.A., R.N.	66
Lima, Ateaya, M.D.	112	Malveaux, Wilsa M. S. Charles, M.D., M.A.	127
Lim, Jongseok	165	Manalai, Partam, M.D.	177
Lim, Russell F., M.D., M.Ed.	88, 113	Mancevski, Branislav, M.D.	110
Lindenmayer, Jean-Pierre, M.D.	118, 169, 177	Mangal, Jed P., M.D.	61
Lin, Joy E., B.S.	160	Mangiardi, Mario, M.D.	155
Links, Paul	79	Mann, Gurtej S., M.D.	177
Lipsitt, Don, M.D., M.A.	82	Manning, James Sloan, M.D.	189
Li, Shuang, M.D., Ph.D.	177	Manocha, Pankaj, M.D.	173
Lisotto, Maria Jose, M.D.	78	Mao, Alice R., M.D.	77
Liu, Lusha, M.D.	87	Marazziti, Donatella, M.D.	177
Liu, Shiyuan, B.A.	165	Marcus, Adeyemi, M.D.	155
Liu, Zhaorui, M.D., Ph.D., M.P.H.	169	Marder, Stephen R., M.D.	64, 83, 88
Lizano, Paulo L., M.D., Ph.D.	169	Mariani, John J., M.D.	129
Lluberes Rincon, Nubia G., M.D.	142	Marino, Leslie, M.D., M.P.H.	66
Lochhead, Jeannie, M.D.	160	Marino, Patricia, Ph.D.	126
Loehr, Colleen, M.D.	67	Markkula, Niina, M.D., M.Sc.	177
Loewen, Gordon R., Ph.D.	177	Markovitz, Paul J., M.D., Ph.D.	117
Lohitsa, Akshay, M.D.	131	Markowitz, John C., M.D.	79
Lokko, Hermioni, M.D., M.P.P.	158	Markx, Sander, M.D.	102
Lolak, Sermsak, M.D.	132	Marlin, Robert P., M.D., Ph.D., M.P.H.	83
Lomax, James W., M.D.	62, 107, 108, 130	Marmar, Charles R., M.D.	70
López-Jaramillo, Carlos, M.D., Ph.D.	169	Martinez, Richard	118
Lowenthal, David, M.D., J.D.	83	Martin, Glenn, M.D.	85
Lowy, Daniel L., L.C.S.W.	134	Martino, Steve, Ph.D.	105
Lubarda, Jovana, Ph.D.	177	Martz, Gloria, D.O.	155
Lubin, Molly, M.D.	85	Marumoto, Megan, M.D.	146
Lu, Francis, M.D.	62, 88, 113, 119, 124, 134, 137	Maruyama, Nancy, M.D.	83
Luo, John, M.D.	82, 99, 112	Mashiana, Amanpreet K., B.S.	158
Luskin, Shari I., M.D.	60	Maskel, Lynn, M.D.	102
Lynch, Alison J., Esq.	128	Mathur, Anu, M.D.	71
Lytle, Sarah M., M.D.	169	Mattingly, Greg, M.D.	169
M			
MacDonald, Kelly, M.D.	165	Mattingly, Gregory W., M.D.	190
MacKenzie, James G., D.O.	145	Maududi, Syed E., M.D.	155
Mackey, Sean, M.D., Ph.D.	115	Mayberg, Helen, M.D.	130
MacLeod, Stephanie, M.Sc.	100	May, Catharine S., M.D.	85
Madan, Alok, Ph.D., M.P.H.	87	Mazhar, Mir N., M.D.	169
Madhusoodanan, Subramoniam, M.D.	169	McBurnett, Keith, Ph.D.	169
Madsen, Helle, M.D.	177	McCabe, Sean Esteban, Ph.D.	136
Maeng, Se-Ri, M.D.	169	McCarron, Robert M., D.O.	67, 80, 86, 137
Mago, Rajnish, M.D.	177	McClure, Deimante, B.A.	173
Maguire, Gerald A., M.D., DFAPA	190	McCracken, James T., M.D.	83, 88
Mahdanian, Artin, M.D.	65, 155	McDonald, William M., M.D.	86
Mahendran, Rathi, M.Ed., M.Med.	162	McDougall, Matthew A., M.D.	160
Maher, John, M.D.	84	McDuff, David R., M.D.	65
Maheshwari, Subani, M.D.	159	McGinnis, MegAnn Kay, B.S.	177
Mahoney, Nicholas, D.O.	165	McGlynn, Lawrence, M.D., M.S.	82, 107, 137
		McGovern, Amanda, Ph.D.	126
		McGraw, Kate, Ph.D.	138

Presenters Index

McHugh, Paul, M.D.	77	Moreira-Almeida, Alexander, M.D., Ph.D.	144
McIntyre, Roger S., M.D.	77, 177	Moreno, Maria E., M.D.	155
McKenzie, Kwame, M.D.	62	Morgan, Theresa A., Ph.D.	126
McLeod, Megan, M.D.	165	Morris, Sapna B., M.D., M.B.A.	104
McMickens, Courtney L., M.D., M.P.H.	61, 101	Morse, Michael D., M.D., M.P.A.	100
McNeil, Shawn E., M.D.	155	Moscicki, Eve, Sc.D., M.P.H.	71
McNiel, Dale E., Ph.D.	74, 88	Mosier, Jessica, M.D.	126
McVoy, Molly, M.D.	67	Moukaddam, Nidal, M.D., Ph.D.	118
Medici, Clara Reece, B.S.	165	Moussaoui, Driss, M.D.	69, 78, 129
Medlock, Morgan, M.D.	102	Moutier, Christine, M.D.	136
Melicher, Tomas, M.D.	155	Mruthyunjaya, Pranathi, M.D.	153
Mellon, Synthia H., Ph.D.	70	Mudgway, Ross J.	173
Meltzer, Herbert Y., M.D.	115	Munjal, Sahil, M.D.	80, 155, 165
Mendiola, Andrea, M.D.	177	Munnangi, Lakshmi Priya, M.D.	162
Merlo, Lisa J., Ph.D.	71	Murphy, Dewey S., M.D.	155
Metzner, Jeffrey L., M.D.	88, 98, 100, 119, 128	Murphy, James, M.D.	76, 136
Meyer-Bahlburg, Heino F. L., Ph.D.	64	Murray, Robin M., M.D.	69
Meyer, Donald J., M.D.	82	Muser, Erik, Pharm.D., M.P.H.	170
Meyer, Eric, M.D.	166	Muskin, Philip R., M.D., M.A.	82, 83, 116
Miccio, Steve, B.A.	85	Muszynski, Irvin L., J.D.	112, 116
Miday, Karen K., M.D.	131	Myers, Michael F., M.D.	118, 131, 136
Mihajlovic, Aida Spahic, M.D., M.S.	71, 173	Myers, Trenton, M.D.	155
Millard, Hun, M.D.	134	Myers, Wade C., M.D.	104
Millegan, Jeffrey, M.D., Ph.D.	169		
Miller, Adam, M.D.	69	N	
Miller, Andrew, M.D.	99	Nadelson, Carol C., M.D.	129
Miller, Gregory, M.D., M.B.A.	101	Naeem, Farooq, Ph.D., M.Sc.	62, 134
Miller, Shefali, M.D.	80	Nagalla, Madhavi, M.D.	112
Mills, Jacob, B.S.	131	Nagurney, Michelle, M.D.	78
Milrod, Barbara, M.D.	67	Nam, Yoonmin	173
Minhas, Hassan M., M.D., M.B.B.S.	126	Narasimhan, Meera, M.D.	102
Mintz, David L., M.D.	80, 106	Nardi, Antonio E., M.D., Ph.D.	169
Mischoulon, David, M.D., Ph.D.	115	Nascimento, Antonio L., M.D., M.Sc.	178
Misri, Shaila, M.D.	60	Nash, Maureen C., M.D., M.S.	79
Mistry, Amit, M.D.	155	Nasrallah, Henry A., M.D.	79, 99, 127, 178, 188, 189
Mitra, Paroma, M.D., M.P.H.	155	Nasrulla, Insiya, M.B.B.S.	165
Moamai, Javad, M.D., M.Sc.	169	Nassan, Malik, M.B.B.S.	115, 173
Moffic, H. Steven, M.D.	78, 86, 105, 118	Navarro, Aniceto, M.D.	61
Mogallapu, Raja, M.D.	155	Naveen, M. M., M.D.	159
Moghimi, Yavar, M.D.	137	Neff, Daniel, M.D.	126
Mohite, Satyajit, M.D., M.P.H.	169, 177	Negbenebor, Nicole, B.S.	169
Mohyuddin, Farooq, M.D., M.B.B.S.	105	Neller, Robert B., Gen.	130, 131
Mohyuddin, Hira	173	Nelson, Christopher, M.D.	88
Mokrani, Marie-Claude, Ph.D.	167, 169	Nelson, Sally, M.Ed., R.N.	146
Molaie, Ali M., B.A.	177	Nemeroff, Charles B., M.D., Ph.D.	77
Moller, Hans-Jurgen, M.D.	114	Nepal, Hitekshya, M.D.	173
Monahan, John, Ph.D.	98, 110	Neramballi, Malini, M.D.	165
Montalvo, Cristina, M.D.	101	Netherton, Elisabeth, M.D.	61
Montano Arteaga, Pamela C., M.D.	78	Neufeld, Ron, Ph.D.	99
MontazerAlghaem, Douna, M.D.	173	New, Antonia S., M.D.	105
Montenegro, Roberto E., M.D., Ph.D.	90	Newmark, Thomas, M.D.	78
Montoya, Ivan D., M.D., M.P.H.	114	Ng-Mak, Daisy S., Ph.D.	178
Montoya, Ivan D., M.D., Ph.D.	86	Nguyen, Sarah A., M.D.	173
Mooney, Larissa	79	Nicolas, Samuel A., M.D.	173
Moore, Kevin D., M.D.	102, 142	Nielsen, Rebecca Z., M.Sc.	178
Moore, Lauren E., M.D.	155	Nijjar, Gursharon, M.D.	173
Moosey, Matthew, M.S.	136	Nikiforov, Ivan, M.D.	169

Presenters Index

Nikzad, Vahid, M.D.	155
Ni, Michael, M.B.B.S., M.P.H.	142, 162
Nisar, Mohammad Asim, M.D.	145
Nissan, David A., M.D.	100, 132
Nissirios, Kalliopi S., M.D.	157, 160
Nitturkar, Abhishek R., M.B.B.S.	155
Niu, Grace C., Ph.D.	60
Niu, Kathy, M.D.	162
Nivet, Marc	110
Nordon, Clementine, M.D., Ph.D.	162
Nordstrom, Kimberly D., M.D., J.D.	99
Norko, Michael, M.D., M.A.	106
Norquist, Grayson, M.D.	86
Norris, Donna M., M.D.	119
Notman, Malkah T., M.D.	82, 129
Nowicki, Stephen, Ph.D.	67
Nunes, Edward V., M.D.	62, 129
Nurmi, Erika L., M.D., Ph.D.	83, 87
Nusair, Furqan, M.B.B.S.	158
Nwankwo, Vincent N., M.B.B.S.	155

O

Obi Berry, Obianuju “Uju”, M.D., M.P.H.	114
O’Brien, Virginia, M.D.	86
O’Gorman, Cedric, M.D.	171
Okereke, Olivia I., M.D., S.M.	115
Okoronkwo, Joshua	162
Okuda, Mayumi, M.D.	101, 114
Okwesili, Meredith A., M.D.	109
Olarte, Silvia W., M.D.	86
Oldham, John M., M.D., M.S.	87, 127, 135, 146
Olson, David P., M.D., Ph.D.	66
Olupona, Tolu, M.D.	145
Ong, Christopher F., M.D.	90
Oquendo, Maria A., M.D.	91, 113, 119, 127
O’Reardon, John P., M.D.	78
Orr, Matt, Ph.D.	142
O’Shaughnessy, Roy, M.D.	98, 117
Osher, Fred C., M.D.	114
Osman, Ekatherina, D.O.	160
Osman, Ossama Tawakol, M.D.	69, 163
Osofsky, Howard J., M.D., Ph.D.	146
Osório, Flávia L.	162, 163
Ospina Duque, Jorge, M.D.	169
Ouanes, Sami, M.D.	173
Ouellette, P. Lynn, M.D.	82
Owen, Andrew, M.S.	155
Owens, Samuel M., Ph.D.	114
Ozbayrak, R. Kaan, M.D., M.B.A.	101
Ozdemir, Armagan	178
Ozel-Kizil, Erguvan T., M.D.	178

P

Padilla Candelario, Auralyd, M.D.	67, 90
Padilla, Vanessa, M.D.	177
Pai, Nagesh, M.D.	169
Palazzolo, Jerome, M.D., Ph.D.	163
Pallanti, Stefano, M.D., Ph.D.	69
Palmer, Brian, M.D., M.P.H.	79, 84, 90
Pandey, Ghanshyam N., Ph.D.	77
Pao, Maryland, M.D.	135
Pardes, Herbert, M.D.	102
Parekh, Ranna, M.D., M.P.H.	90, 109
Parikh, Niketa, B.S.	167
Parikh, Tapan, M.D., M.P.H.	160
Park, Bhinna Pearl, M.D.	134
Park, Dongchan, M.D.	85
Park, Hyemi, M.D.	163
Park, Jiyeon (Regina)	178
Park, Jong-Il, M.D., Ph.D.	167, 171
Park, Sa Eun, M.D.	157
Park, Seon-Cheol	170
Parks, Joseph, M.D.	135
Parmar, Arpit, M.D., M.B.B.S.	163
Parsaik, Ajay, M.D., M.S.	160
Pary, Robert J., M.D.	87
Pashko, Steven, Ph.D.	170
Pasternak, Gavril, M.D., Ph.D.	87
Patel, Ankur, M.D.	170
Patel, Erin L., Psy.D.	71
Patel, Mitesh, M.D.	155
Patel, Rachit, M.D.	170
Patel, Rahul Kumar, M.D., M.P.H.	161
Patel, Ronak, M.D.	155
Patel, Ruchirkumar Arvind, M.B.B.S.	173
Patel, Rupal, M.B.B.S.	163
Patel, Shama, M.D.	143
Patel, Shirali S., M.D.	61
Pate, R. Jill, M.D.	71
Pato, Michele T., M.D.	110
Patriquin, Michelle, Ph.D.	87
Paudel, Shreedhar, M.D., M.P.H.	165
Pazuniak, Markian, M.D.	155
Pearlson, Godfrey D., M.D.	64, 129
Pelka, Bryan M., M.D.	108
Pender, Vivian, M.D.	129, 134
Pendler, Paul, Psy.D.	137
Penesetti, Deepak, M.D.	71
Pengrin, Lauren, D.O.	158
Penninx, Brenda W., Ph.D.	82
Penn, Joseph V., M.D.	77
Penska, Keith, M.D.	70
Penumetcha, Varma, M.D.	158
Penzner, Julie B., M.D.	100
Pereira, Luis, M.D.	155
Perez-Rodriguez, M. Mercedes, M.D., Ph.D.	105, 178
Periclou, Antonia, Ph.D.	178
Perkins, Matthew B., M.D., M.P.H.	101

Presenters Index

Robinson, Gail Erlick, M.D.	79, 110, 129	Santiago, Vincent A., B.Sc.	163
Robles Martínez, María	165	Santos, Eric, M.D.	156
Robles-Ramamurthy, Barbara, M.D.	101, 126	Sapieha, Michal, M.D.	137
Roca, Robert, M.D., M.P.H.	71, 118	Saragoussi, Delphine, M.D., M.P.H.	170
Rodin, Rebecca, M.Sc.	165	Sarhan, Walid, M.D.	144
Rodriguez-Cabezas, Lisette, M.D.	90	Sarikaya Varlik, Dilek, M.D.	174
Rodriguez-Guzman, Juan, B.S.	173	Satcher, David, M.D., Ph.D.	105
Rodriguez, Lorena, M.D.	165	Sattar, Ayesha, M.D., M.B.B.S.	156
Rodriguez-Roman, Laura, M.D.	156	Sauve, William, M.D.	178
Roman, Daniel O., M.D.	156	Savu, Vasile, M.D.	159
Roma, Rebecca S., M.D.	188	Saxena, Ashwini, M.D., Ph.D.	178
Romba, Courtney Ann, M.D.	165	Saxon, Andrew J., M.D.	88, 106, 116
Ronningstam, Elsa F., Ph.D.	61	Scahill, Lawrence, Ph.D., M.S.N.	78
Roof, Jason, M.D.	146	Schaaf, Kathy, B.Sc., R.N.	104
Rosenbaum, Jerrold F., M.D.	101, 102	Schatzberg, Alan F., M.D.	77, 105, 125
Rosenblat, Joshua D., M.D.	178	Scheiber, Stephen C., M.D.	104
Rosenheck, Robert, M.D.	144	Schiff, Miriam, Ph.D.	145
Rosenquist, Peter B., M.D.	125	Schindzielorz, Adam H., M.D.	156
Rosenthal, Richard N., M.D., M.A.	104, 178	Schlozman, Steven, M.D.	67
Rose, Raquel E., B.S.	178	Schmahl, Christian, M.D.	135
Roskes, Erik, M.D.	128	Schmidt, Luisa C., M.D.	178
Rostain, Anthony, M.D.	106, 133	Schmidt, Scott, D.O.	112
Rothbaum, Barbara, Ph.D.	75	Schneider, Brett, M.D.	112
Rothe, Eugenio M., M.D.	137	Schneidman, Barbara S., M.D., M.P.H.	75
Rothenberg, Kasia Gustaw, M.D., Ph.D.	163	Schnellbacher, Sebastian, D.O.	66, 82
Rotter, Merrill, M.D.	114	Schott, Meghan, D.O.	165
Rovner, Barry, M.D.	115	Schuermeyer, Isabel, M.D., M.S.	109
Roy, Arunima, M.B.B.S.	165	Schulz, S. Charles, M.D.	107
Roy III, Alphonse Kenison, M.D.	65, 76	Schwartz, Ann, M.D.	112, 132
Roy, Kamalika, M.D.	126, 156	Schwartz, Patricia, M.D.	69, 134
Rozel, John S., M.D.	104, 142	Schwartz, Thomas L., M.D.	143
Ruedrich, Stephen, M.D.	87	Schwartz, Victor, M.D.	76, 136
Ruiz, Amanda, M.D.	132	Scoggin, Steven, Psy.D.	62
Ruiz, Pedro, M.D.	109, 137	Scott, Charles, M.D.	146
Rumbaugh, William D. Jr., M.D.	136	Scully, Stephenie A., M.D.	174
Russ, Mark J., M.D.	100	Secarea, Cristina M., M.D.	165
Ryan, Deirdre M., M.B.	60	Sederer, Lloyd I., M.D.	113
S		Seegan, Alexis A., M.D.	129, 156
Sabatello, Maya, Ph.D., LL.B.	135	Segal, Andrea G., M.S.	65
Sachdeva, Shilpa, M.D.	173	Seibell, Phillip J., M.D.	65
Saeed, Aliya, M.D.	115, 116	Seibyl, John, M.D.	76
Saeed, Sy A., M.D., M.S.	105	Seo, Wan-Seok, M.D., Ph.D.	170
Safar, Laura, M.D.	110	Serfaty, Marc A., M.D., M.B.B.S.	100
Safin, Daniel, M.D.	83	Serhal, Eva, M.B.A.	118
Sahu, Geetanjali, M.B.B.S.	165	Serrano, Patricia, M.D.	156
Sajatovic, Martha, M.D.	170, 178	Serrano-Villar, Maria, M.S.	179
Salerno, Karen E., M.S.W.	145	Sethi Dalai, Shebani, M.D., M.S.	160
Salgado, Cassandra, M.D., M.S.	85	Seth, Saagar, B.S.	167
Samalin, Ludovic, M.D.	78	Setlow, Barry, Ph.D.	61
Sampathgiri, Kruthika, M.D.	156	Severe, Jennifer, M.D.	71, 101, 157
Samsel, Chase, M.D.	146	Shah, Apeksha, M.B.B.S.	156
Samuels, Susan, M.D.	66	Shah, Asim, M.D.	61, 118
Sánchez-Gómez, Pedro M., M.D.	163	Shah, Pooja, M.D.	161, 165
Sanchez, Katherine, Ph.D., L.C.S.W.	144	Shah, Ravi N., M.D., M.B.A.	136
Sanchez-Rivero, Yuliet, M.D.	90	Shah, Saloni, B.S.	162
Sanislow, Charles A., Ph.D.	128	Shahzadi, Ulfat, M.D., M.B.B.S.	163
		Shakeri, Jalal, M.D.	170

Presenters Index

Shao, Wanda, D.O.	156	Soloway, Scott, M.D.	134
Shapiro, Anna P., B.A.	156	Song, Jaemin, M.D.	170
Shapiro, Edward R., M.D., M.A.	106	Sood, Shabnam, M.D.	171
Shapiro, Gabrielle L., M.D.	76	Sorel, Eliot, M.D.	105
Sharfstein, Steven S., M.D., M.P.A.	61, 67, 71, 76, 105, 110, 116, 119	Sorrentino, Renee, M.D.	117, 137
Sharma, Ashish, M.D.	156	Sosunmolu, Shoyinka O., M.D.	144
Sharma, Shridhar, M.D., D.P.M.	78	Spencer, Andrea E., M.D.	166
Sharon, Haggai, M.D.	165	Sperber, Jacob, M.D.	71, 90
Sharp, Carla, Ph.D.	87, 128	Sperry, Len, M.D.	144
Shayanpour, Mahrokh, M.D.	174	Spiegel, David, M.D.	126
Shear, Matthew, M.D.	66, 90	Spokas, Laima, M.D.	156
Sheehan, David V., M.D.	69	Spollen, John, M.D.	143
Sheehan, Kathleen, M.D., Ph.D.	143	Spoth, Richard, Ph.D.	136
Sheehan, Matthew M., B.A.	156	Sreepathi, Ananya R., M.D.	156
Sheikh, Sarah, M.D.	156	Sreshta, Nina E., M.D.	83
Sheline, Yvette, M.D., M.S.	75, 76	Srinivasan, Shilpa, M.D.	108, 142
Shenava, Manisha, M.D.	156	Srinivasaraghavan, Jagannathan, M.D.	113
Sher, Leo, M.D.	88, 130, 170	Stahl, Stephen M., M.D., Ph.D.	98, 100, 114, 127, 190, 197
Sherman-Stokes, Sarah R., J.D.	83	State, Matthew, M.D.	74, 84
Sher, Yelizaveta, M.D.	64, 82	Stein, Aliza T., B.A.	126
Shim, Ruth, M.D., M.P.H.	112, 127	Steinberg, Leah R., M.D.	166
Shim, Se-Hoon, M.D., Dr.P.H.	179	Steinberg, Louisa J., M.D., Ph.D.	132
Shindler, Maria L., M.S.N.	79	Stepp, Stephanie, Ph.D.	128
Shivaneekar, Sharvari P., M.D.	174	Sterling, Stacy, M.P.H., M.S.W.	90
Shore, Jay, M.D., M.P.H.	102	Stern, Barry L., Ph.D.	127
Short, Jessica M., D.O.	159	Stern, Stephen L., M.D.	170
Shrivastava, Amresh, M.D.	77, 146, 170	Stewart, Altha J., M.D.	85, 126
Shtasel, Derri, M.D., M.P.H.	102	Stokes, Wesley N., Psy.D.	70
Shuara, Saoda, M.D.	156	Stone, Alan, M.D.	113
Shulman, Barbara, M.D.	60	Stone, Alice E., M.D.	174
Sidaros, Rafik, M.D.	159	Stotland, Nada L., M.D., M.P.H.	80, 107, 108, 129
Siegele, Harry, B.S.	77	Strain, James J., M.D.	127
Sierzchula, Jessica J., D.O.	174	Stratton, Tyler E., M.D.	138
Silk, Kenneth R., M.D.	84, 90, 130, 135	Stubbeman, William F., M.D.	179
Silverman, Joel J., M.D.	77	Stupinski, John, B.A.	156
Simkin, Deborah R., M.D.	109	St. Victor, Guitelle, M.D.	90, 112
Simon, Kevin M., M.D.	61	Subedi, Jagannath, M.D.	170
Simpson, Annabelle K., M.D.	71	Subhash, Ajith	174
Singh, Balwinder, M.D., M.S.	158, 159, 160, 165	Subramaniam, Geetha A., M.D.	90
Singh, Gurjot, M.D.	156	Sudak, Donna M., M.D.	82, 117
Singh, Harvinder, M.D.	163	Sugumar, Archana, M.B.B.S.	158
Singh, Jasbir, M.D.	156	Suh, HwaGyu, M.D.	172
Sinha, Preeti, M.D.	100	Sultan, Ryan S., M.D.	166
Siragusa, Joseph, M.D.	158	Summergrad, Paul, M.D.	80, 91, 108, 114, 135
Sisti, Dominic, Ph.D.	65, 88, 108	Summers, Richard F., M.D.	113, 125
Sivrioglu, Yusuf, M.D.	60	Sung, Dawn, M.D.	174
Sjöstrand, Hanna, M.D.	165	Sung II, Jung	179
Skolnick, Phil, Ph.D.	86, 114	Sung, Victor, M.D.	179
Small, Gary W., M.D.	86	Suo, Shannon, M.D.	67
Smith, Mary Kay, M.D.	82	Suryadevara, Uma, M.D.	61
Smith, Paula Marie, M.D.	90	Susaimanickam, Bibiana M., M.B.B.S.	174
Snyder, Elise, M.D.	86	Susser, Leah, M.D.	156
Sockalingam, Sanjeev, M.D.	66, 118, 135, 143	Suzuki, Amanda, M.D.	159
Sohn, Sungyun, M.D.	174	Swann, Alan C., M.D.	179
Sola, Christopher, D.O.	145	Swanson, Jeff O., M.D.	110
Soldinger, Steve, M.D.	143	Swartz, Marvin S., M.D.	82, 114, 132

Presenters Index

Swiggart, William H., M.S.	99	Tseng, Mei-Chih M., M.D., Ph.D.	171
Syed, Sharif	158	Tsuang, John W., M.D.	79
Szerman, Nestor, M.D.	130	Tucci, Veronica, M.D., J.D.	118
T			
Tafet, Gustavo E., M.D., Ph.D.	77	Tuck, Andrew N., B.Sc.	179
Takahashi, Hidetoshi, M.D., Ph.D.	170	Tucker, Phebe M., M.D.	75, 179
Takayesu, Alexandra, M.D., M.P.H.	169	Turkingdon, Douglas, M.D.	60
Talbott, John A., M.D.	78	Turner, Ana, Ph.D.	61
Tamburello, Anthony	128	Turner, Andia H., B.Sc.	160
Tampi, Rajesh R., M.D., M.S.	64, 160, 163	U	
Tandon, Rajiv, M.D.	64	Ucok, Alp, M.D.	179
Tapias, Rafael E., M.D.	159	Ulaj, Jusuf S., M.D.	145
Tardelli, Vitor S., M.D.	174	Umrana, Hiren, M.D.	179
Tarman, Daniel Drew, M.D., M.Eng.	179	Unützer, Jürgen, M.D., M.P.H.	135
Tarshis, Thomas P., M.D., M.P.H.	171	Uzal Fernandez, Cristina, M.D.	163
Taube-Schiff, Marlene, Ph.D.	66	V	
Taylor-Desir, Monica, M.D., M.P.H.	112	Vaaler, Arne E., M.D., Ph.D.	70
Taylor, Doug, M.B.A.	174	Van Ameringen, Michael, M.D.	171
Taylor, Geoffrey P., M.D.	83	Vanderlip, Erik, M.D., M.P.H.	107, 132, 143
Taylor, Jared K., M.D.	132	Vannucci, Adriana, M.D.	171
Taylor, Jerome H., M.D.	101	Vargas Cruz, Cindy, M.D., M.B.A.	67
Tegin, Cuneyt, M.D.	156	Varghese, Celia, M.D.	157
Tendler, Aron, M.D.	179	Varlik, Cenk, M.D.	171
Teo, Alan R., M.D., M.S.	134	Vasan, Nina, M.D.	, 86
Thakrar, Tina S., M.D., M.B.A.	174	Vaughn, Rubiahna, M.D., M.P.H.	117
Thangaraj, Swaminathan, D.O.	156	Vela, Ricardo M., M.D.	109
Thase, Michael E., M.D.	60, 171	Velliz, Philip, Ph.D.	136
Thelen, Mindi	143	Vemuri, Divya, M.D.	157
Thelen, Tim	143	Venigalla, Hema, M.B.B.S.	174
Thiam, Melinda A., M.D.	70	Verduin, Marcia L., M.D.	82
Thiara, Gurmeet S., M.D.	60, 166	Vergare, Michael J., M.D.	77
Thielman, Samuel, M.D., Ph.D.	144	Verma, Chittranjan B., M.D.	157
Thomas, Anil A., M.D.	62	Vermetten, Eric, M.D., Ph.D.	70
Thomas, Christopher R., M.D.	113	Vevera, Jan, M.D., Ph.D.	179
Thomas, Connie, M.D.	84	Vieta, Eduard, M.D., Ph.D.	131
Thomas, Jean M., M.D.	108	Vijapura, Sagar, M.D.	166
Thompson, Kenneth, M.D.	80, 108, 129	Vinacour, Carlos, M.D.	171
Thompson, Sonda, M.S.N.	70	Vinogradov, Sophia, M.D.	107, 115
Thompson, William W., Ph.D.	117	Vinson, Sarah Y., M.D.	87, 127
Tillman, Jane G., Ph.D.	138	Viswanathan, Ramaswamy, M.D.	113
Timmons-Mitchell, Jane C., Ph.D.	126	Vito, Jose, M.D.	62, 166
Titcombe-Parekh, Roseann F., M.D., Ph.D.	174	Vo, Lan Chi Krysti L., M.D.	78
Tobkes, Taylor, M.D.	157	Volkow, Nora, M.D.	69, 127
Toledo, Theresa	134	Volman, Susan F., Ph.D.	62
Toll, Alba, M.D.	166	von Hafften, Alexander H., M.D.	102
Torbey, Souraya, M.D.	157, 159	Vora, Ankita, M.D., M.P.H.	157
Torous, John, M.D.	99, 112, 138	W	
Torres Vilamajó, Imma, Psy.D., M.B.A., M.Sc.	166	Wager, Tor, Ph.D.	115
Trager, Evan J., M.D.	174	Wainberg, Milton, M.D.	100
Tran, David, M.D., M.P.P.	166	Waits, Wendi, M.D.	82, 136, 146
Tran, Shelly T., M.D.	159	Walaszek, Art, M.D.	113
Trestman, Robert L., M.D., Ph.D.	66, 88, 114, 128	Waldman, Randee, Esq.	87
Trevisan, Louis, M.D., M.Ed.	64	Walker, Anitra, L.C.S.W.	104
Trimble, Michael, M.D.	74, 75	Walker, Melissa, M.A.	143
Trivedi, Madhukar, M.D.	144	Walker, Sandra C., M.D.	132
Truong, Anh L., M.D.	174		

Presenters Index

Wallack, Joel J., M.D.	83	Winstead, Daniel K., M.D.	119
Walsh, B. Timothy, M.D.	80	Winter, Christine A., D.O., M.B.A.	134
Wang, Dana, M.D.	87	Wise, Thomas N., M.D.	135
Wang, Dora, M.D., M.A.	107	Wiste, Anna K., M.D., Ph.D.	166
Wang, Jack, D.O.	159	Wittenberg, Gayle M., Ph.D.	82
Wang, Paul, M.D.	78	Witter, Daniel, M.D., Ph.D.	157
Wang, Philip, M.D., Dr.P.H.	112, 128, 128, 86	Wnuk, Susan, Ph.D.	66
Wang, Po, M.D.	80	Wolf, Jonathan P., M.D.	143
Wang, Shao-Cheng, M.D., Ph.D.	166	Wolf, Kari M., M.D.	84, 144
Ward, Herbert, M.D.	100	Wong, Donovan	86
Ward, Martha C., M.D.	112, 132, 179	Wonodi, Ikwunga, M.B.B.S.	144
Warner, Christopher H., M.D.	145	Woo, Benjamin, M.D.	144
Warnick Jr., Stephen J., M.D.	126	Wood, Keith, M.D.	166
Wasser, Tobias, M.D.	106, 118	Woolley, Stephen, D.Sc.	84
Watson, Clarence	128	Works, Lindsay, D.O.	166
Webb, Allison, M.D.	65	Worley, Linda L. M., M.D.	99
Weber, Jenine, D.O.	158	Wrenn, Glenda, M.D.	61
Weiller, Emmanuelle	179	Wright, Jesse H., M.D., Ph.D.	60, 82, 85
Wei, Mike, B.S.	146, 157	Wu, Hanjing E., M.D., Ph.D.	160
Weinberg, Igor	61	Wynn, Gary H., M.D.	112
Weiner, Richard	99		
Weine, Stevan M., M.D.	115, 116	X	
Weinstock, Robert, M.D.	101, 114	Xiang, Shuo, M.D.	163
Weintraub Brendel, Rebecca, M.D., J.D.	85, 104, 109	Y	
Weisensel, Nicolette, M.D.	145	Yager, Joel, M.D.	116
Weiss, Catherine	179	Yakov, Svetlana, M.D., Ph.D.	159
Weisser, Lydia E., D.O., M.B.A.	105	Yamamoto, Kazuhiko, M.D., Ph.D.	170, 171
Weiss, Kenneth J., M.D.	128	Yam, Philip Michael, M.D.	134
Weissman, Anna, M.D.	102	Yancovitch, Alan C., M.D.	171
Weissman, Sidney, M.D.	145	Yang, Fang, M.D., Ph.D.	110, 166
Weiss, Roger D., M.D.	115, 130, 134	Yang, Jong-Chul, M.D., Ph.D.	179
Weiss, Susan R. B., Ph.D.	69	Yao, Lihua, M.Psy.	126
Welch, Stephen, M.D.	61	Yap, Yen Ling, M.Sc.	163
Wendt, Burdette	179	Yaseen, Zimri S., M.D.	144
Wertheimer, Moira, J.D., B.S.N.	132	Yatham, Lakshmi, M.B.B.S.	179
Westermeyer, Joseph J., M.D., Ph.D.	65	Yeaw, Jennifer, Psy.D.	84
West, Joyce C., Ph.D., M.P.P.	71, 107, 112, 116	Ye, Chuanzhong, M.D., Ph.D.	171
West Jr., James C., M.D.	112	Yehia, Baligh R.	142
Westreich, Laurence, M.D.	104	Yehuda, Rachel, Ph.D.	70, 129
White, Christopher, M.D.	174	Yellowlees, Peter, M.D.	102
White, Leigh, M.D.	76, 136	Yeomans, Frank E., M.D.	79, 105, 118
Wick, Paul H., M.D.	75, 107, 108	Yin, Yingying, M.Med.	100
Wiechers, Ilse, M.D., M.H.S.	64	Yohanan, Monique, M.D., M.P.H.	110
Wiegand, Hauke F., M.D., Ph.D.	174	Yohanna, Daniel, M.D.	145
Wigal, Sharon B., Ph.D.	171	Young, Allan H., M.D., Ph.D.	129
Wilcox, Marsha Ann, Ed.D., Sc.D.	82	Young, John Q., M.D., M.P.H.	76, 90
Wilens, Timothy, M.D.	136	Yousuf, Mohammad, M.D.	157
Wiles, Preston, M.D.	71, 136	Yuen, Laura D., B.A.	166
Wilkins, Kirsten, M.D.	64	Yue, Yingying, M.Med.	126
Wilkinson, Samuel, M.D.	85	Yurgelen-Todd, Deborah, Ph.D.	62, 69
Wilkins, Victoria, Ph.D.	126	Yur'yev, Andriy, M.D., Ph.D.	134, 159
Williams, Jill M., M.D.	88, 116	Z	
Williamson, Johnny, M.D.	108	Zafar, Jawad, D.O.	160
Wills, Cheryl, M.D.	135	Zafer, Maryam, M.S.	174
Winfrey, Chris, M.D.	78	Zakers, Aleema, M.D., M.P.H.	117
Wininger, Bryce, M.D.	157		
Winsberg, Mirene, M.D.	86		

Presenters Index

Zalpuri, Isheeta, M.D.	76
Zanarini, Mary C., Ed.D.	128, 135
Zarra, Julio C., M.D., Dr.P.H.	179
Zeid, Dana	166
Zeller, Scott, M.D.	99
Zeng, Mary C., M.D.	102
Zerrate, Maria Carolina, M.D., M.H.S.	102
Zeshan, Muhammad, M.D.	157
Zhan, Chang-Guo, Ph.D., M.Sc.	114
Zhang, Layan, M.B.B.S., M.S.	166
Zhang, Tingting	171
Zhang, Yuqun	174
Zhong, Jun, M.D.	160
Zimmerman, Mark, M.D.	76, 100, 107, 171
Zinns, Rachel, M.D., Ed.M.	101
Zisook, Sidney, M.D.	70, 90, 129, 136
Zohar, Joseph, M.D.	127
Zonana, Howard, M.D.	82
Zonana, Jess, M.D.	76
Zun, Leslie, M.D.	85, 99
Zuschlag, Zachary D., D.O.	160

Women's Brown Bag & Networking Lunch

Sunday, May 15, 2016

11:30 a.m. - 1:30 p.m.

Grand Ballroom B, M4, North Tower

Omni Atlanta Hotel at CNN Center

Women psychiatrists attending the APA Annual Meeting are cordially invited to join the Women's Caucus for fellowship and conversation with a wonderful group of women colleagues from around the world and all career stages!

► **Get advice from over fifteen prominent women psychiatrists on:**

- Building your career
- Balancing your personal and professional roles
- Taking your career in a different direction or to a new level
- Negotiating salary, title, and more
- Seeking national leadership in psychiatry
- Building your practice
- And more!

► **Share your opinions with current and recently elected APA officials**

► **Meet residency and fellowship program directors from around the country**

► **Network with other women in your area who are looking for women colleagues to refer clients to**

► **Or just come by to relax, talk and make friends**

Be sure to bring your brown bag lunch!

AMERICAN
PSYCHIATRIC
ASSOCIATION
ANNUAL MEETING
May 14-18, 2016 • Atlanta





Introducing the New APA Meetings App.

Features:


- View sessions, schedule and speaker information
- Access an interactive exhibitor list and exhibit hall map
- View schedules for Component Meetings and Allied Professional Meetings
- Plan your time by selecting sessions and viewing “My Agenda”
- View an entire feed of event activity, including attendee updates, photos and more

Download:

psychiatry.org/App

Apple and Google App Stores:
Search for [APA Meetings](#)

App presented by:



ADVOCATING
 NURSE PRACTITIONERS
 PATIENTS PSYCHIATRISTS OUTPATIENT SETTING
 NURSE PRACTITIONERS
 HOSPITAL SETTING COLLABORATIVE CARE CAREGIVERS
 OUTPATIENT SETTING COLLABORATIVE CARE
SYMPTOMS COLLABORATIVE CARE
 PSYCHIATRISTS CHRONIC ILLNESS EDUCATING RELAPSE
 SYMPTOMS LIFE-LONG
 OUTPATIENT SETTING
 ADVOCATING NURSES CAREGIVERS
 SOCIAL WORKERS
 PATIENTS FAMILY
 LIFE-LONG
TREATMENT APPROACH
 SYMPTOMS PATIENTS EDUCATING
 CAREGIVERS LIFE-LONG FAMILY RELAPSE
 ADVOCATING
 SYMPTOMS LIFE-LONG
 HOSPITAL SETTING
 LIFE-LONG CAREGIVERS
 SYMPTOM CHRONIC ILLNESS
CAREGIVERS NURSES
 PSYCHIATRISTS CHRONIC ILLNESS
 TREATMENT OPTION
 NURSES LIFE-LONG
 PATIENTS FAMILY
 LIFE-LONG
 SYMPTOMS
 PSYCHOLOGISTS
 EDUCATING RELAPSE
 PSYCHIATRISTS
TREATMENT APPROACH
 SYMPTOMS PATIENTS
 CAREGIVERS LIFE-LONG FAMILY
 RELAPSE
 EDUCATING
 SYMPTOMS
 RELAPSE
 EDUCATING
 NURSES RELAPSE
 PATIENTS
 PSYCHIATRISTS
 CAREGIVERS
 PSYCHIATRISTS
 TREATMENT APPROACH
 TREATMENT TEAM
CAREGIVERS
 PSYCHIATRISTS
 TREATMENT APPROACH
 TREATMENT TEAM
NURSES
 PSYCHIATRISTS
 TREATMENT APPROACH
 TREATMENT TEAM
TREATMENT APPROACH
 SYMPTOMS
 LIFE-LONG
 PSYCHIATRISTS
 RELAPSE
 PSYCHIATRISTS
 LIFE-LONG
 NURSES
 CHRONIC ILLNESS
 FAMILY
 RELAPSE
 PSYCHIATRISTS
 LIFE-LONG
 FAMILY
 LIFE-LONG
 COLLABORATIVE CARE
 SOCIAL WORKERS
 NURSE PRACTITIONERS
CAREGIVERS
RELAPSE
 PSYCHOLOGISTS
 SOCIAL WORKERS
 TREATMENT OPTION
 PATIENTS

FACING SCHIZOPHRENIA

VISIT BOOTH 937 TO
ADVANCE THE CONVERSATION

COLLABORATIVE CARE
RELAPSE
 TREATMENT APPROACH
 HOSPITAL SETTING
 CAREGIVERS
 SYMPTOMS
 COLLABORATIVE CARE
FAMILY
 TREATMENT APPROACH
 OUTPATIENT SETTING
 PSYCHIATRISTS
 CAREGIVERS
 PSYCHOLOGISTS
 SOCIAL WORKERS
 PSYCHIATRISTS
NURSES
 SYMPTOMS
 PSYCHIATRISTS
 SOCIAL WORKERS
 PSYCHOLOGISTS
EDUCATING
 SYMPTOMS
 LIFE-LONG
 PSYCHIATRISTS
 RELAPSE
 CHRONIC ILLNESS
 HOSPITAL SETTING
 TREATMENT OPTION
CAREGIVERS
 PSYCHIATRISTS
 NURSES
 PATIENTS
 NURSES
 LIFE-LONG
 RELAPSE
 CHRONIC ILLNESS
 HOSPITAL SETTING
 TREATMENT OPTION
FAMILY
 SYMPTOMS
 PSYCHIATRISTS
 SOCIAL WORKERS
 SYMPTOMS
 FAMILY
 PSYCHIATRISTS